CN104650235A - 抗原结合构建体 - Google Patents
抗原结合构建体 Download PDFInfo
- Publication number
- CN104650235A CN104650235A CN201410818231.3A CN201410818231A CN104650235A CN 104650235 A CN104650235 A CN 104650235A CN 201410818231 A CN201410818231 A CN 201410818231A CN 104650235 A CN104650235 A CN 104650235A
- Authority
- CN
- China
- Prior art keywords
- antigen
- binding
- binding constructs
- epi
- conjunction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000027455 binding Effects 0.000 claims abstract description 869
- 239000000427 antigen Substances 0.000 claims abstract description 616
- 108091007433 antigens Proteins 0.000 claims abstract description 616
- 102000036639 antigens Human genes 0.000 claims abstract description 616
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 115
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 81
- 108090000978 Interleukin-4 Proteins 0.000 claims description 143
- 102000003816 Interleukin-13 Human genes 0.000 claims description 137
- 108090000176 Interleukin-13 Proteins 0.000 claims description 137
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 115
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 70
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 69
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 59
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 58
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 58
- 108010002616 Interleukin-5 Proteins 0.000 claims description 48
- 101710153593 Albumin A Proteins 0.000 claims description 33
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 13
- 102000019298 Lipocalin Human genes 0.000 claims description 13
- 108050006654 Lipocalin Proteins 0.000 claims description 13
- 102000002070 Transferrins Human genes 0.000 claims description 13
- 108010015865 Transferrins Proteins 0.000 claims description 13
- 150000002505 iron Chemical class 0.000 claims description 12
- 102100024341 10 kDa heat shock protein, mitochondrial Human genes 0.000 claims description 10
- 108010059013 Chaperonin 10 Proteins 0.000 claims description 10
- 101000677856 Stenotrophomonas maltophilia (strain K279a) Actin-binding protein Smlt3054 Proteins 0.000 claims description 8
- 108010067306 Fibronectins Proteins 0.000 claims description 7
- 108090000342 C-Type Lectins Proteins 0.000 claims description 5
- 102000003930 C-Type Lectins Human genes 0.000 claims description 5
- 108090001090 Lectins Proteins 0.000 claims description 5
- 102000004856 Lectins Human genes 0.000 claims description 5
- 108090000848 Ubiquitin Proteins 0.000 claims description 5
- 102000044159 Ubiquitin Human genes 0.000 claims description 5
- 102000013069 gamma-Crystallins Human genes 0.000 claims description 5
- 108010079934 gamma-Crystallins Proteins 0.000 claims description 5
- 239000002523 lectin Substances 0.000 claims description 5
- 239000002795 scorpion venom Substances 0.000 claims description 5
- SBUXRMKDJWEXRL-ZWKOTPCHSA-N trans-body Chemical compound O=C([C@@H]1N(C2=O)[C@H](C3=C(C4=CC=CC=C4N3)C1)CC)N2C1=CC=C(F)C=C1 SBUXRMKDJWEXRL-ZWKOTPCHSA-N 0.000 claims description 5
- 108010004889 Heat-Shock Proteins Proteins 0.000 claims description 4
- 102000002812 Heat-Shock Proteins Human genes 0.000 claims description 4
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 102000016359 Fibronectins Human genes 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 115
- 102000004388 Interleukin-4 Human genes 0.000 description 142
- 229940028885 interleukin-4 Drugs 0.000 description 141
- 210000004027 cell Anatomy 0.000 description 112
- 235000018102 proteins Nutrition 0.000 description 77
- 230000014509 gene expression Effects 0.000 description 68
- 229920001184 polypeptide Polymers 0.000 description 66
- 102000004196 processed proteins & peptides Human genes 0.000 description 66
- 102000000743 Interleukin-5 Human genes 0.000 description 47
- 241000588724 Escherichia coli Species 0.000 description 46
- 235000001014 amino acid Nutrition 0.000 description 46
- 150000001413 amino acids Chemical class 0.000 description 45
- 238000001228 spectrum Methods 0.000 description 41
- 108050007852 Tumour necrosis factor Proteins 0.000 description 34
- 102000018594 Tumour necrosis factor Human genes 0.000 description 34
- 230000008859 change Effects 0.000 description 34
- 239000013604 expression vector Substances 0.000 description 33
- 238000002965 ELISA Methods 0.000 description 32
- -1 bilitrien Chemical class 0.000 description 30
- 238000012360 testing method Methods 0.000 description 30
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 29
- 102000039446 nucleic acids Human genes 0.000 description 29
- 108020004707 nucleic acids Proteins 0.000 description 29
- 150000007523 nucleic acids Chemical class 0.000 description 29
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 28
- 102000003810 Interleukin-18 Human genes 0.000 description 26
- 108090000171 Interleukin-18 Proteins 0.000 description 26
- 108060003951 Immunoglobulin Proteins 0.000 description 24
- 241000282553 Macaca Species 0.000 description 24
- 230000006870 function Effects 0.000 description 24
- 102000018358 immunoglobulin Human genes 0.000 description 24
- 239000003446 ligand Substances 0.000 description 23
- 239000000203 mixture Substances 0.000 description 22
- 238000003556 assay Methods 0.000 description 21
- 102000000905 Cadherin Human genes 0.000 description 20
- 108050007957 Cadherin Proteins 0.000 description 20
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 20
- 102000002111 Neuropilin Human genes 0.000 description 20
- 108050009450 Neuropilin Proteins 0.000 description 20
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 20
- 239000002773 nucleotide Substances 0.000 description 20
- 125000003729 nucleotide group Chemical group 0.000 description 20
- 239000000523 sample Substances 0.000 description 20
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 description 19
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 19
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 19
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 description 19
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 description 19
- 101000851030 Homo sapiens Vascular endothelial growth factor receptor 3 Proteins 0.000 description 19
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 19
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 19
- 238000010790 dilution Methods 0.000 description 19
- 239000012895 dilution Substances 0.000 description 19
- 101100306202 Escherichia coli (strain K12) rpoB gene Proteins 0.000 description 18
- 102000004890 Interleukin-8 Human genes 0.000 description 18
- 108090001007 Interleukin-8 Proteins 0.000 description 18
- 101100306001 Mus musculus Mst1r gene Proteins 0.000 description 18
- 101150006914 TRP1 gene Proteins 0.000 description 18
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 description 18
- 125000003275 alpha amino acid group Chemical group 0.000 description 18
- 239000003085 diluting agent Substances 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- 239000000047 product Substances 0.000 description 18
- 241000894006 Bacteria Species 0.000 description 17
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 description 16
- 101001076418 Homo sapiens Interleukin-1 receptor type 1 Proteins 0.000 description 16
- 101001076430 Homo sapiens Interleukin-13 Proteins 0.000 description 16
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 16
- 102100026016 Interleukin-1 receptor type 1 Human genes 0.000 description 16
- 230000004071 biological effect Effects 0.000 description 16
- 102000019207 human interleukin-13 Human genes 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 16
- 241000282414 Homo sapiens Species 0.000 description 15
- 101001002709 Homo sapiens Interleukin-4 Proteins 0.000 description 15
- 238000010168 coupling process Methods 0.000 description 15
- 238000005859 coupling reaction Methods 0.000 description 15
- 102000055229 human IL4 Human genes 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 15
- 239000013598 vector Substances 0.000 description 15
- 102000004127 Cytokines Human genes 0.000 description 14
- 108090000695 Cytokines Proteins 0.000 description 14
- 238000012258 culturing Methods 0.000 description 14
- 239000007788 liquid Substances 0.000 description 14
- 238000004448 titration Methods 0.000 description 14
- BXSSCSKCOFKPOK-ARGVQFGUSA-N (2s)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-amino-1-oxohexan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3- Chemical compound C([C@@H](C(=O)N[C@@H](CCCC)C(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C(C)C)C1=CC=CC=C1 BXSSCSKCOFKPOK-ARGVQFGUSA-N 0.000 description 13
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 108010065637 Interleukin-23 Proteins 0.000 description 12
- 102000003992 Peroxidases Human genes 0.000 description 12
- 125000000539 amino acid group Chemical group 0.000 description 12
- 210000003979 eosinophil Anatomy 0.000 description 12
- 230000003472 neutralizing effect Effects 0.000 description 12
- 108040007629 peroxidase activity proteins Proteins 0.000 description 12
- 230000004663 cell proliferation Effects 0.000 description 11
- 238000005516 engineering process Methods 0.000 description 11
- 238000003752 polymerase chain reaction Methods 0.000 description 11
- 108091033319 polynucleotide Proteins 0.000 description 11
- 102000040430 polynucleotide Human genes 0.000 description 11
- 239000002157 polynucleotide Substances 0.000 description 11
- 230000008929 regeneration Effects 0.000 description 11
- 238000011069 regeneration method Methods 0.000 description 11
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 11
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 10
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 10
- 108091008605 VEGF receptors Proteins 0.000 description 10
- 230000001580 bacterial effect Effects 0.000 description 10
- 238000010367 cloning Methods 0.000 description 10
- 230000008878 coupling Effects 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 210000004602 germ cell Anatomy 0.000 description 10
- 230000000670 limiting effect Effects 0.000 description 10
- 239000013642 negative control Substances 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 10
- 239000013641 positive control Substances 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 230000000295 complement effect Effects 0.000 description 9
- 239000003550 marker Substances 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 102100023701 C-C motif chemokine 18 Human genes 0.000 description 8
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 8
- 102100036850 C-C motif chemokine 23 Human genes 0.000 description 8
- 101000713081 Homo sapiens C-C motif chemokine 23 Proteins 0.000 description 8
- 108050003558 Interleukin-17 Proteins 0.000 description 8
- 102000013691 Interleukin-17 Human genes 0.000 description 8
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 239000000710 homodimer Substances 0.000 description 8
- 239000011159 matrix material Substances 0.000 description 8
- 238000006386 neutralization reaction Methods 0.000 description 8
- 201000003068 rheumatic fever Diseases 0.000 description 8
- 230000009870 specific binding Effects 0.000 description 8
- 241000282836 Camelus dromedarius Species 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 101000960954 Homo sapiens Interleukin-18 Proteins 0.000 description 7
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- 108010076504 Protein Sorting Signals Proteins 0.000 description 7
- 108020005091 Replication Origin Proteins 0.000 description 7
- 230000000975 bioactive effect Effects 0.000 description 7
- 238000004166 bioassay Methods 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 239000013599 cloning vector Substances 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 150000003141 primary amines Chemical class 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 102000019034 Chemokines Human genes 0.000 description 6
- 108010012236 Chemokines Proteins 0.000 description 6
- 108020004705 Codon Proteins 0.000 description 6
- 102100037362 Fibronectin Human genes 0.000 description 6
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- 102000035195 Peptidases Human genes 0.000 description 6
- 108091005804 Peptidases Proteins 0.000 description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 6
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 6
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 6
- 239000007983 Tris buffer Substances 0.000 description 6
- 230000003321 amplification Effects 0.000 description 6
- 208000006673 asthma Diseases 0.000 description 6
- 239000007853 buffer solution Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000007865 diluting Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000010828 elution Methods 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 238000002823 phage display Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 5
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 5
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 5
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 5
- 102000000589 Interleukin-1 Human genes 0.000 description 5
- 108010002352 Interleukin-1 Proteins 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 229920001213 Polysorbate 20 Polymers 0.000 description 5
- 230000018199 S phase Effects 0.000 description 5
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 5
- 102000013275 Somatomedins Human genes 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 101150117115 V gene Proteins 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 108091008108 affimer Proteins 0.000 description 5
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 5
- 238000007413 biotinylation Methods 0.000 description 5
- 230000006287 biotinylation Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000001516 cell proliferation assay Methods 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000001143 conditioned effect Effects 0.000 description 5
- 230000001186 cumulative effect Effects 0.000 description 5
- 238000010494 dissociation reaction Methods 0.000 description 5
- 230000005593 dissociations Effects 0.000 description 5
- 239000012636 effector Substances 0.000 description 5
- 238000004108 freeze drying Methods 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 5
- 102000043959 human IL18 Human genes 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 210000004962 mammalian cell Anatomy 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 210000001616 monocyte Anatomy 0.000 description 5
- 201000008482 osteoarthritis Diseases 0.000 description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
- 230000002285 radioactive effect Effects 0.000 description 5
- 239000012266 salt solution Substances 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 102000008102 Ankyrins Human genes 0.000 description 4
- 108010049777 Ankyrins Proteins 0.000 description 4
- 102100023995 Beta-nerve growth factor Human genes 0.000 description 4
- 102100023698 C-C motif chemokine 17 Human genes 0.000 description 4
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 4
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 4
- 108010029697 CD40 Ligand Proteins 0.000 description 4
- 101150013553 CD40 gene Proteins 0.000 description 4
- 102100032937 CD40 ligand Human genes 0.000 description 4
- 108010055166 Chemokine CCL5 Proteins 0.000 description 4
- 102100031107 Disintegrin and metalloproteinase domain-containing protein 11 Human genes 0.000 description 4
- 101710121366 Disintegrin and metalloproteinase domain-containing protein 11 Proteins 0.000 description 4
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 4
- 101150021185 FGF gene Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 4
- 102000009465 Growth Factor Receptors Human genes 0.000 description 4
- 108010009202 Growth Factor Receptors Proteins 0.000 description 4
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 4
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 4
- 101000600756 Homo sapiens 3-phosphoinositide-dependent protein kinase 1 Proteins 0.000 description 4
- 101000978362 Homo sapiens C-C motif chemokine 17 Proteins 0.000 description 4
- 101000978371 Homo sapiens C-C motif chemokine 18 Proteins 0.000 description 4
- 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 description 4
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 4
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 description 4
- 101000577881 Homo sapiens Macrophage metalloelastase Proteins 0.000 description 4
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 4
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 description 4
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 description 4
- 101001117146 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Proteins 0.000 description 4
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 4
- 102000003814 Interleukin-10 Human genes 0.000 description 4
- 108090000174 Interleukin-10 Proteins 0.000 description 4
- 108010065805 Interleukin-12 Proteins 0.000 description 4
- 102000013462 Interleukin-12 Human genes 0.000 description 4
- 102100020791 Interleukin-13 receptor subunit alpha-1 Human genes 0.000 description 4
- 108090000172 Interleukin-15 Proteins 0.000 description 4
- 102000003812 Interleukin-15 Human genes 0.000 description 4
- 101800003050 Interleukin-16 Proteins 0.000 description 4
- 102000049772 Interleukin-16 Human genes 0.000 description 4
- 102100030703 Interleukin-22 Human genes 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 108010002335 Interleukin-9 Proteins 0.000 description 4
- 102000000585 Interleukin-9 Human genes 0.000 description 4
- 102100027998 Macrophage metalloelastase Human genes 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 4
- 108010025020 Nerve Growth Factor Proteins 0.000 description 4
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 4
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 description 4
- 101710098940 Pro-epidermal growth factor Proteins 0.000 description 4
- 108010011005 STAT6 Transcription Factor Proteins 0.000 description 4
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 description 4
- 102100035721 Syndecan-1 Human genes 0.000 description 4
- 108020005038 Terminator Codon Proteins 0.000 description 4
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 4
- 102100024148 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Human genes 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 102000003675 cytokine receptors Human genes 0.000 description 4
- 108010057085 cytokine receptors Proteins 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 230000009977 dual effect Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 208000024908 graft versus host disease Diseases 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000013011 mating Effects 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000009696 proliferative response Effects 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 230000006641 stabilisation Effects 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 3
- 108010005853 Anti-Mullerian Hormone Proteins 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 108090000565 Capsid Proteins Proteins 0.000 description 3
- 102100023321 Ceruloplasmin Human genes 0.000 description 3
- 241000251730 Chondrichthyes Species 0.000 description 3
- 208000011231 Crohn disease Diseases 0.000 description 3
- 206010012438 Dermatitis atopic Diseases 0.000 description 3
- 108090000204 Dipeptidase 1 Proteins 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 3
- 108091006905 Human Serum Albumin Proteins 0.000 description 3
- 102000008100 Human Serum Albumin Human genes 0.000 description 3
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 3
- 101710112663 Interleukin-13 receptor subunit alpha-1 Proteins 0.000 description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
- 102100023980 Signal transducer and activator of transcription 6 Human genes 0.000 description 3
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 3
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000009824 affinity maturation Effects 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 239000000868 anti-mullerian hormone Substances 0.000 description 3
- 201000008937 atopic dermatitis Diseases 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000003139 buffering effect Effects 0.000 description 3
- 239000003636 conditioned culture medium Substances 0.000 description 3
- 238000013016 damping Methods 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 108040006852 interleukin-4 receptor activity proteins Proteins 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- 239000003094 microcapsule Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 210000001236 prokaryotic cell Anatomy 0.000 description 3
- 238000012207 quantitative assay Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102100023990 60S ribosomal protein L17 Human genes 0.000 description 2
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 2
- 101100230376 Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) celI gene Proteins 0.000 description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
- 108010025628 Apolipoproteins E Proteins 0.000 description 2
- 102000013918 Apolipoproteins E Human genes 0.000 description 2
- 101000716807 Arabidopsis thaliana Protein SCO1 homolog 1, mitochondrial Proteins 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 108010081589 Becaplermin Proteins 0.000 description 2
- 101710129634 Beta-nerve growth factor Proteins 0.000 description 2
- 101001069913 Bos taurus Growth-regulated protein homolog beta Proteins 0.000 description 2
- 101001069912 Bos taurus Growth-regulated protein homolog gamma Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 2
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 2
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 2
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 2
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 description 2
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 2
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 2
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 2
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 2
- 102100036305 C-C chemokine receptor type 8 Human genes 0.000 description 2
- 102100036841 C-C motif chemokine 1 Human genes 0.000 description 2
- 102100023702 C-C motif chemokine 13 Human genes 0.000 description 2
- 101710112613 C-C motif chemokine 13 Proteins 0.000 description 2
- 102100036846 C-C motif chemokine 21 Human genes 0.000 description 2
- 102100032366 C-C motif chemokine 7 Human genes 0.000 description 2
- 101710155834 C-C motif chemokine 7 Proteins 0.000 description 2
- 102100034871 C-C motif chemokine 8 Human genes 0.000 description 2
- 101710155833 C-C motif chemokine 8 Proteins 0.000 description 2
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 2
- 102100039398 C-X-C motif chemokine 2 Human genes 0.000 description 2
- 102100036189 C-X-C motif chemokine 3 Human genes 0.000 description 2
- 102100036150 C-X-C motif chemokine 5 Human genes 0.000 description 2
- 102100036153 C-X-C motif chemokine 6 Human genes 0.000 description 2
- 101710085504 C-X-C motif chemokine 6 Proteins 0.000 description 2
- 102100032528 C-type lectin domain family 11 member A Human genes 0.000 description 2
- 102100031168 CCN family member 2 Human genes 0.000 description 2
- 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 description 2
- 102100027207 CD27 antigen Human genes 0.000 description 2
- 101150093802 CXCL1 gene Proteins 0.000 description 2
- 101100369802 Caenorhabditis elegans tim-1 gene Proteins 0.000 description 2
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 102100028892 Cardiotrophin-1 Human genes 0.000 description 2
- 108010023798 Charybdotoxin Proteins 0.000 description 2
- 108010082155 Chemokine CCL18 Proteins 0.000 description 2
- 108090000317 Chymotrypsin Proteins 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102400000686 Endothelin-1 Human genes 0.000 description 2
- 101800004490 Endothelin-1 Proteins 0.000 description 2
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 2
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 2
- 108090001047 Fibroblast growth factor 10 Proteins 0.000 description 2
- 102100028412 Fibroblast growth factor 10 Human genes 0.000 description 2
- 102100028071 Fibroblast growth factor 7 Human genes 0.000 description 2
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 2
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 description 2
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 description 2
- 102000004961 Furin Human genes 0.000 description 2
- 108090001126 Furin Proteins 0.000 description 2
- 101710115997 Gamma-tubulin complex component 2 Proteins 0.000 description 2
- 241000251152 Ginglymostoma cirratum Species 0.000 description 2
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 2
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 2
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 2
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 2
- 101000716063 Homo sapiens C-C chemokine receptor type 8 Proteins 0.000 description 2
- 101000713085 Homo sapiens C-C motif chemokine 21 Proteins 0.000 description 2
- 101000947193 Homo sapiens C-X-C motif chemokine 3 Proteins 0.000 description 2
- 101000947186 Homo sapiens C-X-C motif chemokine 5 Proteins 0.000 description 2
- 101000942297 Homo sapiens C-type lectin domain family 11 member A Proteins 0.000 description 2
- 101100382881 Homo sapiens CCL18 gene Proteins 0.000 description 2
- 101000777550 Homo sapiens CCN family member 2 Proteins 0.000 description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 2
- 101000856395 Homo sapiens Cullin-9 Proteins 0.000 description 2
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
- 101000853002 Homo sapiens Interleukin-25 Proteins 0.000 description 2
- 101001033312 Homo sapiens Interleukin-4 receptor subunit alpha Proteins 0.000 description 2
- 101000960969 Homo sapiens Interleukin-5 Proteins 0.000 description 2
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 2
- 101001128431 Homo sapiens Myeloid-derived growth factor Proteins 0.000 description 2
- 101000973997 Homo sapiens Nucleosome assembly protein 1-like 4 Proteins 0.000 description 2
- 101000947178 Homo sapiens Platelet basic protein Proteins 0.000 description 2
- 101001076715 Homo sapiens RNA-binding protein 39 Proteins 0.000 description 2
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 2
- 108010073807 IgG Receptors Proteins 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 2
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 2
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 2
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 2
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 2
- 102100020881 Interleukin-1 alpha Human genes 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 2
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 2
- 108090000177 Interleukin-11 Proteins 0.000 description 2
- 102000003815 Interleukin-11 Human genes 0.000 description 2
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 description 2
- 101710112634 Interleukin-13 receptor subunit alpha-2 Proteins 0.000 description 2
- 102100039898 Interleukin-18 Human genes 0.000 description 2
- 108010082786 Interleukin-1alpha Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 102000013264 Interleukin-23 Human genes 0.000 description 2
- 102100036672 Interleukin-23 receptor Human genes 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- 102000000646 Interleukin-3 Human genes 0.000 description 2
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 2
- 108010002586 Interleukin-7 Proteins 0.000 description 2
- 102000000704 Interleukin-7 Human genes 0.000 description 2
- 102100026244 Interleukin-9 receptor Human genes 0.000 description 2
- 208000003456 Juvenile Arthritis Diseases 0.000 description 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 2
- 241000235058 Komagataella pastoris Species 0.000 description 2
- 101710197062 Lectin 8 Proteins 0.000 description 2
- 102000016267 Leptin Human genes 0.000 description 2
- 108010092277 Leptin Proteins 0.000 description 2
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 2
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 2
- 108010028275 Leukocyte Elastase Proteins 0.000 description 2
- 102000016799 Leukocyte elastase Human genes 0.000 description 2
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 2
- 102100035304 Lymphotactin Human genes 0.000 description 2
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 2
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 2
- 102000034655 MIF Human genes 0.000 description 2
- 108060004872 MIF Proteins 0.000 description 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010058398 Macrophage Colony-Stimulating Factor Receptor Proteins 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 102000007072 Nerve Growth Factors Human genes 0.000 description 2
- 108090000742 Neurotrophin 3 Proteins 0.000 description 2
- 102100029268 Neurotrophin-3 Human genes 0.000 description 2
- 102000003683 Neurotrophin-4 Human genes 0.000 description 2
- 108090000099 Neurotrophin-4 Proteins 0.000 description 2
- 241001452677 Ogataea methanolica Species 0.000 description 2
- 108090000630 Oncostatin M Proteins 0.000 description 2
- 102000004140 Oncostatin M Human genes 0.000 description 2
- 102100040557 Osteopontin Human genes 0.000 description 2
- 108010081689 Osteopontin Proteins 0.000 description 2
- 102100036154 Platelet basic protein Human genes 0.000 description 2
- 102100030304 Platelet factor 4 Human genes 0.000 description 2
- 108090000778 Platelet factor 4 Proteins 0.000 description 2
- 206010065159 Polychondritis Diseases 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 102000014128 RANK Ligand Human genes 0.000 description 2
- 108010025832 RANK Ligand Proteins 0.000 description 2
- 102100023361 SAP domain-containing ribonucleoprotein Human genes 0.000 description 2
- 206010039361 Sacroiliitis Diseases 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- 102100027188 Thyroid peroxidase Human genes 0.000 description 2
- 101710113649 Thyroid peroxidase Proteins 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- 102400001320 Transforming growth factor alpha Human genes 0.000 description 2
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 2
- 102000001400 Tryptase Human genes 0.000 description 2
- 108060005989 Tryptase Proteins 0.000 description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 206010046851 Uveitis Diseases 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 108010026054 apolipoprotein SAA Proteins 0.000 description 2
- 239000008365 aqueous carrier Substances 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- RIIWUGSYXOBDMC-UHFFFAOYSA-N benzene-1,2-diamine;hydron;dichloride Chemical compound Cl.Cl.NC1=CC=CC=C1N RIIWUGSYXOBDMC-UHFFFAOYSA-N 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 235000019846 buffering salt Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 108010041776 cardiotrophin 1 Proteins 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000003399 chemotactic effect Effects 0.000 description 2
- 208000019069 chronic childhood arthritis Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 229960002376 chymotrypsin Drugs 0.000 description 2
- 230000024203 complement activation Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- CNVQLPPZGABUCM-LIGYZCPXSA-N ctx toxin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H]3CSSC[C@@H](C(N[C@@H](CC=4C5=CC=CC=C5NC=4)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC3=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CO)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3NC=NC=3)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N2)C(C)C)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC1=O)=O)CCSC)C(C)C)[C@@H](C)O)NC(=O)[C@H]1NC(=O)CC1)C1=CC=CC=C1 CNVQLPPZGABUCM-LIGYZCPXSA-N 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000008393 encapsulating agent Substances 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 230000012447 hatching Effects 0.000 description 2
- 102000055228 human IL5 Human genes 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 102000014909 interleukin-1 receptor activity proteins Human genes 0.000 description 2
- 108040006732 interleukin-1 receptor activity proteins Proteins 0.000 description 2
- 108040003610 interleukin-12 receptor activity proteins Proteins 0.000 description 2
- 108040002039 interleukin-15 receptor activity proteins Proteins 0.000 description 2
- 102000008616 interleukin-15 receptor activity proteins Human genes 0.000 description 2
- 108040001304 interleukin-17 receptor activity proteins Proteins 0.000 description 2
- 102000053460 interleukin-17 receptor activity proteins Human genes 0.000 description 2
- 108040002014 interleukin-18 receptor activity proteins Proteins 0.000 description 2
- 102000008625 interleukin-18 receptor activity proteins Human genes 0.000 description 2
- 108010074108 interleukin-21 Proteins 0.000 description 2
- 108010074109 interleukin-22 Proteins 0.000 description 2
- 108040001844 interleukin-23 receptor activity proteins Proteins 0.000 description 2
- 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 description 2
- 108010038415 interleukin-8 receptors Proteins 0.000 description 2
- 102000010681 interleukin-8 receptors Human genes 0.000 description 2
- 108040006862 interleukin-9 receptor activity proteins Proteins 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 2
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 2
- 229940039781 leptin Drugs 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 108010019677 lymphotactin Proteins 0.000 description 2
- 230000002934 lysing effect Effects 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- AEUKDPKXTPNBNY-XEYRWQBLSA-N mcp 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229960005108 mepolizumab Drugs 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 239000003471 mutagenic agent Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 229940053128 nerve growth factor Drugs 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 239000003900 neurotrophic factor Substances 0.000 description 2
- 210000004493 neutrocyte Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 108010017843 platelet-derived growth factor A Proteins 0.000 description 2
- 108010000685 platelet-derived growth factor AB Proteins 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000008521 reorganization Effects 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 231100000617 superantigen Toxicity 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 206010043778 thyroiditis Diseases 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000010474 transient expression Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- LAOOXBLMIJHMFO-UHFFFAOYSA-N 1-[2-(diethylamino)ethylamino]-4-methylthioxanthen-9-one;hydron;chloride Chemical compound Cl.S1C2=CC=CC=C2C(=O)C2=C1C(C)=CC=C2NCCN(CC)CC LAOOXBLMIJHMFO-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 108700004676 Bence Jones Proteins 0.000 description 1
- 102000006734 Beta-Globulins Human genes 0.000 description 1
- 108010087504 Beta-Globulins Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 101100123850 Caenorhabditis elegans her-1 gene Proteins 0.000 description 1
- 101100244725 Caenorhabditis elegans pef-1 gene Proteins 0.000 description 1
- 108010059892 Cellulase Proteins 0.000 description 1
- 108010025905 Cystine-Knot Miniproteins Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 201000003066 Diffuse Scleroderma Diseases 0.000 description 1
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102100023688 Eotaxin Human genes 0.000 description 1
- 101710139422 Eotaxin Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000024815 Granulomatous liver disease Diseases 0.000 description 1
- 101150009006 HIS3 gene Proteins 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 101100118549 Homo sapiens EGFR gene Proteins 0.000 description 1
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 1
- 101100232357 Homo sapiens IL13RA1 gene Proteins 0.000 description 1
- 101100232360 Homo sapiens IL13RA2 gene Proteins 0.000 description 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
- 101000589010 Homo sapiens Myomesin-1 Proteins 0.000 description 1
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 description 1
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
- 108010058683 Immobilized Proteins Proteins 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 108010038486 Interleukin-4 Receptors Proteins 0.000 description 1
- 102000010787 Interleukin-4 Receptors Human genes 0.000 description 1
- 102100039078 Interleukin-4 receptor subunit alpha Human genes 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical group [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 108010024121 Janus Kinases Proteins 0.000 description 1
- 102000015617 Janus Kinases Human genes 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000004554 Leishmaniasis Diseases 0.000 description 1
- 241000255777 Lepidoptera Species 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 101001059401 Moraxella bovis Type IV major alpha-pilin Proteins 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 101000574441 Mus musculus Alkaline phosphatase, germ cell type Proteins 0.000 description 1
- 101000589013 Mus musculus Myomesin-1 Proteins 0.000 description 1
- 102100031789 Myeloid-derived growth factor Human genes 0.000 description 1
- 102100032971 Myomesin-1 Human genes 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 102100021584 Neurturin Human genes 0.000 description 1
- 108010015406 Neurturin Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 101100394989 Rhodopseudomonas palustris (strain ATCC BAA-98 / CGA009) hisI gene Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 241001655322 Streptomycetales Species 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 108700007696 Tetrahydrofolate Dehydrogenase Proteins 0.000 description 1
- 102100024554 Tetranectin Human genes 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 108700029229 Transcriptional Regulatory Elements Proteins 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 239000006035 Tryptophane Substances 0.000 description 1
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 1
- 241001416177 Vicugna pacos Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003167 anti-vitamin Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 239000005667 attractant Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940106157 cellulase Drugs 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000031902 chemoattractant activity Effects 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000033581 fucosylation Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000017694 hepatic granuloma Diseases 0.000 description 1
- 231100000843 hepatic granuloma Toxicity 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 102000054663 human IL4R Human genes 0.000 description 1
- 102000006426 human interleukin-13 receptor Human genes 0.000 description 1
- 108010044118 human interleukin-13 receptor Proteins 0.000 description 1
- YQYJSBFKSSDGFO-FWAVGLHBSA-N hygromycin A Chemical compound O[C@H]1[C@H](O)[C@H](C(=O)C)O[C@@H]1Oc1ccc(\C=C(/C)C(=O)N[C@@H]2[C@@H]([C@H]3OCO[C@H]3[C@@H](O)[C@@H]2O)O)cc1O YQYJSBFKSSDGFO-FWAVGLHBSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000011229 interlayer Substances 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000003519 mature b lymphocyte Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 210000002500 microbody Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004879 molecular function Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 108091005763 multidomain proteins Proteins 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 108010068617 neonatal Fc receptor Proteins 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 229950011485 pascolizumab Drugs 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 108700010839 phage proteins Proteins 0.000 description 1
- 230000010363 phase shift Effects 0.000 description 1
- 238000003566 phosphorylation assay Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- XXPDBLUZJRXNNZ-UHFFFAOYSA-N promethazine hydrochloride Chemical compound Cl.C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 XXPDBLUZJRXNNZ-UHFFFAOYSA-N 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 230000029983 protein stabilization Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 230000001843 schistosomicidal effect Effects 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 101150118377 tet gene Proteins 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 108010013645 tetranectin Proteins 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000011735 vitamin B7 Substances 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/247—IL-4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明涉及抗原结合构建体、制备所述构建体的方法及所述构建体的用途,所述抗原结合构建体包含连接一个或多个表位结合结构域的蛋白质骨架,其中所述抗原结合构建体具有至少两个抗原结合位点,其中至少一个来自表位结合结构域,其中至少一个来自配对的VH/VL结构域。
Description
本申请为申请号为200880126310.0的分案申请,要求2007年11月30日的优先权。
背景
抗体在治疗应用方面的用途众所周知。
抗体为包含至少两条重链和两条轻链的异多聚体糖蛋白。除IgM外,完整抗体通常是大约150Kda的异四聚体糖蛋白,其由两条同样的轻(L)链和两条同样的重链(H)链组成。通常每一条轻链由一个共价二硫键与重链连接,同时不同免疫球蛋白同种型重链之间的二硫键的数目不同。每一条重链和轻链也具有链间二硫键桥。每一重链在一端有可变结构域(VH),接着是多个恒定区。每一轻链有可变结构域(VL)并在其另一端有恒定区;轻链恒定区与重链第一恒定区并排,轻链可变结构域与重链可变结构域并排。基于恒定区氨基酸序列,将来自大部分脊椎动物物种的抗体轻链指定为称为κ和λ的两类中的一种。根据其重链恒定区的氨基酸序列,可将人抗体指定为5种不同类别:IgA、IgD、IgE、IgG和IgM。可将IgG和IgA进一步再分为亚类:IgG1、IgG2、IgG3和IgG4;和IgA1和IgA2。在小鼠和大鼠中具有至少IgG2a、IgG2b的物种间变体。抗体可变结构域因抗体含有显示特定变化性的称为互补决定区(CDR)的某些区域而提供结合特异性。可变区更保守的部分被称为构架区(FR)。完整重链和轻链可变结构域各自包含由三个CDR连接的四个FR。各链中的CDR通过FR区紧密接近保持在一起,并与来自其它链的CDR促成抗体的抗原结合位点的形成。恒定区不直接参与抗体抗原间结合,但呈现各种效应器功能,例如参与以下功能:抗体依赖性细胞介导细胞毒性(ADCC)、经由结合Fcγ受体的吞噬作用、经由新生Fc受体(FcRn)的半衰期/清除率和经由补体级联的C1q组分的补体依赖性细胞毒性。
IgG抗体结构的特性是有两个抗原结合位点,其中两个都特异性针对同一表位。因此,它们为单特异性。
双特异性抗体是对至少两种不同的表位有结合特异性的抗体。制备所述抗体的方法为本领域所知。传统上,双特异性抗体的重组制备是基于两个免疫球蛋白H链-L链配对的共表达,其中两个H链具有不同的结合特异性,参见:Millstein等,Nature 305 537-539(1983);WO93/08829;和Traunecker等EMBO,10,1991,3655-3659。因为H链和L链随机分配,产生了十种不同的抗体结构的潜在混合物,其中仅一种具有所需的结合特异性。备选方法涉及让具有所需结合性特异的可变结构域与重链恒定区融合,所述重链恒定区包含至少部分铰链区、CH2和CH3区。优选使含轻链结合所需位点的CH1区存在于融合体中的至少之一中。将编码这些融合体以及需要时的L链的DNA插入到单独的表达载体中,然后共转染到合适的宿主生物体。然而可将两条或所有三条链的编码序列插入到一个表达载体。在一种方法中,双特异性抗体由在一条臂上具有第一结合特异性的H链和在另一条臂上提供第二结合特异性的H-L链对组成,参见WO94/04690。也参见Suresh等Methods in Enzymology 121,210,1986。其它方法包括包含单结构域结合位点的抗体分子,其由WO2007/095338提出。
发明概述
本发明涉及抗原结合构建体,所述构建体包含连接一个或多个表位结合结构域的蛋白质骨架,其中所述抗原结合构建体具有至少两个抗原结合位点,其中至少之一来自表位结合结构域,并且其中至少之一来自配对的VH/VL结构域。
本发明进一步涉及抗原结合构建体,所述构建体包含至少一个包含两个或多个式I结构的同型二聚体:
其中
X代表包含重链恒定结构域2和重链恒定结构域3的抗体恒定区;
R1、R4、R7和R8代表独立选自表位结合结构域的结构域;
R2代表选自重链恒定结构域1和表位结合结构域的结构域;
R3代表选自配对的VH和表位结合结构域的结构域;
R5代表选自轻链恒定结构域和表位结合结构域的结构域;
R6代表选自配对的VL和表位结合结构域的结构域;
n代表独立选自以下的整数:0、1、2、3和4;
m代表独立选自以下的整数:0和1;
其中重链恒定结构域1和轻链恒定结构域相连接(associate);
其中存在至少一个表位结合结构域;
并且当R3代表配对的VH结构域时,R6代表配对的VL结构域,由此两个结构域一起能够结合抗原。
本发明涉及基于IgG的结构和制备所述构建体的方法及其用途,尤其是在治疗中的用途,所述基于IgG的结构包括单克隆抗体或连接一个或多个结构域抗体的片段。
本发明还提供编码本文所述任一种抗原结合构建体的重链的多核苷酸序列和编码本文所述任一种抗原结合构建体轻链的多核苷酸。所述多核苷酸表示对应于等同多肽序列的编码序列,然而,应该理解,可将所述多核苷酸序列连同起始密码子、合适的信号序列和终止密码子一起克隆到表达载体中。
本发明还提供重组转化的或转染的宿主细胞,所述宿主细胞包含一种或多种编码任一种本文所述抗原结合构建体的重链和轻链的多核苷酸。
本发明进一步提供用于制备任一种本文所述抗原结合构建体的方法,所述方法包括在无血清培养基中培养包含第一和第二载体的宿主细胞的步骤,所述第一载体包含编码任一种本文所述抗原结合构建体的重链的多核苷酸,所述第二载体包含编码任一种本文所述抗原结合构建体的轻链的多核苷酸。
本发明进一步提供药用组合物,所述药用组合物包含本文所述抗原结合构建体及可药用载体。
本发明还提供包含SEQ ID NO:2或SEQ ID NO:3所示多肽序列的结构域抗体或由其组成的结构域抗体。本发明一个方面提供从SEQID NO:60或SEQ ID NO:61所示的多核苷酸序列表达的蛋白质。
定义
本文所用术语“蛋白质骨架”包括但不限于免疫球蛋白(Ig)骨架(例如IgG骨架),其可为四链抗体或两链抗体,或其可仅包含抗体的Fc区,或其可包含来自抗体的一个或多个恒定区,所述恒定区可为人源或灵长类源,或其可为人和灵长类恒定区的人造嵌合体。所述蛋白质骨架除一个或多个恒定区外还可包含抗原结合位点,例如所述蛋白质骨架包含全IgG。所述蛋白质骨架能够连接其它蛋白质结构域,例如具有抗原结合位点的蛋白质结构域,例如表位结合结构域或ScFv结构域。
“结构域”是折叠的蛋白质结构,其具有不依赖蛋白质其余部分的三级结构。结构域通常负责蛋白质不相关联的功能特性,在很多情况下可将其添加、除掉或转移到其它蛋白质而不丢失所述蛋白质其余部分和/或结构域的功能。“单一抗体可变结构域”是折叠的多肽结构域,其包含抗体可变结构域的序列特点。因此,其包括完整的抗体可变结构域和经修饰的可变结构域,例如,其中一个或多个环已被不具有抗体可变结构域特性的序列取代的可变结构域,或已被截短的或包含N-或C-末端突出端的抗体可变结构域,以及保留至少全长结构域的结合活性和特异性的可变结构域的折叠片段。
短语“免疫球蛋白单一可变结构域”指抗体可变结构域(VH、VHH、VL),所述抗体可变结构域独立于不同V区或结构域地特异性结合抗原或表位。免疫球蛋白单一可变结构域可以以某种形式(例如同多聚体或异多聚体)与其它不同可变区或可变结构域存在,其中所述其它区或结构域对于通过单一免疫球蛋白可变结构域结合抗原不是必需的(即其中免疫球蛋白单一可变结构域不依赖另外的可变结构域结合抗原)。“结构域抗体”或“dAb”与如本文所用术语“免疫球蛋白单一可变结构域”一样,能够结合抗原。免疫球蛋白单一可变结构域可为人抗体可变结构域,但也包括来自以下其它物种的单一抗体可变结构域:例如啮齿动物(例如如WO 00/29004所公开)、铰口鲨和骆驼(Camelid)VHHdAb。骆驼VHH为源自以下物种的免疫球蛋白单一可变结构域多肽:包括骆驼、美洲驼、羊驼、单峰骆驼和骆马,它们都产生天然缺乏轻链的重链抗体。所述VHH结构域可根据本领域能获得的标准技术人源化,认为所述结构域仍为本发明“结构域抗体”。本文所用VH包括骆驼VHH结构域。NARV是在软骨鱼(包括铰口鲨)中鉴定的另一类免疫球蛋白单一可变结构域。这些结构域也被称为新型抗原受体可变结构域(Novel Antigen Receptor variable region通常缩写为V(NAR)或NARV)。进一步的详细资料参见Mol.Immunol.44,656-665(2006)和US20050043519A。
术语“表位结合结构域”指特异性结合独立于不同的V区或结构域地特异性结合抗原或表位的结构域,所述表位结合结构域可为结构域抗体(dAb),例如人、骆驼或鲨鱼免疫球蛋白单一可变结构域,或其可为选自以下的骨架衍生物结构域:CTLA-4(Evibody);脂质运载蛋白;来源于蛋白A的分子,例如蛋白A的Z-结构域(Affibody,SpA)、A-结构域(Avimer/Maxibody);热休克蛋白,例如GroEl和GroES;转铁蛋白(trans-body);锚蛋白重复蛋白(DARPin);肽适体;C-型凝集素结构域(四连凝集素(Tetranectin));人γ-晶体蛋白和人泛素(affilin);PDZ结构域;人蛋白酶抑制剂蝎毒素kunitz型结构域;和纤连蛋白(adnectin);对它们进行过蛋白质工程改造,以便获得结合不同于天然配体的配体。
CTLA-4(细胞毒性T淋巴细胞相关抗原4)是在主要CD4+T-细胞上表达的CD28-家族受体。其胞外结构域具有可变结构域样Ig折叠。对应于抗体CDR的环可被异源序列取代,以提供不同的结合性质。经过工程改造具有不同结合特异性的CTLA-4分子也被称为Evibody。进一步的详细资料参见Journal of Immunological Methods 248(1-2),31-45(2001)。
脂质运载蛋白是胞外蛋白质家族,其转运小疏水分子如类固醇、胆汁三烯、类视黄醇和脂质。它们具有在锥形结构开放末端处具有多个环的刚性β-折叠二级结构,可以经过工程改造以结合不同靶抗原。Anticalin大小为160-180个氨基酸,源自脂质运载蛋白。进一步的详细资料参见Biochim Biophys Acta 1482:337-350(2000),US7250297B1和US20070224633。
Affibody为源自金黄色葡萄球菌(Staphylococcus aureus)蛋白A的骨架,可将其工程改造以结合抗原。所述结构域由大约58个氨基酸的三螺旋束组成。通过表面残基的随机化产生文库。进一步的详细资料参见Protein Eng.Des.Sel.17,455-462(2004)和EP1641818A1。
Avimer为源自A-结构域骨架家族的多结构域蛋白质。大约35个氨基酸的天然结构域采用明确的二硫键合结构。通过对由A-结构域家族表现的天然变异进行改组来产生多样性。进一步的详细资料参见Nature Biotechnology 23(12),1556-1561(2005)和Expert Opinion onInvestigational Drugs 16(6),909-917(2007年六月)。
转铁蛋白为单体血清转运糖蛋白。可通过在允许的表面环中插入肽序列对转铁蛋白进行工程改造以结合不同的靶抗原。工程改造的转铁蛋白骨架的实例包括Trans-body。进一步的详细资料参见J.Biol.Chem 274,24066-24073(1999)。
设计的锚蛋白重复蛋白(DARPin)源自锚蛋白(Ankyrin),所述锚蛋白为介导内膜蛋白与细胞骨架连接的蛋白质家族。单一锚蛋白重复序列为由两个α-螺旋和β-转角组成的33个残基的基序。可通过使每一重复序列的第一个α-螺旋和β-转角中的残基随机化对其进行工程改造以结合不同靶抗原。可通过增加功能模件(module)的数量来增大其结合界面(亲和力成熟方法)。进一步的详细资料参见J.Mol.Biol.332,489-503(2003)、PNAS 100(4),1700-1705(2003)和J.Mol.Biol.369,1015-1028(2007)和US20040132028A1。
纤连蛋白是可对其进行工程改造以结合抗原的骨架。Adnectin由人纤连蛋白III型(FN3)的15个重复单位的第10个结构域的天然氨基酸序列骨架组成。可对β-夹层的一端的三个环进行工程改造以使Adnectin能特异性识别目的治疗靶标。进一步的详细资料参见ProteinEng.Des.Sel.18,435-444(2005)、US20080139791、WO2005056764和US6818418B1。
肽适体为由固定骨架蛋白组成的组合识别分子,其通常是含有插入到活性位点的限制性可变肽环的硫氧还蛋白(TrxA)。进一步的详细资料参见Expert Opin.Biol.Ther.5,783-797(2005)。
微体源自天然存在的长为25-50个氨基酸的含有3-4个半胱氨酸桥的微蛋白质,微蛋白实例包括KalataB1和食鱼螺毒素和打结素(knottin)。微蛋白具有可工程改造以包括至多25个氨基酸而不影响微蛋白的整体折叠的环。工程改造的打结素结构域的进一步的详细资料参见WO2008098796。
其它表位结合结构域包括用作骨架以工程改造不同靶抗原结合特性的蛋白质,包括在Handbook of Therapeutic Antibodies(2007,由Stefan Dubel主编)第7章-非抗体骨架和Protein Science 15:14-27(2006)中综述的人γ-晶体蛋白和人泛素(affilin)、人蛋白酶抑制剂kunitz型结构域、Ras-结合蛋白AF-6的PDZ-结构域、蝎毒素(卡律布德蝎毒素(charybdotoxin))、C-型凝集素结构域(四连凝集素)。本发明表位结合结构域可源自这些备选蛋白质结构域中的任一种。
本文所用术语“配对的VH结构域”、“配对的VL结构域”和“配对的VH/VL结构域”指仅当与其配偶体(partner)可变结构域配对时特异性结合抗原的抗体可变结构域。在任何配对中总是有一个VH和一个VL,术语“配对的VH结构域”指VH配偶体,术语“配对的VL结构域”指VL配偶体,术语“配对的VH/VL结构域”指两个结构域一起。
在本发明一个实施方案中,抗原结合位点以以下Kd结合抗原:至少1mM的Kd,例如10nM、1nM、500pM、200pM、100pM的Kd,对每一抗原如BiacoreTM所测量,例如在方法4或5中所述的BiacoreTM方法。
本文所用术语“抗原结合位点”指构建体上能够特异性结合抗原的位点,其可为单一结构域,例如表位结合结构域,或其可为如能在标准抗体上发现的配对的VH/VL结构域。在本发明某些方面,单链Fv(ScFv)结构域可提供抗原结合位点。
本文所用术语“mAb/dAb”和“dAb/mAb”指本发明抗原结合构建体。这两个术语可互换使用,意欲具有如本文所用相同的意义。
本文所用术语“重链恒定结构域1”指免疫球蛋白重链的CH1结构域。
本文所用术语“轻链恒定结构域”指免疫球蛋白轻链的恒定结构域。
发明详述
本发明涉及包含蛋白质骨架的抗原结合构建体,所述骨架连接一个或多个表位结合结构域,其中所述抗原结合构建体具有至少两个抗原结合位点,其中至少一个来自表位结合结构域,其中至少一个来自配对的VH/VL结构域。
所述抗原结合构建体包含蛋白质骨架,例如Ig骨架(例如IgG),例如单克隆抗体,所述骨架连接一个或多个表位结合结构域,例如结构域抗体,其中所述结合构建体具有至少两个抗原结合位点,其中至少一个来自表位结合结构域。本发明涉及制备所述抗原结合构建体的方法及其用途,尤其是在治疗中的用途。
本发明抗原结合构建体的某些实例在图1中阐述。
本发明抗原结合构建体也被称为mAbdAb。
在一个实施方案中,本发明抗原结合构建体的蛋白质骨架为Ig骨架,例如IgG骨架或IgA骨架。IgG骨架可包含抗体的所有结构域(即CH1、CH2、CH3、VH、VL)。本发明抗原结合构建体可包含选自IgG1、IgG2、IgG3、IgG4或IgG4PE的IgG骨架。
本发明抗原结合构建体具有至少两个抗原结合位点,例如其具有两个结合位点,例如其中第一个结合位点对抗原第一表位具有特异性,第二结合位点对同一抗原的第二表位具有特异性。在另一实施方案中,有4个抗原结合位点,或6个抗原结合位点,或8个抗原结合位点,或10个或更多个抗原结合位点。在一个实施方案中,所述抗原结合构建体对不止一个抗原具有特异性,例如对两个抗原,或对三个抗原,或对四个抗原具有特异性。
在另一方面,本发明涉及包含至少一个包含两个或更多个式I结构的同型二聚体的抗原结合构建体:
其中
X代表包含重链恒定结构域2和重链恒定结构域3的抗体恒定区;
R1、R4、R7和R8代表独立选自表位结合结构域的结构域;
R2代表选自重链恒定结构域1和表位结合结构域的结构域;
R3代表选自配对的VH和表位结合结构域的结构域;
R5代表选自轻链恒定结构域和表位结合结构域的结构域;
R6代表选自配对的VL和表位结合结构域的结构域;
n代表独立选自以下的整数:0、1、2、3和4;
m代表独立选自以下的整数:0和1;
其中重链恒定结构域1和轻链恒定结构域相连接;
其中存在至少一个表位结合结构域;
当R3代表配对的VH结构域时,R6代表配对的VL结构域,由此两个结构域一起能够结合抗原。
在一个实施方案中,R6代表配对的VL,R3代表配对的VH。
在另一实施方案中,R7和R8任一个或两个都代表表位结合结构域。
在又一实施方案中,R1和R4任一个或两个都代表表位结合结构域。
在一个实施方案中,R4存在。
在一个实施方案中,R1R7和R8代表表位结合结构域。
在一个实施方案中,R1R7和R8及R4代表表位结合结构域。
在一个实施方案中,(R1)n、(R2)m、(R4)m和(R5)m=0,即不存在,R3为配对的VH结构域,R6为配对的VL结构域,R8为VH dAb,而R7为VL dAb。
在另一实施方案中,(R1)n、(R2)m、(R4)m和(R5)m为0,即不存在,R3为配对的VH结构域,R6为配对的VL结构域,R8为VH dAb,而(R7)m=0,即不存在。
在另一实施方案中,(R2)m和(R5)m为0,即不存在,R1为dAb,R4为dAb,R3为配对的VH结构域,R6为配对的VL结构域,(R8)m和(R7)m=0,即不存在。
在本发明一个实施方案中,所述表位结合结构域为dAb。
应该理解,本文所述任一种抗原结合构建体能够中和一种或多种抗原。
本说明书中各处使用的关于本发明抗原结合构建体的术语“中和”及其语法变体,意指在本发明抗原结合构建体存在下靶标的生物活性与在缺乏所述抗原结合构建体时的靶标的活性相比,总体或部分降低了。可由于(但不限于)以下一种或多种原因发生中和:封阻配体结合,妨碍配体激活受体,下调受体或影响效应器功能。
可以若干方法测量中和水平,例如通过使用由下文实施例及方法提出的测定中的任何一种,例如测量配体受体结合抑制的测定,其可如例如方法12、19或21或实施例32中任一个所述进行。通过评估在中和性抗原结合构建体存在下配体与其受体之间结合的降低情况来测量这些测定中VEGF、IL-4、IL-13或HGF的中和。
还可例如在TF1测定中测量中和水平,该测定可例如如方法8、9、10、20或21中所述来实施。在该测定中IL-13、IL-4或这两种细胞因子的中和都可通过评估在中和性抗原结合构建体存在下抑制TF1细胞增殖来测量。或者,可在EGFR磷酸化测定中测量中和,该测定可例如如方法13所述实施。可通过评估在中和性抗原结合构建体存在下受体的酪氨酸激酶磷酸化的抑制来测量该测定中的EGFR中和。或者,可用MRC-5细胞中的IL-8分泌测定来测量中和,该测定可例如如方法14或15中所述来实施。在该测定中可通过评估在中和性抗原结合构建体存在下IL-8分泌的抑制来测量NFα或IL-1R1的中和。
例如,通过评估在中和性抗原结合构建体存在下配体与其受体之间的结合降低情况来评估中和的其它方法在本领域已知,包括例如BiacoreTM测定。
本发明备选方面提供抗原结合构建体,所述抗原结合构建体具有与本文所举例的抗体至少基本上等同的中和活性,例如,分别在实施例4和20中提出的TF1细胞增殖测定或pSTAT6信号转导抑制测定中保留586H-TVAAPS-210或PascoH-G4S-474或PascoH-474、除去GS的PascoH-474、PascoL-G4S-474或PascoHL-G4S-474的中和活性的抗原结合构建体;或例如在实施例14.6和14.7提出的VEGFR结合测定或IGF-1R受体磷酸化的抑制中保留BPC1603、BPC1604、BPC1605、BPC1606的中和活性的抗原结合构建体。
本发明抗原结合构建体包括对IL-13具有特异性的抗原结合构建体,例如包含能够结合IL-13的表位结合结构域的抗原结合构建体,或包含结合IL-13的配对的VH/VL的抗原结合构建体。抗原结合构建体可包含能够结合IL-13的抗体。抗原结合构建体可包含能够结合IL-13的dAb。
在一个实施方案中,本发明抗原结合构建体对不止一种抗原具有特异性,例如其中所述抗原结合构建体能够结合选自IL-13、IL-5和IL-4的两种或更多种抗原,例如其中能够结合IL-13和IL-4,或其中能够结合IL-13和IL-5,或其中能够结合IL-5和IL-4。
在一个实施方案中,本发明抗原结合构建体对不止一种抗原具有特异性,例如其中所述抗原结合构建体能够结合选自IL-13、IL-5和IL-4的两种或更多种抗原,例如其中能够同时结合IL-13和IL-4,或其中能够同时结合IL-13和IL-5,或其中能够同时结合IL-5和IL-4。
应该理解,本文所述任何抗原结合构建体可以能够同时结合两种或更多种抗原,例如其如通过用合适测定的化学计量学分析所测定,所述合适的测定例如实施例部分方法7中所述测定。
本发明抗原结合构建体实例包括具有对IL-4有特异性的表位结合结构域(例如抗-IL-4 dAb,其连接到重链的c-末端或n-末端或轻链的c-末端或n-末端)的IL-13抗体,例如具有SEQ ID NO:16-39、SEQ IDNO:41-43、SEQ ID NO:87-90、SEQ ID NO:151、SEQ ID NO:152或SEQID NO:155所述的重链序列的mAbdAb。本发明抗原结合构建体包括具有连接到重链的n-末端的IL-4表位结合结构域的IL-13抗体。本发明抗原结合构建体包括具有连接到轻链的n-末端的IL-4表位结合结构域的IL-13抗体。本发明抗原结合构建体包括具有连接到重链的c-末端的IL-4表位结合结构域的IL-13抗体。本发明抗原结合构建体包括具有连接到轻链的c-末端的IL-4表位结合结构域的IL-13抗体。所述抗原结合构建体还可具有一个或多个具有相同或不同的抗原特异性的另外的表位结合结构域,所述表位结合结构域连接到重链的c-末端和/或n-末端和/或轻链的c-末端和/或n-末端。
这样的抗原结合构建体的实例包括具有对IL-13有特异性的表位结合结构域(例如抗-IL-13 dAb,其连接到重链的c-末端或n-末端或轻链的c-末端或n-末端)的IL-4抗体,例如具有SEQ ID NO:48-53、SEQID NO:91、SEQ ID NO:92、SEQ ID NO:149、SEQ ID NO:150或SEQ IDNO:157-160中所述的重链序列和/或SEQ ID NO:54-59中所述的轻链序列的mAbdAb。
本发明抗原结合构建体包括具有连接到重链的n-末端的IL-13表位结合结构域的IL-4抗体。本发明抗原结合构建体包括具有连接到轻链的n-末端的IL-13表位结合结构域的IL-4抗体。本发明抗原结合构建体包括具有连接到重链的c-末端的IL-13表位结合结构域的IL-4抗体。本发明抗原结合构建体包括具有连接到轻链的c-末端的IL-13表位结合结构域的IL-4抗体。所述抗原结合构建体还可具有一个或多个具有相同或不同的抗原特异性的另外的表位结合结构域,所述表位结合结构域连接到重链的c-末端和/或n-末端和/或轻链的c-末端和/或n-末端。
所述抗原结合构建体的实例包括具有对IL-5有特异性的表位结合结构域(例如抗-IL-5 dAb,其连接到重链的c-末端或n-末端或轻链的c-末端或n-末端)的IL-13抗体。本发明抗原结合构建体包括具有连接到重链的n-末端的IL-5表位结合结构域的IL-13抗体。本发明抗原结合构建体包括具有连接到轻链的n-末端的IL-5表位结合结构域的IL-13抗体。本发明抗原结合构建体包括具有连接到重链的c-末端的IL-5表位结合结构域的IL-13抗体。本发明抗原结合构建体包括具有连接到轻链的c-末端的IL-5表位结合结构域的IL-13抗体。所述抗原结合构建体还可具有一个或多个具有相同或不同的抗原特异性的另外的表位结合结构域,所述表位结合结构域连接到重链的c-末端和/或n-末端和/或轻链的c-末端和/或n-末端。
所述抗原结合构建体实例包括具有对IL-13有特异性的表位结合结构域(例如抗-IL-13 dAb,其连接到重链的c-末端或n-末端或轻链的c-末端或n-末端)的IL-5抗体,例如具有SEQ ID NO:72中所述的轻链序列的mAbdAb。
本发明抗原结合构建体包括具有连接到重链的n-末端的IL-13表位结合结构域的IL-5抗体。本发明抗原结合构建体包括具有连接到轻链的n-末端的IL-13表位结合结构域的IL-5抗体。本发明抗原结合构建体包括具有连接到重链的c-末端的IL-13表位结合结构域的IL-5抗体。本发明抗原结合构建体包括具有连接到轻链的c-末端的IL-13表位结合结构域的IL-5抗体。所述抗原结合构建体还可具有一个或多个具有相同或不同的抗原特异性的另外的表位结合结构域,所述表位结合结构域连接到重链的c-末端和/或n-末端和/或轻链的c-末端和/或n-末端。
所述抗原结合构建体实例包括具有对IL-5有特异性的表位结合结构域(例如抗-IL-5 dAb,其连接到重链的c-末端或n-末端或轻链的c-末端或n-末端)的IL-4抗体。本发明抗原结合构建体包括具有连接到重链的n-末端的IL-5表位结合结构域的IL-4抗体。本发明抗原结合构建体包括具有连接到轻链的n-末端的IL-5表位结合结构域的IL-4抗体。本发明抗原结合构建体包括具有连接到重链的c-末端的IL-5表位结合结构域的IL-4抗体。本发明抗原结合构建体包括具有连接到轻链的c-末端的IL-5表位结合结构域的IL-4抗体。所述抗原结合构建体还可具有一个或多个具有相同或不同的抗原特异性的另外的表位结合结构域,所述表位结合结构域连接到重链的c-末端和/或n-末端和/或轻链的c-末端和/或n-末端。
所述抗原结合构建体实例包括具有对IL-4有特异性的表位结合结构域(例如抗-IL-4 dAb,其连接到重链的c-末端或n-末端或轻链的c-末端或n-末端)的IL-5抗体,例如具有SEQ ID NO:71中所述的重链序列的mAbdAb。
本发明抗原结合构建体包括具有连接到重链的n-末端的IL-4表位结合结构域的IL-5抗体。本发明抗原结合构建体包括具有连接到轻链的n-末端的IL-4表位结合结构域的IL-5抗体。本发明抗原结合构建体包括具有连接到重链的c-末端的IL-4表位结合结构域的IL-5抗体。本发明抗原结合构建体包括具有连接到轻链的c-末端的IL-4表位结合结构域的IL-5抗体。所述抗原结合构建体还可具有一个或多个具有相同或不同的抗原特异性的另外的表位结合结构域,所述表位结合结构域连接到重链的c-末端和/或n-末端和/或轻链的c-末端和/或n-末端。
本发明还提供三特异性结合构建体,其能够结合IL-4、IL-13和IL-5。
所述抗原结合构建体的实例包括具有对IL-4有特异性的表位结合结构域(例如抗-IL-4 dAb,其连接到重链的c-末端或n-末端或轻链的c-末端或n-末端)和对IL-13有特异性的表位结合结构域(例如抗-IL-13 dAb,其连接到重链的c-末端或n-末端或轻链的c-末端或n-末端)的IL-5抗体。
本发明抗原结合构建体包括具有连接到重链的n-末端的IL-4表位结合结构域和连接到轻链的n-末端的IL-13表位结合结构域的IL-5抗体。
本发明抗原结合构建体包括具有连接到重链的n-末端的IL-4表位结合结构域和连接到轻链的c-末端的IL-13表位结合结构域的IL-5抗体。
本发明抗原结合构建体包括具有连接到重链的n-末端的IL-4表位结合结构域和连接到重链的c-末端的IL-13表位结合结构域的IL-5抗体。
本发明抗原结合构建体包括具有连接到轻链的n-末端的IL-4表位结合结构域和连接到轻链的c-末端的IL-13表位结合结构域的IL-5抗体。
本发明抗原结合构建体包括具有连接到轻链的n-末端的IL-4表位结合结构域和连接到重链的c-末端的IL-13表位结合结构域的IL-5抗体。
本发明抗原结合构建体包括具有连接到轻链的n-末端的IL-4表位结合结构域和连接到重链的n-末端的IL-13表位结合结构域的IL-5抗体。
本发明抗原结合构建体包括具有连接到重链的c-末端的IL-4表位结合结构域和连接到轻链的c-末端的IL-13表位结合结构域的IL-5抗体。
本发明抗原结合构建体包括具有连接到重链的c-末端的IL-4表位结合结构域和连接到轻链的n-末端的IL-13表位结合结构域的IL-5抗体。
本发明抗原结合构建体包括具有连接到重链的c-末端的IL-4表位结合结构域和连接到重链的n-末端的IL-13表位结合结构域的IL-5抗体。
本发明抗原结合构建体包括具有连接到轻链的c-末端的IL-4表位结合结构域和连接到重链的c-末端的IL-13表位结合结构域的IL-5抗体。
本发明抗原结合构建体包括具有连接到轻链的c-末端的IL-4表位结合结构域和连接到重链的n-末端的IL-13表位结合结构域的IL-5抗体。
本发明抗原结合构建体包括具有连接到轻链的c-末端的IL-4表位结合结构域和连接到轻链的n-末端的IL-13表位结合结构域的IL-5抗体。
所述抗原结合构建体还可具有一个或多个具有相同或不同的抗原特异性的另外的表位结合结构域,所述表位结合结构域连接到重链的c-末端和/或n-末端和/或轻链的c-末端和/或n-末端。
本发明抗原结合构建体包括对IL-18具有特异性的抗原结合构建体,例如包含能够结合IL-18的表位结合结构域的抗原结合构建体,或包含结合IL-18的配对的VH/VL的抗原结合构建体。
抗原结合构建体可包含能够结合IL-18的抗体。抗原结合构建体可包含能够结合IL-18的dAb。
本发明还提供能够结合IL-4、IL-13和IL-18的三特异性结合构建体。
所述抗原结合构建体实例包括具有对IL-4具有特异性的表位结合结构域(例如抗-IL-4 dAb,其连接到重链的c-末端或n-末端或轻链的c-末端或n-末端)和对IL-13具有特异性的表位结合结构域(例如抗-IL-13 dAb,其连接到重链的c-末端或n-末端或轻链的c-末端或n-末端)的IL-18抗体。
本发明抗原结合构建体包括具有连接到重链的n-末端的IL-4表位结合结构域和连接到轻链的n-末端的IL-13表位结合结构域的IL-18抗体。
本发明抗原结合构建体包括具有连接到重链的n-末端的IL-4表位结合结构域和连接到轻链的c-末端的IL-13表位结合结构域的IL-18抗体。
本发明抗原结合构建体包括具有连接到重链的n-末端的IL-4表位结合结构域和连接到重链的c-末端的IL-13表位结合结构域的IL-18抗体。
本发明抗原结合构建体包括具有连接到轻链的n-末端的IL-4表位结合结构域和连接到轻链的c-末端的IL-13表位结合结构域的IL-18抗体。
本发明抗原结合构建体包括具有连接到轻链的n-末端的IL-4表位结合结构域和连接到重链的c-末端的IL-13表位结合结构域的IL-18抗体。
本发明抗原结合构建体包括具有连接到轻链的n-末端的IL-4表位结合结构域和连接到重链的n-末端的IL-13表位结合结构域的IL-18抗体。
本发明抗原结合构建体包括具有连接到重链的c-末端的IL-4表位结合结构域和连接到轻链的c-末端的IL-13表位结合结构域的IL-18抗体。
本发明抗原结合构建体包括具有连接到重链的c-末端的IL-4表位结合结构域和连接到轻链的n-末端的IL-13表位结合结构域的IL-18抗体。
本发明抗原结合构建体包括具有连接到重链的c-末端的IL-4表位结合结构域和连接到重链的n-末端的IL-13表位结合结构域的IL-18抗体。
本发明抗原结合构建体包括具有连接到轻链的c-末端的IL-4表位结合结构域和连接到重链的c-末端的IL-13表位结合结构域的IL-18抗体。
本发明抗原结合构建体包括具有连接到轻链的c-末端的IL-4表位结合结构域和连接到重链的n-末端的IL-13表位结合结构域的IL-18抗体。
本发明抗原结合构建体包括具有连接到轻链的c-末端的IL-4表位结合结构域和连接到轻链的n-末端的IL-13表位结合结构域的IL-18抗体。
所述抗原结合构建体还可具有一个或多个具有相同或不同的抗原特异性的另外的表位结合结构域,所述表位结合结构域连接到重链的c-末端和/或n-末端和/或轻链的c-末端和/或n-末端。
本发明抗原结合构建体包括对TNFα具有特异性的抗原结合构建体,例如包含能够结合TNFα的表位结合结构域的抗原结合构建体,或包含结合TNFα的配对的VH/VL的抗原结合构建体。
抗原结合构建体可包含能够结合TNFα的抗体。抗原结合构建体可包含能够结合TNFα的dAb。
在一个实施方案中,本发明抗原结合构建体对不止一种抗原具有特异性,例如其中所述抗原结合构建体能够结合选自TNFα、EGFR和VEGF的两种或更多种抗原,例如其中所述抗原结合构建体能够结合TNFα和EGFR,或其中所述抗原结合构建体能够结合TNFα和VEGF,或其中所述抗原结合构建体能够结合EGFR和VEGF。所述抗原结合构建体实例包括具有对EGFR具有特异性的表位结合结构域(例如抗-EGFR dAb,其连接到重链的c-末端或n-末端或轻链的c-末端或n-末端)的TNFα抗体,例如具有SEQ ID NO:74中所述的重链序列和/或SEQ ID NO:79中所述的轻链序列的mAbdAb。
本发明抗原结合构建体包括具有连接到重链的n-末端的EGFR表位结合结构域的TNFα抗体。本发明抗原结合构建体包括具有连接到轻链的n-末端的EGFR表位结合结构域的TNFα抗体。本发明抗原结合构建体包括具有连接到重链的c-末端的EGFR表位结合结构域的TNFα抗体。本发明抗原结合构建体包括具有连接到轻链的c-末端的EGFR表位结合结构域的TNF抗体。所述抗原结合构建体还可具有一个或多个具有相同或不同的抗原特异性的另外的表位结合结构域,所述表位结合结构域连接到重链的c-末端和/或n-末端和/或轻链的c-末端和/或n-末端。
本发明抗原结合构建体包括具有连接到重链的n-末端的TNFα表位结合结构域的EGFR抗体。本发明抗原结合构建体包括具有连接到轻链的n-末端的TNFα表位结合结构域的EGFR抗体。本发明抗原结合构建体包括具有连接到重链的c-末端的TNFα表位结合结构域的EGFR抗体。本发明抗原结合构建体包括具有连接到轻链的c-末端的TNFα表位结合结构域的EGFR抗体。所述抗原结合构建体还可具有一个或多个具有相同或不同的抗原特异性的另外的表位结合结构域,所述表位结合结构域连接到重链的c-末端和/或n-末端和/或轻链的c-末端和/或n-末端。
所述抗原结合构建体实例包括具有对VEGF具有特异性的表位结合结构域例如抗-VEGF dAb,其连接到重链的c-末端或n-末端或轻链的c-末端或n-末端)的TNFα抗体,例如具有SEQ ID NO:75、78或185中所述的重链序列的mAbdAb。
本发明抗原结合构建体可对不止一种抗原具有特异性,例如其中所述抗原结合构建体能够结合TNFα及选自IL-4和IL-13的一种或两种抗原,例如其中所述抗原结合构建体能够结合TNFα和IL-4,或其中所述抗原结合构建体能够结合TNFα和IL-13,或其中所述抗原结合构建体能够结合TNFα和IL-13和IL-4。所述抗原结合构建体实例包括具有对TNFα具有特异性的表位结合结构域(例如抗-TNFα adnectin,其连接到重链的c-末端或n-末端或轻链的c-末端或n-末端)的IL-13抗体,例如具有SEQ ID NO:134或135中所述的重链序列的mAbdAb。所述抗原结合构建体其它实例包括具有对TNFα具有特异性的表位结合结构域(例如抗-TNFα adnectin,其连接到重链的c-末端或n-末端或轻链的c-末端或n-末端)的IL-4抗体,例如具有SEQ ID NO:146或147中所述的重链序列的mAbdAb。
本发明抗原结合构建体包括具有连接到重链的n-末端的VEGF表位结合结构域的TNFα抗体。本发明抗原结合构建体包括具有连接到轻链的n-末端的VEGF表位结合结构域的TNFα抗体。本发明抗原结合构建体包括具有连接到重链的c-末端的VEGF表位结合结构域的TNFα抗体。本发明抗原结合构建体包括具有连接到轻链的c-末端的VEGF表位结合结构域的TNFα抗体。所述抗原结合构建体还可具有一个或多个具有相同或不同的抗原特异性的另外的表位结合结构域,所述表位结合结构域连接到重链的c-末端和/或n-末端和/或轻链的c-末端和/或n-末端。
本发明抗原结合构建体包括具有连接到重链的n-末端的TNFα表位结合结构域的VEGF抗体。本发明抗原结合构建体包括具有连接到轻链的n-末端的TNFα表位结合结构域的VEGF抗体。本发明抗原结合构建体包括具有连接到重链的c-末端的TNFα表位结合结构域的VEGF抗体。本发明抗原结合构建体包括具有连接到轻链的c-末端的TNFα表位结合结构域的VEGF抗体。所述抗原结合构建体还可具有一个或多个具有相同或不同的抗原特异性的另外的表位结合结构域,所述表位结合结构域连接到重链的c-末端和/或n-末端和/或轻链的c-末端和/或n-末端。
本发明抗原结合构建体包括对CD-20具有特异性的抗原结合构建体,例如包含能够结合CD-20的表位结合结构域的抗原结合构建体,或包含结合CD-20的配对的VH/VL的抗原结合构建体。
抗原结合构建体可包含能够结合CD-20的抗体,例如,其可包含具有SEQ ID NO:120和117的重链和轻链序列的抗体。抗原结合构建体可包含能够结合CD-20的dAb。对CD-20具有特异性的mAbdAb的实例为具有SEQ ID NO:116,118中所述的重链序列的mAbdAb,或具有SEQ ID NO:119或121中所述的轻链序列的mAbdAb。
所述抗原结合构建体还可具有一个或多个具有相同或不同的抗原特异性的另外的表位结合结构域,所述表位结合结构域连接到重链的c-末端和/或n-末端和/或轻链的c-末端和/或n-末端。
本发明抗原结合构建体包括对IL1R1具有特异性的抗原结合构建体,例如包含能够结合IL1R1的表位结合结构域的抗原结合构建体,或包含结合IL1R1的配对的VH/VL的抗原结合构建体。
抗原结合构建体可包含能够结合IL1R1的抗体。抗原结合构建体可包含能够结合IL1R1的dAb。
在一个实施方案中,本发明抗原结合构建体对不止一种抗原具有特异性,例如其中所述抗原结合构建体能够结合IL1R1和第二种抗原,例如其中所述抗原结合构建体能够结合IL1R1和VEGF。所述抗原结合构建体实例包括具有对VEGF具有特异性的表位结合结构域(例如抗-VEGF dAb,其连接到重链的c-末端或n-末端或轻链的c-末端或n-末端)的IL1R1抗体,例如具有SEQ ID NO:77中所述的轻链序列的mAbdAb。
本发明抗原结合构建体包括具有连接到重链的n-末端的VEGF表位结合结构域的IL1R1抗体。本发明抗原结合构建体包括具有连接到轻链的n-末端的VEGF表位结合结构域的IL1R1抗体。本发明抗原结合构建体包括具有连接到重链的c-末端的VEGF表位结合结构域的IL1R1抗体。本发明抗原结合构建体包括具有连接到轻链的c-末端的VEGF表位结合结构域的IL1R1抗体。所述抗原结合构建体还可具有一个或多个具有相同或不同的抗原特异性的另外的表位结合结构域,所述表位结合结构域连接到重链的c-末端和/或n-末端和/或轻链的c-末端和/或n-末端。
本发明抗原结合构建体包括具有连接到重链的n-末端的IL1R1表位结合结构域的VEGF抗体。本发明抗原结合构建体包括具有连接到轻链的n-末端的IL1R1表位结合结构域的VEGF抗体。本发明抗原结合构建体包括具有连接到重链的c-末端的IL1R1表位结合结构域的VEGF抗体。本发明抗原结合构建体包括具有连接到轻链的c-末端的IL1R1表位结合结构域的VEGF抗体。所述抗原结合构建体还可具有一个或多个具有相同或不同的抗原特异性的另外的表位结合结构域,所述表位结合结构域连接到重链的c-末端和/或n-末端和/或轻链的c-末端和/或n-末端。
本发明抗原结合构建体包括对EGFR具有特异性的抗原结合构建体,例如所述抗原结合构建体包含能够结合EGFR的表位结合结构域,或包含结合EGFR的配对的VH/VL。
抗原结合构建体可包含能够结合EGFR的抗体。抗原结合构建体可包含能够结合EGFR的dAb。所述抗原结合构建体某些实例将能够结合包含SEQ ID NO:103的EGFR上的表位,例如,包含SEQ ID NO:97-SEQ ID NO:102和SEQ ID NO:104-SEQ ID NO:107中所述的CDR中的一个或多个的抗原结合构建体。
在一个实施方案中,本发明抗原结合构建体对不止一种抗原具有特异性,例如其中所述抗原结合构建体能够结合选自EGFR、IGF-1R、VEGFR2和VEGF的两个或多个抗原,例如其中所述抗原结合构建体能够结合EGFR和IGF-1R,或其中所述抗原结合构建体能够结合EGFR和VEGF,或其中所述抗原结合构建体能够结合VEGF和IGF-1R,或其中所述抗原结合构建体能够结合EGFR和VEGFR2,或其中所述抗原结合构建体能够结合IGF-1R和VEGFR2,或其中所述抗原结合构建体能够结合VEGF和VEGFR2,或其中所述抗原结合构建体能够结合EGFR、IGF-1R和VEGFR2,或其中所述抗原结合构建体能够结合VEGF、IGF-1R和VEGFR2,或其中所述抗原结合构建体能够结合EGFR、VEGF和VEGFR2,或其中所述抗原结合构建体能够结合EGFR、VEGF和IGF1R。所述抗原结合构建体实例包括具有对VEGFR2具有特异性的表位结合结构域(例如抗-VEGFR2 adnectin,其连接到重链的c-末端或n-末端或轻链的c-末端或n-末端)的EGFR抗体,例如具有SEQ ID NO:136、140或144中所述的重链序列和/或SEQ ID NO:138、142或145中所述的轻链序列的mAbdAb。
所述抗原结合构建体实例包括具有对VEGF具有特异性的表位结合结构域(例如抗-VEGF dAb,其连接到重链的c-末端或n-末端或轻链的c-末端或n-末端)的EGFR抗体,例如具有SEQ ID NO:165、174、176、178、184或186中所述的重链序列和/或SEQ ID NO:188或190中所述的轻链序列的mAbdAb。
所述抗原结合构建体实例包括具有对EGFR具有特异性的表位结合结构域(例如抗-EGFR dAb,其连接到重链的c-末端或n-末端或轻链的c-末端或n-末端)的VEGF抗体,例如具有SEQ ID NO:180中所述的重链序列的mAbdAb。所述mAbdAb还可包含SEQ ID NO:182中所述的轻链序列。
所述抗原结合构建体实例包括具有对VEGF具有特异性的表位结合结构域(例如抗-VEGF脂质运载蛋白,其连接到重链的c-末端或n-末端或轻链的c-末端或n-末端)的IGF-1R抗体,例如具有SEQ ID NO:123或125中所述的重链序列的mAbdAb。所述mAbdAb还可包含SEQID NO:113中所述的轻链序列。
所述抗原结合构建体实例包括具有对VEGFR2具有特异性的表位结合结构域(例如抗-VEGFR2 adnectin,其连接到重链的c-末端或n-末端或轻链的c-末端或n-末端)的IGF-1R抗体,例如具有SEQ ID NO:124或133中所述的重链序列的mAbdAb。所述mAbdAb还可包含SEQID NO:113中所述的轻链序列。
本发明抗原结合构建体包括对IL-23具有特异性的抗原结合构建体,例如包含能够结合IL-23的表位结合结构域的抗原结合构建体,或包含结合IL-23的配对的VH/VL的抗原结合构建体。
抗原结合构建体可包含能够结合IL-23的抗体。抗原结合构建体可包含能够结合IL-23的dAb。
在一个实施方案中,本发明抗原结合构建体对不止一种抗原具有特异性,例如其中所述抗原结合构建体能够结合选自TH17型细胞因子(例如IL-17、IL-22或IL-21)的两种或更多种抗原,例如其中所述抗原结合构建体能够结合IL-23和IL-17,或其中所述抗原结合构建体能够结合IL-23和IL-21,或其中所述抗原结合构建体能够结合IL-23和IL-22。所述抗原结合构建体实例包括具有对IL-17具有特异性的表位结合结构域(例如抗-IL-17 dAb,其连接到重链的c-末端或n-末端或轻链的c-末端或n-末端)的IL-23抗体。
本发明抗原结合构建体包括对PDGFRα具有特异性的抗原结合构建体,例如,包含能够结合PDGFRα的表位结合结构域的抗原结合构建体,或包含结合PDGFRα的配对的VH/VL的抗原结合构建体。抗原结合构建体可包含能够结合PDGFRα的抗体。抗原结合构建体可包含能够结合PDGFRα的dAb。
本发明抗原结合构建体包括对FGFR1具有特异性的抗原结合构建体,例如,包含能够结合FGFR1的表位结合结构域的抗原结合构建体,或包含结合FGFR1的配对的VH/VL的抗原结合构建体。抗原结合构建体可包含能够结合FGFR1的抗体。抗原结合构建体可包含能够结合FGFR1的dAb。
本发明抗原结合构建体包括对FGFR3具有特异性的抗原结合构建体,例如,包含能够结合FGFR3的表位结合结构域的抗原结合构建体,或包含结合FGFR3的配对的VH/VL的抗原结合构建体。抗原结合构建体可包含能够结合FGFR3的抗体。抗原结合构建体可包含能够结合FGFR3的dAb。
本发明抗原结合构建体包括对VEGFR2具有特异性的抗原结合构建体,例如,包含能够结合VEGFR2的表位结合结构域的抗原结合构建体,或包含结合VEGFR2的配对的VH/VL的抗原结合构建体。
抗原结合构建体可包含能够结合VEGFR2的抗体。抗原结合构建体可包含能够结合VEGFR2的dAb。
本发明抗原结合构建体包括对VEGFR3具有特异性的抗原结合构建体,例如,包含能够结合VEGFR3的表位结合结构域的抗原结合构建体,或包含结合VEGFR3的配对的VH/VL的抗原结合构建体。
抗原结合构建体可包含能够结合VEGFR3的抗体。抗原结合构建体可包含能够结合VEGFR3的dAb。
本发明抗原结合构建体包括对VE钙黏着蛋白(cadherin)具有特异性的抗原结合构建体,例如,包含能够结合VE钙黏着蛋白的表位结合结构域的抗原结合构建体,或包含结合VE钙黏着蛋白的配对的VH/VL的抗原结合构建体。
抗原结合构建体可包含能够结合VE钙黏着蛋白的抗体。抗原结合构建体可包含能够结合VE钙黏着蛋白的dAb。
本发明抗原结合构建体包括对神经毡蛋白(neuropilin)具有特异性的抗原结合构建体,例如,包含能够结合神经毡蛋白的表位结合结构域的抗原结合构建体,或包含结合神经毡蛋白的配对的VH/VL的抗原结合构建体。
抗原结合构建体可包含能够结合神经毡蛋白的抗体。抗原结合构建体可包含能够结合神经毡蛋白的dAb。
本发明抗原结合构建体包括对Flt-3具有特异性的抗原结合构建体,例如,包含能够结合Flt-3的表位结合结构域的抗原结合构建体,或包含结合Flt-3的配对的VH/VL的抗原结合构建体。
抗原结合构建体可包含能够结合Flt-3的抗体。抗原结合构建体可包含能够结合Flt-3的dAb。
本发明抗原结合构建体包括对ron具有特异性的抗原结合构建体,例如,包含能够结合ron的表位结合结构域的抗原结合构建体,或包含结合ron的配对的VH/VL的抗原结合构建体。
抗原结合构建体可包含能够结合ron的抗体。抗原结合构建体可包含能够结合ron的dAb。
本发明抗原结合构建体包括对Trp-1具有特异性的抗原结合构建体,例如,包含能够结合Trp-1的表位结合结构域的抗原结合构建体,或包含结合Trp-1的配对的VH/VL的抗原结合构建体。
抗原结合构建体可包含能够结合Trp-1的抗体。抗原结合构建体可包含能够结合Trp-1的dAb。
在一个实施方案中,本发明抗原结合构建体对不止一种抗原具有特异性,例如其中所述抗原结合构建体能够结合牵涉癌症的两种或更多种抗原,例如其中所述抗原结合构建体能够结合选自以下的两种或更多种抗原:PDGFRα、FGFR1、FGFR3、VEGFR2、VEGFR3、IGF1R、EGFR和VEGF、VE钙黏着蛋白、神经毡蛋白、Flt-3、ron、Trp-1、CD-20,例如其中所述抗原结合构建体能够结合PDGFRα和FGFR1,或其中所述抗原结合构建体能够结合PDGFRα和VEGF,或其中所述抗原结合构建体能够结合PDGFRα和FGFR3,或其中所述抗原结合构建体能够结合PDGFRα和VEGFR2,或其中所述抗原结合构建体能够结合PDGFRα和VEGFR3,或其中所述抗原结合构建体能够结合PDGFRα和IGF1R,或其中所述抗原结合构建体能够结合PDGFRα和EGFR,或其中所述抗原结合构建体能够结合PDGFRα和VEGF,或其中所述抗原结合构建体能够结合PDGFRα和VE钙黏着蛋白,或其中所述抗原结合构建体能够结合PDGFRα和神经毡蛋白,或其中所述抗原结合构建体能够结合PDGFRα和Flt-3,或其中所述抗原结合构建体能够结合PDGFRα和ron,或其中所述抗原结合构建体能够结合PDGFRα和Trp1,或其中所述抗原结合构建体能够结合PDGFRα和CD-20,或其中所述抗原结合构建体能够结合FGFR1和FGFR3,或其中所述抗原结合构建体能够结合FGFR1和VEGFR2,或其中所述抗原结合构建体能够结合FGFR1和VEGR3,或其中所述抗原结合构建体能够结合FGFR1和IGF1R,或其中所述抗原结合构建体能够结合FGFR1和EGFR,或其中所述抗原结合构建体能够结合FGFR1和VEGF,或其中所述抗原结合构建体能够结合FGFR1和VE钙黏着蛋白,或其中所述抗原结合构建体能够结合FGFR1和神经毡蛋白,或其中所述抗原结合构建体能够结合FGFR1和Flt-3,或其中所述抗原结合构建体能够结合FGFR1和ron,或其中所述抗原结合构建体能够结合FGFR1和Trp-1,或其中所述抗原结合构建体能够结合FGFR1和CD-20,或其中所述抗原结合构建体能够结合FGFR3和VEGFR2,或其中所述抗原结合构建体能够结合FGFR3和VEGFR3,或其中所述抗原结合构建体能够结合FGFR3和IGF1R,或其中所述抗原结合构建体能够结合FGFR3和EGFR,或其中所述抗原结合构建体能够结合FGFR3和VEGF,或其中所述抗原结合构建体能够结合FGFR3和VE钙黏着蛋白,或其中所述抗原结合构建体能够结合FGFR3和神经毡蛋白,或其中所述抗原结合构建体能够结合FGFR3和Flt-3,或其中所述抗原结合构建体能够结合FGFR3和ron,或其中所述抗原结合构建体能够结合FGFR3和Trp-1,或其中所述抗原结合构建体能够结合FGFR3和CD-20,或其中所述抗原结合构建体能够结合VEGFR2和VEGFR3,或其中所述抗原结合构建体能够结合VEGFR2和IGF1R,或其中所述抗原结合构建体能够结合VEGFR2和EGFR,或其中所述抗原结合构建体能够结合VEGFR2和VEGF,或其中所述抗原结合构建体能够结合VEGFR2和VE钙黏着蛋白,或其中所述抗原结合构建体能够结合VEGFR2和神经毡蛋白,或其中所述抗原结合构建体能够结合VEGFR2和Flt-3,或其中所述抗原结合构建体能够结合VEGFR2和ron,或其中所述抗原结合构建体能够结合VEGFR2和Trp-1,或其中所述抗原结合构建体能够结合VEGFR2和CD-20,或其中所述抗原结合构建体能够结合VEGFR3和IGF-1R,或其中所述抗原结合构建体能够结合VEGFR3和EGFR,或其中所述抗原结合构建体能够结合VEGFR3和VEGF,或其中所述抗原结合构建体能够结合VEGFR3和VE钙黏着蛋白,或其中所述抗原结合构建体能够结合VEGFR3和神经毡蛋白,或其中所述抗原结合构建体能够结合VEGFR3和Flt-3,或其中所述抗原结合构建体能够结合VEGFR3和Trp-1,或其中所述抗原结合构建体能够结合VEGFR3和CD-20,或其中所述抗原结合构建体能够结合IGF1R和EGFR,或其中所述抗原结合构建体能够结合IGF1R和VEGF,或其中所述抗原结合构建体能够结合IGF1R和VE钙黏着蛋白,或其中所述抗原结合构建体能够结合IGF1R和神经毡蛋白,或其中所述抗原结合构建体能够结合IGF1R和Flt-3,或其中所述抗原结合构建体能够结合IGF1R和ron,或其中所述抗原结合构建体能够结合IGF1R和Trp-1,或其中所述抗原结合构建体能够结合IGF1R和CD-20,或其中所述抗原结合构建体能够结合EGFR和VEGF,或其中所述抗原结合构建体能够结合EGFR和VE钙黏着蛋白,或其中所述抗原结合构建体能够结合EGFR和神经毡蛋白,或其中所述抗原结合构建体能够结合EGFR和Flt-3,或其中所述抗原结合构建体能够结合EGFR和ron,或其中所述抗原结合构建体能够结合EGFR和Trp-1,或其中所述抗原结合构建体能够结合EGFR和CD-20,或其中所述抗原结合构建体能够结合VEGF和VE钙黏着蛋白,或其中所述抗原结合构建体能够结合VEGF和神经毡蛋白,或其中所述抗原结合构建体能够结合VEGF和Flt-3,或其中所述抗原结合构建体能够结合VEGF和ron,或其中所述抗原结合构建体能够结合VEGF和Trp-1,或其中所述抗原结合构建体能够结合VEGF和CD-20,或其中所述抗原结合构建体能够结合VE钙黏着蛋白和神经毡蛋白,或其中所述抗原结合构建体能够结合VE钙黏着蛋白和Flt-3,或其中所述抗原结合构建体能够结合VE钙黏着蛋白和ron,或其中所述抗原结合构建体能够结合VE钙黏着蛋白和Trp-1,或其中所述抗原结合构建体能够结合VE钙黏着蛋白和CD-20,或其中所述抗原结合构建体能够结合神经毡蛋白和Flt-3,或其中所述抗原结合构建体能够结合神经毡蛋白和ron,或其中所述抗原结合构建体能够结合神经毡蛋白和Trp-1,或其中所述抗原结合构建体能够结合神经毡蛋白和CD-20,或其中所述抗原结合构建体能够结合Flt-3和ron,或其中所述抗原结合构建体能够结合Flt-3和Trp-1,或其中所述抗原结合构建体能够结合Flt-3和CD-20,或其中所述抗原结合构建体能够结合ron和Trp-1,或其中所述抗原结合构建体能够结合ron和CD-20,或其中所述抗原结合构建体能够结合Trp-1和CD-20。
所述抗原结合构建体还可具有一个或多个具有相同或不同的抗原特异性的另外的表位结合结构域,所述表位结合结构域连接到重链的c-末端和/或n-末端和/或轻链的c-末端和/或n-末端。
本发明抗原结合构建体包括对β淀粉状蛋白具有特异性的抗原结合构建体,例如,包含能够结合β淀粉状蛋白的表位结合结构域的抗原结合构建体,或包含结合β淀粉状蛋白的配对的VH/VL的抗原结合构建体。
抗原结合构建体可包含能够结合β淀粉状蛋白的抗体。抗原结合构建体可包含能够结合β淀粉状蛋白的dAb。
本发明抗原结合构建体包括对CD-3具有特异性的抗原结合构建体,例如,包含能够结合CD-3的表位结合结构域的抗原结合构建体,或包含结合CD-3的配对的VH/VL的抗原结合构建体。
抗原结合构建体可包含能够结合CD-3的抗体。抗原结合构建体可包含能够结合CD-3的dAb。
本发明抗原结合构建体包括对gpIIIb/IIa具有特异性的抗原结合构建体,例如,包含能够结合gpIIIb/IIa的表位结合结构域的抗原结合构建体,或包含结合gpIIIb/IIa的配对的VH/VL的抗原结合构建体。
抗原结合构建体可包含能够结合gpIIIb/IIa的抗体。抗原结合构建体可包含能够结合gpIIIb/IIa的dAb。
本发明抗原结合构建体包括对TGFβ具有特异性的抗原结合构建体,例如,包含能够结合TGFβ的表位结合结构域的抗原结合构建体,或包含结合TGFβ的配对的VH/VL的抗原结合构建体。
抗原结合构建体可包含能够结合TGFβ的抗体。抗原结合构建体可包含能够结合TGFβ的dAb。
在本发明一个实施方案中,提供本文所述的本发明抗原结合构建体,其包含致使抗体具有降低的ADCC和/或补体激活或效应器功能的恒定区。在一个所述实施方案中,重链恒定区可包含IgG2或IgG4同种型的天然丧失能力的恒定区或突变的IgG1恒定区。合适修饰的实例阐述于EP0307434中。一个实例包括在235和237(EU索引编号)位的丙氨酸残基的取代。
在一个实施方案中,本发明抗原结合构建体将保留Fc功能性,例如能够具有ADCC和CDC活性之一或二者。所述抗原结合构建体可包含位于轻链(例如在轻链c-末端)上的表位结合结构域。
本发明还提供通过在抗体轻链上配置表位结合结构域,尤其是通过在轻链c-末端配置表位结合结构域,来保持抗原结合构建体的ADCC和CDC功能的方法。所述ADCC和CDC功能可通过任何合适的测定法来测量,例如实施例15.3中所述的ADCC测定法和实施例15.4中所述的CDC测定法。
本发明还提供通过在抗体重链上配置表位结合结构域,尤其是通过在重链c-末端配置表位结合结构域,来降低抗原结合构建体的CDC功能的方法。所述CDC功能可通过任何合适的测定法来测量,例如实施例15.4中所述的CDC测定法。
在另一实施方案中,本发明抗原结合构建体能够结合选自VEGF、IGF-1R和EGFR的两种或更多种抗原,例如,其能够结合EGFR和VEGF、或EGFR和IGF1R、或IGF1R和VEGF,或例如其能够结合TNF和IL1-R。在包含IGF-1R结合位点的本发明实施方案中,本发明抗原结合构建体的IGF-1R结合位点可包含在蛋白质骨架中的配对的VH/VL结构域,所述配对的VH/VL结构域可包含选自以下的序列中所述的CDR中的一个或多个:SEQ ID NO:80、SEQ ID NO:81、SEQID NO:82、SEQ ID NO:83、SEQ ID NO:84、SEQ ID NO:85和SEQ IDNO:86,例如,其可包含至少SEQ ID NO:80中所述的CDRH3,例如,其可包含SEQ ID NO:80、SEQ ID NO:81、SEQ ID NO:82、SEQ ID NO:83、SEQ ID NO:85和SEQ ID NO:86中所述的所有CDR。
在包含EGFR结合位点的本发明实施方案中,本发明抗原结合构建体可结合包含成熟或正常或野生型EGFR序列的第273-501位残基的表位,例如,其可结合包含成熟或正常或野生型EGFR的第287-302位残基(SEQ ID NO:103)的表位。
在一个实施方案中,本发明抗原结合构建体的EGFR结合位点可包含在蛋白质骨架中的配对的VH/VL结构域,所述配对的VH/VL结构域可包含选自以下序列中所述的CDR中的一个或多个:SEQ ID NO:104、SEQ ID NO:105、SEQ ID NO:106、SEQ ID NO:100、SEQ ID NO:101和SEQ ID NO:102,例如,其可包含SEQ ID NO:106中所述的CDRH3,或其可包含SEQ ID NO:104、SEQ ID NO:105、SEQ ID NO:106、SEQ ID NO:100、SEQ ID NO:101和SEQ ID NO:102中所述的所有6个CDR。所述配对的VH/VL结构域可进一步包含另外的残基,尤其是在重链CDR中,在一个实施方案中,CDRH1可包含SEQ ID NO:104加上至多5个另外的残基,例如,SEQ ID NO:97中所述的5个另外的残基中的一个或多个,CDRH2可包含SEQ ID NO:105加上至多2个另外的残基,例如SEQ ID NO:98和SEQ ID NO:107中所述的2个另外的残基中的一个或两个,而CDRH3可包含SEQ ID NO:106加上至多2个另外的残基,例如SEQ ID NO:99中所述的2个另外的残基中的一个或两个。在一个实施方案中,配对的VH/VL包含以下序列中所述的CDR中的一个或多个:SEQ ID NO:97、SEQ ID NO:98、SEQ ID NO:99、SEQ ID NO:100、SEQ ID NO:101和SEQ ID NO:102,例如,其可包含至少SEQ ID NO:99中所述的CDRH3,例如,其可包含SEQ ID NO:97、SEQ ID NO:98、SEQ ID NO:99、SEQ ID NO:100,SEQ ID NO:101和SEQ ID NO:102中所述的所有6个CDR(合适的抗体的更详细的资料可在WO02/092771和WO2005/081854中找到)。
在一个实施方案中,抗原结合构建体包含作为结构域抗体(dAb)的表位结合结构域,例如所述表位结合结构域可为人VH或人VL、或骆驼VHH或鲨鱼dAb(NARV)。
在一个实施方案中,抗原结合构建体包含作为选自以下的骨架衍生物的表位结合结构域:CTLA-4(Evibody);脂质运载蛋白;诸如蛋白A的Z-结构域等来源于蛋白A的分子(Affibody,SpA)、A-结构域(Avimer/Maxibody);热休克蛋白,例如GroEl和GroES;转铁蛋白(trans-body);锚蛋白重复蛋白(DARPin);肽适体;C-型凝集素结构域(四连凝集素);人γ-晶体蛋白和人泛素(affilin);PDZ结构域;人蛋白酶抑制剂蝎毒素kunitz型结构域;和纤连蛋白(adnectin);对它们都进行蛋白质工程改造以便实现与不同于天然配体的配体结合。
本发明抗原结合构建体可包含连接到表位结合结构域adnectin的蛋白质骨架,例如含连接到重链c-末端的adnectin的IgG骨架;或其可包含连接到adnectin的蛋白质骨架,例如含连接到重链n-末端的adnectin的IgG骨架;或其可包含连接到adnectin的蛋白质骨架,例如含连接到轻链c-末端的adnectin的IgG骨架;或其可包含连接到adnectin的蛋白质骨架,例如含连接到轻链n-末端的adnectin的IgG骨架。
在其它实施方案中,其可包含蛋白质骨架,例如连接到表位结合结构域CTLA-4的IgG骨架,例如含连接到重链n-末端的CTLA-4的IgG骨架;或其可包含例如含连接到重链c-末端的CTLA-4的IgG骨架;或其可包含例如含连接到轻链n-末端的CTLA-4的IgG骨架;或其可包含含连接到轻链c-末端的CTLA-4的IgG骨架。
在其它实施方案中,其可包含蛋白质骨架,例如连接到表位结合结构域脂质运载蛋白的IgG骨架,例如含连接到重链n-末端的脂质运载蛋白的IgG骨架;或其可包含例如含连接到重链c-末端的脂质运载蛋白的IgG骨架;或其可包含例如含连接到轻链n-末端的脂质运载蛋白的IgG骨架;或其可包含含连接到轻链c-末端的脂质运载蛋白的IgG骨架。
在其它实施方案中,其可包含蛋白质骨架,例如连接到表位结合结构域SpA的IgG骨架,例如含连接到重链n-末端的SpA的IgG骨架;或其可包含例如含连接到重链c-末端的SpA的IgG骨架;或其可包含例如含连接到轻链n-末端的SpA的IgG骨架;或其可包含含连接到轻链c-末端的SpA的IgG骨架。
在其它实施方案中,其可包含蛋白质骨架,例如连接到表位结合结构域affibody的IgG骨架,例如含连接到重链n-末端的affibody的IgG骨架;或其可包含例如含连接到重链c-末端的affibody的IgG骨架;或其可包含例如含连接到轻链n-末端的affibody的IgG骨架;或其可包含含连接到轻链c-末端的affibody的IgG骨架。
在其它实施方案中,其可包含蛋白质骨架,例如连接到表位结合结构域affimer的IgG骨架,例如含连接到重链n-末端的affimer的IgG骨架;或其可包含例如含连接到重链c-末端的affimer的IgG骨架;或其可包含例如含连接到轻链n-末端的affimer的IgG骨架;或其可包含含连接到轻链c-末端的affimer的IgG骨架。
在其它实施方案中,其可包含蛋白质骨架,例如连接到表位结合结构域GroEI的IgG骨架,例如含连接到重链n-末端的GroEI的IgG骨架;或其可包含例如含连接到重链c-末端的GroEI的IgG骨架;或其可包含例如含连接到轻链n-末端的GroEI的IgG骨架;或其可包含含连接到轻链c-末端的GroEI的IgG骨架。
在其它实施方案中,其可包含蛋白质骨架,例如连接到表位结合结构域转铁蛋白的IgG骨架,例如含连接到重链的n-末端的转铁蛋白的IgG骨架;或其可包含例如具有连接到重链c-末端的转铁蛋白的IgG骨架;或其可包含例如含连接到轻链n-末端的转铁蛋白的IgG骨架;或其可包含含连接到轻链c-末端的转铁蛋白的IgG骨架。
在其它实施方案中,其可包含蛋白质骨架,例如连接到表位结合结构域GroES的IgG骨架,例如含连接到重链的n-末端的GroES的IgG骨架;或其可包含例如具有连接到重链c-末端的GroES的IgG骨架;或其可包含例如含连接到轻链n-末端的GroES的IgG骨架;或其可包含含连接到轻链c-末端的GroES的IgG骨架。
在其它实施方案中,其可包含蛋白质骨架,例如连接到表位结合结构域DARPin的IgG骨架,例如含连接到重链n-末端的DARPin的IgG骨架;或其可包含例如含连接到重链c-末端的DARPin的IgG骨架;或其可包含例如含连接到轻链n-末端的DARPin的IgG骨架;或其可包含含连接到轻链c-末端的DARPin的IgG骨架。
在其它实施方案中,其可包含蛋白质骨架,例如连接到表位结合结构域肽适体的IgG骨架,例如含连接到重链n-末端的肽适体的IgG骨架;或其可包含例如含连接到重链c-末端的肽适体的IgG骨架;或其可包含例如含连接到轻链n-末端的肽适体的IgG骨架;或其可包含含连接到轻链c-末端的肽适体的IgG骨架。
在本发明一个实施方案中,有4个表位结合结构域,例如4结构域抗体,其中2个表位结合结构域可对相同抗原具有特异性,或存在于抗原结合构建体的所有表位结合结构域可对相同抗原具有特异性。
可通过用接头将本发明蛋白质骨架连接到表位结合结构域。合适的接头实例包括以下氨基酸序列:所述氨基酸序列长度可为1个氨基酸到150个氨基酸,或1个氨基酸到140个氨基酸,例如1个氨基酸-130个氨基酸,或1-120个氨基酸,或1-80个氨基酸,或1-50个氨基酸,或1-20个氨基酸,或1-10个氨基酸,或5-18个氨基酸。所述序列可具有其自己的三级结构,例如,本发明接头可包含单一可变结构域。在一个实施方案中,接头大小等同于单一可变结构域。合适的接头大小可为1-20埃,例如小于15埃或小于10埃或小于5埃。
在本发明一个实施方案中,用接头将至少一个表位结合结构域直接连接到Ig骨架,所述接头包含1-150个氨基酸,例如1-20个氨基酸,例如1-10个氨基酸。所述接头可选自以下接头中的任何一种:SEQID NO:6-11中所述的接头;‘STG’(丝氨酸、苏氨酸、甘氨酸);‘GSTG’或‘RS’;例如接头可为‘TVAAPS’,或接头可为‘GGGGS’。在本发明抗原结合构建体中使用的接头可单独包含或除包含其它接头外还包含一组或多组GS残基,例如‘GSTVAAPS’或‘TVAAPSGS’或‘GSTVAAPSGS’。在另一实施方案中,在表位结合结构域(例如dAb)与Ig骨架之间没有接头。在另一实施方案中,通过接头‘TVAAPS’将表位结合结构域(例如dAb)连接到Ig骨架。在另一实施方案中,通过接头‘TVAAPSGS’将表位结合结构域(例如dAb)连接到Ig骨架。在另一实施方案中,通过接头‘GS’将表位结合结构域(例如dAb)连接到Ig骨架。
在一个实施方案中,本发明抗原结合构建体包含能够结合人血清白蛋白的至少一个表位结合结构域。
在一个实施方案中,有至少3个抗原结合位点,例如有4或5或6或8或10个抗原结合位点,并且抗原结合构建体能够结合至少3或4或5或6或8或10个抗原,例如其能够同时结合3或4或5或6或8或10个抗原。
本发明还提供用于医学的抗原结合构建体,例如用于制备用于治疗癌症或诸如哮喘、风湿性关节炎或骨关节炎等炎性疾病的药物。
本发明提供治疗罹患癌症或诸如哮喘、风湿性关节炎或骨关节炎等炎性疾病的患者的方法,所述方法包括给予治疗量的本发明抗原结合构建体。
本发明抗原结合构建体可用于治疗癌症或诸如哮喘、风湿性关节炎或骨关节炎等炎性疾病。
例如若蛋白质骨架含有源自具有效应器功能的抗体的Fc区,例如若蛋白质骨架包含来自IgG1的CH2和CH3,则本发明抗原结合构建体可具有某些效应器功能。效应器功能的水平可根据已知技术而变化,例如通过CH2结构域突变,例如其中IgG1 CH2结构域在选自239和332和330的位点具有一个或多个突变,例如突变选自S239D和I332E和A330L,致使抗体效应器功能提高,和/或例如改变本发明抗原结合构建体的糖基化概况,致使Fc区的岩藻糖基化降低。
用于本发明的蛋白质骨架包括包含抗体所有结构域的完整单克隆抗体骨架,或本发明蛋白质骨架可包含非常规抗体结构,例如单价抗体。所述单价抗体可包含配对的重链和轻链,其中重链铰链区经过修饰致使重链不会同型二聚体化,例如阐述于WO2007059782中的单价抗体。其它单价抗体可包含配对的重链和轻链,它们与缺乏功能可变结构域和CH1区的第二条重链二聚体化,其中第一条和第二条重链经过修饰致使它们形成异型二聚体而不是同型二聚体,从而产生含两条重链和一条轻链的单价抗体,例如在WO2006015371中所述的单价抗体。所述单价抗体可提供表位结合结构域可连接的本发明蛋白质骨架,例如实施例32所述的抗原结合构建体。
用于本发明的表位结合结构域为独立于不同V区或结构域地特异性结合抗原或表位的结构域,其可为结构域抗体,或可为选自以下的骨架衍生物的结构域:CTLA-4(Evibody);脂质运载蛋白;源自蛋白A的分子,例如蛋白A的Z-结构域(Affibody,SpA)、A-结构域(Avimer/Maxibody);热休克蛋白,例如GroEl和GroES;转铁蛋白(trans-body);锚蛋白重复蛋白(DARPin);肽适体;C-型凝集素结构域(四连凝集素);人γ-晶体蛋白和人泛素(affilin);PDZ结构域;人蛋白酶抑制剂蝎毒素kunitz型结构域;和纤连蛋白(adnectin);它们已经过蛋白质工程改造以实现与不同于天然配体的配体结合。在一个实施方案中,它们可为结构域抗体或其它合适的结构域,例如选自以下的结构域:CTLA-4、脂质运载蛋白、SpA、Affibody、avimer、GroEl、转铁蛋白、GroES和纤连蛋白。在一个实施方案中,它们可选自dAb、Affibody、锚蛋白重复蛋白(DARPin)和adnectin。在另一实施方案中,它们可选自Affibody、锚蛋白重复蛋白(DARPin)和adnectin。在另一实施方案中,它们可为结构域抗体,例如选自人、骆驼或鲨鱼(NARV)结构域抗体的结构域抗体。
可在一个或多个位置将表位结合结构域连接到蛋白质骨架。这些位置包括蛋白质骨架的C-末端和N-末端,例如在IgG重链的C-末端和/或轻链的C-末端,或例如在IgG重链的N-末端和/或轻链的N-末端。
在一个实施方案中,将第一表位结合结构域连接到蛋白质骨架,将第二表位结合结构域连接到第一表位结合结构域,例如,其中所述蛋白质骨架为IgG骨架,可将第一表位结合结构域连接到IgG骨架重链的c-末端,并可将该表位结合结构域以其c-末端连接到第二表位结合结构域;或例如,可将表位结合结构域连接到IgG骨架轻链的c-末端,并可让该第一表位结合结构域进一步以其c-末端连接到第二表位结合结构域;或例如,可将第一表位结合结构域连接到IgG骨架轻链的n-末端,并可让所述第一表位结合结构域进一步以其n-末端连接到第二表位结合结构域;或例如,可将第一表位结合结构域连接到IgG骨架重链的n-末端,并可让该第一表位结合结构域进一步以其n-末端连接到第二表位结合结构域。所述抗原结合构建体实例阐述于实施例31中。
当表位结合结构域为结构域抗体时,某些结构域抗体可适于骨架内的特定位置。
用于本发明的结构域抗体可以在常规IgG重链和/或轻链的C-末端处连接。另外,可将某些dAb连接到常规抗体重链和轻链两者的C-末端。
在将dAb的N-末端融合到抗体恒定结构域(CH3或CL)的构建体中,肽接头可辅助dAb结合抗原。实际上,dAb的N-末端仅挨着涉及抗原结合活性的互补决定区(CDR)。因此,短肽接头在表位结合结构域与蛋白质骨架的恒定结构域之间起间隔物的作用,其可使得dAbCDR更易接触抗原,因此其可以以高亲和力结合。
dAb与IgG连接所处的环境将根据它们所融合的抗体链而不同:
当在IgG骨架的抗体轻链的C-末端处融合时,预期每一个dAb位于抗体铰链和Fc部分附近。很可能所述dAb彼此将离得较远。在常规抗体中,Fab片段之间的角度和每一个Fab片段与Fc部分之间的角度可显著不同。很可能的是,对于mAbdAb而言,Fab片段之间的角度将不会差异很大,同时对于每一Fab片段与Fc部分之间的角度可观察到某程度的角度限制。
当在IgG骨架的抗体重链的C-末端处融合时,预期每一dAb位于Fc部分的CH3结构域附近。预期这不会影响Fc对Fc受体(例如FcγRI、II、III、FcRn)的结合特性,因为这些受体结合(engage with)CH2结构域(对于FcγRI、II和III类受体而言)或结合CH2和CH3结构域之间的铰链(例如FcRn受体)。所述抗原结合构建体的另一特征为预期两个dAb在空间上彼此靠近,前提是由合适接头提供柔韧性,这些dAb甚至可形成同型二聚体,从而累增成(propagate)Fc部分的‘拉链式’四级结构,而这可因此提高构建体的稳定性。
这样的结构上的考虑可有助于选择使表位结合结构域例如dAb连接到蛋白质骨架例如抗体上的最合适的位置。
抗原大小、其位置(在血液中或在细胞表面上)、其四级结构(单体或多聚体结构)可变化。因存在铰链区,常规抗体无需特别设计就能作为衔接构建体(adaptor construct)起作用,其中在Fab片段的末端的两个抗原结合位点的方向可大幅度变化,因此能适应抗原的分子特性及其环境。相比之下,连接到抗体或其它蛋白质骨架(例如包含无铰链区抗体的蛋白质骨架)的dAb可能直接或间接地具有较小的结构柔韧性。
了解溶液状态和Ab的结合模式也是有帮助的。积累了很多体外dAb在溶液中可主要以单体、同型二聚体或多聚体形式存在的证据(Reiter等(1999)J Mol Biol 290第685-698页;Ewert等(2003)J MolBiol 325,第531-553页;Jespers等(2004)J Mol Biol 337第893-903页;Jespers等(2004)Nat Biotechnol 22第1161-1165页;Martin等(1997)Protein Eng.10第607-614页;Sepulvada等(2003)J Mol Biol 333第355-365页)。这很容易让人联想到体内观察到的Ig结构域的多聚体化事件,例如Bence-Jones蛋白(它们为免疫球蛋白轻链的二聚体(Epp等(1975)Biochemistry 14第4943-4952页;Huan等(1994)Biochemistry33第14848-14857页;Huang等(1997)Mol immunol 34第1291-1301页)和淀粉样纤维(James等(2007)J Mol Biol.367:603-8)。
例如,对于易于在溶液中二聚体化的结构域抗体,可能期需使其与Fc部分的C-末端连接优先于与轻链C-末端连接,因为与Fc的C-末端连接将使得那些dAb在本发明抗原结合构建体的情况下二聚体化。
本发明抗原结合构建体可包含对单一抗原具有特异性的抗原结合位点,或可具有对两种或更多种抗原具有特异性或对单一抗原上的两个或多个表位具有特异性的抗原结合位点,或可存在每一个都对相同或不同的抗原上的不同的表位有特异性的抗原结合位点。
抗原结合位点可各自对抗原具有结合特异性,所述抗原例如人或动物蛋白质,包括细胞因子、生长因子、细胞因子受体、生长因子受体、酶(例如蛋白酶)、酶的辅因子、DNA结合蛋白、脂质和糖类。包括细胞因子、生长因子、细胞因子受体、生长因子受体和其它蛋白质在内的合适的靶标包括但不限于:ApoE、Apo-SAA、BDNF、心肌营养蛋白-1、CEA、CD40、CD40配体、CD56、CD38、CD138、EGF、EGF受体、ENA-78、嗜伊红细胞趋化因子(Eotaxin)、嗜伊红细胞趋化因子-2、Exodus-2、FAPα、酸性FGF、碱性FGF、成纤维细胞生长因子-10、FLT3配体、CXXXC趋化分子(CX3C)、GDNF、G-CSF、GM-CSF、GF-β1、人血清白蛋白、胰岛素、IFN-γ、IGF-I、IGF-II、IL-1α、IL-1β、IL-1受体、IL-1受体1型、IL-2、IL-3、IL-4、IL-5、IL-6、IL-7、IL-8(72个氨基酸)、IL-8(77个氨基酸)、IL-9、IL-10、IL-11、IL-12、IL-13、IL-15、IL-16、IL-17、IL-18(IGIF)、抑制素α、抑制素β、IP-10、角质形成细胞生长因子-2(KGF-2)、KGF、瘦素、LIF、淋巴细胞趋化蛋白、穆勒氏抑制物(Mullerian inhibitory substance)、单核细胞集落抑制因子、单核细胞引诱蛋白(monocyte attractant protein)、M-CSF、c-fms、v-fmsMDC(67个氨基酸)、MDC(69个氨基酸)、MCP-1(MCAF)、MCP-2、MCP-3、MCP-4、MDC(67个氨基酸)、MDC(69个氨基酸)、MIG、MIP-1α、MIP-1β、MIP-3α、MIP-3β、MIP-4、骨髓祖细胞抑制因子-1(MPIF-1、)、NAP-2、神经营养因子(Neurturin)、神经生长因子、β-NGF、NT-3、NT-4、制瘤素M、PDGF-AA、PDGF-AB、PDGF-BB、PF-4、RANTES、SDF1α、SDF1β、SCF、SCGF、干细胞因子(SCF)、TARC、TGF-α、TGF-β、TGF-β2、TGF-β3、肿瘤坏死因子(TNF)、TNF-α、TNF-β、TNF受体I、TNF受体II、TNIL-1、TPO、VEGF、VEGF A、VEGF B、VEGF C、VEGF D、VEGF受体1、VEGF受体2、VEGF受体3、GCP-2、GRO/MGSA、GRO-β、GRO-γ、HCC1、1-309、HER 1、HER 2、HER 3、HER 4、血清白蛋白、vWF、淀粉状蛋白(例如淀粉状蛋白α)、MMP12、PDK1、IgE和本文公开的其它靶标。应该理解以上列举内容并不全面。
在某些实施方案中,蛋白酶抗性肽或多肽结合肺组织中的靶标,例如选自以下的靶标:TNFR1、IL-1、IL-1R、IL-4、IL-4R、IL-5、IL-6、IL-6R、IL-8、IL-8R、IL-9、IL-9R、IL-10、IL-12、IL-12R、IL-13、IL-13Rα1、IL-13Rα2、IL-15、IL-15R、IL-16、IL-17R、IL-17、IL-18、IL-18R、IL-23、IL-23R、IL-25、CD2、CD4、CD11a、CD23、CD25、CD27、CD28、CD30、CD40、CD40L、CD56、CD138、ALK5、EGFR、FcER1、TGFb、CCL2、CCL18、CEA、CR8、CTGF、CXCL12(SDF-1)、糜蛋白酶、FGF、弗林蛋白酶、内皮素-1、嗜伊红细胞趋化因子类(例如嗜伊红细胞趋化因子、嗜伊红细胞趋化因子-2、嗜伊红细胞趋化因子-3)、GM-CSF、ICAM-1、ICOS、IgE、IFNa、I-309、整联蛋白、L-选择蛋白、MIF、MIP4、MDC、MCP-1、MMP、中性粒细胞弹性蛋白酶、骨桥蛋白、OX-40、PARC、PD-1、RANTES、SCF、SDF-1、涎免凝集素8、TARC、TGFb、凝血酶、Tim-1、TNF、TRANCE、类胰蛋白酶、VEGF、VLA-4、VCAM、α4β7、CCR2、CCR3、CCR4、CCR5、CCR7、CCR8、αvβ6、αvβ8、cMET、CD8、vWF、淀粉状蛋白(例如淀粉状蛋白α)、MMP12、PDK1和IgE。
具体而言,本发明抗原结合构建体可用于治疗与IL-13、IL-5和IL-4相关的疾病,例如:特应性皮炎、变应性鼻炎、克罗恩氏病(crohn’sdisease)、COPD、纤维化疾病或病况例如特发性肺纤维化、进行性系统性硬化症、肝纤维化、肝肉芽肿、血吸虫病、利什曼病、细胞周期调节病例如何杰金氏病(Hodgkins disease)、B细胞慢性淋巴性白血病,例如所述构建体可用于治疗哮喘。
本发明抗原结合构建体可用于治疗与诸如IGF-1R、VEGF和EGFR等生长因子有关的疾病,例如癌症或风湿性关节炎,其中可使用所述疗法治疗的癌症类型实例有乳腺癌、前列腺癌、肺癌和骨髓瘤。
本发明抗原结合构建体可用于治疗与TNF有关的疾病,例如关节炎,例如风湿性关节炎或骨关节炎。
本发明抗原结合构建体可用于治疗与IL1-R有关的疾病,例如关节炎,例如风湿性关节炎或骨关节炎。
本发明抗原结合构建体可用于治疗与CD-20有关的疾病,例如:自身免疫性疾病,例如牛皮癣、炎性肠病、溃疡性结肠炎、克罗恩氏病、风湿性关节炎、青少年风湿性关节炎、系统性红斑狼疮、诸如多发性硬化症等神经退行性疾病、诸如COPD等中性粒细胞驱动的疾病、Wegener脉管炎、囊肿性纤维变性、斯耶格伦综合症(Sjogrenssyndrome)、慢性移植排斥、1型糖尿病移植物抗宿主病、哮喘、变应性疾病异位性皮炎、湿疹皮炎、变应性鼻炎、包括甲状腺炎、脊柱关节病、强直性脊柱炎、葡萄膜炎、多软骨炎或硬皮病在内的其它自身免疫性疾病;或癌症,例如B-细胞淋巴瘤或成熟B细胞瘤,例如CLL或SLL。
本发明抗原结合构建体可用于治疗与IL-17和IL-23有关的疾病,例如牛皮癣、炎性肠病、溃疡性结肠炎、克罗恩氏病、风湿性关节炎、青少年风湿性关节炎、系统性红斑狼疮、诸如多发性硬化症等神经退行性疾病、诸如COPD等中性粒细胞驱动的疾病、Wegener脉管炎、囊肿性纤维变性、斯耶格伦综合症、慢性移植排斥、1型糖尿病移植物抗宿主病、哮喘、变应性疾病异位性皮炎、湿疹皮炎、变应性鼻炎、包括甲状腺炎、脊柱关节病、强直性脊柱炎、葡萄膜炎、多软骨炎或硬皮病在内的其它自身免疫性疾病。
本发明抗原结合构建体可通过用包含编码本发明抗原结合构建体序列的表达载体转染宿主细胞来产生。表达载体或重组质粒通过使这些编码抗原结合构建体的序列与常规调控序列以可操作方式连接来产生,所述常规调控序列能够在宿主细胞中调控复制和表达和/或调控从宿主细胞分泌。调控序列包括启动子序列(例如CMV启动子)和可源自其它已知抗体的信号序列。同样地,可产生第二表达载体,其具有编码互补的抗原结合构建体轻链或重链的DNA序列。在某些实施方案中,除了考虑编码序列和选择标记外,该第二表达载体与第一表达载体相同,以确保尽可能每一条多肽链都能功能表达。或者,抗原结合构建体的重链和轻链编码序列可位于单个载体上,例如在同一个载体的两个表达盒中。
通过常规技术用第一和第二载体二者来共转染(或简单地通过单个载体转染)所选择的宿主细胞,以制备包含重组或合成的轻链和重链二者的经转染的本发明宿主细胞。然后通过常规技术培养所转染的细胞,以产生工程改造的本发明抗原结合构建体。通过诸如ELISA或RIA等合适的测定法,从培养物中筛选包含重组重链和/或轻链二者结合的抗原结合构建体。可采用类似的常规技术来构建其它抗原结合构建体。
本领域技术人员可选择用于本发明方法及组合物构建中所用的克隆和亚克隆步骤的合适载体。例如,可使用常规pUC系列克隆载体。一种载体pUC19可购自供应商,例如Amersham(Buckinghamshire,United Kingdom)或Pharmacia(Uppsala,Sweden)。另外,能够容易地复制,具有大量的克隆位点及选择基因(例如抗生素抗性)并易于操作的任何载体都可用于克隆。因此,克隆载体的选择不是本发明的限制因素。
表达载体的特征还可在于适用于扩增异源DNA序列表达的基因,例如哺乳动物二氢叶酸还原酶基因(DHFR)。其它优选的载体序列包括聚A信号序列,例如来自牛生长激素(BGH)和β球蛋白启动子序列(βglopro)。可通过本领域技术人员众所周知的技术合成用于本文的表达载体。
可通过市购或天然来源获得或通过已知方法合成所述载体组分,例如复制子、选择基因、增强子、启动子、信号序列等等,用于指导在所选宿主中表达和/或分泌重组DNA产物。为了该目的也可选择本领域已知的用于哺乳动物、细菌、昆虫、酵母和真菌表达的众多类型的其它合适的表达载体。
本发明还包括用含有编码本发明抗原结合构建体的序列的重组质粒转染的细胞系。用于克隆及用于这些克隆载体的其它操作的宿主细胞也为常规宿主细胞。然而,可将来自不同大肠杆菌(E.coli)株系的细胞用于复制克隆载体和构建本发明抗原结合构建体的其它步骤。
用于表达本发明抗原结合构建体的合适的宿主细胞或细胞系包括哺乳动物细胞,例如NS0、Sp2/0、CHO(例如DG44)、COS、HEK、成纤维细胞细胞(例如3T3)和骨髓瘤细胞,例如,其可在CHO或骨髓瘤细胞中表达。可使用人细胞,由此使得分子可以以人糖基化型式来修饰。或者,可使用其它真核细胞系。合适的哺乳动物宿主细胞的选择及用于转化、培养、扩增、筛选和产物产生及纯化的方法为本领域所知。参见例如上面引用的Sambrook等。
可证明细菌细胞作为宿主细胞适用于表达重组FAb或本发明其它实施方案(参见例如Plückthun,A.,Immunol.Rev.,130:151-188(1992))。然而,由于在细菌细胞中表达的蛋白质倾向于非折叠或不恰当折叠形式或呈非糖基化的形式,在细菌细胞中产生的任何重组Fab将必须为保留抗原结合能力接受筛选。如果由细菌细胞表达的分子以合适的折叠形式产生,那么该细菌细胞将是所期需的宿主,或在备选实施方案中该分子可在细菌宿主中表达然后接着重折叠。例如,用于表达的不同株系的大肠杆菌是生物技术领域众所周知的宿主细胞。在该方法中还可采用不同株系的枯草芽孢杆菌(B.subtilis)、链霉菌(Streptomyces)、其它杆菌等。
若需要,本领域技术人员已知的酵母菌细胞株系以及昆虫细胞(例如果蝇(Drosophila)和鳞翅目(Lepidoptera))和病毒表达系统也可作为宿主细胞使用。参见例如Miller等,Genetic Engineering,8:277-298,PlenumPress(1986)及其中引用的参考文献。
可构建载体的通用方法、产生本发明宿主细胞所需的转染方法和从所述宿主细胞产生本发明抗原结合构建体所需的培养方法,都可为常规技术。通常,本发明培养方法为无血清培养方法,通常是通过在无血清混悬液中培养细胞。同样地,产生本发明抗原结合构建体后,可按照本领域标准方法将其从细胞培养内含物中纯化,所述方法包括硫酸铵沉淀、亲和柱、柱色谱、凝胶电泳等等。所述技术在本领域技术范围内,其不构成对本发明的限制。例如,改变的抗体的制备阐述于WO 99/58679和WO 96/16990中。
表达抗原结合构建体的又一方法可利用在转基因动物中的表达,例如如美国专利第4,873,316号所述。其涉及使用动物酪蛋白启动子的表达系统,当将其通过转基因纳入到哺乳动物中时,使得雌性动物可在其乳汁中产生所需的重组蛋白质。
本发明另一方面提供制备本发明抗体的方法,所述方法包括培养用编码本发明抗体轻链和/或重链的载体转化的或转染的宿主细胞并回收藉此产生的抗体的步骤。
本发明提供制备本发明抗原结合构建体的方法,该方法包括以下步骤:
(a)提供编码抗原结合构建体重链的第一载体;
(b)提供编码抗原结合构建体轻链的第二载体;
(c)用所述第一和第二载体转化哺乳动物宿主细胞(例如CHO);
(d)在有助于从所述宿主细胞分泌抗原结合构建体到所述培养基中的条件下培养步骤(c)的宿主细胞;
(e)回收步骤(d)所分泌的抗原结合构建体。
一旦用所需方法表达抗原结合构建体后,通过用合适的测定法来检查其体外活性。目前采用常规ELISA测定方式以评估抗原结合构建体与其靶标的定性及定量结合。另外,还可使用其它体外测定法来验证中和效价,之后进行后续的人临床研究以评估忽略常规清除机制的抗原结合构建体在体内的持续性。
治疗剂量及持续时间涉及本发明分子在人循环中的相对持续时间,可由本领域技术人员根据待治疗病症及患者的一般健康状况来调整。可设想的是,可能需要长期(例如4-6个月)重复给药(例如每周1次或每2周1次)以达到最佳治疗效果。
本发明治疗剂的给药方式可为将药物递送给宿主的任何合适的途径。本发明抗原结合构建体和药用组合物尤其适用于胃肠外给予,即皮下(s.c.)、鞘内、腹膜内、肌肉内(i.m.)、静脉内(i.v.)或鼻内给予。
可将本发明治疗剂制备成在可药用载体中含有作为活性成分的有效量的本发明抗原结合构建体的药用组合物。在本发明预防性药物中,优选以注射即用的形式并优选以生理pH缓冲的含有抗原结合构建体的水性混悬剂或溶液剂。胃肠外给予的组合物通常应包含本发明抗原结合构建体溶液或其溶解于可药用载体(优选水性载体)的混合物。可采用多种水性载体,例如0.9%盐水、0.3%甘氨酸等。这些溶液可无菌制备并通常不含微粒物质。可通过众所周知的常规灭菌技术(例如过滤)使这些溶液无菌。根据接近生理条件的需要,组合物可含有可药用辅助物质(例如pH调节剂和缓冲剂等)。在所述药物制剂中的本发明抗原结合构建体的浓度可大范围变化,即从小于约0.5%、通常为或至少约1%到差不多15或20%重量,其主要基于流液体积、粘度等根据所选的特定给药方式来选择。
因此,用于肌内注射的本发明药用组合物可制备为含有1mL无菌缓冲水及以下量的本发明抗原结合构建体:约1ng-约100mg,例如约50ng-约30mg或更优选约5mg-约25mg。相似地,用于静脉内输注的本发明药用组合物可制备为含有约250ml无菌林格氏液和每毫升林格氏液约1mg-约30mg并优选5mg-约25mg的本发明抗原结合构建体。用于制备可胃肠外给予的组合物的实际方法众所周知,或对本领域技术人员显而易见,其详述于例如Remington′sPharmaceutical Science,第15版,Mack Publishing Company,Easton,Pennsylvania中。关于制备可静脉内给予的本发明抗原结合构建体制剂,参见:Lasmar U和Parkins D“The formulation of Biopharmaceuticalproducts(生物药物制品配制)”,Pharma.Sci.Tech.today,第129-137页,第3卷(200年4月3日);Wang,W“Instability,stabilisation andformulation of liquid protein pharmaceuticals(液体蛋白药物制剂的不稳定性、稳定化及配制)”,Int.J.Pharm 185(1999)129-188;Ahern T.J.,Manning M.C.主编的Stability of Protein Pharmaceuticals Part A and B,New York,NY:Plenum Press(1992);Akers,M.J.“Excipient-Druginteractions in Parenteral Formulations(胃肠外制剂中赋形剂-药物之间的相互作用)”,J.Pharm Sci 91(2002)2283-2300;Imamura,K等“Effectsof types of sugar on stabilization of Protein in the dried state(糖种类对干态蛋白质稳定化的作用)”,J Pharm Sci 92(2003)266-274;Izutsu,Kkojima,S.“Excipient crystalinity and its protein-structure-stabilizingeffect during freeze-drying(在冻干期间赋形剂结晶及其蛋白质结构稳定化作用)”,J Pharm.Pharmacol,54(2002)1033-1039;Johnson,R,“Mannitol-sucrose mixtures-versatile formulations for proteinlyophilization(用于蛋白质冻干的甘露醇-蔗糖混合物多功能制剂)”,J.Pharm.Sci,91(2002)914-922;Ha,E Wang W,Wang Y.j.“Peroxideformation in polysorbate 80 and protein stability(在聚山梨醇酯80中过氧化物的形成和蛋白质稳定性)”,J.Pharm Sci,91,2252-2264,(2002),它们的整体内容在此引作参考,读者尤其应参考这些文献。
优选本发明治疗剂在药物制剂中呈单位剂量形式存在。合适的治疗有效剂量将易于由本领域技术人员确定。可按照其体重计算患者的合适的剂量,例如,合适的剂量可在以下范围内:0.01-20mg/kg,例如0.1-20mg/kg,例如1-20mg/kg,例如10-20mg/kg或例如1-15mg/kg,例如10-15mg/kg。为了有效治疗病症,在本发明中人使用的合适的剂量可在以下范围内:0.01-1000mg,例如0.1-1000mg,例如0.1-500mg,例如500mg,例如0.1-100mg或0.1-80mg,或0.1-60mg或0.1-40mg,或例如1-100mg或1-50mg的本发明抗原结合构建体,它们可经胃肠外给予,例如经皮下、静脉内或肌肉内给予。若有需要,所述剂量可以以合适的时间间隔重复给予,这由医生适当选择。
本文所述抗原结合构建体可冻干储存,并在使用前以合适的载体复溶。该技术显示对常规免疫球蛋白有效,可采用本领域已知的冻干和复溶技术。
有若干种本领域已知的方法可用于发现本发明使用的表位结合结构域。
术语“文库”指异质的多肽或核酸的混合物。文库由成员组成,每一个成员具有单个多肽或核酸序列。在这个意义上,“文库”是“谱(repertoire)”的同义词。文库成员之间的序列差异是造成文库中存在多样性的原因。文库可呈简单的多肽或核酸混合物形式,或可呈用核酸文库转化的生物体或细胞形式,例如细菌、病毒、动物或植物细胞等等。在一个实例中,每一个单独的生物体或细胞仅含有一个或有限个数的文库成员。有利的是,为了使得由核酸编码的多肽表达,可将该核酸纳入到表达载体中。因此,在一个方面,文库可呈宿主生物体群的形式,每一生物体含有表达载体的一个或多个拷贝,所述表达载体含有核酸形式的单个文库成员,其可被表达以产生其对应的多肽成员。因此,宿主生物体群具有编码多种多肽的众多谱的可能性。
“通用构架”是对应于抗体序列保守区的单独的抗体构架序列,其如Kabat所定义(“Sequences of Proteins of Immunological Interest(免疫目的物的蛋白质序列)”,US Department of Health and Human Service),或为对应于人种系免疫球蛋白谱或结构的单独的抗体构架序列,其如Chothia和Lesk,(1987)J.Mol.Biol.196:910-917所定义。可有单一构架或一套所述构架,业已发现它们尽管只在超变区变化,但使得可衍生几乎任何结合特异性。
在一个实施方案中,用算法BLAST 2 Sequences使用缺省参数(Tatusova,T.A.等,FEMS Microbiol Lett,174:187-188(1999)),来制备并测定本文所定义的氨基酸和核苷酸序列比对和同源性、相似性或同一性。
表位结合结构域和抗原结合位点可各自对通用配体(genericligand)或任何所需靶配体具有结合特异性,所述配体例如人或动物蛋白,包括细胞因子、生长因子、细胞因子受体、生长因子受体、酶(例如蛋白酶)、酶的辅因子、DNA结合蛋白、脂质和糖类。包括细胞因子、生长因子、细胞因子受体、生长因子受体和其它蛋白在内的合适的靶标包括但不限于:ApoE、Apo-SAA、BDNF、心肌营养蛋白-1、CEA、CD40、CD40配体、CD56、CD38、CD138、EGF、EGF受体、ENA-78、嗜伊红细胞趋化因子、嗜伊红细胞趋化因子-2、Exodus-2、FAPα、酸性FGF、碱性FGF、成纤维细胞生长因子-10、FLT3配体、CXXXC趋化分子(CX3C)、GDNF、G-CSF、GM-CSF、GF-β1、人血清白蛋白、胰岛素、IFN-γ、IGF-I、IGF-II、IL-1α、IL-1β、IL-1受体、IL-1受体1型、IL-2、IL-3、IL-4、IL-5、IL-6、IL-7、IL-8(72个氨基酸)、IL-8(77个氨基酸)、IL-9、IL-10、IL-11、IL-12、IL-13、IL-15、IL-16、IL-17、IL-18(IGIF)、抑制素α、抑制素β、IP-10、角质形成细胞生长因子-2(KGF-2)、KGF、瘦素、LIF、淋巴细胞趋化蛋白、穆勒氏抑制物、单核细胞集落抑制因子、单核细胞引诱蛋白、M-CSF、c-fms、v-fmsMDC(67个氨基酸)、MDC(69个氨基酸)、MCP-1(MCAF)、MCP-2、MCP-3、MCP-4、MDC(67个氨基酸)、MDC(69个氨基酸)、MIG、MIP-1α、MIP-1β、MIP-3α、MIP-3β、MIP-4、骨髓祖细胞抑制因子-1(MPIF-1)、NAP-2、神经营养因子、神经生长因子、β-NGF、NT-3、NT-4、制瘤素M、PDGF-AA、PDGF-AB、PDGF-BB、PF-4、RANTES、SDF1α、SDF1β、SCF、SCGF、干细胞因子(SCF)、TARC、TGF-α、TGF-β、TGF-β2、TGF-β3、肿瘤坏死因子(TNF)、TNF-α、TNF-β、TNF受体I、TNF受体II、TNIL-1、TPO、VEGF、VEGF A、VEGF B、VEGF C、VEGF D、VEGF受体1、VEGF受体2、VEGF受体3、GCP-2、GRO/MGSA、GRO-β、GRO-γ、HCC1、1-309、HER1、HER 2、HER 3、HER 4、血清白蛋白、vWF、淀粉状蛋白(例如淀粉状蛋白α)、MMP12、PDK1、IgE和本文公开的其它靶标。应该了解该名单并非详尽无遗。
在某些实施方案中,结合的是肺组织中的靶标,例如选自以下的靶标:TNFR1、IL-1、IL-1R、IL-4、IL-4R、IL-5、IL-6、IL-6R、IL-8、IL-8R、IL-9、IL-9R、IL-10、IL-12、IL-12R、IL-13、IL-13Rα1、IL-13Ra2、IL-15、IL-15R、IL-16、IL-17R、IL-17、IL-18、IL-18R、IL-23 IL-23R、IL-25、CD2、CD4、CD11a、CD23、CD25、CD27、CD28、CD30、CD40、CD40L、CD56、CD138、ALK5、EGFR、FcER1、TGFb、CCL2、CCL18、CEA、CR8、CTGF、CXCL12(SDF-1)、糜蛋白酶、FGF、弗林蛋白酶、内皮素-1、嗜伊红细胞趋化因子(例如嗜伊红细胞趋化因子、嗜伊红细胞趋化因子-2、嗜伊红细胞趋化因子-3)、GM-CSF、ICAM-1、ICOS、IgE、IFNa、I-309、整联蛋白、L-选择蛋白、MIF、MIP4、MDC、MCP-1、MMP、中性粒细胞弹性蛋白酶、骨桥蛋白、OX-40、PARC、PD-1、RANTES、SCF、SDF-1、涎免凝集素8、TARC、TGFb、凝血酶、Tim-1、TNF、TRANCE、类胰蛋白酶、VEGF、VLA-4、VCAM、α4β7、CCR2、CCR3、CCR4、CCR5、CCR7、CCR8、αVβ6、αVβ8、cMET、CD8、vWF、淀粉状蛋白(例如淀粉状蛋白α)、MMP12、PDK1和IgE。
当在本文所述方法中使用展示系统(例如联系核酸的编码功能与核酸编码的肽或多肽的功能特性的展示系统)时,例如选择dAb或其它表位结合结构域时,通常有利的是扩增或增加编码所选择的肽或多肽的核酸的拷贝数。这提供了有效方法来获得足够量核酸和/或肽或多肽,以用于通过本文所述方法或其它合适的方法进行另外轮次的选择,或用于制备另外的谱(例如亲和力成熟谱)。因此,在某些实施方案中,选择表位结合结构域的方法包括使用展示系统(例如联系核酸的编码功能和核酸编码的肽或多肽的功能特性的展示系统,例如噬菌体展示),并另外包括扩增或增加编码所选择的肽或多肽的核酸的拷贝数。可用任何合适的方法例如通过噬菌体扩增、细胞生长或聚合酶链式反应扩增核酸。
在一个实例中,所述方法采用联系核酸编码功能和核酸编码的多肽的物理、化学和/或功能特性的展示系统。这样的展示系统可包含多个可复制的遗传包(genetic package),例如噬菌体或细胞(细菌)。展示系统可包含文库,例如噬菌体展示文库。噬菌体展示是展示系统的实例。
业已阐述多种合适的噬菌体展示系统(例如单价展示和多价展示系统)。(参见例如Griffiths等,美国专利第6,555,313B1号(在此引作参考);Johnson等,美国专利第5,733,743号(在此引作参考);McCafferty等,美国专利第5,969,108号(在此引作参考);Mulligan-Kehoe,美国专利第5,702,892号(在此引作参考);Winter,G.等,Annu.Rev.Immunol.12:433-455(1994);Soumillion,P.等,Appl.Biochem.Biotechnol.47(2-3):175-189(1994);Castagnoli,L.等,Comb.Chem.HighThroughput Screen(高通量筛选),4(2):121-133(2001))。在噬菌体展示系统中展示的肽或多肽可在任何合适的噬菌体上展示,举例而言,所述细菌噬菌体例如丝状噬菌体(例如fd、M13、F1)、裂解性噬菌体(例如T4、T7、λ)或RNA噬菌体(例如MS2)。
通常产生或提供展示作为含合适噬菌体衣壳蛋白(例如fd pIII蛋白)的融合蛋白的肽或噬菌体多肽的谱的噬菌体文库。融合蛋白可在噬菌体衣壳蛋白的末端或若需要在内部位置展示肽或多肽。例如,被展示的肽或多肽可存在于pIII的氨基末端到结构域1的位置。(pIII的结构域1也被称为N1)。可将被展示的多肽直接融合到pIII(例如pIII的结构域1的N-末端),或用接头融合到pIII。若有需要,融合体可进一步包含标签(tag)(例如myc表位、His标签)。用任何合适的方法可产生包含作为含噬菌体衣壳蛋白的融合蛋白展示的肽谱或多肽谱的文库,例如通过将编码被展示的肽或多肽的噬菌体载体或噬菌粒载体的文库引入到合适的宿主细菌,并培养所得到的细菌以产生噬菌体(例如若有需要,则用合适的辅助噬菌体或补充质粒(complementingplasmid))。可用任何合适的方法(例如沉淀和离心)从培养物回收噬菌体文库。
展示系统可包含含有任何所需多样性量的肽谱或多肽谱。例如,所述谱可含有具有对应于由一种生物体、一组生物体、所需组织或所需细胞类型表达的天然存在多肽的氨基酸序列的肽或多肽,或可含有具有随机或随机化氨基酸序列的肽或多肽。若有需要,多肽可享有共同核心或骨架。例如,谱或文库中的所有多肽可基于选自以下的骨架:蛋白A、蛋白L、蛋白G、纤连蛋白结构域、anticalin、CTLA4、所需酶(例如聚合酶、纤维素酶)或来自免疫球蛋白超家族的多肽,例如抗体或抗体片段(例如抗体可变结构域)。在谱或文库中的多肽可包含随机或随机化氨基酸序列的限定区及共有氨基酸序列的区。在某些实施方案中,谱中所有或基本上所有多肽为所需类型,例如所需的酶(例如聚合酶)或所需的抗体的抗原结合片段(例如人VH或人VL)。在某些实施方案中,多肽展示系统包含多肽谱,其中每一个多肽包含抗体可变结构域。例如,谱中的每一个多肽可含有VH、VL或Fv(例如单链Fv)。
可用任何合适的方法将氨基酸序列多样性引入到肽或多肽或骨架的任何所需区域中。例如,可通过用任何合适的诱变方法(例如低保真度PCR、寡核苷酸介导的诱变或定点诱变、用NNK密码子多样化)或任何其它合适的方法制备编码多样化的多肽的核酸文库,来将氨基酸序列多样性引入靶区域,例如抗体可变结构域的互补决定区或疏水结构域。若有需要,可使待多样化的多肽区域随机化。
构成谱的多肽的大小是主要的选择问题,多肽大小不必一致。谱中的多肽可具有至少三级结构(形成至少一个结构域)。
选择/分离/回收
可用任何合适的方法从谱或文库(例如在展示系统中)选择、分离和/或回收表位结合结构域或结构域群。例如,基于选择特性(例如物理特性、化学特性、功能特性)来选择或分离结构域。合适的选择性功能特性包括谱中的肽或多肽的生物活性,例如结合通用配体(例如超抗原)、结合靶配体(例如抗原、表位、底物)、结合抗体(例如通过在肽或多肽上表达的表位)和催化活性。(参见例如,Tomlinson等,WO99/20749;WO 01/57065;WO 99/58655)。
在某些实施方案中,从基本上所有结构域共享共同的选择性特征的肽或多肽文库或谱中选择和/或分离蛋白酶抗性肽或多肽。例如,结构域可选自其中基本上所有结构域具有以下特征的文库或谱:结合共同的通用配体、结合共同的靶配体、结合共同抗体(或被共同抗体结合)或拥有共同的催化活性。该选择类型尤其可用于制备基于具有所需生物活性的母体肽或多肽的结构域谱,例如当实施免疫球蛋白单一可变结构域的亲和力成熟时。
基于结合共同通用配体的选择可产生含有作为原始文库或谱组分的所有或基本上所有结构域的结构域集或群。例如,可通过淘选或用合适的亲和基质选择、分离和/或回收结合靶配体或通用配体(例如蛋白A、蛋白L或抗体)的结构域。可通过将配体(例如通用配体、靶配体)溶液加入到合适的容器(例如试管、培养皿)中并使配体沉积或覆盖在容器壁上来实施淘选。可洗掉过量配体,可将结构域加到容器中,并将容器保持在适于肽或多肽结合固定化配体的条件下。可洗掉未结合的结构域,并可例如用任何合适的方法(例如刮擦或降低pH)来回收结合的结构域。
合适的配体亲和基质通常含有配体共价或非共价连接其上的固相支持体或珠粒(例如琼脂糖)。可在适用于使结构域与基质上的配体结合的条件下用批处理、柱处理或任何其它合适的处理使亲和基质与肽或多肽(例如业已与蛋白酶孵育的谱)结合。可洗掉不结合亲和基质的结构域,用任何合适的方法洗脱并回收已结合的结构域,例如用较低pH的缓冲液、用温和变性剂(例如尿素)或用竞争结合配体的肽或结构域洗脱。在一个实例中,在适用于使谱中的结构域与靶配体结合的条件下让生物素化的靶配体与谱结合。用固定化(例如在珠粒上)的亲和素或链霉亲和素回收已结合的结构域。
在某些实施方案中,通用配体或靶配体为抗体或其抗原结合片段。与在文库或谱的肽或多肽中基本上保守的肽或多肽的结构特征结合的抗体或抗原结合片段尤其可用作通用配体。适于用作分离、选择和/或回收蛋白酶抗性肽或多肽所用的配体的抗体和抗原结合片段可为单克隆或多克隆的,并可用任何合适的方法制备。
文库/谱
可用任何合适的方法制备或获得编码和/或含有蛋白酶表位结合结构域的文库。可设计文库以编码基于目标结构域或骨架(例如选自文库的结构域)的结构域,或可用本文所述方法从另一文库中选择文库。例如,可用合适的多肽展示系统来制备富含结构域的文库。
可用任何合适的方法容易地产生编码所需结构域类型的谱的文库。例如,可获得编码所需多肽类型(例如免疫球蛋白可变结构域)的核酸序列,并且可例如通过用易错的聚合酶链式反应(PCR)系统扩增核酸、通过化学诱变(Deng等,J.Biol.Chem.,269:9533(1994))或用细菌增变株(LoW等,J.Mol.Biol.,260:359(1996))来制备每一个含有一个或多个突变的核酸集合。
在其它实施方案中,为了多样化可以特定的核酸区作为靶标。用于在所选择的位置进行突变的方法在本领域亦众所周知,包括例如在用或不用PCR时使用错配的寡核苷酸或简并的寡核苷酸。例如,通过将突变靶向抗原结合环来产生合成的抗体文库。业已将随机或半-随机抗体H3和L3区添加到种系免疫球蛋白V基因区段,以产生含未突变构架区的大文库(Hoogenboom和Winter(1992)上述;Nissim等(1994)见上述;Griffiths等(1994)见上述;DeKruif等(1995)见上述)。业已将所述多样性延伸到包括某些或所有其它抗原结合环(Crameri等(1996)Nature Med.,2:100;Riechmann等(1995)Bio/Technology,13:475;Morphosys,WO 97/08320,见上述)。在其它实施方案中,为了多样化可通过例如采用第一PCR产物为“大引物(mega-primer)”的两步PCR策略来靶向核酸的特定区。(参见例如Landt,O.等,Gene 96:125-128(1990))。例如通过SOE PCR也可完成靶向的多样化。(参见例如Horton,R.M.等,Gene 77:61-68(1989))。
可通过改变确定多肽序列的编码序列致使可将许多可能的氨基酸(例如所有20种氨基酸或其子集)引入到该位置来实现在所选位置的序列多样性。用IUPAC命名法,最多能的密码子是NNK,其编码所有氨基酸以及TAG终止密码子。可使用NNK密码子以引入所需多样性。也使用达到同样目的的其它密码子,包括NNN密码子,该密码子导致产生另外的终止密码子TGA和TAA。这样的靶向方法可使得靶区域的全序列范围得到探索。
某些文库包含作为免疫球蛋白超家族成员(例如抗体或其部分)的结构域。例如,文库可包含具有已知主链构象的结构域。(参见例如Tomlinson等,WO 99/20749)。可在合适的质粒或载体中制备文库。本文所用载体指分离的元件(discrete element),其用于将异源DNA引入到细胞中用于表达和/或其复制。可使用任何合适的载体,包括质粒(例如细菌质粒)、病毒或噬菌体载体、人工染色体和游离型载体。这样的载体可用于简单克隆和诱变,或表达载体可用于驱动文库表达。载体和质粒通常含有一个或多个克隆位点(例如多接头)、复制起始点和至少一个选择标记基因。表达载体可进一步含有驱动多肽转录及翻译的元件,例如增强子元件、启动子、转录终止信号、信号序列等等。可以以使其可操作地连接编码多肽的克隆插入物的方式排列这些元件,由此当所述表达载体保持在适于表达的条件下(例如在合适的宿主细胞中)时可表达并产生所述多肽。
克隆载体和表达载体通常含有使得所述载体可在一个或多个所选择的宿主细胞中复制的核酸序列。在克隆载体中,通常该序列为能使得载体独立于宿主染色体DNA复制的序列,包括复制起始点或自主复制序列。对于多种细菌、酵母和病毒,所述序列众所周知。来自质粒pBR322的复制起始点适用于大部分革兰氏阴性细菌,2微米质粒起始适用于酵母菌,各种病毒复制起始点(例如SV40、腺病毒)可用于在哺乳动物细胞中克隆载体。除非在哺乳动物细胞(例如COS细胞)中使用的复制起始点能够复制高水平DNA,否则哺乳动物表达载体通常不需要复制起始点。
克隆载体或表达载体可含有也被称为选择标记的选择基因。此类标记基因编码使转化的宿主细胞在选择培养基中存活或生长必不可少的蛋白质。因此,未用含有选择基因的载体转化的宿主细胞将不能在培养基中存活。典型的选择基因编码的蛋白赋予抗生素及其它毒素(例如氨苄青霉素(ampicillin)、新霉素(neomycin)、甲氨蝶呤(methotrexate)或四环素(tetracycline))抗性,互补的营养缺陷或提供在生长培养基中不能获得的关键营养素。
合适的表达载体可含有多种组分,例如复制起始点、选择标记基因、诸如转录调控元件(例如启动子、增强子、终止子)等一种或多种表达调控元件和/或一种或多种翻译信号、信号序列或前导序列等。若存在,表达调控元件和信号序列或前导序列可由载体或其它来源提供。例如,编码抗体链的已克隆的核酸的转录和/或翻译调控序列可用于指导表达。
可提供启动子用于在所需宿主细胞中进行表达。启动子可为组成型或诱导型。例如,可让启动子可操作地连接编码抗体、抗体链或其部分的核酸,致使其指导该核酸转录。可利用多种适用于原核宿主的启动子(例如用于大肠杆菌的β-内酰胺酶和乳糖启动子系统、碱性磷酸酶、色氨酸(trp)启动子系统、lac、tac、T3、T7启动子)和真核宿主的启动子(例如,猴肾病毒40早期或晚期启动子、劳氏肉瘤病毒长末端重复启动子、巨细胞病毒启动子、腺病毒晚期启动子、EG-1a启动子)。
另外,表达载体通常包含用于选择携带载体的宿主细胞的选择标记,并在可复制的表达载体情况下包含复制起点。编码赋予抗生素或药物抗性的产物的基因为常用选择标记,可用于原核细胞(例如β-内酰胺酶基因(氨苄青霉素抗性)、四环素抗性的Tet基因)和真核细胞(例如新霉素(G418或遗传霉素(geneticin))、gpt(霉酚酸)、氨苄青霉素或潮霉素(hygromycin)抗性基因)。二氢叶酸还原酶标记基因使得可用甲氨蝶呤在多种宿主中选择。在酵母中通常将编码宿主的营养缺陷型标记物的基因产物的基因(例如LEU2、URA3、HIS3)用作选择标记。还涵盖使用病毒(例如杆状病毒)或噬菌体载体和能够整合到宿主细胞基因组的载体(例如逆转录病毒载体)。
适用于在原核细胞(例如细菌细胞,例如大肠杆菌)或哺乳动物细胞中表达的表达载体包括例如:pET载体(例如pET-12a、pET-36、pET-37、pET-39、pET-40,Novagen等)、噬菌体载体(例如pCANTAB5E,Pharmacia)、pRIT2T(蛋白A融合载体,Pharmacia)、pCDM8、pCDNA1.1/amp、pcDNA3.1、pRc/RSV、pEF-1(Invitrogen,Carlsbad,CA)、pCMV-SCRIPT、pFB、pSG5、pXT1(Stratagene,La Jolla,CA)、pCDEF3(Goldman,L.A.,等,Biotechniques,21:1013-1015(1996))、pSVSPORT(GibcoBRL,Rockville,MD)、pEF-Bos(Mizushima,S.,等,Nucleic Acids Res.,18:5322(1990))等等。可利用适用于不同表达宿主的表达载体,所述不同表达宿主例如原核细胞(大肠杆菌)、昆虫细胞(果蝇(Drosophila Schnieder)S2细胞,Sf9)、酵母(甲醇毕赤酵母(P.methanolica)、巴斯德毕赤酵母(P.pastoris)、酿酒酵母(S.cerevisiae))细胞和哺乳动物细胞(例如COS细胞)。
载体的某些实例为能使对应于多肽文库成员的核苷酸序列表达的表达载体。因此,可通过让表达多肽文库成员的单个克隆单独增殖并表达来进行用通用配体和/或靶配体的选择。如上所述,特定的选择展示系统为噬菌体展示。因此,可使用噬菌体或噬菌粒载体,例如,载体可为具有大肠杆菌复制起始点(用于双链复制)以及此外的噬菌体复制起始点(用于产生单链DNA)的噬菌粒载体。所述载体的操作及表达在本领域众所周知(Hoogenboom和Winter(1992)见上述;Nissim等(1994)见上述)。简言之,载体可含有β-内酰胺酶基因以赋予噬菌粒选择性,并含有表达盒上游的lac启动子,所述表达盒可含有合适的前导序列、多个克隆位点、一个或多个肽标签、一个或多个TAG终止密码子和噬菌体蛋白pIII。因此,用各种大肠杆菌阻抑菌株和非阻抑菌株并加入葡萄糖、异丙基硫代-β-D-半乳糖苷(IPTG)或辅助噬菌体(例如VCS M13),载体能够作为不表达而只产生大量的多肽文库成员的质粒复制,或作为产物噬菌体复制,所述产物噬菌体中某些在其表面含有多肽-pIII融合体的至少一个拷贝。
抗体可变结构域可包含靶配体结合位点和/或通用配体结合位点。在某些实施方案中,通用配体结合位点为超抗原(例如蛋白A、蛋白L或蛋白G)结合位点。可变结构域可基于任何所需的可变结构域,例如人VH(例如VH 1a、VH 1b、VH 2、VH 3、VH 4、VH 5、VH 6)、人Vλ(例如VλI、VλII、VλIII、VλIV、VλV、VλVI或Vκ1)或人Vκ(例如Vκ2、Vκ3、Vκ4、Vκ5、Vκ6、Vκ7、Vκ8、Vκ9或Vκ10)。
另一类技术涉及选择人工分隔间(artificial compartment)的谱,所述人工分隔间使得基因可与其基因产物相连接。例如,可在由油包水乳剂形成的微胶囊中选择编码所需基因产物的核酸的选择系统阐述于WO99/02671、WO00/40712和Tawfik&Griffiths(1998)NatureBiotechnol 16(7),652-6中。可将编码具有所需活性的基因产物的遗传元件分区到微胶囊中,然后在微胶囊内转录和/或翻译以产生其各自的基因产物(RNA或蛋白质)。随后挑选产生具有所需活性的基因产物的遗传元件。本方法通过经由多种手段检测所需活性来选择目的基因产物。
表位结合结构域表征
可通过为本领域技术人员所熟悉的方法检测结构域与其特异性抗原或表位的结合,所述方法包括ELISA。在一个实例中,用单克隆噬菌体ELISA检测结合。
可按照任何合适程序实施噬菌体ELISA:以下提出例示性方案。
可通过ELISA针对所选择的抗原或表位的结合情况来筛选每一轮选择产生的噬菌体群,以鉴定″多克隆″噬菌体抗体。然后可通过ELISA筛选来自这些群中的单个受感染的细菌菌落的噬菌体,以鉴定″单克隆″噬菌体抗体。也期需针对与抗原或表位的结合情况来筛选可溶性抗体片段,这还可通过ELISA用例如针对C-或N-末端标签的试剂来进行(参见例如Winter等(1994)Ann.Rev.Immunology 12,433-55及其中所引用参考文献)。
还可通过PCR产物的凝胶电泳(Marks等1991,上述;Nissim等1994上述)、用探针探测(Tomlinson等,1992J.Mol.Biol.227,776)或通过测定载体DNA序列,来评估所选择的噬菌体单克隆抗体的多样性。E.dAb结构
在例如用本文所述噬菌体展示技术从所选择的V-基因谱选择dAb的情况下,这些可变结构域包含通用构架区,由此可以通过本文所定义的特定通用配体来识别它们。通用构架区、通用配体等的使用阐述于WO99/20749中。
当使用V-基因谱时,多肽序列中的变化可位于可变结构域结构环内。任一可变结构域的多肽序列可通过DNA改组或通过突变来改变,致使提高每一可变结构域与其互补对的相互作用。DNA改组为本领域所知,由例如Stemmer,1994,Nature 370:389-391和美国专利第6,297,053号教导,它们在此引作参考。其它诱变方法为本领域技术人员所熟知。
用于构建dAb的骨架
i.选择主链构象
免疫球蛋白超家族成员在其多肽链方面都共享相似的折叠。例如,尽管抗体就其一级序列而言高度不同,但与预期的相反,序列比较和晶体结构显示抗体的6个抗原结合环中的5个(H1、H2、L1、L2、L3)采用少数主链构象或规范结构(Chothia和Lesk(1987)J.Mol.Biol.,196:901;Chothia等(1989)Nature,342:877)。因此,环长度及关键残基分析使得可预测在大部分人抗体中存在的H1、H2、L1、L2和L3的主链构象(Chothia等(1992)J.Mol.Biol.,227:799;Tomlinson等(1995)EMBOJ.,14:4628;Williams等(1996)J.Mol.Biol.,264:220)。尽管就序列、长度及结构(由于使用D区段)而言H3区更多样,但其由于环长度短而同样形成少数主链构象,这要视长度及环中及抗体构架中关键位置的特定残基的存在情况或残基类型而定(Martin等(1996)J.Mol.Biol.,263:800;Shirai等(1996)FEBS Letters,399:1)。
有利地的是,从结构域文库(例如VH结构域文库和/或VL结构域文库)组装dAb。在一个方面,对结构域文库进行设计,其中选择某些环长度和关键残基以确保成员的主链构象是已知的。有利的是,为了使其无功能的几率最小化,它们是在自然界发现的免疫球蛋白超家族分子的真正构象,其如上所述。种系V基因区段用作一个合适的基本构架用于构建抗体或T-细胞受体文库;其它序列也有用。可以以低频率发生变化,以使少数功能成员可拥有改变的主链构象,所述构象并不影响其功能。
规范结构理论还可用于评估由配体编码的不同的主链构象的数量,以基于配体序列预测主链构象,并为多样化选择不影响规范结构的残基。已知在人Vκ结构域中,L1环可采用4种规范结构中的1种,L2环具有单一的规范结构,对于L3环90%的人Vκ结构域采用4种或5种规范结构中的1种(Tomlinson等(1995)见上述);因此,在单独的Vκ结构域中,不同的规范结构可联合以产生一系列不同的主链构象。已知Vλ结构域编码L1、L2和L3环的一系列不同的规范结构,且Vκ和Vλ结构域可与可编码H1和H2环的若干规范结构的任何VH结构域配对,那么在这5种环中观察到的规范结构组合的数目将极大。这表明主链构象多样性的产生对于产生大范围的结合特异性可能是必需的。然而,通过基于单一已知主链构象构建抗体文库,业已发现与预期相反,对于产生足以靶向基本上所有抗原的多样性并不需要主链构象多样性。甚至更意想不到的是,单一主链构象不必为共有结构-单一天然存在的构象可用作整个文库的基础。因此,在一个特别的方面,dAb拥有单一的已知主链构象。
所选择的单一主链构象可以是所考虑的免疫球蛋白超家族类型分子中的普通的一种。当观察到大量天然存在的分子采用该构象时,所述构象就是普通构象。因此,在一个方面,单独考虑对于免疫球蛋白结构域的每一结合环的不同主链构象的天然存在情况,然后为不同环选择天然存在的可变结构域,所述可变结构域拥有所期需的主链构象组合。如果没有一个可以利用,那么可选择最接近的等同物。可通过选择编码所需主链构象的种系基因区段来产生对于不同环的所期需的主链构象组合。在一个实例中,所选择的种系基因区段在自然界中频繁表达,具体而言,在所有天然种系基因区段中它们可能是最频繁地表达。
在设计文库的过程中,可以单独考虑对于6个抗原结合环中的每一个的不同的主链构象发生率。对于H1、H2、L1、L2和L3,选择20%-100%的天然存在的分子的抗原结合环所采用的既定构象。通常,其观察到的发生率超过35%(即35%至100%之间),理想情况为超过50%或甚至超过65%。由于绝大多数H3环不具有规范结构,因而优选选择在这些不展示规范结构的环中普通的主链构象。因此,对于每一种环,选择在天然谱中最经常观察到的构象。在人抗体中,对于每一种环而言最普遍的规范结构(CS)如下:H1-CS 1(79%所表达的谱)、H2-CS 3(46%)、L1-CS 2Vκ(39%)、L2-CS 1(100%)、L3-CS 1Vκ(36%)(计算假设比率为70∶30,Hood等(1967)Cold SpringHarbor Symp.Quant.Biol.,48:133)。对于具有规范结构的H3环,在第94位残基-第101位残基含有盐桥的长7个残基的CDR3(Kabat等(1991)Sequences of proteins of immunological interest,U.S.Departmentof Health and Human Services)似乎是最普遍的。在EMBL数据库中有至少16种人抗体序列含有形成该构象所需的H3长度和关键残基,在用作抗体建模的基础的蛋白质数据库中有至少两种晶体结构(2cgr和1tet)。规范结构的这种组合的最频繁表达的种系基因区段为VH区段3-23(DP-47)、JH区段JH4b、Vκ区段O2/O12(DPK9)和Jκ区段Jκ1。VH区段DP45和DP38也是合适的。因此,可将这些区段组合用作构建具有所期需单一主链构象的文库的基础。
或者,代替基于处于孤立状态的每一结合环的不同的主链构象的天然发生率来选择单一主链构象,将主链构象组合的天然发生率作为用于选择单一主链构象的基础。例如,在抗体情况下,可确定对于抗原结合环中的任何两个、三个、四个、五个或所有六个的规范结构组合的自然发生率。此时所选择的构象可为天然存在的抗体中的普通构象,并且可在天然谱中最经常地观察到。因此,例如在人抗体中,当考虑5种抗原结合环H1、H2、L1、L2和L3的天然组合时,确定规范结构的最频繁的组合,然后与H3环的最普遍的构象联合,作为选择单一主链构象的基础。
规范序列的多样化
选择了几种已知主链构象或单一已知主链构象后,就可通过改变分子的结合位点来构建dAb,以产生含结构和/或功能多样性的谱。这意味着产生变体,致使在其结构和/或其功能方面具有足够的多样性,由此它们能够提供一系列的活性。
通常通过在一个或多个位置改变所选择的分子来产生所期需的多样性。可随机选择待改变的位置,或它们可能已被选定。然后通过以下方式来实现变异:随机化,在随机化期间由任意氨基酸或其天然或合成的类似物取代氨基酸残基产生极大量的变体;或者用一种或多种限定的氨基酸子集置换氨基酸残基,产生更少量的变体。
业已报道用于引入所述多样性的各种方法。可用易错PCR(Hawkins等(1992)J.Mol.Biol.,226:889)、化学诱变(Deng等(1994)J.Biol.Chem.,269:9533)或细菌增变株(LoW等(1996)J.Mol.Biol.,260:359)来将随机突变引入编码分子的基因中。用于突变所选位置的方法在本领域亦众所周知,包括用或不用PCR使用错配的寡核苷酸或简并寡核苷酸。例如,通过以抗原结合环作为目标进行突变产生若干合成的抗体文库。使结合人破伤风类毒素-Fab的H3区随机化以产生一系列新的结合特异性(Barbas等(1992)Proc.Natl.Acad.Sci.USA,89:4457)。随机或半-随机H3和L3区业已被添加到种系V基因区段以产生含未突变构架区的大文库(Hoogenboom&Winter(1992)J.Mol.Biol.,227:381;Barbas等(1992)Proc.Natl.Acad.Sci.USA,89:4457;Nissim等(1994)EMBOJ.,13:692;Griffiths等(1994)EMBOJ.,13:3245;De Kruif等(1995)J.Mol.Biol.,248:97)。所述多样化业已延伸到包括某些或所有其它抗原结合环(Crameri等(1996)Nature Med.,2:100;Riechmann等(1995)Bio/Technology,13:475;Morphosys,WO97/08320,见上述)。
由于环的随机化有可能产生大约超过1015种针对单独的H3的结构,以及同样大量的其它5种环的变体,因而用目前的转化技术或甚至通过用无细胞系统以产生代表所有可能组合的文库是不可行的。例如,在迄今构建的最大的文库之一中,产生了6x1010种不同的抗体,这仅是该设计的文库的潜在多样性的小部分而已(Griffiths等(1994)见上述)。
在一个实施方案中,仅那些直接参与产生或修饰所期需的分子功能的残基被多样化。对于很多分子而言,功能应为结合靶标,因此多样性应该集中在靶标结合位点,同时避免改变对于分子的整体包装或对于维持所选择的主链构象很重要的残基。
在一个方面,使用其中仅那些抗原结合位点的残基被改变的dAb文库。这些残基在人抗体谱中极具多样性,并且已知为高分辨的抗体/抗原复合体的接触点。例如,在L2中,已知在天然存在的抗体中位置50和53是多变的,并观察到其与抗原接触。相比之下,常规方法将使由Kabat等(1991,上述)定义的相应的互补决定区(CDR1)中的所有残基多样化,与文库中多样化的两个残基相比某些有7个残基被多样化。就产生一系列抗原结合特异性所需的功能多样性而言,这代表显著改进。
实际上,抗体多样性是两个过程的结果:种系V、D和J基因区段的体细胞重组致使产生天然的初始谱(primary repertoire)(所谓的种系和连接多样性)和导致产生重排的V基因的体细胞超突变。人抗体序列分析显示,初始谱多样性集中在抗原结合位点中心,而体细胞超突变将多样性散布在在初始谱中高度保守的抗原结合位点的外围区域(参见Tomlinson等(1996)J.Mol.Biol.,256:813)。这种互补很可能进化为搜寻序列间隔的有效策略,尽管对于抗体明显是独特的,但这可能容易地应用到其它多肽谱。被改变的残基是形成靶标结合位点的那些残基的子集。若有需要,靶标结合位点中不同的(包括重叠的)残基子集在选择期间在不同阶段被多样化。
在抗体谱情况下,当某些而不是所有抗原结合位点残基被多样化时,产生了初始“天然”谱。本文上下文所用术语“天然”或“假体(dummy)”指没有预先确定靶标的抗体分子。这些分子类似于尚未经历免疫多样化的个体的免疫球蛋白基因所编码的分子,所述尚未经历免疫多样化的个体的例子为胎儿及新生儿个体,其免疫系统尚未受到多种抗原刺激物的攻击。然后针对一系列抗原或表位选择该谱。若有需要,可在初始谱中被多样化的区域之外引入另外的多样性。可选择这种成熟的谱用于改变功能、特异性或亲和力。
应该理解的是,本文所述序列包括与本文所述序列具有基本同一性的序列,例如至少90%同一性,例如至少91%或至少92%或至少93%或至少94%或至少95%或至少96%或至少97%或至少98%或至少99%同一性。
对于核酸,术语“基本同一性”表明当对两种核酸或其指定序列以适当的核苷酸插入或缺失进行最佳比对及比较时,它们有至少约80%的核苷酸、通常至少约90%-95%并更优选至少约98%-99.5%的核苷酸相同。或者,当区段在选择性杂交条件下与互补链杂交时存在基本上同一性。
对于核苷酸和氨基酸序列,术语“同一″表明当两个核酸或氨基酸序列之间以适当插入或缺失进行最佳比对和比较时的相同程度。或者,当DNA区段在选择性杂交条件与互补链杂交时存在基本上同一性。
两个序列之间的同一性百分比是序列共有的同一位置数量的函数(即同一性%=同一位置数目/位置总数乘以100),为了两个序列的最佳比对需要考虑空位数目及每一空位长度。可用数学算法完成序列比较和两个序列之间同一性百分比的测定,其如以下非限制性实施例所述。
可用GCG软件包中的GAP程序、用NWSgapdna.CMP矩阵和40、50、60、70或80的空位权重和1、2、3、4、5或6的长度权重,来测定两个核苷酸序列之间的同一性百分比。还可用被整合到ALIGN程序(2.0版)的E.Meyers和W.Miller算法(Comput.Appl.Biosci.,4:11-17(1988))、用PAM120权重残基表、空位长度罚分12和空位罚分4来测定两个核苷酸或氨基酸序列之间的同一性百分比。另外,可用业已整合到GCG软件包中的GAP程序的Needleman和Wunsch(J.Mol.Biol.48:444-453(1970))算法、用Blossum 62矩阵或PAM250矩阵和空位权重16、14、12、10、8、6或4和长度权重1、2、3、4、5或6,来测定两个氨基酸序列之间的同一性百分比。
举例而言,本发明多核苷酸序列可与SEQ ID NO:122参考序列同一,也就是说100%同一,或其与参考序列比较可包括至多某些整数个的核苷酸改变。所述改变选自至少一个核苷酸缺失、置换(包括转换和颠换)或插入,并且其中所述改变可发生在参考核苷酸序列的5′或3′末端位置,或这些末端位置之间的任何位置,其各自散布在参考序列的核苷酸之中的或在参考序列内的一个或多个邻接基团(contiguousgroup)中。通过让SEQ ID NO:122的核苷酸总数乘以各自同一性百分比数值(除以100),并从所述SEQ ID NO:122核苷酸总数减去该乘积,求出核苷酸改变数目,或:
nn≤xn-(xn·y),
其中nn为核苷酸改变数目,xn为SEQ ID NO:122核苷酸总数,y:对于50%为0.50、对于60%为0.60、对于70%为0.70、对于80%为0.80、对于85%为0.85、对于90%为0.90、对于95%为0.95、对于97%为0.97或对于100%为1.00,其中在从xn减去xn与y的任何非整数乘积之前将其四舍五入成最接近的整数。SEQ ID NO:122多核苷酸序列的改变可在该编码序列中产生无意义、错义或移码突变,藉此在所述改变后改变多核苷酸所编码的多肽。
同样地,在另一实施例中,本发明可多肽序列可与SEQ ID NO:26编码的参考序列同一,也就是说100%同一,或其与参考序列比较可包括至多某些整数个的氨基酸改变,致使同一性%小于100%。所述改变选自至少一个核苷酸缺失、取代(包括保守和非保守取代)或插入,其中所述改变可发生在参考多肽序列的氨基末端或羧基末端位置,或这些末端位置之间的任何位置,其各自散布在参考序列的氨基酸之中或在参考序列内的一个或多个邻接基团中。通过让SEQ ID NO:26编码的多肽序列中氨基酸总数乘以各自同一性百分比数值(除以100),然后从所述SEQ ID NO:26编码的多肽序列中氨基酸总数减去该乘积,求出对应于既定同一性%的氨基酸改变数目,或:
na≤xa-(xa·y),
其中na为氨基酸改变数目,xa为SEQ ID NO:26所编码的多肽序列中氨基酸的总数,y为例如:对于70%为0.70、对于80%为0.80、对于85%为0.85等,其中在从xa减去xa与y的任何非整数乘积之前将其四舍五入成最接近的整数。
实施例
以下方法在本文所述实施例中使用。
方法1
通过ELISA测定与大肠杆菌表达的重组人IL-13的结合
在直接结合ELISA中评估mAbdAb分子对大肠杆菌表达的重组人IL-13的结合。简言之,将5μg/ml大肠杆菌表达的重组人IL-13(由GSK制备并纯化)包被到96孔ELISA板。在室温将各孔封闭1小时,然后对所述板滴定出(titrate out)mAbdAb构建体(通常从3倍稀释液中的大约100nM到大约0.01nM)。用抗-人κ轻链过氧化物酶缀合抗体(货号A7164,Sigma-Aldrich)的适当稀释液或抗-人IgGγ链特异性过氧化物酶缀合检测抗体(货号A6029,Sigma-Aldrich)的适当稀释液检测结合。
方法2
通过ELISA测定与大肠杆菌表达的重组人IL-4的结合
在直接结合ELISA中评估mAbdAb构建体对大肠杆菌表达的重组人IL-4的结合。简言之,将5μg/ml大肠杆菌表达的重组人IL-4(由GSK制备并纯化)包被到96孔ELISA板。在室温将各孔封闭1小时,然后对所述板滴定出mAbdAb构建体(通常从3倍稀释液中的大约100nM到大约0.01nM)。用山羊抗-人κ轻链过氧化物酶缀合抗体(货号A7164,Sigma-Aldrich)的适当稀释液或抗-人IgGγ链特异性过氧化物酶缀合检测抗体(货号A6029,Sigma-Aldrich)的适当稀释液检测结合。
方法3
通过ELISA检测与大肠杆菌表达的重组人IL-18的结合
在直接结合ELISA中评估mAbdAb构建体对大肠杆菌表达的重组人IL-18的结合。简言之,将5μg/ml大肠杆菌表达的重组人IL-18(由GSK制备并纯化)包被到96孔ELISA板。在室温将各孔封闭1小时,然后对所述板滴定出mAbdAb构建体(通常从3倍稀释液中的大约100nM到大约0.01nM)。用抗-人κ轻链过氧化物酶缀合抗体(货号A7164,Sigma-Aldrich)的2000倍稀释液或抗-人IgGγ链特异性过氧化物酶缀合检测抗体(货号A6029,Sigma-Aldrich)的2000倍稀释液检测结合。
方法4
对结合大肠杆菌表达的重组人IL-13的Biacore
TM
结合亲和力评估
由BiacoreTM分析评估了mAbdAb构建体对于大肠杆菌表达的重组人IL-13的结合亲和力。用蛋白A或抗-人IgG捕获抗体进行分析。简言之,按照制造商提议通过伯胺偶联将蛋白A或抗-人IgG偶联到CM5芯片上。然后将mAbdAb构建体捕获到该表面上,以限定浓度使人IL-13(由GSK制备并纯化)通过(pass over)。用温和的酸洗脱条件(例如100mM磷酸)使该表面再生为蛋白A表面,这不会显著影响捕获抗体对随后的IL-13结合事件的能力。用与再生蛋白A表面相似的条件或通过用3M MgCl2使抗-人IgG表面再生。在BiacoreTM 3000和/或T100设备上实施该工作,用设备中的评估软件分析数据,并拟合为1∶1的结合模型。在25℃或37℃实施BiacoreTM运行。
方法5
对结合大肠杆菌表达的重组人IL-4的Biacore
TM
结合亲和力评估
由BiacoreTM分析评估了mAbdAb构建体对于大肠杆菌表达的重组人IL-4的结合亲和力。用蛋白A或抗-人IgG捕获抗体进行分析。简言之,按照制造商提议通过伯胺偶联将蛋白A或抗-人IgG偶联到CM5芯片上。然后将mAbdAb构建体捕获到该表面,以限定浓度使人IL-4(由GSK制备并纯化)通过。用温和的酸洗脱条件(例如100mM磷酸)使该表面再生为蛋白A表面,这不会显著影响捕获抗体对随后的IL-4结合事件的能力。用与再生蛋白A表面相似的条件或通过用3M MgCl2使抗-人IgG表面再生。在BiacoreTM 3000和/或T100和/或A100设备上实施该工作,用设备中的评估软件分析数据,并拟合为1∶1的结合模型。在25℃或37℃实施BiacoreTM运行。
方法6
对结合大肠杆菌表达的重组人IL-18的Biacore
TM
结合亲和力评估
由BiacoreTM分析评估了mAbdAb构建体对于大肠杆菌表达的重组人IL-18的结合亲和力。用蛋白A或抗-人IgG捕获抗体进行分析。简言之,按照制造商提议通过伯胺偶联将蛋白A或抗-人IgG偶联到CM5芯片上。然后将mAbdAb构建体捕获到该表面,以限定浓度使人IL-18(由GSK制备并纯化)通过。用温和的酸洗脱条件(例如100mM磷酸)使该表面再生为蛋白A表面,这不会显著影响捕获抗体对随后的IL-18结合事件的能力。用与再生蛋白A表面相似的条件或通过用3M MgCl2使抗-人IgG表面再生。在BiacoreTM 3000和/或T100和/或A100设备上实施该工作,用设备中的评估软件分析数据,并拟合为1∶1的结合模型。在25℃实施BiacoreTM运行。
方法7
对IL-13、IL-4或IL-18的mAbdAb双特异性抗体或三特异性抗体的 化学计量评估(用Biacore TM)
通过伯胺偶联将抗-人IgG固定到CM5生物传感器芯片上。在使单一浓度的IL-13、IL-4或IL-18细胞因子通过后,将mAbdAb构建体捕获到该表面上,该浓度足以使结合表面饱和,所观察到的结合信号达到满R-max。然后用给定公式计算化学计量:
化学计量=Rmax*Mw(配体)/Mw(分析物)*R(被固定或捕获的配体)
当计算不止一种在同一时间结合的分析物的化学计量时,使不同的细胞因子以饱和细胞因子浓度序贯通过,如上计算化学计量。本工作在Biacore 3000上于25℃下用HBS-EP运行缓冲液进行。
方法8
在TF-1细胞增殖生物测定中大肠杆菌表达的重组人IL-13的中和
TF-1细胞因响应包括人IL-13在内的许多不同的细胞因子而增殖。因此,可将这些细胞对IL-13的增殖性响应用于测量IL-13的生物活性,并随后开发出测定mAbdAb构建体对IL-13的中和效能(抑制IL-13生物活性)的测定法。
在无菌条件下于无菌96孔组织培养板中实施测定,所有测试孔以一式三份进行。让大约14ng/ml大肠杆菌表达的重组人IL-13与mAbdAb构建体的各种稀释液(通常从以3倍稀释滴定的200nM到0.02nM)在50μl总体积中于37℃预孵育1小时。然后将这些样品加到无菌96孔组织培养板的50μl的TF-1细胞(以每毫升2x105个细胞的浓度)中。因此,最后100μl测定体积含有各种稀释度的mAbdAb构建体(以从以3倍稀释滴定的100nM到0.01nM的终浓度)、大肠杆菌表达的重组人IL-13(以7ng/ml的终浓度)和TF-1细胞(以每毫升1x105个细胞的终浓度)。让测定板在37℃增湿CO2培养箱中孵育大约3天。然后用来自Prome ga的‘CellTitreNon-Radioactive Cell ProliferationAssay’(货号G4100)如制造商说明书所述测定细胞增殖的量。在板读数器中于570nm处读取96-孔板的样品的吸光度。
将mAbdAb构建体中和大肠杆菌表达的重组人IL-13的生物活性的能力,表示为中和限定量的人IL-13(7ng/ml)的生物活性到50%所需的mAbdAb构建体浓度(=ND50)。所需mAbdAb构建体的浓度越低,中和能力的功效越强。手动或通过用微软excel固有的Robosage软件包计算本文提供的ND50数据。
方法9
在TF-1细胞增殖生物测定中大肠杆菌表达的重组人IL-4的中和
TF-1细胞因响应包括人IL-4在内的许多不同的细胞因子而增殖。因此,可将这些细胞对IL-4的增殖性响应用于测量IL-4的生物活性,并随后开发出测定mAbdAb构建体对IL-4的中和效价(抑制IL-4生物活性)的测定法。
在无菌条件下于无菌96孔组织培养板中实施测定,所有测试孔以一式三份进行。让大约2.2ng/ml大肠杆菌表达的重组人IL-4与mAbdAb构建体的各种稀释液(通常从以3倍稀释滴定的200nM到0.02nM)在50μl总体积中于37℃预孵育1小时。然后将这些样品加到于无菌96孔组织培养板的50μl的TF-1细胞(以每毫升2x105个细胞的浓度)中。因此,最后100μl测定体积含有各种稀释度的mAbdAb构建体(以从以3倍稀释滴定的100nM到0.01nM的终浓度)、大肠杆菌表达的重组人IL-4(以1.1ng/ml的终浓度)和TF-1细胞(以每毫升1x105个细胞的终浓度)。让测定板在37℃增湿CO2培养箱中孵育大约3天。然后用来自Promega的‘CellTitreNon-Radioactive CellProliferation Assay’(货号G4100)如制造商说明书所述测定细胞增殖的量。在板读数器中于570nm处读取96-孔板的样品的吸光度。
将mAbdAb构建体中和大肠杆菌表达的重组人IL-4的生物活性的能力,表示为中和限定量的人IL-4(1.1ng/ml)的生物活性到50%所需的mAbdAb构建体浓度(=ND50)。所需mAbdAb构建体的浓度越低,中和能力的功效越强。手动或通过用微软excel固有的Robosage软件包计算本文提供的ND50数据。
方法10
在TF-1细胞增殖生物测定中大肠杆菌表达的重组人IL-13和大肠杆
菌表达的重组人IL-4的双重中和
TF-1细胞因响应包括人IL-13和人IL-4在内的许多不同的细胞因子而增殖。因此,可将这些细胞对IL-13及IL-4的增殖性响应用于同时测量IL-13及IL-4的生物活性,并随后开发出测定mAbdAb构建体对IL-13及IL-4双重中和效价(IL-13及IL-4生物活性的双重抑制)的测定法。
在无菌条件下于无菌96孔组织培养板中实施测定,所有测试孔以一式三份进行。让大约14ng/ml大肠杆菌表达的重组人IL-13和大约2.2ng/ml大肠杆菌表达的重组人IL-4与mAbdAb构建体的各种稀释液(通常从以3倍稀释滴定的200nM到0.02nM)在50μl总体积中于37℃预孵育1小时。然后将这些样品加到无菌96孔组织培养板的50μl的TF-1细胞(以每毫升2x105个细胞的浓度)中。因此,最后100μl测定体积含有各种稀释度的mAbdAb构建体(以从以3倍稀释滴定的100nM到0.01nM的终浓度)、大肠杆菌表达的重组人IL-13(以7ng/ml的终浓度)、大肠杆菌表达的重组人IL-4(以1.1ng/ml的终浓度)和TF-1细胞(以每毫升1x105个细胞的终浓度)。让测定板在37℃增湿CO2培养箱中孵育大约3天。然后用来自Promega的‘CellTitreNon-Radioactive Cell Proliferation Assay’(货号G4100)如制造商说明书所述测定细胞增殖的量。在板读数器中于570nm处读取96-孔板的样品的吸光度。
方法11
对结合Sf21-表达的重组人IL-5的Biacore
TM
结合亲和力评估
由BiacoreTM分析评估了mAbdAb分子对于Sf21-表达的重组人IL-5的结合亲和力。用蛋白A或抗-人IgG捕获抗体进行分析。简言之,按照制造商提议通过伯胺偶联将蛋白A或抗-人IgG偶联到CM5芯片上。然后将mAbdAb分子捕获到该表面上,以限定浓度使人IL-5(由GSK制备并纯化)通过。用温和的酸洗脱条件(例如100mM磷酸)使该表面再生为蛋白A表面,这不会显著影响捕获抗体对随后的IL-5结合事件的能力。用与再生蛋白A表面相似的条件或通过用3M MgCl2使抗-人IgG表面再生。在BiacoreTM 3000、T100和A100设备上实施该工作,用设备中的评估软件分析数据,并拟合为1∶1的结合模型。在25℃实施BiacoreTM运行。
方法12
VEGF受体结合测定
本测定测量VEGF165与VEGF R2(VEGF受体)的结合及测试分子封阻该相互作用的能力。用VEGF受体(R&D Systems,货号:357-KD-050)(在0.2M碳酸钠/碳酸氢钠pH9.4中0.5μg/ml终浓度)过夜包被ELISA板,洗涤并用2%BSA/PBS封闭。在将VEGF(R&D Systems,货号:293-VE-050)和测试分子(在含0.1%BSA的0.05%Tween 20TMPBS中稀释)预孵育1小时,随后加入到板(3ng/ml VEGF终浓度)中。用生物素化抗-VEGF抗体(0.5μg/ml终浓度)(R&D Systems,货号:BAF293)和过氧化物酶缀合抗-生物素第二抗体(1∶5000稀释)(Stratech,货号:200-032-096)检测VEGF与VEGF受体的结合,并在用等体积1MHCl终止反应后用比色底物(Sure Blue TMB过氧化物酶底物,KPL)在OD450处显示。
方法13
EGFR激酶测定
通过其与EGF的相互作用激活在A431细胞表面表达的EGFR,导致受体的酪氨酸激酶磷酸化。测量EGFR酪氨酸激酶磷酸化的减少以测定测试分子的效价。让A431细胞过夜附着到96孔组织培养板,然后加入测试分子并放置1小时,然后与EGF(300ng/ml)(R&D Systems货号236-EG)孵育10分钟。使细胞裂解,并将裂解的制备物转移到用抗-EGFR抗体(1ug/ml)(R&D Systems,货号AF231)包被的ELISA板。捕获在裂解细胞液中存在的磷酸化和非磷酸化的两种EGFR。洗掉未结合的物质后,用HRP缀合的抗-磷酸酪氨酸抗体(1∶2000稀释)(UpstateBiotechnology,货号16-105)特异性检测磷酸化的EGFR。用显色底物使结合可视化。
方法14
MRC-5/TNF测定
用人肺成纤维细胞MRC-5细胞测定测试分子防止人TNF-a结合人TNFR1及中和IL-8分泌的能力。让系列稀释的测试样品与TNF-a(500pg/ml)(Peprotech)孵育1小时。然后用MRC-5细胞悬浮液(ATCC,货号CCL-171)(5x103细胞/孔)对其进行1∶2稀释。过夜孵育后,将样品稀释10倍,用IL-8ABI 8200细胞检测测定(FMAT)来测定IL-8的释放,其中用抗-IL-8(R&D Systems,货号208-IL)包被的聚苯乙烯珠粒、生物素化抗-IL-8(R&D Systems,货号BAF208)和链霉亲和素Alexafiuor647(Molecular Probes,货号S32357)测定IL-8浓度。以647nm荧光发射来定位测定读数,用包括在该测定中的IL-8标准曲线内推(interpolate)未知IL-8浓度。
方法15
MRC-5/IL-1测定
用人肺成纤维细胞MRC-5细胞测定测试分子防止人IL-1a结合人IL1-R及中和IL-8分泌的能力。用胰蛋白酶处理MRC-5细胞(ATCC,货号CCL-171),然后作为混悬液与测试样品孵育1小时。然后力入IL-1a(200pg/ml终浓度)(R&D Systems货号:200-LA)。过夜孵育后,用IL-8定量ELISA试剂盒(R&D Systems)与抗-IL-8包被的ELISA板、生物素化抗-IL-8和链霉亲和素-HRP来测定IL-8的释放。测定读数为450nm处的色度吸光度,用包括在该测定中的IL-8标准曲线内推未知IL-8浓度。
方法16
在全血磷-STAT6生物测定中大肠杆菌表达的重组人IL-13或IL-4的
中和效价
可用大肠杆菌表达的重组人IL-4(rhIL-14)或IL-13(rhIL-13)离体刺激全血细胞,以表达磷-STAT6(pSTAT6)。本测定被开发为定量测量pSTAT6,并由此测定mAbdAb构建体的中和效价(抑制IL-4或IL-13的生物活性)。
在无菌条件下于无菌96孔组织培养板中实施测定,所有测试孔以一式三份进行。在无血清细胞培养基中制备12ng/ml的rhIL-13或rhIL-4,加31.2μL到96孔板的孔中。以6x的最终测定浓度制备mAbdAb构建体或同种型对照的9点稀释曲线,将31.2μL的各稀释液加到含有rhIL-4或rhIL-13的孔中。将125μL肝素化的人全血加到所有孔中,并在混合器上混合30秒。最终测定体积含有各个稀释度的mAbdAb构建体,连同终浓度为2ng/mL的rhIL-13或rhIL-4。让测定板在37℃、5%CO2中孵育60分钟。
然后通过加入62.5μL的4x裂解缓冲液裂解细胞。裂解缓冲液含有最终测定浓度的50mM Tris盐酸、300mM氯化钠、1%NP40、0.5%脱氧胆酸钠、50mM氟化钠、1mM原钒酸钠、1mM EDTA和蛋白酶抑制剂混合物。将板置于冰上30分钟,然后在-80℃冷冻直到用于pSTAT6测定。
用电致化学发光免疫测定(Meso-Scale-Discovery,MSD)实施全血样品的pSTAT6测量。简言之,用每孔150μL的5%MSD封闭剂A于室温在混合器上以750rpm对亲和素包被的96孔MSD板封闭1小时。用每孔150μL的MSD Tris洗涤缓冲液洗涤板3次。每孔加入25μL的捕获抗体(生物素化小鼠抗-人STAT6单克隆抗体),让板在4℃孵育过夜。让捕获抗体在由50mM Tris、150mM氯化钠、0.2%BSA、0.5%Tween 20、1mM EDTA组成的测定缓冲液中稀释到4μg/mL。用MSDtris洗涤缓冲液洗涤板3次,然后用150μL的5%MSD封闭剂A于室温在混合器上对板封闭1小时。如前述洗涤板3次,然后每孔加入25μL全血裂解物或pSTAT6标定剂(calibrator)。让板于室温在混合器上孵育3小时。洗涤板3次,然后加入25μL兔抗人pSTAT6抗体(在测定缓冲液中以1∶800稀释),然后于室温孵育1小时。进一步洗涤后,每孔加入25μL的1∶500稀释的MSD TAG山羊抗-兔IgG抗体,然后于室温在混合器上孵育1小时。在每孔加入150μL的2x MSD读出缓冲液T之前再次洗涤板。在MSD SECTOR成像器上立即读板。
将mAbdAb构建体中和rhIL-13或rhIL-4生物活性的能力表示为中和2ng/mL人IL-4或人IL-13到50%所需的mAbdAb构建体浓度(IC50)。所需mAbdAb构建体浓度越低,中和能力的功效就越强。
方法17
通过ELISA测定与大肠杆菌表达的重组猕猴IL-13的结合
在直接结合ELISA中评估mAbdAb分子对大肠杆菌表达的重组猕猴(cynomolgus)IL-13的结合。简言之,将5μg/ml大肠杆菌表达的重组猕猴IL-13(由GSK制备并纯化)包被到96孔ELISA板。在室温将各孔封闭1小时,然后对所述板滴定出mAbdAb分子(通常从3倍稀释液中的大约100nM到大约0.01nM)。用抗-人κ轻链过氧化物酶缀合抗体(货号A7164,Sigma-Aldrich)的适当稀释液或抗-人IgGγ链特异性过氧化物酶缀合检测抗体(货号A6029,Sigma-Aldrich)的适当稀释液检测结合。
方法18
未使用
方法19
通过ELISA检测人IL-4与人IL4受体α(IL4Rα)结合的抑制
除非另外指出,否则所有试剂在使用前于封闭液(tris缓冲的盐水和0.05%Tween20中的4%牛血清白蛋白)中稀释到所需浓度。用磷酸盐缓冲盐水中的5μg/ml重组人IL4Rα-Fc嵌合体(R&D Systems,货号604-4R)于4℃过夜包被ELISA板。所有随后的步骤都在室温进行。在加入业已与0.02μg/ml重组人IL-4(由GSK制备)预混合的50μl不同浓度的mAbdAb(或阳性对照mAb或dAb)之前,让板在封闭液中封闭2小时。在用洗涤缓冲液(Tris缓冲的盐水和0.05%Tween20)洗涤板4次之前让板孵育1小时。将50μl的0.5μg/ml生物素化抗-人IL-4(R&D Systems,货号BAF 204)溶液加入到每一孔,并孵育1小时。用洗涤缓冲液洗涤板4次,然后加入50μl/孔的1/2000稀释的Extravadin(Sigma,货号E2886)。1小时后,洗涤板4次,通过与OPD过氧化物酶底物(来自Sigma)孵育来检测色度信号,用终止溶液(3M H2SO4酸)终止该反应,通过在板读数器上于490nm处获得吸光度数据。在GraphPad Prism上对平均吸光度和标准差作图,用Cambridge Soft BioAssay计算IC50值。
方法20
在TF-1细胞增殖生物测定中大肠杆菌表达的重组猕猴IL-13的中和
TF-1细胞因响应包括猕猴IL-13在内的许多不同的细胞因子而增殖。因此,可将这些细胞对IL-13的增殖性响应用于测量IL-13的生物活性,并随后开发出测定mAbdAb构建体对IL-13的中和效价(抑制IL-13生物活性)的测定法。
在无菌条件下于无菌96孔组织培养板中实施测定,所有测试孔以一式三份进行。让大约14ng/ml大肠杆菌表达的重组猕猴IL-13与mAbdAb构建体的各种稀释液(通常从以3倍稀释滴定的1000nM或200nM到1nM或0.02nM)在50μl总体积中于37℃预孵育1小时。然后将这些样品加到无菌96孔组织培养板的50μl的TF-1细胞(以每毫升2x105个细胞的浓度)中。因此,最后100μl测定体积含有各种稀释度的mAbdAb构建体(以从以3倍稀释滴定的500nM或100nM到0.5nM或0.01nM的终浓度)、大肠杆菌表达的重组猕猴IL-13(以7ng/ml的终浓度)和TF-1细胞(以每毫升1x105个细胞的终浓度)。让测定板在37℃增湿CO2培养箱中孵育大约3天。然后用来自Promega的‘CellTitreNon-Radioactive Cell Proliferation Assay’(货号G4100)如制造商说明书所述测定细胞增殖的量。在板读数器中于570nm处读取96-孔板的样品的吸光度。
将mAbdAb构建体中和大肠杆菌表达的重组猕猴IL-13的生物活性的能力,表示为中和限定量的猕猴IL-13(7ng/ml)的生物活性到50%所需的mAbdAb构建体浓度(=ND50)。所需mAbdAb构建体的浓度越低,中和能力的功效越强。手动或通过用微软excel固有的Robosage软件包计算本文提供的ND50数据。
方法21
在TF-1细胞增殖生物测定中大肠杆菌表达的重组猕猴IL-4的中和
TF-1细胞因响应包括猕猴IL-4在内的许多不同的细胞因子而增殖。因此,可将这些细胞对IL-4的增殖性响应用于测量IL-4的生物活性,并随后开发出测定mAbdAb构建体对IL-4的中和效价(抑制IL-4生物活性)的测定。
在无菌条件下于无菌96孔组织培养板中实施测定,所有测试孔以一式三份进行。让大约2.2ng/ml大肠杆菌表达的重组猕猴IL-4与mAbdAb构建体的各种稀释液(通常从以3倍稀释滴定的200nM到0.02nM)在50μl总体积中于37℃预孵育1小时。然后将这些样品加到无菌96孔组织培养板的50μl的TF-1细胞(以每毫升2x105个细胞的浓度)中。因此,最后100μl测定体积含有各种稀释度的mAbdAb构建体(以从以3倍稀释滴定的100nM到0.01nM的终浓度)、大肠杆菌表达的重组猕猴IL-4(以1.1ng/ml的终浓度)和TF-1细胞(以每毫升1x105个细胞的终浓度)。让测定板在37℃增湿CO2培养箱中孵育大约3天。然后用来自Promega的‘CellTitreNon-Radioactive CellProliferation Assay’(货号G4100)如制造商说明书所述测定细胞增殖的量。在板读数器中于570nm处读取96-孔板中的样品的吸光度。
将mAbdAb构建体中和大肠杆菌表达的重组猕猴IL-4的生物活性的能力,表示为中和限定量的猕猴IL-4(1.1ng/ml)的生物活性到50%所需的mAbdAb构建体浓度(=ND50)。所需mAbdAb构建体的浓度越低,中和能力的功效越强。手动或通过用微软excel固有的Robosage软件包计算本文提供的ND50数据。
方法22
通过ELISA测定人IL-13与人IL13受体α2(IL13Rα)结合的抑制
除非另外指出,否则所有试剂在使用前于封闭液(tris缓冲的盐水和0.05%Tween20中的1%牛血清白蛋白)中稀释到所需浓度。用包被缓冲液(0.05M碳酸氢盐pH9.6,Sigma C-3041)溶液中的5μg/ml在Sf21细胞中表达的重组人IL13Rα-Fc嵌合体(R&D Systems,货号614-1R)于4℃过夜包被ELISA板。在加入业已于37℃与30ng/ml重组人IL-13(由GSK制备)预孵育30分钟的不同浓度的mAbdAb(或阳性对照mAb或dAb)之前,让板于室温在封闭液(TBST中的1%BSA)中封闭1小时。在用洗涤缓冲液(Tris缓冲的盐水和0.05%Tween20)洗涤板3次之前,让板于室温孵育1小时。将50μl的0.5μg/ml生物素化抗-人IL-13(R&DSystems,货号BAF 213)溶液加入到每一孔,并在室温孵育1小时。用洗涤缓冲液洗涤板3次,然后加入合适稀释度的Extravadin(Sigma,货号E2886)。1小时后洗涤板,通过与OPD过氧化物酶底物(来自Sigma)孵育来检测色度信号,用终止溶液(3M酸)终止该反应,通过在板读数器上于490nm处获得吸光度数据。在Excel表格上对平均吸光度和标准差作图,用来自微软Excel的Robosage软件计算IC50值。
方法23
对结合大肠杆菌表达的重组猕猴IL-13的Biacore
TM
结合亲和力评估
由BiacoreTM分析评估了mAbdAb(或mAb)分子对于大肠杆菌表达的重组猕猴IL-13的结合亲和力。用蛋白A或抗-人IgG捕获抗体进行分析。简言之,按照制造商提议通过伯胺偶联将蛋白A或抗-人IgG偶联到CM5芯片上。然后将mAbdAb(或mAb)分子捕获到该表面上,以限定浓度使猕猴IL-13(由GSK制备并纯化)通过。用温和的酸洗脱条件使该表面再生为蛋白A表面,这不会显著影响捕获抗体对随后的IL-13结合事件的能力。在BiacoreTM 3000和/或T100设备上实施该工作,用设备中的评估软件分析数据,并拟合为1∶1的结合模型。在25℃或37℃实施BiacoreTM运行。
方法24
对结合大肠杆菌表达的重组猕猴IL-4的Biacore
TM
结合亲和力评估
由BiacoreTM分析评估了mAbdAb(或mAb)分子对于大肠杆菌表达的重组猕猴IL-4的结合亲和力。用蛋白A或抗-人IgG捕获抗体进行分析。简言之,按照制造商提议通过伯胺偶联将蛋白A或抗-人IgG偶联到CM5芯片上。然后将mAbdAb(或mAb)分子捕获到该表面上,以限定浓度使猕猴IL-4(由GSK制备并纯化)通过。用温和的酸洗脱条件(例如100mM磷酸)使该表面再生为蛋白A表面,这不会显著影响捕获抗体对随后的IL-4结合事件的能力。用与再生蛋白A表面相似的条件或通过用3M MgCl2使抗-人IgG表面再生。在BiacoreTM 3000和/或T100和/或A100设备上实施该工作,用设备中的评估软件分析数据,并拟合为1∶1的结合模型。在25℃或37℃实施BiacoreTM运行。
方法25
基于IL-13细胞的中和测定
在IL-13细胞测定中用工程改造的报告细胞系HEK Blue-STAT6测定对IL13具有特异性的mAbdAb的效价。
转录因子STAT6主要由两种具有重叠生物学功能的细胞因子IL-4和IL-13激活,这两种细胞因子结合由IL-4Rα和IL-13Rα1组成的受体复合体。配体结合后,受体复合体激活受体相关的Janus激酶(JAK1和Tyk2),导致STAT6募集及其磷酸化。活化的STAT6形成转移到细胞核的同型二聚体,诱导基因在响应型启动子控制下转录。将HEK Blue-STAT6细胞系工程改造为在所述启动子调控下表达分泌性胎盘碱性磷酸酶(Secreted Embryonic Alkaline Phosphatase,SEAP)。
将细胞接种到96孔板,并与预先平衡的人IL-13及测试分子孵育20-24小时。在该孵育期后,然后用Quanti-blue系统(Invivogen)测量因IL-13刺激而由细胞产生的SEAP量。
实施例1
1.产生双重靶向的mAbdAb
用以下方法构建表1-4中所述的双重靶向的mAbdAb。通过将编码结构域抗体的序列移植到编码单克隆抗体重链或轻链(或二者)的序列上来产生表达构建体,致使表达时dAb被连接到重链或轻链的c-末端。对于某些构建体,将接头序列用于连接结构域抗体与重链CH3或轻链Cκ。在其它构建体中,将结构域抗体不用接头序列直接连接到重链或轻链。这些mAbdAb构建体的总示意图示于图8(mAb重链用灰色画出;mAb轻链用白色画出;dAb用黑色画出)中。
由图8中所述的mAbdAb 1型实例为PascoH-G4S-474。由图8中所述的mAbdAb 2型实例为PascoL-G4S-474。由图8中所述的mAbdAb3型实例为PascoHL-G4S-474。mAbdAb 1型和2型为四价构建体,mAbdAb 3型为六价构建体。
以下显示描述构建mAbdAb重链(上图)或mAbdAb轻链(下图)的示意图。除非另外指出,否则将这些限制性位点用于构建表1-4所述的mAbdAb。
注意对于重链,术语“VH”为单克隆抗体可变重链序列;“CH1、CH2和CH3”为人IgG1重链恒定区序列;“接头”是所用的特定接头区的序列;“dAb”为结构域抗体序列。对于轻链,术语“VL”为单克隆抗体可变轻链序列;“Cκ”为人轻链恒定区序列;“接头”是所用的特定接头区的序列;“dAb”为结构域抗体序列。
某些DNA表达构建体通过寡核苷酸构件(build)从头制备。其它DNA表达构建体通过限制性克隆或位点定向诱变从现存的构建体(其根据上文所述来制备)获得。
用标准分子生物技术将这些构建体(mAbdAb重链或轻链)克隆到哺乳动物表达载体(Rln、Rld或pTT载体系列)。将哺乳动物氨基酸信号序列(如SEQ ID NO:64所示)用于构建这些构建体。
为了表达其中dAb连接到单克隆抗体重链的C-末端的mAbdAb,,让合适的重链mAbdAb表达载体与对于该单克隆抗体的合适轻链表达载体配对。为了表达其中dAb连接到单克隆抗体轻链的C-末端的mAbdAb,让合适的轻链mAbdAb表达载体与对于该单克隆抗体的合适重链表达载体配对。
为了表达其中dAb连接到单克隆抗体重链的C-末端并且其中dAb连接到单克隆抗体轻链的C-末端的mAbdAb,让合适的重链mAbdAb表达载体与合适的轻链mAbdAb表达载体配对。
1.1.命名及所用缩写
单克隆抗体(mAb)
单克隆抗体(mAbs)
结构域抗体(dAb)
结构域抗体(dAbs)
重链(H链)
轻链(L链)
重链可变结构域(VH)
轻链可变结构域(VL)
人IgG1恒定重链区1(CH1)
人IgG1恒定重链区2(CH2)
人IgG1恒定重链区3(CH3)
人κ轻链恒定区(Cκ)
1.2.抗-IL 13mAb-抗-IL4dAb
如上所述构建双特异性抗-IL13mAb-抗-IL4dAb。将多种不同的接头用于将抗-IL4结构域抗体连接到单克隆抗体。某些构建体没有接头。
注意BamHI克隆位点(其编码氨基酸残基G和S)用于将接头和dAb克隆到mAb重链的CH3或克隆到mAb轻链的Cκ。因此,除既定的接头序列外,另外的G和S氨基酸残基也存在于接头序列与重链及轻链表达构建体二者的结构域抗体之间,或于CH3与某些但不是所有重链表达构建体中的接头序列之间。然而,当将G4S接头置于mAbdAb形式的mAb和dAb之间时,已经存在BamHI克隆位点(由于G和S氨基酸残基为G4S接头序列内固有),因此,在CH3或Cκ与用该接头的构建体内的结构域抗体之间不存在另外的G和S氨基酸残基。当在mAbdAb形式的mAb和dAb之间不使用接头序列时,BamHI克隆位点(并因此G和S氨基酸残基)仍存在于CH3或Cκ与结构域抗体之间。关于mAbdAb重链和轻链的氨基酸序列的详细资料在表1阐述。
以下若干实施例使用IL-4mAb为对照抗体。在这些实施例中所用的对照IL-4mAb将为具有SEQ ID NO:14重链序列和SEQ ID NO:15轻链序列的抗体,或将为具有SEQ ID NO:166重链序列和SEQ ID NO:15轻链序列的抗体。这两种IL-4mAb共享相同的CDR,预期它们以同样的方式结合,因此这两种抗体在以下实施例中都被称为帕考珠单抗“帕考珠单抗(Pascolizumab)”或“IL-4mAb”。
以下若干实施例使用IL-5mAb为对照抗体。在这些实施例中所用的对照IL-5mAb应为具有SEQ ID NO:65重链序列和SEQ ID NO:66轻链序列的抗体,或为具有SEQ ID NO:191重链序列和SEQ ID NO:66轻链序列的抗体。这两种IL-5mAb共享相同的CDR,预期它们以同样的方式结合,因此这两种抗体在以下实施例中都被称为“美泊利单抗(Mepolizumab)”或“IL-5mAb”。
在CHOK1细胞上清液中瞬时表达表1中所述的mAbdAb。在定量测定mAbdAb后,分析这些含有mAbdAb的上清液在IL-13和IL-4结合ELISA中的活性。
表1
在CHOK1或CHOE1a细胞上清液中的一种或两者中表达表2所述的mAbdAb,经纯化并在多种IL-13和IL-4活性测定法中分析。
表2
1.3.抗-IL4mAb-抗-IL13dAb
如上所述构建双特异性抗-IL4mAb-抗-IL13dAb。将多种不同的接头用于连接抗-IL13结构域抗体与单克隆抗体。某些构建体没有接头。
注意BamHI克隆位点(其编码氨基酸残基G和S)用于将接头和dAb克隆到mAb重链的CH3或克隆到mAb轻链的Cκ。因此,除几既定接头序列外,另外的G和S氨基酸残基也存在于接头序列与重链及轻链表达构建体二者的结构域抗体之间,或于CH3与某些但不是所有重链表达构建体的接头序列之间。然而,当将G4S接头置于mAbdAb形式的mAb和dAb之间时,已经存在BamHI克隆位点(由于G和S氨基酸残基为G4S接头序列内固有),因此,在CH3或Cκ与用该接头的构建体内的结构域抗体之间不存在另外的G和S氨基酸残基。当在mAbdAb形式的mAb和dAb之间不使用接头序列时,BamHI克隆位点(并因此G和S氨基酸残基)仍存在于CH3或Cκ与结构域抗体之间。关于mAbdAb重链和轻链的氨基酸序列的详细资料在表3中阐述。
在CHOK1细胞上清液中瞬时表达表3中所述的mAbdAb。在定量测定mAbdAb后,分析这些含有mAbdAb的上清液在IL-13和IL-4结合ELISA中的活性。
表3
在CHOK1、CHOE1a或HEK293-6E细胞中的一种或多种中表达表4中所述的mAbdAb。
表4
1.4.单克隆抗体、结构域抗体和接头的序列ID号
用于产生mAbdAb的单克隆抗体(mAb)、结构域抗体(dAb)和接头的序列ID号示于下表5中。
表5
成熟人IL-13氨基酸序列(无信号序列)示于SEQ ID NO:63中。
成熟人IL-4氨基酸序列(无信号序列)示于SEQ ID NO:62中。
1.5.mAbdAb的表达和纯化
将实施例1所述的mAbdAb表达构建体转染到CHOK1细胞、CHOE1a细胞或HEK293-6E细胞中的一种或多种细胞中,小规模(大约3ml)或中等规模(大约50ml-100ml)或大规模(大约1升)表达,然后用固定化的蛋白A柱纯化某些构建体,通过在280nm处读取吸光度来定量测定。
1.6.纯化的mAbdAb的大小排阻色谱分析
通过大小排阻色谱(SEC)和十二烷基硫酸钠聚丙烯酰胺凝胶电泳(SDS PAGE)分析了多种mAbdAb。这些分子中的某些(PascoH-G4S-474,PascoL-G4S-474,PascoH-474和PascoHL-G4S-474.)的代表性数据分别示于图9、10、11和12。显示对这些除掉“GS”基序的分子的SEC和SDS Page分析的代表性数据示于图90-98中。
在某些情况下SEC用于进一步纯化这些分子以除去凝聚物。
实施例2
通过ELISA测定mAbdAb与人IL-13和人IL-4的结合
2.1.抗-IL13mAb-抗-IL4dAb与IL-13和IL-4的结合
在直接结合ELISA(如方法1所述)中测试mAbdAb上清液对人IL-13的结合。这些数据示于图13中。
图13显示所有抗-IL13mAb-抗-IL4dAb结合IL-13。这些mAbdAb的结合活性亦与单独的纯化的抗-人IL13mAb接近相等(在2倍-3倍内),在本测定中包括所述抗-人IL13mAb作为IL-13结合的阳性对照,并为了直接与mAbdAb比较。包括纯化的抗-人IL4mAb(帕考珠单抗)作为IL-13结合的阴性对照。
在直接结合ELISA(如方法2所述)中还测试这些分子与人IL-4的结合。这些数据示于图14中。
图14显示所有抗-IL13mAb-抗-IL4dAb结合IL-4,但未观察到在IL-4结合活性中的某种程度变化。当mAbdAb构建体中不存在抗-IL4dAb时,未观察到与IL-4的结合。也包括纯化的抗-人IL13mAb作为IL-4结合的阴性对照。注意在本测定中没有检测单独的抗-IL-4dAb,因为所述dAb不能被第二检测抗体检测;取而代之的是在本测定中用纯化的抗-人IL4mAb(帕考珠单抗)作为阳性对照以证明IL-4结合。
还可在直接结合ELISA(如方法1所述)中测试纯化的mAbdAb样品对人IL-13的结合。这些数据示于图15中。
这些纯化的抗-IL13mAb-抗-IL4dAb结合IL-13。这些mAbdAb对IL-13的结合活性与单独的纯化的抗-人IL13mAb相等。在本测定中还包括同种型-匹配的mAb(对不相关抗原具有特异性)作为IL-13结合的阴性对照。
在直接结合ELISA(如方法2所述)中还测试这些纯化的mAbdAb与人IL-4的结合。这些数据示于图16中。
所有这些抗-IL13mAb-抗-IL4dAb结合IL-4。注意在本测定中不检测单独的抗-IL-4dAb,因为所述dAb不能被第二检测抗体检测;取而代之的是,在该测定中使用纯化的抗-人IL4mAb(帕考珠单抗)作为阳性对照以证明IL-4结合。在本测定中还包括同种型-匹配的mAb(对不相关抗原具有特异性)作为IL-4结合的阴性对照。
2.2.抗-IL4mAb-抗-IL13dAb与IL-13和IL-4的结合
在直接结合ELISA(如方法2所述)中测试mAbdAb上清液对人IL-4的结合。这些数据示于图17(某些样品一式二份制备和测试,并标注为样品1和样品2)。
图17显示所有这些mAbdAb结合了IL-4。在本测定中包括单独的纯化的抗-人IL4mAb(帕考珠单抗),但不产生结合曲线,因为当稀释该mAb用于测定时出错(帕考珠单抗业已成功用于所有其它随后的IL-4结合ELISA)。包括纯化的抗-人IL13mAb作为IL-4结合的阴性对照。
在直接结合ELISA(如方法1所述)中还测试同一mAbdAb上清液对人IL-13的结合。这些数据示于图18(某些样品一式二份制备和测试,并标注为样品1和样品2)。
图18显示所有这些抗-IL4mAb-抗-IL13dAb结合IL-13。在本测定中包括单独的纯化的抗-人IL13mAb,但不产生结合曲线,因为当稀释该mAb用于测定时出错(纯化的抗-人IL13mAb业已成功用于所有其它随后的IL-13结合ELISA)。包括纯化的抗-人IL4mAb(帕考珠单抗)作为IL-13结合的阴性对照。注意在该测定中不检测单独的抗-IL-13dAb(DOM10-53-474),因为该dAb不能被第二检测抗体检测。
在直接结合ELISA(如方法2所述)中还检测纯化的抗-IL4mAb-抗-IL13dAb、“PascoH-G4S-474”、“PascoH-474”、“PascoL-G4S-474”和“PascoHL-G4S-474”对人IL-4的结合。这些数据示于图19中。
这些纯化的抗-IL4mAb-抗-IL13dAb结合IL-4。这些mAbdAb的结合活性与单独的纯化的抗-IL4mAb(帕考珠单抗)接近相等(在2倍内)。在本测定中还包括同种型-匹配的mAb(对不相关抗原具有特异性)作为IL-4结合的阴性对照。
在直接结合ELISA(如方法1所述)中还检测这些相同的纯化的抗-IL4mAb-抗-IL13dAb、PascoH-G4S-474、PascoH-474、PascoL-G4S-474和PascoHL-G4S-474对人IL-13的结合。这些数据示于图20A。
这些纯化的抗-IL4mAb-抗-IL13dAb结合IL-13。在本测定中还包括同种型-匹配的mAb(对不相关抗原具有特异性)作为IL-13结合的阴性对照。注意在本测定中没有检测单独的抗-IL-13dAb(DOM10-53-474),因为所述dAb不能被第二检测抗体检测;取而代之的是,在本测定中使用抗-人IL13mAb作为阳性对照以证明IL-13结合。
在如方法17所述的直接结合ELISA中,还检测纯化的PascoH-474、PascoH-TVAAPS-474、PascoH-ASTKG-474和PascoH-ELQLE-474对猕猴IL-13的结合(在本测定中也包括去除GS的PascoH-474和去除GS的PascoH-TVAAPS-474,这些分子的构建如实施例18所述)。显示代表性数据的图出示于图20B中。
所有纯化的PascoH-474、PascoH-TVAAPS-474、PascoH-ASTKG-474和PascoH-ELQLE-474都结合猕猴IL-13。在本测定中包括单独的纯化的抗-人IL4mAb(帕考珠单抗)作为IL-13结合的阴性对照。包括纯化的抗-人IL13mAb作为猕猴IL-13结合的阳性对照。注意在本测定中没有检测单独的抗-IL-13dAb(DOM10-53-474),因为该dAb不能被第二检测抗体检测;取而代之的是,在本测定中使用抗-人IL13mAb作为阳性对照以证明IL-13结合。
实施例3
通过表面等离子共振(BIAcore
TM
)检测mAbdAb与人IL-13和人IL-4
的结合
3.1.通过BIAcoreTM检测抗-IL13mAb-抗-IL4dAb与IL-13和IL-4的结合
用BIAcoreTM于25℃(如方法4所述)检测mAbdAb(在CHO细胞上清液中,如1.5章节所述制备)对人IL-13的结合。对于该数据集,评估了两条IL-13浓度曲线(100nM和1nM),关于每一mAbdAb构建体的相对响应捕获水平达到1000至1300(大约)之间。由于使用限定浓度的IL-13,产生的数据更适用于为构建体排等级而不是准确的动力学测量。这些数据示于表6中。
表6
抗体 | 结合亲和力KD(nM) |
586H-25 | 0.39 |
586H-G4S-25 | 0.41 |
586H-TVAAPS-25 | 0.5 |
586H-ASTKG-25 | 0.54 |
586H-EPKSC-25 | 0.55 |
586H-ELQLE-25 | 0.42 |
586H-147 | 0.46 |
586H-G4S-147 | 0.45 |
586H-TVAAPS-147 | 0.56 |
586H-ASTKG-147 | 0.44 |
586H-EPKSC-147 | 0.46 |
586H-ELQLE-147 | 0.51 |
586H-154 | 0.46 |
586H-G4S-154 | 0.37 |
586H-TVAAPS-154 | 0.56 |
586H-ASTKG-154 | 0.44 |
586H-EPKSC-154 | 0.42 |
586H-ELQLE-154 | 0.44 |
586H-210 | 0.44 |
586H-G4S-210 | 0.42 |
586H-TVAAPS-210 | 0.4 |
586H-ASTKG-210 | 0.4 |
586H-EPKSC-210 | 0.43 |
586H-ELQLE-210 | 0.43 |
586H | 0.44 |
586H-ASTKG | 0.32 |
586H-ELQLE | 0.47 |
586H-EPKSC | 0.45 |
抗-人IL-13mAb(纯化的) | 0.38 |
帕考珠单抗(纯化的) | 未结合 |
所有这些抗-IL13mAb-抗-IL4dAb以相似的结合亲和力结合IL-13,所述结合亲和力与单独的纯化的抗-人IL13mAb结合亲和力接近相等。这些数据提示将接头和/或抗-IL4dAb加到抗-IL13mAb重链,不影响这些mAbdAb构建体内mAb组分的IL-13结合亲和力。
也用BIAcoreTM于25℃(如方法5所述)检测这些mAbdAb对人IL-4的结合。这些数据示于表7中。对于该数据集,评估了四个IL-4浓度曲线(512、128、32和8nM),在表中指出了关于所检测的每一mAbdAb的大概相对响应捕获水平。注意在本测定中没有检测单独的抗-IL-4dAb,因为不能将所述dAb捕获到蛋白A或抗-人IgG包被的CM5芯片上;取而代之的是,在本测定中使用抗-人IL4mAb(帕考珠单抗)作为阳性对照以证明IL-4结合。
表7
对上述某些数据集观察到预示(caveat)。对某些数据集(*)观察到次等曲线拟合,因此,应该谨慎处理在这些数据中已经测定的实际结合亲和力值。某些曲线观察到正解离(positive dissociation)(**),因此,应该谨慎处理在这些数据中已经测定的实际结合亲和力值。另外,BIAcoreTM不能(即不够灵敏)测定所有含有DOM9-112-210dAb的mAbdAb构建体的结合速率和解离速率,这是由于这些mAbdAb与IL-4的结合异常紧密。这些mAbdAb对IL-4的结合动力学的测定进一步受到所观察到的正解离作用的妨碍。这些数据示于图21中。
在另外的实验中获得相似数据。这些数据示于图22中。
这2个独立的数据集表明所有抗-IL13mAb-抗-IL4dAb结合IL-4,但结合亲和力根据用于连接抗-IL4dAb与抗-IL13mAb重链的接头而变化。在本实验中,发现接头的存在提高了mAbdAb形式中抗-IL4dAb组分(当位于重链时)对IL-4的结合亲和力。例如,具有TVAAPS或ELQLEESCAEAQDGELDG接头的分子似乎是更有效的结合物(binder)。当mAbdAb构建体中不存在抗-IL4dAb时,没有观察到结合IL-4。由于这些mAbdAb的DOM9-112-210组分结合得极为紧密并因此解离速率太小而不能用BIAcoreTM测定这一事实,测量586-接头-210mAbdAb对于IL-4的结合亲和力是不可能的。
也用BIAcoreTM在25℃(如方法4和5所述)检测纯化的抗-IL13mAb-抗-IL4dAb对人IL-13和人IL-4的结合。这些数据示于表8中。
表8
所有586H-TVAAPS-25、586H-TVAAPS-154和586H-TVAAPS-210都以相似的结合亲和力结合IL-13,所述结合亲和力与单独的纯化的抗-人IL13mAb结合亲和力接近相等。所有586H-TVAAPS-25、586H-TVAAPS-154和586H-TVAAPS-210都结合IL-4。由于该mAbdAb的DOM9-112-210组分结合得极为紧密并因此解离速率太小而不能用BIAcoreTM测定这一事实,测量586-TVAAPS-210对于IL-4的结合亲和力是不可能的。注意在本测定形式中没有检测单独的抗-IL-4dAb(DOM9-155-25、DOM9-155-154和DOM9-112-210),因为不能将该dAb捕获到蛋白A或抗-人IgG包被的CM5芯片上;取而代之的是在本测定中用抗-人IL4mAb(帕考珠单抗)作为阳性对照以证明IL-4结合。
3.2.通过BIAcoreTM测定抗-IL4mAb-抗-IL13dAb与IL-4和IL-13的结合
用BIAcoreTM于25℃(如方法5所述)检测mAbdAb(在CHO细胞上清液中,如1.5章节所述制备)对人IL-4的结合。这些数据示于表9(某些样品以一式二份制备并测试,其被标注为样品1和样品2)。对于该数据集,评估了四个IL-4浓度曲线(100nM、10nM、1nM和0.1nM),表中指示关于所测的每一mAbdAb的大约的相对响应捕获水平。在本测定中还包括同种型-匹配的mAb(对不相关抗原具有特异性)作为IL-4结合的阴性对照。
表9
测试的所有抗-IL4mAb-抗-IL13dAb都以相似结合亲和力结合IL-4,该结合亲和力与单独的抗-人IL4mAb(帕考珠单抗)的结合亲和力接近相等。PascoL-EPKSC-474以比帕考珠单抗小约2倍的效价结合IL-4。这些数据提示将接头和抗-IL13dAb加到帕考珠单抗的重链或轻链,并不明显影响mAbdAb构建体中mAb组分对IL-4的结合亲和力。
也用BIAcoreTM于25℃(如方法4所述)检测这些mAbdAb对人IL-13的结合。这些数据示于表10(某些样品以一式二份制备并测定,其被标注为样品1和样品2)。对于该数据集,评估了四个IL-13浓度曲线(128nM、32nM、8nM和2nM),表中指示关于所测的每一mAbdAb的大约的相对响应捕获水平。
表10
在实验2中所测的构建体的结合亲和力数据也示于图23中。
所有的抗-IL4mAb-抗-IL13dAb都结合IL-13。在大部分情况下,当将接头置于抗-IL4 mAb重链中时,接头的存在似乎不提高抗-IL13dAb组分对IL-13的结合亲和力。然而,当将接头置于抗-IL4 mAb轻链上时,接头的存在似乎不提高抗-IL13 dAb组分对IL-13的结合亲和力。在本实验中,PascoL-TVAAPS-474似乎具有最强的IL-13结合亲和力。
注意在本测定中没有检测单独的抗-IL-13 dAb(DOM10-53-474),因为不能将该dAb捕获到蛋白A或抗-人IgG包被的CM5芯片上;取而代之的是,在本测定中用纯化的抗-人IL13 mAb作为阳性对照以证明IL-13结合。在本测定中还包括同种型-匹配的mAb(对不相关抗原具有特异性)作为IL-13结合的阴性对照。
也用BIAcoreTM于25℃(如方法4和5所述)检测纯化的抗-IL4mAb-抗-IL13dAb对人IL-4和人IL-13的结合。这些数据示于表11中。
表11
在该实验中,所有PascoH-G4S-474、PascoH-474、PascoL-G4S-474和PascoHL-G4S-474都以相似的结合亲和力结合IL-4,该结合亲和力与单独的抗-人IL4 mAb(帕考珠单抗)的结合亲和力接近相等。它们全部也结合IL-13。注意该测定中没有检测单独的抗-IL-13 dAb(DOM10-53-474),因为不能将dAb捕获到蛋白A或抗-人IgG包被的CM5芯片上;取而代之的是,在本测定中将抗-人IL13 mAb用作阳性对照以证明IL-13结合。
3.3.用BIAcoreTM的IL-13和IL-4与抗-IL4mAb-抗-IL13dAb结合的化学计量
用BIAcoreTM(如方法7所述)评估纯化的抗-IL4mAb-抗-IL13dAb结合IL-13和IL-4的化学计量。这些数据示于表12中。
表12
PascoH-G4S-474、PascoH-474和PascoL-G4S-474能够结合几乎两个IL-13分子和两个IL-4分子。PascoHL-G4S-474能够结合几乎两个IL-4分子和几乎4个IL-13分子。这些数据表明所测构建体能够被预期数目的IL-13或IL-4分子完全占据。
实施例4
mAbdAb在IL-13和IL-4生物测定中的中和效价
4.1.抗-IL 13mAb-抗-IL4dAb
在TF-1细胞生物测定(如方法8所述)中测试纯化的抗-IL13mAb-抗-IL4dAb对人IL-13的中和。这些数据示于图24中。
在TF-1细胞生物测定中,纯化的抗-IL13mAb-抗-IL4dAb、586H-TVAAPS-25、586H-TVAAPS-154和586H-TVAAPS-210完全中和IL-13的生物活性。这些mAbdAb的中和效价在单独的纯化的抗-人IL-13 mAb效价的2倍内。在该测定中包括纯化的抗-人IL-4 mAb(帕考珠单抗)和纯化的抗-IL4 dAb(DOM9-155-25、DOM9-155-154或DOM9-112-210)作为中和IL-13的阴性对照。
也在TF-1细胞生物测定(如方法9所述)中检测纯化的抗-IL13mAb-抗-IL4dAb、586H-TVAAPS-25、586H-TVAAPS-154和586H-TVAAPS-210对人IL-4的中和。这些数据示于图25中。
在该TF-1细胞生物测定中,586H-TVAAPS-210完全中和IL-4的生物活性。该mAbdAb的中和效价在单独的纯化的抗-人IL-4 dAb(DOM9-112-210)中和效价的2倍内。586H-TVAAPS-25和586H-TVAAPS-154不中和IL-4的生物活性,这与单独的纯化的抗-人IL-4 dAb(DOM9-155-25和DOM9-155-154)相反。如BIAcoreTM所证明,纯化的586H-TVAAPS-25和586H-TVAAPS-154对于IL-4具有1.1nM和0.49nM的结合亲和力(分别)。IL-4结合IL-4受体极为紧密(在文献出版物中报道大约为50pM的结合亲和力),因此,在TF-1细胞生物测定中观察到586H-TVAAPS-25或586H-TVAAPS-154二者都不能有效中和IL-4的生物活性,这可能是与IL-4对于IL-4受体的效价相比,这些mAbdAb对于IL-4的亲和力相对较低的结果。
在本生物测定中包括纯化的抗-人IL-4 mAb(帕考珠单抗)作为中和IL-4的阳性对照。在本生物测定中包括纯化的抗-人IL-13 mAb作为中和IL-4的阴性对照。
4.2.抗-IL4mAb-抗-IL13dAb
在TF-1细胞生物测定(如方法9所述)中检测纯化的抗-IL4mAb-抗-IL13dAb、PascoH-G4S-474、PascoH-474、PascoL-G4S-474和PascoHL-G4S-474对人IL-4的中和。这些数据示于图26中。
在TF-1细胞生物测定中,纯化的抗-IL4mAb-抗-IL13dAb、PascoH-G4S-474、PascoH-474、PascoL-G4S-474和PascoHL-G4S-474完全中和IL-4的生物活性。这些mAbdAb的中和效价与单独的纯化的抗-人IL4 mAb(帕考珠单抗)、纯化的抗-人IL-13 mAb、纯化的DOM10-53-474 dAb的中和效价接近相等,并且在本生物测定中也包括对不相关抗原具有特异性的dAb(阴性对照dAb)作为IL-4中和的阴性对照。
在TF-1细胞生物测定(如方法8所述)中,检测纯化的抗-IL4mAb-抗-IL13dAb、PascoH-G4S-474、PascoH-474、PascoL-G4S-474和PascoHL-G4S-474对人IL-13的中和。这些数据示于图27中。
在TF-1细胞生物测定中,纯化的抗-IL4mAb-抗-IL13dAb、PascoH-G4S-474、PascoH-474、PascoL-G4S-474和PascoHL-G4S-474完全中和IL-13的生物活性。这些mAbdAb的中和效价在单独的纯化的抗-IL13 dAb(DOM10-53-474)中和效价的3倍内。在本生物测定中还包括纯化的抗-人IL-13 mAb作为IL-13中和的阳性对照。在本生物测定中,还包括对不相关抗原具有特异性的dAb(阴性对照dAb)和单独的纯化的抗-人IL4 mAb(帕考珠单抗)作为IL-4中和的阴性对照。
还在双重中和TF-1细胞生物测定(如方法10所述)中检测纯化的抗-IL4mAb-抗-IL13dAb、PascoH-G4S-474、PascoH-474、PascoL-G4S-474和PascoHL-G4S-474对人IL-4和人IL-13的同时中和。这些数据示于图28中。
在双重中和TF-1细胞生物测定中,纯化的抗-IL4mAb-抗-IL13dAb、PascoH-G4S-474、PascoH-474、PascoL-G4S-474和PascoHL-G4S-474完全中和IL-4和IL-13二者的生物活性。这些mAbdAb的中和效价与纯化的抗-人IL4 mAb(帕考珠单抗)和纯化的抗-IL13 dAb(DOM10-53-474)组合的中和效价接近相等。在该双重IL-4和IL-13中和生物测定中,单独的纯化的抗-人IL-13 mAb、单独的纯化的抗-人IL-4 mAb(帕考珠单抗)和单独的抗-人IL-13 dAb(DOM10-53-474)(其作为阴性对照被包括在内)并不完全中和IL-4和IL-13二者的生物活性。
实施例5
dAb的SEC-MALLS分析
通过SEC-MALLS(大小排阻色谱法-多角度激光散射)表征抗原特异性dAb的溶液状态,结果示于表13中:DOM10-53-474,dAb在溶液中以单体存在,而所有DOM9 dAb(DOM9-112-210、DOM9-155-25、DOM9-155-147和DOM9-155-154)可形成稳定二聚体(在某些情况下为四聚体)。
5.1.蛋白的制备
将样品纯化并透析到合适的缓冲液例如PBS中。透析后过滤样品,测定浓度(0.43mg/ml DOM-155-25)、(1.35mg/ml DOM9-155-147)和1.4mg/ml DOM9-155-159)。将DOM10-53-474和DOM9-112-210调整为1mg/ml。
BSA购自Sigma,无需进一步纯化使用。
5.2.大小排阻色谱法和检测仪设置
将带有自动进样器(SIL-20A)和SPD-20A Prominence紫外/可见光检测仪的Shimadzu LC-20AD Prominence HPLC系统连接到WyattMini Dawn Treos(MALLS,多角度激光散射检测仪)和Wyatt OptilabrEX DRI(示差折光率)检测仪。按以下顺序连接检测仪:LS-UV-RI。RI和LS两种仪器都在488nm波长处操作。以50mM磷酸盐缓冲液(不含盐)或1xPBS(二者都是pH7.4)流动相使用TSK2000(Tosoh公司))柱(基于二氧化硅的HPLC柱)。所用流速为0.5或1ml/分钟,调整运行时间(45或23分钟)来形成不同的流速,不期望对分子的分离有显著影响。在缓冲液中将蛋白制备成1mg/ml的浓度,注射体积为100ul。
5.3.检测仪标定
按照制造商说明书用甲苯标定激光散射检测仪。
5.4.用BSA标定检测仪
将UV检测仪输出和RI检测仪输出连接到光散射设备上,致使能同时用Wyatt ASTRA软件收集来自所有三个检测仪的信号。使若干含BSA的PBS流动相的注射液(1ml/分钟)流过Tosoh TSK2000柱,由Wyatt软件收集UV、LS和RI信号。然后用ASTRA软件分析图录(trace),按照制造商说明书针对谱带增宽对信号进行标准化、比对和校正。然后将标定常数取平均值,并输入到用于将来样品运行的模板中。
5.5.绝对摩尔质量计算
将100ul的各个样品注射到合适的预平衡柱上。
样品经过SEC柱后经过3个在线检测仪-UV检测仪、MALLS(多角度激光散射)检测仪和DRI(示差折光率)检测仪,其使得可测定绝对摩尔质量。在柱上进行的稀释为约10倍,酌情测定溶液状态中的浓度。
ASTRA以及通常在批样品模式中执行的Zimm作图技术的计算基础是来自Zimm的方程式[J.Chem.Phys.16,1093-1099(1948)]:
其中
·C为溶剂中溶质分子的质量浓度(g/mL)
·M为重均分子量(g/mol)
·A2为第二维里系数(mol mL/g2)
·K*=4p2n0 2(dn/dc)2l0 -4NA -1,其为光学常数,其中n0为溶剂在入射辐射(真空)波长的折射率,l0为入射辐射(真空)波长,以纳米表示,NA为阿伏伽德罗数,等于6.022 x 1023mol-1,而dn/dc为溶剂-溶质溶液关于溶质浓度变化的示差折射率增量,以mL/g表示(该系数应该用dRI检测仪独立测量)。
·P(q)为理论推导的波形因素,大约等于1-2μ2<r2>/3!+…,其中μ=(4π/λ)sin(θ/2),而<r2〉为均方半径。P(q)为分子的z-平均大小、形态及结构的函数。
·Rq为超出的瑞利(Rayleigh)比(cm-1)
本方程式假设为垂直偏振入射光,并对于阶(order)c2有效。
为了用Zimm拟合方法进行计算,我们需要展开方程式1一阶c的倒数,所述Zimm拟合方法为拟合到Rq/K*C对比sin2(q/2):
为了用Zimm拟合方法进行计算,我们需要展开方程式1一阶c的倒数,所述Zimm拟合方法为拟合到Rq/K*C对比sin2(q/2):
在该情况下合适的结果是:
和
其中m0=d[K*c/Re]/d[sin2(θ/2)]b-0方程式5
通过ASTRA软件进行自动计算,其产生具有所测的每一部分(slice)的摩尔质量图表[Astra手册]。
将从在色谱图中观察到的每个峰的图获得的摩尔质量与一个单位的蛋白质的预期分子量比较。这提供得到关于蛋白质溶液状态的结论的基础。代表性数据示于表13中。
表13:概述
DOM10-53-474
具有确定为约14kDa的平均摩尔质量的单峰表明在溶液中为单体状态,其示于图29中。
DOM9-112-210
具有确定为30kDa的摩尔质量的单峰表明在溶液中为二聚体状态,其示于图30中。
DOM9-155-25
精致的对称峰,但在缓冲液前面流出。峰的中间部分用作摩尔质量测定(参见含所有三个重叠信号的下图)。摩尔质量为28kDa,其代表二聚体dAb,示于图31中。
所有三个信号重叠(图32)。
DOM9-155-147
主峰的右边部分确定为26kDa摩尔质量,峰的左边向上渐陡的部分确定为高达53kDa。该峰最可能代表二聚体和在快速平衡中的小部分四聚体。在7.6分钟洗脱的更小的峰代表摩尔质量为51kDa的四聚体蛋白质(图33)。
DOM9-155-159
蛋白质作为单个对称峰流动,其确定为约28kDa的平均摩尔质量,这表明在溶液中为二聚体状态(图34)。
用于通过SEC-MALLS确定MW的对照:BSA
上所述的每一次实验的每一次BSA流动产生预期的MW,例如含67及145kDa摩尔质量的2个峰(单体和二聚体)(图35)。
实施例6
产生三特异性mAbdAb
通过组装PCR产生VH和VL序列然后克隆到现有的mAbdAb表达载体,或通过将来自mAb表达载体的现有VH和VL区亚克隆到现有mAbdAb表达载体,来构建三特异性mAb-dAb,致使当表达时,该三特异性mAbdAb具有连接到重链和轻链二者的C-末端的dAb。
将接头序列用于连接结构域抗体与重链CH3或轻链Cκ。三特异性mAbdAb分子的示意图示于图36(mAb重链画为灰色;mAb轻链画为白色;dAb画为黑色)中。
以下显示阐明构建三特异性mAbdAb重链(上图)和三特异性mAbdAb轻链(下图)的示意图。
对于重链,术语“VH”为单克隆抗体可变重链序列;“CH1、CH2和CH3”为人IgG1重链恒定区序列;“接头”是所用的特定接头区的序列;“dAb”为结构域抗体序列。对于轻链:“VL”为单克隆抗体可变轻链序列;“Cκ”为人轻链恒定区序列;“接头”是所用的特定接头区的序列;“dAb”为结构域抗体序列。
将哺乳动物氨基酸信号序列(如SEQ ID NO:64所示)用于产生这些构建体。
6.1.三特异性抗-IL18mAb-抗-IL4dAb-抗-IL13dAb
通过将编码抗-人IL-4结构域抗体(DOM9-112-210)的序列移植到编码重链的序列上,并将编码抗-IL13结构域抗体(DOM10-53-474)的序列移植到编码抗-人IL-18人源化单克隆抗体轻链的序列上,来构建三特异性抗-IL18mAb-抗-IL4dAb-抗-IL13dAb(也称为IL18mAb-210-474)。G4S接头用于将抗-IL4结构域抗体连接到单克隆抗体重链上。G4S接头还用于将抗-IL13结构域抗体连接到单克隆抗体轻链上。
在CHOK1细胞上清液中瞬时表达IL18mAb-210-474,在对细胞上清液中的IL18mAb-210-474定量测定后,以多种IL-18、IL-4和IL-13结合测定法进行分析。
6.2.三特异性抗-IL5mAb-抗-IL4dAb-抗-IL13dAb
通过将编码抗-人IL-4结构域抗体DOM9-112-210的序列(SEQ IDNO:4)移植到编码抗-人IL-5人源化单克隆抗体(SEQ ID NO:65)的重链序列上,并将编码抗-IL13结构域抗体DOM10-53-474的序列(SEQID NO:5)移植到编码抗-人IL-5人源化单克隆抗体轻链的序列(SEQID NO:66)上,来构建三特异性抗-IL5mAb-抗-IL4dAb-抗-IL13dAb(也称为Mepo-210-474)。G4S接头用于将抗-IL4结构域抗体连接到单克隆抗体重链上。G4S接头还用于将抗-IL13结构域抗体连接到单克隆抗体轻链上。
在CHOK1和HEK293-6E细胞上清液中瞬时表达该mAbdAb,在对细胞上清液定量后,以多种IL-4、IL-5和IL-13结合测定法进行分析。
6.3.单克隆抗体、结构域抗体和接头的序列
用于产生三特异性mAbdAb的单克隆抗体、结构域抗体和接头的序列(或在以下举例说明的内容中用作对照试剂)示于下表14中。
表14
成熟人IL-4氨基酸序列(无信号序列)示于SEQ ID NO:62中。
成熟人IL-13氨基酸序列(无信号序列)示于SEQ ID NO:63中。
6.4.三特异性mAbdAb的表达和纯化
用标准分子生物学技术将编码三特异性mAbdAb分子的DNA序列克隆到哺乳动物表达载体(Rln、Rld或pTT)。将三特异性mAbdAb表达构建体瞬时转染到CHOK1或HEK293-6E细胞之一或二者中,以小规模(3ml-150ml)表达。用于产生三特异性mAbdAb的表达程序与常规用于表达单克隆抗体的程序相同。
用固定化的蛋白A柱纯化某些构建体,通过在280nm处读取吸光度来定量测定。
实施例7
通过ELISA测定三特异性mAbdAb与人IL-4、人IL-13和人IL-18
的结合
7.1.通过ELISA测定IL-18mAb-210-474与IL-4、IL-13和IL-18的结合
在直接结合ELISA(如方法1、2和3所述)中,检测如实施例6所述制备的三特异性mAbdAb IL18mAb-210-474(上清液)(SEQ IDNO:69和70)对人IL-18、人IL-13和人IL-4的结合,这些数据分别示于图37、38和39(多次制备并检测IL18mAb-210-474,其在图中被标注为样品1、样品2、样品3等)中。
这些图显示IL18mAb-210-474通过ELISA结合IL-4、IL-13和IL-18。在IL-18结合ELISA中包括纯化的抗-人IL18 mAb作为IL-18结合的阳性对照。在IL-4结合ELISA中没有检测抗-IL-4 dAb(DOM9-112-210),因为该dAb不能被第二检测抗体检测;取而代之的是,在该ELISA中用纯化的抗-人IL4 mAb(帕考珠单抗)作为阳性对照以证明IL-4结合。在IL-13结合ELISA中没有检测抗-IL-13 dAb(DOM10-53-474),因为该dAb不能被第二检测抗体检测;取而代之的是,在该ELISA中用纯化的抗-人IL-13 mAb作为阳性对照以证明IL-13结合。如图所示,在每次结合ELISA中包括针对不相关抗原的阴性对照mAb。
在每次ELISA中,IL18mAb-210-474样品5的结合曲线位置上远离其它IL18mAb-210-474样品的结合曲线。其原因尚不知道,然而,可能是由于在人IgG定量ELISA中对于该特定IL18mAb-210-474样品5的定量问题。
7.2.通过ELISA测定Mepo-210-474与IL-4和IL-13的结合
在直接结合ELISA(分别如方法1和2所述)中,检测如第1部分所述制备的三特异性mAbdAb Mepo-210-474(上清液)(序列ID号为71和72)对人IL-13和人IL-4的结合,这些数据分别示于图40和41(Mepo-210-474以一式四份制备并检测,其被标注为样品1、样品2、样品3和样品4)中。
这些图说明Mepo-210-474通过ELISA结合IL-4和IL-13。在IL-4结合ELISA中没有检测抗-IL-4 dAb(DOM9-112-210),因为该该dAb不能被第二检测抗体检测;取而代之的是,在该ELISA中用纯化的抗-人IL-4 mAb(帕考珠单抗)作为阳性对照以证明IL-4结合。在IL-13结合ELISA中没有检测抗-IL-13 dAb(DOM10-53-474),因为该dAb不能被第二检测抗体检测;取而代之的是,在该ELISA中包括纯化的抗-人IL-13 mAb作为阳性对照以证明IL-13结合。如图40和41所示,在每次结合ELISA中包括针对不相关抗原的阴性对照mAb。
在一个瞬时转染实验中制备Mepo-210-474样品1和样品2,在另一单独的瞬时转染实验中制备Mepo-210-474样品3和样品4。在IL-13和IL-4结合ELISA中,所有四种样品都结合IL-13和IL-4。然而,样品1和2相对样品3和4结合曲线不同的原因尚不知道,但可反映在每一次转染实验中产生的mAbdAb(在上清液中)的质量差异。
实施例8
通过表面等离子共振(BIAcore
TM
)测定三特异性mAbdAb与人IL-4、
人IL-5、人IL-13和人IL-18的结合
8.1.通过BIAcoreTM测定L-18mAb-210-474与IL-4、IL-13和IL-18的结合
用BIAcoreTM于25℃(分别如方法4、5和6所述)检测如实施例6.1所述制备的三特异性mAbdAb IL18mAb-210-474(上清液)(SEQ IDNO:69和70)对人IL-4、人IL-13和人IL-18的结合。捕获水平在大约400-850响应单位范围内。检测每一分析物的三个浓度(256、32和4nM)。得到的数据示于表15(样品以一式三份制备并检测,其被标注为样品1、样品2和样品3)中。
表15
*由于正解离作用和BIAcoreTM技术的灵敏度水平而不能测定KD
用BIAcoreTM确定了三特异性mAbdab结合IL-4、IL-13和IL-18。mAbdAb对IL-18的结合亲和力与单独的纯化的抗-人IL18 mAb的结合亲和力接近相等,在该测定中包括单独的纯化的抗-人IL18 mAb作为IL-18结合的阳性对照,便于直接与mAbdab的结合亲和力比较。由于该三特异性mAbdAb的DOM9-112-210组分极为紧密地结合IL-4并因此解离速率太小而不能用BIAcoreTM测定这一事实,不可能测定mAbdab对IL-4的绝对结合亲和力。在该测定中没有检测单独的抗-IL-4 dAb(DOM9-112-210),因为不能将该dAb捕获到蛋白A或抗-人IgG包被的CM5芯片上;取而代之的是,在该测定中包括抗-人IL4mAb(帕考珠单抗)作为阳性对照以证明IL-4结合。在该测定中没有检测单独的抗-IL-13 dAb(DOM10-53-474),因为不能将该dAb捕获到蛋白A或抗-人IgG包被的CM5芯片上;取而代之的是,在该测定中包括抗-人IL13 mAb作为阳性对照以证明IL-13结合。
8.2.通过BIAcoreTM测定Mepo-210-474与IL-4、IL-5和IL-13的结合
用BIAcoreTM于25℃(分别如方法5、11和4所述)检测如实施例6.2所述制备的三特异性mAbdAb Mepo-210-474(上清液)(SEQ ID NO:71和72)对人IL-4、人IL-5和人IL-13的结合。捕获水平在大约450-900响应单位范围内。对于IL-4和IL-13结合,检测每一分析物的5个浓度(256、64、16、4和1nM)。对于IL-5结合,检测每一分析物的4个浓度(64、16、4和1nM)。得到的数据示于表16中。
表16
用BIAcoreTM测定了Mepo-210-474结合IL-4、IL-5和IL-13。Mepo-210-474对IL-5的结合亲和力与纯化的抗-人IL5 mAb(美泊利单抗)的结合亲和力接近相等,在该测定中包括纯化的抗-人IL5 mAb作为IL-5结合的阳性对照,便于直接与Mepo-210-474的结合亲和力比较。由于该三特异性mAbdAb的DOM9-112-210组分极为紧密地结合IL-4并因此解离速率太小而不能用BIAcoreTM测定这一事实,不可能测定Mepo-210-474对IL-4的绝对结合亲和力。在该测定中没有检测单独的抗-IL-4 dAb(DOM9-112-210),因为不能将该dAb捕获到蛋白A或抗-人IgG包被的CM5芯片上;取而代之的是,在该测定中包括抗-人IL4 mAb(帕考珠单抗)作为阳性对照以证明IL-4结合。在该测定中没有检测单独的抗-IL-13 dAb(DOM10-53-474),因为不能将该dAb捕获到蛋白A或抗-人IgG包被的CM5芯片上;取而代之的是,在该测定中包括抗-人IL13 mAb作为阳性对照以证明IL-13结合。
实施例9
化学计量
9.1.用BIAcoreTM的IL-4、IL-13和IL-18与IL-18mAb-210-474结合的化学计量
用BIAcoreTM(如方法7所述)评估IL18mAb-210-474(在CHO细胞上清液中如第1章节所述制备)(SEQ ID NO:69和70)对IL-4、IL-13和IL-18结合的化学计量。这些数据示于表17(R-max为饱和结合响应,其为按照方法7中给出的公式计算化学计量所需要)中。每种细胞因子的浓度为500nM。注射位置指加入每一种细胞因子的次序。
表17
细胞因子 | 注射位置 | R-max | 化学计量 |
IL-4 | 第一 | 59 | 0.9 |
IL-4 | 第二 | 56 | 0.9 |
IL-4 | 第三 | 51 | 0.8 |
IL-13 | 第一 | 74 | 1.6 |
IL-13 | 第二 | 77 | 1.7 |
IL-13 | 第三 | 80 | 1.8 |
IL-18 | 第一 | 112 | 1.8 |
IL-18 | 第二 | 113 | 1.8 |
IL-18 | 第三 | 110 | 1.7 |
化学计量数据表明IL18mAb-210-474结合大约两个IL-18分子、两个IL-13分子和仅一个IL-4分子。已知单独的抗-IL4 dAb(DOM9-112-210)在溶液状态中为二聚体,仅能够结合一个IL-4分子。因此,IL18mAb-210-474仅结合一个IL-4分子是在意料之中。这些数据表明所测分子能被预期数目的IL-18、IL-13和IL-4分子完全占据。所述化学计量数据还表明细胞因子的捕获次序似乎与加入细胞因子的次序无关。
实施例10
10.1.产生双重靶向的抗-TNF/抗-EGFR mAbdAb
通过让dAb与mAb重链C-末端融合,来构建该双重靶向的mAbdAb。先前业已构建了抗-TNF mAb重链和轻链表达盒。用于克隆的限制性位点在下面显示(图42)。
为了将用于插入dAb的限制性位点引入到重链中,用mAb重链表达载体作为模板将位点定向诱变用于产生SalI和HindIII克隆位点。然后通过PCR(用编码SalI和HindIII末端的引物)扩增编码抗-EGFRdAb(DOM16-39-542)的DNA,并将其插入到经修饰的3’编码区,在mAb和dAb之间产生接头“STG”(丝氨酸、苏氨酸、甘氨酸)。
选择已验证序列的克隆(SEQ ID NO:170和169分别为轻链和重链),按照制造商方案用Qiagen Mega Prep试剂盒大规模制备。通过用瞬时转染技术共转染轻链和重链(SEQ ID NO:73和74)在哺乳动物HEK293-6E细胞中表达mAbdAb。
10.2.双重靶向的抗-TNF/抗-EGFR mAbdAb的纯化和SEC分析
按照已确定的方案用蛋白-A亲和色谱法从澄清的表达上清液中纯化抗-TNF/抗-EGFR mAbdAb。通过分光光度法根据在280nm处的光吸光度测量值确定纯化样品的浓度。纯化的样品的SDS-PAGE分析(图43)显示未经还原的样品泳动至约170kDa,而经还原的样品显示为泳动至约25和约60kDa的两条带,其分别对应于轻链和融合dAb的重链。
对于大小排阻色谱(SEC)分析,将抗-TNF/抗-EGFR mAbdAb上样到预平衡的Superdex-20010/30 HR柱(连接到Akta Express FPLC系统),并用PBS以0.5ml/分钟流动。SEC曲线显示作为对称峰流动的单一物质(图44)。
10.3.双重靶向的抗-TNF/抗-EGFR mAbdAb的结合亲和力
分别如方法13和14所述测定对EGFR和TNF的结合亲和力。用GraphPad Prism分析测定数据。用S形剂量应答曲线测定效价,用最佳拟合模型拟合数据。该mAbdAb的抗-EGFR效价(图45)计算为39.1nM,而对照抗-EGFR mAb给出的EC50值为3.4nM。在抗-TNF生物测定(图46)中,mAbdAb效价为3pM(0.0028nM),而抗-TNF对照mAb产生的EC50为104pM。综上所述,测定数据显示实施例10的构建体即双重靶向的抗-TNF/抗-EGFR mAbdAb对两种抗原都有效。
10.4.双重靶向的抗-TNF/抗-EGFR mAbdAb的大鼠PK
在大鼠中检测该分子的体内药代动力学特性。静脉内给予三只大鼠抗-TNF/抗-EGFR mAbdAb,经7天(168小时)时间采集血清样品。通过针对TNF及EGFR的ELISA评估给药后不同时间点残留的药物浓度。结果示于图125中。
PK参数证实该分子具有长半衰期,与先前观察的未经修饰的阿达木单抗(adalimumab)在同一区域(125小时)。进一步的详细资料示于表17.1中。
表17.1
实施例11
11.1.产生双重靶向的抗-TNF/抗-VEGF mAbdAb
采用实施例10所述相似策略制备抗-TNF/抗-VEGF。为了构建重链表达盒,采用编码实施例10重链的载体DNA作为起始点。用限制性酶SalI和HindIII切割抗-EGFR dAb。通过PCR(用编码SalI和HindIII末端的引物)扩增DOM15-26-593(抗-VEGF dAb),并将其连接到具有先前业已通过相同限制性位点切割的抗-EGFR dAb的载体主链,在mAb和dAb之间产生接头“STG”(丝氨酸、苏氨酸、甘氨酸)。
选择已验证序列的克隆(SEQ ID NO:169和168分别为轻链和重链),大规模制备DNA制备物,通过用瞬时转染技术共转染轻链和重链(SEQ ID NO:73和75)在哺乳动物HEK293-6E细胞中表达抗-TNF/抗-VEG mAbdAb。
11.2.双重靶向的抗-TNF/抗-VEGF mAbdAb的纯化和SEC分析
按照已确定的方案用蛋白-A亲和色谱法从澄清的表达上清液中纯化抗-TNF/抗-VEGF mAbdAb(命名为DMS4000)。通过分光光度法根据在280nm处的光吸光度测量值确定纯化样品的浓度。纯化的样品的SDS-PAGE分析(图47)显示未经还原的样品泳动至约170kDa,而经还原的样品显示为泳动至约25和约60kDa的两条带,其分别对应于轻链和融合dAb的重链。
对于大小排阻色谱(SEC)分析,将抗-TNF/抗-VEGF mAbdAb上样到经预平衡的Superdex-20010/30 HR柱(连接到Akta Express FPLC系统),并用PBS以0.5ml/分钟流动。SEC曲线显示作为对称峰流动的单一物质(图48)。
11.3.双重靶向的抗-TNF/抗-VEGF mAbdAb的结合亲和力
分别如方法12和14所述测定对EGFR和TNF的结合亲和力。用GraphPad Prism分析测定数据。用S形剂量应答曲线测定效价,用最佳拟合模型拟合数据。该mAbdAb的抗-VEGF效价(图49)计算为57pM,而对照抗-VEGF mAb给出的EC50值为366pM。在抗-TNF生物测定(图50)中效价为10pM,而抗-TNF对照mAb产生的EC50为22pM。综上所述,测定数据显示实施例11的分子即双重靶向的抗-TNF/抗-VEGF mAbdAb对两种抗原都有效。
11.4.双重靶向的抗-TNF/抗-VEGF mAbdAb的大鼠PK
在大鼠中检测该分子的体内药代动力学特性。静脉内给予三只大鼠抗-TNF/抗-VEGF mAbdAb,经10天(240小时)时间采集血清样品。通过针对TNF及VEGF二者的ELISA评估给药后不同时间点残留的药物浓度。结果示于图126中。
PK参数证实该分子具有可与未经修饰的阿达木单抗相比的体内药代动力学特性。不认为所观察到的对VEGF组分的较短t1/2β具有意义,其可能是测定假象。进一步的详细资料示于表17.2中。
表17.2
11.5.备选抗-TNF/抗-VEGF mAbdAb的产生
以与上面实施例11.1所述相似的方式构建备选抗-TNF/抗-VEGFmAbdAb,该过程用STG接头将同样的抗-TNF mAb连接到重链C-末端上的VEGF dAb。在该案例中所用抗-VEGF dAb为DOM15-10-11。通过用瞬时转染技术共转染轻链和重链(SEQ ID NO:73和185)在哺乳动物HEK293-6E细胞中表达该分子。该分子经表达获得与实施例11.2所述相似的表达水平的mAbdAb,然而,当如实施例11.3所述在相同的VEGF测定中检测效价时,在该测定中发现具有不可检测的抑制VEGF结合VEGF受体的水平。
实施例12
12.1.产生双重靶向的抗-VEGF/抗-IL 1R1 dAb-延伸的IgG
按照在dAb和两个链的恒定区之间插入假体V结构域(Dummy Vdomain)编码区的策略,用标准分子生物学技术构建两个双重靶向的dAb-延伸IgG分子。
对于轻链,先前将抗-IL1R1 dAb DOM4-130-54克隆到含SalI和BsiWI位点的表达盒(图51),以产生dAb-Ck链。为了制备dAb-延伸的IgG轻链,通过PCR用两端编码BsiWI的引物扩增假体Vk区。用BsiWI消化含有dAb-Ck表达盒的质粒。让BsiWI消化的假体Vk结构域与其连接,产生在两个可变结构域之间含“TVAAPS”接头的dAb-延伸的IgG轻链。
按照同样的策略产生dAb-延伸的IgG重链,其中将PCR扩增的含NheI端的假体VH结构域连接到经NheI消化的dAb重链,在dAbDOM15-26和CH1之间(图51),其在两个可变结构域之间有接头“ASTKGPS”。
其被命名为DMS2090,具有SEQ ID NO:163(SEQ ID NO:162的DNA序列)中所述的序列。其与SEQ ID NO:77(DNA序列SEQ ID NO:171)中所述的轻链配对。
以同样方式但用dAb DOM15-26-593构建第二条重链。其被命名为DMS2091,具有SEQ ID NO:76(DNA序列SEQ ID NO:172)中所述的序列。其与SEQ ID NO:77(DNA序列SEQ ID NO:171)中所述的轻链配对。
选择已验证序列的克隆,按照制造商方案用Qiagen Maxi或MegaPrep试剂盒大规模制备DNA制备物。通过用瞬时转染技术共转染轻链和重链在哺乳动物细胞中表达得到的构建体。
12.2.双重靶向的抗-VEGF/抗-IL1R1 mAbdAb的纯化和SEC分析
按照已确定的方案用蛋白-A亲和色谱法从澄清的表达上清液中纯化两种抗-IL1R1/抗-VEGF dAb-延伸的IgG分子。通过分光光度法根据在280nm处的光吸光度测量值确定纯化样品的浓度。DMS2090的SDS-PAGE分析示于图52,DMS2091的SDS-PAGE分析示于图53。两种纯化的样品都显示未经还原的样品泳动至190kDa,而经还原的样品显示为泳动到35和60kDa的两条带,其分别对应于dAb-延伸的轻链和重链。
对于大小排阻色谱(SEC)分析,将抗-VEGF/抗-IL1R1 dAb-延伸的-IgG上样到经预平衡的Superdex-20010/30 HR柱(连接到Akta ExpressFPLC系统),并用PBS以0.5ml/分钟流动。DMS2090(图54)和DMS2091(图55)二者的SEC曲线都显示作为对称峰流动的单一物质。
12.3.双重靶向的抗-VEGF/抗-IL1R1 mAbdAb的结合亲和力
分别如方法12和15所述测定对VEGF和IL1R1的结合亲和力。用GraphPad Prism分析测定数据。用S形剂量应答曲线测定效价,用最佳拟合模型拟合数据。计算DMS2090的抗-VEGF效价(图57)为158.4pM,而对照抗-VEGF mAb给出的EC50值为689.2pM。计算DMS2091的抗-VEGF效价(图56)为55pM,而对照抗-VEGF mAb给出的EC50值为766pM。
在抗-IL1R1生物测定(图46)中,DMS2090效价(图58)为32pM,而抗-IL1 R1对照mAb产生的EC50为35pM。DMS2091效价(图59)为17.47pM,而抗-IL1-R1对照mAb产生的EC50为35.02pM。
综上所述,测定数据显示实施例12的双重靶向的抗-IL1 R1/抗-VEGF dAb-延伸的IgG对两种抗原都有效。
12.4.双重靶向的抗-VEGF/抗-IL1R1 mAbdAb的大鼠PK
在大鼠中检测该分子的体内药代动力学特性。静脉内给予三只大鼠抗-IL1R1/抗-VEGF dAb-延伸的IgG A,经7天(168小时)时间采集血清样品。通过针对IL1 R1及VEGF两者的ELISA评估给药后不同时间点残留的药物浓度。结果示于图127中。
PK参数示于表17.3中。
表17.3
实施例13
13.1.产生三重靶向的抗-TNF/抗-VEGF/抗-EGFR mAbdAb
用标准分子生物学技术并按照在dAb和两种链的恒定区之间插入mAb V结构域编码区的策略,构建三重靶向的mAb。
对于轻链,先前已将抗-EGFR dAb DOM16-39-542克隆到含SalI和BsiWI位点的表达盒(图15),以产生dAb-Ck链。为了制备mAbdAb轻链,通过PCR用两端编码BsiWI的引物扩增mAb VL区。用BsiWI消化含有dAb-Ck表达盒的质粒。让经BsiWI消化的mAb VL结构域与其连接,以产生mAbdAb轻链,导致产生在两个可变结构域之间的“TVAAPS”接头。
按照同样的策略产生mAbdAb重链,其中将PCR扩增的含NheI端的mAb VH区连接到经NheI消化的dAb重链载体,在dAb(DOM15-26)和CH1之间(图60),导致产生在两个可变结构域之间的接头“ASTKGPS”。
选择已验证序列的克隆(SEQ ID NO:78和79分别为重链和轻链),按照制造商方案用Qiagen Mega Prep试剂盒大规模制备DNA制备物。通过用瞬时转染技术共转染轻链和重链在哺乳动物细胞中表达mAbdAb。
13.2.三重靶向的抗-TNF/抗-VEGF/抗-EGFR mAbdAb的纯化
按照已确定的方案用蛋白-A亲和色谱法从澄清的表达上清液中纯化抗-TNF/抗-VEGF/抗-EGFR mAbdAb。通过分光光度法根据在280nm处的光吸光度测量值确定纯化样品的浓度。经纯化的样品的SDS-PAGE分析(图61)显示未经还原的样品泳动到190kDa,而经还原的样品显示为泳动到35和60kDa的两条带,其分别对应于dAb-延伸的轻链和重链。
13.3.三重靶向的抗-TNF/抗-VEGF/抗-EGFR mAbdAb的结合亲和力
分别如方法12、13和14所述测定对VEGF、EGFR和TNF的结合亲和力。用GraphPad Prism分析测定数据。用S形剂量应答曲线测定效价,用最佳拟合模型拟合数据。该mAbdAb的抗-VEGF效价(图62)计算为1.885mM,而对照抗-VEGF mAb给出的EC50值为0.145nM。
在抗-TNF生物测定(图636)中效价为87pM,而抗-TNF对照mAb产生的EC50为104pM。在抗-EGFR测定(图64)中,三重靶向mAbdAb在约300nM下产生约20%抑制。同时计算VEGF和TNF结合的EC50值,对于EGFR结合,没有产生用于计算EC50值的连续曲线(fullcurve)。
实施例14:IGF-1R/VEGF mAbdAb
14.1.IGF-1R/VEGF mAbdAb的构建
从重叠寡核苷酸的PCR从头开始构建抗IGF-1R可变重链和可变轻链基因序列。用标准分子生物学技术在哺乳动物表达载体中将这些区域融合到人IgG1或κ恒定区。同样用重叠寡核苷酸的PCR构建抗VEGF结构域抗体的基因序列,并如上所述将其融合到抗IGF-1R组分的重链或轻链基因的3’端。融合体在抗体与结构域抗体组分之间并入了两个氨基酸(GS)的接头或8个氨基酸(TVAAPSGS)的接头。此外,构建不含结构域抗体和接头序列的抗体重链和轻链。按照制造商方案用Endofree Qiagen Maxiprep试剂盒选择已验证序列的克隆用于大规模DNA制备。
在序列SEQ ID NO:108、109、111和112中,在抗体和结构域抗体之间的接头序列位置下划线。可通过除掉全部接头或通过用不同的接头,构建备选变体。在SEQ ID NO:6和8-11中提供其它合适的接头实例。表18提供一系列经构建并表达的抗体。
表18-经构建并检测的抗体
实施例14.2:IGF-1R/VEGF mAbdAb的表达、纯化和SEC曲线
在瞬时转染的HEK293-6E中表达重链和轻链载体组合。简言之,用先前与293fectin试剂(Invitrogen#51-0031)孵育的25μg重链和25μg轻链质粒,转染50ml的1.5x106个细胞/ml的HEK293-6E细胞。将细胞置于37℃、5%CO2和95%相对湿度的震荡培养箱中。24小时后,加入蛋白胨养料培养基(feeding media),让细胞再生长72小时。离心收获上清液,接着用0.22μm过滤器过滤。用蛋白A琼脂糖柱纯化表达的蛋白质,并透析到PBS中。通过大小排阻色谱(SEC)分析纯化的蛋白质,示于图65中。
在以下测定中用IGF-1R抗体(H0L0)作为比较物。该分子具有SEQID NO:110中所述的重链序列和SEQ ID NO:113中所述的轻链序列。
在以下测定中将另一具有不相关特异性的mAbdAb用作比较物。该分子具有SEQ ID NO:87中所述的重链序列和SEQ ID NO:13中所述的轻链序列,并被命名为BPC1601。
实施例14.3:IGF-1R结合ELISA
进行结合ELISA以检测纯化的抗-IGF-1R/VEGF mAbdAb与IGF-1R的结合。简言之,将400ng/ml重组人IGF-1R-his标签(R&DSystems 305-GR)的PBS溶液装到用1μg/ml抗-聚组氨酸(AbCamAB9108)包被并用封闭液(在Tris缓冲的盐水中的4%BSA)封闭的ELISA板中。在用TBS+0.05%Tween 20(TBST)洗涤前让板于室温孵育1小时。加入在封闭液中稀释的各种浓度的纯化的mAbdAb以及抗IGF-1R单克隆抗体(H0L0)和不相关的mAbdAb(BPC1601)。在用TBST洗涤前让板于室温孵育1小时。通过加入在封闭液中以1/1000稀释的过氧化物酶标记的抗人κ轻链抗体(Sigma A7164)来检测结合。在用TBST洗涤前让板于室温孵育1小时。通过加入OPD底物(Sigma P9187)使板显色,通过加入3M H2SO4终止显色。在490nm处用板读数器测量吸光度,作图确定平均吸光度。
结合ELISA的结果提供在图66中,其确证所检测的所有IGF1R-VEGF mAbdAb变体(BPC1603-1606)都显示以可比得上抗-IGF-1R抗体H0L0的水平与IGF-1R结合。用Cambridgesoft Bioassay软件计算EC50值,结果如下:H0L0(0.1797μg/ml))、BPC1603(0.1602μg/ml)、BPC1604(0.1160μg/ml)、BPC1605(0.1975μg/ml)、BPC1606(0.1403μg/ml)。不相关的对照双特异性抗体BPC1601显示对IGF-1R没有可检测的结合。
实施例14.4:VEGF结合ELISA
进行结合ELISA以检测经纯化的抗-IGF-1R/VEGF双特异性抗体与VEGF的结合。用PBS中的400ng/ml重组人VEGF(GSK)包被并用封闭液(TBS中的4%BSA)封闭ELISA板。加入在封闭液中稀释的各种浓度的纯化的mAbdAb,包括mAbdAb BPC1601作为阴性对照。在用TBST洗涤前让板于室温孵育1小时。通过加入在封闭液中以1/1000稀释的过氧化物酶标记的抗人κ轻链抗体(Sigma A7164)来检测结合。在用TBST洗涤前让板于室温孵育40分钟。通过加入OPD底物(Sigma P9187)使板显色,通过加入3M H2SO4终止显色。在490nm处用板读数器测量吸光度,作图确定平均吸光度。
结合ELISA的结果提供在图67中,其确证所有四种抗-IGF-1R/VEGF mAbdAb(BPC1603-1606)都可结合固定化VEGF。BPC1605和BPC1606显然更低的结合活性可归因于结构域抗体(位于轻链的C-末端)与检测抗体之间的干扰。用Cambridgesoft Bioassay软件计算EC50值,结果如下:BPC1603(0.044μg/ml)、BPC1604(0.059μg/ml)、BPC1605(0.571μg/ml)。由于较低的响应值而不可能计算BPC1606的精确EC50值。抗-IGF-1R抗体H0L0和不相关的对照mAbdAb BPC1601显示对VEGF没有可检测的结合。
实施例14.5:与VEGF结合的动力学
通过伯胺偶联到CM5生物感受器芯片来固定针对人IgG的小鼠单克隆抗体(Biacore BR-1008-39)。用该表面来捕获抗体构建体。在捕获后,使VEGF通过表面后,然后用3M MgCl2使所述表面再生。用于产生动力学的VEGF浓度为256、64、16、4、1和0.25nM,且仅将缓冲液注入捕获表面上用于双重参考(double referencing)。用1xHBS-EP缓冲液(BR-1006-69)于25℃在Biacore T100设备上进行实验。用其分析软件将数据拟合到设备固有的1∶1模型。来自两个独立实验的数据示于表19中。
表19-结合人VEGF的动力学
实施例14.6:VEGF与受体结合的抑制
如方法12所述用VEGF受体结合测定测量mAbdAb活性。在该测定中获得的抑制VEGF与VEGFR2结合的IC50为:
BPC1603(0.037nM)
BPC1604(0.010nM)
BPC1605(0.167nM)
BPC1606(0.431nM)
这些结果确证所有四种抗原结合构建体抑制配体结合受体。
实施例14.7:IGF-1R受体磷酸化的抑制
将3T3/LISN c4细胞以10000个细胞/孔的密度接种到96孔板中,并在完全DMEM(DMEM-Hepes改良+10%FCS)中孵育过夜。将纯化的mAbdAb加到细胞中并孵育1小时。将rhIGF-1加到处理的细胞中以达到50ng/ml的终浓度,并再孵育30分钟以刺激受体磷酸化。吸出培养基,然后通过加入RIPA裂解缓冲液(150mM NaCl、50mMTrisHCl、6mM脱氧胆酸钠、1%Tween 20)加上蛋白酶抑制剂混合物(Roche 11 697 498 001)来裂解细胞。过夜冷冻所述板。解冻后将各孔的裂解液转移到用2μg/ml抗IGF-1R捕获抗体2B9(GSK)预先包被并用封闭液4%BSA/TBS封闭的96孔ELISA板。用TBST(TBS+0.1%Tween 20)洗涤板,将用4%BSA/TBS以1/2500稀释的铕标记的抗磷酸酪氨酸抗体(PerkinElmer DELFIA Eu-N1PT66)加入到各孔中。孵育1小时后洗涤板,加入DELFIA增强(PerkinElmer 1244-105)溶液。孵育10分钟后,用板读数器装置测定受体磷酸化水平以测量铕时间分辨荧光(TRF)。
实验结果提供在图68和69中。结果确证mAbdAb BPC1603-1606可以以比得上抗-IGF-1R单克隆抗体H0L0的水平抑制IGF-I介导的受体磷酸化。在该测定中不相关抗体(标记为IgG1,Sigma I5154)显示无活性。
实施例15抗-CD20/IL-13抗原结合蛋白
实施例15.1:分子生物学
用基于PCR的方法和标准分子生物学技术从头构建编码SEQ IDNO:117和120中所述的抗-CD20mAb的重链和轻链序列的哺乳动物表达载体。通过将编码抗-CD20mAb重链和轻链可变区的序列克隆到含有融合到抗-人IL-13结构域抗体(DOM10-53-474)的人抗体恒定区的哺乳动物表达载体,来构建双特异性抗-CD20mAb-抗-IL13dAb重链和轻链。
将mAbdAb表达构建体转染到CHOE1a细胞。收获上清液,然后用固定化的蛋白A纯化抗体,通过读取280nm处的吸光度来定量。已构建并检测的mAbdAb(和抗-CD20对照mAb)列于表20中。
表20
实施例15.2:与人IL-13结合的动力学
通过BIAcoreTM分析评估mAbdAb构建体对人IL-13的结合亲和力。进行抗-人IgG捕获分析。简言之,通过伯胺偶联将抗-人IgG(Biacore BR-1008-39)偶联到CM5芯片上。然后将mAbdAb构建体捕获到该表面。以限定浓度使人IL-13(由GSK制备并纯化)通过。用3MMgCl2使该表面再生回抗人IgG表面。该处理不显著影响捕获抗体对随后的IL-13结合事件的能力。用HBS-EP缓冲液在25℃于BIAcoreTMT100设备上进行运作。用设备中的评估软件分析数据,并拟合成1∶1结合模型。分析结果提供在表48中,其确证所有mAbdAb构建体结合IL-13的动力学都相当。
表48-表面等离子共振(BIAcoreTM)数据
通过流式细胞术用CD20阳性细胞系(Wein133)评估mAb-dAb与CD20的结合。所有mAb-dAb(BPC1401-BPC1404)和抗-CD20对照抗体显示平均荧光强度剂量依赖性增加(MFI)(数据未显示)
实施例15.3:用抗-CD20/IL-13双特异性抗体进行ADCC测定
ADCC测定基于Boyd等(1995)J.Imm.Meth.184:29-38公开的方法。简言之,用铕如下标记Raji细胞(靶标)。收获细胞,计数,并在15ml falcon试管中制备为终密度1x107,用Hepes缓冲液(50mMHEPES、83mM NaCl、5mM KCl、2mM MgCl2.H2O、pH7.4)洗涤一次。沉淀细胞,将1ml冰冷的铕标记的缓冲液(HEPES缓冲液加600μMEuCl3、3mM DTPA和25mg/ml硫酸葡聚糖)加入到各管中。在标记开始猛烈弹击细胞悬浮液,然后在冰上孵育的30分钟期间每10分钟弹击一次。加入10ml冰冷的修复缓冲液(含有294mg/l CaCl2.2H2O、1.8g/lD-葡萄糖、pH7.4的Hepes缓冲液),细胞在冰上再孵育10分钟。然后离心细胞,滗出上清液,用修复缓冲液洗涤2次,然后用完全培养基洗涤一次。然后计数标记的细胞,以2x105细胞/ml重新悬浮在无血清培养基中,并储存在冰上。
如下制备人纯化的血单核细胞(PBMC或效应细胞)。以2000rpm将150ml全血离心10分钟以除掉血清。用PBS(Invitrogen/Gibco,#14190)将细胞稀释到原始体积的2倍。通过加15ml淋巴细胞分离剂(lymphoprep)(Axis shield,#NYC 1114547)制备Accuspin密度梯度管(Sigma,#A2055-10EA),以1500rpm离心1分钟。将25ml血混悬液加入到密度梯度管,以2500rpm离心20分钟,让离心机慢慢减速。弃掉10ml顶部上清液。将剩余物(包括“淡黄色”层)倒入干净试管中,用PBS加满,以1500rpm离心5分钟。弃掉上清液,合并细胞沉淀,用RPMI培养基洗涤一次,重新离心并计数。在无血清RPMI培养基中以5x106/ml制备效应细胞。
在96孔圆底板(Nunc 96maxisorb板,#735-0199)中如下设定测定板。在无血清RPMI培养基中以大约12μg/ml的起始浓度制备抗体稀释液,甚至进一步3倍稀释。以下进行板布置,将50μl抗体样品加入合适的孔(仅B-G排)中,使每个稀释度进行6个重复。将50μl RPMI培养基加入A和H排的所有孔中。将50μl的RPMI培养基加入到培养基标记的板的所有孔中。将在RPMI培养基中稀释到4μg/ml(1μg/ml终浓度,GSK内部材料)的50μl重组人IL-13加入到+IL13标记的板的所有孔中。所有板在4℃孵育最少30分钟。将50μl铕标记的靶标细胞加入到所有板。将20μl的10X triton加入到所有板H排的所有孔中。让板在4℃孵育最少30分钟。将50μl RPMI培养基加入到仅标记靶标的列的所有孔中。将50μl PBMC加入到标记的效应器∶靶标为25∶1比率的列的所有孔中。让板以1500rpm离心3分钟,并37℃孵育3-4小时。将200μl的增强液(Wallac/Perkin Elmer,货号1244-105)加入到nunc免疫吸附ELISA板(一个ELISA板对应每一个测定板)的各孔中。将20μl上清液从测定板转移到ELISA板。让ELISA板于室温在板振荡器上孵育最少30分钟,或储存在4℃过夜。用时间滞后荧光测定法(time-delayed fluorimetry)(Wallac Victor板读数器)测量铕释放。自发裂解=只从细胞和培养基中释放的铕的测量值。最大裂解=通过加入Triton-X100(非离子去污剂)靶标细胞的非特异性裂解。
在两个单独的时机用两种不同的供体PBMC进行ADCC测定。来自一个代表性测定的结果提供在图70和71中。另外,在单独的时机用不同的供体PBMC进行使用较窄剂量范围的相似的ADCC测定。将来自该测定的结果示于图72和73中。
实施例15.4:用抗-CD20/IL-13双特异性抗体进行CDC测定
用铕如下标记WEIN细胞(靶标)。简言之,收获细胞,计数,并在15ml falcon试管中制备为终密度1x107,用Hepes缓冲液(50mMHEPES、83mM NaCl、5mM KCl、2mM MgCl2.H2O、pH7.4)洗涤一次。沉淀细胞,将1ml冰冷的铕标记的缓冲液(HEPES缓冲液加上600μMEuCl3、3mM DTPA和25mg/ml硫酸葡聚糖)加入到各管中。在标记开始猛烈弹击细胞悬浮液,然后在冰上孵育的30分钟期间每10分钟弹击一次。加入10ml冰冷的修复缓冲液(含有294mg/l CaCl2.2H2O、1.8g/lD-葡萄糖、pH7.4的Hepes缓冲液),细胞在冰上再孵育10分钟。然后离心细胞,滗出上清液,用修复缓冲液洗涤2次,然后用完全培养基洗涤一次。然后计数标记的细胞,以2x105细胞/ml重新悬浮在无血清培养基中,并储存在冰上。
通过离心从采集自内部供体的全血中移走血清。让一半样品在56℃热处理30分钟灭活。在无血清RPMI培养基中以大约12μg/ml的起始浓度稀释抗体,进行5次3倍稀释。将50μl抗体样品加入到仅B-G排的合适的孔(按照以下所述的板布置)中。将50μl RPMI培养基加入到1-6列的所有孔中。在必要时将50μl的重组人IL-13(以在RPMI培养基中4μg/ml)加入到第7-12列的各孔中。让板在4℃孵育最少30分钟。将50μl铕标记的靶标细胞加入到所有板,并让板在4℃孵育最少30分钟。将50μl血清(活性或热灭活)加入到合适的孔(参见以下板布置)中。让板在37℃培养箱中孵育2-3小时,之后将所述板以1500rpm离心3分钟。将200μl的增强液(Wallac/Perkin Elmer,Catalogue#1244-105)加入到nunc免疫吸附ELISA板(一个ELISA板对应每一个测定板)的各孔中。将20μl上清液从测定板转移到ELISA板。让ELISA板于室温在板振荡器上孵育最少30分钟,或储存在4℃过夜。用时间滞后荧光测定法(Wallac Victor板读数器)测量铕释放。自发裂解=只从细胞和培养基中释放的铕的测量值。最大裂解=通过加入Triton-X100(非离子去污剂)使靶标细胞非特异性裂解。
在三个单独的时机用三种不同的供体血清进行CDC测定。来自一个代表性测定的结果提供在图74和75中,并显示抗体样品的CDC活性比得上无IL-13时的CDC活性。在过量IL-13存在下,抗体样品BPC1401和BPC1402(融合到重链的结构域抗体)的CDC活性降低了,而BPC1403和BPC1404(融合到轻链的结构域抗体)的CDC活性并没有受IL-13存在的较大影响。
实施例16
16.1包含由备选骨架组成的表位结合结构域的抗原结合蛋白的设计与
构建
将以下列出的5种备选骨架与单克隆抗体联合以提供mAb-备选骨架双特异性分子:
●抗VEGF泪液脂质运载蛋白(TLPC)
●抗HER2Affibody(AFFI)
●抗HER2DARPin(DRPN)
●抗鸡蛋白溶菌酶(NARV)
●抗-RNA酶A骆驼VHH
将TLPC(其进一步的资料参见US2007/0224633)、AFFI(其进一步的资料参见WO2005003156A1)、DRPN(其进一步的资料参见Zahnd,C.等(2007)、J.Mol.Biol.,369,1015-1028)和NARV(其进一步的资料参见US20050043519A)的蛋白序列逆翻译为DNA并优化密码子。在这4种备选骨架的每一种中包括在N-末端处的BamHI位点和在C-末端处的EcoR1位点,以方便克隆。
用基于PCR的策略和重叠寡核苷酸从头构建编码这四种备选骨架DNA序列的DNA片段。将TLPC、AFFI和DRPN PCR产物克隆到含有H0L0重链(抗-hIGF-1R抗体)的哺乳动物表达载体。得到的DNA序列编码经由TVAAPSGS接头或GS接头融合到重链的C-末端的备选骨架。将NAR V PCR产物克隆到含有编码帕考珠单抗(抗-IL-4抗体)重链的DNA的哺乳动物表达载体。得到的DNA序列编码经由GS接头融合到重链的C-末端的NAR V。
通过PCR修饰抗-RNA酶A骆驼VHH DNA序列,以在5’端包括BamHI位点并在3’端包括EcoR1位点便于克隆。将PCR产物克隆到含有帕考珠单抗(抗-IL-4抗体)重链的哺乳动物表达载体。得到的DNA序列编码经由GS接头融合到重链的C-末端的骆驼VHH。
以下表21概述了业已构建的抗原结合蛋白。
表21
用293fectin(Invitrogen,12347019)将表21中所述的编码抗原结合蛋白的重链和轻链表达质粒瞬时共转染到HEK 293-6E细胞。在同一天或第二天将蛋白胨养料加入到各细胞培养物中,在初始转染约2-6天后收获上清液物质。用蛋白A柱纯化来自上清液的抗原结合蛋白,然后在结合测定中进行检测。
16.2:rhIGF-1R结合ELISA
用1μg/ml抗-his-标签抗体(Abcam,ab9108)的PBS溶液包被96孔高结合板,并在4℃储存过夜。用含0.05%的Tween-20的Tris-缓冲的盐水洗涤板2次。将200μL封闭液(5%BSA/DPBS缓冲液)加入到各孔中,让板在室温孵育至少1小时。然后再进行另一洗涤步骤。将0.4μg/mL的rhIGF-1R(R&D Systems)以每孔50μL加入到各孔中。让板在室温孵育1小时,然后洗涤。用封闭液在板中对纯化的抗原结合蛋白质/抗体进行连续稀释。1小时孵育后,洗涤板。用封闭液将山羊抗-人κ轻链特异性过氧化物酶缀合抗体稀释到1μg/mL,将50μL加入到各孔中。让板孵育1小时。在进行另一个洗涤步骤后,将50μl的OPD(邻苯二胺二盐酸盐)SigmaFast底物溶液加入到各孔中,15分钟后通过加入25μL的3M硫酸终止反应。在490nm处用VersaMaxTunable微板读数器(Molecular Devices)用碱性终点方案读取吸光度。
图76、78和80显示ELISA结果,并确证抗原结合蛋白BPC1803-BPC1808结合重组人IGF-1R。还显示抗-IGF-1R单克隆抗体H0L0结合重组人IGF-1R,然而阴性对照抗体(sigma I5154)显示不结合IGF-1R。
16.3:VEGF结合ELISA
用0.4μg/ml的hVEGF165(R&D Systems)包被96孔高结合板,并在+4℃孵育过夜。用含0.05%的Tween-20的Tris-缓冲的盐水洗涤板2次。将200μL封闭液(5%BSA/DPBS缓冲液)加入到各孔中,让板在室温孵育至少1小时。然后进行另一个洗涤步骤。用封闭液在板中对纯化的抗原结合蛋白质/抗体进行连续稀释。1小时孵育后,洗涤板。用封闭液将山羊抗-人κ轻链特异性过氧化物酶缀合抗体稀释到1μg/mL,将50μL加入到各孔中。让板孵育1小时。在另一个洗涤步骤后,将50μl的OPD(邻苯二胺二盐酸盐)SigmaFast底物溶液加入到各孔中,15分钟后通过加入25μL的3M硫酸终止反应。在490nm处用VersaMax Tunable微板读数器(Molecular Devices)用碱性终点方案读取吸光度。
图77显示VEGF结合ELISA结果,并确证双特异性抗体BPC1803和BPC1804结合人VEGF。在该测定中抗VEGF双特异性抗体(BPC1603)用作阳性对照,显示结合VEGF。与此相反,显示抗-IGF-1R单克隆抗体H0L0不结合人VEGF。
16.4:HER2结合ELISA
用1μg/ml的HER2(R&D Systems)包被96孔高结合板,并在+4℃孵育过夜。用含0.05%的Tween-20的Tris-缓冲的盐水洗涤板2次。将200μL封闭液(5%BSA/DPBS缓冲液)加入到各孔中,让板在室温孵育至少1小时。然后再进行一次洗涤。用封闭液在板中对纯化的抗原结合蛋白质/抗体进行连续稀释。1小时孵育后,洗涤板。用封闭液将山羊抗-人κ轻链特异性过氧化物酶缀合抗体稀释到1μg/mL,将50μL加入到各孔中。让板孵育1小时。在另一个洗涤步骤后,将50μl的OPD(邻苯二胺二盐酸盐)SigmaFast底物溶液加入到各孔中,15分钟后通过加入25μL的3M硫酸终止反应。在490nm处用VersaMaxTunable微板读数器(Molecular Devices)用碱性终点方案读取吸光度。
图79和80显示HER结合ELISA结果,并确证抗原结合蛋白BPC1805、BPC1806、BPC1807和BPC1808结合重组人HER2。在该测定中赫赛汀(Herceptin)用作阳性对照,显示结合HER2。与此相反,显示抗-IGF-1R单克隆抗体H0L0不结合人HER2。
16.5:IL-4结合ELISA
用5μg/ml人IL-4的PBS溶液包被96孔高结合板,并在4℃储存过夜。用含0.05%的Tween-20的Tris-缓冲的盐水洗涤板2次。将200μL封闭液(5%BSA/DPBS缓冲液)加入到各孔中,让板在室温孵育至少1小时。然后进行另一个洗涤步骤。用封闭液在板中对纯化的抗原结合蛋白质/抗体进行连续稀释。1小时孵育后,洗涤板。用封闭液将山羊抗-人κ轻链特异性过氧化物酶缀合抗体(Sigma,A7164)稀释到1μg/mL,将50μL加入到各孔中。让板孵育1小时。在另一个洗涤步骤后,将50μl的OPD(邻苯二胺二盐酸盐)SigmaFast底物溶液加入到各孔中,15分钟后通过加入25μL的3M硫酸终止反应。在490nm处用VersaMax Tunable微板读数器(Molecular Devices)用碱性终点方案读取吸光度。
图82显示ELISA结果,并确证抗原结合蛋白BPC1809以可比得上抗IL-4单克隆抗体帕考珠单抗的水平结合人IL-4。显示阴性对照抗体(Sigma I5154)不结合IL-4。
图84显示ELISA结果,并确证抗原结合蛋白BPC1816以可比得上抗IL-4单克隆抗体帕考珠单抗的水平结合人IL-4。显示阴性对照抗体(Sigma I5154)不结合IL-4。
16.6:RNA酶A结合ELISA
将业已用PBS稀释的50uL的1ug/mL RNA酶A(Qiagen,19101)加入到96孔Costar板的各孔中。让板在室温孵育2小时,然后用PBST洗涤板,之后将200uL的4%BSA/PBS的封闭液加入到各孔中。让板孵育1小时,并在加入样品前洗涤。以2ug/mL的浓度将纯化的抗体和抗原结合蛋白BPC1809加入到第1列的孔中,然后以1∶2用封闭液对板进行系列稀释。让板孵育1小时然后洗涤。加入50μL用封闭液以1∶1000稀释的山羊抗-人κ轻链特异性过氧化物酶缀合抗体(Sigma,A7164)。让板孵育1小时然后洗涤。将50μl的OPD加入到各孔中,在15-30分钟后用3M硫酸终止反应。在490nm处用VersaMax Tunable微板读数器(Molecular Devices)用碱性终点方案读取吸光度。
图83显示RNA酶A结合ELISA的结果,并确证纯化的人单克隆抗体-骆驼VHH双特异性抗体BPC1809显示结合RNA酶A。与此相反,显示IL-4单克隆抗体帕考珠单抗和阴性对照(sigma I5154)二者都不结合RNA酶A。
16.7:HEL结合ELISA
用5μg/ml的HEL(鸡蛋溶菌酶,Sigma L6876)的PBS溶液包被96孔高结合板,并在4℃储存过夜。用含0.05%的Tween-20的Tris-缓冲的盐水洗涤板2次。将200μL封闭液(5%BSA/DPBS缓冲液)加入到各孔中,让板在室温孵育至少1小时。然后进行另一个洗涤步骤。用封闭液在板中对纯化的抗体进行连续稀释。1小时孵育后,洗涤板。用封闭液将山羊抗-人κ轻链特异性过氧化物酶缀合抗体(Sigma,A7164)稀释到1μg/mL,将50μL加入到各孔中。让板孵育1小时。在另一个洗涤步骤后,将50μl的OPD(邻苯二胺二盐酸盐)SigmaFast底物溶液加入到各孔中,15分钟后通过加入25μL的3M硫酸终止反应。在490nm处用VersaMax Tunable微板读数器(Molecular Devices)用碱性终点方案读取吸光度。
图85显示HEL结合ELISA的结果,并确证纯化的人单克隆抗体-NAR V双特异性抗体BPC1816结合HEL。与此相反,显示IL-4单克隆抗体帕考珠单抗不结合HEL。
实施例17
17.1包含由adnectin组成的表位结合结构域的抗原结合蛋白的设计与
构建
CT01adnectin对VEGFR2(进一步资料参见WO2005/056764)具有特异性。将CT01adnectin蛋白序列逆翻译为DNA并优化密码子。包括N-末端的BamHI位点和C-末端的EcoR1位点以便于克隆。
用基于PCR的策略和重叠寡核苷酸从头构建编码最终CT01DNA序列的DNA片段。将PCR产物克隆到含有H0L0重链(抗-hIGF-1R抗体)的哺乳动物表达载体,使得经由GS接头或TVAAPSGS接头将adnectin融合到重链的C-末端。IGF-1R-VEGFR2双特异性的重链和轻链的蛋白序列示于SEQ ID NO 124、113和133中。
将编码抗-TNF-αadnectin(进一步资料参见US20080139791)的另一adnectin蛋白序列逆翻译为DNA,优化密码子,并在用前述重叠寡核苷酸PCR方法构建之前修饰为包括末端BamHI和EcoR1位点。将PCR产物克隆到含有编码帕考珠单抗(抗-IL-4抗体)重链的DNA的哺乳动物表达载体,使得经由GS接头或TVAAPSGS接头将编码抗-TNF-αadnectin的DNA融合到重链C-末端。IL-4-TNF-α双特异性重链和轻链的蛋白序列示于SEQ ID NO:146、147和15中。
还设计了利用在IL-13单克隆抗体重链C-末端处融合的TNF-α特异性adnectin的抗原结合蛋白。蛋白序列实例示于SEQ ID 134、13和135中。另外,业已设计基于在抗-EGFR抗体爱必妥和IMC-11F8的重链或轻链的C-末端或N-末端处融合CT01的双特异性分子。已设计的蛋白序列的实例示于SEQ ID NO:136-145中。
在这些实例序列中,很多已被构建。已构建了编码SEQ ID NO 136(融合到爱必妥重链的C-末端上的CT01)、SEQ ID NO 144(融合到爱必妥重链N-末端上的CT01)和SEQ ID NO 138(融合到爱必妥轻链C-末端上的CT01)的DNA序列。已用基于PCR的克隆方法构建所有这三种序列,并将其克隆到哺乳动物表达载体。下表22是已被设计和/或构建的抗原结合蛋白的概述。
表22
用293fectin(Invitrogen,12347019)将编码BPC1801、BPC1802、BPC1822、BPC1823、BPC1812、BPC1813和BPC1818的重链和轻链表达质粒瞬时共转染到HEK 293-6E细胞。在同一天或第二天将蛋白胨养料加入到各孔细胞培养物中,在初始转染约2-6天后收获上清液物质。在某些情况下,在结合测定中用上清液材料作为测试物。在其它情况下,用蛋白A柱纯化抗原结合蛋白,然后在结合测定中进行检测。
17.2:rhIGF-1R结合ELISA
用1μg/ml抗-his-标签抗体(Abcam,ab9108)的PBS溶液包被96孔高结合板,并在4℃储存过夜。用含0.05%Tween-20的Tris-缓冲的盐水洗涤板2次。将200μL封闭液(5%BSA/DPBS缓冲液)加入到各孔中,让板在室温孵育至少1小时。然后进行另一个洗涤步骤。将0.4μg/mL的rhIGF-1R(R&D Systems)以每孔50μL加入到各孔中。让板在室温孵育1小时,然后洗涤。用封闭液在板中对纯化的抗原结合蛋白质/抗体进行连续稀释。1小时孵育后,洗涤板。用封闭液将山羊抗-人κ轻链特异性过氧化物酶缀合抗体稀释到1μg/mL,将50μL加入到各孔中。让板孵育1小时。在另一个洗涤步骤后,将50μl的OPD(邻苯二胺二盐酸盐)SigmaFast底物溶液加入到各孔中,15分钟后通过加入25μL的3M硫酸终止反应。在490nm处用VersaMax Tunable微板读数器(Molecular Devices)用碱性终点方案读取吸光度。
图86显示IGF-1R结合ELISA的结果,并确证纯化的人单克隆抗体-adnectin双特异性抗体(BPC1801和BPC 1802)以可比得上抗-IGF-1R单克隆抗体H0L0的水平结合重组人IGF-1R。显示阴性对照抗体(Sigma I5154)不结合IGF-1R。
17.3:VEGFR2结合ELISA
用0.4μg/ml的VEGFR2(R&D Systems)包被96孔高结合板,并在+4℃孵育过夜。用含0.05%的Tween-20的Tris-缓冲的盐水洗涤板2次。将200μL封闭液(5%BSA/DPBS缓冲液)加入到各孔中,让板在室温孵育至少1小时。然后进行另一个洗涤步骤。用封闭液在板中对上清液或经纯化的抗体进行连续稀释。1小时孵育后,洗涤板。用封闭液将山羊抗-人κ轻链特异性过氧化物酶缀合抗体稀释到1μg/mL,将50μL加入到各孔中。让板孵育1小时。在另一个洗涤步骤后,将50μl的OPD(邻苯二胺二盐酸盐)SigmaFast底物溶液加入到各孔中,15分钟后通过加入25μL的3M硫酸终止反应。在490nm处用VersaMaxTunable微板读数器(Molecular Devices)用碱性终点方案读取吸光度。
图87显示VEGFR2结合ELISA的结果,并确证纯化的人单克隆抗体-adnectin双特异性抗体(BPC1801和BPC1802)结合重组人VEGFR2。与此相反,显示抗-IGF-1R单克隆抗体H0L0不结合人VEGFR2。
图172显示VEGFR2结合ELISA的结果,并确证抗原结合蛋白BPC1818和BPC1813结合重组人VEGFR2。与此相反,显示爱必妥不结合人VEGFR2。对于抗原结合蛋白BPC1813和BPC1818而言,上清液中的抗体的量不能被定量,因此图172提供的数据表示为净上清液材料稀释倍数。对于爱必妥而言,在测定中以2μg/ml的起始浓度使用纯化的材料,该起始浓度相当于图172中的稀释倍数1。
图175显示VEGFR2结合ELISA的结果,并确证抗原结合蛋白BPC1812结合重组人VEGFR2。与此相反,显示爱必妥和阴性对照Sigma IgG I5154抗体不结合人VEGFR2。对于抗原结合蛋白BPC1812而言,上清液中的抗体的量不能被定量,因此图175提供的数据表示为净上清液材料稀释倍数。对于爱必妥和Sigma IgG I5154而言,在测定中以2μg/ml的起始浓度使用纯化的材料,该起始浓度相当于图175中的稀释倍数1。
17.4:IL-4结合ELISA
用5μg/ml人IL-4的PBS溶液包被96孔高结合板,并在4℃储存过夜。用含0.05%的Tween-20的Tris-缓冲的盐水洗涤板2次。将200μL封闭液(5%BSA/DPBS缓冲液)加入到各孔中,让板在室温孵育至少1小时。然后进行另一个洗涤步骤。用封闭液在板中对上清液或纯化的抗体/抗原结合蛋白进行连续稀释。1小时孵育后,洗涤板。用封闭液将山羊抗-人κ轻链特异性过氧化物酶缀合抗体稀释到1μg/mL,将50μL加入到各孔中。让板孵育1小时。在另一个洗涤步骤后,将50μl的OPD(邻苯二胺二盐酸盐)SigmaFast底物溶液加入到各孔中,15分钟后通过加入25μL的3M硫酸终止反应。在490nm处用VersaMaxTunable微板读数器(Molecular Devices)用碱性终点方案读取吸光度。
图88显示IL-4结合ELISA的结果,并确证人单克隆抗体-adnectin双特异性抗体(BPC1823和BPC 1822)结合重组人IL-4。显示阳性对照抗-IL-4单克隆抗体帕考珠单抗结合IL-4,显示阴性对照抗体(SigmaI5154)不结合IL-4。
在本实验中重复HEK转染以获得具有较高抗体浓度的上清液材料。图88b显示通过ELISA测定的该较高浓度的上清液人单克隆抗体-adnectin双特异性抗体(BPC1823)与人IL-4的结合。
对于抗原结合蛋白BPC1823和BPC1822而言,上清液中的抗体的量不能被定量,因此图88和88b提供的数据表示为净上清液材料稀释倍数。对于帕考珠单抗和阴性对照抗体(Sigma I5154)而言,在测定中以1μg/ml的起始浓度使用纯化的材料,该起始浓度相当于图88和88b中的稀释倍数1。
17.5:TNF-α结合ELISA
用0.4μg/ml重组人TNFα(RnD Systems 210-TA-050/CF)的PBS溶液包被96孔高结合板,并在4℃储存过夜。用含0.05%的Tween-20的Tris-缓冲的盐水洗涤板2次。将200μL封闭液(5%BSA/DPBS缓冲液)加入到各孔中,让板在室温孵育至少1小时。然后进行另一个洗涤步骤。用封闭液在板中对上清液或纯化的抗体进行连续稀释。1小时孵育后,洗涤板。用封闭液将山羊抗-人κ轻链特异性过氧化物酶缀合抗体(Sigma,A7164)稀释到1μg/mL,将50μL加入到各孔中。让板孵育1小时。在另一个洗涤步骤后,将50μl的OPD(邻苯二胺二盐酸盐)SigmaFast底物溶液加入到各孔中,15分钟后通过加入25μL的3M硫酸终止反应。在490nm处用VersaMax Tunable微板读数器(MolecularDevices)用碱性终点方案读取吸光度。
图89显示TNF-α结合ELISA的结果,并确证人单克隆抗体-adnectin双特异性抗体(BPC1823和BPC1822)结合重组人TNF-α。与此相反,显示抗-IL-4单克隆抗体帕考珠单抗不结合重组人TNF-α。
在本实验中重复HEK转染以获得具有较高抗体浓度的上清液材料。图89b显示通过ELISA测定的该较高浓度的上清液人单克隆抗体-adnectin双特异性抗体(BPC1823)与重组人TNFα的结合。显示IgG对照不结合重组人TNF-α。
对于抗原结合蛋白BPC1822和BPC1823而言,上清液中的抗体的量不能被定量,因此图89和89b提供的数据表示为净上清液材料稀释倍数。对于帕考珠单抗而言,在测定中以1μg/ml的起始浓度使用纯化的材料,该起始浓度相当于图89和89b中的稀释倍数1。
17.6:EGFR结合ELISA
用0.67μg/ml重组人EGFR蛋白的PBS溶液包被96孔高结合板,并在4℃储存过夜。用含0.05%的Tween-20的Tris-缓冲的盐水洗涤板2次。将200μL封闭液(5%BSA/DPBS缓冲液)加入到各孔中,让板在室温孵育至少1小时。然后进行另一个洗涤步骤。用封闭液在板中对抗原结合蛋白质/抗体进行连续稀释。1小时孵育后,洗涤板。用封闭液将山羊抗-人κ轻链特异性过氧化物酶缀合抗体(Sigma,A7164)稀释到1μg/mL,将50μL加入到各孔中。让板孵育1小时。在另一个洗涤步骤后,将50μl的OPD(邻苯二胺二盐酸盐)SigmaFast底物溶液加入到各孔中,25分钟后通过加入25μL的3M硫酸终止反应。在490nm处用VersaMax Tunable微板读数器(Molecular Devices)用碱性终点方案读取吸光度。
图171显示EGFR结合ELISA的结果,并确证双特异性抗体BPC1818和BPC1813结合重组人EGFR。还显示阳性对照抗体爱必妥结合重组人EGFR。与此相反,显示Sigma IgG I5154不结合重组人EGFR。对于双特异性抗体BPC1813和BPC1818而言,上清液中的抗体的量不能被定量,因此图171提供的数据表示为净上清液材料稀释倍数。对于爱必妥和阴性对照抗体(Sigma I5154)而言,在测定中分别以2μg/ml和1μg/ml的起始浓度使用纯化的材料,该起始浓度相当于图171中的稀释倍数1。
图176显示EGFR结合ELISA的结果,并确证双特异性抗体BPC1812结合重组人EGFR。还显示阳性对照抗体爱必妥结合重组人EGFR。与此相反,显示Sigma IgG I5154不结合重组人EGFR。对于双特异性抗体BPC1812而言,上清液中的抗体的量不能被定量,因此图176提供的数据表示为净上清液材料稀释倍数。对于爱必妥和阴性对照抗体(Sigma I5154)而言,在测定中分别以2μg/ml和1μg/m的起始浓度使用纯化的材料,该起始浓度相当于图176中的稀释倍数1。
实施例18
其中“G和S”氨基酸残基已经被除去的IL-13/IL-4 mAbdAb的结合
活性数据
18.1.构建mAbdAb
构建了其中G和S氨基酸残基(紧挨接头序列)被除去的mAbdAb。用标准分子生物学技术构建了表达质粒。这些mAbdAb如表23所述。将它们克隆,然后在HEK293-6E细胞、CHOK1细胞或CHOE1a细胞的一种或多种中表达,将它们纯化(分别如实施例1、1.3和1.5所述),并在多种IL-13和IL-4活性测定中进行分析。
表23
18.2.表达和纯化
通过SEC和SDS PAGE纯化并分析这些mAbdAb。制备多个纯化的制备物,示于图90-98中的SEC和SDS PAGE数据代表这些制备物。
18.3.在直接结合ELISA中结合人IL-4
在直接结合ELISA中如方法2所述检测纯化的除去GS的PascoH-474和除去GS的PascoH-TVAAPS-474对人IL-4的结合(在该测定中还检测PascoH-474、PascoH-TVAAPS-474、PascoH-ASTKG-474和PascoH-ELQLE-474的结合)。完成这些分子的多种ELISA测定,示于图99中的数据代表这些测定。
除去GS的PascoH-474和除去GS的PascoH-TVAAPS-474二者都结合人IL-4。在该测定中包括单独的纯化的抗-人IL4 mAb(帕考珠单抗)作为结合IL-4的阳性对照。包括纯化的抗-人IL13 mAb作为IL-4结合的阴性对照。除去GS的PascoH-474和除去GS的PascoH-TVAAPS-474的结合活性与单独的纯化的抗-IL4 mAb(帕考珠单抗)、PascoH-474、PascoH-TVAAPS-474、PascoH-ASTKG-474和PascoH-ELQLE-474相似。
18.4.在直接结合ELISA中结合人IL-13
在直接结合ELISA中如方法1所述检测纯化的除去GS的PascoH-474和除去GS的PascoH-TVAAPS-474对人IL-13的结合(在该测定中还检测如实施例19所述产生的分子PascoH-616和PascoH-TVAAPS-616的结合)。完成这些分子的多种ELISA测定,示于图100中的数据代表所有测定。
除去GS的PascoH-474、除去GS的PascoH-TVAAPS-474、PascoH-616和PascoH-TVAAPS-616全部都结合人IL-13。在该测定中包括单独的纯化的抗-人IL4 mAb(帕考珠单抗)作为IL-13结合的阴性对照。包括纯化的抗-人IL13 mAb作为IL-13结合的阳性对照。注意在该测定中没有检测单独的抗-IL-13 dAb(DOM10-53-474),因为该dAb不能被第二检测抗体检测;取而代之的是,在该测定中使用抗-人IL13 mAb作为阳性对照以证明IL-13结合。
18.5.在直接结合ELISA中结合猕猴IL-13
还在直接结合ELISA(如方法17所述)中检测纯化的除去GS的PascoH-474、除去GS的PascoH-TVAAPS-474、PascoH-616和PascoH-TVAAPS-616 mAbdAb对猕猴IL-13的结合。完成了这些分子的多种ELISA测定,示于图101中的数据代表所有测定。
除去GS的PascoH-474、除去GS的PascoH-TVAAPS-474、PascoH-616和PascoH-TVAAPS-616全部都结合猕猴IL-13。在该测定中包括单独的纯化的抗-人IL4 mAb(帕考珠单抗)作为IL-13结合的阴性对照。包括纯化的抗-人IL13 mAb作为猕猴IL-13结合的阳性对照。注意在该测定中没有检测单独的抗-IL-13 dAb(DOM10-53-474和DOM10-53-616),因为该dAb不能被第二检测抗体检测;取而代之的是,在该测定中使用抗-人IL13 mAb作为阳性对照以证明IL-13结合。
18.6.结合人IL-4和人IL-13的Biacore分析
用BIAcoreTM T100在25℃(如方法4和5所述)检测纯化的mAbdAb对人IL-4和人IL-13的结合。这些数据示于表24中。
在实验1中,mAbdAb捕获水平达到大约600的相对响应单位,评估了6个IL-13和IL-4浓度曲线(256nM、64nM、16nM、4nM、1nM和0.25nM)。在实验1中对于mAb仅评估一个IL-13(256nM)和IL-4(256nM)浓度曲线。
在实验2中,达到大约400相对响应单位的mAbdAb捕获水平,评估了6个IL-4浓度曲线(64nM、16nM、4nM、1nM、0.25nM和0.0625nM)和6个IL-13浓度曲线(256nM、64nM、16nM、4nM、1nM和0.25nM)。在实验2中,对于抗-IL13 mAb仅评估一个IL-13浓度曲线(256nM),对于帕考珠单抗,评估5个IL-4浓度曲线(64nM、16nM、4nM、1nM和0.25nM)。
在实验3中,达到大约700相对响应单位的mAbdAb或mAb捕获水平,评估了6个IL-4浓度曲线(256nM、64nM、16nM、4nM、1nM和0.25nM)和6个IL-13浓度曲线(256nM、64nM、16nM、4nM、1nM和0.25nM)。
表24
在实验1和2中,除去GS的PascoH-474和除去GS的PascoH-TVAAPS-474二者都以相似的结合亲和力结合IL-4,该结合亲和力与单独的抗-人IL4 mAb(帕考珠单抗)的结合亲和力接近相等。除去GS的PascoH-474和除去GS的PascoH-TVAAPS-474还以相似的结合亲和力结合IL-13。注意在该测定中没有检测单独的抗-IL-13dAb(DOM10-53-474),因为不能将该dAb捕获到蛋白A或抗-人IgG包被的CM5芯片上;取而代之的是,在该测定中使用抗-人IL13 mAb作为阳性对照以证明IL-13结合。
在实验3中,除去GS的586H-210和除去GS的586H-TVAAPS-210二者都以相似的结合亲和力结合IL-13,该结合亲和力与抗-人IL13 mAb的结合亲和力接近相等。除去GS的586H-210和除去GS的586H-TVAAPS-210也极为紧密地结合IL-4,然而由于正解离作用和BIAcoreTM技术的灵敏度水平(*),本方法不能测定其结合亲和力。注意在该测定中没有检测单独的抗-IL-4 dAb(DOM9-112-210),因为不能将该dAb捕获到蛋白A或抗-人IgG包被的CM5芯片上;取而代之的是,在该测定中使用抗-人IL4 mAb(帕考珠单抗)作为阳性对照以证明IL-4结合。
18.7.结合猕猴IL-4和猕猴IL-13的Biacore分析
用BIAcoreTM T100在25℃(如方法24和23所述)检测纯化的mAbdAb对猕猴IL-4和猕猴IL-13的结合。这些数据示于表25中。mAbdAb捕获水平达到大约600相对响应单位,评估了6个IL-13浓度曲线(256、64、16、4、1、0.25nM)和5个IL-4浓度曲线(64、16、4、1、0.25nM)。
表25
除去GS的PascoH-474、除去GS的PascoH-TVAAPS-474、除去第二个GS的PascoH-ASTKGPT-474、PascoH-474、PascoH-TVAAPS-474和PascoH-ASTKG-474全部都以相似结合亲和力结合猕猴IL-4。除去GS的PascoH-474、除去GS的PascoH-TVAAPS-474、除去第二个GS的PascoH-ASTKGPT-474、PascoH-474、PascoH-TVAAPS-474和PascoH-ASTKG-474全部也都以相似结合亲和力结合IL-13。
还用BIAcoreTM T100于25℃(如方法24和23所述)检测纯化的mAbdAb对猕猴IL-4和猕猴IL-13的结合。这些数据示于表26中。mAbdAb捕获水平达到大约600相对响应单位,评估了6个IL13和6个IL-4浓度曲线(256、64、16、4、1和0.25nM)。
表26
除去GS的586H-210和除去GS的586H-TVAAPS-210二者都以相似的结合亲和力结合猕猴IL-13;这些mAbdAb似乎结合IL13比结合抗-人IL13 mAb更有效,然而在该mAb情况中,仅完成一个浓度曲线,这固然不如全浓度范围评估精确。除去GS的586H-210和除去GS的586H-TVAAPS-210也极为紧密地结合IL-4,然而由于正解离作用和BIAcoreTM技术的灵敏度水平(*),本方法不能测定该结合亲和力。注意在该测定中没有检测单独的抗-IL-4 dAb(DOM9-112-210),因为不能将该dAb捕获到蛋白A或抗-人IgG包被的CM5芯片上;取而代之的是,在该测定中使用抗-人IL4 mAb(帕考珠单抗)作为阳性对照以证明IL-4结合。
18.8.IL-4结合mAbdAb对随后的IL-13结合动力学的影响及反之的
Biacore分析;和IL-13结合mAbdAb对随后的IL-4结合动力学的影
响及反之的Biacore分析
也将IL-13和IL-4 BIAcoreTM结合测定用于研究IL-4结合除去GS的PascoH-474对随后的IL-13结合动力学的影响及反之;和IL-13结合586H-TVAAPS-210对随后的IL-4结合动力学后影响及反之。用BIAcoreTM T100设备于25℃用抗-人IgG捕获mAbdAb(或阳性对照mAb)进行分析。简言之,按照制造商建议通过伯胺偶联将抗-人IgG偶联到CM5芯片上。然后将mAbdAb构建体(或阳性对照mAb)捕获到该表面(以大约250-750RU)上,以256nM使第一分析物(人IL-13或人IL-4)通过4分钟。然后以256nM、64nM、16nM、4nM、1nM和0.25nM的浓度使第二分析物(分别为人IL-4或人IL-13)通过,并且为了双重参考,让缓冲注射液通过捕获抗体或mAbdAb表面。用评估软件在设备中分析(拟合成1∶1结合的模型)数据。然后用3M氯化镁再生该表面。将来自这些实验的数据示于表27和28中。
表27
不管人IL-4是否结合除去GS的PascoH-474,该分子对人IL-13的结合亲和力都相似。另外,不管人IL-4是否结合586H-TVAAPS-210,该分子对人IL-13的结合亲和力都相似,并所述结合亲和力也类似于抗-IL13 mAb对人IL-13的结合亲和力。
获得的IL-4结合除去GS的PascoH-474和586H-TVAAPS-210的解离速率(kd)极低,并且超出BIAcoreTM T100的灵敏度范围,因此不能用作结合亲和力(数据未显示)的精确测定。然而,数据确实表明所测的所有构建体对人IL-4结合极为紧密。因此,不管人IL-13是否结合除去GS的PascoH-474,该分子对人IL-4的结合亲和力都极为紧密。另外,不管人IL-13是否结合586H-TVAAPS-210,该分子对人IL-4的结合亲和力都极为紧密。
18.9.mAbdAb效价
通过ELISA如方法19所述检测mAbdAb对人IL-4结合人IL-4Rα的抑制。在一个实验中检测示于表28的所有分子,然而,将数据绘制在两个图中以区分曲线图(586H-TVAAPS-210进行2次,这在表25中被标为样品1和样品2)。这些数据示于图102和103.
除去GS的PascoH-474与帕考珠单抗相似地抑制人IL-4与人IL4Rα的结合。除去GS的586H-210、除去GS的586H-TVAAPS-210、586H-TVAAPS-210、586H-210、586H-G4S-210和586H-ASTKG-210全部都与DOM9-112-210相似地抑制人IL-4与人IL4Rα的结合。包括帕考珠单抗和DOM9-112-210作为抑制IL-4结合IL4Rα的阳性对照。包括DOM10-53-474和同种型-匹配的mAb(对不相关抗原具有特异性)作为抑制IL-4结合IL4Rα的阴性对照。
还用这些数据来测定各种分子的IC50值。IC50值是能够抑制人IL-4与人IL4Rα结合到50%的mAbdAb或mAb或dAb的浓度。IC50值示于表28中。
表28
这些数据确证除去GS的PascoH-474的表现与帕考珠单抗相似,所有586H-210 mAbdAb“家族成员”的表现与DOM9-112-210 dAb相似。
18.10.在TF-1细胞生物测定中mAbdAb对人和猕猴IL-13的中和
在TF-1细胞生物测定(分别如方法8和方法20所述)中检测多种纯化的mAbdAb对人和猕猴IL-13的中和。在这些测定中每种分子检测1-9次,没有显示所有图表,但图104和105分别为显示对
人IL-13和猕猴IL-13的中和数据的代表性图表。在本生物测定中包括DOM10-53-474作为中和人或猕猴IL-13的阳性对照。在本生物测定中还包括对不相关抗原具有特异性的dAb(阴性对照dAb)作为中和人或猕猴IL-13的阴性对照。
在TF-1细胞生物测定中,除去GS的PascoH-474、除去GS的PascoH-TVAAPS-474和除去第二个GS的PascoH-ASTKG-474以及PascoH-616、PascoH-TVAAPS-616和DOM10-53-616(它们如实施例19所述)完全中和人和猕猴IL-13二者的生物活性。
18.11.在TF-1细胞生物测定中mAbdAb对人和猕猴IL-4的中和
在TF-1细胞生物测定(分别如方法9和方法21所述)中检测多种纯化的mAbdAb对人和猕猴IL-4的中和。在这些测定中每种分子检测2次,没有显示所有图表,但图106和107分别为显示人IL-4和猕猴IL-4的中和数据的代表性图表(来自数据集)。在本生物测定中包括抗-IL13 mAb作为中和人或猕猴IL-4的阴性对照,包括帕考珠单抗作为中和人或猕猴IL-4的阳性对照。另外,在这些生物测定中还检测PascoH-474、PascoH-TVAAPS-474、PascoH-ASTKG-474和PascoH-G4S-474对人和猕猴IL-4的中和。
在TF-1细胞生物测定中,除去GS的PascoH-474和除去GS的PascoH-TVAAPS-474完全中和人和猕猴IL-4二者的生物活性。另外,在TF-1细胞生物测定中,PascoH-474、PascoH-TVAAPS-474、PascoH-ASTKG-474和PascoH-G4S-474还完全中和人IL-4的生物活性。
基于从多种不同的实验获得的数据得出ND50值。ND50值是能够中和IL-13或IL-4的生物活性到50%的mAbdAb或mAb或dAb的浓度。平均ND50值、标准偏差(SD)和所测次数(n)示于表29中。
表29
在TF-1细胞生物测定中,除去GS的PascoH-474、除去GS的PascoH-TVAAPS-474和除去第二个GS的PascoH-ASTKGPT-474都完全中和人和猕猴IL-13的生物活性。另外,除去GS的PascoH-474、除去GS的PascoH-TVAAPS-474和除去第二个GS的PascoH-ASTKGPT-474对人IL-13的中和效价(ND50值)都相似,并且在单独的纯化的抗-IL13 dAb(DOM10-53-474)的ND50值的1倍内。
在TF-1细胞生物测定中,除去GS的PascoH-474和除去GS的PascoH-TVAAPS-474二者都完全中和人和猕猴IL-4的生物活性。另外,除去GS的PascoH-474和除去GS的PascoH-TVAAPS-474对人IL-13和猕猴IL-13的中和效价(ND50值)都相似,并且在帕考珠单抗的ND50值的1倍内。
18.12.mAbdAb抑制人IL-13与人IL-13Rα2的结合的能力
通过ELISA如方法22所述检测表30所列分子对人IL-13与人IL-13Rα2结合的抑制。在一个实验中检测所有分子。数据示于图108中。
所测的所有mAbdAb抑制人IL-13与人IL13Rα2的结合。抑制水平与DOM10-53-474、DOM10-53-616和抗-IL13 mAb的抑制水平相似。包括帕考珠单抗和阴性对照dAb(对不相关抗原具有特异性)作为抑制IL-13结合IL13Rα2的阴性对照。
也用这些数据测定各种分子的IC50值。IC50值为能够抑制人IL-13与人IL13Rα2的结合到50%的mAbdAb或mAb或dAb的浓度。IC50值示于表30中。
表30
这些数据确证除去GS的PascoH-474、除去GS的PascoH-TVAAPS-474、PascoH-616和PascoH-TVAAPS-616的表现与DOM10-53-474、DOM10-53-616和抗-IL13 mAb相似。
实施例19
含有抗-IL13 DOM10-53-616 dAb的mAbdAb
19.1.含有抗-IL13 DOM10-53-616 dAb的mAbdAb的构建
通过位点定向诱变如实施例1所述从现有载体克隆表31中所述的两种抗-IL4mAb-抗-IL13dAb。
表31
19.2.含有抗-IL13 DOM10-53-616 dAb的mAbdAb的表达和纯化
如实施例1.3所述在HEK293-6E细胞和CHOE1a细胞中表达这些mAbdAb。
通过SEC和SDS PAGE纯化并分析mAbdAb。制备了PascoH-616和PascoH-TVAAPS-616 mAbdAb的多个纯化的制备物,示于图109(关于PascoH-616的SEC曲线)、110(关于PascoH-TVAAPS_616的SEC曲线)、111(关于PascoH-616的SDS PAGE)和112(关于PascoH-TVAAPS-616的SDS PAGE)中的SEC和SDS PAGE数据代表了这些制备物。
19.3.在直接结合ELISA中mAbdAb与人IL-13的结合
在直接结合ELISA(如方法1所述)中检测PascoH-616和PascoH-TVAAPS-616纯化的mAb dAb对人IL-13的结合。这些数据示于图113中。
纯化的PascoH-616和PascoH-TVAAPS-616二者都结合人IL-13。在该测定中包括单独的纯化的抗-人IL4 mAb(帕考珠单抗)作为IL-13结合的阴性对照。包括纯化的抗-人IL13 mAb作为IL-13结合的阳性对照。注意在该测定中没有检测单独的抗-IL-13 dAb(DOM10-53-616),因为该dAb不能被第二检测抗体检测;取而代之的是,在该测定中使用抗-人IL13 mAb作为阳性对照以证明IL-13结合。
19.4.对结合人IL-4和人IL-13的Biacore分析
用BIAcoreTM T100在25℃(如方法4和5所述)检测纯化的mAbdAb对人IL-4和人IL-13的结合。这些数据示于表32中。
在实验1中,mAbdAb捕获水平达到大约600相对响应单位,评估了6个IL-13和IL-4浓度曲线(256nM、64nM、16nM、4nM、1nM和0.25nM)。在实验1中对于mAb仅评估一个IL-13(256nM)和IL-4(256nM)浓度曲线。
在实验2中,mAbdAb捕获水平达到大约400相对响应单位,评估了6个IL-4(64nM、16nM、4nM、1nM、0.25nM和0.0625nM)和6个IL-13浓度曲线(256nM、64nM、16nM、4nM、1nM和0.25nM)。在实验2中,对于抗-IL13 mAb仅评估一个IL-13浓度曲线(256nM),对于帕考珠单抗,评估5个IL-4浓度曲线(64nM、16nM、4nM、1nM和0.25nM)。
表32
PascoH-616和PascoH-TVAAPS-616二者都以相似的结合亲和力结合IL-4,该结合亲和力与单独的抗-人IL4 mAb(帕考珠单抗)的结合亲和力相似。PascoH-616和PascoH-TVAAPS-616二者都结合IL-13。注意在该测定中没有检测单独的抗-IL-13 dAb(DOM10-53-616),因为不能将该dAb捕获到蛋白A或抗-人IgG包被的CM5芯片上;取而代之的是,在该测定中使用抗-人IL13 mAb作为阳性对照以证明IL-13结合。
19.5.对结合猕猴IL-13的Biacore
也用BIAcoreTM T100在25℃(如方法30所述)检测纯化的mAbdAb对猕猴IL-13的结合。这些数据示于表33中。mAbdAb捕获水平达到大约400相对响应单位,评估了6个IL-13浓度曲线(256、64、16、4、1和0.25nM)。对于抗-IL13 mAb仅有一个IL-13浓度曲线(256nM)。
表33
PascoH-616和PascoH-TVAAPS-616二者都以相似的结合亲和力结合猕猴IL-13。注意在该测定中没有检测单独的抗-IL-13 dAb(DOM10-53-616),因为不能将该dAb捕获到蛋白A或抗-人IgG包被的CM5芯片上;取而代之的是,在该测定中使用抗-人IL13 mAb作为阳性对照以证明IL-13结合。
19.6.在TF-1细胞生物测定中mAbdAb对人和猕猴IL-13的中和
在TF-1细胞生物测定(分别如方法8和方法20所述)中检测纯化的mAbdAb对人IL-13和猕猴IL-13的中和。在每一测定中对这些分子检测3次,图114为显示对人IL-13的中和数据的代表性图表。图114a为显示对猕猴IL-13的中和数据的代表性图表。在本生物测定中包括DOM10-53-616作为中和IL-13的阳性对照。在本生物测定中还包括对不相关抗原具有特异性的dAb(阴性对照dAb)作为中和IL-13的阴性对照。
平均ND50值、标准偏差(SD)和所测次数(n)示于表34中。
表34
在TF-1细胞生物测定中,PascoH-616和PascoH-TVAAPS-616二者以及另外的mAbdAb(除去GS的PascoH-TVAAPS-474和除去GS的PascoH-474)完全中和人和猕猴IL-13的生物活性。
另外,PascoH-616和PascoH-TVAAPS-616对人IL-13的中和效价(ND50值)相似,并且在单独的纯化的抗-IL13 dAb(DOM10-53-616)的ND50值的2倍内。
还通过ELISA如方法22所述检测PascoH-616和PascoH-TVAAPS-616对人IL-13结合人IL-13Rα2的抑制。这些数据提供在实施例18.12中。
实施例20
在人全血磷-STAT6生物测定中mAbdAb中和人IL-13或IL-4的能
力
如方法16所述在人全血磷-STAT6生物测定中检测mAbdAb中和人IL-13或IL-4的能力。
测定了2种mAbdAb构建体(纯化的抗-IL13mAb-抗-IL4dAb、586H-TVAAPS-210;和纯化的抗-IL4mAb-抗-IL13dAb、除去GS的PascoH-474)的IL-4或IL-13中和效价(即抑制IL-4或IL-13生物活性)。在该测定中包括纯化的抗-人IL-4 mAb(帕考珠单抗)和纯化的抗-IL4dAb(DOM9-112-210)作为中和rhIL-4的阳性对照。包括纯化的抗-人IL-13 mAb和纯化的抗-IL13 dAb(DOM10-53-474)作为中和rhIL-13的阳性对照。包括与dAb混合的同种型匹配的mAb(二者都对不相关抗原具有特异性)作为中和rhIL-4或rhIL-13的阴性对照。用来自不同供体的血对每种分子检测至少2次。图115-124为显示代表性数据的图表。
纯化的mAbdAb完全中和rhIL-13和rhIL-4的生物活性。
如方法16所述,将测试分子中和rhIL-13或rhIL-4生物活性的能力表示为中和2ng/mL人IL-4或人IL-13到50%所需的分子(例如mAbdAb)的浓度(IC50)。这些数据示于表35中。出示了关于每一种分子的来自所有供体的合并平均IC50连同标准偏差。
表35
IC50值比较表明586-TVAAPS-210与抗-IL13 mAb和DOM9-112-210相似地抑制IL-13和IL-4诱导的pSTAT-6(分别在IL-13和IL-4全血测定中)。IC50数据的比较还表明除去GS的PascoH-474与DOM10-53-474和帕考珠单抗相似地抑制IL-13和IL-4诱导的pSTAT-6(分别在IL-13和IL-4全血测定中)。对照mAb显示在所有供体中在高达所测的最大浓度661nM下无抑制,对照dAb显示在所有供体中在高达所测的最大浓度2291nM下不中和。
实施例21
双重靶向的抗-IL4/抗-IL13 mAbdAb的大鼠PK研究
在大鼠PK研究(如表35.1所概述)中评估PascoH-G4S-474、PascoL-G4S-474、586H-TVAAPS-210和586H-TVAAPS-154。简言之,以2mg/kg的目标剂量水平将mAbdAb单次静脉内(i/v)给予雄性Sprague-Dawley大鼠(体重大约200克-220克)。在分配的时间点(0小时到312小时)抽取100 l血液样品,处理为血浆。在人IgG检测测定和/或IL-13配体结合测定和/或IL-4配体结合测定中,评估大鼠血浆样品中测试分子的存在情况。另外,还评估血浆中帕考珠单抗(在大鼠中)的PK曲线:在该情况下,在人IgG检测测定和IL-4配体结合测定中评估帕考珠单抗在大鼠血浆样品中的存在情况。
在第一个研究中,将帕考珠单抗给予4只大鼠。在第二个研究中,有4个治疗组(2mg/kg PascoH-G4S-474、2mg/kg PascoL-G4S-474、2mg/kg 586H-TVAAPS-210和2mg/kg 586H-TVAAPS-154),每组4只大鼠。
由血浆浓度-时间曲线数据(未显示)得出PK参数(示于表35.1)。注意在这些测定中不止一次分析某些血浆样品,并且仅从这些数据集之一得出表35.1中的PK参数。还要注意对于个别的动物剂量,没有将PK参数标准化,取而代之的是假定为2mg/kg的标称剂量。注意在对PascoH-G4S-474的IgG PK测定中某些遇到技术困难,因此浓度可能估计过高。另外,在某些情况下进行两次IgG血浆浓度-时间曲线分析(在表35.1中被标注为分析1和分析2)。仅在分析2中对产生自IL-13和IL-4配体结合PK测定的血浆浓度-时间曲线数据进行分析。对PascoL-G4S-474和586H-TVAAPS-154的IL-13和IL-4配体结合测定所产生的血浆浓度-时间曲线数据不用于获得这些分子的PK参数。
表35.1
在对PascoH-G4S-474的IL-13和IL-4测定中产生的血浆浓度-时间曲线数据(及随后获得的PK参数)趋向于类似;在对586H-TVAAPS-210的IL-13、IL-4和IgG PK测定中产生的血浆浓度-时间曲线数据(及随后获得的PK参数)也是这种情况。这表明在整个研究过程中这些mAbdAb在大鼠血浆中是“完好”的。获得的586H-TVAAPS-154的PK参数比起任何其它mAbdAb,似乎与获得的帕考珠单抗的PK参数更相似。
实施例22
猕猴PK研究
在猕猴中进行PK研究。以1mg/kg的目标剂量水平单次静脉内给予动物。在分配的时间点抽取500μl血液样品,处理为血浆。然后在IL-13配体结合测定、IL-4配体结合测定和IL-13/IL-4桥联测定(bridging assay)中,评估猕猴血浆样品中测试分子的存在情况。
来自这些研究的关于“除去GS的PascoH-474”和“586H-TVAAPS-210”mAbdAb的初始数据与上述大鼠PK数据一致,表明这些分子比mAb更快地从系统循环中清除,但比dAb清除慢。
实施例23
23.1.产生双重靶向的抗-EGFR/抗-VEGF mAbdAb
通过将dAb融合到mAb重链的C-末端来构建该双重靶向的mAbdAb。先前已构建抗-EGFR mAb重链和轻链表达盒。用于克隆的限制性位点与由实施例10中所述的限制性位点(SaII和HindIII)一样。
然后通过PCR(用编码SalI和HindIII端的引物)扩增编码抗-VEGF dAb(DOM15-26-593)的DNA,并将其插入到经修饰的3’编码区,在mAb和dAb之间产生接头“STG”(丝氨酸、苏氨酸、甘氨酸)。
选择已验证序列的克隆(SEQ ID NO:164和243分别为轻链和重链),按照制造商方案用Qiagen Mega Prep试剂盒制备大规模DNA制备物。通过用瞬时转染技术共转染轻链和重链(SEQ ID NO:165和137)在哺乳动物HEK293-6E细胞中表达mAbdAb。
23.2.双重靶向的抗-EGFR/抗-VEGF mAbdAb的纯化和SEC分析
按照已建立的方案用蛋白-A亲和色谱法从澄清的表达上清液纯化该双重靶向的mAbdAb。通过分光光度法根据在280nm处的光吸光度测量值确定纯化的样品的浓度。纯化的样品(命名为DMS4010)的SDS-PAGE分析(图128)显示未经还原的样品泳动至约170kDa,而经还原的样品显示泳动至约25和约60kDa的两条带,其分别对应于轻链和融合dAb的重链。
为了进行大小排阻色谱(SEC)分析,将抗-EGFR/抗-VEGFmAbdAb上样到预平衡的S-200 10/300 GL柱(连接到HPLC系统)上,用PBS以1ml/分钟流动。SEC曲线显示作为对称峰流动的单一物质(图129)。
23.3.双重靶向的抗-EGFR/抗-VEGF mAbdAb的效价
分别如方法12和13所述测定该分子中和VEGF和EGFR的能力。用GraphPad Prism分析测定数据。用S形剂量应答曲线测定效价,用最佳拟合模型拟合数据。该mAbdAb(命名为DMS4010)的抗-EGFR效价(图130)计算为4.784nM,而对照抗-EGFR mAb给出的EC50值为4.214nM。在抗-VEGF受体结合测定(图131)中,该mAbdAb(命名为DMS4010)的EC50为58pM(0.058nM),而抗-VEGF对照mAb产生的EC50为214.1pM(0.2141nM)。综上所述,测定数据显示实施例23的构建体即双重靶向的抗-EGFR/抗-VEGF mAbdAb对两种抗原都有效。
23.4.双重靶向的抗-EGFR/抗-VEGF mAbdAb的PK
在将双重靶向的抗-EGFR/抗-VEGF mAbdAb(命名为DMS4010)给予猕猴后测定其药代动力学曲线。以5mg/kg的剂量静脉内给予该化合物,通过在单独的ELISA测定中结合EGFR和VEGF二者来测定给药后多个时间点药物的血清水平。图132显示该测定的结果,其中将数据与业已产生的mAb西妥昔单抗(cetuximab)(抗-EGFR)和贝伐珠单抗(bevacizumab)(抗-VEGF)的历史数据进行比较。进一步的详细资料示于表36中。
表36
23.5.产生备选抗-EGFR/抗-VEGF mAbdAb
以与上面实施例11.1所述相似方式构建备选抗-EGFR/抗-VEGFmAbdAb,用STG接头将相同的抗-EGFR mAb在重链C-末端连接到VEGF dAb上。在该种情况下所用的抗-VEGF dAb为DOM15-10-11。通过用瞬时转染技术共转染轻链和重链(SEQ ID NO:165和186)在哺乳动物HEK293-6E细胞中表达该分子,然而,与实施例23.2所述分子的表达相比,得到显著较低的表达水平。当在如实施例23.3所述的同一VEGF测定中检测效价时,发现在该测定中抑制VEGF结合VEGF受体的水平不可检测。
实施例24
24.1.不用接头产生双重靶向的抗-EGFR/抗-VEGF mAbdAb
制备在上述实施例23中的mAbdAb的衍生物,其中除去dAb和mAb的CH3结构域之间的“STG”接头。SDM用于从编码重链的质粒删去编码STG接头的残基。选择已分别验证轻链和重链序列(SEQID NO:243和SEQ ID NO:174)的克隆,用Qiagen Mega Prep试剂盒按照制造商方案制备大规模的DNA制备物。通过用瞬时转染技术共转染轻链和重链(SEQ ID NO:175和137)在哺乳动物HEK293-6E细胞中表达mAbdAb。
24.2.不含接头的双重靶向的抗-EGFR/抗-VEGF mAbdAb的纯化和
SEC分析
按照已建立的方案用蛋白-A亲和色谱法从澄清的表达上清液纯化该双重靶向的mAbdAb。通过分光光度法根据在280nm处的光吸光度测量值确定纯化的样品的浓度。纯化的样品(命名为DMS4011)的SDS-PAGE分析(图133)显示未经还原的样品泳动至约170kDa,而经还原的样品显示泳动至约25和约60kDa的两条带,其分别对应于轻链和融合dAb的重链。
为了进行大小排阻色谱(SEC)分析,将抗-EGFR/抗-VEGF mAbdAb上样到预平衡的S-200 10/300 GL柱(连接到HPLC系统)上,用PBS以1ml/分钟流动。SEC曲线显示作为对称峰流动的单一物质(图134)。
24.3.不含接头的双重靶向的抗-EGFR/抗-VEGF mAbdAb的效价
分别如方法12和13所述测定该分子中和VEGF和EGFR的能力。用GraphPad Prism分析测定数据。用S形剂量应答曲线测定效价,用最佳拟合模型拟合数据。该mAbdAb(命名为DMS4011)的抗-EGFR效价(图135)计算为3.529nM,而对照抗-EGFR mAb给出的EC50值为3.647nM。在抗-VEGF受体结合测定(图136)中,该mAbdAb(命名为DMS4011)的EC50为34209pM(0.3429nM),而抗-VEGF对照mAb产生的EC50为214.1pM(0.2141nM)。综上所述,测定数据显示实施例24的构建体即不含接头的双重靶向的抗-EGFR/抗-VEGF mAbdAb对两种抗原都有效。
实施例25
25.1.产生含较长接头的双重靶向的抗-EGFR/抗-VEGF mAbdAb
制备在上述实施例23中的mAbdAb的衍生物,其中通过将柔性的“GGGGS”基序的一个或多个重复插入到编码重链的质粒来延长dAb和mAb的CH3结构域之间的接头。
含SEQ ID NO:175中所述的重链序列的第一种分子具有该基序的一个重复,因此具有接头“STGGGGGS”。
含SEQ ID NO:177中所述的重链序列的第二种分子具有该基序的两个重复,因此具有接头“STGGGGGSGGGGS”。
这两者都独立与实施例23(SEQ ID NO:243)中所用的相同的轻链配对。
选择已验证轻链和重链序列的克隆,用Qiagen Mega Prep试剂盒按照制造商方案制备大规模的DNA制备物。通过用瞬时转染技术共转染轻链和重链(命名为DMS4023的SEQ ID NO:176和137;命名为DMS4024的SEQ ID NO:178和137)在哺乳动物HEK293-6E细胞中表达mAbdAb。
25.2.含较长接头的双重靶向的抗-EGFR/抗-VEGF mAbdAb的纯化
和SEC分析
按照已建立的方案用蛋白-A亲和色谱法从澄清的表达上清液纯化这些双重靶向的mAbdAb。通过分光光度法根据在280nm处的光吸光度测量值确定纯化的样品的浓度。纯化的样品DMS4023和DMS4024的SDS-PAGE分析(图137)显示未经还原的样品泳动至约170kDa,而经还原的样品显示泳动至约25和约60kDa的两条带,其分别对应于轻链和融合dAb的重链。
为了进行大小排阻色谱(SEC)分析,将抗-EGFR/抗-VEGFmAbdAb上样到预平衡的S-200 10/300 GL柱(连接到HPLC系统)上,用PBS以1ml/分钟流动。DMS4023(图138)和DMS4024(图139)二者的SEC曲线都显示具有稍微拖尾的峰的单一物质。
25.3.含有较长接头的双重靶向的抗-EGFR/抗-VEGF mAbdAb的效
价
分别如方法12和13所述测定该分子中和VEGF和EGFR的能力。用GraphPad Prism分析测定数据。用S形剂量应答曲线测定效价,用最佳拟合模型拟合数据。mAbdAb DMS4023的抗-EGFR效价(图140)计算为7.066nM并且mAbdAb DMS4024的效价计算为6.420nM,而对照抗-EGFR mAb给出的EC50值为7.291nM。在抗-VEGF受体结合测定(图141)中,mAbdAb DMS4023的EC50为91.79pM(0.091nM)并且mAbdAb DMS4024的EC50为90pM(0.0906nM),而抗-VEGF对照mAb产生的EC50为463.2pM(0.4632nM)。综上所述,测定数据显示实施例25的构建体即含较长接头的双重靶向的抗-EGFR/抗-VEGFmAbdAb对两种抗原都有效。
实施例26
26.1.产生双重靶向的抗-VEGF/抗-EGFR mAbdAb
通过将dAb融合到mAb重链的C-末端来构建该双重靶向的mAbdAb。先前已构建抗-VEGF mAb重链和轻链表达盒。用于克隆的限制性位点与由实施例10中所述的限制性位点(SaII和HindIII)相同。
然后通过PCR(用编码SalI和HindIII端的引物)扩增编码抗-EGFR dAb(DOM16-39-542)的DNA,并将其插入到经修饰的3’编码区,导致产生在mAb和dAb之间的接头“STG”(丝氨酸、苏氨酸、甘氨酸)。
选择已验证序列的克隆(SEQ ID NO:179和181分别为轻链和重链),按照制造商方案用Qiagen Mega Prep试剂盒制备大规模DNA制备物。通过用瞬时转染技术共转染轻链和重链(SEQ ID NO:180和182)在哺乳动物HEK293-6E细胞中表达mAbdAb。
26.2.双重靶向的抗-VEGF/抗-EGFR mAbdAb的纯化和SEC分
析
按照已建立的方案用蛋白-A亲和色谱法从澄清的表达上清液纯化这些双重靶向的mAbdAb。通过分光光度法根据在280nm处的光吸光度测量值确定纯化的样品的浓度。纯化的样品(命名为DMS4009)的SDS-PAGE分析(图142)显示未经还原的样品泳动至约170kDa,而经还原的样品显示泳动至约25和约60kDa的两条带,其分别对应于轻链和融合dAb的重链。
为了进行大小排阻色谱(SEC)分析,将抗-EGFR/抗-VEGFmAbdAb上样到预平衡的S-200 10/300 GL柱(连接到HPLC系统)上,用PBS以1ml/分钟流动。该分子的SEC曲线显示具有对称峰的单一物质(图143)。
26.3.双重靶向的抗-VEGF/抗-EGFR mAbdAb的效价
分别如方法12和13所述测定该分子中和VEGF和EGFR的能力。用GraphPad Prism分析测定数据。用S形剂量应答曲线测定效价,用最佳拟合模型拟合数据。该mAbdAb DMS4009的抗-EGFR效价(图144)计算为132.4nM,而对照抗-EGFR mAb给出的EC50值为6.585nM。在抗-VEGF受体结合测定(图145)中,该mAbdAb的EC50为539.7pM(0.5397nM),而抗-VEGF对照mAb产生的EC50为380.5pM(0.3805nM)。综上所述,测定数据显示实施例26的构建体即双重靶向的抗-EGFR/抗-VEGF mAbdAb对两种抗原都有效。
实施例27
27.1.产生双重靶向的抗-EGFR/抗-IL-13 mAbdAb
通过将dAb融合到mAb重链的C-末端来构建该双重靶向的mAbdAb。先前已构建抗-EGFR mAb重链和轻链表达盒。用于克隆的限制性位点与由实施例10中所述的限制性位点(SaII和HindIII)一样。
然后通过PCR(用编码SalI和HindIII端的引物)扩增编码抗-IL-13dAb(DOM10-53-474)的DNA,并将其插入到经修饰的3’编码区,导致产生在mAb和dAb之间的接头“STG”(丝氨酸、苏氨酸、甘氨酸)。
选择已验证序列的克隆(SEQ ID NO:243和183分别为轻链和重链),按照制造商方案用Qiagen Mega Prep试剂盒制备大规模DNA制备物。通过用瞬时转染技术共转染轻链和重链(SEQ ID NO:137和184)在哺乳动物HEK293-6E细胞中表达mAbdAb。
27.2.双重靶向的抗-EGFR/抗-IL-13 mAbdAb的纯化和SEC分析
按照已建立的方案用蛋白-A亲和色谱法从澄清的表达上清液纯化这些双重靶向的mAbdAb。通过分光光度法根据在280nm处的光吸光度测量值确定纯化的样品的浓度。纯化的样品(命名为DMS4029)的SDS-PAGE分析(图146)显示未经还原的样品泳动至约170kDa,而经还原的样品显示泳动至约25和约60kDa的两条带,其分别对应于轻链和融合dAb的重链。
为了进行大小排阻色谱(SEC)分析,将抗-EGFR/抗-IL-13mAbdAb上样到预平衡的S-200 10/300GL柱(连接到HPLC系统)上,用PBS以0.5ml/分钟流动。该分子的SEC曲线显示具有对称峰的单一物质(图147)。
27.3.双重靶向的抗-EGFR/抗-IL-13mAbdAb的效价
分别如方法13和25所述测定该分子中和EGFR和IL-13的能力。用GraphPad Prism分析测定数据。用S形剂量应答曲线测定效价,用最佳拟合模型拟合数据。mAbdAb DMS4029的抗-EGFR效价(图148)计算为9.033nM,而对照抗-EGFR mAb给出的EC50值为8.874nM。在基于IL-13细胞的中和测定(图149)中,该mAbdAb的EC50为1.654nM,而抗-IL-13对照mAb产生的EC50为0.996nM。综上所述,测定数据显示实施例27的构建体即双重靶向的抗-EGFR/抗-IL-13mAbdAb对两种抗原都有效。
实施例28
28.1.产生其中dAb位于轻链上的双重靶向的抗-EGFR/抗-VEGF
mAbdAb
通过将dAb融合到mAb轻链的C-末端来构建双重靶向的mAbdAb。先前已构建抗-EGFR mAb重链和轻链表达盒。
为了引入用于将dAb插入到轻链的限制性位点,用mAb轻链表达载体作为模板使用位点定向诱变来产生BamHI和HindIII克隆位点。然后通过PCR(用编码SalI和HindIII端的引物)扩增编码抗-VEGFdAb(DOM15-26-593)的DNA,并将其插入到经修饰的3’编码区,导致产生mAb和dAb之间的接头“GSTG”或“GSTVAAPS”。
含SEQ ID NO:187中所述的轻链序列的第一种分子具有接头“GSTG”。
含SEQ ID NO:189中所述的轻链序列的第二种分子具有接头“GSTVAAPS”。
这两者都独立与SEQ ID NO:245重链配对。
选择已验证轻链和重链序列的克隆,按照制造商方案用QiagenMega Prep试剂盒制备大规模DNA制备物。通过用瞬时转染技术共转染轻链和重链(SEQ ID NO:188和139命名为DMS4013;和SEQ ID NO:190和139命名为DMS4027)在哺乳动物HEK293-6E细胞中表达mAbdAb。
28.2.其中dAb位于轻链上的双重靶向的抗-EGFR/抗-VEGF
mAbdAb的纯化和SEC分析
按照已建立的方案用蛋白-A亲和色谱法从澄清的表达上清液纯化这些双重靶向的mAbdAb。通过分光光度法根据在280nm处的光吸光度测量值确定纯化的样品的浓度。纯化的样品DMS4013和DMS4027的SDS-PAGE分析(图150)显示未经还原的样品泳动至约170kDa,而经还原的样品显示泳动至约38和约50kDa的两条带,其分别对应于融合dAb的轻链和重链。
为了进行大小排阻色谱(SEC)分析,将抗-EGFR/抗-VEGFmAbdAb上样到预平衡的S-200 10/300GL柱(连接到HPLC系统)上,用PBS以1ml/分钟流动。DMS4013(图151)和DMS4027(图152)二者的SEC曲线都显示具有对称峰的单一物质。
28.3.其中dAb位于轻链上的双重靶向的抗-EGFR/抗-VEGF
mAbdAb的效价
分别如方法12和13所述测定该分子中和VEGF和EGFR的能力。用GraphPad Prism分析测定数据。用S形剂量应答曲线测定效价,用最佳拟合模型拟合数据。mAbdAb DMS4013的抗-EGFR效价(图153)计算为7.384nM,mAbdAb DMS4027的效价计算为7.554nM,而对照抗-EGFR mAb给出的EC50值为7.093nM。在抗-VEGF受体结合测定(图154)中,mAbdAb DMS4013的EC50为1.179nM,mAbdAbDMS4027的EC50为0.1731nM,而抗-VEGF对照mAb产生的EC50为0.130nM。综上所述,测定数据显示实施例28的构建体即其中dAb位于轻链上的双重靶向的抗-EGFR/抗-VEGF mAbdAb对两种抗原都有效。
实施例29
双重靶向的抗-EGFR/抗-VEGF和抗-TNF/抗-VEGF mAbdAb的
Biacore分析
对在实施例11(抗-TNF/抗-VEGF mAbdAb)和实施例23、24、25和28(抗-EGFR/抗-VEGF mAbdAb)中所述的mAbdAb进行BIAcore分析,以测定它们结合其相应抗原的动力学结合常数及解离常数。在BIAcoreTM3000设备上进行分析。设备温度设定为25℃。将HBS-EP缓冲液用作流动缓冲液。以设备最高可能比率采集实验数据。按照制造商说明书用标准胺偶联化学用蛋白A包被研究级的CM5芯片上的一流动细胞,同样处理第二批流动细胞,但用缓冲液代替蛋白A以产生参考表面。然后将用蛋白A包被的流动细胞用于捕获mAbdAb。抗原如表37中所详述以2x系列稀释液注入。几种稀释液以一式二份来进行。单独的缓冲注入液代替配体用于本底扣除。用设备软件自带的动力学Wizard以随机顺序注入样品。在每一次循环结束时通过注入10mM甘氨酸,pH 1.5来使表面再生。用BIA评估软件4.1来进行数据处理和动力学拟合。显示重复结果(来自同一次运作)平均值的数据示于表37中。显示的DMS4010的多个值代表在单独场合的两次实验运作。因所分析的配体的浓度,787nM的值可能高估了亲和力。
表37
实施例30
包含融合到双特异性抗体骨架上的单一结构域抗体的三特异性抗体
30.1.构建
用合适的限制性酶位点和所加的信号序列,从头构建了编码对IL-18和IL-12抗原具有特异性的双特异性抗体分子的可变重链和轻链结构域的基因(进一步的资料参见WO 2007/024715)。用标准分子生物学技术将可变重链结构域克隆到表达载体,所述表达载体含有经由TVAAPS接头在恒定区的c-末端融合到抗-IL4结构域抗体DOM9-112-210(SEQ ID NO:4)的IgG1重链恒定区。将轻链可变结构域同样地克隆到含有Ck恒定区序列的表达载体中。已构建和表达的抗体列入表38中。
表38
30.2表达和纯化
简言之,用先前与293fectin试剂(Invitrogen#51-0031)孵育的重链和轻链表达质粒共转染25ml 1.5x106细胞/ml的HEK293细胞。将其置于37℃、5%CO2和95%RH的振荡培养箱中。24小时后,加入蛋白胨养分培养基,让细胞再生长48小时。通过离心收获上清液,通过ELISA定量IgG水平。将得到的mAbdAb命名为BPC1616(SEQID NO:193和194)。
30.3.IL-12结合ELISA
评估了转染的细胞上清液对重组人IL-12的结合。简言之,用抗-人IL-12(R&D Systems AF219NA)以2μg/ml包被ELISA板,并用封闭液(Tris缓冲的盐水中的4%BSA)封闭。然后将封闭液中的25ng/ml重组人IL-12(PeproTech#200-12)装入板中。在用TBS+0.05%Tween 20(TBST)洗涤前让板在室温孵育1小时。加入在封闭液中稀释的各种稀释度的细胞上清液以及不相关对照抗体(帕考珠单抗和同种型匹配的对照hIgG)。在用TBST洗涤前让板在室温孵育1小时。通过加入在封闭液中以1/1000稀释的过氧化物酶标记的抗人κ轻链抗体(SigmaA7164)来检测结合。在用TBST洗涤前让板在室温孵育1小时。通过加入OPD底物(Sigma P9187)来使板显色,并通过加入3M H2SO4终止显色。用板读数器在490nm处测量吸光度,作图确定平均吸光度。
结果显示在图155中,其显示BPC1616结合重组人IL-12,而两种对照抗体显示不结合。
30.4.IL-18结合ELISA
评估了转染的细胞上清液对重组人IL-18的结合。简言之,用抗-人IL-18(由GSK制备)以1μg/ml包被ELISA板,并用封闭液(Tris缓冲的盐水中的4%BSA)封闭。加入在封闭液中稀释的各种稀释度的细胞上清液以及不相关抗体(帕考珠单抗和同种型匹配的对照人IgG)。在用TBS+0.05%Tween 20(TBST)洗涤前让板在室温孵育1小时。通过加入在封闭液中以1/1000稀释的过氧化物酶标记的抗人κ轻链抗体(Sigma A7164)来检测结合。在用TBST洗涤前让板在室温孵育1小时。通过加入OPD底物(Sigma P9187)来使板显色,并通过加入3M H2SO4终止显色。在490nm处用板读数器测量吸光度,作图确定平均吸光度。结果显示在图156中,其显示BPC1616结合重组人IL-18,而两种对照抗体显示不结合。
30.5.IL-4结合ELISA
评估了转染的细胞上清液对重组人IL-14的结合。简言之,用IL-4(由GSK制备)以1μg/ml包被ELISA板,并用封闭液(Tris缓冲的盐水中的4%BSA)封闭。加入在封闭液中稀释的各种稀释度的细胞上清液以及抗-IL-4单克隆抗体(帕考珠单抗)和不相关的抗体(同种型匹配的对照hIgG)。在用TBS+0.05%Tween 20(TBST)洗涤前让板在室温孵育1小时。通过加入在封闭液中以1/1000稀释的过氧化物酶标记的抗人κ轻链抗体(Sigma A7164)来检测结合。在用TBST洗涤前让板在室温孵育1小时。通过加入OPD底物(Sigma P9187)来使板显色,并通过加入3M H2SO4终止显色。在490nm处用板读数器测量吸光度,作图确定平均吸光度。
结果显示在图157中,其显示BPC1616和帕考珠单抗结合重组人IL-4,而对照抗体显示不结合。
实施例31
包含线内融合到单克隆抗体C-末端的两个单一结构域抗体的三特异
性mAbdAb
31.1.构建
构建了三种三特异性抗体(mAbdAb-dAb),其中将两个单一结构域抗体线内(in line)融合到单克隆抗体重链的C-末端。
简言之,通过PCR引入N-末端的BglII限制性位点和C-末端的BamHI限制性位点,以使编码结构域抗体的DNA序列位于DOM10-53-474(SEQ ID NO:5)、DOM9-155-154(SEQ ID NO:3)和DOM9-112-210(SEQ ID NO:4)的侧翼。
然后将编码DOM10-53-474结构域抗体的DNA片段克隆到编码与抗IL-4结构域抗体DOM9-112-210(SEQ ID NO:71)融合的抗IL-5单克隆抗体重链的哺乳动物表达载体的BamHI位点。将编码DOM9-155-154和DOM9-112-210结构域抗体的DNA片段二者都独立克隆到编码与抗IL-13结构域抗体DOM10-53-474(SEQ ID NO:116)融合的抗-CD20单克隆抗体重链的哺乳动物表达载体的BamHI位点。得到的表达载体编码含融合到C-末端的两个单一结构域抗体的重链。重链的蛋白质序列示于表39中所述的SEQ ID NO:195、196和197。
表39为业已构建的mAbdAb的概述。
表39
31.2.表达和纯化
用293fectin试剂(Invitrogen,12347019)将编码BPC1008、BPC1009和BPC1010重链和轻链的表达质粒共转染到HEK 2936E细胞中。第二天将蛋白胨养料加入到细胞培养物中,从初始转染约2-6天后收获上清液物质。在用结合测定检测前用蛋白A柱纯化抗体。
31.3.IL-4结合ELISA
用包被缓冲液(0.05M碳酸氢盐pH9.6,Sigma C-3041)3中的5μg/ml人IL-4(GSK)包被96孔高结合板,并在4℃储存过夜。用含0.05%的Tween-20的Tris-缓冲的盐水(TBST)洗涤板2次。将100μL封闭液(含1%BSA的TBST缓冲液)加入到各孔中,让板在室温孵育至少1小时。用封闭液在板中连续稀释纯化的抗体。孵育1小时后,将板洗涤3次。将山羊抗-人κ轻链特异性过氧化物酶缀合抗体(SigmaA7164)在封闭液中以1∶2000稀释,将50μL加入到各孔中。让板孵育1小时。将板洗涤3次,然后将OPD(邻苯二胺二盐酸盐)SigmaFast底物溶液加入到各孔中,5分钟后通过加入25μL的3M硫酸使反应终止。用碱性终点方案用VersaMax Tunable微板读数器(MolecularDevices)在490nm处读取吸光度。
ELISA结果示于图158中,其确证抗体BPC1008、1009和BPC1010结合重组人IL-4。还显示阳性对照帕考珠单抗结合重组IL-4,然而显示阴性对照抗IL-13mAb和美泊利单抗不结合IL-4。也在单独的实验中检测抗体BPC1009和BPC1010,其给出与图158所示相似的结果。
31.4.IL-5结合ELISA
用包被缓冲液(0.05M碳酸氢盐pH9.6)中的5.9μg/ml人IL-5(GSK)包被96孔高结合板,并在4℃储存过夜。用含0.05%的Tween-20的Tris-缓冲的盐水(TBST)洗涤板2次。将100μL封闭液(含1%BSA的TBST缓冲液)加入到各孔中,让板在室温孵育至少1小时。用封闭液在板中连续稀释纯化的抗体。孵育1小时后,将板洗涤3次。将山羊抗-人κ轻链特异性过氧化物酶缀合抗体(Sigma A7164)在封闭液中以1∶2000稀释,将50μL加入到各孔中。让板孵育1小时。将板洗涤3次,然后将OPD(邻苯二胺二盐酸盐)SigmaFast底物溶液加入到各孔中,5分钟后通过加入25μL的3M硫酸使反应终止。用碱性终点方案用VersaMax Tunable微板读数器(Molecular Devices)在490nm处读取吸光度。
图159显示ELISA结果,其确证抗体BPC1008结合重组人IL-5,而BPC1009和BPC1010显示不结合IL-5。也显示阳性对照帕考珠单抗结合重组IL-5,然而显示阴性对照抗IL-13mAb和美泊利单抗不结合IL-5。
IL-13结合ELISA
用包被缓冲液(0.05M碳酸氢盐pH9.6,Sigma C-3041)3中的5μg/ml人IL-13(GSK)包被96孔高结合板,并在4℃储存过夜。用含0.05%的Tween-20的Tris-缓冲的盐水(TBST)洗涤板2次。将100μL封闭液(1%BSA的TBST缓冲液)加入到各孔中,让板在室温孵育至少1小时。用封闭液在板中连续稀释纯化的抗体。孵育1小时后,将板洗涤3次。将山羊抗-人κ轻链特异性过氧化物酶缀合抗体(SigmaA7164)在封闭液中以1∶2000稀释,将50μL加入到各孔中。让板孵育1小时。将板洗涤3次,然后将OPD(邻苯二胺二盐酸盐)SigmaFast底物溶液加入到各孔中,5分钟后通过加入25μL的3M硫酸使反应终止。用碱性终点方案用VersaMax Tunable微板读数器(MolecularDevices)在490nm处读取吸光度。
ELISA结果示于图160中,其确证抗体BPC1008、1009和BPC1010结合重组人IL-13。还显示阳性对照抗IL-13mAb结合重组IL-13,然而显示阴性对照帕考珠单抗和美泊利单抗不结合IL-13。也在单独的实验中检测抗体BPC1009和BPC1010,其给出与图160所示相似的结果。
实施例32
含融合到单价骨架的单一结构域抗体的mAbdAb
32.1.mAbdAb的构建
如下构建包含单价抗体(进一步资料参见WO2006015371和WO2007059782)和结构域抗体DOM-15-26-293融合体的双特异性抗体。用基于PCR的策略接着位点定向诱变构建编码抗-c-MetKnob-into-hole重链(SEQ ID NO:202和203)的DNA序列。用基于PCR的策略接着通过基于PCR的方法除去铰链区构建了编码抗-c-MetUnibody重链(SEQ ID NO:204)的DNA序列。另外,对于融合构建体,在重链表达盒的C-末端包括BamHI和EcoRI限制性位点,以促进作为来自现有载体的BamHI-EcoRI片段的抗VEGF-A结构域抗体(DOM-15-26-593)DNA序列(编码SEQ ID NO:75的455-570位氨基酸)的随后克隆。得到的表达载体编码经由GS接头融合到重链C-末端的抗-VEGFA结构域抗体(SEQ ID NO:198、199和201)。通过基于PCR的策略已构建编码抗-c-Met轻链(SEQ ID NO:200)的DNA序列。
BPC1604的构建如实施例14所述。下表40为业已产生并表达的单价骨架mAbdAb和抗体的概述。
表40
32.2.表达和纯化
用293fectin(Invitrogen,12347019)将编码BPC1017、BPC1018和BPC1020重链的表达质粒共转染到HEK 2936E细胞中。第二天将蛋白胨养料加入到细胞培养物中,从初始转染约2-6天后收获上清液物质。在用结合测定检测前用蛋白A柱纯化抗体。
32.3.HGF受体结合ELISA
用包被缓冲液(0.05M碳酸氢盐pH9.6,Sigma C-3041)3中的5μg/ml重组人HGF R(c-MET)/Fc嵌合体(R&D system,货号:358-MT/CF)包被96孔高结合板,并在4℃储存过夜。用含0.05%的Tween-20的Tris-缓冲的盐水(TBST)洗涤板2次。将100μL封闭液(含1%BSA的TBST缓冲液)加入到各孔中,让板在室温孵育至少30分钟。将板洗涤3次。然后用封闭液在板中连续稀释纯化的抗体。在室温孵育1小时后,将板洗涤3次。将山羊抗-人κ轻链特异性过氧化物酶缀合抗体(Sigma A7164)在封闭液中以1∶2000稀释,并加入到各孔中。让板孵育1小时。将板洗涤3次,然后将OPD(邻苯二胺二盐酸盐)SigmaFast底物溶液加入到各孔中,5分钟后通过加入25μL的3M硫酸使反应终止。用碱性终点方案用VersaMax Tunable微板读数器(Molecular Devices)在490nm处读取吸光度。
ELISA结果示于图161中,其确证mAbdAb BPC1017和BPC1018以可比得上抗体BPC1019和BPC1020的活性结合重组人c-MET。显示阴性对照帕考珠单抗和BPC1604(IGF-1R/VEGF mAbdAb)不结合c-MET。
32.4.VEGF结合ELISA
用PBS中的0.45μg/ml人VEGF(GSK)包被96孔高结合板,并在4℃孵育过夜。用含0.05%的Tween-20的Tris-缓冲的盐水(TBST)洗涤板2次。将100μL封闭液(含1%BSA的TBST缓冲液)加入到各孔中,让板在室温孵育至少1小时。然后进行另一次洗涤步骤。用封闭液在板中连续稀释纯化的抗体。室温孵育1小时后,洗涤板。将山羊抗-人κ轻链特异性过氧化物酶缀合抗体在封闭液中以1∶2000稀释,并加入到各孔中。让板在室温孵育1小时。在另一洗涤步骤后,将OPD(邻苯二胺二盐酸盐)SigmaFast底物溶液加入到各孔中,5分钟后通过加入25μL的3M硫酸使反应终止。用碱性终点方案用VersaMax Tunable微板读数器(Molecular Devices)在490nm处读取吸光度。
图162显示ELISA结果,其确证抗体mAbdAb BPC1017和BPC1018结合重组人VEGF。还显示阳性对照BPC1604结合重组人VEGF,然而显示帕考珠单抗、BPC1019和BPC1020不结合VEGF。
实施例33
含有抗-IL13dAb DOM10-53-546dAb和DOM10-53-567的mAbdAb
33.1.构建、表达和纯化
对示于表41的抗-IL4mAb-抗-IL13dAb进行克隆并在HEK2936E细胞中瞬时表达,纯化(分别如实施例1、1.3和1.5所述)。
表41
通过大小排阻色谱(SEC)和在还原条件下的十二烷基硫酸钠聚丙烯酰胺凝胶电泳(SDS PAGE)分析纯化的PascoH-TVAAPS-546和PascoH-TVAAPS-567mAbdAb。SEC和SDS PAGE数据示于图163、164、165和166中。
33.2.与IL-13和IL-4结合的Biacore分析
用BIAcoreTM T100于25℃(如方法4和5所述)检测纯化的PascoH-TVAAPS-546和PascoH-TVAAPS-567对人IL-13和人IL-4的结合。这些数据示于表42中。
表42
在该测定中所测的二种mAbdAb都以极高亲和力(注意对于PascoH-TVAAPS-567其亲和力超出了设备的灵敏度)结合IL-4,且所述结合亲和力与单独的抗-人IL4mAb(帕考珠单抗)的结合亲和力相似。PascoH-TVAAPS-546和PascoH-TVAAPS-567二者都结合IL-13。注意在该测定中没有检测单独的抗-IL-13dAb(DOM10-53-546和DOM10-53-567),因为不能将该dAb捕获蛋白A或抗-人IgG包被的CM5芯片上;取而代之的是,在该测定中用抗-人IL13mAb作为阳性对照以证明IL-13结合。
还用BIAcoreTM T100于25℃(如方法23所述)检测这些mAbdAb对猕猴IL-13的结合。这些数据示于表43中。mAbdAb捕获水平达到500和750相对响应单位之间,对于mAbdAb和抗-IL13mAb二者都评估6个IL-13浓度曲线(256、64、16、4、1和0.25nM)。
表43
PascoH-TVAAPS-546和PascoH-TVAAPS-567二者都以相似的结合亲和力结合猕猴IL-13。注意在该测定中没有检测单独的抗-IL-13dAb(DOM10-53-546和DOM10-53-567),因为不能将该dAb捕获到蛋白A或抗-人IgG包被的CM5芯片上;取而代之的是,在该测定中用抗-人IL13mAb作为阳性对照以证明IL-13结合。
33.3.在TF-1细胞生物测定中人IL-13和猕猴IL-13的中和
在TF-1细胞生物测定(分别如方法8和方法20所述)中检测纯化的PascoH-TVAAPS-546和PascoH-TVAAPS-567对人IL-13和猕猴IL-13的中和。图167和168分别显示对人IL-13和猕猴IL-13(在TF-1细胞生物测定中)的中和数据。在这些生物测定中包括DOM10-53-616作为中和IL-13的阳性对照。还包括对不相关抗原具有特异性的dAb(阴性对照dAb)作为中和IL-13的阴性对照。另外,在这些测定中还检测PascoH-616和PascoH-TVAAPS-616。
在TF-1细胞生物测定中,PascoH-TVAAPS-546和PascoH-TVAAPS-567二者都完全中和人和猕猴IL-13的生物活性。
从数据集计算ND50值。ND50值是能够中和IL-13的生物活性到50%的mAbdAb或mAb或dAb的浓度。平均ND50值、标准偏差(SD)和所测次数(n)示于表44中。
表44
实施例34
含IgG2、IgG4和IgG4PE重链恒定区的mAbdAb
34.1.mAbdAb的构建
通过PCR从现有构建体扩增人抗体同种型IgG2、IgG4和变体IgG4(IgG4PE)的重链恒定区基因,并用标准分子生物学技术克隆到编码PascoH-GS-474重链(SEQ ID NO:48)的表达载体。已设计并检测的mAbdAb抗体列入表45中。
表45
34.2.表达
表达了表45中所述的mAbdAb连同命名为BPC1000的PascoH-GS-474(SEQ ID NO:48和15)。简言之,用先前与293fectin试剂(Invitrogen#51-0031)孵育的重链和轻链表达质粒共转染含1.5x106细胞/ml的750μl的HEK293细胞。将这些置于37℃、5%CO2和95%RH的震荡培养箱中。1小时后,加入蛋白胨养分培养基,让细胞再生长72小时。通过离心收获上清液。
34.3.IL-4结合ELISA
评估了含这些mAbdAb的上清液对重组人IL-4的结合。简言之,用人IL-4(由GSK制备)以1μg/ml包被ELISA板,并用封闭液(Tris缓冲的盐水中的4%BSA)封闭。加入各种稀释度的细胞上清液、抗IL-4单克隆抗体(帕考珠单抗)和不相关特异性的抗体(586抗IL-13)。所有样品都用封闭液稀释。在用TBS+0.05%Tween 20(TBST)洗涤前让板在室温孵育1小时。通过加入在封闭液中以1/1000稀释的过氧化物酶标记的抗人κ轻链抗体(Sigma A7164)来检测结合。在用TBST洗涤前让板在室温孵育1小时。通过加入OPD底物(Sigma P9187)来使板显色,并通过加入3M H2SO4终止显色。在490nm处用板读数器测量吸光度,作图确定平均吸光度。
在图169中提供的结果显示含有备选同种型的mAbdAb都结合人IL-4。对于mAbdAb BPC1000、BPC1617、BPC1618和BPC1619而言,不能定量测定上清液中的抗体的量,因此,图169提供的数据代表洁净上清液物质稀释倍数。对于抗-IL4和IL-13对照抗体而言,在该测定中使用纯化的物质,所用的起始浓度分别为1μg/ml和1μg/ml(其等同于图169中的稀释倍数1)。
34.4.IL-13结合ELISA
评估了含这些mAbdAb的上清液对重组人IL-13的结合。简言之,用人IL-13(由GSK制备)以5μg/ml包被ELISA板,并用封闭液(Tris缓冲的盐水中的4%BSA)封闭。加入各种稀释度的细胞上清液、抗IL-13单克隆抗体(586)和不相关特异性的抗体(帕考珠单抗抗IL-4)。所有样品都用封闭液稀释。在用TBS+0.05%Tween 20(TBST)洗涤前让板在室温孵育1小时。通过加入在封闭液中以1/1000稀释的过氧化物酶标记的抗人κ轻链抗体(Sigma A7164)来检测结合。在用TBST洗涤前让板在室温孵育1小时。通过加入OPD底物(Sigma P9187)来使板显色,并通过加入3M H2SO4终止显色。在490nm处用板读数器测量吸光度,作图确定平均吸光度。
在图170中提供的结果显示含有备选同种型的双特异性抗体都结合人IL-13。对于双特异性抗体BPC1000、BPC1617、BPC1618和BPC1619而言,不能定量测定上清液中的抗体的量,因此,图170提供的数据表示为净上清液物质稀释倍数。对于抗-IL4和IL-13对照抗体而言,在该测定中分别以1μg/ml和1μg/ml的起始浓度(其等同于图170中的稀释倍数1)使用纯化的物质。
实施例35
备选抗-IL-13/IL-4mAbdAb
35.1.含备选可变区序列的抗-IL-13/IL-4mAbdAb的构建
用标准分子生物学技术将编码命名为“C1”和“D1”的备选重链可变区抗-IL-13mAb的DNA序列,从现有构建体转移到含有编码经由TVAAPSGS接头在恒定区c-末端融合到抗IL-4结构域抗体(DOM9-112-210)的hIgG1恒定区的DNA的表达载体。从头开始组装编码命名为“MO”和“NO”的IL-13mAb的备选轻链可变区的DNA序列,并克隆到含有人Ck恒定区的表达载体。这些备选重链和轻链抗体可变区包含与SEQ ID NO:12和13所述的抗-IL-13抗体相同的CDR区,但含有备选的人源化可变构架区。
35.2.用抗IL-13mAb“656”可变区构建mAbdAb
用标准分子生物学技术将编码人源化抗IL-13mAb“656”重链可变区的DNA序列,从现有构建体转移并克隆到含有编码经由TVAAPS接头在恒定区c-末端融合到抗IL-4结构域抗体(DOM9-112-210)的hIgG1恒定区的DNA的表达载体。将编码可变轻链区的DNA序列从现有构建体转移并克隆到含有人Ck恒定区的表达载体。
35.3.mAbdAb的表达
简言之,用先前与293fectin试剂(Invitrogen#51-0031)孵育的重链和轻链表达质粒共转染25ml 1.5x106细胞/ml的HEK293细胞。将其置于37℃、5%CO2和95%RH的振荡培养箱中。24小时后,加入蛋白胨养分培养基,让细胞再生长72小时。通过离心收获上清液,并通过ELISA定量IgG水平。已构建并表达的抗体列举在表46中。
表46
35.4.mAbdAb与IL-13的结合
通过ELISA评估mAbdAb与IL-13的结合活性。简言之,将5μg/ml大肠杆菌表达的重组人IL-13(由GSK制备并纯化)包被到96孔ELISA板。于室温封闭孔2小时,然后用滴定法测量板中的mAbdAb构建体。用1∶1000稀释的抗-人κ轻链过氧化物酶缀合抗体(货号A7164,Sigma-Aldrich)检测结合。
图177显示所有测试分子都能够结合人IL-13。
尽管在该ELISA中BPC1615显示结合,但不可能准确定量该分子的浓度,因此,在图177中未标出该分子的IL-13结合ELISA数据。在独立的Biacore测定(表47)中,BPC1615也显示具有与IL-13结合的高亲和力。
35.5.通过BIAcore
TM
测定抗-IL13mAb-抗-IL4dAb与IL-13的结合
也用BIAcoreTM于25℃(如方法4所述)检测来自HEK细胞转染的细胞上清液对大肠杆菌表达的重组人IL-13的结合。BPC1601作为纯化的蛋白质被检测。表47所提供的结合亲和力确证所有抗体显示与IL-13结合的高亲和力。
表47
ka | kd | KD(nM) | |
C1-TVAAPSGS-210&MOKappa BPC1607 | 5.15E+5 | 8.89E-4 | 1.73 |
C1-TVAAPSGS-210&NOKappa BPC1608 | 4.90E+5 | 8.83E-4 | 1.80 |
C1-TVAAPSGS-210&586kappa BPC1609 | 7.55E+5 | 7.61E-4 | 1.01 |
D1-TVAAPSGS-210&MOkappa BPC1610 | 3.31E+5 | 4.66E-4 | 1.41 |
D1-TVAAPSGS-210&NOkappa BPC1611 | 2.59E+5 | 3.31E-4 | 1.28 |
D1-TVAAPSGS-210&586kappa BPC1612 | 4.85E+5 | 2.74E-4 | 0.565 |
586H TVAAPS-210&MOkappa BPC1613 | 5.54E+5 | 4.45E-4 | 0.804 |
586H TVAAPS-210&NOkappa BPC1614 | 5.49E+5 | 4.42E-4 | 0.805 |
656H TVAAPS-210&656kappa BPC1615 | 4.89E+6 | 4.17E-4 | 0.085 |
586H-TVAAP-210无GS BPC1602 | 8.21E+5 | 4.62E-4 | 0.562 |
纯化的586H-无接头-210无GS BPC1601 | 8.93E+5 | 3.93E-4 | 0.440 |
Kappa=κ,&=和
实施例36
产生对人IL-5和人IL-13具有特异性的mAbdAb
36.1.mAbdAb的构建和表达
在HEK2936E细胞中表达了具有SEQ ID NO:65中所述的重链和SEQ ID NO:72中所述的轻链的mAbdAb分子。其被命名为美泊利单抗L-G4S-474或BPC1021。
36.2.抗-IL5mAb-抗-IL13dAb与IL-5和IL-13的结合
在直接结合ELISA(如方法1所述)中检测该mAbdAb(在细胞上清液中)对人IL-13的结合。这些数据示于图173中。样品以一式二份被转染并检测,其被标注为样品A和样品B。
该mAbdAb结合IL-13。在该测定中包括单独的纯化的抗-人IL13mAb作为IL-13结合的阳性对照。包括纯化的抗-人IL-4mAb(帕考珠单抗)和抗-人IL-5mAb(美泊利单抗)作为IL-13结合的阴性对照。
还在直接结合ELISA(如实施例31.4所述)中检测该mAbdAb对人IL-5的结合。这些数据示于图174中。
美泊利单抗L-G4S-474结合IL-5。包括纯化的抗-人IL4mAb(帕考珠单抗)和纯化的抗人13mAb作为结合IL-5的阴性对照。在该测定中使用纯化的抗-人IL5mAb(美泊利单抗)作为阳性对照以证明IL-5结合。
序列
表49:
附图简述
图1-7:抗原结合构建体实例。
图8:mAbdAb构建体示意图。
图9:PascoH-G4S-474的SEC和SDS Page分析。
图10:PascoL-G4S-474的SEC和SDS Page分析。
图11:PascoH-474的SEC和SDS Page分析。
图12:PascoHL-G4S-474的SEC和SDS Page分析。
图13:在直接结合ELISA中mAbdAb上清液对人IL-13的结合。
图14:在直接结合ELISA中mAbdAb上清液对人IL-4的结合。
图15:在直接结合ELISA中纯化的mAbdAb对人IL-13的结合。
图16:在直接结合ELISA中纯化的mAbdAb对人IL-4的结合。
图17:在直接结合ELISA中mAbdAb上清液对人IL-4的结合。
图18:在直接结合ELISA中mAbdAb上清液对人IL-13的结合。
图19:在直接结合ELISA中纯化的mAbdAb对人IL-4的结合。
图20A:在直接结合ELISA中纯化的mAbdAb对人IL-13的结合。
图20B:在直接结合ELISA中纯化的mAbdAb对猕猴IL-13的结合。
图21:用BIAcoreTM的mAbdAb对IL-4的结合动力学。
图22:用BIAcoreTM的mAbdAb对IL-4的结合动力学。
图23:用BIAcoreTM的mAbdAb对IL-13的结合动力学。
图24:在TF-1细胞生物测定中纯化的抗-IL13mAb-抗-IL4dAb中和人IL-13的能力。
图25:在TF-1细胞生物测定中纯化的抗-IL13mAb-抗-IL4dAb中和人IL-4的能力。
图26:在TF-1细胞生物测定中纯化的抗-IL4mAb-抗-IL13dAbPascoH-G4S-474、PascoH-474、PascoL-G4S-474和PascoHL-G4S-474中和人IL-4的能力。
图27:在TF-1细胞生物测定中纯化的抗-IL4mAb-抗-IL13dAb、PascoH-G4S-474、PascoH-474、PascoL-G4S-474和PascoHL-G4S-474中和人IL-13的能力。
图28:在双重中和TF-1细胞生物测定中纯化的抗-IL4mAb-抗-IL13dAb、PascoH-G4S-474、PascoH-474、PascoL-G4S-474和PascoHL-G4S-474同时中和人IL-4和人IL-13的能力。
图29:DOM10-53-474SEC-MALLS。
图30:DOM9-112-210SEC-MALLS。
图31:DOM9-155-25SEC-MALLS。
图32:所有三种信号的DOM9-155-25SEC-MALLS重叠。
图33:DOM9-155-147SEC-MALLS
图34:DOM9-155-159SEC-MALLS
图35:用于通过SEC-MALLS确定MW的对照:BSA。
图36:三特异性mAbdAb分子的示意图。
图37:在直接结合ELISA中三特异性mAbdAb IL18mAb-210-474(上清液)对人IL-18的结合。
图38:在直接结合ELISA中三特异性mAbdAb IL18mAb-210-474(上清液)对人IL-13的结合。
图39:在直接结合ELISA中三特异性mAbdAb IL18mAb-210-474(上清液)对人IL-4的结合。
图40:在直接结合ELISA中三特异性mAbdAb Mepo-210-474(上清液)对人IL-13的结合。
图41:在直接结合ELISA中三特异性mAbdAb Mepo-210-474(上清液)对人IL-4的结合。
图42:抗-TNF/抗-EGFR mAb-dAb的克隆。
图43:抗-TNF/抗-EGFR mAb-dAb的SDS-PAGE分析。
图44:抗-TNF/抗-EGFR mAb-dAb的SEC曲线(实施例10)。
图45:实施例10的抗-EGFR活性。
图46:实施例10的抗-TNF活性。
图47:抗-TNF/抗-VEGF mAb-dAb的SDS-PAGE分析(实施例11),
图48:抗-TNF/抗-VEGF mAb-dAb的SEC曲线(实施例11)。
图49:实施例11的抗-VEGF活性。
图50:实施例11的抗-TNF活性。
图51:抗-VEGF/抗-IL1R1dAb-延伸的-IgG的克隆(实施例12)。
图52:抗-TNF/抗-VEGF dAb-延伸的IgG A的SD S-PAGE分析(实施例12)
图53:抗-TNF/抗-VEGF dAb-延伸的IgG B的SDS-PAGE分析(实施例12)
图54:抗-TNF/抗-VEGF dAb-延伸的IgG A的SEC曲线(实施例12)。
图55:抗-TNF/抗-VEGF dAb-延伸的IgG B的SEC曲线(实施例12)。
图56:实施例12(DMS2091)的抗-VEGF活性。
图57:实施例12(DMS2090)的抗-VEGF活性。
图58:实施例12(DMS2090)的抗-IL1R1活性。
图59:实施例12(DMS2091)的抗-IL1R1活性。
图60:抗-TNF/抗-VEGF/抗-EGFR mAb-dAb的克隆(实施例13)。
图61:抗-TNF/抗-VEGF/抗-EGFR mAb-dAb的SDS-PAGE分析(实施例13)。
图62:实施例13的抗-VEGF活性。
图63:实施例13的抗-TNF活性。
图64:实施例13的抗-EGFR活性。
图65:纯化的双特异性抗体BPC1603(A)、BPC1604(B)、BPC1605(C)、BPC1606(D)的SEC分析。
图66:双特异性抗体与固定化的IGF-1R的结合。
图67:双特异性抗体与固定化的VEGF的结合。
图68:不同双特异性抗体对配体介导的受体磷酸化的抑制。
图69:不同双特异性抗体对配体介导的受体磷酸化的抑制。
图70:用抗-CD20/IL-13双特异性抗体进行ADCC测定。
图71:用抗-CD20/IL-13双特异性抗体进行ADCC测定。
图72:用较短的剂量范围用抗-CD20/IL-13双特异性抗体进行ADCC测定。
图73:用较短的剂量范围用抗-CD20/IL-13双特异性抗体进行ADCC测定。
图74:用抗-CD20/IL-13双特异性抗体进行CDC测定。
图75:用抗-CD20/IL-13双特异性抗体进行CDC测定。
图76:在重组人IGF-1R ELISA中BPC1803和BPC1804的结合。
图77:在重组VEGF结合ELISA中BPC1803和BPC1804的结合。
图78:在重组人IGF-1R ELISA中BPC1805和BPC1806的结合。
图79:在重组人HER2ELISA中BPC1805和BPC1806的结合。
图80:在重组人IGF-1R ELISA中BPC1807和BPC1808的结合。
图81:在重组人HER2ELISA中BPC1807和BPC1808的结合。
图82:在重组人IL-4ELISA中BPC1809的结合。
图83:在RNA酶A ELISA中BPC1809的结合。
图84:在重组人IL-4ELISA中BPC1816的结合。
图85:在HEL ELISA中BPC1816的结合。
图86:在重组人IGF-1R ELISA中BPC1801和BPC1802的结合。
图87:在重组人VEGFR2ELISA中BPC1801和BPC1802的结合。
图88:在重组人IL-4ELISA中BPC1823和BPC 1822的结合。
图88b:在重组人IL-4ELISA中BPC1823(较高浓度的上清液)的结合。
图89:在重组人TNF-αELISA中BPC1823和BPC1822的结合。
图89b:在重组人TNF-αELISA中BPC1823(较高浓度的上清液)的结合。
图90:除去GS的PascoH-474的SEC曲线。
图91:除去GS的PascoH-TVAAPS-474的SEC曲线。
图92:除去第二个GS的PascoH-GS-ASTKGPT-474的SEC曲线。
图93:除去GS的586H-210的SEC曲线。
图94:除去GS的586H-TVAAPS-210的SEC曲线。
图95:除去GS的PascoH-474(B泳道)和除去GS的PascoH-TVAAPS-474(A泳道)的SDS PAGE。
图96:除去第二个GS的PascoH-GS-ASTKGPT-474的SDS PAGE[A=非还原条件,B=还原条件]。
图97:除去GS的586H-210的SDS PAGE(A泳道)。
图98:除去GS的586H-TVAAPS-210的SDS PAGE(A泳道)。
图99:在人IL-4ELISA中纯化的除去GS的PascoH-474和除去GS的PascoH-TVAAPS-474的结合。
图100:在人IL-13ELISA中纯化的除去GS的PascoH-474和除去GS的PascoH-TVAAPS-474的结合。
图101:在猕猴IL-13ELISA中纯化的除去GS的PascoH-474、除去GS的PascoH-TVAAPS-474、PascoH-616和PascoH-TVAAPS-616的结合。
图102:通过ELISA测定mAbdAb抑制人IL-4与人IL-4Rα的结合。
图103:通过ELISA测定mAbdAb抑制人IL-4与人IL-4Rα的结合。
图104:在TF-1细胞生物测定中mAbdAb中和人IL-13。
图105:在TF-1细胞生物测定中mAbdAb中和猕猴IL-13。
图106:在TF-1细胞生物测定中mAbdAb中和人IL-4。
图107:在TF-1细胞生物测定中mAbdAb中和猕猴IL-4。
图108:mAbdAb抑制人IL-13结合人IL-13Rα2的能力。
图109:PascoH-616的SEC曲线。
图110:PascoH-TVAAPS_616的SEC曲线。
图111:PascoH-616的SDS PAGE[E1=非还原性条件,E2=还原性条件]。
图112:PascoH-TVAAPS-616的SDS PAGE[A=非还原性条件,B=还原性条件]。
图113:在人IL-13ELISA中纯化的PascoH-616和PascoH-TVAAPS-616的结合。
图114:在TF-1细胞生物测定中mAbdAb中和人IL-13。
图114a:在TF-1细胞生物测定中mAbdAb中和猕猴IL-13。
图115:除去GS的PascoH-474抑制IL-4活性。
图116:除去GS的PascoH-474抑制IL-13活性。
图117:586-TVAAPS-210抑制IL-4活性。
图118:586-TVAAPS-210抑制IL-13活性。
图119:帕考珠单抗抑制IL-4活性。
图120:DOM9-112-210抑制IL-4活性。
图121:抗-IL13mAb抑制IL-13活性。
图122:DOM10-53-474抑制IL-13活性。
图123:在IL-4全血测定中对照mAb和dAb的活性。
图124:在IL-13全血测定中对照mAb和dAb的活性。
图125:通过针对TNF及EGFR二者的ELISA评估在给药后不同时间点的药物残留浓度。
图126:通过针对TNF及VEGF二者的ELISA评估在给药后不同时间点的药物残留浓度。
图127:通过针对IL1R1及VEGF二者的ELISA评估在给药后不同时间点的药物残留浓度。
图128:纯化的DMS4010的SDS-PAGE。
图129:纯化的DMS4010的SEC曲线。
图130:DMS4010的抗-EGFR效价。
图131:抗-VEGF受体结合测定。
图132:双重靶向的抗-EGFR/抗-VEGF mAbdAb的药代动力学曲线。
图133:纯化的DMS4011的SDS-PAGE分析。
图134:纯化的DMS4011的SEC曲线。
图135:DMS4011的抗-EGFR效价。
图136:在抗-VEGF受体结合测定中的DMS4011。
图137:纯化的样品DMS4023和DMS4024的SDS-PAGE分析。
图138:DMS4023的SEC曲线。
图139:DMS4024的SEC曲线。
图140:mAbdAb DMS4023的抗-EGFR效价。
图141:在抗-VEGF受体结合测定中的DMS4023和DMS4024。
图142:纯化的DMS4009的SDS-PAGE分析。
图143:DMS4009的SEC曲线。
图144:mAbdAb DMS4009的抗-EGFR效价。
图145:抗-VEGF受体结合测定中的DMS4009。
图146:纯化的DMS4029的SDS-PAGE分析。
图147:DMS4029的SEC曲线。
图148:mAbdAb DMS4029的抗-EGFR效价。
图149:在基于IL-13细胞的中和测定中的DMS4029。
图150:纯化的样品DMS4013和DMS4027的SDS-PAGE分析。
图151:DMS4013的SEC曲线。
图152:DMS4027的SEC曲线。
图153:mAbdAb DMS4013的抗-EGFR效价。
图154:在抗-VEGF受体结合测定中的DMS4013。
图155:在重组人IL-12ELISA中的BPC1616的结合。
图156:在重组人IL-18ELISA中的BPC1616的结合。
图157:在重组人IL-4ELISA中的BPC1616的结合。
图158:在重组人IL-4ELISA中的BPC1008、1009和BPC1010的结合。
图159:在重组人IL-5ELISA中的BPC1008的结合。
图160:在重组人IL-13ELISA中的BPC1008、1009和BPC1010的结合。
图161:在重组人c-MET ELISA中的BPC1017和BPC1018的结合。
图162:在重组人VEGF ELISA中的BPC1017和BPC1018的结合。
图163:PascoH-TVAAPS-546的SEC曲线。
图164:PascoH-TVAAPS-567的SEC曲线。
图165:PascoH-TVAAPS-546的SDS PAGE[A=非还原性条件,B=还原性条件]。
图166:PascoH-TVAAPS-567的SDS PAGE[A=非还原性条件,B=还原性条件]。
图167:在TF-1细胞生物测定中对人IL-13的中和数据。
图168:在TF-1细胞生物测定中对猕猴IL-13的中和数据。
图169:在人IL-4ELISA中含有备选同种型的mAbdAb的结合。
图170:在人IL-13ELISA中含有备选同种型的mAbdAb的结合。
图171:在重组人EGFR ELISA中BPC1818和BPC1813的结合。
图172:在重组人VEGFR2ELISA中BPC1818和BPC1813的结合。
图173:在IL-13ELISA中抗-IL5mAb-抗-IL13dAb的结合。
图174:在IL-5ELISA中抗-IL5mAb-抗-IL13dAb的结合。
图175:在重组人VEGFR2ELISA中BPC1812的结合。
图176:在重组人EGFR ELISA中BPC1812的结合。
图177:在人IL-13ELISA中mAbdAb的结合。
1.结构域抗体
SEQ ID NO:1=DOM9-155-25
DIQMTQSPSSLSASVGDRVTITCRASRPISDWLHWYQQKPGKAPKLLIAWASTLDSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQEGWGPPTFGQGTKVEIKR
SEQ ID NO:2=DOM9-155-147
DIQMTQSPSSLSASVGDRVTITCRASRPISDWLHWYQQKPGKAPKLLIAWASSLYEGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQEGWGPPTFGQGTKVEIKR
SEQ ID NO:3=DOM9-155-154
DIQMTQSPSSLSASVGDRVTITCRASRPISDWLHWYQQKPGKAPKLLIAWASSLQGGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQEGWGPPTFGQGTKVEIKR
SEQ ID NO:4=DOM9-112-210
EVQLLESGGGLVQPGGSLRLSCAASGFTFRNFGMGWVRQAPGKGLEWVSWIISSGTETYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKSLGRFDYWGQGTLVTVSS
SEQ ID NO:5=DOM10-53-474
GVQLLESGGGLVQPGGSLRLSCAASGFTFAWYDMGWVRQAPGKGLEWVSSIDWHGEVTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCATAEDEPGYDYWGQGTLVTVSS
SEQ ID NO:60=DOM9-155-147的DNA序列(蛋白质=SEQ IDNO:2)
GACATCCAGATGACCCAATCACCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTtGCCGGGCAAGTCGCCCCATtAGCGACTGGTTACATtGGTATCAGCAGAAACCAGGGAAAGCCCCCAAGCTCCTGATCGCCTGGGCGtCCTCGTTGTACGAGGGGGtCCCATCACGtTTCAGTGGCAGTGGGTCGGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCCGAAGATTTCGCTACGTACTACTGTTTGCAGGAGGGGTGGGGTCCTCCGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG
SEQ ID NO:61=DOM9-155-154的DNA序列(蛋白质=SEQ IDNO:3)
GACATCCAGATGACCCAATCACCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCGCCCCATTAGCGACTGGTTACATTGGTATCAGCAGAAACCAGGGAAAGCCCCCAAGCTCCTGATCGCCTGGGCGTCCAGCTTGCAGGGGGGGGTCCCATCACGTTTCAGTGGCAGTGGGTCGGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCCGAAGATTTCGCTACGTACTACTGTTTGCAGGAGGGGTGGGGTCCTCCGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG
2.接头
SEQ ID NO:6=G4S接头
GGGGS
SEQ ID NO:7=接头
TVAAPS
SEQ ID NO:8=接头
ASTKGPT
SEQ ID NO:9=接头
ASTKGPS
SEQ ID NO:10=接头
EPKSCDKTHTCPPCP
SEQ ID NO:11=接头
ELQLEESCAEAQDGELDG
3.单克隆抗体
SEQ ID NO:12=抗-人IL13mAb(H链)
QVQLVQSGAEVKKPGSSVKVSCKASGFYIKDTYMHWVRQAPGQGLEWMGTIDPANGNTKYVPKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARSIYDDYHYDDYYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
SEQ ID NO:13=抗-人IL13mAb(L链)
DIVMTQSPLSLPVTPGEPASISCRSSQNIVHINGNTYLEWYLQKPGQSPRLLIYKISDRFSGVPDRFSGSGSGTDFTLKISRVEADDVGIYYCFQGSHVPWTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
SEQ ID NO:14=帕考珠单抗(H链)
QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMGVSWIRQPPGKGLEWLAHIYWDDDKRYNPSLKSRLTISKDTSRNQVVLTMTNMDPVDTATYYCARRETVFYWYFDVWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
SEQ ID NO:15=帕考珠单抗(L链)
DIVLTQSPSSLSASVGDRVTITCKASQSVDYDGDSYMNWYQQKPGKAPKLLIYAASNLESGIPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQSNEDPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
SEQ ID NO:65=美泊利单抗(H链)
QVTLRESGPALVKPTQTLTLTCTVSGFSLTSYSVHWVRQPPGKGLEWLGVIWASGGTDYNSALMSRLSISKDTSRNQVVLTMTNMDPVDTATYYCARDPPSSLLRLDYWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
SEQ ID NO:66=美泊利单抗(L链)
DIVMTQSPDSLAVSLGERATINCKSSQSLLNSGNQKNYLAWYQQKPGQPPKLLIYGASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNVHSFPFTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
SEQ ID NO:67=抗-人IL-18mAb(H链)
QVQLVQSGAEVKKPGASVKVSCKVSGEISTGYYFHWVRQAPGKGLEWMGRIDPEDDSTKYAERFKDRVTMTEDTSTDTAYMELSSLRSEDTAVYYCTTWRIYRDSSGRPFYVMDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
SEQ ID NO:68=抗-人IL-18mAb(L链)
DIQMTQSPSSVSASVGDRVTITCLASEDIYTYLTWYQQKPGKAPKLLIYGANKLQDGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCLQGSKFPLTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
4.双特异性mAbdAb
注意,序列“粗体”文字的下划线部分对应于接头。“GS”氨基酸残基(其DNA编码序列用作BamHI克隆位点)不以“粗体”文字表示,但下划线。
SEQ ID NO:16=586H-25(H链)
QVQLVQSGAEVKKPGSSVKVSCKASGFYIKDTYMHWVRQAPGQGLEWMGTIDPANGNTKYVPKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARSIYDDYHYDDYYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGSDIQMTQSPSSLSASVGDRVTITCRASRPISDWLHWYQQKPGKAPKLLIAWASTLDSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQEGWGPPTFGQGTKVEIKR
SEQ ID NO:17=586H-147(H链)
QVQLVQSGAEVKKPGSSVKVSCKASGFYIKDTYMHWVRQAPGQGLEWMGTIDPANGNTKYVPKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARSIYDDYHYDDYYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGSDIQMTQSPSSLSASVGDRVTITCRASRPISDWLHWYQQKPGKAPKLLIAWASSLYEGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQEGWGPPTFGQGTKVEIKR
SEQ ID NO:18=586H-154(H链)
QVQLVQSGAEVKKPGSSVKVSCKASGFYIKDTYMHWVRQAPGQGLEWMGTIDPANGNTKYVPKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARSIYDDYHYDDYYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGSDIQMTQSPSSLSASVGDRVTITCRASRPISDWLHWYQQKPGKAPKLLIAWASSLQGGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQEGWGPPTFGQGTKVEIKR
SEQ ID NO:19=586H-210(H链)
QVQLVQSGAEVKKPGSSVKVSCKASGFYIKDTYMHWVRQAPGQGLEWMGTIDPANGNTKYVPKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARSIYDDYHYDDYYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGSEVQLLESGGGLVQPGGSLRLSCAASGFTFRNFGMGWVRQAPGKGLEWVSWIISSGTETYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKSLGRFDYWGQGTLVTVSS
SEQ ID NO:20=586H-G4S-25(H链)
QVQLVQSGAEVKKPGSSVKVSCKASGFYIKDTYMHWVRQAPGQGLEWMGTIDPANGNTKYVPKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARSIYDDYHYDDYYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKDIQMTQSPSSLSASVGDRVTITCRASRPISDWLHWYQQKPGKAPKLLIAWASTLDSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQEGWGPPTFGQGTKVEIKR
SEQ ID NO:21=586H-G4S-147(H链)
QVQLVQSGAEVKKPGSSVKVSCKASGFYIKDTYMHWVRQAPGQGLEWMGTIDPANGNTKYVPKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARSIYDDYHYDDYYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKDIQMTQSPSSLSASVGDRVTITCRASRPISDWLHWYQQKPGKAPKLLIAWASSLYEGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQEGWGPPTFGQGTKVEIKR
SEQ ID NO:22=586H-G4S-154(H链)
QVQLVQSGAEVKKPGSSVKVSCKASGFYIKDTYMHWVRQAPGQGLEWMGTIDPANGNTKYVPKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARSIYDDYHYDDYYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKDIQMTQSPSSLSASVGDRVTITCRASRPISDWLHWYQQKPGKAPKLLIAWASSLQGGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQEGWGPPTFGQGTKVEIKR
SEQ ID NO:23=586H-G4S-210(H链)
QVQLVQSGAEVKKPGSSVKVSCKASGFYIKDTYMHWVRQAPGQGLEWMGTIDPANGNTKYVPKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARSIYDDYHYDDYYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKEVQLLESGGGLVQPGGSLRLSCAASGFTFRNFGMGWVRQAPGKGLEWVSWIISSGTETYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKSLGRFDYWGQGTLVTVSS
SEQ ID NO:24=586H-TVAAPS-25(H链)
QVQLVQSGAEVKKPGSSVKVSCKASGFYIKDTYMHWVRQAPGQGLEWMGTIDPANGNTKYVPKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARSIYDDYHYDDYYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK GSDIQMTQSPSSLSASVGDRVTITCRASRPISDWLHWYQQKPGKAPKLLIAWASTLDSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQEGWGPPTFGQGTKVEIKR
SEQ ID NO:25=586H-TVAAPS-147(H链)
QVQLVQSGAEVKKPGSSVKVSCKASGFYIKDTYMHWVRQAPGQGLEWMGTIDPANGNTKYVPKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARSIYDDYHYDDYYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK GSDIQMTQSPSSLSASVGDRVTITCRASRPISDWLHWYQQKPGKAPKLLIAWASSLYEGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQEGWGPPTFGQGTKVEIKR
SEQ ID NO:26=586H-TVAAPS-154(H链)
QVQLVQSGAEVKKPGSSVKVSCKASGFYIKDTYMHWVRQAPGQGLEWMGTIDPANGNTKYVPKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARSIYDDYHYDDYYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK GSDIQMTQSPSSLSASVGDRVTITCRASRPISDWLHWYQQKPGKAPKLLIAWASSLQGGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQEGWGPPTFGQGTKVEIKR
SEQ ID NO:27=586H-TVAAPS-210(H链)
QVQLVQSGAEVKKPGSSVKVSCKASGFYIKDTYMHWVRQAPGQGLEWMGTIDPANGNTKYVPKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARSIYDDYHYDDYYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK GSEVQLLESGGGLVQPGGSLRLSCAASGFTFRNFGMGWVRQAPGKGLEWVSWIISSGTETYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKSLGRFDYWGQGTLVTVSS
SEQ ID NO:28=586H-ASTKG-25(H链)
QVQLVQSGAEVKKPGSSVKVSCKASGFYIKDTYMHWVRQAPGQGLEWMGTIDPANGNTKYVPKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARSIYDDYHYDDYYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGS GSDIQMTQSPSSLSASVGDRVTITCRASRPISDWLHWYQQKPGKAPKLLIAWASTLDSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQEGWGPPTFGQGTKVEIKR
SEQ ID NO:29=586H-ASTKG-147(H链)
QVQLVQSGAEVKKPGSSVKVSCKASGFYIKDTYMHWVRQAPGQGLEWMGTIDPANGNTKYVPKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARSIYDDYHYDDYYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGS GSDIQMTQSPSSLSASVGDRVTITCRASRPISDWLHWYQQKPGKAPKLLIAWASSLYEGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQEGWGPPTFGQGTKVEIKR
SEQ ID NO:30=586H-ASTKG-154(H链)
QVQLVQSGAEVKKPGSSVKVSCKASGFYIKDTYMHWVRQAPGQGLEWMGTIDPANGNTKYVPKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARSIYDDYHYDDYYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGS GSDIQMTQSPSSLSASVGDRVTITCRASRPISDWLHWYQQKPGKAPKLLIAWASSLQGGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQEGWGPPTFGQGTKVEIKR
SEQ ID NO:31=586H-ASTKG-210(H链)
QVQLVQSGAEVKKPGSSVKVSCKASGFYIKDTYMHWVRQAPGQGLEWMGTIDPANGNTKYVPKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARSIYDDYHYDDYYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGS GSEVQLLESGGGLVQPGGSLRLSCAASGFTFRNFGMGWVRQAPGKGLEWVSWIISSGTETYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKSLGRFDYWGQGTLVTVSS
SEQ ID NO:32=586H-EPKSC-25(H链)
QVQLVQSGAEVKKPGSSVKVSCKASGFYIKDTYMHWVRQAPGQGLEWMGTIDPANGNTKYVPKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARSIYDDYHYDDYYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGS GSDIQMTQSPSSLSASVGDRVTITCRASRPISDWLHWYQQKPGKAPKLLIAWASTLDSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQEGWGPPTFGQGTKVEIKR
SEQ ID NO:33=586H-EPKSC-147(H链)
QVQLVQSGAEVKKPGSSVKVSCKASGFYIKDTYMHWVRQAPGQGLEWMGTIDPANGNTKYVPKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARSIYDDYHYDDYYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGS GSDIQMTQSPSSLSASVGDRVTITCRASRPISDWLHWYQQKPGKAPKLLIAWASSLYEGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQEGWGPPTFGQGTKVEIKR
SEQ ID NO:34=586H-EPKSC-154(H链)
QVQLVQSGAEVKKPGSSVKVSCKASGFYIKDTYMHWVRQAPGQGLEWMGTIDPANGNTKYVPKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARSIYDDYHYDDYYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGS GSDIQMTQSPSSLSASVGDRVTITCRASRPISDWLHWYQQKPGKAPKLLIAWASSLQGGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQEGWGPPTFGQGTKVEIKR
SEQ ID NO:35=586H-EPKSC-210(H链)
QVQLVQSGAEVKKPGSSVKVSCKASGFYIKDTYMHWVRQAPGQGLEWMGTIDPANGNTKYVPKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARSIYDDYHYDDYYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGS GSEVQLLESGGGLVQPGGSLRLSCAASGFTFRNFGMGWVRQAPGKGLEWVSWIISSGTETYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKSLGRFDYWGQGTLVTVSS
SEQ ID NO:36=586H-ELQLE-25(H链)
QVQLVQSGAEVKKPGSSVKVSCKASGFYIKDTYMHWVRQAPGQGLEWMGTIDPANGNTKYVPKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARSIYDDYHYDDYYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGS GSDIQMTQSPSSLSASVGDRVTITCRASRPISDWLHWYQQKPGKAPKLLIAWASTLDSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQEGWGPPTFGQGTKVEIKR
SEQ ID NO:37=586H-ELQLE-147(H链)
QVQLVQSGAEVKKPGSSVKVSCKASGFYIKDTYMHWVRQAPGQGLEWMGTIDPANGNTKYVPKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARSIYDDYHYDDYYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGS GSDIQMTQSPSSLSASVGDRVTITCRASRPISDWLHWYQQKPGKAPKLLIAWASSLYEGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQEGWGPPTFGQGTKVEIKR
SEQ ID NO:38=586H-ELQLE-154(H链)
QVQLVQSGAEVKKPGSSVKVSCKASGFYIKDTYMHWVRQAPGQGLEWMGTIDPANGNTKYVPKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARSIYDDYHYDDYYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGS GSDIQMTQSPSSLSASVGDRVTITCRASRPISDWLHWYQQKPGKAPKLLIAWASSLQGGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQEGWGPPTFGQGTKVEIKR
SEQ ID NO:39=586H-ELQLE-210(H链)
QVQLVQSGAEVKKPGSSVKVSCKASGFYIKDTYMHWVRQAPGQGLEWMGTIDPANGNTKYVPKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARSIYDDYHYDDYYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGS GSEVQLLESGGGLVQPGGSLRLSCAASGFTFRNFGMGWVRQAPGKGLEWVSWIISSGTETYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKSLGRFDYWGQGTLVTVSS
SEQ ID NO:40=586H-GS(H链)
QVQLVQSGAEVKKPGSSVKVSCKASGFYIKDTYMHWVRQAPGQGLEWMGTIDPANGNTKYVPKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARSIYDDYHYDDYYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGS
SEQ ID NO:41=586H-ASTKG(H链)
QVQLVQSGAEVKKPGSSVKVSCKASGFYIKDTYMHWVRQAPGQGLEWMGTIDPANGNTKYVPKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARSIYDDYHYDDYYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGS GS
SEQ ID NO:42=586H-EPKSC(H链)
QVQLVQSGAEVKKPGSSVKVSCKASGFYIKDTYMHWVRQAPGQGLEWMGTIDPANGNTKYVPKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARSIYDDYHYDDYYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGS GS
SEQ ID NO:43=586H-ELQLE(H链)
QVQLVQSGAEVKKPGSSVKVSCKASGFYIKDTYMHWVRQAPGQGLEWMGTIDPANGNTKYVPKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARSIYDDYHYDDYYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGS GS
SEQ ID NO:44=586L-G4S-25(L链)
DIVMTQSPLSLPVTPGEPASISCRSSQNIVHINGNTYLEWYLQKPGQSPRLLIYKISDRFSGVPDRFSGSGSGTDFTLKISRVEADDVGIYYCFQGSHVPWTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECDIQMTQSPSSLSASVGDRVTITCRASRPISDWLHWYQQKPGKAPKLLIAWASTLDSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQEGWGPPTFGQGTKVEIKR
SEQ ID NO:45=586L-G4S-147(L链)
DIVMTQSPLSLPVTPGEPASISCRSSQNIVHINGNTYLEWYLQKPGQSPRLLIYKISDRFSGVPDRFSGSGSGTDFTLKISRVEADDVGIYYCFQGSHVPWTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECDIQMTQSPSSLSASVGDRVTITCRASRPISDWLHWYQQKPGKAPKLLIAWASSLYEGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQEGWGPPTFGQGTKVEIKR
SEQ ID NO:46=586L-G4S-154(L链)
DIVMTQSPLSLPVTPGEPASISCRSSQNIVHINGNTYLEWYLQKPGQSPRLLIYKISDRFSGVPDRFSGSGSGTDFTLKISRVEADDVGIYYCFQGSHVPWTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECDIQMTQSPSSLSASVGDRVTITCRASRPISDWLHWYQQKPGKAPKLLIAWASSLQGGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQEGWGPPTFGQGTKVEIKR
SEQ ID NO:47=586L-G4S-210(L链)
DIVMTQSPLSLPVTPGEPASISCRSSQNIVHINGNTYLEWYLQKPGQSPRLLIYKISDRFSGVPDRFSGSGSGTDFTLKISRVEADDVGIYYCFQGSHVPWTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECEVQLLESGGGLVQPGGSLRLSCAASGFTFRNFGMGWVRQAPGKGLEWVSWIISSGTETYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKSLGRFDYWGQGTLVTVSS
SEQ ID NO:48=PascoH-474(H链)
QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMGVSWIRQPPGKGLEWLAHIYWDDDKRYNPSLKSRLTISKDTSRNQVVLTMTNMDPVDTATYYCARRETVFYWYFDVWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGSGVQLLESGGGLVQPGGSLRLSCAASGFTFAWYDMGWVRQAPGKGLEWVSSIDWHGEVTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCATAEDEPGYDYWGQGTLVTVSS
SEQ ID NO:49=PascoH-G4S-474(H链)
QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMGVSWIRQPPGKGLEWLAHIYWDDDKRYNPSLKSRLTISKDTSRNQVVLTMTNMDPVDTATYYCARRETVFYWYFDVWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGVQLLESGGGLVQPGGSLRLSCAASGFTFAWYDMGWVRQAPGKGLEWVSSIDWHGEVTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCATAEDEPGYDYWGQGTLVTVSS
SEQ ID NO:50=PascoH-TYAAPS-474(H链)
QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMGVSWIRQPPGKGLEWLAHIYWDDDKRYNPSLKSRLTISKDTSRNQVVLTMTNMDPVDTATYYCARRETVFYWYFDVWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK GSGVQLLESGGGLVQPGGSLRLSCAASGFTFAWYDMGWVRQAPGKGLEWVSSIDWHGEVTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCATAEDEPGYDYWGQGTLVTVSS
SEQ ID NO:51=PascoH-ASTKG-474(H链)
QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMGVSWIRQPPGKGLEWLAHIYWDDDKRYNPSLKSRLTISKDTSRNQVVLTMTNMDPVDTATYYCARRETVFYWYFDVWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGS GSGVQLLESGGGLVQPGGSLRLSCAASGFTFAWYDMGWVRQAPGKGLEWVSSIDWHGEVTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCATAEDEPGYDYWGQGTLVTVSS
SEQ ID NO:52=PascoH-EPKSC-474(H链)
QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMGVSWIRQPPGKGLEWLAHIYWDDDKRYNPSLKSRLTISKDTSRNQVVLTMTNMDPVDTATYYCARRETVFYWYFDVWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGS GSGVQLLESGGGLVQPGGSLRLSCAASGFTFAWYDMGWVRQAPGKGLEWVSSIDWHGEVTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCATAEDEPGYDYWGQGTLVTVSS
SEQ ID NO:53=PascoH-ELQLE-474(H链)
QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMGVSWIRQPPGKGLEWLAHIYWDDDKRYNPSLKSRLTISKDTSRNQVVLTMTNMDPVDTATYYCARRETVFYWYFDVWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGS GSGVQLLESGGGLVQPGGSLRLSCAASGFTFAWYDMGWVRQAPGKGLEWVSSIDWHGEVTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCATAEDEPGYDYWGQGTLVTVSS
SEQ ID NO:54=PascoL-474(L链)
DIVLTQSPSSLSASVGDRVTITCKASQSVDYDGDSYMNWYQQKPGKAPKLLIYAASNLESGIPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQSNEDPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECGSGVQLLESGGGLVQPGGSLRLSCAASGFTFAWYDMGWVRQAPGKGLEWVSSIDWHGEVTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCATAEDEPGYDYWGQGTLVTVSS
SEQ ID NO:55=PascoL-G4S-474(L链)
DIVLTQSPSSLSASVGDRVTITCKASQSVDYDGDSYMNWYQQKPGKAPKLLIYAASNLESGIPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQSNEDPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECGVQLLESGGGLVQPGGSLRLSCAASGFTFAWYDMGWVRQAPGKGLEWVSSIDWHGEVTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCATAEDEPGYDYWGQGTLVTVSS
SEQ ID NO:56=PascoL-TYAAPS-474(L链)
DIVLTQSPSSLSASVGDRVTITCKASQSVDYDGDSYMNWYQQKPGKAPKLLIYAASNLESGIPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQSNEDPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC GSGVQLLESGGGLVQPGGSLRLSCAASGFTFAWYDMGWVRQAPGKGLEWVSSIDWHGEVTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCATAEDEPGYDYWGQGTLVTVSS
SEQ ID NO:57=PascoL-ASTKG-474(L链)
DIVLTQSPSSLSASVGDRVTITCKASQSVDYDGDSYMNWYQQKPGKAPKLLIYAASNLESGIPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQSNEDPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC G SGVQLLESGGGLVQPGGSLRLSCAASGFTFAWYDMGWVRQAPGKGLEWVSSIDWHGEVTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCATAEDEPGYDYWGQGTLVTVSS
SEQ ID NO:58=PascoL-EPKSC-474(L链)
DIVLTQSPSSLSASVGDRVTITCKASQSVDYDGDSYMNWYQQKPGKAPKLLIYAASNLESGIPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQSNEDPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC GSGVQLLESGGGLVQPGGSLRLSCAASGFTFAWYDMGWVRQAPGKGLEWVSSIDWHGEVTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCATAEDEPGYDYWGQGTLVTVSS
SEQ ID NO:59=PascoL-ELQLE-474(L链)
DIVLTQSPSSLSASVGDRVTITCKASQSVDYDGDSYMNWYQQKPGKAPKLLIYAASNLESGIPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQSNEDPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC GSGVQLLESGGGLVQPGGSLRLSCAASGFTFAWYDMGWVRQAPGKGLEWVSSIDWHGEVTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCATAEDEPGYDYWGQGTLVTVSS
5.细胞因子
SEQ ID NO:62=IL-4(白介素-4)
HKCDITLQEIIKTLNSLTEQKTLCTELTVTDIFAASKNTTEKETFCRAATVLRQFYSHHEKD
TRCLGATAQQFHRHKQLIRFLKRLDRNLWGLAGLNSCPVKEANQSTLENFLERLKTIMREKY
SKCSS
SEQ ID NO:63=IL-13(白介素-13)
GPVPPSTALRELIEELVNITQNQKAPLCNGSMVWSINLTAGMYCAALESLINVSGCSAIEKTQRMLSGFCPHKVSAGQFSSLHVRDTKIEVAQFVKDLLLHLKKLFREGRFN
6.信号序列
SEQ ID NO:64=哺乳动物氨基酸信号序列
MGWSCIILFLVATATGVHS
7.IGF-1R结合CDR
SEQ ID 80=VH CDR3
WILYYGRSKWYFDV
SEQ ID 81=VH CDR2
NINPNNGGTNYNQKFKD
SEQ ID 82=VH CDR1
DYYMN
SEQ ID 83=VL CDR1
RSSQSIVQSNGDTYLE
SEQ ID 84=备选VL CDR2
RISNRFS
SEQ ID 85=VL CDR3
FQGSHVPYT
SEQ ID 86=VL CDR2
RVSNRFS
8.三特异性mAbdAb
SEQ ID NO:69=IL18mAb-G4S-DOM9-112-210(H链)
QVQLVQSGAEVKKPGASVKVSCKVSGEISTGYYFHWVRQAPGKGLEWMGRIDPEDDSTKYAERFKDRVTMTEDTSTDTAYMELSSLRSEDTAVYYCTTWRIYRDSSGRPFYVMDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKEVQLLESGGGLVQPGGSLRLSCAASGFTFRNFGMGWVRQAPGKGLEWVSWIISSGTETYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKSLGRFDYWGQGTLVTVSS
SEQ ID NO:70=IL18mAb-G4S-DOM10-53-474(L链)
DIQMTQSPSSVSASVGDRVTITCLASEDIYTYLTWYQQKPGKAPKLLIYGANKLQDGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCLQGSKFPLTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECGVQLLESGGGLVQPGGSLRLSCAASGFTFAWYDMGWVRQAPGKGLEWVSSIDWHGEVTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCATAEDEPGYDYWGQGTLVTVSS
SEQ ID NO:71=IL-5mAb-G4S-DOM9-112-210重链
QVTLRESGPALVKPTQTLTLTCTVSGFSLTSYSVHWVRQPPGKGLEWLGVIWASGGTDYNSALMSRLSISKDTSRNQVVLTMTNMDPVDTATYYCARDPPSSLLRLDYWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKEVQLLESGGGLVQPGGSLRLSCAASGFTFRNFGMGWVRQAPGKGLEWVSWIISSGTETYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKSLGRFDYWGQGTLVTVSS
SEQ ID NO:72=IL-5mAb-G4S-DOM10-53-474 轻链
DIVMTQSPDSLAVSLGERATINCKSSQSLLNSGNQKNYLAWYQQKPGQPPKLLIYGASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNVHSFPFTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC GVQLLESGGGLVQPGGSLRLSCAASGFTFAWYDMGWVRQAPGKGLEWVSSIDWHGEVTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCATAEDEPGYDYWGQGTLVTVSS
9.双重靶向的抗-TNF/抗-EGFR mAbdAb
SEQ ID NO:73=抗-TNFmAb(L链)
DIQMTQSPSSLSASVGDRVTITCRASQGIRNYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQRYNRAPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
SEQ ID NO:74=抗-TNFmAb-DOM16-39-542(H链)
EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSAITWNSGHIDYADSVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVSYLSTASSLDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKSTGDIQMTQSPSSLSASVGDRVTITCRASQWIGNLLDWYQQKPGKAPKLLIYYASFLQSGVPSRFSGSGYGTDFTLTISSLQPEDFATYYCQQANPAPLTFGQGTKVEIKR
10.双重靶向的抗-TNF/抗-VEGF mAbdAb
SEQ ID NO:75=抗-TNFmAb-DOM15-26-593(H链)
EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSAITWNSGHIDYADSVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVSYLSTASSLDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKSTGEVQLLVSGGGLVQPGGSLRLSCAASGFTFKAYPMMWVRQAPGKGLEWVSEISPSGSYTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDPRKLDYWGQGTLVTVSS
11.双重靶向的抗-IL1R1/抗-VEGF dAb-延伸的IgG
SEQ ID NO:76=DOM 15-26-593-VH假体(H链)
EVQLLVSGGGLVQPGGSLRLSCAASGFTFKAYPMMWVRQAPGKGLEWVSEISPSGSYTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDPRKLDYWGQGTLVTVSSASTKGPSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKSYGAFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
SEQ ID NO:77=DOM4-130-54-Vk假体(L链)
DIQMTQSPSSLSASVGDRVTITCRASQDIYLNLDWYQQKPGKAPKLLINFGSELQSGVPSRFSGSGYGTDFTLTISSLQPEDFATYYCQPSFYFPYTFGQGTKVEIKRTVAAPSDIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPNTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
12.三重靶向的抗-TNF/抗-EGFR/抗-VEGF mAbdAb
SEQ ID NO:78=DOM 15-26-抗-TNFmAb(H链)
EVQLLESGGGLVQPGGSLRLSCAASGFTFGAYPMMWVRQAPGKGLEWVSEISPSGSYTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDPRKFDYWGQGTLVTVSSASTKGPSEVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSAITWNSGHIDYADSVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVSYLSTASSLDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
SEQ ID NO:79=DOM 16-39-542-抗-TNFmAb(L链)
DIQMTQSPSSLSASVGDRVTITCRASQWIGNLLDWYQQKPGKAPKLLIYYASFLQSGVPSRFSGSGYGTDFTLTISSLQPEDFATYYCQQANPAPLTFGQGTKVEIKRTVAAPSDIQMTQSPSSLSASVGDRVTITCRASQGIRNYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQRYNRAPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
SEQ ID NO:87=除去GS的586H-210(H链)
QVQLVQSGAEVKKPGSSVKVSCKASGFYIKDTYMHWVRQAPGQGLEWMGTIDPANGNTKYVPKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARSIYDDYHYDDYYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKEVQLLESGGGLVQPGGSLRLSCAASGFTFRNFGMGWVRQAPGKGLEWVSWIISSGTETYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKSLGRFDYWGQGTLVTVSS
SEQ ID NO:88=除去GS的586H-TVAAPS-210(H链)
QVQLVQSGAEVKKPGSSVKVSCKASGFYIKDTYMHWVRQAPGQGLEWMGTIDPANGNTKYVPKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARSIYDDYHYDDYYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKEVQLLESGGGLVQPGGSLRLSCAASGFTFRNFGMGWVRQAPGKGLEWVSWIISSGTETYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKSLGRFDYWGQGTLVTVSS
SEQ ID NO:89=两个GS都除去的586H-ASTKGPT-210(H链)
QVQLVQSGAEVKKPGSSVKVSCKASGFYIKDTYMHWVRQAPGQGLEWMGTIDPANGNTKYVPKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARSIYDDYHYDDYYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKEVQLLESGGGLVQPGGSLRLSCAASGFTFRNFGMGWVRQAPGKGLEWVSWIISSGTETYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKSLGRFDYWGQGTLVTVSS
SEQ ID NO:90=两个GS都除去的586H-ASTKGPS-210(H链)
QVQLVQSGAEVKKPGSSVKVSCKASGFYIKDTYMHWVRQAPGQGLEWMGTIDPANGNTKYVPKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARSIYDDYHYDDYYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKEVQLLESGGGLVQPGGSLRLSCAASGFTFRNFGMGWVRQAPGKGLEWVSWIISSGTETYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKSLGRFDYWGQGTLVTVSS
SEQ ID NO:91=除去GS的PascoH-474(H链)
QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMGVSWIRQPPGKGLEWLAHIYWDDDKRYNPSLKSRLTISKDTSRNQVVLTMTNMDPVDTATYYCARRETVFYWYFDVWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGVQLLESGGGLVQPGGSLRLSCAASGFTFAWYDMGWVRQAPGKGLEWVSSIDWHGEVTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCATAEDEPGYDYWGQGTLVTVSS
SEQ ID NO:92=除去GS的PascoH-TVAAPS-474(H链)
QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMGVSWIRQPPGKGLEWLAHIYWDDDKRYNPSLKSRLTISKDTSRNQVVLTMTNMDPVDTATYYCARRETVFYWYFDVWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGVQLLESGGGLVQPGGSLRLSCAASGFTFAWYDMGWVRQAPGKGLEWVSSIDWHGEVTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCATAEDEPGYDYWGQGTLVTVSS
SEQ ID NO:93=两个GS都除去的PascoH-ASTKGPT-474(H链)
QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMGVSWIRQPPGKGLEWLAHIYWDDDKRYNPSLKSRLTISKDTSRNQVVLTMTNMDPVDTATYYCARRETVFYWYFDVWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGVQLLESGGGLVQPGGSLRLSCAASGFTFAWYDMGWVRQAPGKGLEWVSSIDWHGEVTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCATAEDEPGYDYWGQGTLVTVSS
SEQ ID NO:94=两个GS都除去的PascoH-ASTKGPS-474(H链)
QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMGVSWIRQPPGKGLEWLAHIYWDDDKRYNPSLKSRLTISKDTSRNQVVLTMTNMDPVDTATYYCARRETVFYWYFDVWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGVQLLESGGGLVQPGGSLRLSCAASGFTFAWYDMGWVRQAPGKGLEWVSSIDWHGEVTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCATAEDEPGYDYWGQGTLVTVSS
SEQ ID NO:95=除去第二个GS的PascoH-ASTKGPS-474(H链)
QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMGVSWIRQPPGKGLEWLAHIYWDDDKRYNPSLKSRLTISKDTSRNQVVLTMTNMDPVDTATYYCARRETVFYWYFDVWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGS GVQLLESGGGLVQPGGSLRLSCAASGFTFAWYDMGWVRQAPGKGLEWVSSIDWHGEVTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCATAEDEPGYDYWGQGTLVTVSS
SEQ ID NO:96=除去第二个GS的PascoH-ASTKGPT-474(H链)
QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMGVSWIRQPPGKGLEWLAHIYWDDDKRYNPSLKSRLTISKDTSRNQVVLTMTNMDPVDTATYYCARRETVFYWYFDVWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGS GVQLLESGGGLVQPGGSLRLSCAASGFTFAWYDMGWVRQAPGKGLEWVSSIDWHGEVTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCATAEDEPGYDYWGQGTLVTVSS
SEQ ID NO:97=CDRH1
GYSITSDFAWN
SEQ ID NO:98=CDRH2
GYISYSGNYNPSLK
SEQ ID NO:99=CDRH3
VTAGRGFPY
SEQ ID NO:100=CDRL1
HSSQDINSNIG
SEQ ID NO:101=CDRL2
HGINLDD
SEQ ID NO:102=CDRL3
VQYAQFPWT
SEQ ID NO:103=EGFR表位
CGADSYEMEEDGVRKC
SEQ ID NO:104=CDRH1
SDFAWN
SEQ ID NO:105=CDRH2
YISYSGNYNPSLK
SEQ ID NO:106=CDRH3
AGRGFPY
SEQ ID NO:107=CDRH2
YISYSGNYNPSLKS
SEQ ID NO:108=在C-末端用TVAAPSGS接头与DOM15-26-593融合的抗-IGF-1R抗体H0L0重链
QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYYMNWVRQAPGQGLEWMGNINPNNGGTNYNQKFKDRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARWILYYGRSKWYFDVWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKTVAAPSGSEVQLLVSGGGLVQPGGSLRLSCAASGFTFKAYPMMWVRQAPGKGLEWVSEISPSGSYTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDPRKLDYWGQGTLVTVSS
SEQ ID NO:109=在C-末端用GS接头与DOM15-26-593融合的抗-IGF-1R抗体H0L0重链
QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYYMNWVRQAPGQGLEWMGNINPNNGGTNYNQKFKDRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARWILYYGRSKWYFDVWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGSEVQLLVSGGGLVQPGGSLRLSCAASGFTFKAYPMMWVRQAPGKGLEWVSEISPSGSYTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDPRKLDYWGQGTLVTVSS
SEQ ID NO:110=抗-IGF-1R抗体H0L0重链
QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYYMNWVRQAPGQGLEWMGNINPNNGGTNYNQKFKDRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARWILYYGRSKWYFDVWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
SEQ ID NO:111=在C-末端用TVAAPSGS接头与DOM15-26-593融合的抗-IGF-1R抗体H0L0轻链
DIVMTQSPLSLPVTPGEPASISCRSSQSIVQSNGDTYLEWYLQKPGQSPQLLIYRVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECTVAAPS GSEVQLLVSGGGLVQPGGSLRLSCAASGFTFKAYPMMWVRQAPGKGLEWVSEISPSGSYTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDPRKLDYWGQGTLVTVSS
SEQ ID NO:112=在C-末端用GS接头与DOM15-26-593融合的抗-IGF-1R抗体H0L0轻链
DIVMTQSPLSLPVTPGEPASISCRSSQSIVQSNGDTYLEWYLQKPGQSPQLLIYRVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECGSEVQLLVSGGGLVQPGGSLRLSCAASGFTFKAYPMMWVRQAPGKGLEWVSEISPSGSYTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDPRKLDYWGQGTLVTVSS
SEQ ID NO:113=抗-IGF-1R抗体H0L0轻链
DIVMTQSPLSLPVTPGEPASISCRSSQSIVQSNGDTYLEWYLQKPGQSPQLLIYRVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
SEQ ID NO:114=抗体2B9的重链可变结构域
QVQLKQSGPGLVQSSQSLSITCTISGFSLTSHGIYWLRQSPGKGLEWLGVIWSGGSADYNAAFISRLSISKDNSKSQVFFKMNSLQADDTAIYYCARSPYYYRSSLYAMDYWGQGTSVTVSS
SEQ ID NO:115=抗体2B9的轻链可变结构域
NIVLTQSPKSMSMSIGERVTLSCKASENVGTYVSWYQQKAEQSPKLLIYGASNRHTGVPDRFTGSGSSTDFTLTISSVQAEDLADYHCGQSYSDPLTFGAGTKLELKRA
SEQ ID NO:116=含TVAAPSGS接头并在C-末端融合DOM10-53-474结构域抗体的抗-CD20mAb重链蛋白质序列
QVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKTVAAPSGSGVQLLESGGGLVQPGGSLRLSCAASGFTFAWYDMGWVRQAPGKGLEWVSSIDWHGEVTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCATAEDEPGYDYWGQGTLVTVSS
SEQ ID NO:117=抗-CD20mAb VL-人Cκ轻链的蛋白质序列
QIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
SEQ ID NO:118=含GS接头并在C-末端融合DOM10-53-474结构域抗体的抗-CD20mAb重链蛋白质序列
QVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGSGVQLLESGGGLVQPGGSLRLSCAASGFTFAWYDMGWVRQAPGKGLEWVSSIDWHGEVTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCATAEDEPGYDYWGQGTLVTVSS
SEQ ID NO:119=含TVAAPSGS接头并在C-末端融合DOM10-53-474结构域抗体的抗-CD20mAb轻链蛋白质序列
QIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECTVAAPSGSGVQLLESGGGLVQPGGSLRLSCAASGFTFAWYDMGWVRQAPGKGLEWVSSIDWHGEVTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCATAEDEPGYDYWGQGTLVTVSS
SEQ ID NO:120=抗-CD20mAb VH-人IgG1重链的蛋白质序列
QVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
SEQ ID NO:121=含GS接头并在C-末端融合DOM10-53-474结构域抗体的抗-CD20mAb轻链蛋白质序列
QIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECGSGVQLLESGGGLVQPGGSLRLSCAASGFTFAWYDMGWVRQAPGKGLEWVSSIDWHGEVTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCATAEDEPGYDYWGQGTLVTVSS
SEQ ID NO:122:586H-TVAAPS-154重链
CAGGTGCAGCTCGTGCAGAGCGGCGCCGAAGTGAAAAAGCCCGGCAGCAGCGTGAAGGTGAGCTGCAAGGCCTCCGGCTTCTACATCAAGGACACCTACATGCACTGGGTCAGGCAGGCTCCTGGCCAGGGCCTGGAGTGGATGGGCACTATCGACCCCGCCAACGGCAACACCAAGTACGTGCCCAAGTTCCAGGGCAGGGTGACCATCACCGCCGATGAGAGCACCAGCACCGCCTACATGGAACTGAGCAGCCTGAGGTCTGAGGACACCGCCGTGTACTATTGCGCCAGGAGCATCTACGACGACTACCACTACGACGACTACTACGCCATGGACTACTGGGGACAGGGCACACTAGTGACCGTGTCCAGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAGGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCCCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAGACCGTGGCCGCCCCCTCGGGATCCGACATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACCATTACCTGCAGGGCCAGCAGGCCCATCAGCGACTGGCTGCACTGGTACCAACAGAAGCCCGGCAAGGCTCCCAAGCTGCTGATCGCCTGGGCCAGCAGCCTGCAGGGAGGCGTGCCCAGCAGGTTTAGCGGCAGCGGCAGCGGCACCGACTTCACCCTCACCATCTCTTCCCTGCAGCCCGAGGACTTCGCCACCTACTACTGCCTGCAGGAGGGCTGGGGGCCCCCTACTTTCGGCCAGGGCACCAAGGTGGAGATCAAGAGG
SEQ ID NO:123
QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYYMNWVRQAPGQGLEWMGNINPNNGGTNYNQKFKDRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARWILYYGRSKWYFDVWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGSDGGGIRRSMSGTWYLKAMTVDREFPEMNLESVTPMTLTLLKGHNLEAKVTMLISGRCQEVKAVLGRTKERKKYTADGGKHVAYIIPSAVRDHVIFYSEGQLHGKPVRGVKLVGRDPKNNLEALEDFEKAAGARGLSTESILIPRQSETCSPG
SEQ ID NO:124
QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYYMNWVRQAPGQGLEWMGNINPNNGGTNYNQKFKDRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARWILYYGRSKWYFDVWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGSEVVAATPTSLLISWRHPHFPTRYYRITYGETGGNSPVQEFTVPLQPPTATISGLKPGVDYTITVYAVTDGRNGRLLSIPISINYRT
SEQ ID NO:125
QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYYMNWVRQAPGQGLEWMGNINPNNGGTNYNQKFKDRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARWILYYGRSKWYFDVWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKTVAAPSGSDGGGIRRSMSGTWYLKAMTVDREFPEMNLESVTPMTLTLLKGHNLEAKVTMLISGRCQEVKAVLGRTKERKKYTADGGKHVAYIIPSAVRDHVIFYSEGQLHGKPVRGVKLVGRDPKNNLEALEDFEKAAGARGLSTESILIPRQSETCSPG
SEQ ID NO:126
QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYYMNWVRQAPGQGLEWMGNINPNNGGTNYNQKFKDRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARWILYYGRSKWYFDVWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGSVDNKFNKELRQAYWEIQALPNLNWTQSRAFIRSLYDDPSQSANLLAEAKKLNDAQAPK
SEQ ID NO:127
QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYYMNWVRQAPGQGLEWMGNINPNNGGTNYNQKFKDRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARWILYYGRSKWYFDVWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKTVAAPSGSVDNKFNKELRQAYWEIQALPNLNWTQSRAFIRSLYDDPSQSANLLAEAKKLNDAQAPK
SEQ ID NO:128
QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYYMNWVRQAPGQGLEWMGNINPNNGGTNYNQKFKDRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARWILYYGRSKWYFDVWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGSDLGKKLLEAARAGQDDEVRILMANGADVNAKDEYGLTPLYLATAHGHLEIVEVLLKNGADVNAVDAIGFTPLHLAAFIGHLEIAEVLLKHGADVNAQDKFGKTAFDISIGNGNEDLAEILQKL
SEQ ID NO:129
QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYYMNWVRQAPGQGLEWMGNINPNNGGTNYNQKFKDRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARWILYYGRSKWYFDVWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKTVAAPSGSDLGKKLLEAARAGQDDEVRILMANGADVNAKDEYGLTPLYLATAHGHLEIVEVLLKNGADVNAVDAIGFTPLHLAAFIGHLEIAEVLLKHGADVNAQDKFGKTAFDISIGNGNEDLAEILQKL
SEQ ID NO:130
QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMGVSWIRQPPGKGLEWLAHIYWDDDKRYNPSLKSRLTISKDTSRNQVVLTMTNMDPVDTATYYCARRETVFYWYFDVWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGSQVQLVESGGGLVQAGGSLRLSCAASGYAYTYIYMGWFRQAPGKEREGVAAMDSGGGGTLYADSVKGRFTISRDKGKNTVYLQMDSLKPEDTATYYCAAGGYELRDRTYGQWGQGTQVTVSS
SEQ ID NO:131
QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMGVSWIRQPPGKGLEWLAHIYWDDDKRYNPSLKSRLTISKDTSRNQVVLTMTNMDPVDTATYYCARRETVFYWYFDVWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGSARVDQTPRSVTKETGESLTINCVLRDASYALGSTCWYRKKSGEGNEESISKGGRYVETVNSGSKSFSLRINDLTVEDGGTYRCGLGVAGGYCDYALCSSRYAECGDGTAVTVN
SEQ ID NO:132:抗IL-4重链-TVAAPSGS-抗TNF-a adnectin
CAGGTGACCCTGAGGGAGAGCGGCCCCGCCCTGGTGAAGCCCACCCAGACCCTGACCCTGACCTGCACCTTCAGCGGCTTTAGCCTCAGCACCTCCGGCATGGGCGTGAGCTGGATCAGGCAGCCACCCGGCAAAGGCCTGGAGTGGCTGGCCCACATCTACTGGGACGACGACAAGAGGTACAACCCCAGCCTGAAGAGCCGGCTGACCATCAGCAAGGATACCAGCAGGAACCAGGTGGTGCTGACCATGACCAACATGGACCCCGTGGACACCGCTACCTACTACTGCGCCAGGAGGGAGACCGTCTTCTACTGGTACTTCGACGTGTGGGGAAGGGGCACACTAGTGACCGTGTCCAGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAGGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCCCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAGACCGTGGCCGCCCCCTCGGGATCCGTGAGCGACGTGCCAAGGGACCTCGAGGTGGTGGCAGCCACTCCCACCTCTCTGCTGATCAGCTGGGACACACACAACGCCTACAACGGCTACTACAGGATCACCTACGGAGAGACCGGCGGCAATAGCCCCGTGAGGGAGTTCACCGTGCCCCACCCCGAGGTGACCGCCACCATTAGCGGCCTGAAGCCCGGCGTGGACGATACCATCACCGTCTACGCCGTGACCAACCACCACATGCCCCTGAGGATCTTCGGCCCCATCAGCATCAACCATAGGACC
SEQ ID NO:133
QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYYMNWVRQAPGQGLEWMGNINPNNGGTNYNQKFKDRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARWILYYGRSKWYFDVWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKTVAAPSGSEVVAATPTSLLISWRHPHFPTRYYRITYGETGGNSPVQEFTVPLQPPTATISGLKPGVDYTITVYAVTDGRNGRLLSIPISINYRT
SEQ ID NO:134
QVQLVQSGAEVKKPGSSVKVSCKASGFYIKDTYMHWVRQAPGQGLEWMGTIDPANGNTKYVPKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARSIYDDYHYDDYYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGSVSDVPRDLEVVAATPTSLLISWDTHNAYNGYYRITYGETGGNSPVREFTVPHPEVTATISGLKPGVDDTITVYAVTNHHMPLRIFGPISIN小时T
SEQ ID NO:135
QVQLVQSGAEVKKPGSSVKVSCKASGFYIKDTYMHWVRQAPGQGLEWMGTIDPANGNTKYVPKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARSIYDDYHYDDYYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKTVAAPSGSVSDVPRDLEVVAATPTSLLISWDTHNAYNGYYRITYGETGGNSPVREFTVPHPEVTATISGLKPGVDDTITVYAVTNHHMPLRIFGPISINHRT
SEQ ID NO:136
QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKRSEVVAATPTSLLISWRHPHFPTRYYRITYGETGGNSPVQEFTVPLQPPTATISGLKPGVDYTITVYAVTDGRNGRLLSIPISINYRT
SEQ ID NO:137
DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
SEQ ID NO:138
DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECRSEVVAATPTSLLISWRHPHFPTRYYRITYGETGGNSPVQEFTVPLQPPTATISGLKPGVDYTITVYAVTDGRNGRLLSIPISINYRT
SEQ ID NO:139
QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
SEQ ID NO:140
QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGDYYWSWIRQPPGKGLEWIGYIYYSGSTDYNPSLKSRVTMSVDTSKNQFSLKVNSVTAADTAVYYCARVSIFGVGTFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGSEVVAATPTSLLISWRHPHFPTRYYRITYGETGGNSPVQEFTVPLQPPTATISGLKPGVDYTITVYAVTDGRNGRLLSIPISINYRT
SEQ ID NO:141
EIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCHQYGSTPLTFGGGTKAEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
SEQ ID NO:142
EIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCHQYGSTPLTFGGGTKAEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECGSEVVAATPTSLLISWRHPHFPTRYYRITYGETGGNSPVQEFTVPLQPPTATISGLKPGVDYTITVYAVTDGRNGRLLSIPISINYRT
SEQ ID NO:143
QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGDYYWSWIRQPPGKGLEWIGYIYYSGSTDYNPSLKSRVTMSVDTSKNQFSLKVNSVTAADTAVYYCARVSIFGVGTFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
SEQ ID NO:144
EVVAATPTSLLISWRHPHFPTRYYRITYGETGGNSPVQEFTVPLQPPTATISGLKPGVDYTITVYAVTDGRNGRLLSIPISINYRTGSTGQVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
SEQ ID NO:145
EVVAATPTSLLISWRHPHFPTRYYRITYGETGGNSPVQEFTVPLQPPTATISGLKPGVDYTITVYAVTDGRNGRLLSIPISINYRTSTGDILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
SEQ ID NO:146
QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMGVSWIRQPPGKGLEWLAHIYWDDDKRYNPSLKSRLTISKDTSRNQVVLTMTNMDPVDTATYYCARRETVFYWYFDVWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGSVSDVPRDLEVVAATPTSLLISWDTHNAYNGYYRITYGETGGNSPVREFTVPHPEVTATISGLKPGVDDTITVYAVTNHHMPLRIFGPISIN小时T
SEQ ID NO:147
QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMGVSWIRQPPGKGLEWLAHIYWDDDKRYNPSLKSRLTISKDTSRNQVVLTMTNMDPVDTATYYCARRETVFYWYFDVWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKTVAAPSGSVSDVPRDLEVVAATPTSLLISWDTHNAYNGYYRITYGETGGNSPVREFTVPHPEVTATISGLKPGVDDTITVYAVTNHHMPLRIFGPISINHRT
SEQ ID NO:148=DOM10-53-616(dAb)
GVQLLESGGGLVQPGGSLRLSCAASGFVFPWYDMGWVRQAPGKGLEWVSSIDWHGKITYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCATAEDEPGYDYWGQGTLVTVSS
SEQ ID NO:149=PascoH-616(H链)
QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMGVSWIRQPPGKGLEWLAHIYWDDDKRYNPSLKSRLTISKDTSRNQVVLTMTNMDPVDTATYYCARRETVFYWYFDVWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGVQLLESGGGLVQPGGSLRLSCAASGFVFPWYDMGWVRQAPGKGLEWVSSIDWHGKITYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCATAEDEPGYDYWGQGTLVTVSS
SEQ ID NO:150=PascoH-TVAAPS-616(H链)
QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMGVSWIRQPPGKGLEWLAHIYWDDDKRYNPSLKSRLTISKDTSRNQVVLTMTNMDPVDTATYYCARRETVFYWYFDVWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGVQLLESGGGLVQPGGSLRLSCAASGFVFPWYDMGWVRQAPGKGLEWVSSIDWHGKITYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCATAEDEPGYDYWGQGTLVTVSS
SEQ ID NO:151=C1-TVAAPSGS-210(H链)
QVQLVQSGAEVKKPGASVKVSCKASGFYIKDTYMHWVRQAPGQGLEWMGTIDPANGNTKYVPKFQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARSIYDDYHYDDYYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK GSEVQLLESGGGLVQPGGSLRLSCAASGFTFRNFGMGWVRQAPGKGLEWVSWIISSGTETYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKSLGRFDYWGQGTLVTVSS
SEQ ID NO:152=D1-TVAAPSGS-210(H链)
EVQLVQSGAEVKKPGESLKISCKGSGFYIKDTYMHWVRQMPGKGLEWMGTIDPANGNTKYVPKFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARSIYDDYHYDDYYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK GSEVQLLESGGGLVQPGGSLRLSCAASGFTFRNFGMGWVRQAPGKGLEWVSWIISSGTETYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKSLGRFDYWGQGTLVTVSS
SEQ ID NO:153=N0(L链)
EIVLTQSPATLSLSPGERATLSCRSSQNIVHINGNTYLEWYQQKPGQAPRLLIYKISDRFSGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCFQGSHVPWTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
SEQ ID NO:154=M0(L链)
EIVLTQSPATLSLSPGERATLSCRSSQNIVHINGNTYLEWYQQKPGQAPRLLIYKISDRFSGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCFQGSHVPWTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
SEQ ID NO:155=656H-TVAAPS-210_(H链)
QVQLVQSGAEVKKPGASVKVSCKASGYTFIDYEIHWVRQAPGQGLEWMGAIDPETGGTAYNQKFKGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCTRILLYYYPMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKEVQLLESGGGLVQPGGSLRLSCAASGFTFRNFGMGWVRQAPGKGLEWVSWIISSGTETYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKSLGRFDYWGQGTLVTVSS
SEQ ID NO:156=656_(L链)
EIVLTQSPATLSLSPGERATLSCRASQNISDYLHWYQQKPGQAPRLLIYYASQSISGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQNGHSFPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
SEQ ID NO:157=PascoH-TVAAPS-546_(H链)
QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMGVSWIRQPPGKGLEWLAHIYWDDDKRYNPSLKSRLTISKDTSRNQVVLTMTNMDPVDTATYYCARRETVFYWYFDVWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGVQLLESGGGLVQPGGSLRLSCAASGFVFPWYDMGWVRQAPGKGLEWVSSIDWKGGKTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCATAEDEPGYDYWGQGTLVTVSS
SEQ ID NO:158=PascoH-546_(H链)
QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMGVSWIRQPPGKGLEWLAHIYWDDDKRYNPSLKSRLTISKDTSRNQVVLTMTNMDPVDTATYYCARRETVFYWYFDVWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGVQLLESGGGLVQPGGSLRLSCAASGFVFPWYDMGWVRQAPGKGLEWVSSIDWKGGKTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCATAEDEPGYDYWGQGTLVTVSS
SEQ ID NO:159=PascoH-TVAAPS-567_(H链)
QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMGVSWIRQPPGKGLEWLAHIYWDDDKRYNPSLKSRLTISKDTSRNQVVLTMTNMDPVDTATYYCARRETVFYWYFDVWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGVQLLESGGGLVQPGGSLRLSCAASGFVFAWYDMGWVRQAPGKGLEWVSSIDWHGEVTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCATAEDEPGYDYWGQGTLVTVSS
SEQ ID NO:160=PascoH-567_(H链)
QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMGVSWIRQPPGKGLEWLAHIYWDDDKRYNPSLKSRLTISKDTSRNQVVLTMTNMDPVDTATYYCARRETVFYWYFDVWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGVQLLESGGGLVQPGGSLRLSCAASGFVFAWYDMGWVRQAPGKGLEWVSSIDWHGEVTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCATAEDEPGYDYWGQGTLVTVSS
SEQ ID NO:161=656_(H链)
QVQLVQSGAEVKKPGASVKVSCKASGYTFIDYEIHWVRQAPGQGLEWMGAIDPETGGTAYNQKFKGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCTRILLYYYPMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
SEQ ID NO:162
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGGGCTTATCCGATGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGAGATTTCGCCTTCGGGTTCTTATACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGATCCTCGGAAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGCGCTAGCACCAAGGGCCCCAGCGAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGCAGCTATGCCATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGCTATTAGTGGTAGTGGTGGTAGCACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAAGTTATGGTGCTTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCGAGCGCTAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAGCCTGTGACCGTGTCCTGGAATAGCGGAGCCCTGACCTCCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACTCCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGCAACGTGAACCACAAGCCCAGCAACACCAAAGTGGACAAGAAAGTGGAGCCCAAGAGCTGCGATAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGCGGACCTAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGAGCCACGAGGACCCTGAAGTGAAGTTCAACTGGTACGTGGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCCAGAGAGGAGCAGTACAACAGCACCTACCGCGTGGTGTCTGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGCAAAGTGAGCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCTAGAGAGCCCCAGGTCTACACCCTGCCTCCCTCCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGTCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACTCCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCAGCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGTCTGAGCCTGTCCCCTGGCAAG
SEQ ID NO:163
EVQLLESGGGLVQPGGSLRLSCAASGFTFGAYPMMWVRQAPGKGLEWVSEISPSGSYTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDPRKFDYWGQGTLVTVSSASTKGPSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKSYGAFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
SEQ ID NO:164
CAGGTGCAGCTGAAGCAGAGCGGCCCTGGCCTGGTGCAGCCCTCTCAGAGCCTGAGCATCACCTGTACCGTGAGCGGCTTCAGCCTGACCAATTACGGCGTGCATTGGGTGCGGCAGTCTCCAGGCAAGGGCCTGGAATGGCTGGGAGTGATCTGGTCCGGCGGCAACACCGACTACAACACCCCCTTCACCAGCAGACTGAGCATCAACAAGGACAACAGCAAGAGCCAGGTGTTCTTCAAGATGAACAGCCTGCAGAGCAACGACACCGCCATCTACTATTGTGCCAGGGCCCTGACCTACTACGACTACGAGTTCGCCTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCGCCGCTAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAGCCTGTGACCGTGTCCTGGAATAGCGGAGCCCTGACCTCCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACTCCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGCAACGTGAACCACAAGCCCAGCAACACCAAAGTGGACAAGAAAGTGGAGCCCAAGAGCTGCGATAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGCGGACCTAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGAGCCACGAGGACCCTGAAGTGAAGTTCAACTGGTACGTGGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCCAGAGAGGAGCAGTACAACAGCACCTACCGCGTGGTGTCTGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGCAAAGTGAGCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCTAGAGAGCCCCAGGTCTACACCCTGCCTCCCTCCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGTCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACTCCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCAGCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGTCTGAGCCTGTCCCCTGGCAAGTCGACCGGTGAGGTGCAGCTGTTGGTGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGGCTTATCCGATGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTTTCAGAGATTTCGCCTTCGGGTTCTTATACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGATCCTCGGAAGTTAGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC
SEQ ID NO:165:
QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKSTGEVQLLVSGGGLVQPGGSLRLSCAASGFTFKAYPMMWVRQAPGKGLEWVSEISPSGSYTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDPRKLDYWGQGTLVTVSS
SEQ ID NO:166
QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMGVSWIRQPPGKGLEWLAHIYWDDDKRYNPSLKSRLTISKDTSRNQVVLTMTNMDPVDTATYYCARRETVFYWYFDVWGRGTPVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
SEQ ID NO:167 586H-TVAAPS-210重链
CAGGTGCAGCTCGTGCAGAGCGGCGCCGAAGTGAAAAAGCCCGGCAGCAGCGTGAAGGTGAGCTGCAAGGCCTCCGGCTTCTACATCAAGGACACCTACATGCACTGGGTCAGGCAGGCTCCTGGCCAGGGCCTGGAGTGGATGGGCACTATCGACCCCGCCAACGGCAACACCAAGTACGTGCCCAAGTTCCAGGGCAGGGTGACCATCACCGCCGATGAGAGCACCAGCACCGCCTACATGGAACTGAGCAGCCTGAGGTCTGAGGACACCGCCGTGTACTATTGCGCCAGGAGCATCTACGACGACTACCACTACGACGACTACTACGCCATGGACTACTGGGGACAGGGCACACTAGTGACCGTGTCCAGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAGGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCCCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAGACCGTGGCCGCCCCCTCGGGATCCGAAGTGCAGCTCCTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTGAGCTGCGCCGCTAGCGGCTTCACCTTCAGGAACTTCGGCATGGGCTGGGTCAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTCAGCTGGATCATCAGCTCCGGCACCGAGACCTACTACGCCGACAGCGTGAAGGGCAGGTTCACCATCAGCCGCGACAACAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTCTACTACTGCGCCAAGAGCCTGGGCAGGTTCGACTACTGGGGACAGGGGACCCTGGTGACTGTGAGCAGC
SEQ ID NO:168
GAGGTGCAGCTGGTGGAGTCTGGCGGCGGACTGGTGCAGCCCGGCAGAAGCCTGAGACTGAGCTGTGCCGCCAGCGGCTTCACCTTCGACGACTACGCCATGCACTGGGTGAGGCAGGCCCCTGGCAAGGGCCTGGAGTGGGTGTCCGCCATCACCTGGAATAGCGGCCACATCGACTACGCCGACAGCGTGGAGGGCAGATTCACCATCAGCCGGGACAACGCCAAGAACAGCCTGTACCTGCAGATGAACAGCCTGAGAGCCGAGGACACCGCCGTGTACTACTGTGCCAAGGTGTCCTACCTGAGCACCGCCAGCAGCCTGGACTACTGGGGCCAGGGCACCCTGGTGACAGTCTCGAGCGCTAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAGCCTGTGACCGTGTCCTGGAATAGCGGAGCCCTGACCTCCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACTCCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGCAACGTGAACCACAAGCCCAGCAACACCAAAGTGGACAAGAAAGTGGAGCCCAAGAGCTGCGATAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGCGGACCTAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGAGCCACGAGGACCCTGAAGTGAAGTTCAACTGGTACGTGGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCCAGAGAGGAGCAGTACAACAGCACCTACCGCGTGGTGTCTGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGCAAAGTGAGCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCTAGAGAGCCCCAGGTCTACACCCTGCCTCCCTCCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGTCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACTCCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCAGCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGTCTGAGCCTGTCCCCTGGCAAGTCGACCGGTGAGGTGCAGCTGTTGGTGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGGCTTATCCGATGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTTTCAGAGATTTCGCCTTCGGGTTCTTATACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGATCCTCGGAAGTTAGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC
SEQ ID NO:169
GATATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCTCTGTGGGCGATAGAGTGACCATCACCTGCCGGGCCAGCCAGGGCATCAGAAACTACCTGGCCTGGTATCAGCAGAAGCCTGGCAAGGCCCCTAAGCTGCTGATCTACGCCGCCAGCACCCTGCAGAGCGGCGTGCCCAGCAGATTCAGCGGCAGCGGCTCCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCCGAGGACGTGGCCACCTACTACTGCCAGCGGTACAACAGAGCCCCTTACACCTTCGGCCAGGGCACCAAGGTGGAGATCAAGCGTACGGTGGCCGCCCCCAGCGTGTTCATCTTCCCCCCCAGCGATGAGCAGCTCAAGAGCGGCACCGCCAGCGTGGTGTGTCTGCTGAACAACTTCTACCCCCGGGAGGCCAAAGTGCAGTGGAAAGTGGACAACGCCCTGCAGAGCGGCAACAGCCAGGAGAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCTGACCCTGAGCAAGGCCGACTACGAGAAGCACAAAGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCCAGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGC
SEQ ID NO:170
GAGGTGCAGCTGGTGGAGTCTGGCGGCGGACTGGTGCAGCCCGGCAGAAGCCTGAGACTGAGCTGTGCCGCCAGCGGCTTCACCTTCGACGACTACGCCATGCACTGGGTGAGGCAGGCCCCTGGCAAGGGCCTGGAGTGGGTGTCCGCCATCACCTGGAATAGCGGCCACATCGACTACGCCGACAGCGTGGAGGGCAGATTCACCATCAGCCGGGACAACGCCAAGAACAGCCTGTACCTGCAGATGAACAGCCTGAGAGCCGAGGACACCGCCGTGTACTACTGTGCCAAGGTGTCCTACCTGAGCACCGCCAGCAGCCTGGACTACTGGGGCCAGGGCACCCTGGTGACAGTCTCGAGCGCTAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAGCCTGTGACCGTGTCCTGGAATAGCGGAGCCCTGACCTCCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACTCCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGCAACGTGAACCACAAGCCCAGCAACACCAAAGTGGACAAGAAAGTGGAGCCCAAGAGCTGCGATAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGCGGACCTAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGAGCCACGAGGACCCTGAAGTGAAGTTCAACTGGTACGTGGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCCAGAGAGGAGCAGTACAACAGCACCTACCGCGTGGTGTCTGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGCAAAGTGAGCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCTAGAGAGCCCCAGGTCTACACCCTGCCTCCCTCCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGTCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACTCCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCAGCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGTCTGAGCCTGTCCCCTGGCAAGTCGACCGGTGACATCCAGATGACCCAGAGCCCTTCAAGCCTGAGCGCCAGCGTGGGCGACAGAGTGACCATCACCTGCCGGGCCAGCCAGTGGATCGGCAACCTGCTGGACTGGTATCAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACTACGCCAGCTTCCTGCAGAGCGGCGTGCCCAGCCGGTTTAGCGGCAGCGGCTACGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCCGAGGACTTCGCCACCTACTACTGCCAGCAGGCCAACCCTGCCCCCCTGACCTTCGGCCAGGGTACCAAGGTGGAAATCAAACGG
SEQ ID NO:171
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGGATATTTACCTGAATTTAGACTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCAATTTTGGTTCCGAGTTGCAAAGTGGTGTCCCATCACGTTTCAGTGGCAGTGGATATGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTCGCTACGTACTACTGTCAACCGTCTTTTTACTTCCCTTATACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGTACGGTGGCCGCCCCCAGCGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGAGCATTAGCAGCTATTTAAATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCAGTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGAGTTACAGTACCCCTAATACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGTACGGTGGCCGCCCCCAGCGTGTTCATCTTCCCCCCCAGCGATGAGCAGCTCAAGAGCGGCACCGCCAGCGTGGTGTGTCTGCTGAACAACTTCTACCCCCGGGAGGCCAAAGTGCAGTGGAAAGTGGACAACGCCCTGCAGAGCGGCAACAGCCAGGAGAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCTGACCCTGAGCAAGGCCGACTACGAGAAGCACAAAGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCCAGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGC
SEQ ID NO:172
GAGGTGCAGCTGTTGGTGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGGCTTATCCGATGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTTTCAGAGATTTCGCCTTCGGGTTCTTATACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGATCCTCGGAAGTTAGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGCGCTAGCACCAAGGGCCCCAGCGAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGCAGCTATGCCATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGCTATTAGTGGTAGTGGTGGTAGCACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAAGTTATGGTGCTTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCGAGCGCTAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAGCCTGTGACCGTGTCCTGGAATAGCGGAGCCCTGACCTCCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACTCCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGCAACGTGAACCACAAGCCCAGCAACACCAAAGTGGACAAGAAAGTGGAGCCCAAGAGCTGCGATAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGCGGACCTAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGAGCCACGAGGACCCTGAAGTGAAGTTCAACTGGTACGTGGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCCAGAGAGGAGCAGTACAACAGCACCTACCGCGTGGTGTCTGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGCAAAGTGAGCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCTAGAGAGCCCCAGGTCTACACCCTGCCTCCCTCCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGTCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACTCCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCAGCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGTCTGAGCCTGTCCCCTGGCAAG
SEQ ID NO:173
CAGGTGCAGCTGAAGCAGAGCGGCCCTGGCCTGGTGCAGCCCTCTCAGAGCCTGAGCATCACCTGTACCGTGAGCGGCTTCAGCCTGACCAATTACGGCGTGCATTGGGTGCGGCAGTCTCCAGGCAAGGGCCTGGAATGGCTGGGAGTGATCTGGTCCGGCGGCAACACCGACTACAACACCCCCTTCACCAGCAGACTGAGCATCAACAAGGACAACAGCAAGAGCCAGGTGTTCTTCAAGATGAACAGCCTGCAGAGCAACGACACCGCCATCTACTATTGTGCCAGGGCCCTGACCTACTACGACTACGAGTTCGCCTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCGCCGCTAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAGCCTGTGACCGTGTCCTGGAATAGCGGAGCCCTGACCTCCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACTCCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGCAACGTGAACCACAAGCCCAGCAACACCAAAGTGGACAAGAAAGTGGAGCCCAAGAGCTGCGATAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGCGGACCTAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGAGCCACGAGGACCCTGAAGTGAAGTTCAACTGGTACGTGGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCCAGAGAGGAGCAGTACAACAGCACCTACCGCGTGGTGTCTGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGCAAAGTGAGCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCTAGAGAGCCCCAGGTCTACACCCTGCCTCCCTCCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGTCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACTCCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCAGCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGTCTGAGCCTGTCCCCTGGCAAGGAGGTGCAGCTGTTGGTGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGGCTTATCCGATGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTTTCAGAGATTTCGCCTTCGGGTTCTTATACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGATCCTCGGAAGTTAGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC
SEQ ID NO:174
QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKEVQLLVSGGGLVQPGGSLRLSCAASGFTFKAYPMMWVRQAPGKGLEWVSEISPSGSYTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDPRKLDYWGQGTLVTVSS
SEQ ID NO:175
CAGGTGCAGCTGAAGCAGAGCGGCCCTGGCCTGGTGCAGCCCTCTCAGAGCCTGAGCATCACCTGTACCGTGAGCGGCTTCAGCCTGACCAATTACGGCGTGCATTGGGTGCGGCAGTCTCCAGGCAAGGGCCTGGAATGGCTGGGAGTGATCTGGTCCGGCGGCAACACCGACTACAACACCCCCTTCACCAGCAGACTGAGCATCAACAAGGACAACAGCAAGAGCCAGGTGTTCTTCAAGATGAACAGCCTGCAGAGCAACGACACCGCCATCTACTATTGTGCCAGGGCCCTGACCTACTACGACTACGAGTTCGCCTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCGCCGCTAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAGCCTGTGACCGTGTCCTGGAATAGCGGAGCCCTGACCTCCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACTCCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGCAACGTGAACCACAAGCCCAGCAACACCAAAGTGGACAAGAAAGTGGAGCCCAAGAGCTGCGATAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGCGGACCTAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGAGCCACGAGGACCCTGAAGTGAAGTTCAACTGGTACGTGGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCCAGAGAGGAGCAGTACAACAGCACCTACCGCGTGGTGTCTGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGCAAAGTGAGCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCTAGAGAGCCCCAGGTCTACACCCTGCCTCCCTCCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGTCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACTCCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCAGCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGTCTGAGCCTGTCCCCTGGCAAGTCGACCGGTGGTGGAGGTGGATCAGAGGTGCAGCTGTTGGTGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGGCTTATCCGATGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTTTCAGAGATTTCGCCTTCGGGTTCTTATACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGATCCTCGGAAGTTAGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC
SEQ ID NO:176
QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKSTGGGGGSEVQLLVSGGGLVQPGGSLRLSCAASGFTFKAYPMMWVRQAPGKGLEWVSEISPSGSYTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDPRKLDYWGQGTLVTVSS
SEQ ID NO:177
CAGGTGCAGCTGAAGCAGAGCGGCCCTGGCCTGGTGCAGCCCTCTCAGAGCCTGAGCATCACCTGTACCGTGAGCGGCTTCAGCCTGACCAATTACGGCGTGCATTGGGTGCGGCAGTCTCCAGGCAAGGGCCTGGAATGGCTGGGAGTGATCTGGTCCGGCGGCAACACCGACTACAACACCCCCTTCACCAGCAGACTGAGCATCAACAAGGACAACAGCAAGAGCCAGGTGTTCTTCAAGATGAACAGCCTGCAGAGCAACGACACCGCCATCTACTATTGTGCCAGGGCCCTGACCTACTACGACTACGAGTTCGCCTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCGCCGCTAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAGCCTGTGACCGTGTCCTGGAATAGCGGAGCCCTGACCTCCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACTCCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGCAACGTGAACCACAAGCCCAGCAACACCAAAGTGGACAAGAAAGTGGAGCCCAAGAGCTGCGATAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGCGGACCTAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGAGCCACGAGGACCCTGAAGTGAAGTTCAACTGGTACGTGGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCCAGAGAGGAGCAGTACAACAGCACCTACCGCGTGGTGTCTGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGCAAAGTGAGCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCTAGAGAGCCCCAGGTCTACACCCTGCCTCCCTCCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGTCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACTCCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCAGCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGTCTGAGCCTGTCCCCTGGCAAGTCGACCGGTGGTGGAGGTGGATCAGGTGGAGGTGGATCAGAGGTGCAGCTGTTGGTGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGGCTTATCCGATGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTTTCAGAGATTTCGCCTTCGGGTTCTTATACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGATCCTCGGAAGTTAGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC
SEQ ID NO:178
QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKSTGGGGGSGGGGSEVQLLVSGGGLVQPGGSLRLSCAASGFTFKAYPMMWVRQAPGKGLEWVSEISPSGSYTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDPRKLDYWGQGTLVTVSS
SEQ ID NO:179
GAGGTGCAGCTGGTCGAGTCTGGCGGCGGACTGGTGCAGCCTGGCGGCAGCCTGAGACTGAGCTGCGCCGCCAGCGGCTACACCTTCACCAACTACGGCATGAACTGGGTGCGGCAGGCCCCTGGCAAGGGCCTGGAATGGGTGGGCTGGATCAACACCTACACCGGCGAGCCCACCTACGCCGCCGACTTCAAGCGGCGGTTCACCTTCAGCCTGGACACCAGCAAGAGCACCGCCTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGCGCCAAGTACCCCCACTACTACGGCAGCAGCCACTGGTACTTCGACTACTGGGGGCAGGGTACCCTGGTCACCGTCTCGAGCGCTAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAGCCTGTGACCGTGTCCTGGAATAGCGGAGCCCTGACCTCCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACTCCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGCAACGTGAACCACAAGCCCAGCAACACCAAAGTGGACAAGAAAGTGGAGCCCAAGAGCTGCGATAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGCGGACCTAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGAGCCACGAGGACCCTGAAGTGAAGTTCAACTGGTACGTGGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCCAGAGAGGAGCAGTACAACAGCACCTACCGCGTGGTGTCTGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGCAAAGTGAGCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCTAGAGAGCCCCAGGTCTACACCCTGCCTCCCTCCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGTCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACTCCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCAGCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGTCTGAGCCTGTCCCCTGGCAAGTCGACCGGTGACATCCAGATGACCCAGAGCCCTTCAAGCCTGAGCGCCAGCGTGGGCGACAGAGTGACCATCACCTGCCGGGCCAGCCAGTGGATCGGCAACCTGCTGGACTGGTATCAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACTACGCCAGCTTCCTGCAGAGCGGCGTGCCCAGCCGGTTTAGCGGCAGCGGCTACGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCCGAGGACTTCGCCACCTACTACTGCCAGCAGGCCAACCCTGCCCCCCTGACCTTCGGCCAGGGTACCAAGGTGGAAATCAAACGG
SEQ ID NO:180
EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKSTGDIQMTQSPSSLSASVGDRVTITCRASQWIGNLLDWYQQKPGKAPKLLIYYASFLQSGVPSRFSGSGYGTDFTLTISSLQPEDFATYYCQQANPAPLTFGQGTKVEIKR
SEQ ID NO:181
GACATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACAGAGTGACCATCACCTGCAGCGCCAGCCAGGACATCAGCAACTACCTGAACTGGTATCAGCAGAAGCCCGGCAAGGCCCCCAAGGTGCTGATCTACTTCACCAGCTCCCTGCACAGCGGCGTGCCCAGCCGGTTTAGCGGCAGCGGCTCCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCCGAGGACTTCGCCACCTACTACTGCCAGCAGTACAGCACCGTGCCCTGGACCTTCGGCCAGGGTACCAAGGTGGAGATCAAGCGTACGGTGGCCGCTCCCAGCGTGTTCATCTTCCCCCCCAGCGACGAGCAGCTGAAGAGCGGCACCGCCTCCGTGGTGTGCCTGCTGAACAACTTCTACCCCCGGGAGGCCAAGGTGCAGTGGAAGGTGGACAACGCCCTGCAGTCCGGCAACAGCCAGGAAAGCGTCACCGAGCAGGACTCCAAGGACTCCACCTACAGCCTGAGCAGCACCCTGACCCTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCCAGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGC
SEQ ID NO:182
DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
SEQ ID NO:183
CAGGTGCAGCTGAAGCAGAGCGGCCCTGGCCTGGTGCAGCCCTCTCAGAGCCTGAGCATCACCTGTACCGTGAGCGGCTTCAGCCTGACCAATTACGGCGTGCATTGGGTGCGGCAGTCTCCAGGCAAGGGCCTGGAATGGCTGGGAGTGATCTGGTCCGGCGGCAACACCGACTACAACACCCCCTTCACCAGCAGACTGAGCATCAACAAGGACAACAGCAAGAGCCAGGTGTTCTTCAAGATGAACAGCCTGCAGAGCAACGACACCGCCATCTACTATTGTGCCAGGGCCCTGACCTACTACGACTACGAGTTCGCCTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCGCCGCTAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAGCCTGTGACCGTGTCCTGGAATAGCGGAGCCCTGACCTCCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACTCCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGCAACGTGAACCACAAGCCCAGCAACACCAAAGTGGACAAGAAAGTGGAGCCCAAGAGCTGCGATAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGCGGACCTAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGAGCCACGAGGACCCTGAAGTGAAGTTCAACTGGTACGTGGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCCAGAGAGGAGCAGTACAACAGCACCTACCGCGTGGTGTCTGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGCAAAGTGAGCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCTAGAGAGCCCCAGGTCTACACCCTGCCTCCCTCCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGTCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACTCCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCAGCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGTCTGAGCCTGTCCCCTGGCAAGTCGACCGGTGGGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTCGCTTGGTATGATATGGGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTGATTGGCATGGTGAGGTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGACAGCGGAGGACGAGCCGGGGTATGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCGAGC
SEQ ID NO:184
QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKSTGGVQLLESGGGLVQPGGSLRLSCAASGFTFAWYDMGWVRQAPGKGLEWVSSIDWHGEVTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCATAEDEPGYDYWGQGTLVTVSS
SEQ ID NO:185
EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSAITWNSGHIDYADSVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVSYLSTASSLDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKSTGDIQMTQSPSSLSASVGDRVTITCRASQWIGPELRWYQQKPGKAPKLLIYHTSILQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYMFQPMTFGQGTKVEIKR
SEQ ID NO:186
QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKSTGDIQMTQSPSSLSASVGDRVTITCRASQWIGPELRWYQQKPGKAPKLLIYHTSILQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYMFQPMTFGQGTKVEIKR
SEQ ID NO:187
GACATCCTGCTGACCCAGAGCCCCGTGATCCTGAGCGTGAGCCCTGGCGAGAGAGTGAGCTTCAGCTGCCGGGCCAGCCAGAGCATCGGCACCAACATCCACTGGTATCAGCAGCGGACCAACGGCAGCCCCAGGCTGCTGATCAAGTACGCCAGCGAGTCCATCAGCGGCATCCCCAGCCGGTTCAGCGGCAGCGGCTCCGGCACCGACTTCACCCTGAGCATCAACAGCGTGGAGAGCGAGGATATCGCCGACTACTACTGCCAGCAGAACAACAACTGGCCCACCACCTTCGGAGCCGGCACCAAGCTGGAACTGAAGCGTACGGTGGCCGCCCCCAGCGTGTTCATCTTCCCCCCCAGCGATGAGCAGCTCAAGAGCGGCACCGCCAGCGTGGTGTGTCTGCTGAACAACTTCTACCCCCGGGAGGCCAAAGTGCAGTGGAAAGTGGACAACGCCCTGCAGAGCGGCAACAGCCAGGAGAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCTGACCCTGAGCAAGGCCGACTACGAGAAGCACAAAGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCCAGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGCGGATCCACCGGCGAGGTGCAGCTGTTGGTGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGGCTTATCCGATGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTTTCAGAGATTTCGCCTTCGGGTTCTTATACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGATCCTCGGAAGTTAGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC
SEQ ID NO:188
DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECGSTGEVQLLVSGGGLVQPGGSLRLSCAASGFTFKAYPMMWVRQAPGKGLEWVSEISPSGSYTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDPRKLDYWGQGTLVTVSS
SEQ ID NO:189
GACATCCTGCTGACCCAGAGCCCCGTGATCCTGAGCGTGAGCCCTGGCGAGAGAGTGAGCTTCAGCTGCCGGGCCAGCCAGAGCATCGGCACCAACATCCACTGGTATCAGCAGCGGACCAACGGCAGCCCCAGGCTGCTGATCAAGTACGCCAGCGAGTCCATCAGCGGCATCCCCAGCCGGTTCAGCGGCAGCGGCTCCGGCACCGACTTCACCCTGAGCATCAACAGCGTGGAGAGCGAGGATATCGCCGACTACTACTGCCAGCAGAACAACAACTGGCCCACCACCTTCGGAGCCGGCACCAAGCTGGAACTGAAGCGTACGGTGGCCGCCCCCAGCGTGTTCATCTTCCCCCCCAGCGATGAGCAGCTCAAGAGCGGCACCGCCAGCGTGGTGTGTCTGCTGAACAACTTCTACCCCCGGGAGGCCAAAGTGCAGTGGAAAGTGGACAACGCCCTGCAGAGCGGCAACAGCCAGGAGAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCTGACCCTGAGCAAGGCCGACTACGAGAAGCACAAAGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCCAGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGCGGATCCACGGTGGCCGCCCCCAGCGAGGTGCAGCTGTTGGTGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGGCTTATCCGATGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTTTCAGAGATTTCGCCTTCGGGTTCTTATACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGATCCTCGGAAGTTAGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC
SEQ ID NO:190
DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECGSTVAAPSEVQLLVSGGGLVQPGGSLRLSCAASGFTFKAYPMMWVRQAPGKGLEWVSEISPSGSYTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDPRKLDYWGQGTLVTVSS
SEQ ID NO:191
QVTLRESGPALVKPTQTLTLTCTVSGFSLTSYSVHWVRQPPGKGLEWLGVIWASGGTDYNSALMSRLSISKDTSRNQVVLTMTNMDPVDTATYYCARDPPSSLLRLDYWGRGTPVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
SEQ ID NO:192:586H-ASTKG-210重链
CAGGTGCAGCTCGTGCAGAGCGGCGCCGAAGTGAAAAAGCCCGGCAGCAGCGTGAAGGTGAGCTGCAAGGCCTCCGGCTTCTACATCAAGGACACCTACATGCACTGGGTCAGGCAGGCTCCTGGCCAGGGCCTGGAGTGGATGGGCACTATCGACCCCGCCAACGGCAACACCAAGTACGTGCCCAAGTTCCAGGGCAGGGTGACCATCACCGCCGATGAGAGCACCAGCACCGCCTACATGGAACTGAGCAGCCTGAGGTCTGAGGACACCGCCGTGTACTATTGCGCCAGGAGCATCTACGACGACTACCACTACGACGACTACTACGCCATGGACTACTGGGGACAGGGCACACTAGTGACCGTGTCCAGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAGGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCCCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAGGGATCAGCCAGCACCAAGGGCCCCACGGGATCCGAAGTGCAGCTCCTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTGAGCTGCGCCGCTAGCGGCTTCACCTTCAGGAACTTCGGCATGGGCTGGGTCAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTCAGCTGGATCATCAGCTCCGGCACCGAGACCTACTACGCCGACAGCGTGAAGGGCAGGTTCACCATCAGCCGCGACAACAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTCTACTACTGCGCCAAGAGCCTGGGCAGGTTCGACTACTGGGGACAGGGGACCCTGGTGACTGTGAGCAGC
SEQ ID NO:193
EVTLRESGPALVKPTQTLTLTCTFSGFSLSKSVMGVSWIRQPPGKALEWLAHIYWDDDKYYNPSLKSRLTISKDTSKNQVVLTMTNMDPVDTATYYCARRGIRSAMDYWGQGTTVTVSSASTKGPEVQLVQSGTEVKKPGESLKISCKGSGYTVTSYWIGWVRQMPGKGLEWMGFIYPGDSETRYSPTFQGQVTISADKSFNTAFLQWSSLKASDTAMYYCARVGSGWYPYTFDIWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKTVAAPSEVQLLESGGGLVQPGGSLRLSCAASGFTFRNFGMGWVRQAPGKGLEWVSWIISSGTETYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKSLGRFDYWGQGTLVTVSS
SEQ ID NO:194
DIVMTQSPDSLAVSLGERATINCKASQSVSNDVAWYQQKPGQPPKLLIYYASNRYTGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQDYNSPWTFGGGTKVEIKRTVAAPEIVMTQSPATLSVSPGERATLSCRASESASSNLAWYQQKPGQAPRLFIYTASTRATDIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPSITFGQGTRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
SEQ ID NO:195:抗IL-5重链-G4S-dAb474-TVAAPSGS-dAb210
QVTLRESGPALVKPTQTLTLTCTVSGFSLTSYSVHWVRQPPGKGLEWLGVIWASGGTDYNSALMSRLSISKDTSRNQVVLTMTNMDPVDTATYYCARDPPSSLLRLDYWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGVQLLESGGGLVQPGGSLRLSCAASGFTFAWYDMGWVRQAPGKGLEWVSSIDWHGEVTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCATAEDEPGYDYWGQGTLVTVSSTVAAPSGSEVQLLESGGGLVQPGGSLRLSCAASGFTFRNFGMGWVRQAPGKGLEWVSWIISSGTETYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKSLGRFDYWGQGTLVTVSS
SEQ ID NO:196:抗CD-20重链-TVAAPSGS-dAb154-TVAAPSGS-dAb474
QVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKTVAAPSGSDIQMTQSPSSLSASVGDRVTITCRASRPISDWLHWYQQKPGKAPKLLIAWASSLQGGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQEGWGPPTFGQGTKVEIKRTVAAPSGSGVQLLESGGGLVQPGGSLRLSCAASGFTFAWYDMGWVRQAPGKGLEWVSSIDWHGEVTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCATAEDEPGYDYWGQGTLVTVSS
SEQ ID NO:197:抗CD-20重链-TVAAPSGS-dAb210-TVAAPSGS-dAb474
QVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKTVAAPSGSEVQLLESGGGLVQPGGSLRLSCAASGFTFRNFGMGWVRQAPGKGLEWVSWIISSGTETYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKSLGRFDYWGQGTLVTVSSTVAAPSGSGVQLLESGGGLVQPGGSLRLSCAASGFTFAWYDMGWVRQAPGKGLEWVSSIDWHGEVTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCATAEDEPGYDYWGQGTLVTVSS
SEQ ID NO:198:抗cMET 5D5v2重链(hole)-GS-dAb593
EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYWLHWVRQAPGKGLEWVGMIDPSNSDTRFNPNFKDRFTISADTSKNTAYLQMNSLRAEDTAVYYCATYRSYVTPLDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGSEVQLLVSGGGLVQPGGSLRLSCAASGFTFKAYPMMWVRQAPGKGLEWVSEISPSGSYTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDPRKLDYWGQGTLVTVSS
SEQ ID NO:199:抗cMET 5D5v2重链(knob)-GS-dAb593
CPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGSEVQLLVSGGGLVQPGGSLRLSCAASGFTFKAYPMMWVRQAPGKGLEWVSEISPSGSYTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDPRKLDYWGQGTLVTVSS
SEQ ID NO:200:抗cMET 5D5v2轻链
DIQMTQSPSSLSASVGDRVTITCKSSQSLLYTSSQKNYLAWYQQKPGKAPKLLIYWASTRESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYAYPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
SEQ ID NO:201:抗cMET 5D5v2 IgG4重链(UNIBODY)-GS-dAb593
EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYWLHWVRQAPGKGLEWVGMIDPSNSDTRFNPNFKDRFTISADTSKNTAYLQMNSLRAEDTAVYYCATYRSYVTPLDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKGSEVQLLVSGGGLVQPGGSLRLSCAASGFTFKAYPMMWVRQAPGKGLEWVSEISPSGSYTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDPRKLDYWGQGTLVTVSS
SEQ ID NO:202:抗cMET 5D5v2重链(hole)
EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYWLHWVRQAPGKGLEWVGMIDPSNSDTRFNPNFKDRFTISADTSKNTAYLQMNSLRAEDTAVYYCATYRSYVTPLDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
SEQ ID NO:203:抗cMET 5D5v2重链(knob)
CPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
SEQ ID NO:204:抗cMET 5D5v2 IgG4重链(UNIBODY)
EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYWLHWVRQAPGKGLEWVGMIDPSNSDTRFNPNFKDRFTISADTSKNTAYLQMNSLRAEDTAVYYCATYRSYVTPLDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK
SEQ ID NO:205:抗-人IL13mAb重链
CAGGTGCAGCTCGTGCAGAGCGGCGCCGAAGTGAAAAAGCCCGGCAGCAGCGTGAAGGTGAGCTGCAAGGCCTCCGGCTTCTACATCAAGGACACCTACATGCACTGGGTCAGGCAGGCTCCTGGCCAGGGCCTGGAGTGGATGGGCACTATCGACCCCGCCAACGGCAACACCAAGTACGTGCCCAAGTTCCAGGGCAGGGTGACCATCACCGCCGATGAGAGCACCAGCACCGCCTACATGGAACTGAGCAGCCTGAGGTCTGAGGACACCGCCGTGTACTATTGCGCCAGGAGCATCTACGACGACTACCACTACGACGACTACTACGCCATGGACTACTGGGGACAGGGCACACTAGTGACCGTGTCCAGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAGGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCCCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAG
SEQ ID NO:206:备选抗-人IL13mAb重链
CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCTCCTGCAAGGCTTCTGGATTCTACATTAAAGACACCTATATGCACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAACGATTGATCCTGCGAATGGTAATACTAAATATGTCCCGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACGAATCCACGAGCACAGCCTACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCCGTGTATTACTGTGCGAGAAGCATCTATGATGATTACCACTACGACGATTACTATGCTATGGACTACTGGGGCCAAGGGACACTAGTCACAGTCTCCTCAGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA
SEQ ID NO 207:PascoH IgG2-GS-474重链
QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMGVSWIRQPPGKGLEWLAHIYWDDDKRYNPSLKSRLTISKDTSRNQVVLTMTNMDPVDTATYYCARRETVFYWYFDVWGRGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGSGVQLLESGGGLVQPGGSLRLSCAASGFTFAWYDMGWVRQAPGKGLEWVSSIDWHGEVTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCATAEDEPGYDYWGQGTLVTVSS
SEQ ID NO 208:PascoH IgG4-GS-474重链
QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMGVSWIRQPPGKGLEWLAHIYWDDDKRYNPSLKSRLTISKDTSRNQVVLTMTNMDPVDTATYYCARRETVFYWYFDVWGRGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKGSGVQLLESGGGLVQPGGSLRLSCAASGFTFAWYDMGWVRQAPGKGLEWVSSIDWHGEVTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCATAEDEPGYDYWGQGTLVTVSS
SEQ ID NO 209:PascoH IgG4PE-GS-474重链
QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMGVSWIRQPPGKGLEWLAHIYWDDDKRYNPSLKSRLTISKDTSRNQVVLTMTNMDPVDTATYYCARRETVFYWYFDVWGRGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKGSGVQLLESGGGLVQPGGSLRLSCAASGFTFAWYDMGWVRQAPGKGLEWVSSIDWHGEVTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCATAEDEPGYDYWGQGTLVTVSS
SEQ ID NO:210:抗-人IL13mAb轻链
GACATCGTGATGACCCAGTCTCCTCTGAGCCTCCCCGTGACCCCCGGCGAACCAGCCAGCATCTCCTGCAGAAGCAGCCAGAACATCGTGCACATCAACGGCAACACCTACCTGGAGTGGTACCTGCAAAAGCCCGGCCAGAGCCCCAGGCTGCTGATCTACAAGATCAGCGACAGGTTCAGCGGCGTGCCCGATAGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGAAGATCAGCAGGGTGGAGGCCGACGACGTGGGCATCTACTACTGCTTCCAGGGCAGCCACGTCCCCTGGACTTTCGGACAGGGCACCAAGCTGGAGATTAAGCGTACGGTGGCCGCCCCCAGCGTGTTCATCTTCCCCCCCAGCGATGAGCAGCTGAAGAGCGGCACCGCCAGCGTGGTGTGTCTGCTGAACAACTTCTACCCCCGGGAGGCCAAGGTGCAGTGGAAGGTGGACAATGCCCTGCAGAGCGGCAACAGCCAGGAGAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCTGACCCTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGTGAGGTGACCCACCAGGGCCTGTCCAGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGC
SEQ ID NO:211:帕考珠单抗重链
CAGGTGACCCTGAGGGAGAGCGGCCCCGCCCTGGTGAAGCCCACCCAGACCCTGACCCTGACCTGCACCTTCAGCGGCTTTAGCCTCAGCACCTCCGGCATGGGCGTGAGCTGGATCAGGCAGCCACCCGGCAAAGGCCTGGAGTGGCTGGCCCACATCTACTGGGACGACGACAAGAGGTACAACCCCAGCCTGAAGAGCCGGCTGACCATCAGCAAGGATACCAGCAGGAACCAGGTGGTGCTGACCATGACCAACATGGACCCCGTGGACACCGCTACCTACTACTGCGCCAGGAGGGAGACCGTCTTCTACTGGTACTTCGACGTGTGGGGAAGGGGCACACTAGTGACCGTGTCCAGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAGGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCCCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAG
SEQ ID NO:212:帕考珠单抗轻链
GACATCGTGCTGACCCAGAGCCCCTCTTCCCTGAGCGCAAGCGTGGGCGATAGGGTGACCATCACCTGCAAGGCCAGCCAGAGCGTGGACTACGACGGCGACAGCTACATGAACTGGTACCAGCAGAAGCCCGGCAAGGCCCCCAAACTGCTGATCTACGCCGCCAGCAACCTCGAGTCAGGCATTCCCAGCAGGTTTAGCGGCAGCGGCAGCGGCACCGACTTCACCTTCACAATCAGCAGCCTGCAGCCCGAGGACATCGCCACCTACTACTGCCAGCAGAGCAACGAGGACCCTCCCACCTTCGGACAGGGCACCAAGGTCGAGATCAAGCGTACGGTGGCCGCCCCCAGCGTGTTCATCTTCCCCCCCAGCGATGAGCAGCTGAAGAGCGGCACCGCCAGCGTGGTGTGTCTGCTGAACAACTTCTACCCCCGGGAGGCCAAGGTGCAGTGGAAGGTGGACAATGCCCTGCAGAGCGGCAACAGCCAGGAGAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCTGACCCTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGTGAGGTGACCCACCAGGGCCTGTCCAGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGC
SEQ ID NO:213:美泊利单抗重链
CAGGTGACCCTGAGGGAGAGCGGCCCCGCCCTGGTGAAGCCCACACAGACCCTCACTCTGACCTGCACCGTGAGCGGCTTCAGCCTGACCTCCTACAGCGTCCACTGGGTGAGGCAGCCCCCCGGCAAGGGCCTGGAGTGGCTGGGCGTGATCTGGGCAAGCGGCGGCACCGACTACAACAGCGCCCTGATGAGCAGGCTCTCCATCAGCAAGGACACCAGCCGGAACCAGGTGGTGCTGACCATGACCAACATGGACCCCGTGGACACCGCCACCTATTACTGCGCCAGGGACCCTCCCTCTAGCCTGCTGAGGCTGGACTACTGGGGCAGGGGAACACTAGTGACCGTGTCCAGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAGGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCCCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAG
SEQ ID NO:214:美泊利单抗轻链
GACATCGTGATGACCCAGTCTCCCGATTCACTGGCCGTGAGCCTGGGCGAGAGGGCCACCATCAACTGCAAGAGCAGCCAGAGCCTCCTGAACAGCGGCAACCAGAAGAACTACCTGGCCTGGTACCAGCAGAAACCCGGCCAGCCCCCCAAGCTGCTGATCTATGGCGCCTCCACCAGGGAGAGCGGCGTGCCAGACAGGTTTAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACAATCAGCAGCCTGCAGGCCGAGGACGTGGCCGTGTACTACTGCCAGAACGTCCACAGCTTCCCCTTCACCTTCGGCGGGGGAACCAAGCTGGAGATCAAGCGTACGGTGGCCGCCCCCAGCGTGTTCATCTTCCCCCCCAGCGATGAGCAGCTGAAGAGCGGCACCGCCAGCGTGGTGTGTCTGCTGAACAACTTCTACCCCCGGGAGGCCAAGGTGCAGTGGAAGGTGGACAATGCCCTGCAGAGCGGCAACAGCCAGGAGAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCTGACCCTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGTGAGGTGACCCACCAGGGCCTGTCCAGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGC
SEQ ID NO:215:PascoH-474重链
CAGGTGACCCTGAGGGAGAGCGGCCCCGCCCTGGTGAAGCCCACCCAGACCCTGACCCTGACCTGCACCTTCAGCGGCTTTAGCCTCAGCACCTCCGGCATGGGCGTGAGCTGGATCAGGCAGCCACCCGGCAAAGGCCTGGAGTGGCTGGCCCACATCTACTGGGACGACGACAAGAGGTACAACCCCAGCCTGAAGAGCCGGCTGACCATCAGCAAGGATACCAGCAGGAACCAGGTGGTGCTGACCATGACCAACATGGACCCCGTGGACACCGCTACCTACTACTGCGCCAGGAGGGAGACCGTCTTCTACTGGTACTTCGACGTGTGGGGAAGGGGCACACTAGTGACCGTGTCCAGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAGGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCCCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAGGGATCCGGCGTGCAGCTCCTGGAGAGCGGCGGAGGCCTGGTCCAGCCCGGCGGCAGCCTGAGGCTGAGCTGCGCCGCCAGCGGCTTCACCTTCGCCTGGTATGATATGGGCTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGTCCAGCATCGACTGGCACGGGGAGGTGACCTACTACGCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCAGTGTACTACTGCGCCACCGCCGAGGACGAACCCGGCTACGACTACTGGGGCCAGGGCACCCTGGTGACTGTGAGCAGC
SEQ ID NO:216:PascoH-TVAAPS-474重链
CAGGTGACCCTGAGGGAGAGCGGCCCCGCCCTGGTGAAGCCCACCCAGACCCTGACCCTGACCTGCACCTTCAGCGGCTTTAGCCTCAGCACCTCCGGCATGGGCGTGAGCTGGATCAGGCAGCCACCCGGCAAAGGCCTGGAGTGGCTGGCCCACATCTACTGGGACGACGACAAGAGGTACAACCCCAGCCTGAAGAGCCGGCTGACCATCAGCAAGGATACCAGCAGGAACCAGGTGGTGCTGACCATGACCAACATGGACCCCGTGGACACCGCTACCTACTACTGCGCCAGGAGGGAGACCGTCTTCTACTGGTACTTCGACGTGTGGGGAAGGGGCACACTAGTGACCGTGTCCAGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAGGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCCCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAGACCGTGGCCGCCCCCTCGGGATCCGGCGTGCAGCTCCTGGAGAGCGGCGGAGGCCTGGTCCAGCCCGGCGGCAGCCTGAGGCTGAGCTGCGCCGCCAGCGGCTTCACCTTCGCCTGGTATGATATGGGCTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGTCCAGCATCGACTGGCACGGGGAGGTGACCTACTACGCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCAGTGTACTACTGCGCCACCGCCGAGGACGAACCCGGCTACGACTACTGGGGCCAGGGCACCCTGGTGACTGTGAGCAGC
SEQ ID NO:217:PascoL-474轻链
GACATCGTGCTGACCCAGAGCCCCTCTTCCCTGAGCGCAAGCGTGGGCGATAGGGTGACC
ATCACCTGCAAGGCCAGCCAGAGCGTGGACTACGACGGCGACAGCTACATGAACTGGTAC
CAGCAGAAGCCCGGCAAGGCCCCCAAACTGCTGATCTACGCCGCCAGCAACCTCGAGTCA
GGCATTCCCAGCAGGTTTAGCGGCAGCGGCAGCGGCACCGACTTCACCTTCACAATCAGC
AGCCTGCAGCCCGAGGACATCGCCACCTACTACTGCCAGCAGAGCAACGAGGACCCTCCC
ACCTTCGGACAGGGCACCAAGGTCGAGATCAAGCGTACGGTGGCCGCCCCCAGCGTGTTC
ATCTTCCCCCCCAGCGATGAGCAGCTGAAGAGCGGCACCGCCAGCGTGGTGTGTCTGCTG
AACAACTTCTACCCCCGGGAGGCCAAGGTGCAGTGGAAGGTGGACAATGCCCTGCAGAGC
GGCAACAGCCAGGAGAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGC
AGCACCCTGACCCTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGTGAGGTG
ACCCACCAGGGCCTGTCCAGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGTGGATCC
GGCGTGCAGCTCCTGGAGAGCGGCGGAGGCCTGGTCCAGCCCGGCGGCAGCCTGAGGCTG
AGCTGCGCCGCCAGCGGCTTCACCTTCGCCTGGTATGATATGGGCTGGGTGAGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGGTGTCCAGCATCGACTGGCACGGGGAGGTGACCTACTAC
GCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACAGCAAGAACACCCTGTAC
CTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCAGTGTACTACTGCGCCACCGCCGAG
GACGAACCCGGCTACGACTACTGGGGCCAGGGCACCCTGGTGACTGTGAGCAGC
SEQ ID NO:218:PascoL-TVAAPS-474轻链
GACATCGTGCTGACCCAGAGCCCCTCTTCCCTGAGCGCAAGCGTGGGCGATAGGGTGACC
ATCACCTGCAAGGCCAGCCAGAGCGTGGACTACGACGGCGACAGCTACATGAACTGGTAC
CAGCAGAAGCCCGGCAAGGCCCCCAAACTGCTGATCTACGCCGCCAGCAACCTCGAGTCA
GGCATTCCCAGCAGGTTTAGCGGCAGCGGCAGCGGCACCGACTTCACCTTCACAATCAGC
AGCCTGCAGCCCGAGGACATCGCCACCTACTACTGCCAGCAGAGCAACGAGGACCCTCCC
ACCTTCGGACAGGGCACCAAGGTCGAGATCAAGCGTACGGTGGCCGCCCCCAGCGTGTTC
ATCTTCCCCCCCAGCGATGAGCAGCTGAAGAGCGGCACCGCCAGCGTGGTGTGTCTGCTG
AACAACTTCTACCCCCGGGAGGCCAAGGTGCAGTGGAAGGTGGACAATGCCCTGCAGAGC
GGCAACAGCCAGGAGAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGC
AGCACCCTGACCCTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGTGAGGTG
ACCCACCAGGGCCTGTCCAGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGCACCGTG
GCCGCCCCCTCGGGATCCGGCGTGCAGCTCCTGGAGAGCGGCGGAGGCCTGGTCCAGCCC
GGCGGCAGCCTGAGGCTGAGCTGCGCCGCCAGCGGCTTCACCTTCGCCTGGTATGATATG
GGCTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGTCCAGCATCGACTGGCAC
GGGGAGGTGACCTACTACGCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAAC
AGCAAGAACACCCTGTACCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCAGTGTAC
TACTGCGCCACCGCCGAGGACGAACCCGGCTACGACTACTGGGGCCAGGGCACCCTGGTG
ACTGTGAGCAGC
SEQ ID NO:219:IL-5 mAb-G4S-DOM9-112-210重链
CAGGTGACCCTGAGGGAGAGCGGCCCCGCCCTGGTGAAGCCCACACAGACCCTCACTCTGACCTGCACCGTGAGCGGCTTCAGCCTGACCTCCTACAGCGTCCACTGGGTGAGGCAGCCCCCCGGCAAGGGCCTGGAGTGGCTGGGCGTGATCTGGGCAAGCGGCGGCACCGACTACAACAGCGCCCTGATGAGCAGGCTCTCCATCAGCAAGGACACCAGCCGGAACCAGGTGGTGCTGACCATGACCAACATGGACCCCGTGGACACCGCCACCTATTACTGCGCCAGGGACCCTCCCTCTAGCCTGCTGAGGCTGGACTACTGGGGCAGGGGAACACTAGTGACCGTGTCCAGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAGGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCCCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAGGGCGGCGGCGGATCCGAAGTGCAGCTCCTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTGAGCTGCGCCGCTAGCGGCTTCACCTTCAGGAACTTCGGCATGGGCTGGGTCAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTCAGCTGGATCATCAGCTCCGGCACCGAGACCTACTACGCCGACAGCGTGAAGGGCAGGTTCACCATCAGCCGCGACAACAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTCTACTACTGCGCCAAGAGCCTGGGCAGGTTCGACTACTGGGGACAGGGGACCCTGGTGACTGTGAGCAGC
SEQ ID NO:220:IL-5 mAb-G4S-DOM10-53-474轻链
GACATCGTGATGACCCAGTCTCCCGATTCACTGGCCGTGAGCCTGGGCGAGAGGGCCACC
ATCAACTGCAAGAGCAGCCAGAGCCTCCTGAACAGCGGCAACCAGAAGAACTACCTGGCC
TGGTACCAGCAGAAACCCGGCCAGCCCCCCAAGCTGCTGATCTATGGCGCCTCCACCAGG
GAGAGCGGCGTGCCAGACAGGTTTAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACA
ATCAGCAGCCTGCAGGCCGAGGACGTGGCCGTGTACTACTGCCAGAACGTCCACAGCTTC
CCCTTCACCTTCGGCGGGGGAACCAAGCTGGAGATCAAGCGTACGGTGGCCGCCCCCAGC
GTGTTCATCTTCCCCCCCAGCGATGAGCAGCTGAAGAGCGGCACCGCCAGCGTGGTGTGT
CTGCTGAACAACTTCTACCCCCGGGAGGCCAAGGTGCAGTGGAAGGTGGACAATGCCCTG
CAGAGCGGCAACAGCCAGGAGAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGC
CTGAGCAGCACCCTGACCCTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGT
GAGGTGACCCACCAGGGCCTGTCCAGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGC
GGCGGCGGCGGATCCGGCGTGCAGCTCCTGGAGAGCGGCGGAGGCCTGGTCCAGCCCGGC
GGCAGCCTGAGGCTGAGCTGCGCCGCCAGCGGCTTCACCTTCGCCTGGTATGATATGGGC
TGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGTCCAGCATCGACTGGCACGGG
GAGGTGACCTACTACGCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACAGC
AAGAACACCCTGTACCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCAGTGTACTAC
TGCGCCACCGCCGAGGACGAACCCGGCTACGACTACTGGGGCCAGGGCACCCTGGTGACT
GTGAGCAGC
SEQ ID NO:221:586H-210重链(除去GS)
SEQ ID NO:222:586H-TVAAPS-210重链(除去GS)
SEQ ID NO:223:PascoH-474重链(除去GS)
CAGGTGACCCTGAGGGAGAGCGGCCCCGCCCTGGTGAAGCCCACCCAGACCCTGACCCTG
ACCTGCACCTTCAGCGGCTTTAGCCTCAGCACCTCCGGCATGGGCGTGAGCTGGATCAGG
CAGCCACCCGGCAAAGGCCTGGAGTGGCTGGCCCACATCTACTGGGACGACGACAAGAGG
TACAACCCCAGCCTGAAGAGCCGGCTGACCATCAGCAAGGATACCAGCAGGAACCAGGTG
GTGCTGACCATGACCAACATGGACCCCGTGGACACCGCTACCTACTACTGCGCCAGGAGG
GAGACCGTCTTCTACTGGTACTTCGACGTGTGGGGAAGGGGCACACTAGTGACCGTGTCC
AGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGC
GGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTG
TCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGC
AGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAG
ACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAG
CCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGA
GGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACC
CCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAAC
TGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTAC
AACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGC
AAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATC
AGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGAT
GAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGAC
ATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCT
GTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGA
TGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTAC
ACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAGGGCGTGCAGCTCCTGGAGAGCGGCGGA
GGCCTGGTCCAGCCCGGCGGCAGCCTGAGGCTGAGCTGCGCCGCCAGCGGCTTCACCTTC
GCCTGGTATGATATGGGCTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGTCC
AGCATCGACTGGCACGGGGAGGTGACCTACTACGCCGACAGCGTGAAGGGCAGGTTCACC
ATCAGCAGGGACAACAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTGAGGGCCGAG
GACACCGCAGTGTACTACTGCGCCACCGCCGAGGACGAACCCGGCTACGACTACTGGGGC
CAGGGCACCCTGGTGACTGTGAGCAGC
SEQ ID NO:224:PascoH-TVAAPS-474重链(除去GS)
CAGGTGACCCTGAGGGAGAGCGGCCCCGCCCTGGTGAAGCCCACCCAGACCCTGACCCTG
ACCTGCACCTTCAGCGGCTTTAGCCTCAGCACCTCCGGCATGGGCGTGAGCTGGATCAGG
CAGCCACCCGGCAAAGGCCTGGAGTGGCTGGCCCACATCTACTGGGACGACGACAAGAGG
TACAACCCCAGCCTGAAGAGCCGGCTGACCATCAGCAAGGATACCAGCAGGAACCAGGTG
GTGCTGACCATGACCAACATGGACCCCGTGGACACCGCTACCTACTACTGCGCCAGGAGG
GAGACCGTCTTCTACTGGTACTTCGACGTGTGGGGAAGGGGCACACTAGTGACCGTGTCC
AGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGC
GGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTG
TCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGC
AGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAG
ACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAG
CCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGA
GGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACC
CCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAAC
TGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTAC
AACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGC
AAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATC
AGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGAT
GAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGAC
ATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCT
GTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGA
TGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTAC
ACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAGACCGTGGCCGCCCCCTCGGGCGTGCAG
CTCCTGGAGAGCGGCGGAGGCCTGGTCCAGCCCGGCGGCAGCCTGAGGCTGAGCTGCGCC
GCCAGCGGCTTCACCTTCGCCTGGTATGATATGGGCTGGGTGAGGCAGGCCCCCGGCAAG
GGCCTGGAGTGGGTGTCCAGCATCGACTGGCACGGGGAGGTGACCTACTACGCCGACAGC
GTGAAGGGCAGGTTCACCATCAGCAGGGACAACAGCAAGAACACCCTGTACCTGCAGATG
AACAGCCTGAGGGCCGAGGACACCGCAGTGTACTACTGCGCCACCGCCGAGGACGAACCC
GGCTACGACTACTGGGGCCAGGGCACCCTGGTGACTGTGAGCAGC
SEQ ID NO:225:PascoH-ASTKGPT-474重链(除去第二个GS)
CAGGTGACCCTGAGGGAGAGCGGCCCCGCCCTGGTGAAGCCCACCCAGACCCTGACCCTG
ACCTGCACCTTCAGCGGCTTTAGCCTCAGCACCTCCGGCATGGGCGTGAGCTGGATCAGG
CAGCCACCCGGCAAAGGCCTGGAGTGGCTGGCCCACATCTACTGGGACGACGACAAGAGG
TACAACCCCAGCCTGAAGAGCCGGCTGACCATCAGCAAGGATACCAGCAGGAACCAGGTG
GTGCTGACCATGACCAACATGGACCCCGTGGACACCGCTACCTACTACTGCGCCAGGAGG
GAGACCGTCTTCTACTGGTACTTCGACGTGTGGGGAAGGGGCACACTAGTGACCGTGTCC
AGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGC
GGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTG
TCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGC
AGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAG
ACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAG
CCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGA
GGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACC
CCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAAC
TGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTAC
AACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGC
AAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATC
AGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGAT
GAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGAC
ATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCT
GTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGA
TGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTAC
ACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAGGGATCAGCCAGCACCAAGGGCCCCACG
GGCGTGCAGCTCCTGGAGAGCGGCGGAGGCCTGGTCCAGCCCGGCGGCAGCCTGAGGCTG
AGCTGCGCCGCCAGCGGCTTCACCTTCGCCTGGTATGATATGGGCTGGGTGAGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGGTGTCCAGCATCGACTGGCACGGGGAGGTGACCTACTAC
GCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACAGCAAGAACACCCTGTAC
CTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCAGTGTACTACTGCGCCACCGCCGAG
GACGAACCCGGCTACGACTACTGGGGCCAGGGCACCCTGGTGACTGTGAGCAGC
SEQ ID NO:226:在C-末端用TVAAPSGS接头与DOM15-26-593融合的抗-IGF-1R抗体HOL0的重链
CAGGTGCAGCTGGTGCAGAGCGGAGCCGAGGTGAAGAAGCCTGGCGCCAGCGTCAAGGTGTCCTGCAAGGCCAGCGGCTACACCTTCACCGACTACTACATGAACTGGGTGCGGCAGGCCCCAGGCCAGGGACTGGAATGGATGGGCAACATCAACCCCAACAACGGCGGCACCAACTACAACCAGAAGTTCAAGGACCGGGTCACCATGACCACCGACACCAGCACCAGCACCGCCTACATGGAACTGCGGAGCCTGAGAAGCGACGACACCGCCGTGTACTACTGCGCCCGGTGGATCCTGTACTACGGCCGGTCCAAGTGGTACTTCGACGTGTGGGGCAGGGGCACACTAGTGACCGTGTCCAGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTgTAaCgTgAACcACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAGGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCCCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAGACCGTGGCCGCCCCCTCGGGATCCGAGGTGCAGCTCCTGGTCAGCGGCGGCGGCCTGGTCCAGCCCGGAGGCTCACTGAGGCTGAGCTGCGCCGCTAGCGGCTTCACCTTCAAGGCCTACCCCATGATGTGGGTCAGGCAGGCCCCCGGCAAAGGCCTGGAGTGGGTGTCTGAGATCAGCCCCAGCGGCAGCTACACCTACTACGCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACAGCAAGAACACCCTGTACCTGCAGATGAACTCTCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAAGGACCCCAGGAAGCTGGACTATTGGGGCCAGGGCACTCTGGTGACCGTGAGCAGC
SEQ ID NO:227:IGF1RmAb-GS-DOM15-26-593重链
CAGGTGCAGCTGGTGCAGAGCGGAGCCGAGGTGAAGAAGCCTGGCGCCAGCGTCAAGGTGTCCTGCAAGGCCAGCGGCTACACCTTCACCGACTACTACATGAACTGGGTGCGGCAGGCCCCAGGCCAGGGACTGGAATGGATGGGCAACATCAACCCCAACAACGGCGGCACCAACTACAACCAGAAGTTCAAGGACCGGGTCACCATGACCACCGACACCAGCACCAGCACCGCCTACATGGAACTGCGGAGCCTGAGAAGCGACGACACCGCCGTGTACTACTGCGCCCGGTGGATCCTGTACTACGGCCGGTCCAAGTGGTACTTCGACGTGTGGGGCAGGGGCACACTAGTGACCGTGTCCAGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTgTAaCgTgAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAGGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCCCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAGGGATCCGAGGTGCAGCTCCTGGTCAGCGGCGGCGGCCTGGTCCAGCCCGGAGGCTCACTGAGGCTGAGCTGCGCCGCTAGCGGCTTCACCTTCAAGGCCTACCCCATGATGTGGGTCAGGCAGGCCCCCGGCAAAGGCCTGGAGTGGGTGTCTGAGATCAGCCCCAGCGGCAGCTACACCTACTACGCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACAGCAAGAACACCCTGTACCTGCAGATGAACTCTCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAAGGACCCCAGGAAGCTGGACTATTGGGGCCAGGGCACTCTGGTGACCGTGAGCAGC
SEQ ID NO:228:抗-IGF-1R抗体重链
CAGGTGCAGCTGGTGCAGAGCGGAGCCGAGGTGAAGAAGCCTGGCGCCAGCGTCAAGGTGTCCTGCAAGGCCAGCGGCTACACCTTCACCGACTACTACATGAACTGGGTGCGGCAGGCCCCAGGCCAGGGACTGGAATGGATGGGCAACATCAACCCCAACAACGGCGGCACCAACTACAACCAGAAGTTCAAGGACCGGGTCACCATGACCACCGACACCAGCACCAGCACCGCCTACATGGAACTGCGGAGCCTGAGAAGCGACGACACCGCCGTGTACTACTGCGCCCGGTGGATCCTGTACTACGGCCGGTCCAAGTGGTACTTCGACGTGTGGGGCAGGGGCACACTAGTGACCGTGTCCAGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAGGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCCCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAG
SEQ ID NO:229:用TVAAPSGS接头在C-末端与DOM15-26-593融合的抗-IGF-1R抗体HOL0的轻链
GACATCGTGATGACCCAGAGCCCCCTGAGCCTGCCCGTGACCCCTGGCGAGCCCGCCAGCATCAGCTGCAGAAGCAGCCAGAGCATCGTCCAGAGCAACGGCGACACCTACCTGGAATGGTATCTGCAGAAGCCCGGCCAGTCCCCCCAGCTGCTGATCTACAGAGTGAGCAACCGGTTCAGCGGCGTGCCCGACAGATTCAGCGGCAGCGGCTCCGGCACCGACTTCACCCTGAAGATCAGCCGGGTGGAGGCCGAGGACGTGGGCGTGTACTACTGCTTTCAAGGCAGCCACGTGCCCTACACCTTCGGCCAGGGCACCAAGCTGGAAATCAAGCGTACGGTGGCCGCCCCCAGCGTGTTCATCTTCCCCCCCAGCGATGAGCAGCTGAAGAGCGGCACCGCCAGCGTGGTGTGTCTGCTGAACAACTTCTACCCCCGGGAGGCCAAGGTGCAGTGGAAGGTGGACAATGCCCTGCAGAGCGGCAACAGCCAGGAGAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCTGACCCTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGTGAGGTGACCCACCAGGGCCTGTCCAGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGCACCGTGGCCGCCCCCTCGGGATCCGAGGTGCAGCTCCTGGTCAGCGGCGGCGGCCTGGTCCAGCCCGGAGGCTCACTGAGGCTGAGCTGCGCCGCTAGCGGCTTCACCTTCAAGGCCTACCCCATGATGTGGGTCAGGCAGGCCCCCGGCAAAGGCCTGGAGTGGGTGTCTGAGATCAGCCCCAGCGGCAGCTACACCTACTACGCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACAGCAAGAACACCCTGTACCTGCAGATGAACTCTCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAAGGACCCCAGGAAGCTGGACTATTGGGGCCAGGGCACTCTGGTGACCGTGAGCAGC
SEQ ID NO:230:用GS接头在C-末端与DOM15-26-593融合的抗-IGF-1R抗体HOL0的轻链
GACATCGTGATGACCCAGAGCCCCCTGAGCCTGCCCGTGACCCCTGGCGAGCCCGCCAGCATCAGCTGCAGAAGCAGCCAGAGCATCGTCCAGAGCAACGGCGACACCTACCTGGAATGGTATCTGCAGAAGCCCGGCCAGTCCCCCCAGCTGCTGATCTACAGAGTGAGCAACCGGTTCAGCGGCGTGCCCGACAGATTCAGCGGCAGCGGCTCCGGCACCGACTTCACCCTGAAGATCAGCCGGGTGGAGGCCGAGGACGTGGGCGTGTACTACTGCTTTCAAGGCAGCCACGTGCCCTACACCTTCGGCCAGGGCACCAAGCTGGAAATCAAGCGTACGGTGGCCGCCCCCAGCGTGTTCATCTTCCCCCCCAGCGATGAGCAGCTGAAGAGCGGCACCGCCAGCGTGGTGTGTCTGCTGAACAACTTCTACCCCCGGGAGGCCAAGGTGCAGTGGAAGGTGGACAATGCCCTGCAGAGCGGCAACAGCCAGGAGAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCTGACCCTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGTGAGGTGACCCACCAGGGCCTGTCCAGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGTGGATCCGAGGTGCAGCTCCTGGTCAGCGGCGGCGGCCTGGTCCAGCCCGGAGGCTCACTGAGGCTGAGCTGCGCCGCTAGCGGCTTCACCTTCAAGGCCTACCCCATGATGTGGGTCAGGCAGGCCCCCGGCAAAGGCCTGGAGTGGGTGTCTGAGATCAGCCCCAGCGGCAGCTACACCTACTACGCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACAGCAAGAACACCCTGTACCTGCAGATGAACTCTCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAAGGACCCCAGGAAGCTGGACTATTGGGGCCAGGGCACTCTGGTGACCGTGAGCAGC
SEQ ID NO:231:抗-IGF-1R抗体轻链
GACATCGTGATGACCCAGAGCCCCCTGAGCCTGCCCGTGACCCCTGGCGAGCCCGCCAGCATCAGCTGCAGAAGCAGCCAGAGCATCGTCCAGAGCAACGGCGACACCTACCTGGAATGGTATCTGCAGAAGCCCGGCCAGTCCCCCCAGCTGCTGATCTACAGAGTGAGCAACCGGTTCAGCGGCGTGCCCGACAGATTCAGCGGCAGCGGCTCCGGCACCGACTTCACCCTGAAGATCAGCCGGGTGGAGGCCGAGGACGTGGGCGTGTACTACTGCTTTCAAGGCAGCCACGTGCCCTACACCTTCGGCCAGGGCACCAAGCTGGAAATCAAGCGTACGGTGGCCGCCCCCAGCGTGTTCATCTTCCCCCCCAGCGATGAGCAGCTGAAGAGCGGCACCGCCAGCGTGGTGTGTCTGCTGAACAACTTCTACCCCCGGGAGGCCAAGGTGCAGTGGAAGGTGGACAATGCCCTGCAGAGCGGCAACAGCCAGGAGAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCTGACCCTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGTGAGGTGACCCACCAGGGCCTGTCCAGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGC
SEQ ID NO:232:抗-IGF 1R重链-GS-TLPC
CAGGTGCAGCTGGTGCAGAGCGGAGCCGAGGTGAAGAAGCCTGGCGCCAGCGTCAAGGTGTCCTGCAAGGCCAGCGGCTACACCTTCACCGACTACTACATGAACTGGGTGCGGCAGGCCCCAGGCCAGGGACTGGAATGGATGGGCAACATCAACCCCAACAACGGCGGCACCAACTACAACCAGAAGTTCAAGGACCGGGTCACCATGACCACCGACACCAGCACCAGCACCGCCTACATGGAACTGCGGAGCCTGAGAAGCGACGACACCGCCGTGTACTACTGCGCCCGGTGGATCCTGTACTACGGCCGGTCCAAGTGGTACTTCGACGTGTGGGGCAGGGGCACACTAGTGACCGTGTCCAGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAGGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCCCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAGGGATCCGACGGCGGCGGCATTAGGAGGAGCATGAGCGGCACCTGGTACCTGAAGGCCATGACCGTGGATAGGGAGTTCCCCGAGATGAACCTGGAGAGCGTGACCCCCATGACACTGACCCTGCTCAAGGGCCACAACCTGGAGGCCAAGGTCACCATGCTGATCTCAGGCAGGTGCCAGGAGGTGAAGGCAGTGCTGGGCAGGACCAAGGAGAGGAAGAAGTACACCGCCGACGGGGGCAAGCACGTGGCCTATATCATCCCCAGCGCCGTGAGGGACCACGTGATCTTCTACAGCGAGGGCCAGCTCCACGGAAAGCCCGTGAGAGGCGTGAAGCTGGTGGGCAGGGACCCCAAGAACAACCTGGAGGCCCTGGAGGACTTCGAAAAAGCCGCAGGCGCCAGGGGCCTGTCCACTGAGAGCATCCTGATCCCTAGGCAGAGCGAGACCTGCAGCCCCGGC
SEQ ID NO:233:抗-IGF1R重链-GS-CT01 adnectin
CAGGTGCAGCTGGTGCAGAGCGGAGCCGAGGTGAAGAAGCCTGGCGCCAGCGTCAAGGTGTCCTGCAAGGCCAGCGGCTACACCTTCACCGACTACTACATGAACTGGGTGCGGCAGGCCCCAGGCCAGGGACTGGAATGGATGGGCAACATCAACCCCAACAACGGCGGCACCAACTACAACCAGAAGTTCAAGGACCGGGTCACCATGACCACCGACACCAGCACCAGCACCGCCTACATGGAACTGCGGAGCCTGAGAAGCGACGACACCGCCGTGTACTACTGCGCCCGGTGGATCCTGTACTACGGCCGGTCCAAGTGGTACTTCGACGTGTGGGGCAGGGGCACACTAGTGACCGTGTCCAGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAGGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCCCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAGGGATCCGAGGTGGTGGCCGCCACCCCCACCAGCCTGCTGATTTCCTGGAGGCACCCCCACTTCCCCACACGCTACTACAGGATCACCTACGGCGAGACCGGCGGCAACAGCCCCGTGCAGGAGTTCACCGTGCCCCTGCAGCCTCCCACTGCCACCATCAGCGGCCTCAAGCCCGGCGTGGACTACACCATCACCGTGTACGCCGTCACCGACGGAAGGAACGGCAGGCTGCTGAGCATCCCCATCAGCATCAACTACAGGACC
SEQ ID NO:234:抗-IGF 1R重链-TVAAPSGS-TLPC
CAGGTGCAGCTGGTGCAGAGCGGAGCCGAGGTGAAGAAGCCTGGCGCCAGCGTCAAGGTGTCCTGCAAGGCCAGCGGCTACACCTTCACCGACTACTACATGAACTGGGTGCGGCAGGCCCCAGGCCAGGGACTGGAATGGATGGGCAACATCAACCCCAACAACGGCGGCACCAACTACAACCAGAAGTTCAAGGACCGGGTCACCATGACCACCGACACCAGCACCAGCACCGCCTACATGGAACTGCGGAGCCTGAGAAGCGACGACACCGCCGTGTACTACTGCGCCCGGTGGATCCTGTACTACGGCCGGTCCAAGTGGTACTTCGACGTGTGGGGCAGGGGCACACTAGTGACCGTGTCCAGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAGGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCCCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAGACCGTGGCCGCCCCCTCGGGATCCGACGGCGGCGGCATTAGGAGGAGCATGAGCGGCACCTGGTACCTGAAGGCCATGACCGTGGATAGGGAGTTCCCCGAGATGAACCTGGAGAGCGTGACCCCCATGACACTGACCCTGCTCAAGGGCCACAACCTGGAGGCCAAGGTCACCATGCTGATCTCAGGCAGGTGCCAGGAGGTGAAGGCAGTGCTGGGCAGGACCAAGGAGAGGAAGAAGTACACCGCCGACGGGGGCAAGCACGTGGCCTATATCATCCCCAGCGCCGTGAGGGACCACGTGATCTTCTACAGCGAGGGCCAGCTCCACGGAAAGCCCGTGAGAGGCGTGAAGCTGGTGGGCAGGGACCCCAAGAACAACCTGGAGGCCCTGGAGGACTTCGAAAAAGCCGCAGGCGCCAGGGGCCTGTCCACTGAGAGCATCCTGATCCCTAGGCAGAGCGAGACCTGCAGCCCCGGC
SEQ ID NO:235:抗-IGF1R重链-GS-AFFI
CAGGTGCAGCTGGTGCAGAGCGGAGCCGAGGTGAAGAAGCCTGGCGCCAGCGTCAAGGTGTCCTGCAAGGCCAGCGGCTACACCTTCACCGACTACTACATGAACTGGGTGCGGCAGGCCCCAGGCCAGGGACTGGAATGGATGGGCAACATCAACCCCAACAACGGCGGCACCAACTACAACCAGAAGTTCAAGGACCGGGTCACCATGACCACCGACACCAGCACCAGCACCGCCTACATGGAACTGCGGAGCCTGAGAAGCGACGACACCGCCGTGTACTACTGCGCCCGGTGGATCCTGTACTACGGCCGGTCCAAGTGGTACTTCGACGTGTGGGGCAGGGGCACACTAGTGACCGTGTCCAGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAGGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCCCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAGGGATCCGTGGACAACAAGTTCAACAAGGAGCTGAGGCAGGCCTACTGGGAGATCCAGGCCCTGCCCAATCTGAACTGGACCCAGAGCAGGGCCTTCATCAGGAGCCTGTACGACGACCCCAGCCAGAGCGCTAACCTCCTGGCCGAGGCCAAAAAGCTGAACGACGCCCAGGCCCCCAAG
SEQ ID NO:236:抗-IGF1R重链-TVAAPSGS-AFFI
CAGGTGCAGCTGGTGCAGAGCGGAGCCGAGGTGAAGAAGCCTGGCGCCAGCGTCAAGGTGTCCTGCAAGGCCAGCGGCTACACCTTCACCGACTACTACATGAACTGGGTGCGGCAGGCCCCAGGCCAGGGACTGGAATGGATGGGCAACATCAACCCCAACAACGGCGGCACCAACTACAACCAGAAGTTCAAGGACCGGGTCACCATGACCACCGACACCAGCACCAGCACCGCCTACATGGAACTGCGGAGCCTGAGAAGCGACGACACCGCCGTGTACTACTGCGCCCGGTGGATCCTGTACTACGGCCGGTCCAAGTGGTACTTCGACGTGTGGGGCAGGGGCACACTAGTGACCGTGTCCAGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAGGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCCCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAGACCGTGGCCGCCCCCTCGGGATCCGTGGACAACAAGTTCAACAAGGAGCTGAGGCAGGCCTACTGGGAGATCCAGGCCCTGCCCAATCTGAACTGGACCCAGAGCAGGGCCTTCATCAGGAGCCTGTACGACGACCCCAGCCAGAGCGCTAACCTCCTGGCCGAGGCCAAAAAGCTGAACGACGCCCAGGCCCCCAAG
SEQ ID NO:237:抗-IGF1R重链-GS-DRPN
CAGGTGCAGCTGGTGCAGAGCGGAGCCGAGGTGAAGAAGCCTGGCGCCAGCGTCAAGGTGTCCTGCAAGGCCAGCGGCTACACCTTCACCGACTACTACATGAACTGGGTGCGGCAGGCCCCAGGCCAGGGACTGGAATGGATGGGCAACATCAACCCCAACAACGGCGGCACCAACTACAACCAGAAGTTCAAGGACCGGGTCACCATGACCACCGACACCAGCACCAGCACCGCCTACATGGAACTGCGGAGCCTGAGAAGCGACGACACCGCCGTGTACTACTGCGCCCGGTGGATCCTGTACTACGGCCGGTCCAAGTGGTACTTCGACGTGTGGGGCAGGGGCACACTAGTGACCGTGTCCAGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAGGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCCCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAGGGATCCGACCTGGGGAAAAAGCTGCTTGAAGCCGCTAGGGCAGGACAGGATGACGAGGTGAGGATTCTGATGGCAAATGGCGCCGACGTCAATGCCAAAGACGAGTACGGCCTCACCCCTCTTTATCTGGCCACTGCACACGGACACTTGGAGATCGTGGAGGTGCTGCTCAAGAACGGAGCTGATGTGAACGCTGTGGACGCTATTGGGTTCACACCCCTTCACCTCGCAGCCTTTATTGGCCACCTGGAGATCGCCGAAGTTCTCCTGAAACACGGCGCAGACGTCAACGCACAGGATAAGTTCGGGAAGACCGCCTTCGACATCAGCATCGGCAATGGGAACGAGGATCTGGCCGAGATCCTGCAGAAGCTG
SEQ ID NO:238:抗-IGF1R重链-TVAAPSGS-DRPN
CAGGTGCAGCTGGTGCAGAGCGGAGCCGAGGTGAAGAAGCCTGGCGCCAGCGTCAAGGTGTCCTGCAAGGCCAGCGGCTACACCTTCACCGACTACTACATGAACTGGGTGCGGCAGGCCCCAGGCCAGGGACTGGAATGGATGGGCAACATCAACCCCAACAACGGCGGCACCAACTACAACCAGAAGTTCAAGGACCGGGTCACCATGACCACCGACACCAGCACCAGCACCGCCTACATGGAACTGCGGAGCCTGAGAAGCGACGACACCGCCGTGTACTACTGCGCCCGGTGGATCCTGTACTACGGCCGGTCCAAGTGGTACTTCGACGTGTGGGGCAGGGGCACACTAGTGACCGTGTCCAGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAGGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCCCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAGACCGTGGCCGCCCCCTCGGGATCCGACCTGGGGAAAAAGCTGCTTGAAGCCGCTAGGGCAGGACAGGATGACGAGGTGAGGATTCTGATGGCAAATGGCGCCGACGTCAATGCCAAAGACGAGTACGGCCTCACCCCTCTTTATCTGGCCACTGCACACGGACACTTGGAGATCGTGGAGGTGCTGCTCAAGAACGGAGCTGATGTGAACGCTGTGGACGCTATTGGGTTCACACCCCTTCACCTCGCAGCCTTTATTGGCCACCTGGAGATCGCCGAAGTTCTCCTGAAACACGGCGCAGACGTCAACGCACAGGATAAGTTCGGGAAGACCGCCTTCGACATCAGCATCGGCAATGGGAACGAGGATCTGGCCGAGATCCTGCAGAAGCTG
SEQ ID NO:239:抗IL-4重链-GS-抗RNA酶A骆驼VHH
CAGGTGACCCTGAGGGAGAGCGGCCCCGCCCTGGTGAAGCCCACCCAGACCCTGACCCTGACCTGCACCTTCAGCGGCTTTAGCCTCAGCACCTCCGGCATGGGCGTGAGCTGGATCAGGCAGCCACCCGGCAAAGGCCTGGAGTGGCTGGCCCACATCTACTGGGACGACGACAAGAGGTACAACCCCAGCCTGAAGAGCCGGCTGACCATCAGCAAGGATACCAGCAGGAACCAGGTGGTGCTGACCATGACCAACATGGACCCCGTGGACACCGCTACCTACTACTGCGCCAGGAGGGAGACCGTCTTCTACTGGTACTTCGACGTGTGGGGAAGGGGCACACTAGTGACCGTGTCCAGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAGGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCCCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAGGGATCCCAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTGCAGGCTGGGGGGTCTCTGAGACTCTCCTGTGCAGCCTCTGGATACGCATACACTTACATCTACATGGGCTGGTTCCGCCAGGCTCCAGGGAAAGAGCGTGAGGGGGTCGCAGCTATGGATAGTGGTGGTGGTGGCACACTCTACGCCGACTCCGTGAAGGGCCGATTCACCATCTCCCGCGACAAAGGCAAGAACACGGTGTATCTGCAAATGGACAGCCTGAAACCTGAGGACACGGCCACGTATTACTGTGCTGCAGGTGGCTACGAGCTGCGTGACCGGACATATGGGCAGTGGGGCCAGGGGACCCAGGTCACCGTCTCCTCA
SEQ ID NO:240:抗IL-4重链-GS-NARV
CAGGTGACCCTGAGGGAGAGCGGCCCCGCCCTGGTGAAGCCCACCCAGACCCTGACCCTGACCTGCACCTTCAGCGGCTTTAGCCTCAGCACCTCCGGCATGGGCGTGAGCTGGATCAGGCAGCCACCCGGCAAAGGCCTGGAGTGGCTGGCCCACATCTACTGGGACGACGACAAGAGGTACAACCCCAGCCTGAAGAGCCGGCTGACCATCAGCAAGGATACCAGCAGGAACCAGGTGGTGCTGACCATGACCAACATGGACCCCGTGGACACCGCTACCTACTACTGCGCCAGGAGGGAGACCGTCTTCTACTGGTACTTCGACGTGTGGGGAAGGGGCACACTAGTGACCGTGTCCAGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAGGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCCCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAGGGATCCGCGCGCGTCGACCAGACGCCGCGCAGCGTCACGAAGGAAACCGGCGAGTCCCTCACCATCAACTGCGTGCTGCGGGATGCCTCCTACGCCCTGGGCAGCACATGTTGGTACAGAAAGAAGAGCGGGGAAGGCAACGAGGAGTCCATCTCCAAGGGGGGAAGATACGTCGAGACCGTGAACAGCGGAAGCAAGAGCTTCAGCCTGCGGATCAACGACCTCACCGTCGAGGACGGGGGCACCTACCGTTGCGGTCTGGGCGTGGCCGGCGGCTATTGCGATTACGCCCTGTGCAGTAGCCGGTATGCTGAGTGCGGCGACGGCACCGCTGTGACCGTGAAC
SEQ ID NO:241:抗-IGF1R重链-TVAAPSGS-CT01 adnectin
CAGGTGCAGCTGGTGCAGAGCGGAGCCGAGGTGAAGAAGCCTGGCGCCAGCGTCAAGGTGTCCTGCAAGGCCAGCGGCTACACCTTCACCGACTACTACATGAACTGGGTGCGGCAGGCCCCAGGCCAGGGACTGGAATGGATGGGCAACATCAACCCCAACAACGGCGGCACCAACTACAACCAGAAGTTCAAGGACCGGGTCACCATGACCACCGACACCAGCACCAGCACCGCCTACATGGAACTGCGGAGCCTGAGAAGCGACGACACCGCCGTGTACTACTGCGCCCGGTGGATCCTGTACTACGGCCGGTCCAAGTGGTACTTCGACGTGTGGGGCAGGGGCACACTAGTGACCGTGTCCAGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAGGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCCCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAGACCGTGGCCGCCCCCTCGGGATCCGAGGTGGTGGCCGCCACCCCCACCAGCCTGCTGATTTCCTGGAGGCACCCCCACTTCCCCACACGCTACTACAGGATCACCTACGGCGAGACCGGCGGCAACAGCCCCGTGCAGGAGTTCACCGTGCCCCTGCAGCCTCCCACTGCCACCATCAGCGGCCTCAAGCCCGGCGTGGACTACACCATCACCGTGTACGCCGTCACCGACGGAAGGAACGGCAGGCTGCTGAGCATCCCCATCAGCATCAACTACAGGACC
SEQ ID NO:242:爱必妥重链-RS-CT01 adnectin
CAGGTGCAGCTGAAGCAGAGCGGCCCTGGCCTGGTGCAGCCCTCTCAGAGCCTGAGCATCACCTGTACCGTGAGCGGCTTCAGCCTGACCAATTACGGCGTGCATTGGGTGCGGCAGTCTCCAGGCAAGGGCCTGGAATGGCTGGGAGTGATCTGGTCCGGCGGCAACACCGACTACAACACCCCCTTCACCAGCAGACTGAGCATCAACAAGGACAACAGCAAGAGCCAGGTGTTCTTCAAGATGAACAGCCTGCAGAGCAACGACACCGCCATCTACTATTGTGCCAGGGCCCTGACCTACTACGACTACGAGTTCGCCTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCGCCGCTAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAGCCTGTGACCGTGTCCTGGAATAGCGGAGCCCTGACCTCCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACTCCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGCAACGTGAACCACAAGCCCAGCAACACCAAAGTGGACAAGAAAGTGGAGCCCAAGAGCTGCGATAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGCGGACCTAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGAGCCACGAGGACCCTGAAGTGAAGTTCAACTGGTACGTGGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCCAGAGAGGAGCAGTACAACAGCACCTACCGCGTGGTGTCTGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGCAAAGTGAGCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCTAGAGAGCCCCAGGTCTACACCCTGCCTCCCTCCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGTCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACTCCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCAGCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGTCTGAGCCTGTCTCCTGGCAAGAGATCCGAGGTGGTGGCCGCCACCCCCACCAGCCTGCTGATTTCCTGGAGGCACCCCCACTTCCCCACACGCTACTACAGGATCACCTACGGCGAGACCGGCGGCAACAGCCCCGTGCAGGAGTTCACCGTGCCCCTGCAGCCTCCCACTGCCACCATCAGCGGCCTCAAGCCCGGCGTGGACTACACCATCACCGTGTACGCCGTCACCGACGGAAGGAACGGCAGGCTGCTGAGCATCCCCATCAGCATCAACTACAGGACC
SEQ ID NO:243:爱必妥轻链
GACATCCTGCTGACCCAGAGCCCCGTGATCCTGAGCGTGAGCCCTGGCGAGAGAGTGAGCTTCAGCTGCCGGGCCAGCCAGAGCATCGGCACCAACATCCACTGGTATCAGCAGCGGACCAACGGCAGCCCCAGGCTGCTGATCAAGTACGCCAGCGAGTCCATCAGCGGCATCCCCAGCCGGTTCAGCGGCAGCGGCTCCGGCACCGACTTCACCCTGAGCATCAACAGCGTGGAGAGCGAGGATATCGCCGACTACTACTGCCAGCAGAACAACAACTGGCCCACCACCTTCGGAGCCGGCACCAAGCTGGAACTGAAGCGTACGGTGGCCGCCCCCAGCGTGTTCATCTTCCCCCCCAGCGATGAGCAGCTCAAGAGCGGCACCGCCAGCGTGGTGTGTCTGCTGAACAACTTCTACCCCCGGGAGGCCAAAGTGCAGTGGAAAGTGGACAACGCCCTGCAGAGCGGCAACAGCCAGGAGAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCTGACCCTGAGCAAGGCCGACTACGAGAAGCACAAAGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCCAGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGC
SEQ ID NO:244:爱必妥轻链-RS-CT01 adnectin
GACATCCTGCTGACCCAGAGCCCCGTGATCCTGAGCGTGAGCCCTGGCGAGAGAGTGAGCTTCAGCTGCCGGGCCAGCCAGAGCATCGGCACCAACATCCACTGGTATCAGCAGCGGACCAACGGCAGCCCCAGGCTGCTGATCAAGTACGCCAGCGAGTCCATCAGCGGCATCCCCAGCCGGTTCAGCGGCAGCGGCTCCGGCACCGACTTCACCCTGAGCATCAACAGCGTGGAGAGCGAGGATATCGCCGACTACTACTGCCAGCAGAACAACAACTGGCCCACCACCTTCGGAGCCGGCACCAAGCTGGAACTGAAGCGTACGGTGGCCGCCCCCAGCGTGTTCATCTTCCCCCCCAGCGATGAGCAGCTCAAGAGCGGCACCGCCAGCGTGGTGTGTCTGCTGAACAACTTCTACCCCCGGGAGGCCAAAGTGCAGTGGAAAGTGGACAACGCCCTGCAGAGCGGCAACAGCCAGGAGAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCTGACCCTGAGCAAGGCCGACTACGAGAAGCACAAAGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCCAGCCCCGTGACCAAGAGCTTCAACCGAGGCGAGTGCAGATCCGAGGTGGTGGCCGCCACCCCCACCAGCCTGCTGATTTCCTGGAGGCACCCCCACTTCCCCACACGCTACTACAGGATCACCTACGGCGAGACCGGCGGCAACAGCCCCGTGCAGGAGTTCACCGTGCCCCTGCAGCCTCCCACTGCCACCATCAGCGGCCTCAAGCCCGGCGTGGACTACACCATCACCGTGTACGCCGTCACCGACGGAAGGAACGGCAGGCTGCTGAGCATCCCCATCAGCATCAACTACAGGACC
SEQ ID NO:245:爱必妥重链
CAGGTGCAGCTGAAGCAGAGCGGCCCTGGCCTGGTGCAGCCCTCTCAGAGCCTGAGCATCACCTGTACCGTGAGCGGCTTCAGCCTGACCAATTACGGCGTGCATTGGGTGCGGCAGTCTCCAGGCAAGGGCCTGGAATGGCTGGGAGTGATCTGGTCCGGCGGCAACACCGACTACAACACCCCCTTCACCAGCAGACTGAGCATCAACAAGGACAACAGCAAGAGCCAGGTGTTCTTCAAGATGAACAGCCTGCAGAGCAACGACACCGCCATCTACTATTGTGCCAGGGCCCTGACCTACTACGACTACGAGTTCGCCTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCGCCGCTAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAGCCTGTGACCGTGTCCTGGAATAGCGGAGCCCTGACCTCCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACTCCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGCAACGTGAACCACAAGCCCAGCAACACCAAAGTGGACAAGAAAGTGGAGCCCAAGAGCTGCGATAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGCGGACCTAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGAGCCACGAGGACCCTGAAGTGAAGTTCAACTGGTACGTGGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCCAGAGAGGAGCAGTACAACAGCACCTACCGCGTGGTGTCTGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGCAAAGTGAGCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCTAGAGAGCCCCAGGTCTACACCCTGCCTCCCTCCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGTCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACTCCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCAGCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGTCTGAGCCTGTCCCCTGGCAAG
SEQ ID NO:246:CT01 adnectin-GSTG-爱必妥重链
GAGGTGGTGGCCGCCACCCCCACCAGCCTGCTGATTTCCTGGAGGCACCCCCACTTCCCCACACGCTACTACAGGATCACCTACGGCGAGACCGGCGGCAACAGCCCCGTGCAGGAGTTCACCGTGCCCCTGCAGCCTCCCACTGCCACCATCAGCGGCCTCAAGCCCGGCGTGGACTACACCATCACCGTGTACGCCGTCACCGACGGAAGGAACGGCAGGCTGCTGAGCATCCCCATCAGCATCAACTACAGGACCGGATCCACCGGCCAGGTGCAGCTGAAGCAGAGCGGCCCTGGCCTGGTGCAGCCCTCTCAGAGCCTGAGCATCACCTGTACCGTGAGCGGCTTCAGCCTGACCAATTACGGCGTGCATTGGGTGCGGCAGTCTCCAGGCAAGGGCCTGGAATGGCTGGGAGTGATCTGGTCCGGCGGCAACACCGACTACAACACCCCCTTCACCAGCAGACTGAGCATCAACAAGGACAACAGCAAGAGCCAGGTGTTCTTCAAGATGAACAGCCTGCAGAGCAACGACACCGCCATCTACTATTGTGCCAGGGCCCTGACCTACTACGACTACGAGTTCGCCTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCGCCGCTAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAGCCTGTGACCGTGTCCTGGAATAGCGGAGCCCTGACCTCCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACTCCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGCAACGTGAACCACAAGCCCAGCAACACCAAAGTGGACAAGAAAGTGGAGCCCAAGAGCTGCGATAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGCGGACCTAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGAGCCACGAGGACCCTGAAGTGAAGTTCAACTGGTACGTGGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCCAGAGAGGAGCAGTACAACAGCACCTACCGCGTGGTGTCTGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGCAAAGTGAGCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCTAGAGAGCCCCAGGTCTACACCCTGCCTCCCTCCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGTCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACTCCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCAGCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGTCTGAGCCTGTCCCCTGGCAAG
SEQ ID NO:247:CT01 adnectin-STG-爱必妥轻链
GAGGTGGTGGCCGCCACCCCCACCAGCCTGCTGATTTCCTGGAGGCACCCCCACTTCCCCACACGCTACTACAGGATCACCTACGGCGAGACCGGCGGCAACAGCCCCGTGCAGGAGTTCACCGTGCCCCTGCAGCCTCCCACTGCCACCATCAGCGGCCTCAAGCCCGGCGTGGACTACACCATCACCGTGTACGCCGTCACCGACGGAAGGAACGGCAGGCTGCTGAGCATCCCCATCAGCATCAACTACAGGACGTCGACCGGTGACATCCTGCTGACCCAGAGCCCCGTGATCCTGAGCGTGAGCCCTGGCGAGAGAGTGAGCTTCAGCTGCCGGGCCAGCCAGAGCATCGGCACCAACATCCACTGGTATCAGCAGCGGACCAACGGCAGCCCCAGGCTGCTGATCAAGTACGCCAGCGAGTCCATCAGCGGCATCCCCAGCCGGTTCAGCGGCAGCGGCTCCGGCACCGACTTCACCCTGAGCATCAACAGCGTGGAGAGCGAGGATATCGCCGACTACTACTGCCAGCAGAACAACAACTGGCCCACCACCTTCGGAGCCGGCACCAAGCTGGAACTGAAGCGTACGGTGGCCGCCCCCAGCGTGTTCATCTTCCCCCCCAGCGATGAGCAGCTCAAGAGCGGCACCGCCAGCGTGGTGTGTCTGCTGAACAACTTCTACCCCCGGGAGGCCAAAGTGCAGTGGAAAGTGGACAACGCCCTGCAGAGCGGCAACAGCCAGGAGAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCTGACCCTGAGCAAGGCCGACTACGAGAAGCACAAAGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCCAGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGC
SEQ ID NO:248(PascoH-616重链)
CAGGTGACCCTGAGGGAGAGCGGCCCCGCCCTGGTGAAGCCCACCCAGACCCTGACCCTG
ACCTGCACCTTCAGCGGCTTTAGCCTCAGCACCTCCGGCATGGGCGTGAGCTGGATCAGG
CAGCCACCCGGCAAAGGCCTGGAGTGGCTGGCCCACATCTACTGGGACGACGACAAGAGG
TACAACCCCAGCCTGAAGAGCCGGCTGACCATCAGCAAGGATACCAGCAGGAACCAGGTG
GTGCTGACCATGACCAACATGGACCCCGTGGACACCGCTACCTACTACTGCGCCAGGAGG
GAGACCGTCTTCTACTGGTACTTCGACGTGTGGGGAAGGGGCACACTAGTGACCGTGTCC
AGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGC
GGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTG
TCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGC
AGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAG
ACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAG
CCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGA
GGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACC
CCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAAC
TGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTAC
AACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGC
AAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATC
AGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGAT
GAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGAC
ATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCT
GTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGA
TGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTAC
ACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAGGGCGTGCAGCTCCTGGAGAGCGGCGGA
GGCCTGGTCCAGCCCGGCGGCAGCCTGAGGCTGAGCTGCGCCGCCAGCGGCTTCGTGTTC
CCCTGGTATGATATGGGCTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGTCC
AGCATCGACTGGCACGGGAAGATCACCTACTACGCCGACAGCGTGAAGGGCAGGTTCACC
ATCAGCAGGGACAACAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTGAGGGCCGAG
GACACCGCAGTGTACTACTGCGCCACCGCCGAGGACGAACCCGGCTACGACTACTGGGGC
CAGGGCACCCTGGTGACTGTGAGCAGC
SEQ ID NO:249(PascoH-TVAAPS-616重链)
CAGGTGACCCTGAGGGAGAGCGGCCCCGCCCTGGTGAAGCCCACCCAGACCCTGACCCTG
ACCTGCACCTTCAGCGGCTTTAGCCTCAGCACCTCCGGCATGGGCGTGAGCTGGATCAGG
CAGCCACCCGGCAAAGGCCTGGAGTGGCTGGCCCACATCTACTGGGACGACGACAAGAGG
TACAACCCCAGCCTGAAGAGCCGGCTGACCATCAGCAAGGATACCAGCAGGAACCAGGTG
GTGCTGACCATGACCAACATGGACCCCGTGGACACCGCTACCTACTACTGCGCCAGGAGG
GAGACCGTCTTCTACTGGTACTTCGACGTGTGGGGAAGGGGCACACTAGTGACCGTGTCC
AGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGC
GGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTG
TCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGC
AGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAG
ACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAG
CCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGA
GGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACC
CCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAAC
TGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTAC
AACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGC
AAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATC
AGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGAT
GAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGAC
ATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCT
GTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGA
TGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTAC
ACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAGACCGTGGCCGCCCCCTCGGGCGTGCAG
CTCCTGGAGAGCGGCGGAGGCCTGGTCCAGCCCGGCGGCAGCCTGAGGCTGAGCTGCGCC
GCCAGCGGCTTCGTGTTCCCCTGGTATGATATGGGCTGGGTGAGGCAGGCCCCCGGCAAG
GGCCTGGAGTGGGTGTCCAGCATCGACTGGCACGGGAAGATCACCTACTACGCCGACAGC
GTGAAGGGCAGGTTCACCATCAGCAGGGACAACAGCAAGAACACCCTGTACCTGCAGATG
AACAGCCTGAGGGCCGAGGACACCGCAGTGTACTACTGCGCCACCGCCGAGGACGAACCC
GGCTACGACTACTGGGGCCAGGGCACCCTGGTGACTGTGAGCAGC
SEQ ID NO:250:656H-TVAAPS-210重链
CAGGTGCAGCTCGTCCAGTCTGGGGCCGAGGTGAAGAAGCCCGGAGCTTCTGTGAAGGTGTCCTGCAAGGCCAGCGGCTATACCTTCATCGACTACGAGATCCATTGGGTGAGGCAGGCTCCCGGGCAGGGCCTGGAGTGGATGGGCGCCATCGACCCAGAGACCGGAGGCACGGCGTACAACCAGAAGTTCAAGGGACGGGTCACCATGACAACCGATACCAGCACCTCCACCGCTTACATGGAGCTGCGCAGCCTGAGAAGCGACGACACCGCGGTGTACTACTGTACGCGCATCCTGCTCTACTACTACCCCATGGATTACTGGGGCCAGGGCACACTAGTGACCGTGTCTAGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCAcCCAGACCTACATCTgTAACgTgAACCACAaGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAGGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCCCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAGACCGTGGCCGCCCCCTCGGAAGTGCAGCTCCTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTGAGCTGCGCCGCTAGCGGCTTCACCTTCAGGAACTTCGGCATGGGCTGGGTCAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTCAGCTGGATCATCAGCTCCGGCACCGAGACCTACTACGCCGACAGCGTGAAGGGCAGGTTCACCATCAGCCGCGACAACAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTCTACTACTGCGCCAAGAGCCTGGGCAGGTTCGACTACTGGGGACAGGGGACCCTGGTGACTGTGAGCAGC
SEQ ID NO:251:656轻链
GAGATCGTGCTGACCCAGAGTCCAGCCACCCTCAGCCTGAGCCCTGGGGAACGCGCCACCCTGTCCTGCCGGGCGAGTCAGAACATCTCCGACTACCTGCATTGGTACCAGCAGAAGCCCGGCCAGGCCCCTCGCCTGCTGATCTACTACGCCTCCCAGAGCATCAGCGGAATCCCCGCCCGGTTCTCCGGAAGTGGGTCCGGAACCGACTTTACCCTGACCATCAGCTCTCTCGAGCCAGAGGACTTCGCGGTGTACTACTGCCAGAACGGGCATAGTTTCCCACTGACCTTCGGAGGGGGCACAAAGGTGGAGATCAAGCGTACGGTGGCCGCCCCCAGCGTGTTCATCTTCCCCCCCAGCGATGAGCAGCTGAAGAGCGGCACCGCCAGCGTGGTGTGTCTGCTGAACAACTTCTACCCCCGGGAGGCCAAGGTGCAGTGGAAGGTGGACAATGCCCTGCAGAGCGGCAACAGCCAGGAGAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCTGACCCTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGTGAGGTGACCCACCAGGGCCTGTCCAGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGC
SEQ ID NO:252:PascoH-TVAAPS-546_重链
CAGGTGACCCTGAGGGAGAGCGGCCCCGCCCTGGTGAAGCCCACCCAGACCCTGACCCTG
ACCTGCACCTTCAGCGGCTTTAGCCTCAGCACCTCCGGCATGGGCGTGAGCTGGATCAGG
CAGCCACCCGGCAAAGGCCTGGAGTGGCTGGCCCACATCTACTGGGACGACGACAAGAGG
TACAACCCCAGCCTGAAGAGCCGGCTGACCATCAGCAAGGATACCAGCAGGAACCAGGTG
GTGCTGACCATGACCAACATGGACCCCGTGGACACCGCTACCTACTACTGCGCCAGGAGG
GAGACCGTCTTCTACTGGTACTTCGACGTGTGGGGAAGGGGCACACTAGTGACCGTGTCC
AGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGC
GGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTG
TCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGC
AGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAG
ACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAG
CCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGA
GGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACC
CCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAAC
TGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTAC
AACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGC
AAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATC
AGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGAT
GAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGAC
ATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCT
GTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGA
TGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTAC
ACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAGACCGTGGCCGCCCCCTCGGGCGTGCAG
CTCCTGGAGAGCGGCGGAGGCCTGGTCCAGCCCGGCGGCAGCCTGAGGCTGAGCTGCGCC
GCCAGCGGCTTCGTGTTCCCCTGGTATGATATGGGCTGGGTGAGGCAGGCCCCCGGCAAG
GGCCTGGAGTGGGTGTCCAGCATCGACTGGAAGGGGGGCAAGACCTACTACGCCGACAGC
GTGAAGGGCAGGTTCACCATCAGCAGGGACAACAGCAAGAACACCCTGTACCTGCAGATG
AACAGCCTGAGGGCCGAGGACACCGCAGTGTACTACTGCGCCACCGCCGAGGACGAACCC
GGCTACGACTACTGGGGCCAGGGCACCCTGGTGACTGTGAGCAGC
SEQ ID NO:253:PascoH-546_重链
CAGGTGACCCTGAGGGAGAGCGGCCCCGCCCTGGTGAAGCCCACCCAGACCCTGACCCTGACCTGCACCTTCAGCGGCTTTAGCCTCAGCACCTCCGGCATGGGCGTGAGCTGGATCAGGCAGCCACCCGGCAAAGGCCTGGAGTGGCTGGCCCACATCTACTGGGACGACGACAAGAGGTACAACCCCAGCCTGAAGAGCCGGCTGACCATCAGCAAGGATACCAGCAGGAACCAGGTGGTGCTGACCATGACCAACATGGACCCCGTGGACACCGCTACCTACTACTGCGCCAGGAGGGAGACCGTCTTCTACTGGTACTTCGACGTGTGGGGAAGGGGCACACTAGTGACCGTGTCCAGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAGGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCCCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAGGGCGTGCAGCTCCTGGAGAGCGGCGGAGGCCTGGTCCAGCCCGGCGGCAGCCTGAGGCTGAGCTGCGCCGCCAGCGGCTTCGTGTTCCCCTGGTATGATATGGGCTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGTCCAGCATCGACTGGAAGGGGGGCAAGACCTACTACGCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCAGTGTACTACTGCGCCACCGCCGAGGACGAACCCGGCTACGACTACTGGGGCCAGGGCACCCTGGTGACTGTGAGCAGC
SEQ ID NO:254:PascoH-TVAAPS-567_重链
CAGGTGACCCTGAGGGAGAGCGGCCCCGCCCTGGTGAAGCCCACCCAGACCCTGACCCTG
ACCTGCACCTTCAGCGGCTTTAGCCTCAGCACCTCCGGCATGGGCGTGAGCTGGATCAGG
CAGCCACCCGGCAAAGGCCTGGAGTGGCTGGCCCACATCTACTGGGACGACGACAAGAGG
TACAACCCCAGCCTGAAGAGCCGGCTGACCATCAGCAAGGATACCAGCAGGAACCAGGTG
GTGCTGACCATGACCAACATGGACCCCGTGGACACCGCTACCTACTACTGCGCCAGGAGG
GAGACCGTCTTCTACTGGTACTTCGACGTGTGGGGAAGGGGCACACTAGTGACCGTGTCC
AGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGC
GGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTG
TCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGC
AGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAG
ACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAG
CCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGA
GGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACC
CCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAAC
TGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTAC
AACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGC
AAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATC
AGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGAT
GAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGAC
ATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCT
GTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGA
TGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTAC
ACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAGACCGTGGCCGCCCCCTCGGGCGTGCAG
CTCCTGGAGAGCGGCGGAGGCCTGGTCCAGCCCGGCGGCAGCCTGAGGCTGAGCTGCGCC
GCCAGCGGCTTCGTGTTCGCCTGGTATGATATGGGCTGGGTGAGGCAGGCCCCCGGCAAG
GGCCTGGAGTGGGTGTCCAGCATCGACTGGCACGGGGAGGTGACCTACTACGCCGACAGC
GTGAAGGGCAGGTTCACCATCAGCAGGGACAACAGCAAGAACACCCTGTACCTGCAGATG
AACAGCCTGAGGGCCGAGGACACCGCAGTGTACTACTGCGCCACCGCCGAGGACGAACCC
GGCTACGACTACTGGGGCCAGGGCACCCTGGTGACTGTGAGCAGC
SEQ ID NO:255(PascoH-567_重链)
CAGGTGACCCTGAGGGAGAGCGGCCCCGCCCTGGTGAAGCCCACCCAGACCCTGACCCTG
ACCTGCACCTTCAGCGGCTTTAGCCTCAGCACCTCCGGCATGGGCGTGAGCTGGATCAGG
CAGCCACCCGGCAAAGGCCTGGAGTGGCTGGCCCACATCTACTGGGACGACGACAAGAGG
TACAACCCCAGCCTGAAGAGCCGGCTGACCATCAGCAAGGATACCAGCAGGAACCAGGTG
GTGCTGACCATGACCAACATGGACCCCGTGGACACCGCTACCTACTACTGCGCCAGGAGG
GAGACCGTCTTCTACTGGTACTTCGACGTGTGGGGAAGGGGCACACTAGTGACCGTGTCC
AGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGC
GGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTG
TCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGC
AGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAG
ACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAG
CCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGA
GGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACC
CCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAAC
TGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTAC
AACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGC
AAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATC
AGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGAT
GAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGAC
ATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCT
GTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGA
TGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTAC
ACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAGGGCGTGCAGCTCCTGGAGAGCGGCGGA
GGCCTGGTCCAGCCCGGCGGCAGCCTGAGGCTGAGCTGCGCCGCCAGCGGCTTCGTGTTC
GCCTGGTATGATATGGGCTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGTCC
AGCATCGACTGGCACGGGGAGGTGACCTACTACGCCGACAGCGTGAAGGGCAGGTTCACC
ATCAGCAGGGACAACAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTGAGGGCCGAG
GACACCGCAGTGTACTACTGCGCCACCGCCGAGGACGAACCCGGCTACGACTACTGGGGC
CAGGGCACCCTGGTGACTGTGAGCAGC
SEQ ID NO:256:656重链
CAGGTGCAGCTCGTCCAGTCTGGGGCCGAGGTGAAGAAGCCCGGAGCTTCTGTGAAGGTGTCCTGCAAGGCCAGCGGCTATACCTTCATCGACTACGAGATCCATTGGGTGAGGCAGGCTCCCGGGCAGGGCCTGGAGTGGATGGGCGCCATCGACCCAGAGACCGGAGGCACGGCGTACAACCAGAAGTTCAAGGGACGGGTCACCATGACAACCGATACCAGCACCTCCACCGCTTACATGGAGCTGCGCAGCCTGAGAAGCGACGACACCGCGGTGTACTACTGTACGCGCATCCTGCTCTACTACTACCCCATGGATTACTGGGGCCAGGGCACACTAGTCACAGTCTCCTCAGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA
SEQ ID NO:257:抗IL-5重链-G4S-dAb474-TVAAPSGS-dAb210
CAGGTGACCCTGAGGGAGAGCGGCCCCGCCCTGGTGAAGCCCACACAGACCCTCACTCTG
ACCTGCACCGTGAGCGGCTTCAGCCTGACCTCCTACAGCGTCCACTGGGTGAGGCAGCCC
CCCGGCAAGGGCCTGGAGTGGCTGGGCGTGATCTGGGCAAGCGGCGGCACCGACTACAAC
AGCGCCCTGATGAGCAGGCTCTCCATCAGCAAGGACACCAGCCGGAACCAGGTGGTGCTG
ACCATGACCAACATGGACCCCGTGGACACCGCCACCTATTACTGCGCCAGGGACCCTCCC
TCTAGCCTGCTGAGGCTGGACTACTGGGGCAGGGGAACACTAGTGACCGTGTCCAGCGCC
AGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGC
ACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTGTCCTGG
AACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGC
CTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTAC
ATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCAAG
AGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAGGCCCC
AGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCCCCGAG
GTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTGGTAC
GTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGC
ACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAG
TACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAG
GCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAGCTG
ACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCC
GTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTG
GACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCAG
CAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAG
AAGAGCCTGAGCCTGTCCCCTGGCAAGGGCGGCGGCGGATCTGGCGTGCAGCTCCTGGAG
AGCGGCGGAGGCCTGGTCCAGCCCGGCGGCAGCCTGAGGCTGAGCTGCGCCGCCAGCGGC
TTCACCTTCGCCTGGTATGATATGGGCTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAG
TGGGTGTCCAGCATCGACTGGCACGGGGAGGTGACCTACTACGCCGACAGCGTGAAGGGC
AGGTTCACCATCAGCAGGGACAACAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTG
AGGGCCGAGGACACCGCAGTGTACTACTGCGCCACCGCCGAGGACGAACCCGGCTACGAC
TACTGGGGCCAGGGCACCCTGGTGACTGTGAGCAGCACCGTGGCCGCCCCCTCGGGATCC
GAAGTGCAGCTCCTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTG
AGCTGCGCCGCTAGCGGCTTCACCTTCAGGAACTTCGGCATGGGCTGGGTCAGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGGTCAGCTGGATCATCAGCTCCGGCACCGAGACCTACTAC
GCCGACAGCGTGAAGGGCAGGTTCACCATCAGCCGCGACAACAGCAAGAACACCCTGTAC
CTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTCTACTACTGCGCCAAGAGCCTG
GGCAGGTTCGACTACTGGGGACAGGGGACCCTGGTGACTGTGAGCAGC
SEQ ID NO:258:抗CD-20重链-TVAAPSGS-dAb154-TVAAPSGS-dAb474
CAGGTGCAGCTGCAGCAGCCTGGAGCCGAGCTGGTGAAGCCCGGCGCCAGCGTGAAAATG
TCCTGCAAGGCCAGCGGCTACACCTTCACCAGCTACAACATGCACTGGGTGAAGCAGACC
CCCGGCAGGGGCCTCGAGTGGATCGGAGCTATCTACCCCGGCAACGGCGACACTAGCTAC
AACCAGAAGTTCAAGGGCAAGGCCACCCTGACCGCCGACAAGAGCAGCAGCACCGCCTAC
ATGCAGCTGAGCAGCCTGACCAGCGAGGACAGCGCCGTGTATTACTGCGCCAGGAGCACC
TACTACGGCGGCGACTGGTACTTCAACGTCTGGGGCGCCGGCACACTAGTGACCGTGTCC
AGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGC
GGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTG
TCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGC
AGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAG
ACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAG
CCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGA
GGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACC
CCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAAC
TGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTAC
AACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGC
AAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATC
AGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGAT
GAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGAC
ATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCT
GTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGA
TGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTAC
ACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAGACCGTGGCCGCCCCCTCGGGATCTGAC
ATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACCATT
ACCTGCAGGGCCAGCAGGCCCATCAGCGACTGGCTGCACTGGTACCAACAGAAGCCCGGC
AAGGCTCCCAAGCTGCTGATCGCCTGGGCCAGCAGCCTGCAGGGAGGCGTGCCCAGCAGG
TTTAGCGGCAGCGGCAGCGGCACCGACTTCACCCTCACCATCTCTTCCCTGCAGCCCGAG
GACTTCGCCACCTACTACTGCCTGCAGGAGGGCTGGGGGCCCCCTACTTTCGGCCAGGGC
ACCAAGGTGGAGATCAAGAGGACCGTGGCCGCCCCCTCGGGATCCGGCGTGCAGCTCCTG
GAGAGCGGCGGAGGCCTGGTCCAGCCCGGCGGCAGCCTGAGGCTGAGCTGCGCCGCCAGC
GGCTTCACCTTCGCCTGGTATGATATGGGCTGGGTGAGGCAGGCCCCCGGCAAGGGCCTG
GAGTGGGTGTCCAGCATCGACTGGCACGGGGAGGTGACCTACTACGCCGACAGCGTGAAG
GGCAGGTTCACCATCAGCAGGGACAACAGCAAGAACACCCTGTACCTGCAGATGAACAGC
CTGAGGGCCGAGGACACCGCAGTGTACTACTGCGCCACCGCCGAGGACGAACCCGGCTAC
GACTACTGGGGCCAGGGCACCCTGGTGACTGTGAGCAGC
SEQ ID NO:259:抗CD-20重链-TVAAPSGS-dAb210-TVAAPSGS-dAb474
CAGGTGCAGCTGCAGCAGCCTGGAGCCGAGCTGGTGAAGCCCGGCGCCAGCGTGAAAATG
TCCTGCAAGGCCAGCGGCTACACCTTCACCAGCTACAACATGCACTGGGTGAAGCAGACC
CCCGGCAGGGGCCTCGAGTGGATCGGAGCTATCTACCCCGGCAACGGCGACACTAGCTAC
AACCAGAAGTTCAAGGGCAAGGCCACCCTGACCGCCGACAAGAGCAGCAGCACCGCCTAC
ATGCAGCTGAGCAGCCTGACCAGCGAGGACAGCGCCGTGTATTACTGCGCCAGGAGCACC
TACTACGGCGGCGACTGGTACTTCAACGTCTGGGGCGCCGGCACACTAGTGACCGTGTCC
AGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGC
GGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTG
TCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGC
AGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAG
ACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAG
CCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGA
GGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACC
CCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAAC
TGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTAC
AACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGC
AAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATC
AGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGAT
GAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGAC
ATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCT
GTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGA
TGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTAC
ACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAGACCGTGGCCGCCCCCTCGGGATCTGAA
GTGCAGCTCCTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTGAGC
TGCGCCGCTAGCGGCTTCACCTTCAGGAACTTCGGCATGGGCTGGGTCAGGCAGGCCCCC
GGCAAGGGCCTGGAGTGGGTCAGCTGGATCATCAGCTCCGGCACCGAGACCTACTACGCC
GACAGCGTGAAGGGCAGGTTCACCATCAGCCGCGACAACAGCAAGAACACCCTGTACCTG
CAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTCTACTACTGCGCCAAGAGCCTGGGC
AGGTTCGACTACTGGGGACAGGGGACCCTGGTGACTGTGAGCAGCACCGTGGCCGCCCCC
TCGGGATCCGGCGTGCAGCTCCTGGAGAGCGGCGGAGGCCTGGTCCAGCCCGGCGGCAGC
CTGAGGCTGAGCTGCGCCGCCAGCGGCTTCACCTTCGCCTGGTATGATATGGGCTGGGTG
AGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGTCCAGCATCGACTGGCACGGGGAGGTG
ACCTACTACGCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACAGCAAGAAC
ACCCTGTACCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCAGTGTACTACTGCGCC
ACCGCCGAGGACGAACCCGGCTACGACTACTGGGGCCAGGGCACCCTGGTGACTGTGAGC
AGC
SEQ ID NO:260:抗cMET 5D5v2重链(hole)-GS-dAb593
GAGGTGCAGCTGGTGGAAAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCTCCCTGAGGCTGAGCTGCGCCGCTAGCGGCTACACCTTCACCAGCTACTGGCTCCACTGGGTCAGGCAGGCCCCAGGCAAGGGACTGGAGTGGGTGGGCATGATCGACCCCAGCAACAGCGACACCAGGTTCAACCCCAACTTCAAGGACAGGTTCACCATCAGCGCCGACACTAGCAAGAACACCGCCTACCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTATTACTGCGCCACCTACAGGAGCTACGTCACCCCCCTGGATTACTGGGGCCAGGGCACACTAGTGACCGTGTCCAGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAGGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCCCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGAGCTGCGCCGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGGTGAGCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAGGGATCCGAGGTGCAGCTCCTGGTCAGCGGCGGCGGCCTGGTCCAGCCCGGAGGCTCACTGAGGCTGAGCTGCGCCGCTAGCGGCTTCACCTTCAAGGCCTACCCCATGATGTGGGTCAGGCAGGCCCCCGGCAAAGGCCTGGAGTGGGTGTCTGAGATCAGCCCCAGCGGCAGCTACACCTACTACGCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACAGCAAGAACACCCTGTACCTGCAGATGAACTCTCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAAGGACCCCAGGAAGCTGGACTATTGGGGCCAGGGCACTCTGGTGACCGTGAGCAGC
SEQ ID NO:261:抗cMET 5D5v2重链(knob)-GS-dAb593
TGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAGGCCCCAGCGTGTTCCTGTTCCCCCCC
AAGCCTAAGGACACCCTGATGATCAGCAGAACCCCCGAGGTGACCTGTGTGGTGGTGGAT
GTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCAC
AATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGCACCTACCGGGTGGTGTCCGTG
CTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAGGTGTCCAAC
AAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAG
CCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTG
TGGTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGC
CAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTC
CTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGC
TCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGCCTGAGCCTGTCCCCT
GGCAAGGGATCCGAGGTGCAGCTCCTGGTCAGCGGCGGCGGCCTGGTCCAGCCCGGAGGC
TCACTGAGGCTGAGCTGCGCCGCTAGCGGCTTCACCTTCAAGGCCTACCCCATGATGTGG
GTCAGGCAGGCCCCCGGCAAAGGCCTGGAGTGGGTGTCTGAGATCAGCCCCAGCGGCAGC
TACACCTACTACGCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACAGCAAG
AACACCCTGTACCTGCAGATGAACTCTCTGAGGGCCGAGGACACCGCCGTGTACTACTGC
GCCAAGGACCCCAGGAAGCTGGACTATTGGGGCCAGGGCACTCTGGTGACCGTGAGCAGC
SEQ ID NO:262:抗cMET 5D5v2轻链
GACATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCTCAGTGGGAGACAGGGTGACC
ATCACCTGCAAGAGCAGCCAGAGCCTCCTGTACACCAGCAGCCAGAAGAACTACCTGGCC
TGGTACCAGCAGAAACCCGGCAAGGCCCCCAAGCTGCTGATCTACTGGGCTAGCACCAGG
GAGTCAGGCGTGCCCAGCAGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACTCTGACC
ATCAGCAGCCTGCAGCCCGAGGACTTCGCCACCTACTACTGCCAGCAGTACTACGCCTAT
CCCTGGACCTTCGGCCAGGGCACCAAGGTGGAGATCAAGCGTACGGTGGCCGCCCCCAGC
GTGTTCATCTTCCCCCCCAGCGATGAGCAGCTGAAGAGCGGCACCGCCAGCGTGGTGTGT
CTGCTGAACAACTTCTACCCCCGGGAGGCCAAGGTGCAGTGGAAGGTGGACAATGCCCTG
CAGAGCGGCAACAGCCAGGAGAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGC
CTGAGCAGCACCCTGACCCTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGT
GAGGTGACCCACCAGGGCCTGTCCAGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGC
SEQ ID NO:263:抗cMET 5D5v2 IgG4重链(UNIBODY)-GS-dAb593
GAGGTGCAGCTGGTGGAAAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCTCCCTGAGGCTG
AGCTGCGCCGCTAGCGGCTACACCTTCACCAGCTACTGGCTCCACTGGGTCAGGCAGGCC
CCAGGCAAGGGACTGGAGTGGGTGGGCATGATCGACCCCAGCAACAGCGACACCAGGTTC
AACCCCAACTTCAAGGACAGGTTCACCATCAGCGCCGACACTAGCAAGAACACCGCCTAC
CTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTATTACTGCGCCACCTACAGG
AGCTACGTCACCCCCCTGGATTACTGGGGCCAGGGCACACTAGTCACCGTGAGCAGCGCC
AGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCTGCAGCAGAAGCACCAGCGAGAGC
ACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAGCCCGTGACCGTGAGCTGG
AACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGC
CTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCAAGACCTAC
ACCTGCAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGGCCCCCGAG
TTCCTGGGCGGACCCTCCGTGTTCCTGTTCCCCCCCAAGCCCAAGGACACCCTGATGATC
AGCCGGACCCCCGAGGTGACCTGCGTGGTGGTGGACGTGAGCCAGGAAGATCCCGAGGTC
CAGTTCAATTGGTACGTGGACGGCGTGGAGGTGCACAACGCCAAGACCAAGCCCCGGGAG
GAACAGTTCAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGACTGG
CTGAACGGCAAAGAATACAAGTGCAAGGTGTCCAACAAGGGCCTGCCCAGCTCCATCGAG
AAAACCATCAGCAAGGCCAAGGGCCAGCCTCGGGAGCCCCAGGTGTACACCCTGCCCCCA
TCCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGACCTGTCTGGTGAAGGGCTTCTAC
CCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACC
ACCCCCCCTGTGCTGGACAGCGACGGCAGCTTCTTCCTGTACAGCAGGCTGACCGTGGAC
AAGAGCCGGTGGCAGGAAGGCAACGTCTTTAGCTGCAGCGTGATGCACGAGGCCCTGCAC
AACCACTACACCCAGAAGAGCCTGAGCCTGTCCCTGGGCAAGGGATCCGAGGTGCAGCTC
CTGGTCAGCGGCGGCGGCCTGGTCCAGCCCGGAGGCTCACTGAGGCTGAGCTGCGCCGCT
AGCGGCTTCACCTTCAAGGCCTACCCCATGATGTGGGTCAGGCAGGCCCCCGGCAAAGGC
CTGGAGTGGGTGTCTGAGATCAGCCCCAGCGGCAGCTACACCTACTACGCCGACAGCGTG
AAGGGCAGGTTCACCATCAGCAGGGACAACAGCAAGAACACCCTGTACCTGCAGATGAAC
TCTCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAAGGACCCCAGGAAGCTGGAC
TATTGGGGCCAGGGCACTCTGGTGACCGTGAGCAGC
SEQ ID NO:264:抗cMET 5D5v2重链(hole)
GAGGTGCAGCTGGTGGAAAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCTCCCTGAGGCTG
AGCTGCGCCGCTAGCGGCTACACCTTCACCAGCTACTGGCTCCACTGGGTCAGGCAGGCC
CCAGGCAAGGGACTGGAGTGGGTGGGCATGATCGACCCCAGCAACAGCGACACCAGGTTC
AACCCCAACTTCAAGGACAGGTTCACCATCAGCGCCGACACTAGCAAGAACACCGCCTAC
CTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTATTACTGCGCCACCTACAGG
AGCTACGTCACCCCCCTGGATTACTGGGGCCAGGGCACACTAGTGACCGTGTCCAGCGCC
AGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGC
ACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTGTCCTGG
AACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGC
CTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTAC
ATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCAAG
AGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAGGCCCC
AGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCCCCGAG
GTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTGGTAC
GTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGC
ACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAG
TACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAG
GCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAGCTG
ACCAAGAACCAGGTGTCCCTGAGCTGCGCCGTGAAGGGCTTCTACCCCAGCGACATCGCC
GTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTG
GACAGCGATGGCAGCTTCTTCCTGGTGAGCAAGCTGACCGTGGACAAGAGCAGATGGCAG
CAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAG
AAGAGCCTGAGCCTGTCCCCTGGCAAG
SEQ ID NO:265:抗cMET 5D5v2重链(knob)
TGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAGGCCCCAGCGTGTTCCTGTTCCCCCCC
AAGCCTAAGGACACCCTGATGATCAGCAGAACCCCCGAGGTGACCTGTGTGGTGGTGGAT
GTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCAC
AATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGCACCTACCGGGTGGTGTCCGTG
CTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAGGTGTCCAAC
AAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAG
CCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTG
TGGTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGC
CAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTC
CTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGC
TCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGCCTGAGCCTGTCCCCT
GGCAAG
SEQ ID NO:266:抗cMET 5D5v2 IgG4重链(UNIBODY)
GAGGTGCAGCTGGTGGAAAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCTCCCTGAGGCTG
AGCTGCGCCGCTAGCGGCTACACCTTCACCAGCTACTGGCTCCACTGGGTCAGGCAGGCC
CCAGGCAAGGGACTGGAGTGGGTGGGCATGATCGACCCCAGCAACAGCGACACCAGGTTC
AACCCCAACTTCAAGGACAGGTTCACCATCAGCGCCGACACTAGCAAGAACACCGCCTAC
CTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTATTACTGCGCCACCTACAGG
AGCTACGTCACCCCCCTGGATTACTGGGGCCAGGGCACACTAGTCACCGTGAGCAGCGCC
AGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCTGCAGCAGAAGCACCAGCGAGAGC
ACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAGCCCGTGACCGTGAGCTGG
AACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGC
CTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCAAGACCTAC
ACCTGCAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGGCCCCCGAG
TTCCTGGGCGGACCCTCCGTGTTCCTGTTCCCCCCCAAGCCCAAGGACACCCTGATGATC
AGCCGGACCCCCGAGGTGACCTGCGTGGTGGTGGACGTGAGCCAGGAAGATCCCGAGGTC
CAGTTCAATTGGTACGTGGACGGCGTGGAGGTGCACAACGCCAAGACCAAGCCCCGGGAG
GAACAGTTCAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGACTGG
CTGAACGGCAAAGAATACAAGTGCAAGGTGTCCAACAAGGGCCTGCCCAGCTCCATCGAG
AAAACCATCAGCAAGGCCAAGGGCCAGCCTCGGGAGCCCCAGGTGTACACCCTGCCCCCA
TCCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGACCTGTCTGGTGAAGGGCTTCTAC
CCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACC
ACCCCCCCTGTGCTGGACAGCGACGGCAGCTTCTTCCTGTACAGCAGGCTGACCGTGGAC
AAGAGCCGGTGGCAGGAAGGCAACGTCTTTAGCTGCAGCGTGATGCACGAGGCCCTGCAC
AACCACTACACCCAGAAGAGCCTGAGCCTGTCCCTGGGCAAG
SEQ ID NO:267:PascoH IgG2-GS-474重链
CAGGTGACCCTGAGGGAGAGCGGCCCCGCCCTGGTGAAGCCCACCCAGACCCTGACCCTGACCTGCACCTTCAGCGGCTTTAGCCTCAGCACCTCCGGCATGGGCGTGAGCTGGATCAGGCAGCCACCCGGCAAAGGCCTGGAGTGGCTGGCCCACATCTACTGGGACGACGACAAGAGGTACAACCCCAGCCTGAAGAGCCGGCTGACCATCAGCAAGGATACCAGCAGGAACCAGGTGGTGCTGACCATGACCAACATGGACCCCGTGGACACCGCTACCTACTACTGCGCCAGGAGGGAGACCGTCTTCTACTGGTACTTCGACGTGTGGGGAAGGGGCACACTAGTCACCGTGAGCAGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCTGCAGCAGAAGCACCAGCGAGAGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAGCCCGTGACCGTGAGCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAACTTCGGCACCCAGACCTACACCTGCAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGACCGTGGAGCGGAAGTGCTGCGTGGAGTGCCCCCCCTGCCCTGCCCCTCCTGTGGCCGGACCCTCCGTGTTCCTGTTCCCCCCCAAGCCCAAGGACACCCTGATGATCAGCCGGACCCCCGAGGTGACCTGCGTGGTGGTGGACGTGAGCCACGAGGACCCCGAGGTGCAGTTCAATTGGTACGTGGACGGCGTGGAGGTGCACAACGCCAAGACCAAGCCCCGGGAGGAACAGTTCAACAGCACCTTCCGGGTGGTGTCCGTGCTGACCGTGGTGCACCAGGACTGGCTGAACGGCAAAGAATACAAGTGCAAGGTGTCCAACAAGGGCCTGCCTGCCCCCATCGAGAAAACCATCAGCAAGACCAAGGGCCAGCCCAGGGAACCCCAGGTGTACACCCTGCCCCCCAGCCGGGAGGAAATGACCAAGAACCAGGTGTCCCTGACCTGTCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCCATGCTGGACAGCGACGGCAGCTTCTTCCTGTACAGCAAGCTGACAGTGGACAAGAGCCGGTGGCAGCAGGGCAACGTGTTCAGCTGCAGCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGAGCCTGAGCCTGTCCCCCGGCAAGGGATCCGGCGTGCAGCTCCTGGAGAGCGGCGGAGGCCTGGTCCAGCCCGGCGGCAGCCTGAGGCTGAGCTGCGCCGCCAGCGGCTTCACCTTCGCCTGGTATGATATGGGCTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGTCCAGCATCGACTGGCACGGGGAGGTGACCTACTACGCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCAGTGTACTACTGCGCCACCGCCGAGGACGAACCCGGCTACGACTACTGGGGCCAGGGCACCCTGGTGACTGTGAGCAGC
SEQ ID NO:268:PascoH IgG4-GS-474重链
CAGGTGACCCTGAGGGAGAGCGGCCCCGCCCTGGTGAAGCCCACCCAGACCCTGACCCTGACCTGCACCTTCAGCGGCTTTAGCCTCAGCACCTCCGGCATGGGCGTGAGCTGGATCAGGCAGCCACCCGGCAAAGGCCTGGAGTGGCTGGCCCACATCTACTGGGACGACGACAAGAGGTACAACCCCAGCCTGAAGAGCCGGCTGACCATCAGCAAGGATACCAGCAGGAACCAGGTGGTGCTGACCATGACCAACATGGACCCCGTGGACACCGCTACCTACTACTGCGCCAGGAGGGAGACCGTCTTCTACTGGTACTTCGACGTGTGGGGAAGGGGCACACTAGTCACCGTGAGCAGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCTGCAGCAGAAGCACCAGCGAGAGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAGCCCGTGACCGTGAGCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCAAGACCTACACCTGCAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGGAGAGCAAGTACGGCCCTCCCTGCCCCAGCTGCCCTGCCCCCGAGTTCCTGGGCGGACCCTCCGTGTTCCTGTTCCCCCCCAAGCCCAAGGACACCCTGATGATCAGCCGGACCCCCGAGGTGACCTGCGTGGTGGTGGACGTGAGCCAGGAAGATCCCGAGGTCCAGTTCAATTGGTACGTGGACGGCGTGGAGGTGCACAACGCCAAGACCAAGCCCCGGGAGGAACAGTTCAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAGAATACAAGTGCAAGGTGTCCAACAAGGGCCTGCCCAGCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCTCGGGAGCCCCAGGTGTACACCCTGCCCCCATCCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGACCTGTCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGACGGCAGCTTCTTCCTGTACAGCAGGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAACGTCTTTAGCTGCAGCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGAGCCTGAGCCTGTCCCTGGGCAAGGGATCCGGCGTGCAGCTCCTGGAGAGCGGCGGAGGCCTGGTCCAGCCCGGCGGCAGCCTGAGGCTGAGCTGCGCCGCCAGCGGCTTCACCTTCGCCTGGTATGATATGGGCTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGTCCAGCATCGACTGGCACGGGGAGGTGACCTACTACGCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCAGTGTACTACTGCGCCACCGCCGAGGACGAACCCGGCTACGACTACTGGGGCCAGGGCACCCTGGTGACTGTGAGCAGC
SEQ ID NO:269:PascoH IgG4PE-GS-474重链
CAGGTGACCCTGAGGGAGAGCGGCCCCGCCCTGGTGAAGCCCACCCAGACCCTGACCCTGACCTGCACCTTCAGCGGCTTTAGCCTCAGCACCTCCGGCATGGGCGTGAGCTGGATCAGGCAGCCACCCGGCAAAGGCCTGGAGTGGCTGGCCCACATCTACTGGGACGACGACAAGAGGTACAACCCCAGCCTGAAGAGCCGGCTGACCATCAGCAAGGATACCAGCAGGAACCAGGTGGTGCTGACCATGACCAACATGGACCCCGTGGACACCGCTACCTACTACTGCGCCAGGAGGGAGACCGTCTTCTACTGGTACTTCGACGTGTGGGGAAGGGGCACACTAGTCACCGTGAGCAGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCTGCAGCAGAAGCACCAGCGAGAGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAGCCCGTGACCGTGAGCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCAAGACCTACACCTGCAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGGAGAGCAAGTACGGCCCTCCCTGCCCCCCCTGCCCTGCCCCCGAGTTCGAGGGCGGACCCTCCGTGTTCCTGTTCCCCCCCAAGCCCAAGGACACCCTGATGATCAGCCGGACCCCCGAGGTGACCTGCGTGGTGGTGGACGTGAGCCAGGAAGATCCCGAGGTCCAGTTCAATTGGTACGTGGACGGCGTGGAGGTGCACAACGCCAAGACCAAGCCCCGGGAGGAACAGTTCAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAGAATACAAGTGCAAGGTGTCCAACAAGGGCCTGCCCAGCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCTCGGGAGCCCCAGGTGTACACCCTGCCCCCATCCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGACCTGTCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGACGGCAGCTTCTTCCTGTACAGCAGGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAACGTCTTTAGCTGCAGCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGAGCCTGAGCCTGTCCCTGGGCAAGGGATCCGGCGTGCAGCTCCTGGAGAGCGGCGGAGGCCTGGTCCAGCCCGGCGGCAGCCTGAGGCTGAGCTGCGCCGCCAGCGGCTTCACCTTCGCCTGGTATGATATGGGCTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGTCCAGCATCGACTGGCACGGGGAGGTGACCTACTACGCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCAGTGTACTACTGCGCCACCGCCGAGGACGAACCCGGCTACGACTACTGGGGCCAGGGCACCCTGGTGACTGTGAGCAGC
SEQ ID NO:270:抗IL-4重链-GS-抗TNF-a adnectin
CAGGTGACCCTGAGGGAGAGCGGCCCCGCCCTGGTGAAGCCCACCCAGACCCTGACCCTGACCTGCACCTTCAGCGGCTTTAGCCTCAGCACCTCCGGCATGGGCGTGAGCTGGATCAGGCAGCCACCCGGCAAAGGCCTGGAGTGGCTGGCCCACATCTACTGGGACGACGACAAGAGGTACAACCCCAGCCTGAAGAGCCGGCTGACCATCAGCAAGGATACCAGCAGGAACCAGGTGGTGCTGACCATGACCAACATGGACCCCGTGGACACCGCTACCTACTACTGCGCCAGGAGGGAGACCGTCTTCTACTGGTACTTCGACGTGTGGGGAAGGGGCACACTAGTGACCGTGTCCAGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAGGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCCCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAGGGATCCGTGAGCGACGTGCCAAGGGACCTCGAGGTGGTGGCAGCCACTCCCACCTCTCTGCTGATCAGCTGGGACACACACAACGCCTACAACGGCTACTACAGGATCACCTACGGAGAGACCGGCGGCAATAGCCCCGTGAGGGAGTTCACCGTGCCCCACCCCGAGGTGACCGCCACCATTAGCGGCCTGAAGCCCGGCGTGGACGATACCATCACCGTCTACGCCGTGACCAACCACCACATGCCCCTGAGGATCTTCGGCCCCATCAGCATCAACCATAGGACC
序列表
<110> 葛兰素集团有限公司
C. 阿什曼
M. N. 伯登
J. H. 艾利斯
S. J. 克莱格
P. A. 汉布林
R. M. 德 威尔德特
T. 巴图万加拉
F. 侯赛因
L. 耶斯珀斯
A. 路易斯
M. 斯图尔德
M. A. 奥雷基亚
R. 夏
<120> 抗原结合构建体
<130> PB62748
<150> US60/991449
<151> 2007-11-30
<150> US61/027858
<151> 2008-02-12
<150> US61/046572
<151> 2008-04-21
<150> US61/081,191
<151> 2008-07-16
<150> US61/084,431
<151> 2008-07-29
<160> 270
<170> FastSEQ for Windows Version 4.0
<210> 1
<211> 108
<212> PRT
<213> 人(Homo Sapiens)
<400> 1
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Arg Pro Ile Ser Asp Trp
20 25 30
Leu His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Ala Trp Ala Ser Thr Leu Asp Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Glu Gly Trp Gly Pro Pro
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
100 105
<210> 2
<211> 108
<212> PRT
<213> 人
<400> 2
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Arg Pro Ile Ser Asp Trp
20 25 30
Leu His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Ala Trp Ala Ser Ser Leu Tyr Glu Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Glu Gly Trp Gly Pro Pro
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
100 105
<210> 3
<211> 108
<212> PRT
<213> 人
<400> 3
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Arg Pro Ile Ser Asp Trp
20 25 30
Leu His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Ala Trp Ala Ser Ser Leu Gln Gly Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Glu Gly Trp Gly Pro Pro
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
100 105
<210> 4
<211> 116
<212> PRT
<213> 人
<400> 4
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Asn Phe
20 25 30
Gly Met Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Trp Ile Ile Ser Ser Gly Thr Glu Thr Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Ser Leu Gly Arg Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val
100 105 110
Thr Val Ser Ser
115
<210> 5
<211> 118
<212> PRT
<213> 人
<400> 5
Gly Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ala Trp Tyr
20 25 30
Asp Met Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ser Ile Asp Trp His Gly Glu Val Thr Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Thr Ala Glu Asp Glu Pro Gly Tyr Asp Tyr Trp Gly Gln Gly Thr
100 105 110
Leu Val Thr Val Ser Ser
115
<210> 6
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 接头
<400> 6
Gly Gly Gly Gly Ser
1 5
<210> 7
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 接头
<400> 7
Thr Val Ala Ala Pro Ser
1 5
<210> 8
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 接头
<400> 8
Ala Ser Thr Lys Gly Pro Thr
1 5
<210> 9
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 接头
<400> 9
Ala Ser Thr Lys Gly Pro Ser
1 5
<210> 10
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 接头
<400> 10
Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro
1 5 10 15
<210> 11
<211> 18
<212> PRT
<213> 人工序列
<220>
<223> 接头
<400> 11
Glu Leu Gln Leu Glu Glu Ser Cys Ala Glu Ala Gln Asp Gly Glu Leu
1 5 10 15
Asp Gly
<210> 12
<211> 455
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 12
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Tyr Ile Lys Asp Thr
20 25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Thr Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Val Pro Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Ile Tyr Asp Asp Tyr His Tyr Asp Asp Tyr Tyr Ala Met
100 105 110
Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr
115 120 125
Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser
130 135 140
Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu
145 150 155 160
Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His
165 170 175
Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser
180 185 190
Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys
195 200 205
Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu
210 215 220
Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
225 230 235 240
Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
245 250 255
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
260 265 270
Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp
275 280 285
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
290 295 300
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
305 310 315 320
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu
325 330 335
Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
340 345 350
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys
355 360 365
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
370 375 380
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
385 390 395 400
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
405 410 415
Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
420 425 430
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
435 440 445
Leu Ser Leu Ser Pro Gly Lys
450 455
<210> 13
<211> 219
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 13
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
1 5 10 15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Asn Ile Val His Ile
20 25 30
Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Arg Leu Leu Ile Tyr Lys Ile Ser Asp Arg Phe Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Asp Asp Val Gly Ile Tyr Tyr Cys Phe Gln Gly
85 90 95
Ser His Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105 110
Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
115 120 125
Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
130 135 140
Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
145 150 155 160
Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser
165 170 175
Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu
180 185 190
Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser
195 200 205
Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
210 215
<210> 14
<211> 451
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 14
Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln
1 5 10 15
Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser
20 25 30
Gly Met Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45
Trp Leu Ala His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Arg Asn Gln Val
65 70 75 80
Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr
85 90 95
Cys Ala Arg Arg Glu Thr Val Phe Tyr Trp Tyr Phe Asp Val Trp Gly
100 105 110
Arg Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
115 120 125
Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
130 135 140
Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
145 150 155 160
Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
165 170 175
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
180 185 190
Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
195 200 205
Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys
210 215 220
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
225 230 235 240
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
245 250 255
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
260 265 270
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
275 280 285
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
290 295 300
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
305 310 315 320
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
325 330 335
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
340 345 350
Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
355 360 365
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
370 375 380
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
385 390 395 400
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
405 410 415
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
420 425 430
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
435 440 445
Pro Gly Lys
450
<210> 15
<211> 218
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 15
Asp Ile Val Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Ser Val Asp Tyr Asp
20 25 30
Gly Asp Ser Tyr Met Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro
35 40 45
Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Glu Ser Gly Ile Pro Ser
50 55 60
Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser
65 70 75 80
Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Ser Asn
85 90 95
Glu Asp Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
100 105 110
Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln
115 120 125
Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr
130 135 140
Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser
145 150 155 160
Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr
165 170 175
Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys
180 185 190
His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro
195 200 205
Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
210 215
<210> 16
<211> 565
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 16
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Tyr Ile Lys Asp Thr
20 25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Thr Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Val Pro Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Ile Tyr Asp Asp Tyr His Tyr Asp Asp Tyr Tyr Ala Met
100 105 110
Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr
115 120 125
Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser
130 135 140
Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu
145 150 155 160
Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His
165 170 175
Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser
180 185 190
Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys
195 200 205
Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu
210 215 220
Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
225 230 235 240
Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
245 250 255
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
260 265 270
Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp
275 280 285
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
290 295 300
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
305 310 315 320
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu
325 330 335
Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
340 345 350
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys
355 360 365
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
370 375 380
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
385 390 395 400
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
405 410 415
Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
420 425 430
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
435 440 445
Leu Ser Leu Ser Pro Gly Lys Gly Ser Asp Ile Gln Met Thr Gln Ser
450 455 460
Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys
465 470 475 480
Arg Ala Ser Arg Pro Ile Ser Asp Trp Leu His Trp Tyr Gln Gln Lys
485 490 495
Pro Gly Lys Ala Pro Lys Leu Leu Ile Ala Trp Ala Ser Thr Leu Asp
500 505 510
Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe
515 520 525
Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr
530 535 540
Cys Leu Gln Glu Gly Trp Gly Pro Pro Thr Phe Gly Gln Gly Thr Lys
545 550 555 560
Val Glu Ile Lys Arg
565
<210> 17
<211> 565
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 17
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Tyr Ile Lys Asp Thr
20 25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Thr Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Val Pro Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Ile Tyr Asp Asp Tyr His Tyr Asp Asp Tyr Tyr Ala Met
100 105 110
Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr
115 120 125
Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser
130 135 140
Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu
145 150 155 160
Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His
165 170 175
Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser
180 185 190
Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys
195 200 205
Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu
210 215 220
Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
225 230 235 240
Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
245 250 255
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
260 265 270
Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp
275 280 285
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
290 295 300
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
305 310 315 320
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu
325 330 335
Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
340 345 350
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys
355 360 365
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
370 375 380
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
385 390 395 400
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
405 410 415
Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
420 425 430
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
435 440 445
Leu Ser Leu Ser Pro Gly Lys Gly Ser Asp Ile Gln Met Thr Gln Ser
450 455 460
Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys
465 470 475 480
Arg Ala Ser Arg Pro Ile Ser Asp Trp Leu His Trp Tyr Gln Gln Lys
485 490 495
Pro Gly Lys Ala Pro Lys Leu Leu Ile Ala Trp Ala Ser Ser Leu Tyr
500 505 510
Glu Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe
515 520 525
Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr
530 535 540
Cys Leu Gln Glu Gly Trp Gly Pro Pro Thr Phe Gly Gln Gly Thr Lys
545 550 555 560
Val Glu Ile Lys Arg
565
<210> 18
<211> 565
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 18
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Tyr Ile Lys Asp Thr
20 25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Thr Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Val Pro Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Ile Tyr Asp Asp Tyr His Tyr Asp Asp Tyr Tyr Ala Met
100 105 110
Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr
115 120 125
Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser
130 135 140
Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu
145 150 155 160
Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His
165 170 175
Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser
180 185 190
Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys
195 200 205
Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu
210 215 220
Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
225 230 235 240
Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
245 250 255
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
260 265 270
Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp
275 280 285
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
290 295 300
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
305 310 315 320
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu
325 330 335
Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
340 345 350
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys
355 360 365
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
370 375 380
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
385 390 395 400
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
405 410 415
Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
420 425 430
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
435 440 445
Leu Ser Leu Ser Pro Gly Lys Gly Ser Asp Ile Gln Met Thr Gln Ser
450 455 460
Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys
465 470 475 480
Arg Ala Ser Arg Pro Ile Ser Asp Trp Leu His Trp Tyr Gln Gln Lys
485 490 495
Pro Gly Lys Ala Pro Lys Leu Leu Ile Ala Trp Ala Ser Ser Leu Gln
500 505 510
Gly Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe
515 520 525
Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr
530 535 540
Cys Leu Gln Glu Gly Trp Gly Pro Pro Thr Phe Gly Gln Gly Thr Lys
545 550 555 560
Val Glu Ile Lys Arg
565
<210> 19
<211> 573
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 19
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Tyr Ile Lys Asp Thr
20 25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Thr Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Val Pro Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Ile Tyr Asp Asp Tyr His Tyr Asp Asp Tyr Tyr Ala Met
100 105 110
Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr
115 120 125
Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser
130 135 140
Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu
145 150 155 160
Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His
165 170 175
Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser
180 185 190
Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys
195 200 205
Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu
210 215 220
Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
225 230 235 240
Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
245 250 255
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
260 265 270
Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp
275 280 285
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
290 295 300
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
305 310 315 320
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu
325 330 335
Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
340 345 350
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys
355 360 365
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
370 375 380
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
385 390 395 400
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
405 410 415
Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
420 425 430
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
435 440 445
Leu Ser Leu Ser Pro Gly Lys Gly Ser Glu Val Gln Leu Leu Glu Ser
450 455 460
Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala
465 470 475 480
Ala Ser Gly Phe Thr Phe Arg Asn Phe Gly Met Gly Trp Val Arg Gln
485 490 495
Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Trp Ile Ile Ser Ser Gly
500 505 510
Thr Glu Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser
515 520 525
Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg
530 535 540
Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Ser Leu Gly Arg Phe
545 550 555 560
Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
565 570
<210> 20
<211> 568
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 20
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Tyr Ile Lys Asp Thr
20 25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Thr Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Val Pro Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Ile Tyr Asp Asp Tyr His Tyr Asp Asp Tyr Tyr Ala Met
100 105 110
Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr
115 120 125
Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser
130 135 140
Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu
145 150 155 160
Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His
165 170 175
Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser
180 185 190
Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys
195 200 205
Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu
210 215 220
Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
225 230 235 240
Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
245 250 255
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
260 265 270
Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp
275 280 285
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
290 295 300
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
305 310 315 320
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu
325 330 335
Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
340 345 350
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys
355 360 365
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
370 375 380
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
385 390 395 400
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
405 410 415
Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
420 425 430
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
435 440 445
Leu Ser Leu Ser Pro Gly Lys Gly Gly Gly Gly Ser Asp Ile Gln Met
450 455 460
Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr
465 470 475 480
Ile Thr Cys Arg Ala Ser Arg Pro Ile Ser Asp Trp Leu His Trp Tyr
485 490 495
Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Ala Trp Ala Ser
500 505 510
Thr Leu Asp Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly
515 520 525
Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala
530 535 540
Thr Tyr Tyr Cys Leu Gln Glu Gly Trp Gly Pro Pro Thr Phe Gly Gln
545 550 555 560
Gly Thr Lys Val Glu Ile Lys Arg
565
<210> 21
<211> 568
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 21
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Tyr Ile Lys Asp Thr
20 25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Thr Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Val Pro Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Ile Tyr Asp Asp Tyr His Tyr Asp Asp Tyr Tyr Ala Met
100 105 110
Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr
115 120 125
Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser
130 135 140
Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu
145 150 155 160
Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His
165 170 175
Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser
180 185 190
Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys
195 200 205
Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu
210 215 220
Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
225 230 235 240
Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
245 250 255
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
260 265 270
Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp
275 280 285
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
290 295 300
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
305 310 315 320
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu
325 330 335
Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
340 345 350
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys
355 360 365
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
370 375 380
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
385 390 395 400
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
405 410 415
Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
420 425 430
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
435 440 445
Leu Ser Leu Ser Pro Gly Lys Gly Gly Gly Gly Ser Asp Ile Gln Met
450 455 460
Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr
465 470 475 480
Ile Thr Cys Arg Ala Ser Arg Pro Ile Ser Asp Trp Leu His Trp Tyr
485 490 495
Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Ala Trp Ala Ser
500 505 510
Ser Leu Tyr Glu Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly
515 520 525
Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala
530 535 540
Thr Tyr Tyr Cys Leu Gln Glu Gly Trp Gly Pro Pro Thr Phe Gly Gln
545 550 555 560
Gly Thr Lys Val Glu Ile Lys Arg
565
<210> 22
<211> 568
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 22
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Tyr Ile Lys Asp Thr
20 25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Thr Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Val Pro Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Ile Tyr Asp Asp Tyr His Tyr Asp Asp Tyr Tyr Ala Met
100 105 110
Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr
115 120 125
Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser
130 135 140
Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu
145 150 155 160
Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His
165 170 175
Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser
180 185 190
Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys
195 200 205
Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu
210 215 220
Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
225 230 235 240
Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
245 250 255
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
260 265 270
Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp
275 280 285
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
290 295 300
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
305 310 315 320
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu
325 330 335
Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
340 345 350
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys
355 360 365
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
370 375 380
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
385 390 395 400
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
405 410 415
Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
420 425 430
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
435 440 445
Leu Ser Leu Ser Pro Gly Lys Gly Gly Gly Gly Ser Asp Ile Gln Met
450 455 460
Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr
465 470 475 480
Ile Thr Cys Arg Ala Ser Arg Pro Ile Ser Asp Trp Leu His Trp Tyr
485 490 495
Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Ala Trp Ala Ser
500 505 510
Ser Leu Gln Gly Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly
515 520 525
Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala
530 535 540
Thr Tyr Tyr Cys Leu Gln Glu Gly Trp Gly Pro Pro Thr Phe Gly Gln
545 550 555 560
Gly Thr Lys Val Glu Ile Lys Arg
565
<210> 23
<211> 576
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 23
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Tyr Ile Lys Asp Thr
20 25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Thr Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Val Pro Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Ile Tyr Asp Asp Tyr His Tyr Asp Asp Tyr Tyr Ala Met
100 105 110
Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr
115 120 125
Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser
130 135 140
Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu
145 150 155 160
Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His
165 170 175
Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser
180 185 190
Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys
195 200 205
Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu
210 215 220
Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
225 230 235 240
Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
245 250 255
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
260 265 270
Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp
275 280 285
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
290 295 300
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
305 310 315 320
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu
325 330 335
Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
340 345 350
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys
355 360 365
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
370 375 380
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
385 390 395 400
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
405 410 415
Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
420 425 430
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
435 440 445
Leu Ser Leu Ser Pro Gly Lys Gly Gly Gly Gly Ser Glu Val Gln Leu
450 455 460
Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu
465 470 475 480
Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Asn Phe Gly Met Gly Trp
485 490 495
Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Trp Ile Ile
500 505 510
Ser Ser Gly Thr Glu Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe
515 520 525
Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn
530 535 540
Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Ser Leu
545 550 555 560
Gly Arg Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
565 570 575
<210> 24
<211> 571
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 24
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Tyr Ile Lys Asp Thr
20 25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Thr Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Val Pro Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Ile Tyr Asp Asp Tyr His Tyr Asp Asp Tyr Tyr Ala Met
100 105 110
Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr
115 120 125
Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser
130 135 140
Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu
145 150 155 160
Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His
165 170 175
Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser
180 185 190
Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys
195 200 205
Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu
210 215 220
Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
225 230 235 240
Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
245 250 255
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
260 265 270
Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp
275 280 285
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
290 295 300
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
305 310 315 320
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu
325 330 335
Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
340 345 350
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys
355 360 365
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
370 375 380
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
385 390 395 400
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
405 410 415
Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
420 425 430
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
435 440 445
Leu Ser Leu Ser Pro Gly Lys Thr Val Ala Ala Pro Ser Gly Ser Asp
450 455 460
Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp
465 470 475 480
Arg Val Thr Ile Thr Cys Arg Ala Ser Arg Pro Ile Ser Asp Trp Leu
485 490 495
His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Ala
500 505 510
Trp Ala Ser Thr Leu Asp Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
515 520 525
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu
530 535 540
Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Glu Gly Trp Gly Pro Pro Thr
545 550 555 560
Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
565 570
<210> 25
<211> 571
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 25
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Tyr Ile Lys Asp Thr
20 25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Thr Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Val Pro Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Ile Tyr Asp Asp Tyr His Tyr Asp Asp Tyr Tyr Ala Met
100 105 110
Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr
115 120 125
Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser
130 135 140
Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu
145 150 155 160
Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His
165 170 175
Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser
180 185 190
Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys
195 200 205
Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu
210 215 220
Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
225 230 235 240
Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
245 250 255
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
260 265 270
Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp
275 280 285
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
290 295 300
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
305 310 315 320
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu
325 330 335
Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
340 345 350
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys
355 360 365
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
370 375 380
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
385 390 395 400
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
405 410 415
Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
420 425 430
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
435 440 445
Leu Ser Leu Ser Pro Gly Lys Thr Val Ala Ala Pro Ser Gly Ser Asp
450 455 460
Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp
465 470 475 480
Arg Val Thr Ile Thr Cys Arg Ala Ser Arg Pro Ile Ser Asp Trp Leu
485 490 495
His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Ala
500 505 510
Trp Ala Ser Ser Leu Tyr Glu Gly Val Pro Ser Arg Phe Ser Gly Ser
515 520 525
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu
530 535 540
Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Glu Gly Trp Gly Pro Pro Thr
545 550 555 560
Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
565 570
<210> 26
<211> 571
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 26
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Tyr Ile Lys Asp Thr
20 25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Thr Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Val Pro Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Ile Tyr Asp Asp Tyr His Tyr Asp Asp Tyr Tyr Ala Met
100 105 110
Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr
115 120 125
Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser
130 135 140
Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu
145 150 155 160
Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His
165 170 175
Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser
180 185 190
Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys
195 200 205
Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu
210 215 220
Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
225 230 235 240
Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
245 250 255
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
260 265 270
Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp
275 280 285
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
290 295 300
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
305 310 315 320
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu
325 330 335
Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
340 345 350
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys
355 360 365
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
370 375 380
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
385 390 395 400
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
405 410 415
Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
420 425 430
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
435 440 445
Leu Ser Leu Ser Pro Gly Lys Thr Val Ala Ala Pro Ser Gly Ser Asp
450 455 460
Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp
465 470 475 480
Arg Val Thr Ile Thr Cys Arg Ala Ser Arg Pro Ile Ser Asp Trp Leu
485 490 495
His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Ala
500 505 510
Trp Ala Ser Ser Leu Gln Gly Gly Val Pro Ser Arg Phe Ser Gly Ser
515 520 525
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu
530 535 540
Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Glu Gly Trp Gly Pro Pro Thr
545 550 555 560
Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
565 570
<210> 27
<211> 579
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 27
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Tyr Ile Lys Asp Thr
20 25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Thr Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Val Pro Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Ile Tyr Asp Asp Tyr His Tyr Asp Asp Tyr Tyr Ala Met
100 105 110
Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr
115 120 125
Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser
130 135 140
Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu
145 150 155 160
Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His
165 170 175
Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser
180 185 190
Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys
195 200 205
Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu
210 215 220
Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
225 230 235 240
Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
245 250 255
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
260 265 270
Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp
275 280 285
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
290 295 300
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
305 310 315 320
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu
325 330 335
Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
340 345 350
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys
355 360 365
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
370 375 380
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
385 390 395 400
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
405 410 415
Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
420 425 430
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
435 440 445
Leu Ser Leu Ser Pro Gly Lys Thr Val Ala Ala Pro Ser Gly Ser Glu
450 455 460
Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser
465 470 475 480
Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Asn Phe Gly
485 490 495
Met Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser
500 505 510
Trp Ile Ile Ser Ser Gly Thr Glu Thr Tyr Tyr Ala Asp Ser Val Lys
515 520 525
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
530 535 540
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
545 550 555 560
Lys Ser Leu Gly Arg Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr
565 570 575
Val Ser Ser
<210> 28
<211> 574
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 28
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Tyr Ile Lys Asp Thr
20 25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Thr Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Val Pro Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Ile Tyr Asp Asp Tyr His Tyr Asp Asp Tyr Tyr Ala Met
100 105 110
Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr
115 120 125
Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser
130 135 140
Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu
145 150 155 160
Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His
165 170 175
Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser
180 185 190
Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys
195 200 205
Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu
210 215 220
Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
225 230 235 240
Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
245 250 255
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
260 265 270
Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp
275 280 285
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
290 295 300
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
305 310 315 320
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu
325 330 335
Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
340 345 350
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys
355 360 365
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
370 375 380
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
385 390 395 400
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
405 410 415
Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
420 425 430
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
435 440 445
Leu Ser Leu Ser Pro Gly Lys Gly Ser Ala Ser Thr Lys Gly Pro Thr
450 455 460
Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser
465 470 475 480
Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Arg Pro Ile Ser
485 490 495
Asp Trp Leu His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu
500 505 510
Leu Ile Ala Trp Ala Ser Thr Leu Asp Ser Gly Val Pro Ser Arg Phe
515 520 525
Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu
530 535 540
Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Glu Gly Trp Gly
545 550 555 560
Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
565 570
<210> 29
<211> 574
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 29
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Tyr Ile Lys Asp Thr
20 25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Thr Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Val Pro Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Ile Tyr Asp Asp Tyr His Tyr Asp Asp Tyr Tyr Ala Met
100 105 110
Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr
115 120 125
Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser
130 135 140
Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu
145 150 155 160
Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His
165 170 175
Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser
180 185 190
Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys
195 200 205
Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu
210 215 220
Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
225 230 235 240
Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
245 250 255
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
260 265 270
Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp
275 280 285
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
290 295 300
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
305 310 315 320
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu
325 330 335
Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
340 345 350
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys
355 360 365
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
370 375 380
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
385 390 395 400
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
405 410 415
Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
420 425 430
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
435 440 445
Leu Ser Leu Ser Pro Gly Lys Gly Ser Ala Ser Thr Lys Gly Pro Thr
450 455 460
Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser
465 470 475 480
Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Arg Pro Ile Ser
485 490 495
Asp Trp Leu His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu
500 505 510
Leu Ile Ala Trp Ala Ser Ser Leu Tyr Glu Gly Val Pro Ser Arg Phe
515 520 525
Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu
530 535 540
Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Glu Gly Trp Gly
545 550 555 560
Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
565 570
<210> 30
<211> 574
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 30
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Tyr Ile Lys Asp Thr
20 25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Thr Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Val Pro Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Ile Tyr Asp Asp Tyr His Tyr Asp Asp Tyr Tyr Ala Met
100 105 110
Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr
115 120 125
Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser
130 135 140
Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu
145 150 155 160
Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His
165 170 175
Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser
180 185 190
Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys
195 200 205
Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu
210 215 220
Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
225 230 235 240
Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
245 250 255
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
260 265 270
Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp
275 280 285
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
290 295 300
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
305 310 315 320
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu
325 330 335
Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
340 345 350
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys
355 360 365
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
370 375 380
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
385 390 395 400
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
405 410 415
Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
420 425 430
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
435 440 445
Leu Ser Leu Ser Pro Gly Lys Gly Ser Ala Ser Thr Lys Gly Pro Thr
450 455 460
Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser
465 470 475 480
Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Arg Pro Ile Ser
485 490 495
Asp Trp Leu His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu
500 505 510
Leu Ile Ala Trp Ala Ser Ser Leu Gln Gly Gly Val Pro Ser Arg Phe
515 520 525
Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu
530 535 540
Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Glu Gly Trp Gly
545 550 555 560
Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
565 570
<210> 31
<211> 582
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 31
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Tyr Ile Lys Asp Thr
20 25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Thr Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Val Pro Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Ile Tyr Asp Asp Tyr His Tyr Asp Asp Tyr Tyr Ala Met
100 105 110
Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr
115 120 125
Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser
130 135 140
Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu
145 150 155 160
Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His
165 170 175
Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser
180 185 190
Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys
195 200 205
Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu
210 215 220
Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
225 230 235 240
Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
245 250 255
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
260 265 270
Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp
275 280 285
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
290 295 300
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
305 310 315 320
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu
325 330 335
Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
340 345 350
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys
355 360 365
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
370 375 380
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
385 390 395 400
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
405 410 415
Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
420 425 430
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
435 440 445
Leu Ser Leu Ser Pro Gly Lys Gly Ser Ala Ser Thr Lys Gly Pro Thr
450 455 460
Gly Ser Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro
465 470 475 480
Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg
485 490 495
Asn Phe Gly Met Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu
500 505 510
Trp Val Ser Trp Ile Ile Ser Ser Gly Thr Glu Thr Tyr Tyr Ala Asp
515 520 525
Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr
530 535 540
Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
545 550 555 560
Tyr Cys Ala Lys Ser Leu Gly Arg Phe Asp Tyr Trp Gly Gln Gly Thr
565 570 575
Leu Val Thr Val Ser Ser
580
<210> 32
<211> 582
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 32
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Tyr Ile Lys Asp Thr
20 25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Thr Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Val Pro Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Ile Tyr Asp Asp Tyr His Tyr Asp Asp Tyr Tyr Ala Met
100 105 110
Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr
115 120 125
Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser
130 135 140
Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu
145 150 155 160
Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His
165 170 175
Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser
180 185 190
Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys
195 200 205
Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu
210 215 220
Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
225 230 235 240
Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
245 250 255
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
260 265 270
Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp
275 280 285
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
290 295 300
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
305 310 315 320
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu
325 330 335
Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
340 345 350
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys
355 360 365
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
370 375 380
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
385 390 395 400
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
405 410 415
Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
420 425 430
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
435 440 445
Leu Ser Leu Ser Pro Gly Lys Gly Ser Glu Pro Lys Ser Cys Asp Lys
450 455 460
Thr His Thr Cys Pro Pro Cys Pro Gly Ser Asp Ile Gln Met Thr Gln
465 470 475 480
Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr
485 490 495
Cys Arg Ala Ser Arg Pro Ile Ser Asp Trp Leu His Trp Tyr Gln Gln
500 505 510
Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Ala Trp Ala Ser Thr Leu
515 520 525
Asp Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp
530 535 540
Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr
545 550 555 560
Tyr Cys Leu Gln Glu Gly Trp Gly Pro Pro Thr Phe Gly Gln Gly Thr
565 570 575
Lys Val Glu Ile Lys Arg
580
<210> 33
<211> 582
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 33
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Tyr Ile Lys Asp Thr
20 25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Thr Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Val Pro Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Ile Tyr Asp Asp Tyr His Tyr Asp Asp Tyr Tyr Ala Met
100 105 110
Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr
115 120 125
Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser
130 135 140
Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu
145 150 155 160
Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His
165 170 175
Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser
180 185 190
Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys
195 200 205
Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu
210 215 220
Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
225 230 235 240
Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
245 250 255
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
260 265 270
Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp
275 280 285
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
290 295 300
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
305 310 315 320
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu
325 330 335
Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
340 345 350
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys
355 360 365
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
370 375 380
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
385 390 395 400
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
405 410 415
Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
420 425 430
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
435 440 445
Leu Ser Leu Ser Pro Gly Lys Gly Ser Glu Pro Lys Ser Cys Asp Lys
450 455 460
Thr His Thr Cys Pro Pro Cys Pro Gly Ser Asp Ile Gln Met Thr Gln
465 470 475 480
Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr
485 490 495
Cys Arg Ala Ser Arg Pro Ile Ser Asp Trp Leu His Trp Tyr Gln Gln
500 505 510
Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Ala Trp Ala Ser Ser Leu
515 520 525
Tyr Glu Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp
530 535 540
Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr
545 550 555 560
Tyr Cys Leu Gln Glu Gly Trp Gly Pro Pro Thr Phe Gly Gln Gly Thr
565 570 575
Lys Val Glu Ile Lys Arg
580
<210> 34
<211> 582
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 34
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Tyr Ile Lys Asp Thr
20 25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Thr Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Val Pro Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Ile Tyr Asp Asp Tyr His Tyr Asp Asp Tyr Tyr Ala Met
100 105 110
Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr
115 120 125
Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser
130 135 140
Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu
145 150 155 160
Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His
165 170 175
Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser
180 185 190
Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys
195 200 205
Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu
210 215 220
Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
225 230 235 240
Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
245 250 255
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
260 265 270
Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp
275 280 285
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
290 295 300
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
305 310 315 320
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu
325 330 335
Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
340 345 350
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys
355 360 365
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
370 375 380
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
385 390 395 400
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
405 410 415
Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
420 425 430
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
435 440 445
Leu Ser Leu Ser Pro Gly Lys Gly Ser Glu Pro Lys Ser Cys Asp Lys
450 455 460
Thr His Thr Cys Pro Pro Cys Pro Gly Ser Asp Ile Gln Met Thr Gln
465 470 475 480
Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr
485 490 495
Cys Arg Ala Ser Arg Pro Ile Ser Asp Trp Leu His Trp Tyr Gln Gln
500 505 510
Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Ala Trp Ala Ser Ser Leu
515 520 525
Gln Gly Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp
530 535 540
Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr
545 550 555 560
Tyr Cys Leu Gln Glu Gly Trp Gly Pro Pro Thr Phe Gly Gln Gly Thr
565 570 575
Lys Val Glu Ile Lys Arg
580
<210> 35
<211> 590
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 35
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Tyr Ile Lys Asp Thr
20 25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Thr Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Val Pro Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Ile Tyr Asp Asp Tyr His Tyr Asp Asp Tyr Tyr Ala Met
100 105 110
Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr
115 120 125
Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser
130 135 140
Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu
145 150 155 160
Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His
165 170 175
Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser
180 185 190
Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys
195 200 205
Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu
210 215 220
Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
225 230 235 240
Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
245 250 255
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
260 265 270
Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp
275 280 285
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
290 295 300
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
305 310 315 320
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu
325 330 335
Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
340 345 350
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys
355 360 365
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
370 375 380
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
385 390 395 400
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
405 410 415
Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
420 425 430
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
435 440 445
Leu Ser Leu Ser Pro Gly Lys Gly Ser Glu Pro Lys Ser Cys Asp Lys
450 455 460
Thr His Thr Cys Pro Pro Cys Pro Gly Ser Glu Val Gln Leu Leu Glu
465 470 475 480
Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys
485 490 495
Ala Ala Ser Gly Phe Thr Phe Arg Asn Phe Gly Met Gly Trp Val Arg
500 505 510
Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Trp Ile Ile Ser Ser
515 520 525
Gly Thr Glu Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile
530 535 540
Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu
545 550 555 560
Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Ser Leu Gly Arg
565 570 575
Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
580 585 590
<210> 36
<211> 585
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 36
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Tyr Ile Lys Asp Thr
20 25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Thr Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Val Pro Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Ile Tyr Asp Asp Tyr His Tyr Asp Asp Tyr Tyr Ala Met
100 105 110
Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr
115 120 125
Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser
130 135 140
Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu
145 150 155 160
Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His
165 170 175
Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser
180 185 190
Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys
195 200 205
Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu
210 215 220
Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
225 230 235 240
Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
245 250 255
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
260 265 270
Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp
275 280 285
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
290 295 300
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
305 310 315 320
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu
325 330 335
Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
340 345 350
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys
355 360 365
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
370 375 380
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
385 390 395 400
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
405 410 415
Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
420 425 430
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
435 440 445
Leu Ser Leu Ser Pro Gly Lys Gly Ser Glu Leu Gln Leu Glu Glu Ser
450 455 460
Cys Ala Glu Ala Gln Asp Gly Glu Leu Asp Gly Gly Ser Asp Ile Gln
465 470 475 480
Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val
485 490 495
Thr Ile Thr Cys Arg Ala Ser Arg Pro Ile Ser Asp Trp Leu His Trp
500 505 510
Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Ala Trp Ala
515 520 525
Ser Thr Leu Asp Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser
530 535 540
Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe
545 550 555 560
Ala Thr Tyr Tyr Cys Leu Gln Glu Gly Trp Gly Pro Pro Thr Phe Gly
565 570 575
Gln Gly Thr Lys Val Glu Ile Lys Arg
580 585
<210> 37
<211> 585
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 37
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Tyr Ile Lys Asp Thr
20 25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Thr Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Val Pro Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Ile Tyr Asp Asp Tyr His Tyr Asp Asp Tyr Tyr Ala Met
100 105 110
Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr
115 120 125
Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser
130 135 140
Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu
145 150 155 160
Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His
165 170 175
Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser
180 185 190
Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys
195 200 205
Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu
210 215 220
Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
225 230 235 240
Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
245 250 255
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
260 265 270
Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp
275 280 285
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
290 295 300
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
305 310 315 320
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu
325 330 335
Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
340 345 350
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys
355 360 365
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
370 375 380
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
385 390 395 400
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
405 410 415
Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
420 425 430
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
435 440 445
Leu Ser Leu Ser Pro Gly Lys Gly Ser Glu Leu Gln Leu Glu Glu Ser
450 455 460
Cys Ala Glu Ala Gln Asp Gly Glu Leu Asp Gly Gly Ser Asp Ile Gln
465 470 475 480
Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val
485 490 495
Thr Ile Thr Cys Arg Ala Ser Arg Pro Ile Ser Asp Trp Leu His Trp
500 505 510
Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Ala Trp Ala
515 520 525
Ser Ser Leu Tyr Glu Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser
530 535 540
Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe
545 550 555 560
Ala Thr Tyr Tyr Cys Leu Gln Glu Gly Trp Gly Pro Pro Thr Phe Gly
565 570 575
Gln Gly Thr Lys Val Glu Ile Lys Arg
580 585
<210> 38
<211> 585
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 38
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Tyr Ile Lys Asp Thr
20 25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Thr Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Val Pro Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Ile Tyr Asp Asp Tyr His Tyr Asp Asp Tyr Tyr Ala Met
100 105 110
Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr
115 120 125
Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser
130 135 140
Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu
145 150 155 160
Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His
165 170 175
Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser
180 185 190
Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys
195 200 205
Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu
210 215 220
Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
225 230 235 240
Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
245 250 255
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
260 265 270
Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp
275 280 285
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
290 295 300
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
305 310 315 320
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu
325 330 335
Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
340 345 350
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys
355 360 365
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
370 375 380
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
385 390 395 400
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
405 410 415
Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
420 425 430
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
435 440 445
Leu Ser Leu Ser Pro Gly Lys Gly Ser Glu Leu Gln Leu Glu Glu Ser
450 455 460
Cys Ala Glu Ala Gln Asp Gly Glu Leu Asp Gly Gly Ser Asp Ile Gln
465 470 475 480
Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val
485 490 495
Thr Ile Thr Cys Arg Ala Ser Arg Pro Ile Ser Asp Trp Leu His Trp
500 505 510
Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Ala Trp Ala
515 520 525
Ser Ser Leu Gln Gly Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser
530 535 540
Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe
545 550 555 560
Ala Thr Tyr Tyr Cys Leu Gln Glu Gly Trp Gly Pro Pro Thr Phe Gly
565 570 575
Gln Gly Thr Lys Val Glu Ile Lys Arg
580 585
<210> 39
<211> 593
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 39
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Tyr Ile Lys Asp Thr
20 25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Thr Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Val Pro Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Ile Tyr Asp Asp Tyr His Tyr Asp Asp Tyr Tyr Ala Met
100 105 110
Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr
115 120 125
Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser
130 135 140
Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu
145 150 155 160
Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His
165 170 175
Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser
180 185 190
Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys
195 200 205
Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu
210 215 220
Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
225 230 235 240
Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
245 250 255
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
260 265 270
Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp
275 280 285
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
290 295 300
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
305 310 315 320
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu
325 330 335
Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
340 345 350
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys
355 360 365
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
370 375 380
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
385 390 395 400
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
405 410 415
Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
420 425 430
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
435 440 445
Leu Ser Leu Ser Pro Gly Lys Gly Ser Glu Leu Gln Leu Glu Glu Ser
450 455 460
Cys Ala Glu Ala Gln Asp Gly Glu Leu Asp Gly Gly Ser Glu Val Gln
465 470 475 480
Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg
485 490 495
Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Asn Phe Gly Met Gly
500 505 510
Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Trp Ile
515 520 525
Ile Ser Ser Gly Thr Glu Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg
530 535 540
Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met
545 550 555 560
Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Ser
565 570 575
Leu Gly Arg Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser
580 585 590
Ser
<210> 40
<211> 457
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 40
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Tyr Ile Lys Asp Thr
20 25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Thr Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Val Pro Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Ile Tyr Asp Asp Tyr His Tyr Asp Asp Tyr Tyr Ala Met
100 105 110
Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr
115 120 125
Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser
130 135 140
Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu
145 150 155 160
Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His
165 170 175
Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser
180 185 190
Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys
195 200 205
Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu
210 215 220
Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
225 230 235 240
Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
245 250 255
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
260 265 270
Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp
275 280 285
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
290 295 300
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
305 310 315 320
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu
325 330 335
Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
340 345 350
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys
355 360 365
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
370 375 380
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
385 390 395 400
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
405 410 415
Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
420 425 430
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
435 440 445
Leu Ser Leu Ser Pro Gly Lys Gly Ser
450 455
<210> 41
<211> 466
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 41
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Tyr Ile Lys Asp Thr
20 25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Thr Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Val Pro Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Ile Tyr Asp Asp Tyr His Tyr Asp Asp Tyr Tyr Ala Met
100 105 110
Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr
115 120 125
Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser
130 135 140
Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu
145 150 155 160
Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His
165 170 175
Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser
180 185 190
Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys
195 200 205
Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu
210 215 220
Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
225 230 235 240
Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
245 250 255
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
260 265 270
Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp
275 280 285
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
290 295 300
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
305 310 315 320
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu
325 330 335
Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
340 345 350
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys
355 360 365
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
370 375 380
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
385 390 395 400
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
405 410 415
Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
420 425 430
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
435 440 445
Leu Ser Leu Ser Pro Gly Lys Gly Ser Ala Ser Thr Lys Gly Pro Thr
450 455 460
Gly Ser
465
<210> 42
<211> 474
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 42
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Tyr Ile Lys Asp Thr
20 25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Thr Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Val Pro Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Ile Tyr Asp Asp Tyr His Tyr Asp Asp Tyr Tyr Ala Met
100 105 110
Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr
115 120 125
Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser
130 135 140
Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu
145 150 155 160
Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His
165 170 175
Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser
180 185 190
Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys
195 200 205
Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu
210 215 220
Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
225 230 235 240
Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
245 250 255
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
260 265 270
Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp
275 280 285
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
290 295 300
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
305 310 315 320
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu
325 330 335
Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
340 345 350
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys
355 360 365
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
370 375 380
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
385 390 395 400
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
405 410 415
Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
420 425 430
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
435 440 445
Leu Ser Leu Ser Pro Gly Lys Gly Ser Glu Pro Lys Ser Cys Asp Lys
450 455 460
Thr His Thr Cys Pro Pro Cys Pro Gly Ser
465 470
<210> 43
<211> 477
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 43
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Tyr Ile Lys Asp Thr
20 25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Thr Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Val Pro Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Ile Tyr Asp Asp Tyr His Tyr Asp Asp Tyr Tyr Ala Met
100 105 110
Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr
115 120 125
Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser
130 135 140
Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu
145 150 155 160
Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His
165 170 175
Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser
180 185 190
Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys
195 200 205
Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu
210 215 220
Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
225 230 235 240
Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
245 250 255
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
260 265 270
Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp
275 280 285
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
290 295 300
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
305 310 315 320
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu
325 330 335
Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
340 345 350
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys
355 360 365
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
370 375 380
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
385 390 395 400
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
405 410 415
Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
420 425 430
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
435 440 445
Leu Ser Leu Ser Pro Gly Lys Gly Ser Glu Leu Gln Leu Glu Glu Ser
450 455 460
Cys Ala Glu Ala Gln Asp Gly Glu Leu Asp Gly Gly Ser
465 470 475
<210> 44
<211> 332
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 44
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
1 5 10 15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Asn Ile Val His Ile
20 25 30
Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Arg Leu Leu Ile Tyr Lys Ile Ser Asp Arg Phe Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Asp Asp Val Gly Ile Tyr Tyr Cys Phe Gln Gly
85 90 95
Ser His Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105 110
Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
115 120 125
Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
130 135 140
Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
145 150 155 160
Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser
165 170 175
Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu
180 185 190
Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser
195 200 205
Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys Gly Gly Gly Gly Ser
210 215 220
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
225 230 235 240
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Arg Pro Ile Ser Asp Trp
245 250 255
Leu His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
260 265 270
Ala Trp Ala Ser Thr Leu Asp Ser Gly Val Pro Ser Arg Phe Ser Gly
275 280 285
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
290 295 300
Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Glu Gly Trp Gly Pro Pro
305 310 315 320
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
325 330
<210> 45
<211> 332
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 45
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
1 5 10 15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Asn Ile Val His Ile
20 25 30
Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Arg Leu Leu Ile Tyr Lys Ile Ser Asp Arg Phe Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Asp Asp Val Gly Ile Tyr Tyr Cys Phe Gln Gly
85 90 95
Ser His Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105 110
Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
115 120 125
Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
130 135 140
Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
145 150 155 160
Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser
165 170 175
Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu
180 185 190
Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser
195 200 205
Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys Gly Gly Gly Gly Ser
210 215 220
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
225 230 235 240
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Arg Pro Ile Ser Asp Trp
245 250 255
Leu His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
260 265 270
Ala Trp Ala Ser Ser Leu Tyr Glu Gly Val Pro Ser Arg Phe Ser Gly
275 280 285
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
290 295 300
Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Glu Gly Trp Gly Pro Pro
305 310 315 320
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
325 330
<210> 46
<211> 332
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 46
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
1 5 10 15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Asn Ile Val His Ile
20 25 30
Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Arg Leu Leu Ile Tyr Lys Ile Ser Asp Arg Phe Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Asp Asp Val Gly Ile Tyr Tyr Cys Phe Gln Gly
85 90 95
Ser His Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105 110
Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
115 120 125
Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
130 135 140
Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
145 150 155 160
Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser
165 170 175
Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu
180 185 190
Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser
195 200 205
Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys Gly Gly Gly Gly Ser
210 215 220
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
225 230 235 240
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Arg Pro Ile Ser Asp Trp
245 250 255
Leu His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
260 265 270
Ala Trp Ala Ser Ser Leu Gln Gly Gly Val Pro Ser Arg Phe Ser Gly
275 280 285
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
290 295 300
Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Glu Gly Trp Gly Pro Pro
305 310 315 320
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
325 330
<210> 47
<211> 340
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 47
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
1 5 10 15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Asn Ile Val His Ile
20 25 30
Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Arg Leu Leu Ile Tyr Lys Ile Ser Asp Arg Phe Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Asp Asp Val Gly Ile Tyr Tyr Cys Phe Gln Gly
85 90 95
Ser His Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105 110
Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
115 120 125
Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
130 135 140
Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
145 150 155 160
Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser
165 170 175
Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu
180 185 190
Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser
195 200 205
Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys Gly Gly Gly Gly Ser
210 215 220
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
225 230 235 240
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Asn Phe
245 250 255
Gly Met Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
260 265 270
Ser Trp Ile Ile Ser Ser Gly Thr Glu Thr Tyr Tyr Ala Asp Ser Val
275 280 285
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
290 295 300
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
305 310 315 320
Ala Lys Ser Leu Gly Arg Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val
325 330 335
Thr Val Ser Ser
340
<210> 48
<211> 571
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 48
Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln
1 5 10 15
Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser
20 25 30
Gly Met Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45
Trp Leu Ala His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Arg Asn Gln Val
65 70 75 80
Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr
85 90 95
Cys Ala Arg Arg Glu Thr Val Phe Tyr Trp Tyr Phe Asp Val Trp Gly
100 105 110
Arg Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
115 120 125
Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
130 135 140
Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
145 150 155 160
Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
165 170 175
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
180 185 190
Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
195 200 205
Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys
210 215 220
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
225 230 235 240
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
245 250 255
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
260 265 270
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
275 280 285
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
290 295 300
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
305 310 315 320
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
325 330 335
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
340 345 350
Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
355 360 365
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
370 375 380
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
385 390 395 400
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
405 410 415
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
420 425 430
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
435 440 445
Pro Gly Lys Gly Ser Gly Val Gln Leu Leu Glu Ser Gly Gly Gly Leu
450 455 460
Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe
465 470 475 480
Thr Phe Ala Trp Tyr Asp Met Gly Trp Val Arg Gln Ala Pro Gly Lys
485 490 495
Gly Leu Glu Trp Val Ser Ser Ile Asp Trp His Gly Glu Val Thr Tyr
500 505 510
Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser
515 520 525
Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr
530 535 540
Ala Val Tyr Tyr Cys Ala Thr Ala Glu Asp Glu Pro Gly Tyr Asp Tyr
545 550 555 560
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
565 570
<210> 49
<211> 574
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 49
Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln
1 5 10 15
Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser
20 25 30
Gly Met Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45
Trp Leu Ala His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Arg Asn Gln Val
65 70 75 80
Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr
85 90 95
Cys Ala Arg Arg Glu Thr Val Phe Tyr Trp Tyr Phe Asp Val Trp Gly
100 105 110
Arg Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
115 120 125
Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
130 135 140
Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
145 150 155 160
Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
165 170 175
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
180 185 190
Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
195 200 205
Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys
210 215 220
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
225 230 235 240
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
245 250 255
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
260 265 270
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
275 280 285
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
290 295 300
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
305 310 315 320
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
325 330 335
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
340 345 350
Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
355 360 365
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
370 375 380
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
385 390 395 400
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
405 410 415
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
420 425 430
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
435 440 445
Pro Gly Lys Gly Gly Gly Gly Ser Gly Val Gln Leu Leu Glu Ser Gly
450 455 460
Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala
465 470 475 480
Ser Gly Phe Thr Phe Ala Trp Tyr Asp Met Gly Trp Val Arg Gln Ala
485 490 495
Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile Asp Trp His Gly Glu
500 505 510
Val Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg
515 520 525
Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala
530 535 540
Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Ala Glu Asp Glu Pro Gly
545 550 555 560
Tyr Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
565 570
<210> 50
<211> 577
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 50
Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln
1 5 10 15
Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser
20 25 30
Gly Met Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45
Trp Leu Ala His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Arg Asn Gln Val
65 70 75 80
Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr
85 90 95
Cys Ala Arg Arg Glu Thr Val Phe Tyr Trp Tyr Phe Asp Val Trp Gly
100 105 110
Arg Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
115 120 125
Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
130 135 140
Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
145 150 155 160
Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
165 170 175
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
180 185 190
Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
195 200 205
Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys
210 215 220
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
225 230 235 240
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
245 250 255
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
260 265 270
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
275 280 285
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
290 295 300
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
305 310 315 320
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
325 330 335
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
340 345 350
Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
355 360 365
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
370 375 380
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
385 390 395 400
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
405 410 415
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
420 425 430
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
435 440 445
Pro Gly Lys Thr Val Ala Ala Pro Ser Gly Ser Gly Val Gln Leu Leu
450 455 460
Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser
465 470 475 480
Cys Ala Ala Ser Gly Phe Thr Phe Ala Trp Tyr Asp Met Gly Trp Val
485 490 495
Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile Asp Trp
500 505 510
His Gly Glu Val Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr
515 520 525
Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser
530 535 540
Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Ala Glu Asp
545 550 555 560
Glu Pro Gly Tyr Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser
565 570 575
Ser
<210> 51
<211> 580
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 51
Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln
1 5 10 15
Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser
20 25 30
Gly Met Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45
Trp Leu Ala His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Arg Asn Gln Val
65 70 75 80
Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr
85 90 95
Cys Ala Arg Arg Glu Thr Val Phe Tyr Trp Tyr Phe Asp Val Trp Gly
100 105 110
Arg Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
115 120 125
Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
130 135 140
Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
145 150 155 160
Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
165 170 175
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
180 185 190
Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
195 200 205
Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys
210 215 220
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
225 230 235 240
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
245 250 255
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
260 265 270
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
275 280 285
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
290 295 300
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
305 310 315 320
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
325 330 335
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
340 345 350
Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
355 360 365
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
370 375 380
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
385 390 395 400
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
405 410 415
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
420 425 430
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
435 440 445
Pro Gly Lys Gly Ser Ala Ser Thr Lys Gly Pro Thr Gly Ser Gly Val
450 455 460
Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu
465 470 475 480
Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ala Trp Tyr Asp Met
485 490 495
Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser
500 505 510
Ile Asp Trp His Gly Glu Val Thr Tyr Tyr Ala Asp Ser Val Lys Gly
515 520 525
Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln
530 535 540
Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr
545 550 555 560
Ala Glu Asp Glu Pro Gly Tyr Asp Tyr Trp Gly Gln Gly Thr Leu Val
565 570 575
Thr Val Ser Ser
580
<210> 52
<211> 588
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 52
Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln
1 5 10 15
Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser
20 25 30
Gly Met Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45
Trp Leu Ala His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Arg Asn Gln Val
65 70 75 80
Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr
85 90 95
Cys Ala Arg Arg Glu Thr Val Phe Tyr Trp Tyr Phe Asp Val Trp Gly
100 105 110
Arg Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
115 120 125
Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
130 135 140
Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
145 150 155 160
Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
165 170 175
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
180 185 190
Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
195 200 205
Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys
210 215 220
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
225 230 235 240
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
245 250 255
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
260 265 270
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
275 280 285
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
290 295 300
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
305 310 315 320
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
325 330 335
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
340 345 350
Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
355 360 365
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
370 375 380
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
385 390 395 400
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
405 410 415
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
420 425 430
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
435 440 445
Pro Gly Lys Gly Ser Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys
450 455 460
Pro Pro Cys Pro Gly Ser Gly Val Gln Leu Leu Glu Ser Gly Gly Gly
465 470 475 480
Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly
485 490 495
Phe Thr Phe Ala Trp Tyr Asp Met Gly Trp Val Arg Gln Ala Pro Gly
500 505 510
Lys Gly Leu Glu Trp Val Ser Ser Ile Asp Trp His Gly Glu Val Thr
515 520 525
Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn
530 535 540
Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp
545 550 555 560
Thr Ala Val Tyr Tyr Cys Ala Thr Ala Glu Asp Glu Pro Gly Tyr Asp
565 570 575
Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
580 585
<210> 53
<211> 591
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 53
Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln
1 5 10 15
Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser
20 25 30
Gly Met Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45
Trp Leu Ala His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Arg Asn Gln Val
65 70 75 80
Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr
85 90 95
Cys Ala Arg Arg Glu Thr Val Phe Tyr Trp Tyr Phe Asp Val Trp Gly
100 105 110
Arg Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
115 120 125
Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
130 135 140
Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
145 150 155 160
Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
165 170 175
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
180 185 190
Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
195 200 205
Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys
210 215 220
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
225 230 235 240
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
245 250 255
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
260 265 270
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
275 280 285
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
290 295 300
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
305 310 315 320
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
325 330 335
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
340 345 350
Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
355 360 365
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
370 375 380
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
385 390 395 400
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
405 410 415
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
420 425 430
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
435 440 445
Pro Gly Lys Gly Ser Glu Leu Gln Leu Glu Glu Ser Cys Ala Glu Ala
450 455 460
Gln Asp Gly Glu Leu Asp Gly Gly Ser Gly Val Gln Leu Leu Glu Ser
465 470 475 480
Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala
485 490 495
Ala Ser Gly Phe Thr Phe Ala Trp Tyr Asp Met Gly Trp Val Arg Gln
500 505 510
Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile Asp Trp His Gly
515 520 525
Glu Val Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser
530 535 540
Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg
545 550 555 560
Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Ala Glu Asp Glu Pro
565 570 575
Gly Tyr Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
580 585 590
<210> 54
<211> 338
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 54
Asp Ile Val Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Ser Val Asp Tyr Asp
20 25 30
Gly Asp Ser Tyr Met Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro
35 40 45
Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Glu Ser Gly Ile Pro Ser
50 55 60
Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser
65 70 75 80
Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Ser Asn
85 90 95
Glu Asp Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
100 105 110
Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln
115 120 125
Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr
130 135 140
Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser
145 150 155 160
Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr
165 170 175
Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys
180 185 190
His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro
195 200 205
Val Thr Lys Ser Phe Asn Arg Gly Glu Cys Gly Ser Gly Val Gln Leu
210 215 220
Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu
225 230 235 240
Ser Cys Ala Ala Ser Gly Phe Thr Phe Ala Trp Tyr Asp Met Gly Trp
245 250 255
Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile Asp
260 265 270
Trp His Gly Glu Val Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe
275 280 285
Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn
290 295 300
Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Ala Glu
305 310 315 320
Asp Glu Pro Gly Tyr Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val
325 330 335
Ser Ser
<210> 55
<211> 341
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 55
Asp Ile Val Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Ser Val Asp Tyr Asp
20 25 30
Gly Asp Ser Tyr Met Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro
35 40 45
Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Glu Ser Gly Ile Pro Ser
50 55 60
Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser
65 70 75 80
Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Ser Asn
85 90 95
Glu Asp Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
100 105 110
Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln
115 120 125
Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr
130 135 140
Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser
145 150 155 160
Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr
165 170 175
Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys
180 185 190
His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro
195 200 205
Val Thr Lys Ser Phe Asn Arg Gly Glu Cys Gly Gly Gly Gly Ser Gly
210 215 220
Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser
225 230 235 240
Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ala Trp Tyr Asp
245 250 255
Met Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser
260 265 270
Ser Ile Asp Trp His Gly Glu Val Thr Tyr Tyr Ala Asp Ser Val Lys
275 280 285
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
290 295 300
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
305 310 315 320
Thr Ala Glu Asp Glu Pro Gly Tyr Asp Tyr Trp Gly Gln Gly Thr Leu
325 330 335
Val Thr Val Ser Ser
340
<210> 56
<211> 344
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 56
Asp Ile Val Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Ser Val Asp Tyr Asp
20 25 30
Gly Asp Ser Tyr Met Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro
35 40 45
Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Glu Ser Gly Ile Pro Ser
50 55 60
Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser
65 70 75 80
Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Ser Asn
85 90 95
Glu Asp Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
100 105 110
Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln
115 120 125
Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr
130 135 140
Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser
145 150 155 160
Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr
165 170 175
Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys
180 185 190
His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro
195 200 205
Val Thr Lys Ser Phe Asn Arg Gly Glu Cys Thr Val Ala Ala Pro Ser
210 215 220
Gly Ser Gly Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro
225 230 235 240
Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ala
245 250 255
Trp Tyr Asp Met Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu
260 265 270
Trp Val Ser Ser Ile Asp Trp His Gly Glu Val Thr Tyr Tyr Ala Asp
275 280 285
Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr
290 295 300
Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
305 310 315 320
Tyr Cys Ala Thr Ala Glu Asp Glu Pro Gly Tyr Asp Tyr Trp Gly Gln
325 330 335
Gly Thr Leu Val Thr Val Ser Ser
340
<210> 57
<211> 345
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 57
Asp Ile Val Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Ser Val Asp Tyr Asp
20 25 30
Gly Asp Ser Tyr Met Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro
35 40 45
Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Glu Ser Gly Ile Pro Ser
50 55 60
Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser
65 70 75 80
Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Ser Asn
85 90 95
Glu Asp Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
100 105 110
Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln
115 120 125
Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr
130 135 140
Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser
145 150 155 160
Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr
165 170 175
Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys
180 185 190
His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro
195 200 205
Val Thr Lys Ser Phe Asn Arg Gly Glu Cys Ala Ser Thr Lys Gly Pro
210 215 220
Thr Gly Ser Gly Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln
225 230 235 240
Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
245 250 255
Ala Trp Tyr Asp Met Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
260 265 270
Glu Trp Val Ser Ser Ile Asp Trp His Gly Glu Val Thr Tyr Tyr Ala
275 280 285
Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn
290 295 300
Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
305 310 315 320
Tyr Tyr Cys Ala Thr Ala Glu Asp Glu Pro Gly Tyr Asp Tyr Trp Gly
325 330 335
Gln Gly Thr Leu Val Thr Val Ser Ser
340 345
<210> 58
<211> 353
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 58
Asp Ile Val Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Ser Val Asp Tyr Asp
20 25 30
Gly Asp Ser Tyr Met Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro
35 40 45
Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Glu Ser Gly Ile Pro Ser
50 55 60
Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser
65 70 75 80
Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Ser Asn
85 90 95
Glu Asp Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
100 105 110
Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln
115 120 125
Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr
130 135 140
Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser
145 150 155 160
Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr
165 170 175
Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys
180 185 190
His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro
195 200 205
Val Thr Lys Ser Phe Asn Arg Gly Glu Cys Glu Pro Lys Ser Cys Asp
210 215 220
Lys Thr His Thr Cys Pro Pro Cys Pro Gly Ser Gly Val Gln Leu Leu
225 230 235 240
Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser
245 250 255
Cys Ala Ala Ser Gly Phe Thr Phe Ala Trp Tyr Asp Met Gly Trp Val
260 265 270
Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile Asp Trp
275 280 285
His Gly Glu Val Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr
290 295 300
Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser
305 310 315 320
Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Ala Glu Asp
325 330 335
Glu Pro Gly Tyr Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser
340 345 350
Ser
<210> 59
<211> 356
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 59
Asp Ile Val Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Ser Val Asp Tyr Asp
20 25 30
Gly Asp Ser Tyr Met Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro
35 40 45
Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Glu Ser Gly Ile Pro Ser
50 55 60
Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser
65 70 75 80
Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Ser Asn
85 90 95
Glu Asp Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
100 105 110
Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln
115 120 125
Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr
130 135 140
Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser
145 150 155 160
Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr
165 170 175
Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys
180 185 190
His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro
195 200 205
Val Thr Lys Ser Phe Asn Arg Gly Glu Cys Glu Leu Gln Leu Glu Glu
210 215 220
Ser Cys Ala Glu Ala Gln Asp Gly Glu Leu Asp Gly Gly Ser Gly Val
225 230 235 240
Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu
245 250 255
Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ala Trp Tyr Asp Met
260 265 270
Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser
275 280 285
Ile Asp Trp His Gly Glu Val Thr Tyr Tyr Ala Asp Ser Val Lys Gly
290 295 300
Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln
305 310 315 320
Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr
325 330 335
Ala Glu Asp Glu Pro Gly Tyr Asp Tyr Trp Gly Gln Gly Thr Leu Val
340 345 350
Thr Val Ser Ser
355
<210> 60
<211> 324
<212> DNA
<213> 人
<400> 60
gacatccaga tgacccaatc accatcctcc ctgtctgcat ctgtaggaga ccgtgtcacc 60
atcacttgcc gggcaagtcg ccccattagc gactggttac attggtatca gcagaaacca 120
gggaaagccc ccaagctcct gatcgcctgg gcgtcctcgt tgtacgaggg ggtcccatca 180
cgtttcagtg gcagtgggtc ggggacagat ttcactctca ccatcagcag tctgcaaccc 240
gaagatttcg ctacgtacta ctgtttgcag gaggggtggg gtcctccgac gttcggccaa 300
gggaccaagg tggaaatcaa acgg 324
<210> 61
<211> 324
<212> DNA
<213> 人
<400> 61
gacatccaga tgacccaatc accatcctcc ctgtctgcat ctgtaggaga ccgtgtcacc 60
atcacttgcc gggcaagtcg ccccattagc gactggttac attggtatca gcagaaacca 120
gggaaagccc ccaagctcct gatcgcctgg gcgtccagct tgcagggggg ggtcccatca 180
cgtttcagtg gcagtgggtc ggggacagat ttcactctca ccatcagcag tctgcaaccc 240
gaagatttcg ctacgtacta ctgtttgcag gaggggtggg gtcctccgac gttcggccaa 300
gggaccaagg tggaaatcaa acgg 324
<210> 62
<211> 129
<212> PRT
<213> 人
<400> 62
His Lys Cys Asp Ile Thr Leu Gln Glu Ile Ile Lys Thr Leu Asn Ser
1 5 10 15
Leu Thr Glu Gln Lys Thr Leu Cys Thr Glu Leu Thr Val Thr Asp Ile
20 25 30
Phe Ala Ala Ser Lys Asn Thr Thr Glu Lys Glu Thr Phe Cys Arg Ala
35 40 45
Ala Thr Val Leu Arg Gln Phe Tyr Ser His His Glu Lys Asp Thr Arg
50 55 60
Cys Leu Gly Ala Thr Ala Gln Gln Phe His Arg His Lys Gln Leu Ile
65 70 75 80
Arg Phe Leu Lys Arg Leu Asp Arg Asn Leu Trp Gly Leu Ala Gly Leu
85 90 95
Asn Ser Cys Pro Val Lys Glu Ala Asn Gln Ser Thr Leu Glu Asn Phe
100 105 110
Leu Glu Arg Leu Lys Thr Ile Met Arg Glu Lys Tyr Ser Lys Cys Ser
115 120 125
Ser
<210> 63
<211> 112
<212> PRT
<213> 人
<400> 63
Gly Pro Val Pro Pro Ser Thr Ala Leu Arg Glu Leu Ile Glu Glu Leu
1 5 10 15
Val Asn Ile Thr Gln Asn Gln Lys Ala Pro Leu Cys Asn Gly Ser Met
20 25 30
Val Trp Ser Ile Asn Leu Thr Ala Gly Met Tyr Cys Ala Ala Leu Glu
35 40 45
Ser Leu Ile Asn Val Ser Gly Cys Ser Ala Ile Glu Lys Thr Gln Arg
50 55 60
Met Leu Ser Gly Phe Cys Pro His Lys Val Ser Ala Gly Gln Phe Ser
65 70 75 80
Ser Leu His Val Arg Asp Thr Lys Ile Glu Val Ala Gln Phe Val Lys
85 90 95
Asp Leu Leu Leu His Leu Lys Lys Leu Phe Arg Glu Gly Arg Phe Asn
100 105 110
<210> 64
<211> 19
<212> PRT
<213> 未知
<220>
<223> 哺乳动物信号序列
<400> 64
Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly
1 5 10 15
Val His Ser
<210> 65
<211> 449
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 65
Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln
1 5 10 15
Thr Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr
20 25 30
Ser Val His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu
35 40 45
Gly Val Ile Trp Ala Ser Gly Gly Thr Asp Tyr Asn Ser Ala Leu Met
50 55 60
Ser Arg Leu Ser Ile Ser Lys Asp Thr Ser Arg Asn Gln Val Val Leu
65 70 75 80
Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala
85 90 95
Arg Asp Pro Pro Ser Ser Leu Leu Arg Leu Asp Tyr Trp Gly Arg Gly
100 105 110
Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe
115 120 125
Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu
130 135 140
Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp
145 150 155 160
Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu
165 170 175
Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser
180 185 190
Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro
195 200 205
Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys
210 215 220
Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro
225 230 235 240
Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser
245 250 255
Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp
260 265 270
Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn
275 280 285
Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val
290 295 300
Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu
305 310 315 320
Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys
325 330 335
Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr
340 345 350
Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr
355 360 365
Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu
370 375 380
Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu
385 390 395 400
Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys
405 410 415
Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu
420 425 430
Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
435 440 445
Lys
<210> 66
<211> 220
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 66
Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
1 5 10 15
Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser
20 25 30
Gly Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
35 40 45
Pro Pro Lys Leu Leu Ile Tyr Gly Ala Ser Thr Arg Glu Ser Gly Val
50 55 60
Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65 70 75 80
Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Asn
85 90 95
Val His Ser Phe Pro Phe Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile
100 105 110
Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp
115 120 125
Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn
130 135 140
Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu
145 150 155 160
Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp
165 170 175
Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr
180 185 190
Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser
195 200 205
Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
210 215 220
<210> 67
<211> 456
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 67
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Val Ser Gly Glu Ile Ser Thr Gly Tyr
20 25 30
Tyr Phe His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met
35 40 45
Gly Arg Ile Asp Pro Glu Asp Asp Ser Thr Lys Tyr Ala Glu Arg Phe
50 55 60
Lys Asp Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Thr Thr Trp Arg Ile Tyr Arg Asp Ser Ser Gly Arg Pro Phe Tyr Val
100 105 110
Met Asp Ala Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser
115 120 125
Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr
130 135 140
Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro
145 150 155 160
Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val
165 170 175
His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser
180 185 190
Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile
195 200 205
Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val
210 215 220
Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala
225 230 235 240
Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro
245 250 255
Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val
260 265 270
Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val
275 280 285
Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln
290 295 300
Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln
305 310 315 320
Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala
325 330 335
Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro
340 345 350
Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr
355 360 365
Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser
370 375 380
Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr
385 390 395 400
Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr
405 410 415
Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe
420 425 430
Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys
435 440 445
Ser Leu Ser Leu Ser Pro Gly Lys
450 455
<210> 68
<211> 214
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 68
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Leu Ala Ser Glu Asp Ile Tyr Thr Tyr
20 25 30
Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Gly Ala Asn Lys Leu Gln Asp Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Gly Ser Lys Phe Pro Leu
85 90 95
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 69
<211> 577
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 69
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Val Ser Gly Glu Ile Ser Thr Gly Tyr
20 25 30
Tyr Phe His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met
35 40 45
Gly Arg Ile Asp Pro Glu Asp Asp Ser Thr Lys Tyr Ala Glu Arg Phe
50 55 60
Lys Asp Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Thr Thr Trp Arg Ile Tyr Arg Asp Ser Ser Gly Arg Pro Phe Tyr Val
100 105 110
Met Asp Ala Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser
115 120 125
Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr
130 135 140
Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro
145 150 155 160
Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val
165 170 175
His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser
180 185 190
Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile
195 200 205
Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val
210 215 220
Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala
225 230 235 240
Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro
245 250 255
Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val
260 265 270
Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val
275 280 285
Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln
290 295 300
Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln
305 310 315 320
Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala
325 330 335
Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro
340 345 350
Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr
355 360 365
Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser
370 375 380
Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr
385 390 395 400
Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr
405 410 415
Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe
420 425 430
Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys
435 440 445
Ser Leu Ser Leu Ser Pro Gly Lys Gly Gly Gly Gly Ser Glu Val Gln
450 455 460
Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg
465 470 475 480
Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Asn Phe Gly Met Gly
485 490 495
Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Trp Ile
500 505 510
Ile Ser Ser Gly Thr Glu Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg
515 520 525
Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met
530 535 540
Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Ser
545 550 555 560
Leu Gly Arg Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser
565 570 575
Ser
<210> 70
<211> 337
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 70
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Leu Ala Ser Glu Asp Ile Tyr Thr Tyr
20 25 30
Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Gly Ala Asn Lys Leu Gln Asp Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Gly Ser Lys Phe Pro Leu
85 90 95
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys Gly Gly Gly Gly Ser Gly Val Gln Leu Leu
210 215 220
Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser
225 230 235 240
Cys Ala Ala Ser Gly Phe Thr Phe Ala Trp Tyr Asp Met Gly Trp Val
245 250 255
Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile Asp Trp
260 265 270
His Gly Glu Val Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr
275 280 285
Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser
290 295 300
Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Ala Glu Asp
305 310 315 320
Glu Pro Gly Tyr Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser
325 330 335
Ser
<210> 71
<211> 570
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 71
Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln
1 5 10 15
Thr Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr
20 25 30
Ser Val His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu
35 40 45
Gly Val Ile Trp Ala Ser Gly Gly Thr Asp Tyr Asn Ser Ala Leu Met
50 55 60
Ser Arg Leu Ser Ile Ser Lys Asp Thr Ser Arg Asn Gln Val Val Leu
65 70 75 80
Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala
85 90 95
Arg Asp Pro Pro Ser Ser Leu Leu Arg Leu Asp Tyr Trp Gly Arg Gly
100 105 110
Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe
115 120 125
Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu
130 135 140
Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp
145 150 155 160
Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu
165 170 175
Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser
180 185 190
Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro
195 200 205
Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys
210 215 220
Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro
225 230 235 240
Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser
245 250 255
Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp
260 265 270
Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn
275 280 285
Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val
290 295 300
Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu
305 310 315 320
Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys
325 330 335
Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr
340 345 350
Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr
355 360 365
Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu
370 375 380
Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu
385 390 395 400
Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys
405 410 415
Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu
420 425 430
Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
435 440 445
Lys Gly Gly Gly Gly Ser Glu Val Gln Leu Leu Glu Ser Gly Gly Gly
450 455 460
Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly
465 470 475 480
Phe Thr Phe Arg Asn Phe Gly Met Gly Trp Val Arg Gln Ala Pro Gly
485 490 495
Lys Gly Leu Glu Trp Val Ser Trp Ile Ile Ser Ser Gly Thr Glu Thr
500 505 510
Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn
515 520 525
Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp
530 535 540
Thr Ala Val Tyr Tyr Cys Ala Lys Ser Leu Gly Arg Phe Asp Tyr Trp
545 550 555 560
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
565 570
<210> 72
<211> 343
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 72
Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
1 5 10 15
Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser
20 25 30
Gly Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
35 40 45
Pro Pro Lys Leu Leu Ile Tyr Gly Ala Ser Thr Arg Glu Ser Gly Val
50 55 60
Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65 70 75 80
Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Asn
85 90 95
Val His Ser Phe Pro Phe Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile
100 105 110
Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp
115 120 125
Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn
130 135 140
Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu
145 150 155 160
Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp
165 170 175
Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr
180 185 190
Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser
195 200 205
Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys Gly Gly Gly Gly
210 215 220
Ser Gly Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly
225 230 235 240
Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ala Trp
245 250 255
Tyr Asp Met Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
260 265 270
Val Ser Ser Ile Asp Trp His Gly Glu Val Thr Tyr Tyr Ala Asp Ser
275 280 285
Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu
290 295 300
Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr
305 310 315 320
Cys Ala Thr Ala Glu Asp Glu Pro Gly Tyr Asp Tyr Trp Gly Gln Gly
325 330 335
Thr Leu Val Thr Val Ser Ser
340
<210> 73
<211> 214
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 73
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Tyr
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Val Ala Thr Tyr Tyr Cys Gln Arg Tyr Asn Arg Ala Pro Tyr
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 74
<211> 562
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 74
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr
20 25 30
Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Thr Trp Asn Ser Gly His Ile Asp Tyr Ala Asp Ser Val
50 55 60
Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Val Ser Tyr Leu Ser Thr Ala Ser Ser Leu Asp Tyr Trp Gly
100 105 110
Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
115 120 125
Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
130 135 140
Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
145 150 155 160
Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
165 170 175
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
180 185 190
Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
195 200 205
Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys
210 215 220
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
225 230 235 240
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
245 250 255
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
260 265 270
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
275 280 285
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
290 295 300
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
305 310 315 320
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
325 330 335
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
340 345 350
Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
355 360 365
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
370 375 380
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
385 390 395 400
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
405 410 415
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
420 425 430
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
435 440 445
Pro Gly Lys Ser Thr Gly Asp Ile Gln Met Thr Gln Ser Pro Ser Ser
450 455 460
Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser
465 470 475 480
Gln Trp Ile Gly Asn Leu Leu Asp Trp Tyr Gln Gln Lys Pro Gly Lys
485 490 495
Ala Pro Lys Leu Leu Ile Tyr Tyr Ala Ser Phe Leu Gln Ser Gly Val
500 505 510
Pro Ser Arg Phe Ser Gly Ser Gly Tyr Gly Thr Asp Phe Thr Leu Thr
515 520 525
Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln
530 535 540
Ala Asn Pro Ala Pro Leu Thr Phe Gly Gln Gly Thr Lys Val Glu Ile
545 550 555 560
Lys Arg
<210> 75
<211> 570
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 75
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr
20 25 30
Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Thr Trp Asn Ser Gly His Ile Asp Tyr Ala Asp Ser Val
50 55 60
Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Val Ser Tyr Leu Ser Thr Ala Ser Ser Leu Asp Tyr Trp Gly
100 105 110
Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
115 120 125
Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
130 135 140
Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
145 150 155 160
Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
165 170 175
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
180 185 190
Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
195 200 205
Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys
210 215 220
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
225 230 235 240
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
245 250 255
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
260 265 270
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
275 280 285
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
290 295 300
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
305 310 315 320
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
325 330 335
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
340 345 350
Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
355 360 365
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
370 375 380
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
385 390 395 400
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
405 410 415
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
420 425 430
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
435 440 445
Pro Gly Lys Ser Thr Gly Glu Val Gln Leu Leu Val Ser Gly Gly Gly
450 455 460
Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly
465 470 475 480
Phe Thr Phe Lys Ala Tyr Pro Met Met Trp Val Arg Gln Ala Pro Gly
485 490 495
Lys Gly Leu Glu Trp Val Ser Glu Ile Ser Pro Ser Gly Ser Tyr Thr
500 505 510
Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn
515 520 525
Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp
530 535 540
Thr Ala Val Tyr Tyr Cys Ala Lys Asp Pro Arg Lys Leu Asp Tyr Trp
545 550 555 560
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
565 570
<210> 76
<211> 569
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 76
Glu Val Gln Leu Leu Val Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Lys Ala Tyr
20 25 30
Pro Met Met Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Glu Ile Ser Pro Ser Gly Ser Tyr Thr Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Asp Pro Arg Lys Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val
100 105 110
Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Glu Val Gln Leu Leu
115 120 125
Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser
130 135 140
Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val
145 150 155 160
Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly
165 170 175
Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr
180 185 190
Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser
195 200 205
Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Ser Tyr Gly
210 215 220
Ala Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala
225 230 235 240
Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser
245 250 255
Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe
260 265 270
Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly
275 280 285
Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu
290 295 300
Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr
305 310 315 320
Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys
325 330 335
Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro
340 345 350
Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys
355 360 365
Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val
370 375 380
Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
385 390 395 400
Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu
405 410 415
Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His
420 425 430
Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys
435 440 445
Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln
450 455 460
Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu
465 470 475 480
Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro
485 490 495
Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn
500 505 510
Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu
515 520 525
Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val
530 535 540
Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln
545 550 555 560
Lys Ser Leu Ser Leu Ser Pro Gly Lys
565
<210> 77
<211> 328
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 77
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Tyr Leu Asn
20 25 30
Leu Asp Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Asn Phe Gly Ser Glu Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Tyr Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Pro Ser Phe Tyr Phe Pro Tyr
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser
115 120 125
Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser
130 135 140
Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu
145 150 155 160
Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe
165 170 175
Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu
180 185 190
Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr
195 200 205
Pro Asn Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val
210 215 220
Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys
225 230 235 240
Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg
245 250 255
Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn
260 265 270
Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser
275 280 285
Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys
290 295 300
Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr
305 310 315 320
Lys Ser Phe Asn Arg Gly Glu Cys
325
<210> 78
<211> 574
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 78
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Gly Ala Tyr
20 25 30
Pro Met Met Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Glu Ile Ser Pro Ser Gly Ser Tyr Thr Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Asp Pro Arg Lys Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val
100 105 110
Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Glu Val Gln Leu Val
115 120 125
Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg Ser Leu Arg Leu Ser
130 135 140
Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr Ala Met His Trp Val
145 150 155 160
Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Thr Trp
165 170 175
Asn Ser Gly His Ile Asp Tyr Ala Asp Ser Val Glu Gly Arg Phe Thr
180 185 190
Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser
195 200 205
Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Val Ser Tyr
210 215 220
Leu Ser Thr Ala Ser Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val
225 230 235 240
Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala
245 250 255
Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu
260 265 270
Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly
275 280 285
Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser
290 295 300
Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu
305 310 315 320
Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr
325 330 335
Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr
340 345 350
Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe
355 360 365
Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro
370 375 380
Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val
385 390 395 400
Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr
405 410 415
Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val
420 425 430
Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys
435 440 445
Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser
450 455 460
Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro
465 470 475 480
Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val
485 490 495
Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly
500 505 510
Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp
515 520 525
Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp
530 535 540
Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His
545 550 555 560
Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
565 570
<210> 79
<211> 328
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 79
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Trp Ile Gly Asn Leu
20 25 30
Leu Asp Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Tyr Ala Ser Phe Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Tyr Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Asn Pro Ala Pro Leu
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser
115 120 125
Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg
130 135 140
Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu
145 150 155 160
Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe
165 170 175
Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu
180 185 190
Gln Pro Glu Asp Val Ala Thr Tyr Tyr Cys Gln Arg Tyr Asn Arg Ala
195 200 205
Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val
210 215 220
Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys
225 230 235 240
Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg
245 250 255
Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn
260 265 270
Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser
275 280 285
Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys
290 295 300
Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr
305 310 315 320
Lys Ser Phe Asn Arg Gly Glu Cys
325
<210> 80
<211> 14
<212> PRT
<213> 小鼠(Mus Musculus)
<400> 80
Trp Ile Leu Tyr Tyr Gly Arg Ser Lys Trp Tyr Phe Asp Val
1 5 10
<210> 81
<211> 17
<212> PRT
<213> 小鼠
<400> 81
Asn Ile Asn Pro Asn Asn Gly Gly Thr Asn Tyr Asn Gln Lys Phe Lys
1 5 10 15
Asp
<210> 82
<211> 5
<212> PRT
<213> 小鼠
<400> 82
Asp Tyr Tyr Met Asn
1 5
<210> 83
<211> 16
<212> PRT
<213> 小鼠
<400> 83
Arg Ser Ser Gln Ser Ile Val Gln Ser Asn Gly Asp Thr Tyr Leu Glu
1 5 10 15
<210> 84
<211> 7
<212> PRT
<213> 小鼠
<400> 84
Arg Ile Ser Asn Arg Phe Ser
1 5
<210> 85
<211> 9
<212> PRT
<213> 小鼠
<400> 85
Phe Gln Gly Ser His Val Pro Tyr Thr
1 5
<210> 86
<211> 7
<212> PRT
<213> 小鼠
<400> 86
Arg Val Ser Asn Arg Phe Ser
1 5
<210> 87
<211> 571
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 87
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Tyr Ile Lys Asp Thr
20 25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Thr Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Val Pro Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Ile Tyr Asp Asp Tyr His Tyr Asp Asp Tyr Tyr Ala Met
100 105 110
Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr
115 120 125
Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser
130 135 140
Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu
145 150 155 160
Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His
165 170 175
Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser
180 185 190
Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys
195 200 205
Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu
210 215 220
Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
225 230 235 240
Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
245 250 255
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
260 265 270
Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp
275 280 285
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
290 295 300
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
305 310 315 320
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu
325 330 335
Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
340 345 350
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys
355 360 365
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
370 375 380
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
385 390 395 400
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
405 410 415
Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
420 425 430
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
435 440 445
Leu Ser Leu Ser Pro Gly Lys Glu Val Gln Leu Leu Glu Ser Gly Gly
450 455 460
Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser
465 470 475 480
Gly Phe Thr Phe Arg Asn Phe Gly Met Gly Trp Val Arg Gln Ala Pro
485 490 495
Gly Lys Gly Leu Glu Trp Val Ser Trp Ile Ile Ser Ser Gly Thr Glu
500 505 510
Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp
515 520 525
Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu
530 535 540
Asp Thr Ala Val Tyr Tyr Cys Ala Lys Ser Leu Gly Arg Phe Asp Tyr
545 550 555 560
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
565 570
<210> 88
<211> 577
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 88
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Tyr Ile Lys Asp Thr
20 25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Thr Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Val Pro Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Ile Tyr Asp Asp Tyr His Tyr Asp Asp Tyr Tyr Ala Met
100 105 110
Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr
115 120 125
Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser
130 135 140
Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu
145 150 155 160
Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His
165 170 175
Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser
180 185 190
Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys
195 200 205
Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu
210 215 220
Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
225 230 235 240
Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
245 250 255
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
260 265 270
Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp
275 280 285
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
290 295 300
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
305 310 315 320
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu
325 330 335
Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
340 345 350
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys
355 360 365
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
370 375 380
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
385 390 395 400
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
405 410 415
Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
420 425 430
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
435 440 445
Leu Ser Leu Ser Pro Gly Lys Thr Val Ala Ala Pro Ser Glu Val Gln
450 455 460
Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg
465 470 475 480
Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Asn Phe Gly Met Gly
485 490 495
Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Trp Ile
500 505 510
Ile Ser Ser Gly Thr Glu Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg
515 520 525
Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met
530 535 540
Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Ser
545 550 555 560
Leu Gly Arg Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser
565 570 575
Ser
<210> 89
<211> 578
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 89
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Tyr Ile Lys Asp Thr
20 25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Thr Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Val Pro Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Ile Tyr Asp Asp Tyr His Tyr Asp Asp Tyr Tyr Ala Met
100 105 110
Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr
115 120 125
Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser
130 135 140
Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu
145 150 155 160
Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His
165 170 175
Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser
180 185 190
Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys
195 200 205
Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu
210 215 220
Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
225 230 235 240
Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
245 250 255
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
260 265 270
Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp
275 280 285
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
290 295 300
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
305 310 315 320
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu
325 330 335
Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
340 345 350
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys
355 360 365
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
370 375 380
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
385 390 395 400
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
405 410 415
Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
420 425 430
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
435 440 445
Leu Ser Leu Ser Pro Gly Lys Ala Ser Thr Lys Gly Pro Thr Glu Val
450 455 460
Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu
465 470 475 480
Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Asn Phe Gly Met
485 490 495
Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Trp
500 505 510
Ile Ile Ser Ser Gly Thr Glu Thr Tyr Tyr Ala Asp Ser Val Lys Gly
515 520 525
Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln
530 535 540
Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys
545 550 555 560
Ser Leu Gly Arg Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val
565 570 575
Ser Ser
<210> 90
<211> 578
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 90
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Tyr Ile Lys Asp Thr
20 25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Thr Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Val Pro Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Ile Tyr Asp Asp Tyr His Tyr Asp Asp Tyr Tyr Ala Met
100 105 110
Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr
115 120 125
Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser
130 135 140
Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu
145 150 155 160
Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His
165 170 175
Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser
180 185 190
Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys
195 200 205
Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu
210 215 220
Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
225 230 235 240
Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
245 250 255
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
260 265 270
Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp
275 280 285
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
290 295 300
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
305 310 315 320
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu
325 330 335
Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
340 345 350
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys
355 360 365
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
370 375 380
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
385 390 395 400
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
405 410 415
Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
420 425 430
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
435 440 445
Leu Ser Leu Ser Pro Gly Lys Ala Ser Thr Lys Gly Pro Ser Glu Val
450 455 460
Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu
465 470 475 480
Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Asn Phe Gly Met
485 490 495
Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Trp
500 505 510
Ile Ile Ser Ser Gly Thr Glu Thr Tyr Tyr Ala Asp Ser Val Lys Gly
515 520 525
Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln
530 535 540
Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys
545 550 555 560
Ser Leu Gly Arg Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val
565 570 575
Ser Ser
<210> 91
<211> 569
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 91
Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln
1 5 10 15
Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser
20 25 30
Gly Met Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45
Trp Leu Ala His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Arg Asn Gln Val
65 70 75 80
Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr
85 90 95
Cys Ala Arg Arg Glu Thr Val Phe Tyr Trp Tyr Phe Asp Val Trp Gly
100 105 110
Arg Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
115 120 125
Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
130 135 140
Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
145 150 155 160
Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
165 170 175
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
180 185 190
Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
195 200 205
Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys
210 215 220
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
225 230 235 240
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
245 250 255
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
260 265 270
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
275 280 285
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
290 295 300
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
305 310 315 320
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
325 330 335
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
340 345 350
Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
355 360 365
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
370 375 380
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
385 390 395 400
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
405 410 415
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
420 425 430
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
435 440 445
Pro Gly Lys Gly Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln
450 455 460
Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
465 470 475 480
Ala Trp Tyr Asp Met Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
485 490 495
Glu Trp Val Ser Ser Ile Asp Trp His Gly Glu Val Thr Tyr Tyr Ala
500 505 510
Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn
515 520 525
Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
530 535 540
Tyr Tyr Cys Ala Thr Ala Glu Asp Glu Pro Gly Tyr Asp Tyr Trp Gly
545 550 555 560
Gln Gly Thr Leu Val Thr Val Ser Ser
565
<210> 92
<211> 575
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 92
Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln
1 5 10 15
Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser
20 25 30
Gly Met Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45
Trp Leu Ala His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Arg Asn Gln Val
65 70 75 80
Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr
85 90 95
Cys Ala Arg Arg Glu Thr Val Phe Tyr Trp Tyr Phe Asp Val Trp Gly
100 105 110
Arg Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
115 120 125
Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
130 135 140
Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
145 150 155 160
Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
165 170 175
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
180 185 190
Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
195 200 205
Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys
210 215 220
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
225 230 235 240
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
245 250 255
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
260 265 270
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
275 280 285
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
290 295 300
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
305 310 315 320
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
325 330 335
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
340 345 350
Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
355 360 365
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
370 375 380
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
385 390 395 400
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
405 410 415
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
420 425 430
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
435 440 445
Pro Gly Lys Thr Val Ala Ala Pro Ser Gly Val Gln Leu Leu Glu Ser
450 455 460
Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala
465 470 475 480
Ala Ser Gly Phe Thr Phe Ala Trp Tyr Asp Met Gly Trp Val Arg Gln
485 490 495
Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile Asp Trp His Gly
500 505 510
Glu Val Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser
515 520 525
Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg
530 535 540
Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Ala Glu Asp Glu Pro
545 550 555 560
Gly Tyr Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
565 570 575
<210> 93
<211> 576
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 93
Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln
1 5 10 15
Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser
20 25 30
Gly Met Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45
Trp Leu Ala His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Arg Asn Gln Val
65 70 75 80
Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr
85 90 95
Cys Ala Arg Arg Glu Thr Val Phe Tyr Trp Tyr Phe Asp Val Trp Gly
100 105 110
Arg Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
115 120 125
Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
130 135 140
Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
145 150 155 160
Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
165 170 175
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
180 185 190
Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
195 200 205
Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys
210 215 220
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
225 230 235 240
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
245 250 255
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
260 265 270
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
275 280 285
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
290 295 300
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
305 310 315 320
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
325 330 335
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
340 345 350
Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
355 360 365
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
370 375 380
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
385 390 395 400
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
405 410 415
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
420 425 430
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
435 440 445
Pro Gly Lys Ala Ser Thr Lys Gly Pro Thr Gly Val Gln Leu Leu Glu
450 455 460
Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys
465 470 475 480
Ala Ala Ser Gly Phe Thr Phe Ala Trp Tyr Asp Met Gly Trp Val Arg
485 490 495
Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile Asp Trp His
500 505 510
Gly Glu Val Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile
515 520 525
Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu
530 535 540
Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Ala Glu Asp Glu
545 550 555 560
Pro Gly Tyr Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
565 570 575
<210> 94
<211> 576
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 94
Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln
1 5 10 15
Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser
20 25 30
Gly Met Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45
Trp Leu Ala His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Arg Asn Gln Val
65 70 75 80
Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr
85 90 95
Cys Ala Arg Arg Glu Thr Val Phe Tyr Trp Tyr Phe Asp Val Trp Gly
100 105 110
Arg Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
115 120 125
Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
130 135 140
Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
145 150 155 160
Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
165 170 175
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
180 185 190
Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
195 200 205
Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys
210 215 220
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
225 230 235 240
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
245 250 255
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
260 265 270
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
275 280 285
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
290 295 300
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
305 310 315 320
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
325 330 335
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
340 345 350
Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
355 360 365
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
370 375 380
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
385 390 395 400
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
405 410 415
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
420 425 430
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
435 440 445
Pro Gly Lys Ala Ser Thr Lys Gly Pro Ser Gly Val Gln Leu Leu Glu
450 455 460
Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys
465 470 475 480
Ala Ala Ser Gly Phe Thr Phe Ala Trp Tyr Asp Met Gly Trp Val Arg
485 490 495
Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile Asp Trp His
500 505 510
Gly Glu Val Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile
515 520 525
Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu
530 535 540
Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Ala Glu Asp Glu
545 550 555 560
Pro Gly Tyr Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
565 570 575
<210> 95
<211> 578
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 95
Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln
1 5 10 15
Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser
20 25 30
Gly Met Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45
Trp Leu Ala His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Arg Asn Gln Val
65 70 75 80
Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr
85 90 95
Cys Ala Arg Arg Glu Thr Val Phe Tyr Trp Tyr Phe Asp Val Trp Gly
100 105 110
Arg Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
115 120 125
Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
130 135 140
Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
145 150 155 160
Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
165 170 175
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
180 185 190
Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
195 200 205
Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys
210 215 220
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
225 230 235 240
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
245 250 255
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
260 265 270
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
275 280 285
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
290 295 300
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
305 310 315 320
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
325 330 335
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
340 345 350
Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
355 360 365
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
370 375 380
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
385 390 395 400
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
405 410 415
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
420 425 430
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
435 440 445
Pro Gly Lys Gly Ser Ala Ser Thr Lys Gly Pro Ser Gly Val Gln Leu
450 455 460
Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu
465 470 475 480
Ser Cys Ala Ala Ser Gly Phe Thr Phe Ala Trp Tyr Asp Met Gly Trp
485 490 495
Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile Asp
500 505 510
Trp His Gly Glu Val Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe
515 520 525
Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn
530 535 540
Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Ala Glu
545 550 555 560
Asp Glu Pro Gly Tyr Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val
565 570 575
Ser Ser
<210> 96
<211> 578
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 96
Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln
1 5 10 15
Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser
20 25 30
Gly Met Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45
Trp Leu Ala His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Arg Asn Gln Val
65 70 75 80
Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr
85 90 95
Cys Ala Arg Arg Glu Thr Val Phe Tyr Trp Tyr Phe Asp Val Trp Gly
100 105 110
Arg Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
115 120 125
Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
130 135 140
Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
145 150 155 160
Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
165 170 175
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
180 185 190
Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
195 200 205
Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys
210 215 220
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
225 230 235 240
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
245 250 255
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
260 265 270
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
275 280 285
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
290 295 300
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
305 310 315 320
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
325 330 335
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
340 345 350
Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
355 360 365
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
370 375 380
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
385 390 395 400
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
405 410 415
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
420 425 430
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
435 440 445
Pro Gly Lys Gly Ser Ala Ser Thr Lys Gly Pro Thr Gly Val Gln Leu
450 455 460
Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu
465 470 475 480
Ser Cys Ala Ala Ser Gly Phe Thr Phe Ala Trp Tyr Asp Met Gly Trp
485 490 495
Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile Asp
500 505 510
Trp His Gly Glu Val Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe
515 520 525
Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn
530 535 540
Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Ala Glu
545 550 555 560
Asp Glu Pro Gly Tyr Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val
565 570 575
Ser Ser
<210> 97
<211> 11
<212> PRT
<213> 小鼠
<400> 97
Gly Tyr Ser Ile Thr Ser Asp Phe Ala Trp Asn
1 5 10
<210> 98
<211> 14
<212> PRT
<213> 小鼠
<400> 98
Gly Tyr Ile Ser Tyr Ser Gly Asn Tyr Asn Pro Ser Leu Lys
1 5 10
<210> 99
<211> 9
<212> PRT
<213> 小鼠
<400> 99
Val Thr Ala Gly Arg Gly Phe Pro Tyr
1 5
<210> 100
<211> 11
<212> PRT
<213> 小鼠
<400> 100
His Ser Ser Gln Asp Ile Asn Ser Asn Ile Gly
1 5 10
<210> 101
<211> 7
<212> PRT
<213> 小鼠
<400> 101
His Gly Ile Asn Leu Asp Asp
1 5
<210> 102
<211> 9
<212> PRT
<213> 小鼠
<400> 102
Val Gln Tyr Ala Gln Phe Pro Trp Thr
1 5
<210> 103
<211> 16
<212> PRT
<213> 人
<400> 103
Cys Gly Ala Asp Ser Tyr Glu Met Glu Glu Asp Gly Val Arg Lys Cys
1 5 10 15
<210> 104
<211> 6
<212> PRT
<213> 小鼠
<400> 104
Ser Asp Phe Ala Trp Asn
1 5
<210> 105
<211> 13
<212> PRT
<213> 小鼠
<400> 105
Tyr Ile Ser Tyr Ser Gly Asn Tyr Asn Pro Ser Leu Lys
1 5 10
<210> 106
<211> 7
<212> PRT
<213> 小鼠
<400> 106
Ala Gly Arg Gly Phe Pro Tyr
1 5
<210> 107
<211> 14
<212> PRT
<213> 小鼠
<400> 107
Tyr Ile Ser Tyr Ser Gly Asn Tyr Asn Pro Ser Leu Lys Ser
1 5 10
<210> 108
<211> 577
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 108
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
20 25 30
Tyr Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Asn Ile Asn Pro Asn Asn Gly Gly Thr Asn Tyr Asn Gln Lys Phe
50 55 60
Lys Asp Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Trp Ile Leu Tyr Tyr Gly Arg Ser Lys Trp Tyr Phe Asp Val
100 105 110
Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
225 230 235 240
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Lys Thr Val Ala Ala Pro Ser Gly Ser Glu Val Gln
450 455 460
Leu Leu Val Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg
465 470 475 480
Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Lys Ala Tyr Pro Met Met
485 490 495
Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Glu Ile
500 505 510
Ser Pro Ser Gly Ser Tyr Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg
515 520 525
Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met
530 535 540
Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Asp
545 550 555 560
Pro Arg Lys Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser
565 570 575
Ser
<210> 109
<211> 571
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 109
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
20 25 30
Tyr Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Asn Ile Asn Pro Asn Asn Gly Gly Thr Asn Tyr Asn Gln Lys Phe
50 55 60
Lys Asp Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Trp Ile Leu Tyr Tyr Gly Arg Ser Lys Trp Tyr Phe Asp Val
100 105 110
Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
225 230 235 240
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Lys Gly Ser Glu Val Gln Leu Leu Val Ser Gly Gly
450 455 460
Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser
465 470 475 480
Gly Phe Thr Phe Lys Ala Tyr Pro Met Met Trp Val Arg Gln Ala Pro
485 490 495
Gly Lys Gly Leu Glu Trp Val Ser Glu Ile Ser Pro Ser Gly Ser Tyr
500 505 510
Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp
515 520 525
Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu
530 535 540
Asp Thr Ala Val Tyr Tyr Cys Ala Lys Asp Pro Arg Lys Leu Asp Tyr
545 550 555 560
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
565 570
<210> 110
<211> 453
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 110
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
20 25 30
Tyr Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Asn Ile Asn Pro Asn Asn Gly Gly Thr Asn Tyr Asn Gln Lys Phe
50 55 60
Lys Asp Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Trp Ile Leu Tyr Tyr Gly Arg Ser Lys Trp Tyr Phe Asp Val
100 105 110
Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
225 230 235 240
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Lys
450
<210> 111
<211> 343
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 111
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
1 5 10 15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Val Gln Ser
20 25 30
Asn Gly Asp Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Gln Leu Leu Ile Tyr Arg Val Ser Asn Arg Phe Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Phe Gln Gly
85 90 95
Ser His Val Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105 110
Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
115 120 125
Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
130 135 140
Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
145 150 155 160
Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser
165 170 175
Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu
180 185 190
Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser
195 200 205
Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys Thr Val Ala Ala Pro
210 215 220
Ser Gly Ser Glu Val Gln Leu Leu Val Ser Gly Gly Gly Leu Val Gln
225 230 235 240
Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
245 250 255
Lys Ala Tyr Pro Met Met Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
260 265 270
Glu Trp Val Ser Glu Ile Ser Pro Ser Gly Ser Tyr Thr Tyr Tyr Ala
275 280 285
Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn
290 295 300
Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
305 310 315 320
Tyr Tyr Cys Ala Lys Asp Pro Arg Lys Leu Asp Tyr Trp Gly Gln Gly
325 330 335
Thr Leu Val Thr Val Ser Ser
340
<210> 112
<211> 337
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 112
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
1 5 10 15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Val Gln Ser
20 25 30
Asn Gly Asp Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Gln Leu Leu Ile Tyr Arg Val Ser Asn Arg Phe Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Phe Gln Gly
85 90 95
Ser His Val Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105 110
Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
115 120 125
Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
130 135 140
Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
145 150 155 160
Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser
165 170 175
Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu
180 185 190
Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser
195 200 205
Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys Gly Ser Glu Val Gln
210 215 220
Leu Leu Val Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg
225 230 235 240
Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Lys Ala Tyr Pro Met Met
245 250 255
Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Glu Ile
260 265 270
Ser Pro Ser Gly Ser Tyr Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg
275 280 285
Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met
290 295 300
Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Asp
305 310 315 320
Pro Arg Lys Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser
325 330 335
Ser
<210> 113
<211> 219
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 113
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
1 5 10 15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Val Gln Ser
20 25 30
Asn Gly Asp Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Gln Leu Leu Ile Tyr Arg Val Ser Asn Arg Phe Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Phe Gln Gly
85 90 95
Ser His Val Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105 110
Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
115 120 125
Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
130 135 140
Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
145 150 155 160
Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser
165 170 175
Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu
180 185 190
Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser
195 200 205
Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
210 215
<210> 114
<211> 122
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 114
Gln Val Gln Leu Lys Gln Ser Gly Pro Gly Leu Val Gln Ser Ser Gln
1 5 10 15
Ser Leu Ser Ile Thr Cys Thr Ile Ser Gly Phe Ser Leu Thr Ser His
20 25 30
Gly Ile Tyr Trp Leu Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu
35 40 45
Gly Val Ile Trp Ser Gly Gly Ser Ala Asp Tyr Asn Ala Ala Phe Ile
50 55 60
Ser Arg Leu Ser Ile Ser Lys Asp Asn Ser Lys Ser Gln Val Phe Phe
65 70 75 80
Lys Met Asn Ser Leu Gln Ala Asp Asp Thr Ala Ile Tyr Tyr Cys Ala
85 90 95
Arg Ser Pro Tyr Tyr Tyr Arg Ser Ser Leu Tyr Ala Met Asp Tyr Trp
100 105 110
Gly Gln Gly Thr Ser Val Thr Val Ser Ser
115 120
<210> 115
<211> 109
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 115
Asn Ile Val Leu Thr Gln Ser Pro Lys Ser Met Ser Met Ser Ile Gly
1 5 10 15
Glu Arg Val Thr Leu Ser Cys Lys Ala Ser Glu Asn Val Gly Thr Tyr
20 25 30
Val Ser Trp Tyr Gln Gln Lys Ala Glu Gln Ser Pro Lys Leu Leu Ile
35 40 45
Tyr Gly Ala Ser Asn Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly
50 55 60
Ser Gly Ser Ser Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Ala
65 70 75 80
Glu Asp Leu Ala Asp Tyr His Cys Gly Gln Ser Tyr Ser Asp Pro Leu
85 90 95
Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Ala
100 105
<210> 116
<211> 577
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 116
Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30
Asn Met His Trp Val Lys Gln Thr Pro Gly Arg Gly Leu Glu Trp Ile
35 40 45
Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe
50 55 60
Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr
65 70 75 80
Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Thr Tyr Tyr Gly Gly Asp Trp Tyr Phe Asn Val Trp Gly
100 105 110
Ala Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
115 120 125
Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
130 135 140
Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
145 150 155 160
Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
165 170 175
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
180 185 190
Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
195 200 205
Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys
210 215 220
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
225 230 235 240
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
245 250 255
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
260 265 270
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
275 280 285
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
290 295 300
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
305 310 315 320
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
325 330 335
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
340 345 350
Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
355 360 365
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
370 375 380
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
385 390 395 400
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
405 410 415
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
420 425 430
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
435 440 445
Pro Gly Lys Thr Val Ala Ala Pro Ser Gly Ser Gly Val Gln Leu Leu
450 455 460
Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser
465 470 475 480
Cys Ala Ala Ser Gly Phe Thr Phe Ala Trp Tyr Asp Met Gly Trp Val
485 490 495
Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile Asp Trp
500 505 510
His Gly Glu Val Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr
515 520 525
Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser
530 535 540
Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Ala Glu Asp
545 550 555 560
Glu Pro Gly Tyr Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser
565 570 575
Ser
<210> 117
<211> 213
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 117
Gln Ile Val Leu Ser Gln Ser Pro Ala Ile Leu Ser Ala Ser Pro Gly
1 5 10 15
Glu Lys Val Thr Met Thr Cys Arg Ala Ser Ser Ser Val Ser Tyr Ile
20 25 30
His Trp Phe Gln Gln Lys Pro Gly Ser Ser Pro Lys Pro Trp Ile Tyr
35 40 45
Ala Thr Ser Asn Leu Ala Ser Gly Val Pro Val Arg Phe Ser Gly Ser
50 55 60
Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Val Glu Ala Glu
65 70 75 80
Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Thr Ser Asn Pro Pro Thr
85 90 95
Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro
100 105 110
Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr
115 120 125
Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys
130 135 140
Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu
145 150 155 160
Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser
165 170 175
Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala
180 185 190
Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe
195 200 205
Asn Arg Gly Glu Cys
210
<210> 118
<211> 571
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 118
Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30
Asn Met His Trp Val Lys Gln Thr Pro Gly Arg Gly Leu Glu Trp Ile
35 40 45
Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe
50 55 60
Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr
65 70 75 80
Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Thr Tyr Tyr Gly Gly Asp Trp Tyr Phe Asn Val Trp Gly
100 105 110
Ala Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
115 120 125
Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
130 135 140
Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
145 150 155 160
Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
165 170 175
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
180 185 190
Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
195 200 205
Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys
210 215 220
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
225 230 235 240
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
245 250 255
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
260 265 270
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
275 280 285
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
290 295 300
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
305 310 315 320
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
325 330 335
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
340 345 350
Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
355 360 365
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
370 375 380
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
385 390 395 400
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
405 410 415
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
420 425 430
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
435 440 445
Pro Gly Lys Gly Ser Gly Val Gln Leu Leu Glu Ser Gly Gly Gly Leu
450 455 460
Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe
465 470 475 480
Thr Phe Ala Trp Tyr Asp Met Gly Trp Val Arg Gln Ala Pro Gly Lys
485 490 495
Gly Leu Glu Trp Val Ser Ser Ile Asp Trp His Gly Glu Val Thr Tyr
500 505 510
Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser
515 520 525
Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr
530 535 540
Ala Val Tyr Tyr Cys Ala Thr Ala Glu Asp Glu Pro Gly Tyr Asp Tyr
545 550 555 560
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
565 570
<210> 119
<211> 339
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 119
Gln Ile Val Leu Ser Gln Ser Pro Ala Ile Leu Ser Ala Ser Pro Gly
1 5 10 15
Glu Lys Val Thr Met Thr Cys Arg Ala Ser Ser Ser Val Ser Tyr Ile
20 25 30
His Trp Phe Gln Gln Lys Pro Gly Ser Ser Pro Lys Pro Trp Ile Tyr
35 40 45
Ala Thr Ser Asn Leu Ala Ser Gly Val Pro Val Arg Phe Ser Gly Ser
50 55 60
Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Val Glu Ala Glu
65 70 75 80
Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Thr Ser Asn Pro Pro Thr
85 90 95
Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro
100 105 110
Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr
115 120 125
Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys
130 135 140
Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu
145 150 155 160
Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser
165 170 175
Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala
180 185 190
Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe
195 200 205
Asn Arg Gly Glu Cys Thr Val Ala Ala Pro Ser Gly Ser Gly Val Gln
210 215 220
Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg
225 230 235 240
Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ala Trp Tyr Asp Met Gly
245 250 255
Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile
260 265 270
Asp Trp His Gly Glu Val Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg
275 280 285
Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met
290 295 300
Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Ala
305 310 315 320
Glu Asp Glu Pro Gly Tyr Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr
325 330 335
Val Ser Ser
<210> 120
<211> 451
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 120
Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30
Asn Met His Trp Val Lys Gln Thr Pro Gly Arg Gly Leu Glu Trp Ile
35 40 45
Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe
50 55 60
Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr
65 70 75 80
Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Thr Tyr Tyr Gly Gly Asp Trp Tyr Phe Asn Val Trp Gly
100 105 110
Ala Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
115 120 125
Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
130 135 140
Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
145 150 155 160
Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
165 170 175
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
180 185 190
Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
195 200 205
Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys
210 215 220
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
225 230 235 240
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
245 250 255
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
260 265 270
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
275 280 285
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
290 295 300
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
305 310 315 320
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
325 330 335
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
340 345 350
Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
355 360 365
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
370 375 380
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
385 390 395 400
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
405 410 415
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
420 425 430
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
435 440 445
Pro Gly Lys
450
<210> 121
<211> 333
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 121
Gln Ile Val Leu Ser Gln Ser Pro Ala Ile Leu Ser Ala Ser Pro Gly
1 5 10 15
Glu Lys Val Thr Met Thr Cys Arg Ala Ser Ser Ser Val Ser Tyr Ile
20 25 30
His Trp Phe Gln Gln Lys Pro Gly Ser Ser Pro Lys Pro Trp Ile Tyr
35 40 45
Ala Thr Ser Asn Leu Ala Ser Gly Val Pro Val Arg Phe Ser Gly Ser
50 55 60
Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Val Glu Ala Glu
65 70 75 80
Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Thr Ser Asn Pro Pro Thr
85 90 95
Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro
100 105 110
Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr
115 120 125
Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys
130 135 140
Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu
145 150 155 160
Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser
165 170 175
Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala
180 185 190
Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe
195 200 205
Asn Arg Gly Glu Cys Gly Ser Gly Val Gln Leu Leu Glu Ser Gly Gly
210 215 220
Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser
225 230 235 240
Gly Phe Thr Phe Ala Trp Tyr Asp Met Gly Trp Val Arg Gln Ala Pro
245 250 255
Gly Lys Gly Leu Glu Trp Val Ser Ser Ile Asp Trp His Gly Glu Val
260 265 270
Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp
275 280 285
Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu
290 295 300
Asp Thr Ala Val Tyr Tyr Cys Ala Thr Ala Glu Asp Glu Pro Gly Tyr
305 310 315 320
Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
325 330
<210> 122
<211> 1713
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 122
caggtgcagc tcgtgcagag cggcgccgaa gtgaaaaagc ccggcagcag cgtgaaggtg 60
agctgcaagg cctccggctt ctacatcaag gacacctaca tgcactgggt caggcaggct 120
cctggccagg gcctggagtg gatgggcact atcgaccccg ccaacggcaa caccaagtac 180
gtgcccaagt tccagggcag ggtgaccatc accgccgatg agagcaccag caccgcctac 240
atggaactga gcagcctgag gtctgaggac accgccgtgt actattgcgc caggagcatc 300
tacgacgact accactacga cgactactac gccatggact actggggaca gggcacacta 360
gtgaccgtgt ccagcgccag caccaagggc cccagcgtgt tccccctggc ccccagcagc 420
aagagcacca gcggcggcac agccgccctg ggctgcctgg tgaaggacta cttccccgaa 480
ccggtgaccg tgtcctggaa cagcggagcc ctgaccagcg gcgtgcacac cttccccgcc 540
gtgctgcaga gcagcggcct gtacagcctg agcagcgtgg tgaccgtgcc cagcagcagc 600
ctgggcaccc agacctacat ctgtaacgtg aaccacaagc ccagcaacac caaggtggac 660
aagaaggtgg agcccaagag ctgtgacaag acccacacct gccccccctg ccctgccccc 720
gagctgctgg gaggccccag cgtgttcctg ttccccccca agcctaagga caccctgatg 780
atcagcagaa cccccgaggt gacctgtgtg gtggtggatg tgagccacga ggaccctgag 840
gtgaagttca actggtacgt ggacggcgtg gaggtgcaca atgccaagac caagcccagg 900
gaggagcagt acaacagcac ctaccgggtg gtgtccgtgc tgaccgtgct gcaccaggat 960
tggctgaacg gcaaggagta caagtgtaag gtgtccaaca aggccctgcc tgcccctatc 1020
gagaaaacca tcagcaaggc caagggccag cccagagagc cccaggtgta caccctgccc 1080
cctagcagag atgagctgac caagaaccag gtgtccctga cctgcctggt gaagggcttc 1140
taccccagcg acatcgccgt ggagtgggag agcaacggcc agcccgagaa caactacaag 1200
accacccccc ctgtgctgga cagcgatggc agcttcttcc tgtacagcaa gctgaccgtg 1260
gacaagagca gatggcagca gggcaacgtg ttcagctgct ccgtgatgca cgaggccctg 1320
cacaatcact acacccagaa gagcctgagc ctgtcccctg gcaagaccgt ggccgccccc 1380
tcgggatccg acatccagat gacccagagc cccagcagcc tgagcgccag cgtgggcgac 1440
agggtgacca ttacctgcag ggccagcagg cccatcagcg actggctgca ctggtaccaa 1500
cagaagcccg gcaaggctcc caagctgctg atcgcctggg ccagcagcct gcagggaggc 1560
gtgcccagca ggtttagcgg cagcggcagc ggcaccgact tcaccctcac catctcttcc 1620
ctgcagcccg aggacttcgc cacctactac tgcctgcagg agggctgggg gccccctact 1680
ttcggccagg gcaccaaggt ggagatcaag agg 1713
<210> 123
<211> 607
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 123
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
20 25 30
Tyr Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Asn Ile Asn Pro Asn Asn Gly Gly Thr Asn Tyr Asn Gln Lys Phe
50 55 60
Lys Asp Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Trp Ile Leu Tyr Tyr Gly Arg Ser Lys Trp Tyr Phe Asp Val
100 105 110
Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
225 230 235 240
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Lys Gly Ser Asp Gly Gly Gly Ile Arg Arg Ser Met
450 455 460
Ser Gly Thr Trp Tyr Leu Lys Ala Met Thr Val Asp Arg Glu Phe Pro
465 470 475 480
Glu Met Asn Leu Glu Ser Val Thr Pro Met Thr Leu Thr Leu Leu Lys
485 490 495
Gly His Asn Leu Glu Ala Lys Val Thr Met Leu Ile Ser Gly Arg Cys
500 505 510
Gln Glu Val Lys Ala Val Leu Gly Arg Thr Lys Glu Arg Lys Lys Tyr
515 520 525
Thr Ala Asp Gly Gly Lys His Val Ala Tyr Ile Ile Pro Ser Ala Val
530 535 540
Arg Asp His Val Ile Phe Tyr Ser Glu Gly Gln Leu His Gly Lys Pro
545 550 555 560
Val Arg Gly Val Lys Leu Val Gly Arg Asp Pro Lys Asn Asn Leu Glu
565 570 575
Ala Leu Glu Asp Phe Glu Lys Ala Ala Gly Ala Arg Gly Leu Ser Thr
580 585 590
Glu Ser Ile Leu Ile Pro Arg Gln Ser Glu Thr Cys Ser Pro Gly
595 600 605
<210> 124
<211> 541
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 124
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
20 25 30
Tyr Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Asn Ile Asn Pro Asn Asn Gly Gly Thr Asn Tyr Asn Gln Lys Phe
50 55 60
Lys Asp Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Trp Ile Leu Tyr Tyr Gly Arg Ser Lys Trp Tyr Phe Asp Val
100 105 110
Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
225 230 235 240
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Lys Gly Ser Glu Val Val Ala Ala Thr Pro Thr Ser
450 455 460
Leu Leu Ile Ser Trp Arg His Pro His Phe Pro Thr Arg Tyr Tyr Arg
465 470 475 480
Ile Thr Tyr Gly Glu Thr Gly Gly Asn Ser Pro Val Gln Glu Phe Thr
485 490 495
Val Pro Leu Gln Pro Pro Thr Ala Thr Ile Ser Gly Leu Lys Pro Gly
500 505 510
Val Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr Asp Gly Arg Asn Gly
515 520 525
Arg Leu Leu Ser Ile Pro Ile Ser Ile Asn Tyr Arg Thr
530 535 540
<210> 125
<211> 613
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 125
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
20 25 30
Tyr Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Asn Ile Asn Pro Asn Asn Gly Gly Thr Asn Tyr Asn Gln Lys Phe
50 55 60
Lys Asp Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Trp Ile Leu Tyr Tyr Gly Arg Ser Lys Trp Tyr Phe Asp Val
100 105 110
Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
225 230 235 240
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Lys Thr Val Ala Ala Pro Ser Gly Ser Asp Gly Gly
450 455 460
Gly Ile Arg Arg Ser Met Ser Gly Thr Trp Tyr Leu Lys Ala Met Thr
465 470 475 480
Val Asp Arg Glu Phe Pro Glu Met Asn Leu Glu Ser Val Thr Pro Met
485 490 495
Thr Leu Thr Leu Leu Lys Gly His Asn Leu Glu Ala Lys Val Thr Met
500 505 510
Leu Ile Ser Gly Arg Cys Gln Glu Val Lys Ala Val Leu Gly Arg Thr
515 520 525
Lys Glu Arg Lys Lys Tyr Thr Ala Asp Gly Gly Lys His Val Ala Tyr
530 535 540
Ile Ile Pro Ser Ala Val Arg Asp His Val Ile Phe Tyr Ser Glu Gly
545 550 555 560
Gln Leu His Gly Lys Pro Val Arg Gly Val Lys Leu Val Gly Arg Asp
565 570 575
Pro Lys Asn Asn Leu Glu Ala Leu Glu Asp Phe Glu Lys Ala Ala Gly
580 585 590
Ala Arg Gly Leu Ser Thr Glu Ser Ile Leu Ile Pro Arg Gln Ser Glu
595 600 605
Thr Cys Ser Pro Gly
610
<210> 126
<211> 513
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 126
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
20 25 30
Tyr Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Asn Ile Asn Pro Asn Asn Gly Gly Thr Asn Tyr Asn Gln Lys Phe
50 55 60
Lys Asp Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Trp Ile Leu Tyr Tyr Gly Arg Ser Lys Trp Tyr Phe Asp Val
100 105 110
Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
225 230 235 240
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Lys Gly Ser Val Asp Asn Lys Phe Asn Lys Glu Leu
450 455 460
Arg Gln Ala Tyr Trp Glu Ile Gln Ala Leu Pro Asn Leu Asn Trp Thr
465 470 475 480
Gln Ser Arg Ala Phe Ile Arg Ser Leu Tyr Asp Asp Pro Ser Gln Ser
485 490 495
Ala Asn Leu Leu Ala Glu Ala Lys Lys Leu Asn Asp Ala Gln Ala Pro
500 505 510
Lys
<210> 127
<211> 519
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 127
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
20 25 30
Tyr Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Asn Ile Asn Pro Asn Asn Gly Gly Thr Asn Tyr Asn Gln Lys Phe
50 55 60
Lys Asp Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Trp Ile Leu Tyr Tyr Gly Arg Ser Lys Trp Tyr Phe Asp Val
100 105 110
Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
225 230 235 240
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Lys Thr Val Ala Ala Pro Ser Gly Ser Val Asp Asn
450 455 460
Lys Phe Asn Lys Glu Leu Arg Gln Ala Tyr Trp Glu Ile Gln Ala Leu
465 470 475 480
Pro Asn Leu Asn Trp Thr Gln Ser Arg Ala Phe Ile Arg Ser Leu Tyr
485 490 495
Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala Lys Lys Leu
500 505 510
Asn Asp Ala Gln Ala Pro Lys
515
<210> 128
<211> 578
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 128
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
20 25 30
Tyr Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Asn Ile Asn Pro Asn Asn Gly Gly Thr Asn Tyr Asn Gln Lys Phe
50 55 60
Lys Asp Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Trp Ile Leu Tyr Tyr Gly Arg Ser Lys Trp Tyr Phe Asp Val
100 105 110
Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
225 230 235 240
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Lys Gly Ser Asp Leu Gly Lys Lys Leu Leu Glu Ala
450 455 460
Ala Arg Ala Gly Gln Asp Asp Glu Val Arg Ile Leu Met Ala Asn Gly
465 470 475 480
Ala Asp Val Asn Ala Lys Asp Glu Tyr Gly Leu Thr Pro Leu Tyr Leu
485 490 495
Ala Thr Ala His Gly His Leu Glu Ile Val Glu Val Leu Leu Lys Asn
500 505 510
Gly Ala Asp Val Asn Ala Val Asp Ala Ile Gly Phe Thr Pro Leu His
515 520 525
Leu Ala Ala Phe Ile Gly His Leu Glu Ile Ala Glu Val Leu Leu Lys
530 535 540
His Gly Ala Asp Val Asn Ala Gln Asp Lys Phe Gly Lys Thr Ala Phe
545 550 555 560
Asp Ile Ser Ile Gly Asn Gly Asn Glu Asp Leu Ala Glu Ile Leu Gln
565 570 575
Lys Leu
<210> 129
<211> 584
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 129
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
20 25 30
Tyr Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Asn Ile Asn Pro Asn Asn Gly Gly Thr Asn Tyr Asn Gln Lys Phe
50 55 60
Lys Asp Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Trp Ile Leu Tyr Tyr Gly Arg Ser Lys Trp Tyr Phe Asp Val
100 105 110
Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
225 230 235 240
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Lys Thr Val Ala Ala Pro Ser Gly Ser Asp Leu Gly
450 455 460
Lys Lys Leu Leu Glu Ala Ala Arg Ala Gly Gln Asp Asp Glu Val Arg
465 470 475 480
Ile Leu Met Ala Asn Gly Ala Asp Val Asn Ala Lys Asp Glu Tyr Gly
485 490 495
Leu Thr Pro Leu Tyr Leu Ala Thr Ala His Gly His Leu Glu Ile Val
500 505 510
Glu Val Leu Leu Lys Asn Gly Ala Asp Val Asn Ala Val Asp Ala Ile
515 520 525
Gly Phe Thr Pro Leu His Leu Ala Ala Phe Ile Gly His Leu Glu Ile
530 535 540
Ala Glu Val Leu Leu Lys His Gly Ala Asp Val Asn Ala Gln Asp Lys
545 550 555 560
Phe Gly Lys Thr Ala Phe Asp Ile Ser Ile Gly Asn Gly Asn Glu Asp
565 570 575
Leu Ala Glu Ile Leu Gln Lys Leu
580
<210> 130
<211> 574
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 130
Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln
1 5 10 15
Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser
20 25 30
Gly Met Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45
Trp Leu Ala His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Arg Asn Gln Val
65 70 75 80
Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr
85 90 95
Cys Ala Arg Arg Glu Thr Val Phe Tyr Trp Tyr Phe Asp Val Trp Gly
100 105 110
Arg Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
115 120 125
Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
130 135 140
Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
145 150 155 160
Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
165 170 175
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
180 185 190
Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
195 200 205
Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys
210 215 220
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
225 230 235 240
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
245 250 255
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
260 265 270
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
275 280 285
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
290 295 300
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
305 310 315 320
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
325 330 335
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
340 345 350
Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
355 360 365
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
370 375 380
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
385 390 395 400
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
405 410 415
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
420 425 430
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
435 440 445
Pro Gly Lys Gly Ser Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu
450 455 460
Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr
465 470 475 480
Ala Tyr Thr Tyr Ile Tyr Met Gly Trp Phe Arg Gln Ala Pro Gly Lys
485 490 495
Glu Arg Glu Gly Val Ala Ala Met Asp Ser Gly Gly Gly Gly Thr Leu
500 505 510
Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Lys Gly
515 520 525
Lys Asn Thr Val Tyr Leu Gln Met Asp Ser Leu Lys Pro Glu Asp Thr
530 535 540
Ala Thr Tyr Tyr Cys Ala Ala Gly Gly Tyr Glu Leu Arg Asp Arg Thr
545 550 555 560
Tyr Gly Gln Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser
565 570
<210> 131
<211> 566
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 131
Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln
1 5 10 15
Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser
20 25 30
Gly Met Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45
Trp Leu Ala His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Arg Asn Gln Val
65 70 75 80
Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr
85 90 95
Cys Ala Arg Arg Glu Thr Val Phe Tyr Trp Tyr Phe Asp Val Trp Gly
100 105 110
Arg Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
115 120 125
Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
130 135 140
Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
145 150 155 160
Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
165 170 175
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
180 185 190
Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
195 200 205
Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys
210 215 220
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
225 230 235 240
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
245 250 255
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
260 265 270
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
275 280 285
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
290 295 300
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
305 310 315 320
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
325 330 335
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
340 345 350
Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
355 360 365
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
370 375 380
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
385 390 395 400
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
405 410 415
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
420 425 430
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
435 440 445
Pro Gly Lys Gly Ser Ala Arg Val Asp Gln Thr Pro Arg Ser Val Thr
450 455 460
Lys Glu Thr Gly Glu Ser Leu Thr Ile Asn Cys Val Leu Arg Asp Ala
465 470 475 480
Ser Tyr Ala Leu Gly Ser Thr Cys Trp Tyr Arg Lys Lys Ser Gly Glu
485 490 495
Gly Asn Glu Glu Ser Ile Ser Lys Gly Gly Arg Tyr Val Glu Thr Val
500 505 510
Asn Ser Gly Ser Lys Ser Phe Ser Leu Arg Ile Asn Asp Leu Thr Val
515 520 525
Glu Asp Gly Gly Thr Tyr Arg Cys Gly Leu Gly Val Ala Gly Gly Tyr
530 535 540
Cys Asp Tyr Ala Leu Cys Ser Ser Arg Tyr Ala Glu Cys Gly Asp Gly
545 550 555 560
Thr Ala Val Thr Val Asn
565
<210> 132
<211> 1659
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 132
Cys Ala Gly Gly Thr Gly Ala Cys Cys Cys Thr Gly Ala Gly Gly Gly
1 5 10 15
Ala Gly Ala Gly Cys Gly Gly Cys Cys Cys Cys Gly Cys Cys Cys Thr
20 25 30
Gly Gly Thr Gly Ala Ala Gly Cys Cys Cys Ala Cys Cys Cys Ala Gly
35 40 45
Ala Cys Cys Cys Thr Gly Ala Cys Cys Cys Thr Gly Ala Cys Cys Thr
50 55 60
Gly Cys Ala Cys Cys Thr Thr Cys Ala Gly Cys Gly Gly Cys Thr Thr
65 70 75 80
Thr Ala Gly Cys Cys Thr Cys Ala Gly Cys Ala Cys Cys Thr Cys Cys
85 90 95
Gly Gly Cys Ala Thr Gly Gly Gly Cys Gly Thr Gly Ala Gly Cys Thr
100 105 110
Gly Gly Ala Thr Cys Ala Gly Gly Cys Ala Gly Cys Cys Ala Cys Cys
115 120 125
Cys Gly Gly Cys Ala Ala Ala Gly Gly Cys Cys Thr Gly Gly Ala Gly
130 135 140
Thr Gly Gly Cys Thr Gly Gly Cys Cys Cys Ala Cys Ala Thr Cys Thr
145 150 155 160
Ala Cys Thr Gly Gly Gly Ala Cys Gly Ala Cys Gly Ala Cys Ala Ala
165 170 175
Gly Ala Gly Gly Thr Ala Cys Ala Ala Cys Cys Cys Cys Ala Gly Cys
180 185 190
Cys Thr Gly Ala Ala Gly Ala Gly Cys Cys Gly Gly Cys Thr Gly Ala
195 200 205
Cys Cys Ala Thr Cys Ala Gly Cys Ala Ala Gly Gly Ala Thr Ala Cys
210 215 220
Cys Ala Gly Cys Ala Gly Gly Ala Ala Cys Cys Ala Gly Gly Thr Gly
225 230 235 240
Gly Thr Gly Cys Thr Gly Ala Cys Cys Ala Thr Gly Ala Cys Cys Ala
245 250 255
Ala Cys Ala Thr Gly Gly Ala Cys Cys Cys Cys Gly Thr Gly Gly Ala
260 265 270
Cys Ala Cys Cys Gly Cys Thr Ala Cys Cys Thr Ala Cys Thr Ala Cys
275 280 285
Thr Gly Cys Gly Cys Cys Ala Gly Gly Ala Gly Gly Gly Ala Gly Ala
290 295 300
Cys Cys Gly Thr Cys Thr Thr Cys Thr Ala Cys Thr Gly Gly Thr Ala
305 310 315 320
Cys Thr Thr Cys Gly Ala Cys Gly Thr Gly Thr Gly Gly Gly Gly Ala
325 330 335
Ala Gly Gly Gly Gly Cys Ala Cys Ala Cys Thr Ala Gly Thr Gly Ala
340 345 350
Cys Cys Gly Thr Gly Thr Cys Cys Ala Gly Cys Gly Cys Cys Ala Gly
355 360 365
Cys Ala Cys Cys Ala Ala Gly Gly Gly Cys Cys Cys Cys Ala Gly Cys
370 375 380
Gly Thr Gly Thr Thr Cys Cys Cys Cys Cys Thr Gly Gly Cys Cys Cys
385 390 395 400
Cys Cys Ala Gly Cys Ala Gly Cys Ala Ala Gly Ala Gly Cys Ala Cys
405 410 415
Cys Ala Gly Cys Gly Gly Cys Gly Gly Cys Ala Cys Ala Gly Cys Cys
420 425 430
Gly Cys Cys Cys Thr Gly Gly Gly Cys Thr Gly Cys Cys Thr Gly Gly
435 440 445
Thr Gly Ala Ala Gly Gly Ala Cys Thr Ala Cys Thr Thr Cys Cys Cys
450 455 460
Cys Gly Ala Ala Cys Cys Gly Gly Thr Gly Ala Cys Cys Gly Thr Gly
465 470 475 480
Thr Cys Cys Thr Gly Gly Ala Ala Cys Ala Gly Cys Gly Gly Ala Gly
485 490 495
Cys Cys Cys Thr Gly Ala Cys Cys Ala Gly Cys Gly Gly Cys Gly Thr
500 505 510
Gly Cys Ala Cys Ala Cys Cys Thr Thr Cys Cys Cys Cys Gly Cys Cys
515 520 525
Gly Thr Gly Cys Thr Gly Cys Ala Gly Ala Gly Cys Ala Gly Cys Gly
530 535 540
Gly Cys Cys Thr Gly Thr Ala Cys Ala Gly Cys Cys Thr Gly Ala Gly
545 550 555 560
Cys Ala Gly Cys Gly Thr Gly Gly Thr Gly Ala Cys Cys Gly Thr Gly
565 570 575
Cys Cys Cys Ala Gly Cys Ala Gly Cys Ala Gly Cys Cys Thr Gly Gly
580 585 590
Gly Cys Ala Cys Cys Cys Ala Gly Ala Cys Cys Thr Ala Cys Ala Thr
595 600 605
Cys Thr Gly Thr Ala Ala Cys Gly Thr Gly Ala Ala Cys Cys Ala Cys
610 615 620
Ala Ala Gly Cys Cys Cys Ala Gly Cys Ala Ala Cys Ala Cys Cys Ala
625 630 635 640
Ala Gly Gly Thr Gly Gly Ala Cys Ala Ala Gly Ala Ala Gly Gly Thr
645 650 655
Gly Gly Ala Gly Cys Cys Cys Ala Ala Gly Ala Gly Cys Thr Gly Thr
660 665 670
Gly Ala Cys Ala Ala Gly Ala Cys Cys Cys Ala Cys Ala Cys Cys Thr
675 680 685
Gly Cys Cys Cys Cys Cys Cys Cys Thr Gly Cys Cys Cys Thr Gly Cys
690 695 700
Cys Cys Cys Cys Gly Ala Gly Cys Thr Gly Cys Thr Gly Gly Gly Ala
705 710 715 720
Gly Gly Cys Cys Cys Cys Ala Gly Cys Gly Thr Gly Thr Thr Cys Cys
725 730 735
Thr Gly Thr Thr Cys Cys Cys Cys Cys Cys Cys Ala Ala Gly Cys Cys
740 745 750
Thr Ala Ala Gly Gly Ala Cys Ala Cys Cys Cys Thr Gly Ala Thr Gly
755 760 765
Ala Thr Cys Ala Gly Cys Ala Gly Ala Ala Cys Cys Cys Cys Cys Gly
770 775 780
Ala Gly Gly Thr Gly Ala Cys Cys Thr Gly Thr Gly Thr Gly Gly Thr
785 790 795 800
Gly Gly Thr Gly Gly Ala Thr Gly Thr Gly Ala Gly Cys Cys Ala Cys
805 810 815
Gly Ala Gly Gly Ala Cys Cys Cys Thr Gly Ala Gly Gly Thr Gly Ala
820 825 830
Ala Gly Thr Thr Cys Ala Ala Cys Thr Gly Gly Thr Ala Cys Gly Thr
835 840 845
Gly Gly Ala Cys Gly Gly Cys Gly Thr Gly Gly Ala Gly Gly Thr Gly
850 855 860
Cys Ala Cys Ala Ala Thr Gly Cys Cys Ala Ala Gly Ala Cys Cys Ala
865 870 875 880
Ala Gly Cys Cys Cys Ala Gly Gly Gly Ala Gly Gly Ala Gly Cys Ala
885 890 895
Gly Thr Ala Cys Ala Ala Cys Ala Gly Cys Ala Cys Cys Thr Ala Cys
900 905 910
Cys Gly Gly Gly Thr Gly Gly Thr Gly Thr Cys Cys Gly Thr Gly Cys
915 920 925
Thr Gly Ala Cys Cys Gly Thr Gly Cys Thr Gly Cys Ala Cys Cys Ala
930 935 940
Gly Gly Ala Thr Thr Gly Gly Cys Thr Gly Ala Ala Cys Gly Gly Cys
945 950 955 960
Ala Ala Gly Gly Ala Gly Thr Ala Cys Ala Ala Gly Thr Gly Thr Ala
965 970 975
Ala Gly Gly Thr Gly Thr Cys Cys Ala Ala Cys Ala Ala Gly Gly Cys
980 985 990
Cys Cys Thr Gly Cys Cys Thr Gly Cys Cys Cys Cys Thr Ala Thr Cys
995 1000 1005
Gly Ala Gly Ala Ala Ala Ala Cys Cys Ala Thr Cys Ala Gly Cys Ala
1010 1015 1020
Ala Gly Gly Cys Cys Ala Ala Gly Gly Gly Cys Cys Ala Gly Cys Cys
1025 1030 1035 1040
Cys Ala Gly Ala Gly Ala Gly Cys Cys Cys Cys Ala Gly Gly Thr Gly
1045 1050 1055
Thr Ala Cys Ala Cys Cys Cys Thr Gly Cys Cys Cys Cys Cys Thr Ala
1060 1065 1070
Gly Cys Ala Gly Ala Gly Ala Thr Gly Ala Gly Cys Thr Gly Ala Cys
1075 1080 1085
Cys Ala Ala Gly Ala Ala Cys Cys Ala Gly Gly Thr Gly Thr Cys Cys
1090 1095 1100
Cys Thr Gly Ala Cys Cys Thr Gly Cys Cys Thr Gly Gly Thr Gly Ala
1105 1110 1115 1120
Ala Gly Gly Gly Cys Thr Thr Cys Thr Ala Cys Cys Cys Cys Ala Gly
1125 1130 1135
Cys Gly Ala Cys Ala Thr Cys Gly Cys Cys Gly Thr Gly Gly Ala Gly
1140 1145 1150
Thr Gly Gly Gly Ala Gly Ala Gly Cys Ala Ala Cys Gly Gly Cys Cys
1155 1160 1165
Ala Gly Cys Cys Cys Gly Ala Gly Ala Ala Cys Ala Ala Cys Thr Ala
1170 1175 1180
Cys Ala Ala Gly Ala Cys Cys Ala Cys Cys Cys Cys Cys Cys Cys Thr
1185 1190 1195 1200
Gly Thr Gly Cys Thr Gly Gly Ala Cys Ala Gly Cys Gly Ala Thr Gly
1205 1210 1215
Gly Cys Ala Gly Cys Thr Thr Cys Thr Thr Cys Cys Thr Gly Thr Ala
1220 1225 1230
Cys Ala Gly Cys Ala Ala Gly Cys Thr Gly Ala Cys Cys Gly Thr Gly
1235 1240 1245
Gly Ala Cys Ala Ala Gly Ala Gly Cys Ala Gly Ala Thr Gly Gly Cys
1250 1255 1260
Ala Gly Cys Ala Gly Gly Gly Cys Ala Ala Cys Gly Thr Gly Thr Thr
1265 1270 1275 1280
Cys Ala Gly Cys Thr Gly Cys Thr Cys Cys Gly Thr Gly Ala Thr Gly
1285 1290 1295
Cys Ala Cys Gly Ala Gly Gly Cys Cys Cys Thr Gly Cys Ala Cys Ala
1300 1305 1310
Ala Thr Cys Ala Cys Thr Ala Cys Ala Cys Cys Cys Ala Gly Ala Ala
1315 1320 1325
Gly Ala Gly Cys Cys Thr Gly Ala Gly Cys Cys Thr Gly Thr Cys Cys
1330 1335 1340
Cys Cys Thr Gly Gly Cys Ala Ala Gly Ala Cys Cys Gly Thr Gly Gly
1345 1350 1355 1360
Cys Cys Gly Cys Cys Cys Cys Cys Thr Cys Gly Gly Gly Ala Thr Cys
1365 1370 1375
Cys Gly Thr Gly Ala Gly Cys Gly Ala Cys Gly Thr Gly Cys Cys Ala
1380 1385 1390
Ala Gly Gly Gly Ala Cys Cys Thr Cys Gly Ala Gly Gly Thr Gly Gly
1395 1400 1405
Thr Gly Gly Cys Ala Gly Cys Cys Ala Cys Thr Cys Cys Cys Ala Cys
1410 1415 1420
Cys Thr Cys Thr Cys Thr Gly Cys Thr Gly Ala Thr Cys Ala Gly Cys
1425 1430 1435 1440
Thr Gly Gly Gly Ala Cys Ala Cys Ala Cys Ala Cys Ala Ala Cys Gly
1445 1450 1455
Cys Cys Thr Ala Cys Ala Ala Cys Gly Gly Cys Thr Ala Cys Thr Ala
1460 1465 1470
Cys Ala Gly Gly Ala Thr Cys Ala Cys Cys Thr Ala Cys Gly Gly Ala
1475 1480 1485
Gly Ala Gly Ala Cys Cys Gly Gly Cys Gly Gly Cys Ala Ala Thr Ala
1490 1495 1500
Gly Cys Cys Cys Cys Gly Thr Gly Ala Gly Gly Gly Ala Gly Thr Thr
1505 1510 1515 1520
Cys Ala Cys Cys Gly Thr Gly Cys Cys Cys Cys Ala Cys Cys Cys Cys
1525 1530 1535
Gly Ala Gly Gly Thr Gly Ala Cys Cys Gly Cys Cys Ala Cys Cys Ala
1540 1545 1550
Thr Thr Ala Gly Cys Gly Gly Cys Cys Thr Gly Ala Ala Gly Cys Cys
1555 1560 1565
Cys Gly Gly Cys Gly Thr Gly Gly Ala Cys Gly Ala Thr Ala Cys Cys
1570 1575 1580
Ala Thr Cys Ala Cys Cys Gly Thr Cys Thr Ala Cys Gly Cys Cys Gly
1585 1590 1595 1600
Thr Gly Ala Cys Cys Ala Ala Cys Cys Ala Cys Cys Ala Cys Ala Thr
1605 1610 1615
Gly Cys Cys Cys Cys Thr Gly Ala Gly Gly Ala Thr Cys Thr Thr Cys
1620 1625 1630
Gly Gly Cys Cys Cys Cys Ala Thr Cys Ala Gly Cys Ala Thr Cys Ala
1635 1640 1645
Ala Cys Cys Ala Thr Ala Gly Gly Ala Cys Cys
1650 1655
<210> 133
<211> 547
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 133
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
20 25 30
Tyr Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Asn Ile Asn Pro Asn Asn Gly Gly Thr Asn Tyr Asn Gln Lys Phe
50 55 60
Lys Asp Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Trp Ile Leu Tyr Tyr Gly Arg Ser Lys Trp Tyr Phe Asp Val
100 105 110
Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
225 230 235 240
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Lys Thr Val Ala Ala Pro Ser Gly Ser Glu Val Val
450 455 460
Ala Ala Thr Pro Thr Ser Leu Leu Ile Ser Trp Arg His Pro His Phe
465 470 475 480
Pro Thr Arg Tyr Tyr Arg Ile Thr Tyr Gly Glu Thr Gly Gly Asn Ser
485 490 495
Pro Val Gln Glu Phe Thr Val Pro Leu Gln Pro Pro Thr Ala Thr Ile
500 505 510
Ser Gly Leu Lys Pro Gly Val Asp Tyr Thr Ile Thr Val Tyr Ala Val
515 520 525
Thr Asp Gly Arg Asn Gly Arg Leu Leu Ser Ile Pro Ile Ser Ile Asn
530 535 540
Tyr Arg Thr
545
<210> 134
<211> 551
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 134
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Tyr Ile Lys Asp Thr
20 25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Thr Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Val Pro Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Ile Tyr Asp Asp Tyr His Tyr Asp Asp Tyr Tyr Ala Met
100 105 110
Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr
115 120 125
Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser
130 135 140
Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu
145 150 155 160
Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His
165 170 175
Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser
180 185 190
Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys
195 200 205
Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu
210 215 220
Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
225 230 235 240
Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
245 250 255
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
260 265 270
Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp
275 280 285
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
290 295 300
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
305 310 315 320
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu
325 330 335
Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
340 345 350
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys
355 360 365
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
370 375 380
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
385 390 395 400
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
405 410 415
Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
420 425 430
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
435 440 445
Leu Ser Leu Ser Pro Gly Lys Gly Ser Val Ser Asp Val Pro Arg Asp
450 455 460
Leu Glu Val Val Ala Ala Thr Pro Thr Ser Leu Leu Ile Ser Trp Asp
465 470 475 480
Thr His Asn Ala Tyr Asn Gly Tyr Tyr Arg Ile Thr Tyr Gly Glu Thr
485 490 495
Gly Gly Asn Ser Pro Val Arg Glu Phe Thr Val Pro His Pro Glu Val
500 505 510
Thr Ala Thr Ile Ser Gly Leu Lys Pro Gly Val Asp Asp Thr Ile Thr
515 520 525
Val Tyr Ala Val Thr Asn His His Met Pro Leu Arg Ile Phe Gly Pro
530 535 540
Ile Ser Ile Asn His Arg Thr
545 550
<210> 135
<211> 557
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 135
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Tyr Ile Lys Asp Thr
20 25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Thr Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Val Pro Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Ile Tyr Asp Asp Tyr His Tyr Asp Asp Tyr Tyr Ala Met
100 105 110
Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr
115 120 125
Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser
130 135 140
Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu
145 150 155 160
Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His
165 170 175
Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser
180 185 190
Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys
195 200 205
Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu
210 215 220
Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
225 230 235 240
Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
245 250 255
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
260 265 270
Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp
275 280 285
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
290 295 300
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
305 310 315 320
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu
325 330 335
Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
340 345 350
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys
355 360 365
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
370 375 380
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
385 390 395 400
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
405 410 415
Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
420 425 430
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
435 440 445
Leu Ser Leu Ser Pro Gly Lys Thr Val Ala Ala Pro Ser Gly Ser Val
450 455 460
Ser Asp Val Pro Arg Asp Leu Glu Val Val Ala Ala Thr Pro Thr Ser
465 470 475 480
Leu Leu Ile Ser Trp Asp Thr His Asn Ala Tyr Asn Gly Tyr Tyr Arg
485 490 495
Ile Thr Tyr Gly Glu Thr Gly Gly Asn Ser Pro Val Arg Glu Phe Thr
500 505 510
Val Pro His Pro Glu Val Thr Ala Thr Ile Ser Gly Leu Lys Pro Gly
515 520 525
Val Asp Asp Thr Ile Thr Val Tyr Ala Val Thr Asn His His Met Pro
530 535 540
Leu Arg Ile Phe Gly Pro Ile Ser Ile Asn His Arg Thr
545 550 555
<210> 136
<211> 537
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 136
Gln Val Gln Leu Lys Gln Ser Gly Pro Gly Leu Val Gln Pro Ser Gln
1 5 10 15
Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Asn Tyr
20 25 30
Gly Val His Trp Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu
35 40 45
Gly Val Ile Trp Ser Gly Gly Asn Thr Asp Tyr Asn Thr Pro Phe Thr
50 55 60
Ser Arg Leu Ser Ile Asn Lys Asp Asn Ser Lys Ser Gln Val Phe Phe
65 70 75 80
Lys Met Asn Ser Leu Gln Ser Asn Asp Thr Ala Ile Tyr Tyr Cys Ala
85 90 95
Arg Ala Leu Thr Tyr Tyr Asp Tyr Glu Phe Ala Tyr Trp Gly Gln Gly
100 105 110
Thr Leu Val Thr Val Ser Ala Ala Ser Thr Lys Gly Pro Ser Val Phe
115 120 125
Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu
130 135 140
Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp
145 150 155 160
Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu
165 170 175
Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser
180 185 190
Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro
195 200 205
Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys
210 215 220
Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro
225 230 235 240
Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser
245 250 255
Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp
260 265 270
Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn
275 280 285
Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val
290 295 300
Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu
305 310 315 320
Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys
325 330 335
Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr
340 345 350
Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr
355 360 365
Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu
370 375 380
Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu
385 390 395 400
Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys
405 410 415
Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu
420 425 430
Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
435 440 445
Lys Arg Ser Glu Val Val Ala Ala Thr Pro Thr Ser Leu Leu Ile Ser
450 455 460
Trp Arg His Pro His Phe Pro Thr Arg Tyr Tyr Arg Ile Thr Tyr Gly
465 470 475 480
Glu Thr Gly Gly Asn Ser Pro Val Gln Glu Phe Thr Val Pro Leu Gln
485 490 495
Pro Pro Thr Ala Thr Ile Ser Gly Leu Lys Pro Gly Val Asp Tyr Thr
500 505 510
Ile Thr Val Tyr Ala Val Thr Asp Gly Arg Asn Gly Arg Leu Leu Ser
515 520 525
Ile Pro Ile Ser Ile Asn Tyr Arg Thr
530 535
<210> 137
<211> 214
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 137
Asp Ile Leu Leu Thr Gln Ser Pro Val Ile Leu Ser Val Ser Pro Gly
1 5 10 15
Glu Arg Val Ser Phe Ser Cys Arg Ala Ser Gln Ser Ile Gly Thr Asn
20 25 30
Ile His Trp Tyr Gln Gln Arg Thr Asn Gly Ser Pro Arg Leu Leu Ile
35 40 45
Lys Tyr Ala Ser Glu Ser Ile Ser Gly Ile Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser Ile Asn Ser Val Glu Ser
65 70 75 80
Glu Asp Ile Ala Asp Tyr Tyr Cys Gln Gln Asn Asn Asn Trp Pro Thr
85 90 95
Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 138
<211> 302
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 138
Asp Ile Leu Leu Thr Gln Ser Pro Val Ile Leu Ser Val Ser Pro Gly
1 5 10 15
Glu Arg Val Ser Phe Ser Cys Arg Ala Ser Gln Ser Ile Gly Thr Asn
20 25 30
Ile His Trp Tyr Gln Gln Arg Thr Asn Gly Ser Pro Arg Leu Leu Ile
35 40 45
Lys Tyr Ala Ser Glu Ser Ile Ser Gly Ile Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser Ile Asn Ser Val Glu Ser
65 70 75 80
Glu Asp Ile Ala Asp Tyr Tyr Cys Gln Gln Asn Asn Asn Trp Pro Thr
85 90 95
Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys Arg Ser Glu Val Val Ala Ala Thr Pro Thr
210 215 220
Ser Leu Leu Ile Ser Trp Arg His Pro His Phe Pro Thr Arg Tyr Tyr
225 230 235 240
Arg Ile Thr Tyr Gly Glu Thr Gly Gly Asn Ser Pro Val Gln Glu Phe
245 250 255
Thr Val Pro Leu Gln Pro Pro Thr Ala Thr Ile Ser Gly Leu Lys Pro
260 265 270
Gly Val Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr Asp Gly Arg Asn
275 280 285
Gly Arg Leu Leu Ser Ile Pro Ile Ser Ile Asn Tyr Arg Thr
290 295 300
<210> 139
<211> 449
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 139
Gln Val Gln Leu Lys Gln Ser Gly Pro Gly Leu Val Gln Pro Ser Gln
1 5 10 15
Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Asn Tyr
20 25 30
Gly Val His Trp Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu
35 40 45
Gly Val Ile Trp Ser Gly Gly Asn Thr Asp Tyr Asn Thr Pro Phe Thr
50 55 60
Ser Arg Leu Ser Ile Asn Lys Asp Asn Ser Lys Ser Gln Val Phe Phe
65 70 75 80
Lys Met Asn Ser Leu Gln Ser Asn Asp Thr Ala Ile Tyr Tyr Cys Ala
85 90 95
Arg Ala Leu Thr Tyr Tyr Asp Tyr Glu Phe Ala Tyr Trp Gly Gln Gly
100 105 110
Thr Leu Val Thr Val Ser Ala Ala Ser Thr Lys Gly Pro Ser Val Phe
115 120 125
Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu
130 135 140
Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp
145 150 155 160
Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu
165 170 175
Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser
180 185 190
Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro
195 200 205
Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys
210 215 220
Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro
225 230 235 240
Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser
245 250 255
Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp
260 265 270
Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn
275 280 285
Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val
290 295 300
Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu
305 310 315 320
Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys
325 330 335
Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr
340 345 350
Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr
355 360 365
Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu
370 375 380
Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu
385 390 395 400
Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys
405 410 415
Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu
420 425 430
Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
435 440 445
Lys
<210> 140
<211> 539
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 140
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Gly
20 25 30
Asp Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45
Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asp Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Val Asn Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Arg Val Ser Ile Phe Gly Val Gly Thr Phe Asp Tyr Trp Gly
100 105 110
Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
115 120 125
Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
130 135 140
Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
145 150 155 160
Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
165 170 175
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
180 185 190
Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
195 200 205
Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys
210 215 220
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
225 230 235 240
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
245 250 255
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
260 265 270
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
275 280 285
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
290 295 300
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
305 310 315 320
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
325 330 335
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
340 345 350
Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
355 360 365
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
370 375 380
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
385 390 395 400
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
405 410 415
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
420 425 430
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
435 440 445
Pro Gly Lys Gly Ser Glu Val Val Ala Ala Thr Pro Thr Ser Leu Leu
450 455 460
Ile Ser Trp Arg His Pro His Phe Pro Thr Arg Tyr Tyr Arg Ile Thr
465 470 475 480
Tyr Gly Glu Thr Gly Gly Asn Ser Pro Val Gln Glu Phe Thr Val Pro
485 490 495
Leu Gln Pro Pro Thr Ala Thr Ile Ser Gly Leu Lys Pro Gly Val Asp
500 505 510
Tyr Thr Ile Thr Val Tyr Ala Val Thr Asp Gly Arg Asn Gly Arg Leu
515 520 525
Leu Ser Ile Pro Ile Ser Ile Asn Tyr Arg Thr
530 535
<210> 141
<211> 214
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 141
Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys His Gln Tyr Gly Ser Thr Pro Leu
85 90 95
Thr Phe Gly Gly Gly Thr Lys Ala Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 142
<211> 302
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 142
Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys His Gln Tyr Gly Ser Thr Pro Leu
85 90 95
Thr Phe Gly Gly Gly Thr Lys Ala Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys Gly Ser Glu Val Val Ala Ala Thr Pro Thr
210 215 220
Ser Leu Leu Ile Ser Trp Arg His Pro His Phe Pro Thr Arg Tyr Tyr
225 230 235 240
Arg Ile Thr Tyr Gly Glu Thr Gly Gly Asn Ser Pro Val Gln Glu Phe
245 250 255
Thr Val Pro Leu Gln Pro Pro Thr Ala Thr Ile Ser Gly Leu Lys Pro
260 265 270
Gly Val Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr Asp Gly Arg Asn
275 280 285
Gly Arg Leu Leu Ser Ile Pro Ile Ser Ile Asn Tyr Arg Thr
290 295 300
<210> 143
<211> 451
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 143
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Gly
20 25 30
Asp Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45
Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asp Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Val Asn Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Arg Val Ser Ile Phe Gly Val Gly Thr Phe Asp Tyr Trp Gly
100 105 110
Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
115 120 125
Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
130 135 140
Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
145 150 155 160
Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
165 170 175
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
180 185 190
Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
195 200 205
Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys
210 215 220
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
225 230 235 240
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
245 250 255
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
260 265 270
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
275 280 285
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
290 295 300
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
305 310 315 320
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
325 330 335
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
340 345 350
Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
355 360 365
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
370 375 380
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
385 390 395 400
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
405 410 415
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
420 425 430
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
435 440 445
Pro Gly Lys
450
<210> 144
<211> 539
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 144
Glu Val Val Ala Ala Thr Pro Thr Ser Leu Leu Ile Ser Trp Arg His
1 5 10 15
Pro His Phe Pro Thr Arg Tyr Tyr Arg Ile Thr Tyr Gly Glu Thr Gly
20 25 30
Gly Asn Ser Pro Val Gln Glu Phe Thr Val Pro Leu Gln Pro Pro Thr
35 40 45
Ala Thr Ile Ser Gly Leu Lys Pro Gly Val Asp Tyr Thr Ile Thr Val
50 55 60
Tyr Ala Val Thr Asp Gly Arg Asn Gly Arg Leu Leu Ser Ile Pro Ile
65 70 75 80
Ser Ile Asn Tyr Arg Thr Gly Ser Thr Gly Gln Val Gln Leu Lys Gln
85 90 95
Ser Gly Pro Gly Leu Val Gln Pro Ser Gln Ser Leu Ser Ile Thr Cys
100 105 110
Thr Val Ser Gly Phe Ser Leu Thr Asn Tyr Gly Val His Trp Val Arg
115 120 125
Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu Gly Val Ile Trp Ser Gly
130 135 140
Gly Asn Thr Asp Tyr Asn Thr Pro Phe Thr Ser Arg Leu Ser Ile Asn
145 150 155 160
Lys Asp Asn Ser Lys Ser Gln Val Phe Phe Lys Met Asn Ser Leu Gln
165 170 175
Ser Asn Asp Thr Ala Ile Tyr Tyr Cys Ala Arg Ala Leu Thr Tyr Tyr
180 185 190
Asp Tyr Glu Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser
195 200 205
Ala Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser
210 215 220
Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp
225 230 235 240
Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr
245 250 255
Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr
260 265 270
Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln
275 280 285
Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp
290 295 300
Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro
305 310 315 320
Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro
325 330 335
Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr
340 345 350
Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn
355 360 365
Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg
370 375 380
Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val
385 390 395 400
Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser
405 410 415
Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys
420 425 430
Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp
435 440 445
Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe
450 455 460
Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu
465 470 475 480
Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe
485 490 495
Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly
500 505 510
Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr
515 520 525
Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
530 535
<210> 145
<211> 303
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 145
Glu Val Val Ala Ala Thr Pro Thr Ser Leu Leu Ile Ser Trp Arg His
1 5 10 15
Pro His Phe Pro Thr Arg Tyr Tyr Arg Ile Thr Tyr Gly Glu Thr Gly
20 25 30
Gly Asn Ser Pro Val Gln Glu Phe Thr Val Pro Leu Gln Pro Pro Thr
35 40 45
Ala Thr Ile Ser Gly Leu Lys Pro Gly Val Asp Tyr Thr Ile Thr Val
50 55 60
Tyr Ala Val Thr Asp Gly Arg Asn Gly Arg Leu Leu Ser Ile Pro Ile
65 70 75 80
Ser Ile Asn Tyr Arg Thr Ser Thr Gly Asp Ile Leu Leu Thr Gln Ser
85 90 95
Pro Val Ile Leu Ser Val Ser Pro Gly Glu Arg Val Ser Phe Ser Cys
100 105 110
Arg Ala Ser Gln Ser Ile Gly Thr Asn Ile His Trp Tyr Gln Gln Arg
115 120 125
Thr Asn Gly Ser Pro Arg Leu Leu Ile Lys Tyr Ala Ser Glu Ser Ile
130 135 140
Ser Gly Ile Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe
145 150 155 160
Thr Leu Ser Ile Asn Ser Val Glu Ser Glu Asp Ile Ala Asp Tyr Tyr
165 170 175
Cys Gln Gln Asn Asn Asn Trp Pro Thr Thr Phe Gly Ala Gly Thr Lys
180 185 190
Leu Glu Leu Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro
195 200 205
Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu
210 215 220
Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp
225 230 235 240
Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp
245 250 255
Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys
260 265 270
Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln
275 280 285
Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
290 295 300
<210> 146
<211> 547
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 146
Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln
1 5 10 15
Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser
20 25 30
Gly Met Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45
Trp Leu Ala His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Arg Asn Gln Val
65 70 75 80
Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr
85 90 95
Cys Ala Arg Arg Glu Thr Val Phe Tyr Trp Tyr Phe Asp Val Trp Gly
100 105 110
Arg Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
115 120 125
Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
130 135 140
Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
145 150 155 160
Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
165 170 175
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
180 185 190
Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
195 200 205
Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys
210 215 220
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
225 230 235 240
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
245 250 255
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
260 265 270
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
275 280 285
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
290 295 300
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
305 310 315 320
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
325 330 335
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
340 345 350
Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
355 360 365
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
370 375 380
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
385 390 395 400
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
405 410 415
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
420 425 430
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
435 440 445
Pro Gly Lys Gly Ser Val Ser Asp Val Pro Arg Asp Leu Glu Val Val
450 455 460
Ala Ala Thr Pro Thr Ser Leu Leu Ile Ser Trp Asp Thr His Asn Ala
465 470 475 480
Tyr Asn Gly Tyr Tyr Arg Ile Thr Tyr Gly Glu Thr Gly Gly Asn Ser
485 490 495
Pro Val Arg Glu Phe Thr Val Pro His Pro Glu Val Thr Ala Thr Ile
500 505 510
Ser Gly Leu Lys Pro Gly Val Asp Asp Thr Ile Thr Val Tyr Ala Val
515 520 525
Thr Asn His His Met Pro Leu Arg Ile Phe Gly Pro Ile Ser Ile Asn
530 535 540
His Arg Thr
545
<210> 147
<211> 553
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 147
Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln
1 5 10 15
Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser
20 25 30
Gly Met Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45
Trp Leu Ala His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Arg Asn Gln Val
65 70 75 80
Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr
85 90 95
Cys Ala Arg Arg Glu Thr Val Phe Tyr Trp Tyr Phe Asp Val Trp Gly
100 105 110
Arg Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
115 120 125
Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
130 135 140
Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
145 150 155 160
Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
165 170 175
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
180 185 190
Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
195 200 205
Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys
210 215 220
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
225 230 235 240
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
245 250 255
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
260 265 270
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
275 280 285
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
290 295 300
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
305 310 315 320
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
325 330 335
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
340 345 350
Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
355 360 365
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
370 375 380
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
385 390 395 400
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
405 410 415
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
420 425 430
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
435 440 445
Pro Gly Lys Thr Val Ala Ala Pro Ser Gly Ser Val Ser Asp Val Pro
450 455 460
Arg Asp Leu Glu Val Val Ala Ala Thr Pro Thr Ser Leu Leu Ile Ser
465 470 475 480
Trp Asp Thr His Asn Ala Tyr Asn Gly Tyr Tyr Arg Ile Thr Tyr Gly
485 490 495
Glu Thr Gly Gly Asn Ser Pro Val Arg Glu Phe Thr Val Pro His Pro
500 505 510
Glu Val Thr Ala Thr Ile Ser Gly Leu Lys Pro Gly Val Asp Asp Thr
515 520 525
Ile Thr Val Tyr Ala Val Thr Asn His His Met Pro Leu Arg Ile Phe
530 535 540
Gly Pro Ile Ser Ile Asn His Arg Thr
545 550
<210> 148
<211> 118
<212> PRT
<213> 人
<400> 148
Gly Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Val Phe Pro Trp Tyr
20 25 30
Asp Met Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ser Ile Asp Trp His Gly Lys Ile Thr Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Thr Ala Glu Asp Glu Pro Gly Tyr Asp Tyr Trp Gly Gln Gly Thr
100 105 110
Leu Val Thr Val Ser Ser
115
<210> 149
<211> 569
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 149
Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln
1 5 10 15
Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser
20 25 30
Gly Met Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45
Trp Leu Ala His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Arg Asn Gln Val
65 70 75 80
Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr
85 90 95
Cys Ala Arg Arg Glu Thr Val Phe Tyr Trp Tyr Phe Asp Val Trp Gly
100 105 110
Arg Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
115 120 125
Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
130 135 140
Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
145 150 155 160
Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
165 170 175
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
180 185 190
Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
195 200 205
Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys
210 215 220
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
225 230 235 240
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
245 250 255
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
260 265 270
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
275 280 285
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
290 295 300
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
305 310 315 320
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
325 330 335
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
340 345 350
Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
355 360 365
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
370 375 380
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
385 390 395 400
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
405 410 415
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
420 425 430
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
435 440 445
Pro Gly Lys Gly Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln
450 455 460
Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Val Phe
465 470 475 480
Pro Trp Tyr Asp Met Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
485 490 495
Glu Trp Val Ser Ser Ile Asp Trp His Gly Lys Ile Thr Tyr Tyr Ala
500 505 510
Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn
515 520 525
Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
530 535 540
Tyr Tyr Cys Ala Thr Ala Glu Asp Glu Pro Gly Tyr Asp Tyr Trp Gly
545 550 555 560
Gln Gly Thr Leu Val Thr Val Ser Ser
565
<210> 150
<211> 575
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 150
Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln
1 5 10 15
Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser
20 25 30
Gly Met Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45
Trp Leu Ala His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Arg Asn Gln Val
65 70 75 80
Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr
85 90 95
Cys Ala Arg Arg Glu Thr Val Phe Tyr Trp Tyr Phe Asp Val Trp Gly
100 105 110
Arg Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
115 120 125
Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
130 135 140
Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
145 150 155 160
Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
165 170 175
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
180 185 190
Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
195 200 205
Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys
210 215 220
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
225 230 235 240
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
245 250 255
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
260 265 270
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
275 280 285
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
290 295 300
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
305 310 315 320
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
325 330 335
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
340 345 350
Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
355 360 365
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
370 375 380
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
385 390 395 400
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
405 410 415
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
420 425 430
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
435 440 445
Pro Gly Lys Thr Val Ala Ala Pro Ser Gly Val Gln Leu Leu Glu Ser
450 455 460
Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala
465 470 475 480
Ala Ser Gly Phe Val Phe Pro Trp Tyr Asp Met Gly Trp Val Arg Gln
485 490 495
Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile Asp Trp His Gly
500 505 510
Lys Ile Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser
515 520 525
Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg
530 535 540
Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Ala Glu Asp Glu Pro
545 550 555 560
Gly Tyr Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
565 570 575
<210> 151
<211> 579
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 151
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Tyr Ile Lys Asp Thr
20 25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Thr Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Val Pro Lys Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Ile Tyr Asp Asp Tyr His Tyr Asp Asp Tyr Tyr Ala Met
100 105 110
Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr
115 120 125
Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser
130 135 140
Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu
145 150 155 160
Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His
165 170 175
Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser
180 185 190
Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys
195 200 205
Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu
210 215 220
Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
225 230 235 240
Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
245 250 255
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
260 265 270
Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp
275 280 285
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
290 295 300
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
305 310 315 320
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu
325 330 335
Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
340 345 350
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys
355 360 365
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
370 375 380
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
385 390 395 400
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
405 410 415
Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
420 425 430
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
435 440 445
Leu Ser Leu Ser Pro Gly Lys Thr Val Ala Ala Pro Ser Gly Ser Glu
450 455 460
Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser
465 470 475 480
Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Asn Phe Gly
485 490 495
Met Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser
500 505 510
Trp Ile Ile Ser Ser Gly Thr Glu Thr Tyr Tyr Ala Asp Ser Val Lys
515 520 525
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
530 535 540
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
545 550 555 560
Lys Ser Leu Gly Arg Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr
565 570 575
Val Ser Ser
<210> 152
<211> 579
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 152
Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
1 5 10 15
Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Phe Tyr Ile Lys Asp Thr
20 25 30
Tyr Met His Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
35 40 45
Gly Thr Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Val Pro Lys Phe
50 55 60
Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
65 70 75 80
Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys
85 90 95
Ala Arg Ser Ile Tyr Asp Asp Tyr His Tyr Asp Asp Tyr Tyr Ala Met
100 105 110
Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr
115 120 125
Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser
130 135 140
Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu
145 150 155 160
Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His
165 170 175
Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser
180 185 190
Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys
195 200 205
Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu
210 215 220
Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
225 230 235 240
Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
245 250 255
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
260 265 270
Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp
275 280 285
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
290 295 300
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
305 310 315 320
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu
325 330 335
Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
340 345 350
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys
355 360 365
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
370 375 380
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
385 390 395 400
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
405 410 415
Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
420 425 430
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
435 440 445
Leu Ser Leu Ser Pro Gly Lys Thr Val Ala Ala Pro Ser Gly Ser Glu
450 455 460
Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser
465 470 475 480
Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Asn Phe Gly
485 490 495
Met Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser
500 505 510
Trp Ile Ile Ser Ser Gly Thr Glu Thr Tyr Tyr Ala Asp Ser Val Lys
515 520 525
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
530 535 540
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
545 550 555 560
Lys Ser Leu Gly Arg Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr
565 570 575
Val Ser Ser
<210> 153
<211> 219
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 153
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ser Ser Gln Asn Ile Val His Ile
20 25 30
Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Gln Gln Lys Pro Gly Gln Ala
35 40 45
Pro Arg Leu Leu Ile Tyr Lys Ile Ser Asp Arg Phe Ser Gly Ile Pro
50 55 60
Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile
65 70 75 80
Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Phe Gln Gly
85 90 95
Ser His Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105 110
Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
115 120 125
Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
130 135 140
Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
145 150 155 160
Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser
165 170 175
Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu
180 185 190
Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser
195 200 205
Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
210 215
<210> 154
<211> 219
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 154
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ser Ser Gln Asn Ile Val His Ile
20 25 30
Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Gln Gln Lys Pro Gly Gln Ala
35 40 45
Pro Arg Leu Leu Ile Tyr Lys Ile Ser Asp Arg Phe Ser Gly Ile Pro
50 55 60
Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile
65 70 75 80
Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Phe Gln Gly
85 90 95
Ser His Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105 110
Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
115 120 125
Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
130 135 140
Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
145 150 155 160
Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser
165 170 175
Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu
180 185 190
Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser
195 200 205
Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
210 215
<210> 155
<211> 571
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 155
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ile Asp Tyr
20 25 30
Glu Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Ala Ile Asp Pro Glu Thr Gly Gly Thr Ala Tyr Asn Gln Lys Phe
50 55 60
Lys Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Thr Arg Ile Leu Leu Tyr Tyr Tyr Pro Met Asp Tyr Trp Gly Gln Gly
100 105 110
Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe
115 120 125
Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu
130 135 140
Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp
145 150 155 160
Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu
165 170 175
Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser
180 185 190
Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro
195 200 205
Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys
210 215 220
Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro
225 230 235 240
Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser
245 250 255
Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp
260 265 270
Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn
275 280 285
Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val
290 295 300
Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu
305 310 315 320
Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys
325 330 335
Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr
340 345 350
Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr
355 360 365
Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu
370 375 380
Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu
385 390 395 400
Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys
405 410 415
Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu
420 425 430
Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
435 440 445
Lys Thr Val Ala Ala Pro Ser Glu Val Gln Leu Leu Glu Ser Gly Gly
450 455 460
Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser
465 470 475 480
Gly Phe Thr Phe Arg Asn Phe Gly Met Gly Trp Val Arg Gln Ala Pro
485 490 495
Gly Lys Gly Leu Glu Trp Val Ser Trp Ile Ile Ser Ser Gly Thr Glu
500 505 510
Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp
515 520 525
Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu
530 535 540
Asp Thr Ala Val Tyr Tyr Cys Ala Lys Ser Leu Gly Arg Phe Asp Tyr
545 550 555 560
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
565 570
<210> 156
<211> 214
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 156
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Asn Ile Ser Asp Tyr
20 25 30
Leu His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Tyr Tyr Ala Ser Gln Ser Ile Ser Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Asn Gly His Ser Phe Pro Leu
85 90 95
Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 157
<211> 575
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 157
Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln
1 5 10 15
Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser
20 25 30
Gly Met Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45
Trp Leu Ala His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Arg Asn Gln Val
65 70 75 80
Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr
85 90 95
Cys Ala Arg Arg Glu Thr Val Phe Tyr Trp Tyr Phe Asp Val Trp Gly
100 105 110
Arg Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
115 120 125
Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
130 135 140
Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
145 150 155 160
Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
165 170 175
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
180 185 190
Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
195 200 205
Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys
210 215 220
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
225 230 235 240
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
245 250 255
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
260 265 270
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
275 280 285
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
290 295 300
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
305 310 315 320
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
325 330 335
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
340 345 350
Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
355 360 365
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
370 375 380
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
385 390 395 400
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
405 410 415
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
420 425 430
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
435 440 445
Pro Gly Lys Thr Val Ala Ala Pro Ser Gly Val Gln Leu Leu Glu Ser
450 455 460
Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala
465 470 475 480
Ala Ser Gly Phe Val Phe Pro Trp Tyr Asp Met Gly Trp Val Arg Gln
485 490 495
Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile Asp Trp Lys Gly
500 505 510
Gly Lys Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser
515 520 525
Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg
530 535 540
Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Ala Glu Asp Glu Pro
545 550 555 560
Gly Tyr Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
565 570 575
<210> 158
<211> 569
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 158
Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln
1 5 10 15
Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser
20 25 30
Gly Met Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45
Trp Leu Ala His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Arg Asn Gln Val
65 70 75 80
Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr
85 90 95
Cys Ala Arg Arg Glu Thr Val Phe Tyr Trp Tyr Phe Asp Val Trp Gly
100 105 110
Arg Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
115 120 125
Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
130 135 140
Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
145 150 155 160
Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
165 170 175
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
180 185 190
Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
195 200 205
Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys
210 215 220
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
225 230 235 240
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
245 250 255
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
260 265 270
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
275 280 285
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
290 295 300
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
305 310 315 320
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
325 330 335
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
340 345 350
Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
355 360 365
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
370 375 380
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
385 390 395 400
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
405 410 415
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
420 425 430
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
435 440 445
Pro Gly Lys Gly Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln
450 455 460
Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Val Phe
465 470 475 480
Pro Trp Tyr Asp Met Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
485 490 495
Glu Trp Val Ser Ser Ile Asp Trp Lys Gly Gly Lys Thr Tyr Tyr Ala
500 505 510
Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn
515 520 525
Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
530 535 540
Tyr Tyr Cys Ala Thr Ala Glu Asp Glu Pro Gly Tyr Asp Tyr Trp Gly
545 550 555 560
Gln Gly Thr Leu Val Thr Val Ser Ser
565
<210> 159
<211> 575
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 159
Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln
1 5 10 15
Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser
20 25 30
Gly Met Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45
Trp Leu Ala His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Arg Asn Gln Val
65 70 75 80
Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr
85 90 95
Cys Ala Arg Arg Glu Thr Val Phe Tyr Trp Tyr Phe Asp Val Trp Gly
100 105 110
Arg Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
115 120 125
Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
130 135 140
Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
145 150 155 160
Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
165 170 175
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
180 185 190
Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
195 200 205
Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys
210 215 220
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
225 230 235 240
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
245 250 255
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
260 265 270
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
275 280 285
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
290 295 300
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
305 310 315 320
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
325 330 335
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
340 345 350
Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
355 360 365
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
370 375 380
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
385 390 395 400
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
405 410 415
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
420 425 430
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
435 440 445
Pro Gly Lys Thr Val Ala Ala Pro Ser Gly Val Gln Leu Leu Glu Ser
450 455 460
Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala
465 470 475 480
Ala Ser Gly Phe Val Phe Ala Trp Tyr Asp Met Gly Trp Val Arg Gln
485 490 495
Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile Asp Trp His Gly
500 505 510
Glu Val Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser
515 520 525
Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg
530 535 540
Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Ala Glu Asp Glu Pro
545 550 555 560
Gly Tyr Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
565 570 575
<210> 160
<211> 569
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 160
Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln
1 5 10 15
Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser
20 25 30
Gly Met Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45
Trp Leu Ala His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Arg Asn Gln Val
65 70 75 80
Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr
85 90 95
Cys Ala Arg Arg Glu Thr Val Phe Tyr Trp Tyr Phe Asp Val Trp Gly
100 105 110
Arg Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
115 120 125
Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
130 135 140
Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
145 150 155 160
Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
165 170 175
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
180 185 190
Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
195 200 205
Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys
210 215 220
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
225 230 235 240
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
245 250 255
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
260 265 270
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
275 280 285
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
290 295 300
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
305 310 315 320
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
325 330 335
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
340 345 350
Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
355 360 365
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
370 375 380
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
385 390 395 400
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
405 410 415
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
420 425 430
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
435 440 445
Pro Gly Lys Gly Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln
450 455 460
Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Val Phe
465 470 475 480
Ala Trp Tyr Asp Met Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
485 490 495
Glu Trp Val Ser Ser Ile Asp Trp His Gly Glu Val Thr Tyr Tyr Ala
500 505 510
Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn
515 520 525
Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
530 535 540
Tyr Tyr Cys Ala Thr Ala Glu Asp Glu Pro Gly Tyr Asp Tyr Trp Gly
545 550 555 560
Gln Gly Thr Leu Val Thr Val Ser Ser
565
<210> 161
<211> 449
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 161
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ile Asp Tyr
20 25 30
Glu Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Ala Ile Asp Pro Glu Thr Gly Gly Thr Ala Tyr Asn Gln Lys Phe
50 55 60
Lys Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Thr Arg Ile Leu Leu Tyr Tyr Tyr Pro Met Asp Tyr Trp Gly Gln Gly
100 105 110
Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe
115 120 125
Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu
130 135 140
Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp
145 150 155 160
Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu
165 170 175
Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser
180 185 190
Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro
195 200 205
Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys
210 215 220
Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro
225 230 235 240
Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser
245 250 255
Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp
260 265 270
Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn
275 280 285
Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val
290 295 300
Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu
305 310 315 320
Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys
325 330 335
Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr
340 345 350
Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr
355 360 365
Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu
370 375 380
Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu
385 390 395 400
Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys
405 410 415
Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu
420 425 430
Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
435 440 445
Lys
<210> 162
<211> 1707
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 162
gaggtgcagc tgttggagtc tgggggaggc ttggtacagc ctggggggtc cctgcgtctc 60
tcctgtgcag cctccggatt cacctttggg gcttatccga tgatgtgggt ccgccaggct 120
ccagggaagg gtctagagtg ggtctcagag atttcgcctt cgggttctta tacatactac 180
gcagactccg tgaagggccg gttcaccatc tcccgcgaca attccaagaa cacgctgtat 240
ctgcaaatga acagcctgcg tgccgaggac accgcggtat attactgtgc gaaagatcct 300
cggaagtttg actactgggg tcagggaacc ctggtcaccg tctcgagcgc tagcaccaag 360
ggccccagcg aggtgcagct gttggagtct gggggaggct tggtacagcc tggggggtcc 420
ctgcgtctct cctgtgcagc ctccggattc acctttagca gctatgccat gagctgggtc 480
cgccaggctc cagggaaggg tctagagtgg gtctcagcta ttagtggtag tggtggtagc 540
acatactacg cagactccgt gaagggccgg ttcaccatct cccgcgacaa ttccaagaac 600
acgctgtatc tgcaaatgaa cagcctgcgt gccgaggaca ccgcggtata ttactgtgcg 660
aaaagttatg gtgcttttga ctactggggc cagggaaccc tggtcaccgt ctcgagcgct 720
agcaccaagg gccccagcgt gttccccctg gcccccagca gcaagagcac cagcggcggc 780
acagccgccc tgggctgcct ggtgaaggac tacttccccg agcctgtgac cgtgtcctgg 840
aatagcggag ccctgacctc cggcgtgcac accttccccg ccgtgctgca gagcagcggc 900
ctgtactccc tgagcagcgt ggtgaccgtg cccagcagca gcctgggcac ccagacctac 960
atctgcaacg tgaaccacaa gcccagcaac accaaagtgg acaagaaagt ggagcccaag 1020
agctgcgata agacccacac ctgccccccc tgccctgccc ccgagctgct gggcggacct 1080
agcgtgttcc tgttcccccc caagcctaag gacaccctga tgatcagcag gacccccgaa 1140
gtgacctgcg tggtggtgga tgtgagccac gaggaccctg aagtgaagtt caactggtac 1200
gtggacggcg tggaagtgca caacgccaag accaagccca gagaggagca gtacaacagc 1260
acctaccgcg tggtgtctgt gctgaccgtg ctgcaccagg attggctgaa cggcaaggag 1320
tacaagtgca aagtgagcaa caaggccctg cctgccccta tcgagaaaac catcagcaag 1380
gccaagggcc agcctagaga gccccaggtc tacaccctgc ctccctccag agatgagctg 1440
accaagaacc aggtgtccct gacctgtctg gtgaagggct tctaccccag cgacatcgcc 1500
gtggagtggg agagcaacgg ccagcccgag aacaactaca agaccacccc ccctgtgctg 1560
gacagcgatg gcagcttctt cctgtactcc aagctgaccg tggacaagag cagatggcag 1620
cagggcaacg tgttcagctg cagcgtgatg cacgaggccc tgcacaatca ctacacccag 1680
aagagtctga gcctgtcccc tggcaag 1707
<210> 163
<211> 569
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 163
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Gly Ala Tyr
20 25 30
Pro Met Met Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Glu Ile Ser Pro Ser Gly Ser Tyr Thr Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Asp Pro Arg Lys Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val
100 105 110
Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Glu Val Gln Leu Leu
115 120 125
Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser
130 135 140
Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val
145 150 155 160
Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly
165 170 175
Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr
180 185 190
Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser
195 200 205
Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Ser Tyr Gly
210 215 220
Ala Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala
225 230 235 240
Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser
245 250 255
Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe
260 265 270
Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly
275 280 285
Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu
290 295 300
Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr
305 310 315 320
Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys
325 330 335
Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro
340 345 350
Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys
355 360 365
Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val
370 375 380
Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
385 390 395 400
Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu
405 410 415
Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His
420 425 430
Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys
435 440 445
Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln
450 455 460
Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu
465 470 475 480
Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro
485 490 495
Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn
500 505 510
Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu
515 520 525
Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val
530 535 540
Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln
545 550 555 560
Lys Ser Leu Ser Leu Ser Pro Gly Lys
565
<210> 164
<211> 1704
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 164
caggtgcagc tgaagcagag cggccctggc ctggtgcagc cctctcagag cctgagcatc 60
acctgtaccg tgagcggctt cagcctgacc aattacggcg tgcattgggt gcggcagtct 120
ccaggcaagg gcctggaatg gctgggagtg atctggtccg gcggcaacac cgactacaac 180
acccccttca ccagcagact gagcatcaac aaggacaaca gcaagagcca ggtgttcttc 240
aagatgaaca gcctgcagag caacgacacc gccatctact attgtgccag ggccctgacc 300
tactacgact acgagttcgc ctactggggc cagggcaccc tggtgaccgt gagcgccgct 360
agcaccaagg gccccagcgt gttccccctg gcccccagca gcaagagcac cagcggcggc 420
acagccgccc tgggctgcct ggtgaaggac tacttccccg agcctgtgac cgtgtcctgg 480
aatagcggag ccctgacctc cggcgtgcac accttccccg ccgtgctgca gagcagcggc 540
ctgtactccc tgagcagcgt ggtgaccgtg cccagcagca gcctgggcac ccagacctac 600
atctgcaacg tgaaccacaa gcccagcaac accaaagtgg acaagaaagt ggagcccaag 660
agctgcgata agacccacac ctgccccccc tgccctgccc ccgagctgct gggcggacct 720
agcgtgttcc tgttcccccc caagcctaag gacaccctga tgatcagcag gacccccgaa 780
gtgacctgcg tggtggtgga tgtgagccac gaggaccctg aagtgaagtt caactggtac 840
gtggacggcg tggaagtgca caacgccaag accaagccca gagaggagca gtacaacagc 900
acctaccgcg tggtgtctgt gctgaccgtg ctgcaccagg attggctgaa cggcaaggag 960
tacaagtgca aagtgagcaa caaggccctg cctgccccta tcgagaaaac catcagcaag 1020
gccaagggcc agcctagaga gccccaggtc tacaccctgc ctccctccag agatgagctg 1080
accaagaacc aggtgtccct gacctgtctg gtgaagggct tctaccccag cgacatcgcc 1140
gtggagtggg agagcaacgg ccagcccgag aacaactaca agaccacccc ccctgtgctg 1200
gacagcgatg gcagcttctt cctgtactcc aagctgaccg tggacaagag cagatggcag 1260
cagggcaacg tgttcagctg cagcgtgatg cacgaggccc tgcacaatca ctacacccag 1320
aagagtctga gcctgtcccc tggcaagtcg accggtgagg tgcagctgtt ggtgtctggg 1380
ggaggcttgg tacagcctgg ggggtccctg cgtctctcct gtgcagcctc cggattcacc 1440
tttaaggctt atccgatgat gtgggtccgc caggctccag ggaagggtct agagtgggtt 1500
tcagagattt cgccttcggg ttcttataca tactacgcag actccgtgaa gggccggttc 1560
accatctccc gcgacaattc caagaacacg ctgtatctgc aaatgaacag cctgcgtgcc 1620
gaggacaccg cggtatatta ctgtgcgaaa gatcctcgga agttagacta ctggggtcag 1680
ggaaccctgg tcaccgtctc gagc 1704
<210> 165
<211> 568
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 165
Gln Val Gln Leu Lys Gln Ser Gly Pro Gly Leu Val Gln Pro Ser Gln
1 5 10 15
Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Asn Tyr
20 25 30
Gly Val His Trp Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu
35 40 45
Gly Val Ile Trp Ser Gly Gly Asn Thr Asp Tyr Asn Thr Pro Phe Thr
50 55 60
Ser Arg Leu Ser Ile Asn Lys Asp Asn Ser Lys Ser Gln Val Phe Phe
65 70 75 80
Lys Met Asn Ser Leu Gln Ser Asn Asp Thr Ala Ile Tyr Tyr Cys Ala
85 90 95
Arg Ala Leu Thr Tyr Tyr Asp Tyr Glu Phe Ala Tyr Trp Gly Gln Gly
100 105 110
Thr Leu Val Thr Val Ser Ala Ala Ser Thr Lys Gly Pro Ser Val Phe
115 120 125
Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu
130 135 140
Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp
145 150 155 160
Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu
165 170 175
Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser
180 185 190
Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro
195 200 205
Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys
210 215 220
Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro
225 230 235 240
Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser
245 250 255
Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp
260 265 270
Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn
275 280 285
Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val
290 295 300
Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu
305 310 315 320
Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys
325 330 335
Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr
340 345 350
Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr
355 360 365
Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu
370 375 380
Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu
385 390 395 400
Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys
405 410 415
Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu
420 425 430
Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
435 440 445
Lys Ser Thr Gly Glu Val Gln Leu Leu Val Ser Gly Gly Gly Leu Val
450 455 460
Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr
465 470 475 480
Phe Lys Ala Tyr Pro Met Met Trp Val Arg Gln Ala Pro Gly Lys Gly
485 490 495
Leu Glu Trp Val Ser Glu Ile Ser Pro Ser Gly Ser Tyr Thr Tyr Tyr
500 505 510
Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys
515 520 525
Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala
530 535 540
Val Tyr Tyr Cys Ala Lys Asp Pro Arg Lys Leu Asp Tyr Trp Gly Gln
545 550 555 560
Gly Thr Leu Val Thr Val Ser Ser
565
<210> 166
<211> 451
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 166
Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln
1 5 10 15
Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser
20 25 30
Gly Met Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45
Trp Leu Ala His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Arg Asn Gln Val
65 70 75 80
Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr
85 90 95
Cys Ala Arg Arg Glu Thr Val Phe Tyr Trp Tyr Phe Asp Val Trp Gly
100 105 110
Arg Gly Thr Pro Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
115 120 125
Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
130 135 140
Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
145 150 155 160
Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
165 170 175
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
180 185 190
Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
195 200 205
Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys
210 215 220
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
225 230 235 240
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
245 250 255
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
260 265 270
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
275 280 285
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
290 295 300
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
305 310 315 320
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
325 330 335
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
340 345 350
Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser
355 360 365
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
370 375 380
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
385 390 395 400
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
405 410 415
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
420 425 430
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
435 440 445
Pro Gly Lys
450
<210> 167
<211> 1737
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 167
caggtgcagc tcgtgcagag cggcgccgaa gtgaaaaagc ccggcagcag cgtgaaggtg 60
agctgcaagg cctccggctt ctacatcaag gacacctaca tgcactgggt caggcaggct 120
cctggccagg gcctggagtg gatgggcact atcgaccccg ccaacggcaa caccaagtac 180
gtgcccaagt tccagggcag ggtgaccatc accgccgatg agagcaccag caccgcctac 240
atggaactga gcagcctgag gtctgaggac accgccgtgt actattgcgc caggagcatc 300
tacgacgact accactacga cgactactac gccatggact actggggaca gggcacacta 360
gtgaccgtgt ccagcgccag caccaagggc cccagcgtgt tccccctggc ccccagcagc 420
aagagcacca gcggcggcac agccgccctg ggctgcctgg tgaaggacta cttccccgaa 480
ccggtgaccg tgtcctggaa cagcggagcc ctgaccagcg gcgtgcacac cttccccgcc 540
gtgctgcaga gcagcggcct gtacagcctg agcagcgtgg tgaccgtgcc cagcagcagc 600
ctgggcaccc agacctacat ctgtaacgtg aaccacaagc ccagcaacac caaggtggac 660
aagaaggtgg agcccaagag ctgtgacaag acccacacct gccccccctg ccctgccccc 720
gagctgctgg gaggccccag cgtgttcctg ttccccccca agcctaagga caccctgatg 780
atcagcagaa cccccgaggt gacctgtgtg gtggtggatg tgagccacga ggaccctgag 840
gtgaagttca actggtacgt ggacggcgtg gaggtgcaca atgccaagac caagcccagg 900
gaggagcagt acaacagcac ctaccgggtg gtgtccgtgc tgaccgtgct gcaccaggat 960
tggctgaacg gcaaggagta caagtgtaag gtgtccaaca aggccctgcc tgcccctatc 1020
gagaaaacca tcagcaaggc caagggccag cccagagagc cccaggtgta caccctgccc 1080
cctagcagag atgagctgac caagaaccag gtgtccctga cctgcctggt gaagggcttc 1140
taccccagcg acatcgccgt ggagtgggag agcaacggcc agcccgagaa caactacaag 1200
accacccccc ctgtgctgga cagcgatggc agcttcttcc tgtacagcaa gctgaccgtg 1260
gacaagagca gatggcagca gggcaacgtg ttcagctgct ccgtgatgca cgaggccctg 1320
cacaatcact acacccagaa gagcctgagc ctgtcccctg gcaagaccgt ggccgccccc 1380
tcgggatccg aagtgcagct cctggagagc ggcggcggcc tggtgcagcc cggcggcagc 1440
ctgaggctga gctgcgccgc tagcggcttc accttcagga acttcggcat gggctgggtc 1500
aggcaggccc ccggcaaggg cctggagtgg gtcagctgga tcatcagctc cggcaccgag 1560
acctactacg ccgacagcgt gaagggcagg ttcaccatca gccgcgacaa cagcaagaac 1620
accctgtacc tgcagatgaa cagcctgagg gccgaggaca ccgccgtcta ctactgcgcc 1680
aagagcctgg gcaggttcga ctactgggga caggggaccc tggtgactgt gagcagc 1737
<210> 168
<211> 1710
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 168
gaggtgcagc tggtggagtc tggcggcgga ctggtgcagc ccggcagaag cctgagactg 60
agctgtgccg ccagcggctt caccttcgac gactacgcca tgcactgggt gaggcaggcc 120
cctggcaagg gcctggagtg ggtgtccgcc atcacctgga atagcggcca catcgactac 180
gccgacagcg tggagggcag attcaccatc agccgggaca acgccaagaa cagcctgtac 240
ctgcagatga acagcctgag agccgaggac accgccgtgt actactgtgc caaggtgtcc 300
tacctgagca ccgccagcag cctggactac tggggccagg gcaccctggt gacagtctcg 360
agcgctagca ccaagggccc cagcgtgttc cccctggccc ccagcagcaa gagcaccagc 420
ggcggcacag ccgccctggg ctgcctggtg aaggactact tccccgagcc tgtgaccgtg 480
tcctggaata gcggagccct gacctccggc gtgcacacct tccccgccgt gctgcagagc 540
agcggcctgt actccctgag cagcgtggtg accgtgccca gcagcagcct gggcacccag 600
acctacatct gcaacgtgaa ccacaagccc agcaacacca aagtggacaa gaaagtggag 660
cccaagagct gcgataagac ccacacctgc cccccctgcc ctgcccccga gctgctgggc 720
ggacctagcg tgttcctgtt cccccccaag cctaaggaca ccctgatgat cagcaggacc 780
cccgaagtga cctgcgtggt ggtggatgtg agccacgagg accctgaagt gaagttcaac 840
tggtacgtgg acggcgtgga agtgcacaac gccaagacca agcccagaga ggagcagtac 900
aacagcacct accgcgtggt gtctgtgctg accgtgctgc accaggattg gctgaacggc 960
aaggagtaca agtgcaaagt gagcaacaag gccctgcctg cccctatcga gaaaaccatc 1020
agcaaggcca agggccagcc tagagagccc caggtctaca ccctgcctcc ctccagagat 1080
gagctgacca agaaccaggt gtccctgacc tgtctggtga agggcttcta ccccagcgac 1140
atcgccgtgg agtgggagag caacggccag cccgagaaca actacaagac caccccccct 1200
gtgctggaca gcgatggcag cttcttcctg tactccaagc tgaccgtgga caagagcaga 1260
tggcagcagg gcaacgtgtt cagctgcagc gtgatgcacg aggccctgca caatcactac 1320
acccagaaga gtctgagcct gtcccctggc aagtcgaccg gtgaggtgca gctgttggtg 1380
tctgggggag gcttggtaca gcctgggggg tccctgcgtc tctcctgtgc agcctccgga 1440
ttcaccttta aggcttatcc gatgatgtgg gtccgccagg ctccagggaa gggtctagag 1500
tgggtttcag agatttcgcc ttcgggttct tatacatact acgcagactc cgtgaagggc 1560
cggttcacca tctcccgcga caattccaag aacacgctgt atctgcaaat gaacagcctg 1620
cgtgccgagg acaccgcggt atattactgt gcgaaagatc ctcggaagtt agactactgg 1680
ggtcagggaa ccctggtcac cgtctcgagc 1710
<210> 169
<211> 642
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 169
gatatccaga tgacccagag ccccagcagc ctgagcgcct ctgtgggcga tagagtgacc 60
atcacctgcc gggccagcca gggcatcaga aactacctgg cctggtatca gcagaagcct 120
ggcaaggccc ctaagctgct gatctacgcc gccagcaccc tgcagagcgg cgtgcccagc 180
agattcagcg gcagcggctc cggcaccgac ttcaccctga ccatcagcag cctgcagccc 240
gaggacgtgg ccacctacta ctgccagcgg tacaacagag ccccttacac cttcggccag 300
ggcaccaagg tggagatcaa gcgtacggtg gccgccccca gcgtgttcat cttccccccc 360
agcgatgagc agctcaagag cggcaccgcc agcgtggtgt gtctgctgaa caacttctac 420
ccccgggagg ccaaagtgca gtggaaagtg gacaacgccc tgcagagcgg caacagccag 480
gagagcgtga ccgagcagga cagcaaggac tccacctaca gcctgagcag caccctgacc 540
ctgagcaagg ccgactacga gaagcacaaa gtgtacgcct gcgaagtgac ccaccagggc 600
ctgtccagcc ccgtgaccaa gagcttcaac cggggcgagt gc 642
<210> 170
<211> 1686
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 170
gaggtgcagc tggtggagtc tggcggcgga ctggtgcagc ccggcagaag cctgagactg 60
agctgtgccg ccagcggctt caccttcgac gactacgcca tgcactgggt gaggcaggcc 120
cctggcaagg gcctggagtg ggtgtccgcc atcacctgga atagcggcca catcgactac 180
gccgacagcg tggagggcag attcaccatc agccgggaca acgccaagaa cagcctgtac 240
ctgcagatga acagcctgag agccgaggac accgccgtgt actactgtgc caaggtgtcc 300
tacctgagca ccgccagcag cctggactac tggggccagg gcaccctggt gacagtctcg 360
agcgctagca ccaagggccc cagcgtgttc cccctggccc ccagcagcaa gagcaccagc 420
ggcggcacag ccgccctggg ctgcctggtg aaggactact tccccgagcc tgtgaccgtg 480
tcctggaata gcggagccct gacctccggc gtgcacacct tccccgccgt gctgcagagc 540
agcggcctgt actccctgag cagcgtggtg accgtgccca gcagcagcct gggcacccag 600
acctacatct gcaacgtgaa ccacaagccc agcaacacca aagtggacaa gaaagtggag 660
cccaagagct gcgataagac ccacacctgc cccccctgcc ctgcccccga gctgctgggc 720
ggacctagcg tgttcctgtt cccccccaag cctaaggaca ccctgatgat cagcaggacc 780
cccgaagtga cctgcgtggt ggtggatgtg agccacgagg accctgaagt gaagttcaac 840
tggtacgtgg acggcgtgga agtgcacaac gccaagacca agcccagaga ggagcagtac 900
aacagcacct accgcgtggt gtctgtgctg accgtgctgc accaggattg gctgaacggc 960
aaggagtaca agtgcaaagt gagcaacaag gccctgcctg cccctatcga gaaaaccatc 1020
agcaaggcca agggccagcc tagagagccc caggtctaca ccctgcctcc ctccagagat 1080
gagctgacca agaaccaggt gtccctgacc tgtctggtga agggcttcta ccccagcgac 1140
atcgccgtgg agtgggagag caacggccag cccgagaaca actacaagac caccccccct 1200
gtgctggaca gcgatggcag cttcttcctg tactccaagc tgaccgtgga caagagcaga 1260
tggcagcagg gcaacgtgtt cagctgcagc gtgatgcacg aggccctgca caatcactac 1320
acccagaaga gtctgagcct gtcccctggc aagtcgaccg gtgacatcca gatgacccag 1380
agcccttcaa gcctgagcgc cagcgtgggc gacagagtga ccatcacctg ccgggccagc 1440
cagtggatcg gcaacctgct ggactggtat cagcagaagc ccggcaaggc ccccaagctg 1500
ctgatctact acgccagctt cctgcagagc ggcgtgccca gccggtttag cggcagcggc 1560
tacggcaccg acttcaccct gaccatcagc agcctgcagc ccgaggactt cgccacctac 1620
tactgccagc aggccaaccc tgcccccctg accttcggcc agggtaccaa ggtggaaatc 1680
aaacgg 1686
<210> 171
<211> 984
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 171
gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga ccgtgtcacc 60
atcacttgcc gggcaagtca ggatatttac ctgaatttag actggtatca gcagaaacca 120
gggaaagccc ctaagctcct gatcaatttt ggttccgagt tgcaaagtgg tgtcccatca 180
cgtttcagtg gcagtggata tgggacagat ttcactctca ccatcagcag tctgcaacct 240
gaagatttcg ctacgtacta ctgtcaaccg tctttttact tcccttatac gttcggccaa 300
gggaccaagg tggaaatcaa acgtacggtg gccgccccca gcgacatcca gatgacccag 360
tctccatcct ccctgtctgc atctgtagga gaccgtgtca ccatcacttg ccgggcaagt 420
cagagcatta gcagctattt aaattggtac cagcagaaac cagggaaagc ccctaagctc 480
ctgatctatg ctgcatccag tttgcaaagt ggggtcccat cacgtttcag tggcagtgga 540
tctgggacag atttcactct caccatcagc agtctgcaac ctgaagattt tgctacgtac 600
tactgtcaac agagttacag tacccctaat acgttcggcc aagggaccaa ggtggaaatc 660
aaacgtacgg tggccgcccc cagcgtgttc atcttccccc ccagcgatga gcagctcaag 720
agcggcaccg ccagcgtggt gtgtctgctg aacaacttct acccccggga ggccaaagtg 780
cagtggaaag tggacaacgc cctgcagagc ggcaacagcc aggagagcgt gaccgagcag 840
gacagcaagg actccaccta cagcctgagc agcaccctga ccctgagcaa ggccgactac 900
gagaagcaca aagtgtacgc ctgcgaagtg acccaccagg gcctgtccag ccccgtgacc 960
aagagcttca accggggcga gtgc 984
<210> 172
<211> 1707
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 172
gaggtgcagc tgttggtgtc tgggggaggc ttggtacagc ctggggggtc cctgcgtctc 60
tcctgtgcag cctccggatt cacctttaag gcttatccga tgatgtgggt ccgccaggct 120
ccagggaagg gtctagagtg ggtttcagag atttcgcctt cgggttctta tacatactac 180
gcagactccg tgaagggccg gttcaccatc tcccgcgaca attccaagaa cacgctgtat 240
ctgcaaatga acagcctgcg tgccgaggac accgcggtat attactgtgc gaaagatcct 300
cggaagttag actactgggg tcagggaacc ctggtcaccg tctcgagcgc tagcaccaag 360
ggccccagcg aggtgcagct gttggagtct gggggaggct tggtacagcc tggggggtcc 420
ctgcgtctct cctgtgcagc ctccggattc acctttagca gctatgccat gagctgggtc 480
cgccaggctc cagggaaggg tctagagtgg gtctcagcta ttagtggtag tggtggtagc 540
acatactacg cagactccgt gaagggccgg ttcaccatct cccgcgacaa ttccaagaac 600
acgctgtatc tgcaaatgaa cagcctgcgt gccgaggaca ccgcggtata ttactgtgcg 660
aaaagttatg gtgcttttga ctactggggc cagggaaccc tggtcaccgt ctcgagcgct 720
agcaccaagg gccccagcgt gttccccctg gcccccagca gcaagagcac cagcggcggc 780
acagccgccc tgggctgcct ggtgaaggac tacttccccg agcctgtgac cgtgtcctgg 840
aatagcggag ccctgacctc cggcgtgcac accttccccg ccgtgctgca gagcagcggc 900
ctgtactccc tgagcagcgt ggtgaccgtg cccagcagca gcctgggcac ccagacctac 960
atctgcaacg tgaaccacaa gcccagcaac accaaagtgg acaagaaagt ggagcccaag 1020
agctgcgata agacccacac ctgccccccc tgccctgccc ccgagctgct gggcggacct 1080
agcgtgttcc tgttcccccc caagcctaag gacaccctga tgatcagcag gacccccgaa 1140
gtgacctgcg tggtggtgga tgtgagccac gaggaccctg aagtgaagtt caactggtac 1200
gtggacggcg tggaagtgca caacgccaag accaagccca gagaggagca gtacaacagc 1260
acctaccgcg tggtgtctgt gctgaccgtg ctgcaccagg attggctgaa cggcaaggag 1320
tacaagtgca aagtgagcaa caaggccctg cctgccccta tcgagaaaac catcagcaag 1380
gccaagggcc agcctagaga gccccaggtc tacaccctgc ctccctccag agatgagctg 1440
accaagaacc aggtgtccct gacctgtctg gtgaagggct tctaccccag cgacatcgcc 1500
gtggagtggg agagcaacgg ccagcccgag aacaactaca agaccacccc ccctgtgctg 1560
gacagcgatg gcagcttctt cctgtactcc aagctgaccg tggacaagag cagatggcag 1620
cagggcaacg tgttcagctg cagcgtgatg cacgaggccc tgcacaatca ctacacccag 1680
aagagtctga gcctgtcccc tggcaag 1707
<210> 173
<211> 1695
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 173
caggtgcagc tgaagcagag cggccctggc ctggtgcagc cctctcagag cctgagcatc 60
acctgtaccg tgagcggctt cagcctgacc aattacggcg tgcattgggt gcggcagtct 120
ccaggcaagg gcctggaatg gctgggagtg atctggtccg gcggcaacac cgactacaac 180
acccccttca ccagcagact gagcatcaac aaggacaaca gcaagagcca ggtgttcttc 240
aagatgaaca gcctgcagag caacgacacc gccatctact attgtgccag ggccctgacc 300
tactacgact acgagttcgc ctactggggc cagggcaccc tggtgaccgt gagcgccgct 360
agcaccaagg gccccagcgt gttccccctg gcccccagca gcaagagcac cagcggcggc 420
acagccgccc tgggctgcct ggtgaaggac tacttccccg agcctgtgac cgtgtcctgg 480
aatagcggag ccctgacctc cggcgtgcac accttccccg ccgtgctgca gagcagcggc 540
ctgtactccc tgagcagcgt ggtgaccgtg cccagcagca gcctgggcac ccagacctac 600
atctgcaacg tgaaccacaa gcccagcaac accaaagtgg acaagaaagt ggagcccaag 660
agctgcgata agacccacac ctgccccccc tgccctgccc ccgagctgct gggcggacct 720
agcgtgttcc tgttcccccc caagcctaag gacaccctga tgatcagcag gacccccgaa 780
gtgacctgcg tggtggtgga tgtgagccac gaggaccctg aagtgaagtt caactggtac 840
gtggacggcg tggaagtgca caacgccaag accaagccca gagaggagca gtacaacagc 900
acctaccgcg tggtgtctgt gctgaccgtg ctgcaccagg attggctgaa cggcaaggag 960
tacaagtgca aagtgagcaa caaggccctg cctgccccta tcgagaaaac catcagcaag 1020
gccaagggcc agcctagaga gccccaggtc tacaccctgc ctccctccag agatgagctg 1080
accaagaacc aggtgtccct gacctgtctg gtgaagggct tctaccccag cgacatcgcc 1140
gtggagtggg agagcaacgg ccagcccgag aacaactaca agaccacccc ccctgtgctg 1200
gacagcgatg gcagcttctt cctgtactcc aagctgaccg tggacaagag cagatggcag 1260
cagggcaacg tgttcagctg cagcgtgatg cacgaggccc tgcacaatca ctacacccag 1320
aagagtctga gcctgtcccc tggcaaggag gtgcagctgt tggtgtctgg gggaggcttg 1380
gtacagcctg gggggtccct gcgtctctcc tgtgcagcct ccggattcac ctttaaggct 1440
tatccgatga tgtgggtccg ccaggctcca gggaagggtc tagagtgggt ttcagagatt 1500
tcgccttcgg gttcttatac atactacgca gactccgtga agggccggtt caccatctcc 1560
cgcgacaatt ccaagaacac gctgtatctg caaatgaaca gcctgcgtgc cgaggacacc 1620
gcggtatatt actgtgcgaa agatcctcgg aagttagact actggggtca gggaaccctg 1680
gtcaccgtct cgagc 1695
<210> 174
<211> 565
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 174
Gln Val Gln Leu Lys Gln Ser Gly Pro Gly Leu Val Gln Pro Ser Gln
1 5 10 15
Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Asn Tyr
20 25 30
Gly Val His Trp Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu
35 40 45
Gly Val Ile Trp Ser Gly Gly Asn Thr Asp Tyr Asn Thr Pro Phe Thr
50 55 60
Ser Arg Leu Ser Ile Asn Lys Asp Asn Ser Lys Ser Gln Val Phe Phe
65 70 75 80
Lys Met Asn Ser Leu Gln Ser Asn Asp Thr Ala Ile Tyr Tyr Cys Ala
85 90 95
Arg Ala Leu Thr Tyr Tyr Asp Tyr Glu Phe Ala Tyr Trp Gly Gln Gly
100 105 110
Thr Leu Val Thr Val Ser Ala Ala Ser Thr Lys Gly Pro Ser Val Phe
115 120 125
Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu
130 135 140
Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp
145 150 155 160
Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu
165 170 175
Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser
180 185 190
Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro
195 200 205
Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys
210 215 220
Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro
225 230 235 240
Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser
245 250 255
Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp
260 265 270
Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn
275 280 285
Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val
290 295 300
Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu
305 310 315 320
Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys
325 330 335
Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr
340 345 350
Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr
355 360 365
Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu
370 375 380
Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu
385 390 395 400
Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys
405 410 415
Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu
420 425 430
Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
435 440 445
Lys Glu Val Gln Leu Leu Val Ser Gly Gly Gly Leu Val Gln Pro Gly
450 455 460
Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Lys Ala
465 470 475 480
Tyr Pro Met Met Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
485 490 495
Val Ser Glu Ile Ser Pro Ser Gly Ser Tyr Thr Tyr Tyr Ala Asp Ser
500 505 510
Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu
515 520 525
Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr
530 535 540
Cys Ala Lys Asp Pro Arg Lys Leu Asp Tyr Trp Gly Gln Gly Thr Leu
545 550 555 560
Val Thr Val Ser Ser
565
<210> 175
<211> 1719
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 175
caggtgcagc tgaagcagag cggccctggc ctggtgcagc cctctcagag cctgagcatc 60
acctgtaccg tgagcggctt cagcctgacc aattacggcg tgcattgggt gcggcagtct 120
ccaggcaagg gcctggaatg gctgggagtg atctggtccg gcggcaacac cgactacaac 180
acccccttca ccagcagact gagcatcaac aaggacaaca gcaagagcca ggtgttcttc 240
aagatgaaca gcctgcagag caacgacacc gccatctact attgtgccag ggccctgacc 300
tactacgact acgagttcgc ctactggggc cagggcaccc tggtgaccgt gagcgccgct 360
agcaccaagg gccccagcgt gttccccctg gcccccagca gcaagagcac cagcggcggc 420
acagccgccc tgggctgcct ggtgaaggac tacttccccg agcctgtgac cgtgtcctgg 480
aatagcggag ccctgacctc cggcgtgcac accttccccg ccgtgctgca gagcagcggc 540
ctgtactccc tgagcagcgt ggtgaccgtg cccagcagca gcctgggcac ccagacctac 600
atctgcaacg tgaaccacaa gcccagcaac accaaagtgg acaagaaagt ggagcccaag 660
agctgcgata agacccacac ctgccccccc tgccctgccc ccgagctgct gggcggacct 720
agcgtgttcc tgttcccccc caagcctaag gacaccctga tgatcagcag gacccccgaa 780
gtgacctgcg tggtggtgga tgtgagccac gaggaccctg aagtgaagtt caactggtac 840
gtggacggcg tggaagtgca caacgccaag accaagccca gagaggagca gtacaacagc 900
acctaccgcg tggtgtctgt gctgaccgtg ctgcaccagg attggctgaa cggcaaggag 960
tacaagtgca aagtgagcaa caaggccctg cctgccccta tcgagaaaac catcagcaag 1020
gccaagggcc agcctagaga gccccaggtc tacaccctgc ctccctccag agatgagctg 1080
accaagaacc aggtgtccct gacctgtctg gtgaagggct tctaccccag cgacatcgcc 1140
gtggagtggg agagcaacgg ccagcccgag aacaactaca agaccacccc ccctgtgctg 1200
gacagcgatg gcagcttctt cctgtactcc aagctgaccg tggacaagag cagatggcag 1260
cagggcaacg tgttcagctg cagcgtgatg cacgaggccc tgcacaatca ctacacccag 1320
aagagtctga gcctgtcccc tggcaagtcg accggtggtg gaggtggatc agaggtgcag 1380
ctgttggtgt ctgggggagg cttggtacag cctggggggt ccctgcgtct ctcctgtgca 1440
gcctccggat tcacctttaa ggcttatccg atgatgtggg tccgccaggc tccagggaag 1500
ggtctagagt gggtttcaga gatttcgcct tcgggttctt atacatacta cgcagactcc 1560
gtgaagggcc ggttcaccat ctcccgcgac aattccaaga acacgctgta tctgcaaatg 1620
aacagcctgc gtgccgagga caccgcggta tattactgtg cgaaagatcc tcggaagtta 1680
gactactggg gtcagggaac cctggtcacc gtctcgagc 1719
<210> 176
<211> 573
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 176
Gln Val Gln Leu Lys Gln Ser Gly Pro Gly Leu Val Gln Pro Ser Gln
1 5 10 15
Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Asn Tyr
20 25 30
Gly Val His Trp Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu
35 40 45
Gly Val Ile Trp Ser Gly Gly Asn Thr Asp Tyr Asn Thr Pro Phe Thr
50 55 60
Ser Arg Leu Ser Ile Asn Lys Asp Asn Ser Lys Ser Gln Val Phe Phe
65 70 75 80
Lys Met Asn Ser Leu Gln Ser Asn Asp Thr Ala Ile Tyr Tyr Cys Ala
85 90 95
Arg Ala Leu Thr Tyr Tyr Asp Tyr Glu Phe Ala Tyr Trp Gly Gln Gly
100 105 110
Thr Leu Val Thr Val Ser Ala Ala Ser Thr Lys Gly Pro Ser Val Phe
115 120 125
Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu
130 135 140
Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp
145 150 155 160
Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu
165 170 175
Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser
180 185 190
Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro
195 200 205
Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys
210 215 220
Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro
225 230 235 240
Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser
245 250 255
Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp
260 265 270
Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn
275 280 285
Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val
290 295 300
Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu
305 310 315 320
Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys
325 330 335
Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr
340 345 350
Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr
355 360 365
Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu
370 375 380
Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu
385 390 395 400
Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys
405 410 415
Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu
420 425 430
Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
435 440 445
Lys Ser Thr Gly Gly Gly Gly Gly Ser Glu Val Gln Leu Leu Val Ser
450 455 460
Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala
465 470 475 480
Ala Ser Gly Phe Thr Phe Lys Ala Tyr Pro Met Met Trp Val Arg Gln
485 490 495
Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Glu Ile Ser Pro Ser Gly
500 505 510
Ser Tyr Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser
515 520 525
Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg
530 535 540
Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Asp Pro Arg Lys Leu
545 550 555 560
Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
565 570
<210> 177
<211> 1734
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 177
caggtgcagc tgaagcagag cggccctggc ctggtgcagc cctctcagag cctgagcatc 60
acctgtaccg tgagcggctt cagcctgacc aattacggcg tgcattgggt gcggcagtct 120
ccaggcaagg gcctggaatg gctgggagtg atctggtccg gcggcaacac cgactacaac 180
acccccttca ccagcagact gagcatcaac aaggacaaca gcaagagcca ggtgttcttc 240
aagatgaaca gcctgcagag caacgacacc gccatctact attgtgccag ggccctgacc 300
tactacgact acgagttcgc ctactggggc cagggcaccc tggtgaccgt gagcgccgct 360
agcaccaagg gccccagcgt gttccccctg gcccccagca gcaagagcac cagcggcggc 420
acagccgccc tgggctgcct ggtgaaggac tacttccccg agcctgtgac cgtgtcctgg 480
aatagcggag ccctgacctc cggcgtgcac accttccccg ccgtgctgca gagcagcggc 540
ctgtactccc tgagcagcgt ggtgaccgtg cccagcagca gcctgggcac ccagacctac 600
atctgcaacg tgaaccacaa gcccagcaac accaaagtgg acaagaaagt ggagcccaag 660
agctgcgata agacccacac ctgccccccc tgccctgccc ccgagctgct gggcggacct 720
agcgtgttcc tgttcccccc caagcctaag gacaccctga tgatcagcag gacccccgaa 780
gtgacctgcg tggtggtgga tgtgagccac gaggaccctg aagtgaagtt caactggtac 840
gtggacggcg tggaagtgca caacgccaag accaagccca gagaggagca gtacaacagc 900
acctaccgcg tggtgtctgt gctgaccgtg ctgcaccagg attggctgaa cggcaaggag 960
tacaagtgca aagtgagcaa caaggccctg cctgccccta tcgagaaaac catcagcaag 1020
gccaagggcc agcctagaga gccccaggtc tacaccctgc ctccctccag agatgagctg 1080
accaagaacc aggtgtccct gacctgtctg gtgaagggct tctaccccag cgacatcgcc 1140
gtggagtggg agagcaacgg ccagcccgag aacaactaca agaccacccc ccctgtgctg 1200
gacagcgatg gcagcttctt cctgtactcc aagctgaccg tggacaagag cagatggcag 1260
cagggcaacg tgttcagctg cagcgtgatg cacgaggccc tgcacaatca ctacacccag 1320
aagagtctga gcctgtcccc tggcaagtcg accggtggtg gaggtggatc aggtggaggt 1380
ggatcagagg tgcagctgtt ggtgtctggg ggaggcttgg tacagcctgg ggggtccctg 1440
cgtctctcct gtgcagcctc cggattcacc tttaaggctt atccgatgat gtgggtccgc 1500
caggctccag ggaagggtct agagtgggtt tcagagattt cgccttcggg ttcttataca 1560
tactacgcag actccgtgaa gggccggttc accatctccc gcgacaattc caagaacacg 1620
ctgtatctgc aaatgaacag cctgcgtgcc gaggacaccg cggtatatta ctgtgcgaaa 1680
gatcctcgga agttagacta ctggggtcag ggaaccctgg tcaccgtctc gagc 1734
<210> 178
<211> 578
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 178
Gln Val Gln Leu Lys Gln Ser Gly Pro Gly Leu Val Gln Pro Ser Gln
1 5 10 15
Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Asn Tyr
20 25 30
Gly Val His Trp Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu
35 40 45
Gly Val Ile Trp Ser Gly Gly Asn Thr Asp Tyr Asn Thr Pro Phe Thr
50 55 60
Ser Arg Leu Ser Ile Asn Lys Asp Asn Ser Lys Ser Gln Val Phe Phe
65 70 75 80
Lys Met Asn Ser Leu Gln Ser Asn Asp Thr Ala Ile Tyr Tyr Cys Ala
85 90 95
Arg Ala Leu Thr Tyr Tyr Asp Tyr Glu Phe Ala Tyr Trp Gly Gln Gly
100 105 110
Thr Leu Val Thr Val Ser Ala Ala Ser Thr Lys Gly Pro Ser Val Phe
115 120 125
Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu
130 135 140
Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp
145 150 155 160
Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu
165 170 175
Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser
180 185 190
Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro
195 200 205
Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys
210 215 220
Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro
225 230 235 240
Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser
245 250 255
Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp
260 265 270
Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn
275 280 285
Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val
290 295 300
Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu
305 310 315 320
Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys
325 330 335
Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr
340 345 350
Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr
355 360 365
Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu
370 375 380
Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu
385 390 395 400
Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys
405 410 415
Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu
420 425 430
Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
435 440 445
Lys Ser Thr Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Val
450 455 460
Gln Leu Leu Val Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu
465 470 475 480
Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Lys Ala Tyr Pro Met
485 490 495
Met Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Glu
500 505 510
Ile Ser Pro Ser Gly Ser Tyr Thr Tyr Tyr Ala Asp Ser Val Lys Gly
515 520 525
Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln
530 535 540
Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys
545 550 555 560
Asp Pro Arg Lys Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val
565 570 575
Ser Ser
<210> 179
<211> 1692
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 179
gaggtgcagc tggtcgagtc tggcggcgga ctggtgcagc ctggcggcag cctgagactg 60
agctgcgccg ccagcggcta caccttcacc aactacggca tgaactgggt gcggcaggcc 120
cctggcaagg gcctggaatg ggtgggctgg atcaacacct acaccggcga gcccacctac 180
gccgccgact tcaagcggcg gttcaccttc agcctggaca ccagcaagag caccgcctac 240
ctgcagatga acagcctgcg ggccgaggac accgccgtgt actactgcgc caagtacccc 300
cactactacg gcagcagcca ctggtacttc gactactggg ggcagggtac cctggtcacc 360
gtctcgagcg ctagcaccaa gggccccagc gtgttccccc tggcccccag cagcaagagc 420
accagcggcg gcacagccgc cctgggctgc ctggtgaagg actacttccc cgagcctgtg 480
accgtgtcct ggaatagcgg agccctgacc tccggcgtgc acaccttccc cgccgtgctg 540
cagagcagcg gcctgtactc cctgagcagc gtggtgaccg tgcccagcag cagcctgggc 600
acccagacct acatctgcaa cgtgaaccac aagcccagca acaccaaagt ggacaagaaa 660
gtggagccca agagctgcga taagacccac acctgccccc cctgccctgc ccccgagctg 720
ctgggcggac ctagcgtgtt cctgttcccc cccaagccta aggacaccct gatgatcagc 780
aggacccccg aagtgacctg cgtggtggtg gatgtgagcc acgaggaccc tgaagtgaag 840
ttcaactggt acgtggacgg cgtggaagtg cacaacgcca agaccaagcc cagagaggag 900
cagtacaaca gcacctaccg cgtggtgtct gtgctgaccg tgctgcacca ggattggctg 960
aacggcaagg agtacaagtg caaagtgagc aacaaggccc tgcctgcccc tatcgagaaa 1020
accatcagca aggccaaggg ccagcctaga gagccccagg tctacaccct gcctccctcc 1080
agagatgagc tgaccaagaa ccaggtgtcc ctgacctgtc tggtgaaggg cttctacccc 1140
agcgacatcg ccgtggagtg ggagagcaac ggccagcccg agaacaacta caagaccacc 1200
ccccctgtgc tggacagcga tggcagcttc ttcctgtact ccaagctgac cgtggacaag 1260
agcagatggc agcagggcaa cgtgttcagc tgcagcgtga tgcacgaggc cctgcacaat 1320
cactacaccc agaagagtct gagcctgtcc cctggcaagt cgaccggtga catccagatg 1380
acccagagcc cttcaagcct gagcgccagc gtgggcgaca gagtgaccat cacctgccgg 1440
gccagccagt ggatcggcaa cctgctggac tggtatcagc agaagcccgg caaggccccc 1500
aagctgctga tctactacgc cagcttcctg cagagcggcg tgcccagccg gtttagcggc 1560
agcggctacg gcaccgactt caccctgacc atcagcagcc tgcagcccga ggacttcgcc 1620
acctactact gccagcaggc caaccctgcc cccctgacct tcggccaggg taccaaggtg 1680
gaaatcaaac gg 1692
<210> 180
<211> 564
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 180
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro His Tyr Tyr Gly Ser Ser His Trp Tyr Phe Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
225 230 235 240
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Lys Ser Thr Gly Asp Ile Gln Met Thr Gln Ser Pro
450 455 460
Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg
465 470 475 480
Ala Ser Gln Trp Ile Gly Asn Leu Leu Asp Trp Tyr Gln Gln Lys Pro
485 490 495
Gly Lys Ala Pro Lys Leu Leu Ile Tyr Tyr Ala Ser Phe Leu Gln Ser
500 505 510
Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Tyr Gly Thr Asp Phe Thr
515 520 525
Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys
530 535 540
Gln Gln Ala Asn Pro Ala Pro Leu Thr Phe Gly Gln Gly Thr Lys Val
545 550 555 560
Glu Ile Lys Arg
<210> 181
<211> 642
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 181
gacatccaga tgacccagag ccccagcagc ctgagcgcca gcgtgggcga cagagtgacc 60
atcacctgca gcgccagcca ggacatcagc aactacctga actggtatca gcagaagccc 120
ggcaaggccc ccaaggtgct gatctacttc accagctccc tgcacagcgg cgtgcccagc 180
cggtttagcg gcagcggctc cggcaccgac ttcaccctga ccatcagcag cctgcagccc 240
gaggacttcg ccacctacta ctgccagcag tacagcaccg tgccctggac cttcggccag 300
ggtaccaagg tggagatcaa gcgtacggtg gccgctccca gcgtgttcat cttccccccc 360
agcgacgagc agctgaagag cggcaccgcc tccgtggtgt gcctgctgaa caacttctac 420
ccccgggagg ccaaggtgca gtggaaggtg gacaacgccc tgcagtccgg caacagccag 480
gaaagcgtca ccgagcagga ctccaaggac tccacctaca gcctgagcag caccctgacc 540
ctgagcaagg ccgactacga gaagcacaag gtgtacgcct gcgaagtgac ccaccagggc 600
ctgtccagcc ccgtgaccaa gagcttcaac cggggcgagt gc 642
<210> 182
<211> 214
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 182
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 183
<211> 1710
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 183
caggtgcagc tgaagcagag cggccctggc ctggtgcagc cctctcagag cctgagcatc 60
acctgtaccg tgagcggctt cagcctgacc aattacggcg tgcattgggt gcggcagtct 120
ccaggcaagg gcctggaatg gctgggagtg atctggtccg gcggcaacac cgactacaac 180
acccccttca ccagcagact gagcatcaac aaggacaaca gcaagagcca ggtgttcttc 240
aagatgaaca gcctgcagag caacgacacc gccatctact attgtgccag ggccctgacc 300
tactacgact acgagttcgc ctactggggc cagggcaccc tggtgaccgt gagcgccgct 360
agcaccaagg gccccagcgt gttccccctg gcccccagca gcaagagcac cagcggcggc 420
acagccgccc tgggctgcct ggtgaaggac tacttccccg agcctgtgac cgtgtcctgg 480
aatagcggag ccctgacctc cggcgtgcac accttccccg ccgtgctgca gagcagcggc 540
ctgtactccc tgagcagcgt ggtgaccgtg cccagcagca gcctgggcac ccagacctac 600
atctgcaacg tgaaccacaa gcccagcaac accaaagtgg acaagaaagt ggagcccaag 660
agctgcgata agacccacac ctgccccccc tgccctgccc ccgagctgct gggcggacct 720
agcgtgttcc tgttcccccc caagcctaag gacaccctga tgatcagcag gacccccgaa 780
gtgacctgcg tggtggtgga tgtgagccac gaggaccctg aagtgaagtt caactggtac 840
gtggacggcg tggaagtgca caacgccaag accaagccca gagaggagca gtacaacagc 900
acctaccgcg tggtgtctgt gctgaccgtg ctgcaccagg attggctgaa cggcaaggag 960
tacaagtgca aagtgagcaa caaggccctg cctgccccta tcgagaaaac catcagcaag 1020
gccaagggcc agcctagaga gccccaggtc tacaccctgc ctccctccag agatgagctg 1080
accaagaacc aggtgtccct gacctgtctg gtgaagggct tctaccccag cgacatcgcc 1140
gtggagtggg agagcaacgg ccagcccgag aacaactaca agaccacccc ccctgtgctg 1200
gacagcgatg gcagcttctt cctgtactcc aagctgaccg tggacaagag cagatggcag 1260
cagggcaacg tgttcagctg cagcgtgatg cacgaggccc tgcacaatca ctacacccag 1320
aagagtctga gcctgtcccc tggcaagtcg accggtgggg tgcagctgtt ggagtctggg 1380
ggaggcttgg tacagcctgg ggggtccctg cgtctctcct gtgcagcctc cggattcacc 1440
ttcgcttggt atgatatggg gtgggtccgc caggctccag ggaagggtct agagtgggtc 1500
tcaagtattg attggcatgg tgaggttaca tactacgcag actccgtgaa gggccggttc 1560
accatctccc gcgacaattc caagaacacg ctgtatctgc aaatgaacag cctgcgtgcc 1620
gaggacaccg cggtatatta ctgtgcgaca gcggaggacg agccggggta tgactactgg 1680
ggccagggaa ccctggtcac cgtctcgagc 1710
<210> 184
<211> 570
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 184
Gln Val Gln Leu Lys Gln Ser Gly Pro Gly Leu Val Gln Pro Ser Gln
1 5 10 15
Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Asn Tyr
20 25 30
Gly Val His Trp Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu
35 40 45
Gly Val Ile Trp Ser Gly Gly Asn Thr Asp Tyr Asn Thr Pro Phe Thr
50 55 60
Ser Arg Leu Ser Ile Asn Lys Asp Asn Ser Lys Ser Gln Val Phe Phe
65 70 75 80
Lys Met Asn Ser Leu Gln Ser Asn Asp Thr Ala Ile Tyr Tyr Cys Ala
85 90 95
Arg Ala Leu Thr Tyr Tyr Asp Tyr Glu Phe Ala Tyr Trp Gly Gln Gly
100 105 110
Thr Leu Val Thr Val Ser Ala Ala Ser Thr Lys Gly Pro Ser Val Phe
115 120 125
Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu
130 135 140
Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp
145 150 155 160
Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu
165 170 175
Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser
180 185 190
Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro
195 200 205
Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys
210 215 220
Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro
225 230 235 240
Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser
245 250 255
Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp
260 265 270
Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn
275 280 285
Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val
290 295 300
Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu
305 310 315 320
Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys
325 330 335
Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr
340 345 350
Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr
355 360 365
Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu
370 375 380
Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu
385 390 395 400
Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys
405 410 415
Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu
420 425 430
Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
435 440 445
Lys Ser Thr Gly Gly Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val
450 455 460
Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr
465 470 475 480
Phe Ala Trp Tyr Asp Met Gly Trp Val Arg Gln Ala Pro Gly Lys Gly
485 490 495
Leu Glu Trp Val Ser Ser Ile Asp Trp His Gly Glu Val Thr Tyr Tyr
500 505 510
Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys
515 520 525
Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala
530 535 540
Val Tyr Tyr Cys Ala Thr Ala Glu Asp Glu Pro Gly Tyr Asp Tyr Trp
545 550 555 560
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
565 570
<210> 185
<211> 562
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 185
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr
20 25 30
Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Thr Trp Asn Ser Gly His Ile Asp Tyr Ala Asp Ser Val
50 55 60
Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Val Ser Tyr Leu Ser Thr Ala Ser Ser Leu Asp Tyr Trp Gly
100 105 110
Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
115 120 125
Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
130 135 140
Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
145 150 155 160
Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
165 170 175
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
180 185 190
Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
195 200 205
Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys
210 215 220
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
225 230 235 240
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
245 250 255
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
260 265 270
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
275 280 285
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
290 295 300
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
305 310 315 320
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
325 330 335
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
340 345 350
Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
355 360 365
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
370 375 380
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
385 390 395 400
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
405 410 415
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
420 425 430
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
435 440 445
Pro Gly Lys Ser Thr Gly Asp Ile Gln Met Thr Gln Ser Pro Ser Ser
450 455 460
Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser
465 470 475 480
Gln Trp Ile Gly Pro Glu Leu Arg Trp Tyr Gln Gln Lys Pro Gly Lys
485 490 495
Ala Pro Lys Leu Leu Ile Tyr His Thr Ser Ile Leu Gln Ser Gly Val
500 505 510
Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
515 520 525
Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln
530 535 540
Tyr Met Phe Gln Pro Met Thr Phe Gly Gln Gly Thr Lys Val Glu Ile
545 550 555 560
Lys Arg
<210> 186
<211> 560
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 186
Gln Val Gln Leu Lys Gln Ser Gly Pro Gly Leu Val Gln Pro Ser Gln
1 5 10 15
Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Asn Tyr
20 25 30
Gly Val His Trp Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu
35 40 45
Gly Val Ile Trp Ser Gly Gly Asn Thr Asp Tyr Asn Thr Pro Phe Thr
50 55 60
Ser Arg Leu Ser Ile Asn Lys Asp Asn Ser Lys Ser Gln Val Phe Phe
65 70 75 80
Lys Met Asn Ser Leu Gln Ser Asn Asp Thr Ala Ile Tyr Tyr Cys Ala
85 90 95
Arg Ala Leu Thr Tyr Tyr Asp Tyr Glu Phe Ala Tyr Trp Gly Gln Gly
100 105 110
Thr Leu Val Thr Val Ser Ala Ala Ser Thr Lys Gly Pro Ser Val Phe
115 120 125
Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu
130 135 140
Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp
145 150 155 160
Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu
165 170 175
Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser
180 185 190
Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro
195 200 205
Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys
210 215 220
Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro
225 230 235 240
Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser
245 250 255
Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp
260 265 270
Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn
275 280 285
Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val
290 295 300
Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu
305 310 315 320
Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys
325 330 335
Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr
340 345 350
Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr
355 360 365
Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu
370 375 380
Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu
385 390 395 400
Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys
405 410 415
Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu
420 425 430
Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
435 440 445
Lys Ser Thr Gly Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser
450 455 460
Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Trp
465 470 475 480
Ile Gly Pro Glu Leu Arg Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro
485 490 495
Lys Leu Leu Ile Tyr His Thr Ser Ile Leu Gln Ser Gly Val Pro Ser
500 505 510
Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
515 520 525
Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Met
530 535 540
Phe Gln Pro Met Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
545 550 555 560
<210> 187
<211> 1002
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 187
gacatcctgc tgacccagag ccccgtgatc ctgagcgtga gccctggcga gagagtgagc 60
ttcagctgcc gggccagcca gagcatcggc accaacatcc actggtatca gcagcggacc 120
aacggcagcc ccaggctgct gatcaagtac gccagcgagt ccatcagcgg catccccagc 180
cggttcagcg gcagcggctc cggcaccgac ttcaccctga gcatcaacag cgtggagagc 240
gaggatatcg ccgactacta ctgccagcag aacaacaact ggcccaccac cttcggagcc 300
ggcaccaagc tggaactgaa gcgtacggtg gccgccccca gcgtgttcat cttccccccc 360
agcgatgagc agctcaagag cggcaccgcc agcgtggtgt gtctgctgaa caacttctac 420
ccccgggagg ccaaagtgca gtggaaagtg gacaacgccc tgcagagcgg caacagccag 480
gagagcgtga ccgagcagga cagcaaggac tccacctaca gcctgagcag caccctgacc 540
ctgagcaagg ccgactacga gaagcacaaa gtgtacgcct gcgaagtgac ccaccagggc 600
ctgtccagcc ccgtgaccaa gagcttcaac cggggcgagt gcggatccac cggcgaggtg 660
cagctgttgg tgtctggggg aggcttggta cagcctgggg ggtccctgcg tctctcctgt 720
gcagcctccg gattcacctt taaggcttat ccgatgatgt gggtccgcca ggctccaggg 780
aagggtctag agtgggtttc agagatttcg ccttcgggtt cttatacata ctacgcagac 840
tccgtgaagg gccggttcac catctcccgc gacaattcca agaacacgct gtatctgcaa 900
atgaacagcc tgcgtgccga ggacaccgcg gtatattact gtgcgaaaga tcctcggaag 960
ttagactact ggggtcaggg aaccctggtc accgtctcga gc 1002
<210> 188
<211> 334
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 188
Asp Ile Leu Leu Thr Gln Ser Pro Val Ile Leu Ser Val Ser Pro Gly
1 5 10 15
Glu Arg Val Ser Phe Ser Cys Arg Ala Ser Gln Ser Ile Gly Thr Asn
20 25 30
Ile His Trp Tyr Gln Gln Arg Thr Asn Gly Ser Pro Arg Leu Leu Ile
35 40 45
Lys Tyr Ala Ser Glu Ser Ile Ser Gly Ile Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser Ile Asn Ser Val Glu Ser
65 70 75 80
Glu Asp Ile Ala Asp Tyr Tyr Cys Gln Gln Asn Asn Asn Trp Pro Thr
85 90 95
Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys Gly Ser Thr Gly Glu Val Gln Leu Leu Val
210 215 220
Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys
225 230 235 240
Ala Ala Ser Gly Phe Thr Phe Lys Ala Tyr Pro Met Met Trp Val Arg
245 250 255
Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Glu Ile Ser Pro Ser
260 265 270
Gly Ser Tyr Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile
275 280 285
Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu
290 295 300
Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Asp Pro Arg Lys
305 310 315 320
Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
325 330
<210> 189
<211> 1014
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 189
gacatcctgc tgacccagag ccccgtgatc ctgagcgtga gccctggcga gagagtgagc 60
ttcagctgcc gggccagcca gagcatcggc accaacatcc actggtatca gcagcggacc 120
aacggcagcc ccaggctgct gatcaagtac gccagcgagt ccatcagcgg catccccagc 180
cggttcagcg gcagcggctc cggcaccgac ttcaccctga gcatcaacag cgtggagagc 240
gaggatatcg ccgactacta ctgccagcag aacaacaact ggcccaccac cttcggagcc 300
ggcaccaagc tggaactgaa gcgtacggtg gccgccccca gcgtgttcat cttccccccc 360
agcgatgagc agctcaagag cggcaccgcc agcgtggtgt gtctgctgaa caacttctac 420
ccccgggagg ccaaagtgca gtggaaagtg gacaacgccc tgcagagcgg caacagccag 480
gagagcgtga ccgagcagga cagcaaggac tccacctaca gcctgagcag caccctgacc 540
ctgagcaagg ccgactacga gaagcacaaa gtgtacgcct gcgaagtgac ccaccagggc 600
ctgtccagcc ccgtgaccaa gagcttcaac cggggcgagt gcggatccac ggtggccgcc 660
cccagcgagg tgcagctgtt ggtgtctggg ggaggcttgg tacagcctgg ggggtccctg 720
cgtctctcct gtgcagcctc cggattcacc tttaaggctt atccgatgat gtgggtccgc 780
caggctccag ggaagggtct agagtgggtt tcagagattt cgccttcggg ttcttataca 840
tactacgcag actccgtgaa gggccggttc accatctccc gcgacaattc caagaacacg 900
ctgtatctgc aaatgaacag cctgcgtgcc gaggacaccg cggtatatta ctgtgcgaaa 960
gatcctcgga agttagacta ctggggtcag ggaaccctgg tcaccgtctc gagc 1014
<210> 190
<211> 338
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 190
Asp Ile Leu Leu Thr Gln Ser Pro Val Ile Leu Ser Val Ser Pro Gly
1 5 10 15
Glu Arg Val Ser Phe Ser Cys Arg Ala Ser Gln Ser Ile Gly Thr Asn
20 25 30
Ile His Trp Tyr Gln Gln Arg Thr Asn Gly Ser Pro Arg Leu Leu Ile
35 40 45
Lys Tyr Ala Ser Glu Ser Ile Ser Gly Ile Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser Ile Asn Ser Val Glu Ser
65 70 75 80
Glu Asp Ile Ala Asp Tyr Tyr Cys Gln Gln Asn Asn Asn Trp Pro Thr
85 90 95
Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys Gly Ser Thr Val Ala Ala Pro Ser Glu Val
210 215 220
Gln Leu Leu Val Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu
225 230 235 240
Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Lys Ala Tyr Pro Met
245 250 255
Met Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Glu
260 265 270
Ile Ser Pro Ser Gly Ser Tyr Thr Tyr Tyr Ala Asp Ser Val Lys Gly
275 280 285
Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln
290 295 300
Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys
305 310 315 320
Asp Pro Arg Lys Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val
325 330 335
Ser Ser
<210> 191
<211> 449
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 191
Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln
1 5 10 15
Thr Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr
20 25 30
Ser Val His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu
35 40 45
Gly Val Ile Trp Ala Ser Gly Gly Thr Asp Tyr Asn Ser Ala Leu Met
50 55 60
Ser Arg Leu Ser Ile Ser Lys Asp Thr Ser Arg Asn Gln Val Val Leu
65 70 75 80
Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala
85 90 95
Arg Asp Pro Pro Ser Ser Leu Leu Arg Leu Asp Tyr Trp Gly Arg Gly
100 105 110
Thr Pro Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe
115 120 125
Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu
130 135 140
Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp
145 150 155 160
Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu
165 170 175
Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser
180 185 190
Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro
195 200 205
Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys
210 215 220
Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro
225 230 235 240
Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser
245 250 255
Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp
260 265 270
Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn
275 280 285
Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val
290 295 300
Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu
305 310 315 320
Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys
325 330 335
Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr
340 345 350
Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr
355 360 365
Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu
370 375 380
Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu
385 390 395 400
Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys
405 410 415
Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu
420 425 430
Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
435 440 445
Lys
<210> 192
<211> 1746
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 192
caggtgcagc tcgtgcagag cggcgccgaa gtgaaaaagc ccggcagcag cgtgaaggtg 60
agctgcaagg cctccggctt ctacatcaag gacacctaca tgcactgggt caggcaggct 120
cctggccagg gcctggagtg gatgggcact atcgaccccg ccaacggcaa caccaagtac 180
gtgcccaagt tccagggcag ggtgaccatc accgccgatg agagcaccag caccgcctac 240
atggaactga gcagcctgag gtctgaggac accgccgtgt actattgcgc caggagcatc 300
tacgacgact accactacga cgactactac gccatggact actggggaca gggcacacta 360
gtgaccgtgt ccagcgccag caccaagggc cccagcgtgt tccccctggc ccccagcagc 420
aagagcacca gcggcggcac agccgccctg ggctgcctgg tgaaggacta cttccccgaa 480
ccggtgaccg tgtcctggaa cagcggagcc ctgaccagcg gcgtgcacac cttccccgcc 540
gtgctgcaga gcagcggcct gtacagcctg agcagcgtgg tgaccgtgcc cagcagcagc 600
ctgggcaccc agacctacat ctgtaacgtg aaccacaagc ccagcaacac caaggtggac 660
aagaaggtgg agcccaagag ctgtgacaag acccacacct gccccccctg ccctgccccc 720
gagctgctgg gaggccccag cgtgttcctg ttccccccca agcctaagga caccctgatg 780
atcagcagaa cccccgaggt gacctgtgtg gtggtggatg tgagccacga ggaccctgag 840
gtgaagttca actggtacgt ggacggcgtg gaggtgcaca atgccaagac caagcccagg 900
gaggagcagt acaacagcac ctaccgggtg gtgtccgtgc tgaccgtgct gcaccaggat 960
tggctgaacg gcaaggagta caagtgtaag gtgtccaaca aggccctgcc tgcccctatc 1020
gagaaaacca tcagcaaggc caagggccag cccagagagc cccaggtgta caccctgccc 1080
cctagcagag atgagctgac caagaaccag gtgtccctga cctgcctggt gaagggcttc 1140
taccccagcg acatcgccgt ggagtgggag agcaacggcc agcccgagaa caactacaag 1200
accacccccc ctgtgctgga cagcgatggc agcttcttcc tgtacagcaa gctgaccgtg 1260
gacaagagca gatggcagca gggcaacgtg ttcagctgct ccgtgatgca cgaggccctg 1320
cacaatcact acacccagaa gagcctgagc ctgtcccctg gcaagggatc agccagcacc 1380
aagggcccca cgggatccga agtgcagctc ctggagagcg gcggcggcct ggtgcagccc 1440
ggcggcagcc tgaggctgag ctgcgccgct agcggcttca ccttcaggaa cttcggcatg 1500
ggctgggtca ggcaggcccc cggcaagggc ctggagtggg tcagctggat catcagctcc 1560
ggcaccgaga cctactacgc cgacagcgtg aagggcaggt tcaccatcag ccgcgacaac 1620
agcaagaaca ccctgtacct gcagatgaac agcctgaggg ccgaggacac cgccgtctac 1680
tactgcgcca agagcctggg caggttcgac tactggggac aggggaccct ggtgactgtg 1740
agcagc 1746
<210> 193
<211> 698
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 193
Glu Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln
1 5 10 15
Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Lys Ser
20 25 30
Val Met Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu
35 40 45
Trp Leu Ala His Ile Tyr Trp Asp Asp Asp Lys Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val
65 70 75 80
Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr
85 90 95
Cys Ala Arg Arg Gly Ile Arg Ser Ala Met Asp Tyr Trp Gly Gln Gly
100 105 110
Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Glu Val Gln
115 120 125
Leu Val Gln Ser Gly Thr Glu Val Lys Lys Pro Gly Glu Ser Leu Lys
130 135 140
Ile Ser Cys Lys Gly Ser Gly Tyr Thr Val Thr Ser Tyr Trp Ile Gly
145 150 155 160
Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly Phe Ile
165 170 175
Tyr Pro Gly Asp Ser Glu Thr Arg Tyr Ser Pro Thr Phe Gln Gly Gln
180 185 190
Val Thr Ile Ser Ala Asp Lys Ser Phe Asn Thr Ala Phe Leu Gln Trp
195 200 205
Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys Ala Arg Val
210 215 220
Gly Ser Gly Trp Tyr Pro Tyr Thr Phe Asp Ile Trp Gly Gln Gly Thr
225 230 235 240
Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro
245 250 255
Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly
260 265 270
Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn
275 280 285
Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln
290 295 300
Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser
305 310 315 320
Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser
325 330 335
Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr
340 345 350
His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser
355 360 365
Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg
370 375 380
Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro
385 390 395 400
Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala
405 410 415
Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val
420 425 430
Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
435 440 445
Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr
450 455 460
Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu
465 470 475 480
Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys
485 490 495
Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
500 505 510
Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp
515 520 525
Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser
530 535 540
Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala
545 550 555 560
Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
565 570 575
Thr Val Ala Ala Pro Ser Glu Val Gln Leu Leu Glu Ser Gly Gly Gly
580 585 590
Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly
595 600 605
Phe Thr Phe Arg Asn Phe Gly Met Gly Trp Val Arg Gln Ala Pro Gly
610 615 620
Lys Gly Leu Glu Trp Val Ser Trp Ile Ile Ser Ser Gly Thr Glu Thr
625 630 635 640
Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn
645 650 655
Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp
660 665 670
Thr Ala Val Tyr Tyr Cys Ala Lys Ser Leu Gly Arg Phe Asp Tyr Trp
675 680 685
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
690 695
<210> 194
<211> 328
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 194
Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
1 5 10 15
Glu Arg Ala Thr Ile Asn Cys Lys Ala Ser Gln Ser Val Ser Asn Asp
20 25 30
Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile
35 40 45
Tyr Tyr Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala
65 70 75 80
Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Asp Tyr Asn Ser Pro Trp
85 90 95
Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro
115 120 125
Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Glu Ser Ala Ser Ser
130 135 140
Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Phe
145 150 155 160
Ile Tyr Thr Ala Ser Thr Arg Ala Thr Asp Ile Pro Ala Arg Phe Ser
165 170 175
Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln
180 185 190
Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro
195 200 205
Ser Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys Arg Thr Val
210 215 220
Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys
225 230 235 240
Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg
245 250 255
Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn
260 265 270
Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser
275 280 285
Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys
290 295 300
Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr
305 310 315 320
Lys Ser Phe Asn Arg Gly Glu Cys
325
<210> 195
<211> 696
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 195
Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln
1 5 10 15
Thr Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr
20 25 30
Ser Val His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu
35 40 45
Gly Val Ile Trp Ala Ser Gly Gly Thr Asp Tyr Asn Ser Ala Leu Met
50 55 60
Ser Arg Leu Ser Ile Ser Lys Asp Thr Ser Arg Asn Gln Val Val Leu
65 70 75 80
Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala
85 90 95
Arg Asp Pro Pro Ser Ser Leu Leu Arg Leu Asp Tyr Trp Gly Arg Gly
100 105 110
Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe
115 120 125
Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu
130 135 140
Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp
145 150 155 160
Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu
165 170 175
Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser
180 185 190
Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro
195 200 205
Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys
210 215 220
Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro
225 230 235 240
Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser
245 250 255
Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp
260 265 270
Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn
275 280 285
Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val
290 295 300
Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu
305 310 315 320
Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys
325 330 335
Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr
340 345 350
Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr
355 360 365
Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu
370 375 380
Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu
385 390 395 400
Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys
405 410 415
Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu
420 425 430
Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
435 440 445
Lys Gly Gly Gly Gly Ser Gly Val Gln Leu Leu Glu Ser Gly Gly Gly
450 455 460
Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly
465 470 475 480
Phe Thr Phe Ala Trp Tyr Asp Met Gly Trp Val Arg Gln Ala Pro Gly
485 490 495
Lys Gly Leu Glu Trp Val Ser Ser Ile Asp Trp His Gly Glu Val Thr
500 505 510
Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn
515 520 525
Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp
530 535 540
Thr Ala Val Tyr Tyr Cys Ala Thr Ala Glu Asp Glu Pro Gly Tyr Asp
545 550 555 560
Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Thr Val Ala Ala
565 570 575
Pro Ser Gly Ser Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val
580 585 590
Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr
595 600 605
Phe Arg Asn Phe Gly Met Gly Trp Val Arg Gln Ala Pro Gly Lys Gly
610 615 620
Leu Glu Trp Val Ser Trp Ile Ile Ser Ser Gly Thr Glu Thr Tyr Tyr
625 630 635 640
Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys
645 650 655
Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala
660 665 670
Val Tyr Tyr Cys Ala Lys Ser Leu Gly Arg Phe Asp Tyr Trp Gly Gln
675 680 685
Gly Thr Leu Val Thr Val Ser Ser
690 695
<210> 196
<211> 693
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 196
Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30
Asn Met His Trp Val Lys Gln Thr Pro Gly Arg Gly Leu Glu Trp Ile
35 40 45
Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe
50 55 60
Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr
65 70 75 80
Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Thr Tyr Tyr Gly Gly Asp Trp Tyr Phe Asn Val Trp Gly
100 105 110
Ala Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
115 120 125
Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
130 135 140
Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
145 150 155 160
Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
165 170 175
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
180 185 190
Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
195 200 205
Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys
210 215 220
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
225 230 235 240
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
245 250 255
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
260 265 270
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
275 280 285
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
290 295 300
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
305 310 315 320
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
325 330 335
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
340 345 350
Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
355 360 365
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
370 375 380
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
385 390 395 400
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
405 410 415
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
420 425 430
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
435 440 445
Pro Gly Lys Thr Val Ala Ala Pro Ser Gly Ser Asp Ile Gln Met Thr
450 455 460
Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile
465 470 475 480
Thr Cys Arg Ala Ser Arg Pro Ile Ser Asp Trp Leu His Trp Tyr Gln
485 490 495
Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Ala Trp Ala Ser Ser
500 505 510
Leu Gln Gly Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr
515 520 525
Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr
530 535 540
Tyr Tyr Cys Leu Gln Glu Gly Trp Gly Pro Pro Thr Phe Gly Gln Gly
545 550 555 560
Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Gly Ser Gly
565 570 575
Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser
580 585 590
Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ala Trp Tyr Asp
595 600 605
Met Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser
610 615 620
Ser Ile Asp Trp His Gly Glu Val Thr Tyr Tyr Ala Asp Ser Val Lys
625 630 635 640
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
645 650 655
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
660 665 670
Thr Ala Glu Asp Glu Pro Gly Tyr Asp Tyr Trp Gly Gln Gly Thr Leu
675 680 685
Val Thr Val Ser Ser
690
<210> 197
<211> 701
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 197
Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30
Asn Met His Trp Val Lys Gln Thr Pro Gly Arg Gly Leu Glu Trp Ile
35 40 45
Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe
50 55 60
Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr
65 70 75 80
Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Thr Tyr Tyr Gly Gly Asp Trp Tyr Phe Asn Val Trp Gly
100 105 110
Ala Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
115 120 125
Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
130 135 140
Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
145 150 155 160
Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
165 170 175
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
180 185 190
Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
195 200 205
Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys
210 215 220
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
225 230 235 240
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
245 250 255
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
260 265 270
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
275 280 285
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
290 295 300
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
305 310 315 320
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
325 330 335
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
340 345 350
Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
355 360 365
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
370 375 380
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
385 390 395 400
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
405 410 415
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
420 425 430
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
435 440 445
Pro Gly Lys Thr Val Ala Ala Pro Ser Gly Ser Glu Val Gln Leu Leu
450 455 460
Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser
465 470 475 480
Cys Ala Ala Ser Gly Phe Thr Phe Arg Asn Phe Gly Met Gly Trp Val
485 490 495
Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Trp Ile Ile Ser
500 505 510
Ser Gly Thr Glu Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr
515 520 525
Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser
530 535 540
Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Ser Leu Gly
545 550 555 560
Arg Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Thr
565 570 575
Val Ala Ala Pro Ser Gly Ser Gly Val Gln Leu Leu Glu Ser Gly Gly
580 585 590
Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser
595 600 605
Gly Phe Thr Phe Ala Trp Tyr Asp Met Gly Trp Val Arg Gln Ala Pro
610 615 620
Gly Lys Gly Leu Glu Trp Val Ser Ser Ile Asp Trp His Gly Glu Val
625 630 635 640
Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp
645 650 655
Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu
660 665 670
Asp Thr Ala Val Tyr Tyr Cys Ala Thr Ala Glu Asp Glu Pro Gly Tyr
675 680 685
Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
690 695 700
<210> 198
<211> 567
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 198
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30
Trp Leu His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Met Ile Asp Pro Ser Asn Ser Asp Thr Arg Phe Asn Pro Asn Phe
50 55 60
Lys Asp Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Thr Tyr Arg Ser Tyr Val Thr Pro Leu Asp Tyr Trp Gly Gln Gly
100 105 110
Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe
115 120 125
Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu
130 135 140
Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp
145 150 155 160
Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu
165 170 175
Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser
180 185 190
Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro
195 200 205
Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys
210 215 220
Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro
225 230 235 240
Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser
245 250 255
Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp
260 265 270
Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn
275 280 285
Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val
290 295 300
Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu
305 310 315 320
Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys
325 330 335
Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr
340 345 350
Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Ser
355 360 365
Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu
370 375 380
Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu
385 390 395 400
Asp Ser Asp Gly Ser Phe Phe Leu Val Ser Lys Leu Thr Val Asp Lys
405 410 415
Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu
420 425 430
Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
435 440 445
Lys Gly Ser Glu Val Gln Leu Leu Val Ser Gly Gly Gly Leu Val Gln
450 455 460
Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
465 470 475 480
Lys Ala Tyr Pro Met Met Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
485 490 495
Glu Trp Val Ser Glu Ile Ser Pro Ser Gly Ser Tyr Thr Tyr Tyr Ala
500 505 510
Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn
515 520 525
Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
530 535 540
Tyr Tyr Cys Ala Lys Asp Pro Arg Lys Leu Asp Tyr Trp Gly Gln Gly
545 550 555 560
Thr Leu Val Thr Val Ser Ser
565
<210> 199
<211> 340
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 199
Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe
1 5 10 15
Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro
20 25 30
Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val
35 40 45
Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr
50 55 60
Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val
65 70 75 80
Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys
85 90 95
Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser
100 105 110
Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro
115 120 125
Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Trp Cys Leu Val
130 135 140
Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly
145 150 155 160
Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp
165 170 175
Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp
180 185 190
Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His
195 200 205
Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys Gly Ser
210 215 220
Glu Val Gln Leu Leu Val Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
225 230 235 240
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Lys Ala Tyr
245 250 255
Pro Met Met Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
260 265 270
Ser Glu Ile Ser Pro Ser Gly Ser Tyr Thr Tyr Tyr Ala Asp Ser Val
275 280 285
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
290 295 300
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
305 310 315 320
Ala Lys Asp Pro Arg Lys Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val
325 330 335
Thr Val Ser Ser
340
<210> 200
<211> 220
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 200
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Tyr Thr
20 25 30
Ser Ser Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys
35 40 45
Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
50 55 60
Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65 70 75 80
Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln
85 90 95
Tyr Tyr Ala Tyr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile
100 105 110
Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp
115 120 125
Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn
130 135 140
Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu
145 150 155 160
Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp
165 170 175
Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr
180 185 190
Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser
195 200 205
Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
210 215 220
<210> 201
<211> 552
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 201
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30
Trp Leu His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Met Ile Asp Pro Ser Asn Ser Asp Thr Arg Phe Asn Pro Asn Phe
50 55 60
Lys Asp Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Thr Tyr Arg Ser Tyr Val Thr Pro Leu Asp Tyr Trp Gly Gln Gly
100 105 110
Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe
115 120 125
Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu
130 135 140
Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp
145 150 155 160
Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu
165 170 175
Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser
180 185 190
Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro
195 200 205
Ser Asn Thr Lys Val Asp Lys Arg Val Ala Pro Glu Phe Leu Gly Gly
210 215 220
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
225 230 235 240
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu
245 250 255
Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
260 265 270
Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg
275 280 285
Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
290 295 300
Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu
305 310 315 320
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
325 330 335
Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu
340 345 350
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
355 360 365
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
370 375 380
Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp
385 390 395 400
Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His
405 410 415
Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu
420 425 430
Gly Lys Gly Ser Glu Val Gln Leu Leu Val Ser Gly Gly Gly Leu Val
435 440 445
Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr
450 455 460
Phe Lys Ala Tyr Pro Met Met Trp Val Arg Gln Ala Pro Gly Lys Gly
465 470 475 480
Leu Glu Trp Val Ser Glu Ile Ser Pro Ser Gly Ser Tyr Thr Tyr Tyr
485 490 495
Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys
500 505 510
Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala
515 520 525
Val Tyr Tyr Cys Ala Lys Asp Pro Arg Lys Leu Asp Tyr Trp Gly Gln
530 535 540
Gly Thr Leu Val Thr Val Ser Ser
545 550
<210> 202
<211> 449
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 202
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30
Trp Leu His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Met Ile Asp Pro Ser Asn Ser Asp Thr Arg Phe Asn Pro Asn Phe
50 55 60
Lys Asp Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Thr Tyr Arg Ser Tyr Val Thr Pro Leu Asp Tyr Trp Gly Gln Gly
100 105 110
Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe
115 120 125
Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu
130 135 140
Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp
145 150 155 160
Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu
165 170 175
Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser
180 185 190
Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro
195 200 205
Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys
210 215 220
Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro
225 230 235 240
Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser
245 250 255
Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp
260 265 270
Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn
275 280 285
Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val
290 295 300
Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu
305 310 315 320
Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys
325 330 335
Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr
340 345 350
Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Ser
355 360 365
Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu
370 375 380
Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu
385 390 395 400
Asp Ser Asp Gly Ser Phe Phe Leu Val Ser Lys Leu Thr Val Asp Lys
405 410 415
Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu
420 425 430
Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
435 440 445
Lys
<210> 203
<211> 222
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 203
Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe
1 5 10 15
Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro
20 25 30
Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val
35 40 45
Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr
50 55 60
Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val
65 70 75 80
Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys
85 90 95
Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser
100 105 110
Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro
115 120 125
Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Trp Cys Leu Val
130 135 140
Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly
145 150 155 160
Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp
165 170 175
Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp
180 185 190
Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His
195 200 205
Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
210 215 220
<210> 204
<211> 434
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 204
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30
Trp Leu His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Met Ile Asp Pro Ser Asn Ser Asp Thr Arg Phe Asn Pro Asn Phe
50 55 60
Lys Asp Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Thr Tyr Arg Ser Tyr Val Thr Pro Leu Asp Tyr Trp Gly Gln Gly
100 105 110
Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe
115 120 125
Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu
130 135 140
Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp
145 150 155 160
Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu
165 170 175
Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser
180 185 190
Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro
195 200 205
Ser Asn Thr Lys Val Asp Lys Arg Val Ala Pro Glu Phe Leu Gly Gly
210 215 220
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
225 230 235 240
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu
245 250 255
Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
260 265 270
Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg
275 280 285
Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
290 295 300
Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu
305 310 315 320
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
325 330 335
Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu
340 345 350
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
355 360 365
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
370 375 380
Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp
385 390 395 400
Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His
405 410 415
Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu
420 425 430
Gly Lys
<210> 205
<211> 1365
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 205
caggtgcagc tcgtgcagag cggcgccgaa gtgaaaaagc ccggcagcag cgtgaaggtg 60
agctgcaagg cctccggctt ctacatcaag gacacctaca tgcactgggt caggcaggct 120
cctggccagg gcctggagtg gatgggcact atcgaccccg ccaacggcaa caccaagtac 180
gtgcccaagt tccagggcag ggtgaccatc accgccgatg agagcaccag caccgcctac 240
atggaactga gcagcctgag gtctgaggac accgccgtgt actattgcgc caggagcatc 300
tacgacgact accactacga cgactactac gccatggact actggggaca gggcacacta 360
gtgaccgtgt ccagcgccag caccaagggc cccagcgtgt tccccctggc ccccagcagc 420
aagagcacca gcggcggcac agccgccctg ggctgcctgg tgaaggacta cttccccgaa 480
ccggtgaccg tgtcctggaa cagcggagcc ctgaccagcg gcgtgcacac cttccccgcc 540
gtgctgcaga gcagcggcct gtacagcctg agcagcgtgg tgaccgtgcc cagcagcagc 600
ctgggcaccc agacctacat ctgtaacgtg aaccacaagc ccagcaacac caaggtggac 660
aagaaggtgg agcccaagag ctgtgacaag acccacacct gccccccctg ccctgccccc 720
gagctgctgg gaggccccag cgtgttcctg ttccccccca agcctaagga caccctgatg 780
atcagcagaa cccccgaggt gacctgtgtg gtggtggatg tgagccacga ggaccctgag 840
gtgaagttca actggtacgt ggacggcgtg gaggtgcaca atgccaagac caagcccagg 900
gaggagcagt acaacagcac ctaccgggtg gtgtccgtgc tgaccgtgct gcaccaggat 960
tggctgaacg gcaaggagta caagtgtaag gtgtccaaca aggccctgcc tgcccctatc 1020
gagaaaacca tcagcaaggc caagggccag cccagagagc cccaggtgta caccctgccc 1080
cctagcagag atgagctgac caagaaccag gtgtccctga cctgcctggt gaagggcttc 1140
taccccagcg acatcgccgt ggagtgggag agcaacggcc agcccgagaa caactacaag 1200
accacccccc ctgtgctgga cagcgatggc agcttcttcc tgtacagcaa gctgaccgtg 1260
gacaagagca gatggcagca gggcaacgtg ttcagctgct ccgtgatgca cgaggccctg 1320
cacaatcact acacccagaa gagcctgagc ctgtcccctg gcaag 1365
<210> 206
<211> 1365
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 206
caggtgcagc tggtgcagtc tggggctgag gtgaagaagc ctgggtcctc ggtgaaggtc 60
tcctgcaagg cttctggatt ctacattaaa gacacctata tgcactgggt gcgacaggcc 120
cctggacaag ggcttgagtg gatgggaacg attgatcctg cgaatggtaa tactaaatat 180
gtcccgaagt tccagggcag agtcacgatt accgcggacg aatccacgag cacagcctac 240
atggagctga gcagcctgag atctgaggac acggccgtgt attactgtgc gagaagcatc 300
tatgatgatt accactacga cgattactat gctatggact actggggcca agggacacta 360
gtcacagtct cctcagcctc caccaagggc ccatcggtct tccccctggc accctcctcc 420
aagagcacct ctgggggcac agcggccctg ggctgcctgg tcaaggacta cttccccgaa 480
ccggtgacgg tgtcgtggaa ctcaggcgcc ctgaccagcg gcgtgcacac cttcccggct 540
gtcctacagt cctcaggact ctactccctc agcagcgtgg tgaccgtgcc ctccagcagc 600
ttgggcaccc agacctacat ctgcaacgtg aatcacaagc ccagcaacac caaggtggac 660
aagaaagttg agcccaaatc ttgtgacaaa actcacacat gcccaccgtg cccagcacct 720
gaactcctgg ggggaccgtc agtcttcctc ttccccccaa aacccaagga caccctcatg 780
atctcccgga cccctgaggt cacatgcgtg gtggtggacg tgagccacga agaccctgag 840
gtcaagttca actggtacgt ggacggcgtg gaggtgcata atgccaagac aaagccgcgg 900
gaggagcagt acaacagcac gtaccgtgtg gtcagcgtcc tcaccgtcct gcaccaggac 960
tggctgaatg gcaaggagta caagtgcaag gtctccaaca aagccctccc agcccccatc 1020
gagaaaacca tctccaaagc caaagggcag ccccgagaac cacaggtgta caccctgccc 1080
ccatcccggg atgagctgac caagaaccag gtcagcctga cctgcctggt caaaggcttc 1140
tatcccagcg acatcgccgt ggagtgggag agcaatgggc agccggagaa caactacaag 1200
accacgcctc ccgtgctgga ctccgacggc tccttcttcc tctacagcaa gctcaccgtg 1260
gacaagagca ggtggcagca ggggaacgtc ttctcatgct ccgtgatgca tgaggctctg 1320
cacaaccact acacgcagaa gagcctctcc ctgtctccgg gtaaa 1365
<210> 207
<211> 567
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 207
Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln
1 5 10 15
Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser
20 25 30
Gly Met Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45
Trp Leu Ala His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Arg Asn Gln Val
65 70 75 80
Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr
85 90 95
Cys Ala Arg Arg Glu Thr Val Phe Tyr Trp Tyr Phe Asp Val Trp Gly
100 105 110
Arg Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
115 120 125
Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala
130 135 140
Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
145 150 155 160
Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
165 170 175
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
180 185 190
Pro Ser Ser Asn Phe Gly Thr Gln Thr Tyr Thr Cys Asn Val Asp His
195 200 205
Lys Pro Ser Asn Thr Lys Val Asp Lys Thr Val Glu Arg Lys Cys Cys
210 215 220
Val Glu Cys Pro Pro Cys Pro Ala Pro Pro Val Ala Gly Pro Ser Val
225 230 235 240
Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
245 250 255
Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu
260 265 270
Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
275 280 285
Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Phe Arg Val Val Ser
290 295 300
Val Leu Thr Val Val His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
305 310 315 320
Cys Lys Val Ser Asn Lys Gly Leu Pro Ala Pro Ile Glu Lys Thr Ile
325 330 335
Ser Lys Thr Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro
340 345 350
Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
355 360 365
Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn
370 375 380
Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Met Leu Asp Ser
385 390 395 400
Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg
405 410 415
Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
420 425 430
His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys Gly
435 440 445
Ser Gly Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly
450 455 460
Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ala Trp
465 470 475 480
Tyr Asp Met Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
485 490 495
Val Ser Ser Ile Asp Trp His Gly Glu Val Thr Tyr Tyr Ala Asp Ser
500 505 510
Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu
515 520 525
Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr
530 535 540
Cys Ala Thr Ala Glu Asp Glu Pro Gly Tyr Asp Tyr Trp Gly Gln Gly
545 550 555 560
Thr Leu Val Thr Val Ser Ser
565
<210> 208
<211> 568
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 208
Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln
1 5 10 15
Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser
20 25 30
Gly Met Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45
Trp Leu Ala His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Arg Asn Gln Val
65 70 75 80
Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr
85 90 95
Cys Ala Arg Arg Glu Thr Val Phe Tyr Trp Tyr Phe Asp Val Trp Gly
100 105 110
Arg Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
115 120 125
Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala
130 135 140
Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
145 150 155 160
Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
165 170 175
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
180 185 190
Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His
195 200 205
Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly
210 215 220
Pro Pro Cys Pro Ser Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser
225 230 235 240
Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg
245 250 255
Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro
260 265 270
Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala
275 280 285
Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val
290 295 300
Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
305 310 315 320
Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr
325 330 335
Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu
340 345 350
Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys
355 360 365
Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
370 375 380
Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp
385 390 395 400
Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser
405 410 415
Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala
420 425 430
Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys
435 440 445
Gly Ser Gly Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro
450 455 460
Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ala
465 470 475 480
Trp Tyr Asp Met Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu
485 490 495
Trp Val Ser Ser Ile Asp Trp His Gly Glu Val Thr Tyr Tyr Ala Asp
500 505 510
Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr
515 520 525
Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
530 535 540
Tyr Cys Ala Thr Ala Glu Asp Glu Pro Gly Tyr Asp Tyr Trp Gly Gln
545 550 555 560
Gly Thr Leu Val Thr Val Ser Ser
565
<210> 209
<211> 568
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 209
Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln
1 5 10 15
Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser
20 25 30
Gly Met Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45
Trp Leu Ala His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Arg Asn Gln Val
65 70 75 80
Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr
85 90 95
Cys Ala Arg Arg Glu Thr Val Phe Tyr Trp Tyr Phe Asp Val Trp Gly
100 105 110
Arg Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
115 120 125
Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala
130 135 140
Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
145 150 155 160
Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
165 170 175
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
180 185 190
Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His
195 200 205
Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly
210 215 220
Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Glu Gly Gly Pro Ser
225 230 235 240
Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg
245 250 255
Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro
260 265 270
Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala
275 280 285
Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val
290 295 300
Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
305 310 315 320
Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr
325 330 335
Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu
340 345 350
Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys
355 360 365
Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
370 375 380
Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp
385 390 395 400
Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser
405 410 415
Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala
420 425 430
Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys
435 440 445
Gly Ser Gly Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro
450 455 460
Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ala
465 470 475 480
Trp Tyr Asp Met Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu
485 490 495
Trp Val Ser Ser Ile Asp Trp His Gly Glu Val Thr Tyr Tyr Ala Asp
500 505 510
Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr
515 520 525
Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
530 535 540
Tyr Cys Ala Thr Ala Glu Asp Glu Pro Gly Tyr Asp Tyr Trp Gly Gln
545 550 555 560
Gly Thr Leu Val Thr Val Ser Ser
565
<210> 210
<211> 657
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 210
gacatcgtga tgacccagtc tcctctgagc ctccccgtga cccccggcga accagccagc 60
atctcctgca gaagcagcca gaacatcgtg cacatcaacg gcaacaccta cctggagtgg 120
tacctgcaaa agcccggcca gagccccagg ctgctgatct acaagatcag cgacaggttc 180
agcggcgtgc ccgataggtt cagcggcagc ggcagcggca ccgacttcac cctgaagatc 240
agcagggtgg aggccgacga cgtgggcatc tactactgct tccagggcag ccacgtcccc 300
tggactttcg gacagggcac caagctggag attaagcgta cggtggccgc ccccagcgtg 360
ttcatcttcc cccccagcga tgagcagctg aagagcggca ccgccagcgt ggtgtgtctg 420
ctgaacaact tctacccccg ggaggccaag gtgcagtgga aggtggacaa tgccctgcag 480
agcggcaaca gccaggagag cgtgaccgag caggacagca aggactccac ctacagcctg 540
agcagcaccc tgaccctgag caaggccgac tacgagaagc acaaggtgta cgcctgtgag 600
gtgacccacc agggcctgtc cagccccgtg accaagagct tcaaccgggg cgagtgc 657
<210> 211
<211> 1353
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 211
caggtgaccc tgagggagag cggccccgcc ctggtgaagc ccacccagac cctgaccctg 60
acctgcacct tcagcggctt tagcctcagc acctccggca tgggcgtgag ctggatcagg 120
cagccacccg gcaaaggcct ggagtggctg gcccacatct actgggacga cgacaagagg 180
tacaacccca gcctgaagag ccggctgacc atcagcaagg ataccagcag gaaccaggtg 240
gtgctgacca tgaccaacat ggaccccgtg gacaccgcta cctactactg cgccaggagg 300
gagaccgtct tctactggta cttcgacgtg tggggaaggg gcacactagt gaccgtgtcc 360
agcgccagca ccaagggccc cagcgtgttc cccctggccc ccagcagcaa gagcaccagc 420
ggcggcacag ccgccctggg ctgcctggtg aaggactact tccccgaacc ggtgaccgtg 480
tcctggaaca gcggagccct gaccagcggc gtgcacacct tccccgccgt gctgcagagc 540
agcggcctgt acagcctgag cagcgtggtg accgtgccca gcagcagcct gggcacccag 600
acctacatct gtaacgtgaa ccacaagccc agcaacacca aggtggacaa gaaggtggag 660
cccaagagct gtgacaagac ccacacctgc cccccctgcc ctgcccccga gctgctggga 720
ggccccagcg tgttcctgtt cccccccaag cctaaggaca ccctgatgat cagcagaacc 780
cccgaggtga cctgtgtggt ggtggatgtg agccacgagg accctgaggt gaagttcaac 840
tggtacgtgg acggcgtgga ggtgcacaat gccaagacca agcccaggga ggagcagtac 900
aacagcacct accgggtggt gtccgtgctg accgtgctgc accaggattg gctgaacggc 960
aaggagtaca agtgtaaggt gtccaacaag gccctgcctg cccctatcga gaaaaccatc 1020
agcaaggcca agggccagcc cagagagccc caggtgtaca ccctgccccc tagcagagat 1080
gagctgacca agaaccaggt gtccctgacc tgcctggtga agggcttcta ccccagcgac 1140
atcgccgtgg agtgggagag caacggccag cccgagaaca actacaagac caccccccct 1200
gtgctggaca gcgatggcag cttcttcctg tacagcaagc tgaccgtgga caagagcaga 1260
tggcagcagg gcaacgtgtt cagctgctcc gtgatgcacg aggccctgca caatcactac 1320
acccagaaga gcctgagcct gtcccctggc aag 1353
<210> 212
<211> 654
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 212
gacatcgtgc tgacccagag cccctcttcc ctgagcgcaa gcgtgggcga tagggtgacc 60
atcacctgca aggccagcca gagcgtggac tacgacggcg acagctacat gaactggtac 120
cagcagaagc ccggcaaggc ccccaaactg ctgatctacg ccgccagcaa cctcgagtca 180
ggcattccca gcaggtttag cggcagcggc agcggcaccg acttcacctt cacaatcagc 240
agcctgcagc ccgaggacat cgccacctac tactgccagc agagcaacga ggaccctccc 300
accttcggac agggcaccaa ggtcgagatc aagcgtacgg tggccgcccc cagcgtgttc 360
atcttccccc ccagcgatga gcagctgaag agcggcaccg ccagcgtggt gtgtctgctg 420
aacaacttct acccccggga ggccaaggtg cagtggaagg tggacaatgc cctgcagagc 480
ggcaacagcc aggagagcgt gaccgagcag gacagcaagg actccaccta cagcctgagc 540
agcaccctga ccctgagcaa ggccgactac gagaagcaca aggtgtacgc ctgtgaggtg 600
acccaccagg gcctgtccag ccccgtgacc aagagcttca accggggcga gtgc 654
<210> 213
<211> 1347
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 213
caggtgaccc tgagggagag cggccccgcc ctggtgaagc ccacacagac cctcactctg 60
acctgcaccg tgagcggctt cagcctgacc tcctacagcg tccactgggt gaggcagccc 120
cccggcaagg gcctggagtg gctgggcgtg atctgggcaa gcggcggcac cgactacaac 180
agcgccctga tgagcaggct ctccatcagc aaggacacca gccggaacca ggtggtgctg 240
accatgacca acatggaccc cgtggacacc gccacctatt actgcgccag ggaccctccc 300
tctagcctgc tgaggctgga ctactggggc aggggaacac tagtgaccgt gtccagcgcc 360
agcaccaagg gccccagcgt gttccccctg gcccccagca gcaagagcac cagcggcggc 420
acagccgccc tgggctgcct ggtgaaggac tacttccccg aaccggtgac cgtgtcctgg 480
aacagcggag ccctgaccag cggcgtgcac accttccccg ccgtgctgca gagcagcggc 540
ctgtacagcc tgagcagcgt ggtgaccgtg cccagcagca gcctgggcac ccagacctac 600
atctgtaacg tgaaccacaa gcccagcaac accaaggtgg acaagaaggt ggagcccaag 660
agctgtgaca agacccacac ctgccccccc tgccctgccc ccgagctgct gggaggcccc 720
agcgtgttcc tgttcccccc caagcctaag gacaccctga tgatcagcag aacccccgag 780
gtgacctgtg tggtggtgga tgtgagccac gaggaccctg aggtgaagtt caactggtac 840
gtggacggcg tggaggtgca caatgccaag accaagccca gggaggagca gtacaacagc 900
acctaccggg tggtgtccgt gctgaccgtg ctgcaccagg attggctgaa cggcaaggag 960
tacaagtgta aggtgtccaa caaggccctg cctgccccta tcgagaaaac catcagcaag 1020
gccaagggcc agcccagaga gccccaggtg tacaccctgc cccctagcag agatgagctg 1080
accaagaacc aggtgtccct gacctgcctg gtgaagggct tctaccccag cgacatcgcc 1140
gtggagtggg agagcaacgg ccagcccgag aacaactaca agaccacccc ccctgtgctg 1200
gacagcgatg gcagcttctt cctgtacagc aagctgaccg tggacaagag cagatggcag 1260
cagggcaacg tgttcagctg ctccgtgatg cacgaggccc tgcacaatca ctacacccag 1320
aagagcctga gcctgtcccc tggcaag 1347
<210> 214
<211> 660
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 214
gacatcgtga tgacccagtc tcccgattca ctggccgtga gcctgggcga gagggccacc 60
atcaactgca agagcagcca gagcctcctg aacagcggca accagaagaa ctacctggcc 120
tggtaccagc agaaacccgg ccagcccccc aagctgctga tctatggcgc ctccaccagg 180
gagagcggcg tgccagacag gtttagcggc agcggcagcg gcaccgactt caccctgaca 240
atcagcagcc tgcaggccga ggacgtggcc gtgtactact gccagaacgt ccacagcttc 300
cccttcacct tcggcggggg aaccaagctg gagatcaagc gtacggtggc cgcccccagc 360
gtgttcatct tcccccccag cgatgagcag ctgaagagcg gcaccgccag cgtggtgtgt 420
ctgctgaaca acttctaccc ccgggaggcc aaggtgcagt ggaaggtgga caatgccctg 480
cagagcggca acagccagga gagcgtgacc gagcaggaca gcaaggactc cacctacagc 540
ctgagcagca ccctgaccct gagcaaggcc gactacgaga agcacaaggt gtacgcctgt 600
gaggtgaccc accagggcct gtccagcccc gtgaccaaga gcttcaaccg gggcgagtgc 660
<210> 215
<211> 1713
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 215
caggtgaccc tgagggagag cggccccgcc ctggtgaagc ccacccagac cctgaccctg 60
acctgcacct tcagcggctt tagcctcagc acctccggca tgggcgtgag ctggatcagg 120
cagccacccg gcaaaggcct ggagtggctg gcccacatct actgggacga cgacaagagg 180
tacaacccca gcctgaagag ccggctgacc atcagcaagg ataccagcag gaaccaggtg 240
gtgctgacca tgaccaacat ggaccccgtg gacaccgcta cctactactg cgccaggagg 300
gagaccgtct tctactggta cttcgacgtg tggggaaggg gcacactagt gaccgtgtcc 360
agcgccagca ccaagggccc cagcgtgttc cccctggccc ccagcagcaa gagcaccagc 420
ggcggcacag ccgccctggg ctgcctggtg aaggactact tccccgaacc ggtgaccgtg 480
tcctggaaca gcggagccct gaccagcggc gtgcacacct tccccgccgt gctgcagagc 540
agcggcctgt acagcctgag cagcgtggtg accgtgccca gcagcagcct gggcacccag 600
acctacatct gtaacgtgaa ccacaagccc agcaacacca aggtggacaa gaaggtggag 660
cccaagagct gtgacaagac ccacacctgc cccccctgcc ctgcccccga gctgctggga 720
ggccccagcg tgttcctgtt cccccccaag cctaaggaca ccctgatgat cagcagaacc 780
cccgaggtga cctgtgtggt ggtggatgtg agccacgagg accctgaggt gaagttcaac 840
tggtacgtgg acggcgtgga ggtgcacaat gccaagacca agcccaggga ggagcagtac 900
aacagcacct accgggtggt gtccgtgctg accgtgctgc accaggattg gctgaacggc 960
aaggagtaca agtgtaaggt gtccaacaag gccctgcctg cccctatcga gaaaaccatc 1020
agcaaggcca agggccagcc cagagagccc caggtgtaca ccctgccccc tagcagagat 1080
gagctgacca agaaccaggt gtccctgacc tgcctggtga agggcttcta ccccagcgac 1140
atcgccgtgg agtgggagag caacggccag cccgagaaca actacaagac caccccccct 1200
gtgctggaca gcgatggcag cttcttcctg tacagcaagc tgaccgtgga caagagcaga 1260
tggcagcagg gcaacgtgtt cagctgctcc gtgatgcacg aggccctgca caatcactac 1320
acccagaaga gcctgagcct gtcccctggc aagggatccg gcgtgcagct cctggagagc 1380
ggcggaggcc tggtccagcc cggcggcagc ctgaggctga gctgcgccgc cagcggcttc 1440
accttcgcct ggtatgatat gggctgggtg aggcaggccc ccggcaaggg cctggagtgg 1500
gtgtccagca tcgactggca cggggaggtg acctactacg ccgacagcgt gaagggcagg 1560
ttcaccatca gcagggacaa cagcaagaac accctgtacc tgcagatgaa cagcctgagg 1620
gccgaggaca ccgcagtgta ctactgcgcc accgccgagg acgaacccgg ctacgactac 1680
tggggccagg gcaccctggt gactgtgagc agc 1713
<210> 216
<211> 1731
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 216
caggtgaccc tgagggagag cggccccgcc ctggtgaagc ccacccagac cctgaccctg 60
acctgcacct tcagcggctt tagcctcagc acctccggca tgggcgtgag ctggatcagg 120
cagccacccg gcaaaggcct ggagtggctg gcccacatct actgggacga cgacaagagg 180
tacaacccca gcctgaagag ccggctgacc atcagcaagg ataccagcag gaaccaggtg 240
gtgctgacca tgaccaacat ggaccccgtg gacaccgcta cctactactg cgccaggagg 300
gagaccgtct tctactggta cttcgacgtg tggggaaggg gcacactagt gaccgtgtcc 360
agcgccagca ccaagggccc cagcgtgttc cccctggccc ccagcagcaa gagcaccagc 420
ggcggcacag ccgccctggg ctgcctggtg aaggactact tccccgaacc ggtgaccgtg 480
tcctggaaca gcggagccct gaccagcggc gtgcacacct tccccgccgt gctgcagagc 540
agcggcctgt acagcctgag cagcgtggtg accgtgccca gcagcagcct gggcacccag 600
acctacatct gtaacgtgaa ccacaagccc agcaacacca aggtggacaa gaaggtggag 660
cccaagagct gtgacaagac ccacacctgc cccccctgcc ctgcccccga gctgctggga 720
ggccccagcg tgttcctgtt cccccccaag cctaaggaca ccctgatgat cagcagaacc 780
cccgaggtga cctgtgtggt ggtggatgtg agccacgagg accctgaggt gaagttcaac 840
tggtacgtgg acggcgtgga ggtgcacaat gccaagacca agcccaggga ggagcagtac 900
aacagcacct accgggtggt gtccgtgctg accgtgctgc accaggattg gctgaacggc 960
aaggagtaca agtgtaaggt gtccaacaag gccctgcctg cccctatcga gaaaaccatc 1020
agcaaggcca agggccagcc cagagagccc caggtgtaca ccctgccccc tagcagagat 1080
gagctgacca agaaccaggt gtccctgacc tgcctggtga agggcttcta ccccagcgac 1140
atcgccgtgg agtgggagag caacggccag cccgagaaca actacaagac caccccccct 1200
gtgctggaca gcgatggcag cttcttcctg tacagcaagc tgaccgtgga caagagcaga 1260
tggcagcagg gcaacgtgtt cagctgctcc gtgatgcacg aggccctgca caatcactac 1320
acccagaaga gcctgagcct gtcccctggc aagaccgtgg ccgccccctc gggatccggc 1380
gtgcagctcc tggagagcgg cggaggcctg gtccagcccg gcggcagcct gaggctgagc 1440
tgcgccgcca gcggcttcac cttcgcctgg tatgatatgg gctgggtgag gcaggccccc 1500
ggcaagggcc tggagtgggt gtccagcatc gactggcacg gggaggtgac ctactacgcc 1560
gacagcgtga agggcaggtt caccatcagc agggacaaca gcaagaacac cctgtacctg 1620
cagatgaaca gcctgagggc cgaggacacc gcagtgtact actgcgccac cgccgaggac 1680
gaacccggct acgactactg gggccagggc accctggtga ctgtgagcag c 1731
<210> 217
<211> 1014
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 217
gacatcgtgc tgacccagag cccctcttcc ctgagcgcaa gcgtgggcga tagggtgacc 60
atcacctgca aggccagcca gagcgtggac tacgacggcg acagctacat gaactggtac 120
cagcagaagc ccggcaaggc ccccaaactg ctgatctacg ccgccagcaa cctcgagtca 180
ggcattccca gcaggtttag cggcagcggc agcggcaccg acttcacctt cacaatcagc 240
agcctgcagc ccgaggacat cgccacctac tactgccagc agagcaacga ggaccctccc 300
accttcggac agggcaccaa ggtcgagatc aagcgtacgg tggccgcccc cagcgtgttc 360
atcttccccc ccagcgatga gcagctgaag agcggcaccg ccagcgtggt gtgtctgctg 420
aacaacttct acccccggga ggccaaggtg cagtggaagg tggacaatgc cctgcagagc 480
ggcaacagcc aggagagcgt gaccgagcag gacagcaagg actccaccta cagcctgagc 540
agcaccctga ccctgagcaa ggccgactac gagaagcaca aggtgtacgc ctgtgaggtg 600
acccaccagg gcctgtccag ccccgtgacc aagagcttca accggggcga gtgtggatcc 660
ggcgtgcagc tcctggagag cggcggaggc ctggtccagc ccggcggcag cctgaggctg 720
agctgcgccg ccagcggctt caccttcgcc tggtatgata tgggctgggt gaggcaggcc 780
cccggcaagg gcctggagtg ggtgtccagc atcgactggc acggggaggt gacctactac 840
gccgacagcg tgaagggcag gttcaccatc agcagggaca acagcaagaa caccctgtac 900
ctgcagatga acagcctgag ggccgaggac accgcagtgt actactgcgc caccgccgag 960
gacgaacccg gctacgacta ctggggccag ggcaccctgg tgactgtgag cagc 1014
<210> 218
<211> 1032
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 218
gacatcgtgc tgacccagag cccctcttcc ctgagcgcaa gcgtgggcga tagggtgacc 60
atcacctgca aggccagcca gagcgtggac tacgacggcg acagctacat gaactggtac 120
cagcagaagc ccggcaaggc ccccaaactg ctgatctacg ccgccagcaa cctcgagtca 180
ggcattccca gcaggtttag cggcagcggc agcggcaccg acttcacctt cacaatcagc 240
agcctgcagc ccgaggacat cgccacctac tactgccagc agagcaacga ggaccctccc 300
accttcggac agggcaccaa ggtcgagatc aagcgtacgg tggccgcccc cagcgtgttc 360
atcttccccc ccagcgatga gcagctgaag agcggcaccg ccagcgtggt gtgtctgctg 420
aacaacttct acccccggga ggccaaggtg cagtggaagg tggacaatgc cctgcagagc 480
ggcaacagcc aggagagcgt gaccgagcag gacagcaagg actccaccta cagcctgagc 540
agcaccctga ccctgagcaa ggccgactac gagaagcaca aggtgtacgc ctgtgaggtg 600
acccaccagg gcctgtccag ccccgtgacc aagagcttca accggggcga gtgcaccgtg 660
gccgccccct cgggatccgg cgtgcagctc ctggagagcg gcggaggcct ggtccagccc 720
ggcggcagcc tgaggctgag ctgcgccgcc agcggcttca ccttcgcctg gtatgatatg 780
ggctgggtga ggcaggcccc cggcaagggc ctggagtggg tgtccagcat cgactggcac 840
ggggaggtga cctactacgc cgacagcgtg aagggcaggt tcaccatcag cagggacaac 900
agcaagaaca ccctgtacct gcagatgaac agcctgaggg ccgaggacac cgcagtgtac 960
tactgcgcca ccgccgagga cgaacccggc tacgactact ggggccaggg caccctggtg 1020
actgtgagca gc 1032
<210> 219
<211> 1710
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 219
caggtgaccc tgagggagag cggccccgcc ctggtgaagc ccacacagac cctcactctg 60
acctgcaccg tgagcggctt cagcctgacc tcctacagcg tccactgggt gaggcagccc 120
cccggcaagg gcctggagtg gctgggcgtg atctgggcaa gcggcggcac cgactacaac 180
agcgccctga tgagcaggct ctccatcagc aaggacacca gccggaacca ggtggtgctg 240
accatgacca acatggaccc cgtggacacc gccacctatt actgcgccag ggaccctccc 300
tctagcctgc tgaggctgga ctactggggc aggggaacac tagtgaccgt gtccagcgcc 360
agcaccaagg gccccagcgt gttccccctg gcccccagca gcaagagcac cagcggcggc 420
acagccgccc tgggctgcct ggtgaaggac tacttccccg aaccggtgac cgtgtcctgg 480
aacagcggag ccctgaccag cggcgtgcac accttccccg ccgtgctgca gagcagcggc 540
ctgtacagcc tgagcagcgt ggtgaccgtg cccagcagca gcctgggcac ccagacctac 600
atctgtaacg tgaaccacaa gcccagcaac accaaggtgg acaagaaggt ggagcccaag 660
agctgtgaca agacccacac ctgccccccc tgccctgccc ccgagctgct gggaggcccc 720
agcgtgttcc tgttcccccc caagcctaag gacaccctga tgatcagcag aacccccgag 780
gtgacctgtg tggtggtgga tgtgagccac gaggaccctg aggtgaagtt caactggtac 840
gtggacggcg tggaggtgca caatgccaag accaagccca gggaggagca gtacaacagc 900
acctaccggg tggtgtccgt gctgaccgtg ctgcaccagg attggctgaa cggcaaggag 960
tacaagtgta aggtgtccaa caaggccctg cctgccccta tcgagaaaac catcagcaag 1020
gccaagggcc agcccagaga gccccaggtg tacaccctgc cccctagcag agatgagctg 1080
accaagaacc aggtgtccct gacctgcctg gtgaagggct tctaccccag cgacatcgcc 1140
gtggagtggg agagcaacgg ccagcccgag aacaactaca agaccacccc ccctgtgctg 1200
gacagcgatg gcagcttctt cctgtacagc aagctgaccg tggacaagag cagatggcag 1260
cagggcaacg tgttcagctg ctccgtgatg cacgaggccc tgcacaatca ctacacccag 1320
aagagcctga gcctgtcccc tggcaagggc ggcggcggat ccgaagtgca gctcctggag 1380
agcggcggcg gcctggtgca gcccggcggc agcctgaggc tgagctgcgc cgctagcggc 1440
ttcaccttca ggaacttcgg catgggctgg gtcaggcagg cccccggcaa gggcctggag 1500
tgggtcagct ggatcatcag ctccggcacc gagacctact acgccgacag cgtgaagggc 1560
aggttcacca tcagccgcga caacagcaag aacaccctgt acctgcagat gaacagcctg 1620
agggccgagg acaccgccgt ctactactgc gccaagagcc tgggcaggtt cgactactgg 1680
ggacagggga ccctggtgac tgtgagcagc 1710
<210> 220
<211> 1029
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 220
gacatcgtga tgacccagtc tcccgattca ctggccgtga gcctgggcga gagggccacc 60
atcaactgca agagcagcca gagcctcctg aacagcggca accagaagaa ctacctggcc 120
tggtaccagc agaaacccgg ccagcccccc aagctgctga tctatggcgc ctccaccagg 180
gagagcggcg tgccagacag gtttagcggc agcggcagcg gcaccgactt caccctgaca 240
atcagcagcc tgcaggccga ggacgtggcc gtgtactact gccagaacgt ccacagcttc 300
cccttcacct tcggcggggg aaccaagctg gagatcaagc gtacggtggc cgcccccagc 360
gtgttcatct tcccccccag cgatgagcag ctgaagagcg gcaccgccag cgtggtgtgt 420
ctgctgaaca acttctaccc ccgggaggcc aaggtgcagt ggaaggtgga caatgccctg 480
cagagcggca acagccagga gagcgtgacc gagcaggaca gcaaggactc cacctacagc 540
ctgagcagca ccctgaccct gagcaaggcc gactacgaga agcacaaggt gtacgcctgt 600
gaggtgaccc accagggcct gtccagcccc gtgaccaaga gcttcaaccg gggcgagtgc 660
ggcggcggcg gatccggcgt gcagctcctg gagagcggcg gaggcctggt ccagcccggc 720
ggcagcctga ggctgagctg cgccgccagc ggcttcacct tcgcctggta tgatatgggc 780
tgggtgaggc aggcccccgg caagggcctg gagtgggtgt ccagcatcga ctggcacggg 840
gaggtgacct actacgccga cagcgtgaag ggcaggttca ccatcagcag ggacaacagc 900
aagaacaccc tgtacctgca gatgaacagc ctgagggccg aggacaccgc agtgtactac 960
tgcgccaccg ccgaggacga acccggctac gactactggg gccagggcac cctggtgact 1020
gtgagcagc 1029
<210> 221
<211> 1713
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 221
caggtgcagc tcgtgcagag cggcgccgaa gtgaaaaagc ccggcagcag cgtgaaggtg 60
agctgcaagg cctccggctt ctacatcaag gacacctaca tgcactgggt caggcaggct 120
cctggccagg gcctggagtg gatgggcact atcgaccccg ccaacggcaa caccaagtac 180
gtgcccaagt tccagggcag ggtgaccatc accgccgatg agagcaccag caccgcctac 240
atggaactga gcagcctgag gtctgaggac accgccgtgt actattgcgc caggagcatc 300
tacgacgact accactacga cgactactac gccatggact actggggaca gggcacacta 360
gtgaccgtgt ccagcgccag caccaagggc cccagcgtgt tccccctggc ccccagcagc 420
aagagcacca gcggcggcac agccgccctg ggctgcctgg tgaaggacta cttccccgaa 480
ccggtgaccg tgtcctggaa cagcggagcc ctgaccagcg gcgtgcacac cttccccgcc 540
gtgctgcaga gcagcggcct gtacagcctg agcagcgtgg tgaccgtgcc cagcagcagc 600
ctgggcaccc agacctacat ctgtaacgtg aaccacaagc ccagcaacac caaggtggac 660
aagaaggtgg agcccaagag ctgtgacaag acccacacct gccccccctg ccctgccccc 720
gagctgctgg gaggccccag cgtgttcctg ttccccccca agcctaagga caccctgatg 780
atcagcagaa cccccgaggt gacctgtgtg gtggtggatg tgagccacga ggaccctgag 840
gtgaagttca actggtacgt ggacggcgtg gaggtgcaca atgccaagac caagcccagg 900
gaggagcagt acaacagcac ctaccgggtg gtgtccgtgc tgaccgtgct gcaccaggat 960
tggctgaacg gcaaggagta caagtgtaag gtgtccaaca aggccctgcc tgcccctatc 1020
gagaaaacca tcagcaaggc caagggccag cccagagagc cccaggtgta caccctgccc 1080
cctagcagag atgagctgac caagaaccag gtgtccctga cctgcctggt gaagggcttc 1140
taccccagcg acatcgccgt ggagtgggag agcaacggcc agcccgagaa caactacaag 1200
accacccccc ctgtgctgga cagcgatggc agcttcttcc tgtacagcaa gctgaccgtg 1260
gacaagagca gatggcagca gggcaacgtg ttcagctgct ccgtgatgca cgaggccctg 1320
cacaatcact acacccagaa gagcctgagc ctgtcccctg gcaaggaagt gcagctcctg 1380
gagagcggcg gcggcctggt gcagcccggc ggcagcctga ggctgagctg cgccgctagc 1440
ggcttcacct tcaggaactt cggcatgggc tgggtcaggc aggcccccgg caagggcctg 1500
gagtgggtca gctggatcat cagctccggc accgagacct actacgccga cagcgtgaag 1560
ggcaggttca ccatcagccg cgacaacagc aagaacaccc tgtacctgca gatgaacagc 1620
ctgagggccg aggacaccgc cgtctactac tgcgccaaga gcctgggcag gttcgactac 1680
tggggacagg ggaccctggt gactgtgagc agc 1713
<210> 222
<211> 1731
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 222
caggtgcagc tcgtgcagag cggcgccgaa gtgaaaaagc ccggcagcag cgtgaaggtg 60
agctgcaagg cctccggctt ctacatcaag gacacctaca tgcactgggt caggcaggct 120
cctggccagg gcctggagtg gatgggcact atcgaccccg ccaacggcaa caccaagtac 180
gtgcccaagt tccagggcag ggtgaccatc accgccgatg agagcaccag caccgcctac 240
atggaactga gcagcctgag gtctgaggac accgccgtgt actattgcgc caggagcatc 300
tacgacgact accactacga cgactactac gccatggact actggggaca gggcacacta 360
gtgaccgtgt ctagcgccag caccaagggc cccagcgtgt tccccctggc ccccagcagc 420
aagagcacca gcggcggcac agccgccctg ggctgcctgg tgaaggacta cttccccgaa 480
ccggtgaccg tgtcctggaa cagcggagcc ctgaccagcg gcgtgcacac cttccccgcc 540
gtgctgcaga gcagcggcct gtacagcctg agcagcgtgg tgaccgtgcc cagcagcagc 600
ctgggcaccc agacctacat ctgtaacgtg aaccacaagc ccagcaacac caaggtggac 660
aagaaggtgg agcccaagag ctgtgacaag acccacacct gccccccctg ccctgccccc 720
gagctgctgg gaggccccag cgtgttcctg ttccccccca agcctaagga caccctgatg 780
atcagcagaa cccccgaggt gacctgtgtg gtggtggatg tgagccacga ggaccctgag 840
gtgaagttca actggtacgt ggacggcgtg gaggtgcaca atgccaagac caagcccagg 900
gaggagcagt acaacagcac ctaccgggtg gtgtccgtgc tgaccgtgct gcaccaggat 960
tggctgaacg gcaaggagta caagtgtaag gtgtccaaca aggccctgcc tgcccctatc 1020
gagaaaacca tcagcaaggc caagggccag cccagagagc cccaggtgta caccctgccc 1080
cctagcagag atgagctgac caagaaccag gtgtccctga cctgcctggt gaagggcttc 1140
taccccagcg acatcgccgt ggagtgggag agcaacggcc agcccgagaa caactacaag 1200
accacccccc ctgtgctgga cagcgatggc agcttcttcc tgtacagcaa gctgaccgtg 1260
gacaagagca gatggcagca gggcaacgtg ttcagctgct ccgtgatgca cgaggccctg 1320
cacaatcact acacccagaa gagcctgagc ctgtcccctg gcaagaccgt ggccgccccc 1380
tcggaagtgc agctcctgga gagcggcggc ggcctggtgc agcccggcgg cagcctgagg 1440
ctgagctgcg ccgctagcgg cttcaccttc aggaacttcg gcatgggctg ggtcaggcag 1500
gcccccggca agggcctgga gtgggtcagc tggatcatca gctccggcac cgagacctac 1560
tacgccgaca gcgtgaaggg caggttcacc atcagccgcg acaacagcaa gaacaccctg 1620
tacctgcaga tgaacagcct gagggccgag gacaccgccg tctactactg cgccaagagc 1680
ctgggcaggt tcgactactg gggacagggg accctggtga ctgtgagcag c 1731
<210> 223
<211> 1707
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 223
caggtgaccc tgagggagag cggccccgcc ctggtgaagc ccacccagac cctgaccctg 60
acctgcacct tcagcggctt tagcctcagc acctccggca tgggcgtgag ctggatcagg 120
cagccacccg gcaaaggcct ggagtggctg gcccacatct actgggacga cgacaagagg 180
tacaacccca gcctgaagag ccggctgacc atcagcaagg ataccagcag gaaccaggtg 240
gtgctgacca tgaccaacat ggaccccgtg gacaccgcta cctactactg cgccaggagg 300
gagaccgtct tctactggta cttcgacgtg tggggaaggg gcacactagt gaccgtgtcc 360
agcgccagca ccaagggccc cagcgtgttc cccctggccc ccagcagcaa gagcaccagc 420
ggcggcacag ccgccctggg ctgcctggtg aaggactact tccccgaacc ggtgaccgtg 480
tcctggaaca gcggagccct gaccagcggc gtgcacacct tccccgccgt gctgcagagc 540
agcggcctgt acagcctgag cagcgtggtg accgtgccca gcagcagcct gggcacccag 600
acctacatct gtaacgtgaa ccacaagccc agcaacacca aggtggacaa gaaggtggag 660
cccaagagct gtgacaagac ccacacctgc cccccctgcc ctgcccccga gctgctggga 720
ggccccagcg tgttcctgtt cccccccaag cctaaggaca ccctgatgat cagcagaacc 780
cccgaggtga cctgtgtggt ggtggatgtg agccacgagg accctgaggt gaagttcaac 840
tggtacgtgg acggcgtgga ggtgcacaat gccaagacca agcccaggga ggagcagtac 900
aacagcacct accgggtggt gtccgtgctg accgtgctgc accaggattg gctgaacggc 960
aaggagtaca agtgtaaggt gtccaacaag gccctgcctg cccctatcga gaaaaccatc 1020
agcaaggcca agggccagcc cagagagccc caggtgtaca ccctgccccc tagcagagat 1080
gagctgacca agaaccaggt gtccctgacc tgcctggtga agggcttcta ccccagcgac 1140
atcgccgtgg agtgggagag caacggccag cccgagaaca actacaagac caccccccct 1200
gtgctggaca gcgatggcag cttcttcctg tacagcaagc tgaccgtgga caagagcaga 1260
tggcagcagg gcaacgtgtt cagctgctcc gtgatgcacg aggccctgca caatcactac 1320
acccagaaga gcctgagcct gtcccctggc aagggcgtgc agctcctgga gagcggcgga 1380
ggcctggtcc agcccggcgg cagcctgagg ctgagctgcg ccgccagcgg cttcaccttc 1440
gcctggtatg atatgggctg ggtgaggcag gcccccggca agggcctgga gtgggtgtcc 1500
agcatcgact ggcacgggga ggtgacctac tacgccgaca gcgtgaaggg caggttcacc 1560
atcagcaggg acaacagcaa gaacaccctg tacctgcaga tgaacagcct gagggccgag 1620
gacaccgcag tgtactactg cgccaccgcc gaggacgaac ccggctacga ctactggggc 1680
cagggcaccc tggtgactgt gagcagc 1707
<210> 224
<211> 1725
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 224
caggtgaccc tgagggagag cggccccgcc ctggtgaagc ccacccagac cctgaccctg 60
acctgcacct tcagcggctt tagcctcagc acctccggca tgggcgtgag ctggatcagg 120
cagccacccg gcaaaggcct ggagtggctg gcccacatct actgggacga cgacaagagg 180
tacaacccca gcctgaagag ccggctgacc atcagcaagg ataccagcag gaaccaggtg 240
gtgctgacca tgaccaacat ggaccccgtg gacaccgcta cctactactg cgccaggagg 300
gagaccgtct tctactggta cttcgacgtg tggggaaggg gcacactagt gaccgtgtcc 360
agcgccagca ccaagggccc cagcgtgttc cccctggccc ccagcagcaa gagcaccagc 420
ggcggcacag ccgccctggg ctgcctggtg aaggactact tccccgaacc ggtgaccgtg 480
tcctggaaca gcggagccct gaccagcggc gtgcacacct tccccgccgt gctgcagagc 540
agcggcctgt acagcctgag cagcgtggtg accgtgccca gcagcagcct gggcacccag 600
acctacatct gtaacgtgaa ccacaagccc agcaacacca aggtggacaa gaaggtggag 660
cccaagagct gtgacaagac ccacacctgc cccccctgcc ctgcccccga gctgctggga 720
ggccccagcg tgttcctgtt cccccccaag cctaaggaca ccctgatgat cagcagaacc 780
cccgaggtga cctgtgtggt ggtggatgtg agccacgagg accctgaggt gaagttcaac 840
tggtacgtgg acggcgtgga ggtgcacaat gccaagacca agcccaggga ggagcagtac 900
aacagcacct accgggtggt gtccgtgctg accgtgctgc accaggattg gctgaacggc 960
aaggagtaca agtgtaaggt gtccaacaag gccctgcctg cccctatcga gaaaaccatc 1020
agcaaggcca agggccagcc cagagagccc caggtgtaca ccctgccccc tagcagagat 1080
gagctgacca agaaccaggt gtccctgacc tgcctggtga agggcttcta ccccagcgac 1140
atcgccgtgg agtgggagag caacggccag cccgagaaca actacaagac caccccccct 1200
gtgctggaca gcgatggcag cttcttcctg tacagcaagc tgaccgtgga caagagcaga 1260
tggcagcagg gcaacgtgtt cagctgctcc gtgatgcacg aggccctgca caatcactac 1320
acccagaaga gcctgagcct gtcccctggc aagaccgtgg ccgccccctc gggcgtgcag 1380
ctcctggaga gcggcggagg cctggtccag cccggcggca gcctgaggct gagctgcgcc 1440
gccagcggct tcaccttcgc ctggtatgat atgggctggg tgaggcaggc ccccggcaag 1500
ggcctggagt gggtgtccag catcgactgg cacggggagg tgacctacta cgccgacagc 1560
gtgaagggca ggttcaccat cagcagggac aacagcaaga acaccctgta cctgcagatg 1620
aacagcctga gggccgagga caccgcagtg tactactgcg ccaccgccga ggacgaaccc 1680
ggctacgact actggggcca gggcaccctg gtgactgtga gcagc 1725
<210> 225
<211> 1734
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 225
caggtgaccc tgagggagag cggccccgcc ctggtgaagc ccacccagac cctgaccctg 60
acctgcacct tcagcggctt tagcctcagc acctccggca tgggcgtgag ctggatcagg 120
cagccacccg gcaaaggcct ggagtggctg gcccacatct actgggacga cgacaagagg 180
tacaacccca gcctgaagag ccggctgacc atcagcaagg ataccagcag gaaccaggtg 240
gtgctgacca tgaccaacat ggaccccgtg gacaccgcta cctactactg cgccaggagg 300
gagaccgtct tctactggta cttcgacgtg tggggaaggg gcacactagt gaccgtgtcc 360
agcgccagca ccaagggccc cagcgtgttc cccctggccc ccagcagcaa gagcaccagc 420
ggcggcacag ccgccctggg ctgcctggtg aaggactact tccccgaacc ggtgaccgtg 480
tcctggaaca gcggagccct gaccagcggc gtgcacacct tccccgccgt gctgcagagc 540
agcggcctgt acagcctgag cagcgtggtg accgtgccca gcagcagcct gggcacccag 600
acctacatct gtaacgtgaa ccacaagccc agcaacacca aggtggacaa gaaggtggag 660
cccaagagct gtgacaagac ccacacctgc cccccctgcc ctgcccccga gctgctggga 720
ggccccagcg tgttcctgtt cccccccaag cctaaggaca ccctgatgat cagcagaacc 780
cccgaggtga cctgtgtggt ggtggatgtg agccacgagg accctgaggt gaagttcaac 840
tggtacgtgg acggcgtgga ggtgcacaat gccaagacca agcccaggga ggagcagtac 900
aacagcacct accgggtggt gtccgtgctg accgtgctgc accaggattg gctgaacggc 960
aaggagtaca agtgtaaggt gtccaacaag gccctgcctg cccctatcga gaaaaccatc 1020
agcaaggcca agggccagcc cagagagccc caggtgtaca ccctgccccc tagcagagat 1080
gagctgacca agaaccaggt gtccctgacc tgcctggtga agggcttcta ccccagcgac 1140
atcgccgtgg agtgggagag caacggccag cccgagaaca actacaagac caccccccct 1200
gtgctggaca gcgatggcag cttcttcctg tacagcaagc tgaccgtgga caagagcaga 1260
tggcagcagg gcaacgtgtt cagctgctcc gtgatgcacg aggccctgca caatcactac 1320
acccagaaga gcctgagcct gtcccctggc aagggatcag ccagcaccaa gggccccacg 1380
ggcgtgcagc tcctggagag cggcggaggc ctggtccagc ccggcggcag cctgaggctg 1440
agctgcgccg ccagcggctt caccttcgcc tggtatgata tgggctgggt gaggcaggcc 1500
cccggcaagg gcctggagtg ggtgtccagc atcgactggc acggggaggt gacctactac 1560
gccgacagcg tgaagggcag gttcaccatc agcagggaca acagcaagaa caccctgtac 1620
ctgcagatga acagcctgag ggccgaggac accgcagtgt actactgcgc caccgccgag 1680
gacgaacccg gctacgacta ctggggccag ggcaccctgg tgactgtgag cagc 1734
<210> 226
<211> 1731
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 226
caggtgcagc tggtgcagag cggagccgag gtgaagaagc ctggcgccag cgtcaaggtg 60
tcctgcaagg ccagcggcta caccttcacc gactactaca tgaactgggt gcggcaggcc 120
ccaggccagg gactggaatg gatgggcaac atcaacccca acaacggcgg caccaactac 180
aaccagaagt tcaaggaccg ggtcaccatg accaccgaca ccagcaccag caccgcctac 240
atggaactgc ggagcctgag aagcgacgac accgccgtgt actactgcgc ccggtggatc 300
ctgtactacg gccggtccaa gtggtacttc gacgtgtggg gcaggggcac actagtgacc 360
gtgtccagcg ccagcaccaa gggccccagc gtgttccccc tggcccccag cagcaagagc 420
accagcggcg gcacagccgc cctgggctgc ctggtgaagg actacttccc cgaaccggtg 480
accgtgtcct ggaacagcgg agccctgacc agcggcgtgc acaccttccc cgccgtgctg 540
cagagcagcg gcctgtacag cctgagcagc gtggtgaccg tgcccagcag cagcctgggc 600
acccagacct acatctgtaa cgtgaaccac aagcccagca acaccaaggt ggacaagaag 660
gtggagccca agagctgtga caagacccac acctgccccc cctgccctgc ccccgagctg 720
ctgggaggcc ccagcgtgtt cctgttcccc cccaagccta aggacaccct gatgatcagc 780
agaacccccg aggtgacctg tgtggtggtg gatgtgagcc acgaggaccc tgaggtgaag 840
ttcaactggt acgtggacgg cgtggaggtg cacaatgcca agaccaagcc cagggaggag 900
cagtacaaca gcacctaccg ggtggtgtcc gtgctgaccg tgctgcacca ggattggctg 960
aacggcaagg agtacaagtg taaggtgtcc aacaaggccc tgcctgcccc tatcgagaaa 1020
accatcagca aggccaaggg ccagcccaga gagccccagg tgtacaccct gccccctagc 1080
agagatgagc tgaccaagaa ccaggtgtcc ctgacctgcc tggtgaaggg cttctacccc 1140
agcgacatcg ccgtggagtg ggagagcaac ggccagcccg agaacaacta caagaccacc 1200
ccccctgtgc tggacagcga tggcagcttc ttcctgtaca gcaagctgac cgtggacaag 1260
agcagatggc agcagggcaa cgtgttcagc tgctccgtga tgcacgaggc cctgcacaat 1320
cactacaccc agaagagcct gagcctgtcc cctggcaaga ccgtggccgc cccctcggga 1380
tccgaggtgc agctcctggt cagcggcggc ggcctggtcc agcccggagg ctcactgagg 1440
ctgagctgcg ccgctagcgg cttcaccttc aaggcctacc ccatgatgtg ggtcaggcag 1500
gcccccggca aaggcctgga gtgggtgtct gagatcagcc ccagcggcag ctacacctac 1560
tacgccgaca gcgtgaaggg caggttcacc atcagcaggg acaacagcaa gaacaccctg 1620
tacctgcaga tgaactctct gagggccgag gacaccgccg tgtactactg cgccaaggac 1680
cccaggaagc tggactattg gggccagggc actctggtga ccgtgagcag c 1731
<210> 227
<211> 1713
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 227
caggtgcagc tggtgcagag cggagccgag gtgaagaagc ctggcgccag cgtcaaggtg 60
tcctgcaagg ccagcggcta caccttcacc gactactaca tgaactgggt gcggcaggcc 120
ccaggccagg gactggaatg gatgggcaac atcaacccca acaacggcgg caccaactac 180
aaccagaagt tcaaggaccg ggtcaccatg accaccgaca ccagcaccag caccgcctac 240
atggaactgc ggagcctgag aagcgacgac accgccgtgt actactgcgc ccggtggatc 300
ctgtactacg gccggtccaa gtggtacttc gacgtgtggg gcaggggcac actagtgacc 360
gtgtccagcg ccagcaccaa gggccccagc gtgttccccc tggcccccag cagcaagagc 420
accagcggcg gcacagccgc cctgggctgc ctggtgaagg actacttccc cgaaccggtg 480
accgtgtcct ggaacagcgg agccctgacc agcggcgtgc acaccttccc cgccgtgctg 540
cagagcagcg gcctgtacag cctgagcagc gtggtgaccg tgcccagcag cagcctgggc 600
acccagacct acatctgtaa cgtgaaccac aagcccagca acaccaaggt ggacaagaag 660
gtggagccca agagctgtga caagacccac acctgccccc cctgccctgc ccccgagctg 720
ctgggaggcc ccagcgtgtt cctgttcccc cccaagccta aggacaccct gatgatcagc 780
agaacccccg aggtgacctg tgtggtggtg gatgtgagcc acgaggaccc tgaggtgaag 840
ttcaactggt acgtggacgg cgtggaggtg cacaatgcca agaccaagcc cagggaggag 900
cagtacaaca gcacctaccg ggtggtgtcc gtgctgaccg tgctgcacca ggattggctg 960
aacggcaagg agtacaagtg taaggtgtcc aacaaggccc tgcctgcccc tatcgagaaa 1020
accatcagca aggccaaggg ccagcccaga gagccccagg tgtacaccct gccccctagc 1080
agagatgagc tgaccaagaa ccaggtgtcc ctgacctgcc tggtgaaggg cttctacccc 1140
agcgacatcg ccgtggagtg ggagagcaac ggccagcccg agaacaacta caagaccacc 1200
ccccctgtgc tggacagcga tggcagcttc ttcctgtaca gcaagctgac cgtggacaag 1260
agcagatggc agcagggcaa cgtgttcagc tgctccgtga tgcacgaggc cctgcacaat 1320
cactacaccc agaagagcct gagcctgtcc cctggcaagg gatccgaggt gcagctcctg 1380
gtcagcggcg gcggcctggt ccagcccgga ggctcactga ggctgagctg cgccgctagc 1440
ggcttcacct tcaaggccta ccccatgatg tgggtcaggc aggcccccgg caaaggcctg 1500
gagtgggtgt ctgagatcag ccccagcggc agctacacct actacgccga cagcgtgaag 1560
ggcaggttca ccatcagcag ggacaacagc aagaacaccc tgtacctgca gatgaactct 1620
ctgagggccg aggacaccgc cgtgtactac tgcgccaagg accccaggaa gctggactat 1680
tggggccagg gcactctggt gaccgtgagc agc 1713
<210> 228
<211> 1359
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 228
caggtgcagc tggtgcagag cggagccgag gtgaagaagc ctggcgccag cgtcaaggtg 60
tcctgcaagg ccagcggcta caccttcacc gactactaca tgaactgggt gcggcaggcc 120
ccaggccagg gactggaatg gatgggcaac atcaacccca acaacggcgg caccaactac 180
aaccagaagt tcaaggaccg ggtcaccatg accaccgaca ccagcaccag caccgcctac 240
atggaactgc ggagcctgag aagcgacgac accgccgtgt actactgcgc ccggtggatc 300
ctgtactacg gccggtccaa gtggtacttc gacgtgtggg gcaggggcac actagtgacc 360
gtgtccagcg ccagcaccaa gggccccagc gtgttccccc tggcccccag cagcaagagc 420
accagcggcg gcacagccgc cctgggctgc ctggtgaagg actacttccc cgaaccggtg 480
accgtgtcct ggaacagcgg agccctgacc agcggcgtgc acaccttccc cgccgtgctg 540
cagagcagcg gcctgtacag cctgagcagc gtggtgaccg tgcccagcag cagcctgggc 600
acccagacct acatctgtaa cgtgaaccac aagcccagca acaccaaggt ggacaagaag 660
gtggagccca agagctgtga caagacccac acctgccccc cctgccctgc ccccgagctg 720
ctgggaggcc ccagcgtgtt cctgttcccc cccaagccta aggacaccct gatgatcagc 780
agaacccccg aggtgacctg tgtggtggtg gatgtgagcc acgaggaccc tgaggtgaag 840
ttcaactggt acgtggacgg cgtggaggtg cacaatgcca agaccaagcc cagggaggag 900
cagtacaaca gcacctaccg ggtggtgtcc gtgctgaccg tgctgcacca ggattggctg 960
aacggcaagg agtacaagtg taaggtgtcc aacaaggccc tgcctgcccc tatcgagaaa 1020
accatcagca aggccaaggg ccagcccaga gagccccagg tgtacaccct gccccctagc 1080
agagatgagc tgaccaagaa ccaggtgtcc ctgacctgcc tggtgaaggg cttctacccc 1140
agcgacatcg ccgtggagtg ggagagcaac ggccagcccg agaacaacta caagaccacc 1200
ccccctgtgc tggacagcga tggcagcttc ttcctgtaca gcaagctgac cgtggacaag 1260
agcagatggc agcagggcaa cgtgttcagc tgctccgtga tgcacgaggc cctgcacaat 1320
cactacaccc agaagagcct gagcctgtcc cctggcaag 1359
<210> 229
<211> 1029
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 229
gacatcgtga tgacccagag ccccctgagc ctgcccgtga cccctggcga gcccgccagc 60
atcagctgca gaagcagcca gagcatcgtc cagagcaacg gcgacaccta cctggaatgg 120
tatctgcaga agcccggcca gtccccccag ctgctgatct acagagtgag caaccggttc 180
agcggcgtgc ccgacagatt cagcggcagc ggctccggca ccgacttcac cctgaagatc 240
agccgggtgg aggccgagga cgtgggcgtg tactactgct ttcaaggcag ccacgtgccc 300
tacaccttcg gccagggcac caagctggaa atcaagcgta cggtggccgc ccccagcgtg 360
ttcatcttcc cccccagcga tgagcagctg aagagcggca ccgccagcgt ggtgtgtctg 420
ctgaacaact tctacccccg ggaggccaag gtgcagtgga aggtggacaa tgccctgcag 480
agcggcaaca gccaggagag cgtgaccgag caggacagca aggactccac ctacagcctg 540
agcagcaccc tgaccctgag caaggccgac tacgagaagc acaaggtgta cgcctgtgag 600
gtgacccacc agggcctgtc cagccccgtg accaagagct tcaaccgggg cgagtgcacc 660
gtggccgccc cctcgggatc cgaggtgcag ctcctggtca gcggcggcgg cctggtccag 720
cccggaggct cactgaggct gagctgcgcc gctagcggct tcaccttcaa ggcctacccc 780
atgatgtggg tcaggcaggc ccccggcaaa ggcctggagt gggtgtctga gatcagcccc 840
agcggcagct acacctacta cgccgacagc gtgaagggca ggttcaccat cagcagggac 900
aacagcaaga acaccctgta cctgcagatg aactctctga gggccgagga caccgccgtg 960
tactactgcg ccaaggaccc caggaagctg gactattggg gccagggcac tctggtgacc 1020
gtgagcagc 1029
<210> 230
<211> 1011
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 230
gacatcgtga tgacccagag ccccctgagc ctgcccgtga cccctggcga gcccgccagc 60
atcagctgca gaagcagcca gagcatcgtc cagagcaacg gcgacaccta cctggaatgg 120
tatctgcaga agcccggcca gtccccccag ctgctgatct acagagtgag caaccggttc 180
agcggcgtgc ccgacagatt cagcggcagc ggctccggca ccgacttcac cctgaagatc 240
agccgggtgg aggccgagga cgtgggcgtg tactactgct ttcaaggcag ccacgtgccc 300
tacaccttcg gccagggcac caagctggaa atcaagcgta cggtggccgc ccccagcgtg 360
ttcatcttcc cccccagcga tgagcagctg aagagcggca ccgccagcgt ggtgtgtctg 420
ctgaacaact tctacccccg ggaggccaag gtgcagtgga aggtggacaa tgccctgcag 480
agcggcaaca gccaggagag cgtgaccgag caggacagca aggactccac ctacagcctg 540
agcagcaccc tgaccctgag caaggccgac tacgagaagc acaaggtgta cgcctgtgag 600
gtgacccacc agggcctgtc cagccccgtg accaagagct tcaaccgggg cgagtgtgga 660
tccgaggtgc agctcctggt cagcggcggc ggcctggtcc agcccggagg ctcactgagg 720
ctgagctgcg ccgctagcgg cttcaccttc aaggcctacc ccatgatgtg ggtcaggcag 780
gcccccggca aaggcctgga gtgggtgtct gagatcagcc ccagcggcag ctacacctac 840
tacgccgaca gcgtgaaggg caggttcacc atcagcaggg acaacagcaa gaacaccctg 900
tacctgcaga tgaactctct gagggccgag gacaccgccg tgtactactg cgccaaggac 960
cccaggaagc tggactattg gggccagggc actctggtga ccgtgagcag c 1011
<210> 231
<211> 657
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 231
gacatcgtga tgacccagag ccccctgagc ctgcccgtga cccctggcga gcccgccagc 60
atcagctgca gaagcagcca gagcatcgtc cagagcaacg gcgacaccta cctggaatgg 120
tatctgcaga agcccggcca gtccccccag ctgctgatct acagagtgag caaccggttc 180
agcggcgtgc ccgacagatt cagcggcagc ggctccggca ccgacttcac cctgaagatc 240
agccgggtgg aggccgagga cgtgggcgtg tactactgct ttcaaggcag ccacgtgccc 300
tacaccttcg gccagggcac caagctggaa atcaagcgta cggtggccgc ccccagcgtg 360
ttcatcttcc cccccagcga tgagcagctg aagagcggca ccgccagcgt ggtgtgtctg 420
ctgaacaact tctacccccg ggaggccaag gtgcagtgga aggtggacaa tgccctgcag 480
agcggcaaca gccaggagag cgtgaccgag caggacagca aggactccac ctacagcctg 540
agcagcaccc tgaccctgag caaggccgac tacgagaagc acaaggtgta cgcctgtgag 600
gtgacccacc agggcctgtc cagccccgtg accaagagct tcaaccgggg cgagtgc 657
<210> 232
<211> 1821
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 232
caggtgcagc tggtgcagag cggagccgag gtgaagaagc ctggcgccag cgtcaaggtg 60
tcctgcaagg ccagcggcta caccttcacc gactactaca tgaactgggt gcggcaggcc 120
ccaggccagg gactggaatg gatgggcaac atcaacccca acaacggcgg caccaactac 180
aaccagaagt tcaaggaccg ggtcaccatg accaccgaca ccagcaccag caccgcctac 240
atggaactgc ggagcctgag aagcgacgac accgccgtgt actactgcgc ccggtggatc 300
ctgtactacg gccggtccaa gtggtacttc gacgtgtggg gcaggggcac actagtgacc 360
gtgtccagcg ccagcaccaa gggccccagc gtgttccccc tggcccccag cagcaagagc 420
accagcggcg gcacagccgc cctgggctgc ctggtgaagg actacttccc cgaaccggtg 480
accgtgtcct ggaacagcgg agccctgacc agcggcgtgc acaccttccc cgccgtgctg 540
cagagcagcg gcctgtacag cctgagcagc gtggtgaccg tgcccagcag cagcctgggc 600
acccagacct acatctgtaa cgtgaaccac aagcccagca acaccaaggt ggacaagaag 660
gtggagccca agagctgtga caagacccac acctgccccc cctgccctgc ccccgagctg 720
ctgggaggcc ccagcgtgtt cctgttcccc cccaagccta aggacaccct gatgatcagc 780
agaacccccg aggtgacctg tgtggtggtg gatgtgagcc acgaggaccc tgaggtgaag 840
ttcaactggt acgtggacgg cgtggaggtg cacaatgcca agaccaagcc cagggaggag 900
cagtacaaca gcacctaccg ggtggtgtcc gtgctgaccg tgctgcacca ggattggctg 960
aacggcaagg agtacaagtg taaggtgtcc aacaaggccc tgcctgcccc tatcgagaaa 1020
accatcagca aggccaaggg ccagcccaga gagccccagg tgtacaccct gccccctagc 1080
agagatgagc tgaccaagaa ccaggtgtcc ctgacctgcc tggtgaaggg cttctacccc 1140
agcgacatcg ccgtggagtg ggagagcaac ggccagcccg agaacaacta caagaccacc 1200
ccccctgtgc tggacagcga tggcagcttc ttcctgtaca gcaagctgac cgtggacaag 1260
agcagatggc agcagggcaa cgtgttcagc tgctccgtga tgcacgaggc cctgcacaat 1320
cactacaccc agaagagcct gagcctgtcc cctggcaagg gatccgacgg cggcggcatt 1380
aggaggagca tgagcggcac ctggtacctg aaggccatga ccgtggatag ggagttcccc 1440
gagatgaacc tggagagcgt gacccccatg acactgaccc tgctcaaggg ccacaacctg 1500
gaggccaagg tcaccatgct gatctcaggc aggtgccagg aggtgaaggc agtgctgggc 1560
aggaccaagg agaggaagaa gtacaccgcc gacgggggca agcacgtggc ctatatcatc 1620
cccagcgccg tgagggacca cgtgatcttc tacagcgagg gccagctcca cggaaagccc 1680
gtgagaggcg tgaagctggt gggcagggac cccaagaaca acctggaggc cctggaggac 1740
ttcgaaaaag ccgcaggcgc caggggcctg tccactgaga gcatcctgat ccctaggcag 1800
agcgagacct gcagccccgg c 1821
<210> 233
<211> 1623
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 233
caggtgcagc tggtgcagag cggagccgag gtgaagaagc ctggcgccag cgtcaaggtg 60
tcctgcaagg ccagcggcta caccttcacc gactactaca tgaactgggt gcggcaggcc 120
ccaggccagg gactggaatg gatgggcaac atcaacccca acaacggcgg caccaactac 180
aaccagaagt tcaaggaccg ggtcaccatg accaccgaca ccagcaccag caccgcctac 240
atggaactgc ggagcctgag aagcgacgac accgccgtgt actactgcgc ccggtggatc 300
ctgtactacg gccggtccaa gtggtacttc gacgtgtggg gcaggggcac actagtgacc 360
gtgtccagcg ccagcaccaa gggccccagc gtgttccccc tggcccccag cagcaagagc 420
accagcggcg gcacagccgc cctgggctgc ctggtgaagg actacttccc cgaaccggtg 480
accgtgtcct ggaacagcgg agccctgacc agcggcgtgc acaccttccc cgccgtgctg 540
cagagcagcg gcctgtacag cctgagcagc gtggtgaccg tgcccagcag cagcctgggc 600
acccagacct acatctgtaa cgtgaaccac aagcccagca acaccaaggt ggacaagaag 660
gtggagccca agagctgtga caagacccac acctgccccc cctgccctgc ccccgagctg 720
ctgggaggcc ccagcgtgtt cctgttcccc cccaagccta aggacaccct gatgatcagc 780
agaacccccg aggtgacctg tgtggtggtg gatgtgagcc acgaggaccc tgaggtgaag 840
ttcaactggt acgtggacgg cgtggaggtg cacaatgcca agaccaagcc cagggaggag 900
cagtacaaca gcacctaccg ggtggtgtcc gtgctgaccg tgctgcacca ggattggctg 960
aacggcaagg agtacaagtg taaggtgtcc aacaaggccc tgcctgcccc tatcgagaaa 1020
accatcagca aggccaaggg ccagcccaga gagccccagg tgtacaccct gccccctagc 1080
agagatgagc tgaccaagaa ccaggtgtcc ctgacctgcc tggtgaaggg cttctacccc 1140
agcgacatcg ccgtggagtg ggagagcaac ggccagcccg agaacaacta caagaccacc 1200
ccccctgtgc tggacagcga tggcagcttc ttcctgtaca gcaagctgac cgtggacaag 1260
agcagatggc agcagggcaa cgtgttcagc tgctccgtga tgcacgaggc cctgcacaat 1320
cactacaccc agaagagcct gagcctgtcc cctggcaagg gatccgaggt ggtggccgcc 1380
acccccacca gcctgctgat ttcctggagg cacccccact tccccacacg ctactacagg 1440
atcacctacg gcgagaccgg cggcaacagc cccgtgcagg agttcaccgt gcccctgcag 1500
cctcccactg ccaccatcag cggcctcaag cccggcgtgg actacaccat caccgtgtac 1560
gccgtcaccg acggaaggaa cggcaggctg ctgagcatcc ccatcagcat caactacagg 1620
acc 1623
<210> 234
<211> 1839
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 234
caggtgcagc tggtgcagag cggagccgag gtgaagaagc ctggcgccag cgtcaaggtg 60
tcctgcaagg ccagcggcta caccttcacc gactactaca tgaactgggt gcggcaggcc 120
ccaggccagg gactggaatg gatgggcaac atcaacccca acaacggcgg caccaactac 180
aaccagaagt tcaaggaccg ggtcaccatg accaccgaca ccagcaccag caccgcctac 240
atggaactgc ggagcctgag aagcgacgac accgccgtgt actactgcgc ccggtggatc 300
ctgtactacg gccggtccaa gtggtacttc gacgtgtggg gcaggggcac actagtgacc 360
gtgtccagcg ccagcaccaa gggccccagc gtgttccccc tggcccccag cagcaagagc 420
accagcggcg gcacagccgc cctgggctgc ctggtgaagg actacttccc cgaaccggtg 480
accgtgtcct ggaacagcgg agccctgacc agcggcgtgc acaccttccc cgccgtgctg 540
cagagcagcg gcctgtacag cctgagcagc gtggtgaccg tgcccagcag cagcctgggc 600
acccagacct acatctgtaa cgtgaaccac aagcccagca acaccaaggt ggacaagaag 660
gtggagccca agagctgtga caagacccac acctgccccc cctgccctgc ccccgagctg 720
ctgggaggcc ccagcgtgtt cctgttcccc cccaagccta aggacaccct gatgatcagc 780
agaacccccg aggtgacctg tgtggtggtg gatgtgagcc acgaggaccc tgaggtgaag 840
ttcaactggt acgtggacgg cgtggaggtg cacaatgcca agaccaagcc cagggaggag 900
cagtacaaca gcacctaccg ggtggtgtcc gtgctgaccg tgctgcacca ggattggctg 960
aacggcaagg agtacaagtg taaggtgtcc aacaaggccc tgcctgcccc tatcgagaaa 1020
accatcagca aggccaaggg ccagcccaga gagccccagg tgtacaccct gccccctagc 1080
agagatgagc tgaccaagaa ccaggtgtcc ctgacctgcc tggtgaaggg cttctacccc 1140
agcgacatcg ccgtggagtg ggagagcaac ggccagcccg agaacaacta caagaccacc 1200
ccccctgtgc tggacagcga tggcagcttc ttcctgtaca gcaagctgac cgtggacaag 1260
agcagatggc agcagggcaa cgtgttcagc tgctccgtga tgcacgaggc cctgcacaat 1320
cactacaccc agaagagcct gagcctgtcc cctggcaaga ccgtggccgc cccctcggga 1380
tccgacggcg gcggcattag gaggagcatg agcggcacct ggtacctgaa ggccatgacc 1440
gtggataggg agttccccga gatgaacctg gagagcgtga cccccatgac actgaccctg 1500
ctcaagggcc acaacctgga ggccaaggtc accatgctga tctcaggcag gtgccaggag 1560
gtgaaggcag tgctgggcag gaccaaggag aggaagaagt acaccgccga cgggggcaag 1620
cacgtggcct atatcatccc cagcgccgtg agggaccacg tgatcttcta cagcgagggc 1680
cagctccacg gaaagcccgt gagaggcgtg aagctggtgg gcagggaccc caagaacaac 1740
ctggaggccc tggaggactt cgaaaaagcc gcaggcgcca ggggcctgtc cactgagagc 1800
atcctgatcc ctaggcagag cgagacctgc agccccggc 1839
<210> 235
<211> 1539
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 235
caggtgcagc tggtgcagag cggagccgag gtgaagaagc ctggcgccag cgtcaaggtg 60
tcctgcaagg ccagcggcta caccttcacc gactactaca tgaactgggt gcggcaggcc 120
ccaggccagg gactggaatg gatgggcaac atcaacccca acaacggcgg caccaactac 180
aaccagaagt tcaaggaccg ggtcaccatg accaccgaca ccagcaccag caccgcctac 240
atggaactgc ggagcctgag aagcgacgac accgccgtgt actactgcgc ccggtggatc 300
ctgtactacg gccggtccaa gtggtacttc gacgtgtggg gcaggggcac actagtgacc 360
gtgtccagcg ccagcaccaa gggccccagc gtgttccccc tggcccccag cagcaagagc 420
accagcggcg gcacagccgc cctgggctgc ctggtgaagg actacttccc cgaaccggtg 480
accgtgtcct ggaacagcgg agccctgacc agcggcgtgc acaccttccc cgccgtgctg 540
cagagcagcg gcctgtacag cctgagcagc gtggtgaccg tgcccagcag cagcctgggc 600
acccagacct acatctgtaa cgtgaaccac aagcccagca acaccaaggt ggacaagaag 660
gtggagccca agagctgtga caagacccac acctgccccc cctgccctgc ccccgagctg 720
ctgggaggcc ccagcgtgtt cctgttcccc cccaagccta aggacaccct gatgatcagc 780
agaacccccg aggtgacctg tgtggtggtg gatgtgagcc acgaggaccc tgaggtgaag 840
ttcaactggt acgtggacgg cgtggaggtg cacaatgcca agaccaagcc cagggaggag 900
cagtacaaca gcacctaccg ggtggtgtcc gtgctgaccg tgctgcacca ggattggctg 960
aacggcaagg agtacaagtg taaggtgtcc aacaaggccc tgcctgcccc tatcgagaaa 1020
accatcagca aggccaaggg ccagcccaga gagccccagg tgtacaccct gccccctagc 1080
agagatgagc tgaccaagaa ccaggtgtcc ctgacctgcc tggtgaaggg cttctacccc 1140
agcgacatcg ccgtggagtg ggagagcaac ggccagcccg agaacaacta caagaccacc 1200
ccccctgtgc tggacagcga tggcagcttc ttcctgtaca gcaagctgac cgtggacaag 1260
agcagatggc agcagggcaa cgtgttcagc tgctccgtga tgcacgaggc cctgcacaat 1320
cactacaccc agaagagcct gagcctgtcc cctggcaagg gatccgtgga caacaagttc 1380
aacaaggagc tgaggcaggc ctactgggag atccaggccc tgcccaatct gaactggacc 1440
cagagcaggg ccttcatcag gagcctgtac gacgacccca gccagagcgc taacctcctg 1500
gccgaggcca aaaagctgaa cgacgcccag gcccccaag 1539
<210> 236
<211> 1557
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 236
caggtgcagc tggtgcagag cggagccgag gtgaagaagc ctggcgccag cgtcaaggtg 60
tcctgcaagg ccagcggcta caccttcacc gactactaca tgaactgggt gcggcaggcc 120
ccaggccagg gactggaatg gatgggcaac atcaacccca acaacggcgg caccaactac 180
aaccagaagt tcaaggaccg ggtcaccatg accaccgaca ccagcaccag caccgcctac 240
atggaactgc ggagcctgag aagcgacgac accgccgtgt actactgcgc ccggtggatc 300
ctgtactacg gccggtccaa gtggtacttc gacgtgtggg gcaggggcac actagtgacc 360
gtgtccagcg ccagcaccaa gggccccagc gtgttccccc tggcccccag cagcaagagc 420
accagcggcg gcacagccgc cctgggctgc ctggtgaagg actacttccc cgaaccggtg 480
accgtgtcct ggaacagcgg agccctgacc agcggcgtgc acaccttccc cgccgtgctg 540
cagagcagcg gcctgtacag cctgagcagc gtggtgaccg tgcccagcag cagcctgggc 600
acccagacct acatctgtaa cgtgaaccac aagcccagca acaccaaggt ggacaagaag 660
gtggagccca agagctgtga caagacccac acctgccccc cctgccctgc ccccgagctg 720
ctgggaggcc ccagcgtgtt cctgttcccc cccaagccta aggacaccct gatgatcagc 780
agaacccccg aggtgacctg tgtggtggtg gatgtgagcc acgaggaccc tgaggtgaag 840
ttcaactggt acgtggacgg cgtggaggtg cacaatgcca agaccaagcc cagggaggag 900
cagtacaaca gcacctaccg ggtggtgtcc gtgctgaccg tgctgcacca ggattggctg 960
aacggcaagg agtacaagtg taaggtgtcc aacaaggccc tgcctgcccc tatcgagaaa 1020
accatcagca aggccaaggg ccagcccaga gagccccagg tgtacaccct gccccctagc 1080
agagatgagc tgaccaagaa ccaggtgtcc ctgacctgcc tggtgaaggg cttctacccc 1140
agcgacatcg ccgtggagtg ggagagcaac ggccagcccg agaacaacta caagaccacc 1200
ccccctgtgc tggacagcga tggcagcttc ttcctgtaca gcaagctgac cgtggacaag 1260
agcagatggc agcagggcaa cgtgttcagc tgctccgtga tgcacgaggc cctgcacaat 1320
cactacaccc agaagagcct gagcctgtcc cctggcaaga ccgtggccgc cccctcggga 1380
tccgtggaca acaagttcaa caaggagctg aggcaggcct actgggagat ccaggccctg 1440
cccaatctga actggaccca gagcagggcc ttcatcagga gcctgtacga cgaccccagc 1500
cagagcgcta acctcctggc cgaggccaaa aagctgaacg acgcccaggc ccccaag 1557
<210> 237
<211> 1734
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 237
caggtgcagc tggtgcagag cggagccgag gtgaagaagc ctggcgccag cgtcaaggtg 60
tcctgcaagg ccagcggcta caccttcacc gactactaca tgaactgggt gcggcaggcc 120
ccaggccagg gactggaatg gatgggcaac atcaacccca acaacggcgg caccaactac 180
aaccagaagt tcaaggaccg ggtcaccatg accaccgaca ccagcaccag caccgcctac 240
atggaactgc ggagcctgag aagcgacgac accgccgtgt actactgcgc ccggtggatc 300
ctgtactacg gccggtccaa gtggtacttc gacgtgtggg gcaggggcac actagtgacc 360
gtgtccagcg ccagcaccaa gggccccagc gtgttccccc tggcccccag cagcaagagc 420
accagcggcg gcacagccgc cctgggctgc ctggtgaagg actacttccc cgaaccggtg 480
accgtgtcct ggaacagcgg agccctgacc agcggcgtgc acaccttccc cgccgtgctg 540
cagagcagcg gcctgtacag cctgagcagc gtggtgaccg tgcccagcag cagcctgggc 600
acccagacct acatctgtaa cgtgaaccac aagcccagca acaccaaggt ggacaagaag 660
gtggagccca agagctgtga caagacccac acctgccccc cctgccctgc ccccgagctg 720
ctgggaggcc ccagcgtgtt cctgttcccc cccaagccta aggacaccct gatgatcagc 780
agaacccccg aggtgacctg tgtggtggtg gatgtgagcc acgaggaccc tgaggtgaag 840
ttcaactggt acgtggacgg cgtggaggtg cacaatgcca agaccaagcc cagggaggag 900
cagtacaaca gcacctaccg ggtggtgtcc gtgctgaccg tgctgcacca ggattggctg 960
aacggcaagg agtacaagtg taaggtgtcc aacaaggccc tgcctgcccc tatcgagaaa 1020
accatcagca aggccaaggg ccagcccaga gagccccagg tgtacaccct gccccctagc 1080
agagatgagc tgaccaagaa ccaggtgtcc ctgacctgcc tggtgaaggg cttctacccc 1140
agcgacatcg ccgtggagtg ggagagcaac ggccagcccg agaacaacta caagaccacc 1200
ccccctgtgc tggacagcga tggcagcttc ttcctgtaca gcaagctgac cgtggacaag 1260
agcagatggc agcagggcaa cgtgttcagc tgctccgtga tgcacgaggc cctgcacaat 1320
cactacaccc agaagagcct gagcctgtcc cctggcaagg gatccgacct ggggaaaaag 1380
ctgcttgaag ccgctagggc aggacaggat gacgaggtga ggattctgat ggcaaatggc 1440
gccgacgtca atgccaaaga cgagtacggc ctcacccctc tttatctggc cactgcacac 1500
ggacacttgg agatcgtgga ggtgctgctc aagaacggag ctgatgtgaa cgctgtggac 1560
gctattgggt tcacacccct tcacctcgca gcctttattg gccacctgga gatcgccgaa 1620
gttctcctga aacacggcgc agacgtcaac gcacaggata agttcgggaa gaccgccttc 1680
gacatcagca tcggcaatgg gaacgaggat ctggccgaga tcctgcagaa gctg 1734
<210> 238
<211> 1752
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 238
caggtgcagc tggtgcagag cggagccgag gtgaagaagc ctggcgccag cgtcaaggtg 60
tcctgcaagg ccagcggcta caccttcacc gactactaca tgaactgggt gcggcaggcc 120
ccaggccagg gactggaatg gatgggcaac atcaacccca acaacggcgg caccaactac 180
aaccagaagt tcaaggaccg ggtcaccatg accaccgaca ccagcaccag caccgcctac 240
atggaactgc ggagcctgag aagcgacgac accgccgtgt actactgcgc ccggtggatc 300
ctgtactacg gccggtccaa gtggtacttc gacgtgtggg gcaggggcac actagtgacc 360
gtgtccagcg ccagcaccaa gggccccagc gtgttccccc tggcccccag cagcaagagc 420
accagcggcg gcacagccgc cctgggctgc ctggtgaagg actacttccc cgaaccggtg 480
accgtgtcct ggaacagcgg agccctgacc agcggcgtgc acaccttccc cgccgtgctg 540
cagagcagcg gcctgtacag cctgagcagc gtggtgaccg tgcccagcag cagcctgggc 600
acccagacct acatctgtaa cgtgaaccac aagcccagca acaccaaggt ggacaagaag 660
gtggagccca agagctgtga caagacccac acctgccccc cctgccctgc ccccgagctg 720
ctgggaggcc ccagcgtgtt cctgttcccc cccaagccta aggacaccct gatgatcagc 780
agaacccccg aggtgacctg tgtggtggtg gatgtgagcc acgaggaccc tgaggtgaag 840
ttcaactggt acgtggacgg cgtggaggtg cacaatgcca agaccaagcc cagggaggag 900
cagtacaaca gcacctaccg ggtggtgtcc gtgctgaccg tgctgcacca ggattggctg 960
aacggcaagg agtacaagtg taaggtgtcc aacaaggccc tgcctgcccc tatcgagaaa 1020
accatcagca aggccaaggg ccagcccaga gagccccagg tgtacaccct gccccctagc 1080
agagatgagc tgaccaagaa ccaggtgtcc ctgacctgcc tggtgaaggg cttctacccc 1140
agcgacatcg ccgtggagtg ggagagcaac ggccagcccg agaacaacta caagaccacc 1200
ccccctgtgc tggacagcga tggcagcttc ttcctgtaca gcaagctgac cgtggacaag 1260
agcagatggc agcagggcaa cgtgttcagc tgctccgtga tgcacgaggc cctgcacaat 1320
cactacaccc agaagagcct gagcctgtcc cctggcaaga ccgtggccgc cccctcggga 1380
tccgacctgg ggaaaaagct gcttgaagcc gctagggcag gacaggatga cgaggtgagg 1440
attctgatgg caaatggcgc cgacgtcaat gccaaagacg agtacggcct cacccctctt 1500
tatctggcca ctgcacacgg acacttggag atcgtggagg tgctgctcaa gaacggagct 1560
gatgtgaacg ctgtggacgc tattgggttc acaccccttc acctcgcagc ctttattggc 1620
cacctggaga tcgccgaagt tctcctgaaa cacggcgcag acgtcaacgc acaggataag 1680
ttcgggaaga ccgccttcga catcagcatc ggcaatggga acgaggatct ggccgagatc 1740
ctgcagaagc tg 1752
<210> 239
<211> 1722
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 239
caggtgaccc tgagggagag cggccccgcc ctggtgaagc ccacccagac cctgaccctg 60
acctgcacct tcagcggctt tagcctcagc acctccggca tgggcgtgag ctggatcagg 120
cagccacccg gcaaaggcct ggagtggctg gcccacatct actgggacga cgacaagagg 180
tacaacccca gcctgaagag ccggctgacc atcagcaagg ataccagcag gaaccaggtg 240
gtgctgacca tgaccaacat ggaccccgtg gacaccgcta cctactactg cgccaggagg 300
gagaccgtct tctactggta cttcgacgtg tggggaaggg gcacactagt gaccgtgtcc 360
agcgccagca ccaagggccc cagcgtgttc cccctggccc ccagcagcaa gagcaccagc 420
ggcggcacag ccgccctggg ctgcctggtg aaggactact tccccgaacc ggtgaccgtg 480
tcctggaaca gcggagccct gaccagcggc gtgcacacct tccccgccgt gctgcagagc 540
agcggcctgt acagcctgag cagcgtggtg accgtgccca gcagcagcct gggcacccag 600
acctacatct gtaacgtgaa ccacaagccc agcaacacca aggtggacaa gaaggtggag 660
cccaagagct gtgacaagac ccacacctgc cccccctgcc ctgcccccga gctgctggga 720
ggccccagcg tgttcctgtt cccccccaag cctaaggaca ccctgatgat cagcagaacc 780
cccgaggtga cctgtgtggt ggtggatgtg agccacgagg accctgaggt gaagttcaac 840
tggtacgtgg acggcgtgga ggtgcacaat gccaagacca agcccaggga ggagcagtac 900
aacagcacct accgggtggt gtccgtgctg accgtgctgc accaggattg gctgaacggc 960
aaggagtaca agtgtaaggt gtccaacaag gccctgcctg cccctatcga gaaaaccatc 1020
agcaaggcca agggccagcc cagagagccc caggtgtaca ccctgccccc tagcagagat 1080
gagctgacca agaaccaggt gtccctgacc tgcctggtga agggcttcta ccccagcgac 1140
atcgccgtgg agtgggagag caacggccag cccgagaaca actacaagac caccccccct 1200
gtgctggaca gcgatggcag cttcttcctg tacagcaagc tgaccgtgga caagagcaga 1260
tggcagcagg gcaacgtgtt cagctgctcc gtgatgcacg aggccctgca caatcactac 1320
acccagaaga gcctgagcct gtcccctggc aagggatccc aggtgcagct ggtggagtct 1380
gggggaggct tggtgcaggc tggggggtct ctgagactct cctgtgcagc ctctggatac 1440
gcatacactt acatctacat gggctggttc cgccaggctc cagggaaaga gcgtgagggg 1500
gtcgcagcta tggatagtgg tggtggtggc acactctacg ccgactccgt gaagggccga 1560
ttcaccatct cccgcgacaa aggcaagaac acggtgtatc tgcaaatgga cagcctgaaa 1620
cctgaggaca cggccacgta ttactgtgct gcaggtggct acgagctgcg tgaccggaca 1680
tatgggcagt ggggccaggg gacccaggtc accgtctcct ca 1722
<210> 240
<211> 1698
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 240
caggtgaccc tgagggagag cggccccgcc ctggtgaagc ccacccagac cctgaccctg 60
acctgcacct tcagcggctt tagcctcagc acctccggca tgggcgtgag ctggatcagg 120
cagccacccg gcaaaggcct ggagtggctg gcccacatct actgggacga cgacaagagg 180
tacaacccca gcctgaagag ccggctgacc atcagcaagg ataccagcag gaaccaggtg 240
gtgctgacca tgaccaacat ggaccccgtg gacaccgcta cctactactg cgccaggagg 300
gagaccgtct tctactggta cttcgacgtg tggggaaggg gcacactagt gaccgtgtcc 360
agcgccagca ccaagggccc cagcgtgttc cccctggccc ccagcagcaa gagcaccagc 420
ggcggcacag ccgccctggg ctgcctggtg aaggactact tccccgaacc ggtgaccgtg 480
tcctggaaca gcggagccct gaccagcggc gtgcacacct tccccgccgt gctgcagagc 540
agcggcctgt acagcctgag cagcgtggtg accgtgccca gcagcagcct gggcacccag 600
acctacatct gtaacgtgaa ccacaagccc agcaacacca aggtggacaa gaaggtggag 660
cccaagagct gtgacaagac ccacacctgc cccccctgcc ctgcccccga gctgctggga 720
ggccccagcg tgttcctgtt cccccccaag cctaaggaca ccctgatgat cagcagaacc 780
cccgaggtga cctgtgtggt ggtggatgtg agccacgagg accctgaggt gaagttcaac 840
tggtacgtgg acggcgtgga ggtgcacaat gccaagacca agcccaggga ggagcagtac 900
aacagcacct accgggtggt gtccgtgctg accgtgctgc accaggattg gctgaacggc 960
aaggagtaca agtgtaaggt gtccaacaag gccctgcctg cccctatcga gaaaaccatc 1020
agcaaggcca agggccagcc cagagagccc caggtgtaca ccctgccccc tagcagagat 1080
gagctgacca agaaccaggt gtccctgacc tgcctggtga agggcttcta ccccagcgac 1140
atcgccgtgg agtgggagag caacggccag cccgagaaca actacaagac caccccccct 1200
gtgctggaca gcgatggcag cttcttcctg tacagcaagc tgaccgtgga caagagcaga 1260
tggcagcagg gcaacgtgtt cagctgctcc gtgatgcacg aggccctgca caatcactac 1320
acccagaaga gcctgagcct gtcccctggc aagggatccg cgcgcgtcga ccagacgccg 1380
cgcagcgtca cgaaggaaac cggcgagtcc ctcaccatca actgcgtgct gcgggatgcc 1440
tcctacgccc tgggcagcac atgttggtac agaaagaaga gcggggaagg caacgaggag 1500
tccatctcca aggggggaag atacgtcgag accgtgaaca gcggaagcaa gagcttcagc 1560
ctgcggatca acgacctcac cgtcgaggac gggggcacct accgttgcgg tctgggcgtg 1620
gccggcggct attgcgatta cgccctgtgc agtagccggt atgctgagtg cggcgacggc 1680
accgctgtga ccgtgaac 1698
<210> 241
<211> 1641
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 241
caggtgcagc tggtgcagag cggagccgag gtgaagaagc ctggcgccag cgtcaaggtg 60
tcctgcaagg ccagcggcta caccttcacc gactactaca tgaactgggt gcggcaggcc 120
ccaggccagg gactggaatg gatgggcaac atcaacccca acaacggcgg caccaactac 180
aaccagaagt tcaaggaccg ggtcaccatg accaccgaca ccagcaccag caccgcctac 240
atggaactgc ggagcctgag aagcgacgac accgccgtgt actactgcgc ccggtggatc 300
ctgtactacg gccggtccaa gtggtacttc gacgtgtggg gcaggggcac actagtgacc 360
gtgtccagcg ccagcaccaa gggccccagc gtgttccccc tggcccccag cagcaagagc 420
accagcggcg gcacagccgc cctgggctgc ctggtgaagg actacttccc cgaaccggtg 480
accgtgtcct ggaacagcgg agccctgacc agcggcgtgc acaccttccc cgccgtgctg 540
cagagcagcg gcctgtacag cctgagcagc gtggtgaccg tgcccagcag cagcctgggc 600
acccagacct acatctgtaa cgtgaaccac aagcccagca acaccaaggt ggacaagaag 660
gtggagccca agagctgtga caagacccac acctgccccc cctgccctgc ccccgagctg 720
ctgggaggcc ccagcgtgtt cctgttcccc cccaagccta aggacaccct gatgatcagc 780
agaacccccg aggtgacctg tgtggtggtg gatgtgagcc acgaggaccc tgaggtgaag 840
ttcaactggt acgtggacgg cgtggaggtg cacaatgcca agaccaagcc cagggaggag 900
cagtacaaca gcacctaccg ggtggtgtcc gtgctgaccg tgctgcacca ggattggctg 960
aacggcaagg agtacaagtg taaggtgtcc aacaaggccc tgcctgcccc tatcgagaaa 1020
accatcagca aggccaaggg ccagcccaga gagccccagg tgtacaccct gccccctagc 1080
agagatgagc tgaccaagaa ccaggtgtcc ctgacctgcc tggtgaaggg cttctacccc 1140
agcgacatcg ccgtggagtg ggagagcaac ggccagcccg agaacaacta caagaccacc 1200
ccccctgtgc tggacagcga tggcagcttc ttcctgtaca gcaagctgac cgtggacaag 1260
agcagatggc agcagggcaa cgtgttcagc tgctccgtga tgcacgaggc cctgcacaat 1320
cactacaccc agaagagcct gagcctgtcc cctggcaaga ccgtggccgc cccctcggga 1380
tccgaggtgg tggccgccac ccccaccagc ctgctgattt cctggaggca cccccacttc 1440
cccacacgct actacaggat cacctacggc gagaccggcg gcaacagccc cgtgcaggag 1500
ttcaccgtgc ccctgcagcc tcccactgcc accatcagcg gcctcaagcc cggcgtggac 1560
tacaccatca ccgtgtacgc cgtcaccgac ggaaggaacg gcaggctgct gagcatcccc 1620
atcagcatca actacaggac c 1641
<210> 242
<211> 1611
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 242
caggtgcagc tgaagcagag cggccctggc ctggtgcagc cctctcagag cctgagcatc 60
acctgtaccg tgagcggctt cagcctgacc aattacggcg tgcattgggt gcggcagtct 120
ccaggcaagg gcctggaatg gctgggagtg atctggtccg gcggcaacac cgactacaac 180
acccccttca ccagcagact gagcatcaac aaggacaaca gcaagagcca ggtgttcttc 240
aagatgaaca gcctgcagag caacgacacc gccatctact attgtgccag ggccctgacc 300
tactacgact acgagttcgc ctactggggc cagggcaccc tggtgaccgt gagcgccgct 360
agcaccaagg gccccagcgt gttccccctg gcccccagca gcaagagcac cagcggcggc 420
acagccgccc tgggctgcct ggtgaaggac tacttccccg agcctgtgac cgtgtcctgg 480
aatagcggag ccctgacctc cggcgtgcac accttccccg ccgtgctgca gagcagcggc 540
ctgtactccc tgagcagcgt ggtgaccgtg cccagcagca gcctgggcac ccagacctac 600
atctgcaacg tgaaccacaa gcccagcaac accaaagtgg acaagaaagt ggagcccaag 660
agctgcgata agacccacac ctgccccccc tgccctgccc ccgagctgct gggcggacct 720
agcgtgttcc tgttcccccc caagcctaag gacaccctga tgatcagcag gacccccgaa 780
gtgacctgcg tggtggtgga tgtgagccac gaggaccctg aagtgaagtt caactggtac 840
gtggacggcg tggaagtgca caacgccaag accaagccca gagaggagca gtacaacagc 900
acctaccgcg tggtgtctgt gctgaccgtg ctgcaccagg attggctgaa cggcaaggag 960
tacaagtgca aagtgagcaa caaggccctg cctgccccta tcgagaaaac catcagcaag 1020
gccaagggcc agcctagaga gccccaggtc tacaccctgc ctccctccag agatgagctg 1080
accaagaacc aggtgtccct gacctgtctg gtgaagggct tctaccccag cgacatcgcc 1140
gtggagtggg agagcaacgg ccagcccgag aacaactaca agaccacccc ccctgtgctg 1200
gacagcgatg gcagcttctt cctgtactcc aagctgaccg tggacaagag cagatggcag 1260
cagggcaacg tgttcagctg cagcgtgatg cacgaggccc tgcacaatca ctacacccag 1320
aagagtctga gcctgtctcc tggcaagaga tccgaggtgg tggccgccac ccccaccagc 1380
ctgctgattt cctggaggca cccccacttc cccacacgct actacaggat cacctacggc 1440
gagaccggcg gcaacagccc cgtgcaggag ttcaccgtgc ccctgcagcc tcccactgcc 1500
accatcagcg gcctcaagcc cggcgtggac tacaccatca ccgtgtacgc cgtcaccgac 1560
ggaaggaacg gcaggctgct gagcatcccc atcagcatca actacaggac c 1611
<210> 243
<211> 642
<212> PRT
<213> 人工序列
<220>
<223> 人源化的
<400> 243
Gly Ala Cys Ala Thr Cys Cys Thr Gly Cys Thr Gly Ala Cys Cys Cys
1 5 10 15
Ala Gly Ala Gly Cys Cys Cys Cys Gly Thr Gly Ala Thr Cys Cys Thr
20 25 30
Gly Ala Gly Cys Gly Thr Gly Ala Gly Cys Cys Cys Thr Gly Gly Cys
35 40 45
Gly Ala Gly Ala Gly Ala Gly Thr Gly Ala Gly Cys Thr Thr Cys Ala
50 55 60
Gly Cys Thr Gly Cys Cys Gly Gly Gly Cys Cys Ala Gly Cys Cys Ala
65 70 75 80
Gly Ala Gly Cys Ala Thr Cys Gly Gly Cys Ala Cys Cys Ala Ala Cys
85 90 95
Ala Thr Cys Cys Ala Cys Thr Gly Gly Thr Ala Thr Cys Ala Gly Cys
100 105 110
Ala Gly Cys Gly Gly Ala Cys Cys Ala Ala Cys Gly Gly Cys Ala Gly
115 120 125
Cys Cys Cys Cys Ala Gly Gly Cys Thr Gly Cys Thr Gly Ala Thr Cys
130 135 140
Ala Ala Gly Thr Ala Cys Gly Cys Cys Ala Gly Cys Gly Ala Gly Thr
145 150 155 160
Cys Cys Ala Thr Cys Ala Gly Cys Gly Gly Cys Ala Thr Cys Cys Cys
165 170 175
Cys Ala Gly Cys Cys Gly Gly Thr Thr Cys Ala Gly Cys Gly Gly Cys
180 185 190
Ala Gly Cys Gly Gly Cys Thr Cys Cys Gly Gly Cys Ala Cys Cys Gly
195 200 205
Ala Cys Thr Thr Cys Ala Cys Cys Cys Thr Gly Ala Gly Cys Ala Thr
210 215 220
Cys Ala Ala Cys Ala Gly Cys Gly Thr Gly Gly Ala Gly Ala Gly Cys
225 230 235 240
Gly Ala Gly Gly Ala Thr Ala Thr Cys Gly Cys Cys Gly Ala Cys Thr
245 250 255
Ala Cys Thr Ala Cys Thr Gly Cys Cys Ala Gly Cys Ala Gly Ala Ala
260 265 270
Cys Ala Ala Cys Ala Ala Cys Thr Gly Gly Cys Cys Cys Ala Cys Cys
275 280 285
Ala Cys Cys Thr Thr Cys Gly Gly Ala Gly Cys Cys Gly Gly Cys Ala
290 295 300
Cys Cys Ala Ala Gly Cys Thr Gly Gly Ala Ala Cys Thr Gly Ala Ala
305 310 315 320
Gly Cys Gly Thr Ala Cys Gly Gly Thr Gly Gly Cys Cys Gly Cys Cys
325 330 335
Cys Cys Cys Ala Gly Cys Gly Thr Gly Thr Thr Cys Ala Thr Cys Thr
340 345 350
Thr Cys Cys Cys Cys Cys Cys Cys Ala Gly Cys Gly Ala Thr Gly Ala
355 360 365
Gly Cys Ala Gly Cys Thr Cys Ala Ala Gly Ala Gly Cys Gly Gly Cys
370 375 380
Ala Cys Cys Gly Cys Cys Ala Gly Cys Gly Thr Gly Gly Thr Gly Thr
385 390 395 400
Gly Thr Cys Thr Gly Cys Thr Gly Ala Ala Cys Ala Ala Cys Thr Thr
405 410 415
Cys Thr Ala Cys Cys Cys Cys Cys Gly Gly Gly Ala Gly Gly Cys Cys
420 425 430
Ala Ala Ala Gly Thr Gly Cys Ala Gly Thr Gly Gly Ala Ala Ala Gly
435 440 445
Thr Gly Gly Ala Cys Ala Ala Cys Gly Cys Cys Cys Thr Gly Cys Ala
450 455 460
Gly Ala Gly Cys Gly Gly Cys Ala Ala Cys Ala Gly Cys Cys Ala Gly
465 470 475 480
Gly Ala Gly Ala Gly Cys Gly Thr Gly Ala Cys Cys Gly Ala Gly Cys
485 490 495
Ala Gly Gly Ala Cys Ala Gly Cys Ala Ala Gly Gly Ala Cys Thr Cys
500 505 510
Cys Ala Cys Cys Thr Ala Cys Ala Gly Cys Cys Thr Gly Ala Gly Cys
515 520 525
Ala Gly Cys Ala Cys Cys Cys Thr Gly Ala Cys Cys Cys Thr Gly Ala
530 535 540
Gly Cys Ala Ala Gly Gly Cys Cys Gly Ala Cys Thr Ala Cys Gly Ala
545 550 555 560
Gly Ala Ala Gly Cys Ala Cys Ala Ala Ala Gly Thr Gly Thr Ala Cys
565 570 575
Gly Cys Cys Thr Gly Cys Gly Ala Ala Gly Thr Gly Ala Cys Cys Cys
580 585 590
Ala Cys Cys Ala Gly Gly Gly Cys Cys Thr Gly Thr Cys Cys Ala Gly
595 600 605
Cys Cys Cys Cys Gly Thr Gly Ala Cys Cys Ala Ala Gly Ala Gly Cys
610 615 620
Thr Thr Cys Ala Ala Cys Cys Gly Gly Gly Gly Cys Gly Ala Gly Thr
625 630 635 640
Gly Cys
<210> 244
<211> 906
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 244
gacatcctgc tgacccagag ccccgtgatc ctgagcgtga gccctggcga gagagtgagc 60
ttcagctgcc gggccagcca gagcatcggc accaacatcc actggtatca gcagcggacc 120
aacggcagcc ccaggctgct gatcaagtac gccagcgagt ccatcagcgg catccccagc 180
cggttcagcg gcagcggctc cggcaccgac ttcaccctga gcatcaacag cgtggagagc 240
gaggatatcg ccgactacta ctgccagcag aacaacaact ggcccaccac cttcggagcc 300
ggcaccaagc tggaactgaa gcgtacggtg gccgccccca gcgtgttcat cttccccccc 360
agcgatgagc agctcaagag cggcaccgcc agcgtggtgt gtctgctgaa caacttctac 420
ccccgggagg ccaaagtgca gtggaaagtg gacaacgccc tgcagagcgg caacagccag 480
gagagcgtga ccgagcagga cagcaaggac tccacctaca gcctgagcag caccctgacc 540
ctgagcaagg ccgactacga gaagcacaaa gtgtacgcct gcgaagtgac ccaccagggc 600
ctgtccagcc ccgtgaccaa gagcttcaac cgaggcgagt gcagatccga ggtggtggcc 660
gccaccccca ccagcctgct gatttcctgg aggcaccccc acttccccac acgctactac 720
aggatcacct acggcgagac cggcggcaac agccccgtgc aggagttcac cgtgcccctg 780
cagcctccca ctgccaccat cagcggcctc aagcccggcg tggactacac catcaccgtg 840
tacgccgtca ccgacggaag gaacggcagg ctgctgagca tccccatcag catcaactac 900
aggacc 906
<210> 245
<211> 1347
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 245
caggtgcagc tgaagcagag cggccctggc ctggtgcagc cctctcagag cctgagcatc 60
acctgtaccg tgagcggctt cagcctgacc aattacggcg tgcattgggt gcggcagtct 120
ccaggcaagg gcctggaatg gctgggagtg atctggtccg gcggcaacac cgactacaac 180
acccccttca ccagcagact gagcatcaac aaggacaaca gcaagagcca ggtgttcttc 240
aagatgaaca gcctgcagag caacgacacc gccatctact attgtgccag ggccctgacc 300
tactacgact acgagttcgc ctactggggc cagggcaccc tggtgaccgt gagcgccgct 360
agcaccaagg gccccagcgt gttccccctg gcccccagca gcaagagcac cagcggcggc 420
acagccgccc tgggctgcct ggtgaaggac tacttccccg agcctgtgac cgtgtcctgg 480
aatagcggag ccctgacctc cggcgtgcac accttccccg ccgtgctgca gagcagcggc 540
ctgtactccc tgagcagcgt ggtgaccgtg cccagcagca gcctgggcac ccagacctac 600
atctgcaacg tgaaccacaa gcccagcaac accaaagtgg acaagaaagt ggagcccaag 660
agctgcgata agacccacac ctgccccccc tgccctgccc ccgagctgct gggcggacct 720
agcgtgttcc tgttcccccc caagcctaag gacaccctga tgatcagcag gacccccgaa 780
gtgacctgcg tggtggtgga tgtgagccac gaggaccctg aagtgaagtt caactggtac 840
gtggacggcg tggaagtgca caacgccaag accaagccca gagaggagca gtacaacagc 900
acctaccgcg tggtgtctgt gctgaccgtg ctgcaccagg attggctgaa cggcaaggag 960
tacaagtgca aagtgagcaa caaggccctg cctgccccta tcgagaaaac catcagcaag 1020
gccaagggcc agcctagaga gccccaggtc tacaccctgc ctccctccag agatgagctg 1080
accaagaacc aggtgtccct gacctgtctg gtgaagggct tctaccccag cgacatcgcc 1140
gtggagtggg agagcaacgg ccagcccgag aacaactaca agaccacccc ccctgtgctg 1200
gacagcgatg gcagcttctt cctgtactcc aagctgaccg tggacaagag cagatggcag 1260
cagggcaacg tgttcagctg cagcgtgatg cacgaggccc tgcacaatca ctacacccag 1320
aagagtctga gcctgtcccc tggcaag 1347
<210> 246
<211> 1617
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 246
gaggtggtgg ccgccacccc caccagcctg ctgatttcct ggaggcaccc ccacttcccc 60
acacgctact acaggatcac ctacggcgag accggcggca acagccccgt gcaggagttc 120
accgtgcccc tgcagcctcc cactgccacc atcagcggcc tcaagcccgg cgtggactac 180
accatcaccg tgtacgccgt caccgacgga aggaacggca ggctgctgag catccccatc 240
agcatcaact acaggaccgg atccaccggc caggtgcagc tgaagcagag cggccctggc 300
ctggtgcagc cctctcagag cctgagcatc acctgtaccg tgagcggctt cagcctgacc 360
aattacggcg tgcattgggt gcggcagtct ccaggcaagg gcctggaatg gctgggagtg 420
atctggtccg gcggcaacac cgactacaac acccccttca ccagcagact gagcatcaac 480
aaggacaaca gcaagagcca ggtgttcttc aagatgaaca gcctgcagag caacgacacc 540
gccatctact attgtgccag ggccctgacc tactacgact acgagttcgc ctactggggc 600
cagggcaccc tggtgaccgt gagcgccgct agcaccaagg gccccagcgt gttccccctg 660
gcccccagca gcaagagcac cagcggcggc acagccgccc tgggctgcct ggtgaaggac 720
tacttccccg agcctgtgac cgtgtcctgg aatagcggag ccctgacctc cggcgtgcac 780
accttccccg ccgtgctgca gagcagcggc ctgtactccc tgagcagcgt ggtgaccgtg 840
cccagcagca gcctgggcac ccagacctac atctgcaacg tgaaccacaa gcccagcaac 900
accaaagtgg acaagaaagt ggagcccaag agctgcgata agacccacac ctgccccccc 960
tgccctgccc ccgagctgct gggcggacct agcgtgttcc tgttcccccc caagcctaag 1020
gacaccctga tgatcagcag gacccccgaa gtgacctgcg tggtggtgga tgtgagccac 1080
gaggaccctg aagtgaagtt caactggtac gtggacggcg tggaagtgca caacgccaag 1140
accaagccca gagaggagca gtacaacagc acctaccgcg tggtgtctgt gctgaccgtg 1200
ctgcaccagg attggctgaa cggcaaggag tacaagtgca aagtgagcaa caaggccctg 1260
cctgccccta tcgagaaaac catcagcaag gccaagggcc agcctagaga gccccaggtc 1320
tacaccctgc ctccctccag agatgagctg accaagaacc aggtgtccct gacctgtctg 1380
gtgaagggct tctaccccag cgacatcgcc gtggagtggg agagcaacgg ccagcccgag 1440
aacaactaca agaccacccc ccctgtgctg gacagcgatg gcagcttctt cctgtactcc 1500
aagctgaccg tggacaagag cagatggcag cagggcaacg tgttcagctg cagcgtgatg 1560
cacgaggccc tgcacaatca ctacacccag aagagtctga gcctgtcccc tggcaag 1617
<210> 247
<211> 909
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 247
gaggtggtgg ccgccacccc caccagcctg ctgatttcct ggaggcaccc ccacttcccc 60
acacgctact acaggatcac ctacggcgag accggcggca acagccccgt gcaggagttc 120
accgtgcccc tgcagcctcc cactgccacc atcagcggcc tcaagcccgg cgtggactac 180
accatcaccg tgtacgccgt caccgacgga aggaacggca ggctgctgag catccccatc 240
agcatcaact acaggacgtc gaccggtgac atcctgctga cccagagccc cgtgatcctg 300
agcgtgagcc ctggcgagag agtgagcttc agctgccggg ccagccagag catcggcacc 360
aacatccact ggtatcagca gcggaccaac ggcagcccca ggctgctgat caagtacgcc 420
agcgagtcca tcagcggcat ccccagccgg ttcagcggca gcggctccgg caccgacttc 480
accctgagca tcaacagcgt ggagagcgag gatatcgccg actactactg ccagcagaac 540
aacaactggc ccaccacctt cggagccggc accaagctgg aactgaagcg tacggtggcc 600
gcccccagcg tgttcatctt cccccccagc gatgagcagc tcaagagcgg caccgccagc 660
gtggtgtgtc tgctgaacaa cttctacccc cgggaggcca aagtgcagtg gaaagtggac 720
aacgccctgc agagcggcaa cagccaggag agcgtgaccg agcaggacag caaggactcc 780
acctacagcc tgagcagcac cctgaccctg agcaaggccg actacgagaa gcacaaagtg 840
tacgcctgcg aagtgaccca ccagggcctg tccagccccg tgaccaagag cttcaaccgg 900
ggcgagtgc 909
<210> 248
<211> 1707
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 248
caggtgaccc tgagggagag cggccccgcc ctggtgaagc ccacccagac cctgaccctg 60
acctgcacct tcagcggctt tagcctcagc acctccggca tgggcgtgag ctggatcagg 120
cagccacccg gcaaaggcct ggagtggctg gcccacatct actgggacga cgacaagagg 180
tacaacccca gcctgaagag ccggctgacc atcagcaagg ataccagcag gaaccaggtg 240
gtgctgacca tgaccaacat ggaccccgtg gacaccgcta cctactactg cgccaggagg 300
gagaccgtct tctactggta cttcgacgtg tggggaaggg gcacactagt gaccgtgtcc 360
agcgccagca ccaagggccc cagcgtgttc cccctggccc ccagcagcaa gagcaccagc 420
ggcggcacag ccgccctggg ctgcctggtg aaggactact tccccgaacc ggtgaccgtg 480
tcctggaaca gcggagccct gaccagcggc gtgcacacct tccccgccgt gctgcagagc 540
agcggcctgt acagcctgag cagcgtggtg accgtgccca gcagcagcct gggcacccag 600
acctacatct gtaacgtgaa ccacaagccc agcaacacca aggtggacaa gaaggtggag 660
cccaagagct gtgacaagac ccacacctgc cccccctgcc ctgcccccga gctgctggga 720
ggccccagcg tgttcctgtt cccccccaag cctaaggaca ccctgatgat cagcagaacc 780
cccgaggtga cctgtgtggt ggtggatgtg agccacgagg accctgaggt gaagttcaac 840
tggtacgtgg acggcgtgga ggtgcacaat gccaagacca agcccaggga ggagcagtac 900
aacagcacct accgggtggt gtccgtgctg accgtgctgc accaggattg gctgaacggc 960
aaggagtaca agtgtaaggt gtccaacaag gccctgcctg cccctatcga gaaaaccatc 1020
agcaaggcca agggccagcc cagagagccc caggtgtaca ccctgccccc tagcagagat 1080
gagctgacca agaaccaggt gtccctgacc tgcctggtga agggcttcta ccccagcgac 1140
atcgccgtgg agtgggagag caacggccag cccgagaaca actacaagac caccccccct 1200
gtgctggaca gcgatggcag cttcttcctg tacagcaagc tgaccgtgga caagagcaga 1260
tggcagcagg gcaacgtgtt cagctgctcc gtgatgcacg aggccctgca caatcactac 1320
acccagaaga gcctgagcct gtcccctggc aagggcgtgc agctcctgga gagcggcgga 1380
ggcctggtcc agcccggcgg cagcctgagg ctgagctgcg ccgccagcgg cttcgtgttc 1440
ccctggtatg atatgggctg ggtgaggcag gcccccggca agggcctgga gtgggtgtcc 1500
agcatcgact ggcacgggaa gatcacctac tacgccgaca gcgtgaaggg caggttcacc 1560
atcagcaggg acaacagcaa gaacaccctg tacctgcaga tgaacagcct gagggccgag 1620
gacaccgcag tgtactactg cgccaccgcc gaggacgaac ccggctacga ctactggggc 1680
cagggcaccc tggtgactgt gagcagc 1707
<210> 249
<211> 1725
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 249
caggtgaccc tgagggagag cggccccgcc ctggtgaagc ccacccagac cctgaccctg 60
acctgcacct tcagcggctt tagcctcagc acctccggca tgggcgtgag ctggatcagg 120
cagccacccg gcaaaggcct ggagtggctg gcccacatct actgggacga cgacaagagg 180
tacaacccca gcctgaagag ccggctgacc atcagcaagg ataccagcag gaaccaggtg 240
gtgctgacca tgaccaacat ggaccccgtg gacaccgcta cctactactg cgccaggagg 300
gagaccgtct tctactggta cttcgacgtg tggggaaggg gcacactagt gaccgtgtcc 360
agcgccagca ccaagggccc cagcgtgttc cccctggccc ccagcagcaa gagcaccagc 420
ggcggcacag ccgccctggg ctgcctggtg aaggactact tccccgaacc ggtgaccgtg 480
tcctggaaca gcggagccct gaccagcggc gtgcacacct tccccgccgt gctgcagagc 540
agcggcctgt acagcctgag cagcgtggtg accgtgccca gcagcagcct gggcacccag 600
acctacatct gtaacgtgaa ccacaagccc agcaacacca aggtggacaa gaaggtggag 660
cccaagagct gtgacaagac ccacacctgc cccccctgcc ctgcccccga gctgctggga 720
ggccccagcg tgttcctgtt cccccccaag cctaaggaca ccctgatgat cagcagaacc 780
cccgaggtga cctgtgtggt ggtggatgtg agccacgagg accctgaggt gaagttcaac 840
tggtacgtgg acggcgtgga ggtgcacaat gccaagacca agcccaggga ggagcagtac 900
aacagcacct accgggtggt gtccgtgctg accgtgctgc accaggattg gctgaacggc 960
aaggagtaca agtgtaaggt gtccaacaag gccctgcctg cccctatcga gaaaaccatc 1020
agcaaggcca agggccagcc cagagagccc caggtgtaca ccctgccccc tagcagagat 1080
gagctgacca agaaccaggt gtccctgacc tgcctggtga agggcttcta ccccagcgac 1140
atcgccgtgg agtgggagag caacggccag cccgagaaca actacaagac caccccccct 1200
gtgctggaca gcgatggcag cttcttcctg tacagcaagc tgaccgtgga caagagcaga 1260
tggcagcagg gcaacgtgtt cagctgctcc gtgatgcacg aggccctgca caatcactac 1320
acccagaaga gcctgagcct gtcccctggc aagaccgtgg ccgccccctc gggcgtgcag 1380
ctcctggaga gcggcggagg cctggtccag cccggcggca gcctgaggct gagctgcgcc 1440
gccagcggct tcgtgttccc ctggtatgat atgggctggg tgaggcaggc ccccggcaag 1500
ggcctggagt gggtgtccag catcgactgg cacgggaaga tcacctacta cgccgacagc 1560
gtgaagggca ggttcaccat cagcagggac aacagcaaga acaccctgta cctgcagatg 1620
aacagcctga gggccgagga caccgcagtg tactactgcg ccaccgccga ggacgaaccc 1680
ggctacgact actggggcca gggcaccctg gtgactgtga gcagc 1725
<210> 250
<211> 1713
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 250
caggtgcagc tcgtccagtc tggggccgag gtgaagaagc ccggagcttc tgtgaaggtg 60
tcctgcaagg ccagcggcta taccttcatc gactacgaga tccattgggt gaggcaggct 120
cccgggcagg gcctggagtg gatgggcgcc atcgacccag agaccggagg cacggcgtac 180
aaccagaagt tcaagggacg ggtcaccatg acaaccgata ccagcacctc caccgcttac 240
atggagctgc gcagcctgag aagcgacgac accgcggtgt actactgtac gcgcatcctg 300
ctctactact accccatgga ttactggggc cagggcacac tagtgaccgt gtctagcgcc 360
agcaccaagg gccccagcgt gttccccctg gcccccagca gcaagagcac cagcggcggc 420
acagccgccc tgggctgcct ggtgaaggac tacttccccg aaccggtgac cgtgtcctgg 480
aacagcggag ccctgaccag cggcgtgcac accttccccg ccgtgctgca gagcagcggc 540
ctgtacagcc tgagcagcgt ggtgaccgtg cccagcagca gcctgggcac ccagacctac 600
atctgtaacg tgaaccacaa gcccagcaac accaaggtgg acaagaaggt ggagcccaag 660
agctgtgaca agacccacac ctgccccccc tgccctgccc ccgagctgct gggaggcccc 720
agcgtgttcc tgttcccccc caagcctaag gacaccctga tgatcagcag aacccccgag 780
gtgacctgtg tggtggtgga tgtgagccac gaggaccctg aggtgaagtt caactggtac 840
gtggacggcg tggaggtgca caatgccaag accaagccca gggaggagca gtacaacagc 900
acctaccggg tggtgtccgt gctgaccgtg ctgcaccagg attggctgaa cggcaaggag 960
tacaagtgta aggtgtccaa caaggccctg cctgccccta tcgagaaaac catcagcaag 1020
gccaagggcc agcccagaga gccccaggtg tacaccctgc cccctagcag agatgagctg 1080
accaagaacc aggtgtccct gacctgcctg gtgaagggct tctaccccag cgacatcgcc 1140
gtggagtggg agagcaacgg ccagcccgag aacaactaca agaccacccc ccctgtgctg 1200
gacagcgatg gcagcttctt cctgtacagc aagctgaccg tggacaagag cagatggcag 1260
cagggcaacg tgttcagctg ctccgtgatg cacgaggccc tgcacaatca ctacacccag 1320
aagagcctga gcctgtcccc tggcaagacc gtggccgccc cctcggaagt gcagctcctg 1380
gagagcggcg gcggcctggt gcagcccggc ggcagcctga ggctgagctg cgccgctagc 1440
ggcttcacct tcaggaactt cggcatgggc tgggtcaggc aggcccccgg caagggcctg 1500
gagtgggtca gctggatcat cagctccggc accgagacct actacgccga cagcgtgaag 1560
ggcaggttca ccatcagccg cgacaacagc aagaacaccc tgtacctgca gatgaacagc 1620
ctgagggccg aggacaccgc cgtctactac tgcgccaaga gcctgggcag gttcgactac 1680
tggggacagg ggaccctggt gactgtgagc agc 1713
<210> 251
<211> 642
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 251
gagatcgtgc tgacccagag tccagccacc ctcagcctga gccctgggga acgcgccacc 60
ctgtcctgcc gggcgagtca gaacatctcc gactacctgc attggtacca gcagaagccc 120
ggccaggccc ctcgcctgct gatctactac gcctcccaga gcatcagcgg aatccccgcc 180
cggttctccg gaagtgggtc cggaaccgac tttaccctga ccatcagctc tctcgagcca 240
gaggacttcg cggtgtacta ctgccagaac gggcatagtt tcccactgac cttcggaggg 300
ggcacaaagg tggagatcaa gcgtacggtg gccgccccca gcgtgttcat cttccccccc 360
agcgatgagc agctgaagag cggcaccgcc agcgtggtgt gtctgctgaa caacttctac 420
ccccgggagg ccaaggtgca gtggaaggtg gacaatgccc tgcagagcgg caacagccag 480
gagagcgtga ccgagcagga cagcaaggac tccacctaca gcctgagcag caccctgacc 540
ctgagcaagg ccgactacga gaagcacaag gtgtacgcct gtgaggtgac ccaccagggc 600
ctgtccagcc ccgtgaccaa gagcttcaac cggggcgagt gc 642
<210> 252
<211> 1725
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 252
caggtgaccc tgagggagag cggccccgcc ctggtgaagc ccacccagac cctgaccctg 60
acctgcacct tcagcggctt tagcctcagc acctccggca tgggcgtgag ctggatcagg 120
cagccacccg gcaaaggcct ggagtggctg gcccacatct actgggacga cgacaagagg 180
tacaacccca gcctgaagag ccggctgacc atcagcaagg ataccagcag gaaccaggtg 240
gtgctgacca tgaccaacat ggaccccgtg gacaccgcta cctactactg cgccaggagg 300
gagaccgtct tctactggta cttcgacgtg tggggaaggg gcacactagt gaccgtgtcc 360
agcgccagca ccaagggccc cagcgtgttc cccctggccc ccagcagcaa gagcaccagc 420
ggcggcacag ccgccctggg ctgcctggtg aaggactact tccccgaacc ggtgaccgtg 480
tcctggaaca gcggagccct gaccagcggc gtgcacacct tccccgccgt gctgcagagc 540
agcggcctgt acagcctgag cagcgtggtg accgtgccca gcagcagcct gggcacccag 600
acctacatct gtaacgtgaa ccacaagccc agcaacacca aggtggacaa gaaggtggag 660
cccaagagct gtgacaagac ccacacctgc cccccctgcc ctgcccccga gctgctggga 720
ggccccagcg tgttcctgtt cccccccaag cctaaggaca ccctgatgat cagcagaacc 780
cccgaggtga cctgtgtggt ggtggatgtg agccacgagg accctgaggt gaagttcaac 840
tggtacgtgg acggcgtgga ggtgcacaat gccaagacca agcccaggga ggagcagtac 900
aacagcacct accgggtggt gtccgtgctg accgtgctgc accaggattg gctgaacggc 960
aaggagtaca agtgtaaggt gtccaacaag gccctgcctg cccctatcga gaaaaccatc 1020
agcaaggcca agggccagcc cagagagccc caggtgtaca ccctgccccc tagcagagat 1080
gagctgacca agaaccaggt gtccctgacc tgcctggtga agggcttcta ccccagcgac 1140
atcgccgtgg agtgggagag caacggccag cccgagaaca actacaagac caccccccct 1200
gtgctggaca gcgatggcag cttcttcctg tacagcaagc tgaccgtgga caagagcaga 1260
tggcagcagg gcaacgtgtt cagctgctcc gtgatgcacg aggccctgca caatcactac 1320
acccagaaga gcctgagcct gtcccctggc aagaccgtgg ccgccccctc gggcgtgcag 1380
ctcctggaga gcggcggagg cctggtccag cccggcggca gcctgaggct gagctgcgcc 1440
gccagcggct tcgtgttccc ctggtatgat atgggctggg tgaggcaggc ccccggcaag 1500
ggcctggagt gggtgtccag catcgactgg aaggggggca agacctacta cgccgacagc 1560
gtgaagggca ggttcaccat cagcagggac aacagcaaga acaccctgta cctgcagatg 1620
aacagcctga gggccgagga caccgcagtg tactactgcg ccaccgccga ggacgaaccc 1680
ggctacgact actggggcca gggcaccctg gtgactgtga gcagc 1725
<210> 253
<211> 1707
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 253
caggtgaccc tgagggagag cggccccgcc ctggtgaagc ccacccagac cctgaccctg 60
acctgcacct tcagcggctt tagcctcagc acctccggca tgggcgtgag ctggatcagg 120
cagccacccg gcaaaggcct ggagtggctg gcccacatct actgggacga cgacaagagg 180
tacaacccca gcctgaagag ccggctgacc atcagcaagg ataccagcag gaaccaggtg 240
gtgctgacca tgaccaacat ggaccccgtg gacaccgcta cctactactg cgccaggagg 300
gagaccgtct tctactggta cttcgacgtg tggggaaggg gcacactagt gaccgtgtcc 360
agcgccagca ccaagggccc cagcgtgttc cccctggccc ccagcagcaa gagcaccagc 420
ggcggcacag ccgccctggg ctgcctggtg aaggactact tccccgaacc ggtgaccgtg 480
tcctggaaca gcggagccct gaccagcggc gtgcacacct tccccgccgt gctgcagagc 540
agcggcctgt acagcctgag cagcgtggtg accgtgccca gcagcagcct gggcacccag 600
acctacatct gtaacgtgaa ccacaagccc agcaacacca aggtggacaa gaaggtggag 660
cccaagagct gtgacaagac ccacacctgc cccccctgcc ctgcccccga gctgctggga 720
ggccccagcg tgttcctgtt cccccccaag cctaaggaca ccctgatgat cagcagaacc 780
cccgaggtga cctgtgtggt ggtggatgtg agccacgagg accctgaggt gaagttcaac 840
tggtacgtgg acggcgtgga ggtgcacaat gccaagacca agcccaggga ggagcagtac 900
aacagcacct accgggtggt gtccgtgctg accgtgctgc accaggattg gctgaacggc 960
aaggagtaca agtgtaaggt gtccaacaag gccctgcctg cccctatcga gaaaaccatc 1020
agcaaggcca agggccagcc cagagagccc caggtgtaca ccctgccccc tagcagagat 1080
gagctgacca agaaccaggt gtccctgacc tgcctggtga agggcttcta ccccagcgac 1140
atcgccgtgg agtgggagag caacggccag cccgagaaca actacaagac caccccccct 1200
gtgctggaca gcgatggcag cttcttcctg tacagcaagc tgaccgtgga caagagcaga 1260
tggcagcagg gcaacgtgtt cagctgctcc gtgatgcacg aggccctgca caatcactac 1320
acccagaaga gcctgagcct gtcccctggc aagggcgtgc agctcctgga gagcggcgga 1380
ggcctggtcc agcccggcgg cagcctgagg ctgagctgcg ccgccagcgg cttcgtgttc 1440
ccctggtatg atatgggctg ggtgaggcag gcccccggca agggcctgga gtgggtgtcc 1500
agcatcgact ggaagggggg caagacctac tacgccgaca gcgtgaaggg caggttcacc 1560
atcagcaggg acaacagcaa gaacaccctg tacctgcaga tgaacagcct gagggccgag 1620
gacaccgcag tgtactactg cgccaccgcc gaggacgaac ccggctacga ctactggggc 1680
cagggcaccc tggtgactgt gagcagc 1707
<210> 254
<211> 1725
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 254
caggtgaccc tgagggagag cggccccgcc ctggtgaagc ccacccagac cctgaccctg 60
acctgcacct tcagcggctt tagcctcagc acctccggca tgggcgtgag ctggatcagg 120
cagccacccg gcaaaggcct ggagtggctg gcccacatct actgggacga cgacaagagg 180
tacaacccca gcctgaagag ccggctgacc atcagcaagg ataccagcag gaaccaggtg 240
gtgctgacca tgaccaacat ggaccccgtg gacaccgcta cctactactg cgccaggagg 300
gagaccgtct tctactggta cttcgacgtg tggggaaggg gcacactagt gaccgtgtcc 360
agcgccagca ccaagggccc cagcgtgttc cccctggccc ccagcagcaa gagcaccagc 420
ggcggcacag ccgccctggg ctgcctggtg aaggactact tccccgaacc ggtgaccgtg 480
tcctggaaca gcggagccct gaccagcggc gtgcacacct tccccgccgt gctgcagagc 540
agcggcctgt acagcctgag cagcgtggtg accgtgccca gcagcagcct gggcacccag 600
acctacatct gtaacgtgaa ccacaagccc agcaacacca aggtggacaa gaaggtggag 660
cccaagagct gtgacaagac ccacacctgc cccccctgcc ctgcccccga gctgctggga 720
ggccccagcg tgttcctgtt cccccccaag cctaaggaca ccctgatgat cagcagaacc 780
cccgaggtga cctgtgtggt ggtggatgtg agccacgagg accctgaggt gaagttcaac 840
tggtacgtgg acggcgtgga ggtgcacaat gccaagacca agcccaggga ggagcagtac 900
aacagcacct accgggtggt gtccgtgctg accgtgctgc accaggattg gctgaacggc 960
aaggagtaca agtgtaaggt gtccaacaag gccctgcctg cccctatcga gaaaaccatc 1020
agcaaggcca agggccagcc cagagagccc caggtgtaca ccctgccccc tagcagagat 1080
gagctgacca agaaccaggt gtccctgacc tgcctggtga agggcttcta ccccagcgac 1140
atcgccgtgg agtgggagag caacggccag cccgagaaca actacaagac caccccccct 1200
gtgctggaca gcgatggcag cttcttcctg tacagcaagc tgaccgtgga caagagcaga 1260
tggcagcagg gcaacgtgtt cagctgctcc gtgatgcacg aggccctgca caatcactac 1320
acccagaaga gcctgagcct gtcccctggc aagaccgtgg ccgccccctc gggcgtgcag 1380
ctcctggaga gcggcggagg cctggtccag cccggcggca gcctgaggct gagctgcgcc 1440
gccagcggct tcgtgttcgc ctggtatgat atgggctggg tgaggcaggc ccccggcaag 1500
ggcctggagt gggtgtccag catcgactgg cacggggagg tgacctacta cgccgacagc 1560
gtgaagggca ggttcaccat cagcagggac aacagcaaga acaccctgta cctgcagatg 1620
aacagcctga gggccgagga caccgcagtg tactactgcg ccaccgccga ggacgaaccc 1680
ggctacgact actggggcca gggcaccctg gtgactgtga gcagc 1725
<210> 255
<211> 1707
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 255
caggtgaccc tgagggagag cggccccgcc ctggtgaagc ccacccagac cctgaccctg 60
acctgcacct tcagcggctt tagcctcagc acctccggca tgggcgtgag ctggatcagg 120
cagccacccg gcaaaggcct ggagtggctg gcccacatct actgggacga cgacaagagg 180
tacaacccca gcctgaagag ccggctgacc atcagcaagg ataccagcag gaaccaggtg 240
gtgctgacca tgaccaacat ggaccccgtg gacaccgcta cctactactg cgccaggagg 300
gagaccgtct tctactggta cttcgacgtg tggggaaggg gcacactagt gaccgtgtcc 360
agcgccagca ccaagggccc cagcgtgttc cccctggccc ccagcagcaa gagcaccagc 420
ggcggcacag ccgccctggg ctgcctggtg aaggactact tccccgaacc ggtgaccgtg 480
tcctggaaca gcggagccct gaccagcggc gtgcacacct tccccgccgt gctgcagagc 540
agcggcctgt acagcctgag cagcgtggtg accgtgccca gcagcagcct gggcacccag 600
acctacatct gtaacgtgaa ccacaagccc agcaacacca aggtggacaa gaaggtggag 660
cccaagagct gtgacaagac ccacacctgc cccccctgcc ctgcccccga gctgctggga 720
ggccccagcg tgttcctgtt cccccccaag cctaaggaca ccctgatgat cagcagaacc 780
cccgaggtga cctgtgtggt ggtggatgtg agccacgagg accctgaggt gaagttcaac 840
tggtacgtgg acggcgtgga ggtgcacaat gccaagacca agcccaggga ggagcagtac 900
aacagcacct accgggtggt gtccgtgctg accgtgctgc accaggattg gctgaacggc 960
aaggagtaca agtgtaaggt gtccaacaag gccctgcctg cccctatcga gaaaaccatc 1020
agcaaggcca agggccagcc cagagagccc caggtgtaca ccctgccccc tagcagagat 1080
gagctgacca agaaccaggt gtccctgacc tgcctggtga agggcttcta ccccagcgac 1140
atcgccgtgg agtgggagag caacggccag cccgagaaca actacaagac caccccccct 1200
gtgctggaca gcgatggcag cttcttcctg tacagcaagc tgaccgtgga caagagcaga 1260
tggcagcagg gcaacgtgtt cagctgctcc gtgatgcacg aggccctgca caatcactac 1320
acccagaaga gcctgagcct gtcccctggc aagggcgtgc agctcctgga gagcggcgga 1380
ggcctggtcc agcccggcgg cagcctgagg ctgagctgcg ccgccagcgg cttcgtgttc 1440
gcctggtatg atatgggctg ggtgaggcag gcccccggca agggcctgga gtgggtgtcc 1500
agcatcgact ggcacgggga ggtgacctac tacgccgaca gcgtgaaggg caggttcacc 1560
atcagcaggg acaacagcaa gaacaccctg tacctgcaga tgaacagcct gagggccgag 1620
gacaccgcag tgtactactg cgccaccgcc gaggacgaac ccggctacga ctactggggc 1680
cagggcaccc tggtgactgt gagcagc 1707
<210> 256
<211> 1347
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 256
caggtgcagc tcgtccagtc tggggccgag gtgaagaagc ccggagcttc tgtgaaggtg 60
tcctgcaagg ccagcggcta taccttcatc gactacgaga tccattgggt gaggcaggct 120
cccgggcagg gcctggagtg gatgggcgcc atcgacccag agaccggagg cacggcgtac 180
aaccagaagt tcaagggacg ggtcaccatg acaaccgata ccagcacctc caccgcttac 240
atggagctgc gcagcctgag aagcgacgac accgcggtgt actactgtac gcgcatcctg 300
ctctactact accccatgga ttactggggc cagggcacac tagtcacagt ctcctcagcc 360
tccaccaagg gcccatcggt cttccccctg gcaccctcct ccaagagcac ctctgggggc 420
acagcggccc tgggctgcct ggtcaaggac tacttccccg aaccggtgac ggtgtcgtgg 480
aactcaggcg ccctgaccag cggcgtgcac accttcccgg ctgtcctaca gtcctcagga 540
ctctactccc tcagcagcgt ggtgaccgtg ccctccagca gcttgggcac ccagacctac 600
atctgcaacg tgaatcacaa gcccagcaac accaaggtgg acaagaaagt tgagcccaaa 660
tcttgtgaca aaactcacac atgcccaccg tgcccagcac ctgaactcct ggggggaccg 720
tcagtcttcc tcttcccccc aaaacccaag gacaccctca tgatctcccg gacccctgag 780
gtcacatgcg tggtggtgga cgtgagccac gaagaccctg aggtcaagtt caactggtac 840
gtggacggcg tggaggtgca taatgccaag acaaagccgc gggaggagca gtacaacagc 900
acgtaccgtg tggtcagcgt cctcaccgtc ctgcaccagg actggctgaa tggcaaggag 960
tacaagtgca aggtctccaa caaagccctc ccagccccca tcgagaaaac catctccaaa 1020
gccaaagggc agccccgaga accacaggtg tacaccctgc ccccatcccg ggatgagctg 1080
accaagaacc aggtcagcct gacctgcctg gtcaaaggct tctatcccag cgacatcgcc 1140
gtggagtggg agagcaatgg gcagccggag aacaactaca agaccacgcc tcccgtgctg 1200
gactccgacg gctccttctt cctctacagc aagctcaccg tggacaagag caggtggcag 1260
caggggaacg tcttctcatg ctccgtgatg catgaggctc tgcacaacca ctacacgcag 1320
aagagcctct ccctgtctcc gggtaaa 1347
<210> 257
<211> 2088
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 257
caggtgaccc tgagggagag cggccccgcc ctggtgaagc ccacacagac cctcactctg 60
acctgcaccg tgagcggctt cagcctgacc tcctacagcg tccactgggt gaggcagccc 120
cccggcaagg gcctggagtg gctgggcgtg atctgggcaa gcggcggcac cgactacaac 180
agcgccctga tgagcaggct ctccatcagc aaggacacca gccggaacca ggtggtgctg 240
accatgacca acatggaccc cgtggacacc gccacctatt actgcgccag ggaccctccc 300
tctagcctgc tgaggctgga ctactggggc aggggaacac tagtgaccgt gtccagcgcc 360
agcaccaagg gccccagcgt gttccccctg gcccccagca gcaagagcac cagcggcggc 420
acagccgccc tgggctgcct ggtgaaggac tacttccccg aaccggtgac cgtgtcctgg 480
aacagcggag ccctgaccag cggcgtgcac accttccccg ccgtgctgca gagcagcggc 540
ctgtacagcc tgagcagcgt ggtgaccgtg cccagcagca gcctgggcac ccagacctac 600
atctgtaacg tgaaccacaa gcccagcaac accaaggtgg acaagaaggt ggagcccaag 660
agctgtgaca agacccacac ctgccccccc tgccctgccc ccgagctgct gggaggcccc 720
agcgtgttcc tgttcccccc caagcctaag gacaccctga tgatcagcag aacccccgag 780
gtgacctgtg tggtggtgga tgtgagccac gaggaccctg aggtgaagtt caactggtac 840
gtggacggcg tggaggtgca caatgccaag accaagccca gggaggagca gtacaacagc 900
acctaccggg tggtgtccgt gctgaccgtg ctgcaccagg attggctgaa cggcaaggag 960
tacaagtgta aggtgtccaa caaggccctg cctgccccta tcgagaaaac catcagcaag 1020
gccaagggcc agcccagaga gccccaggtg tacaccctgc cccctagcag agatgagctg 1080
accaagaacc aggtgtccct gacctgcctg gtgaagggct tctaccccag cgacatcgcc 1140
gtggagtggg agagcaacgg ccagcccgag aacaactaca agaccacccc ccctgtgctg 1200
gacagcgatg gcagcttctt cctgtacagc aagctgaccg tggacaagag cagatggcag 1260
cagggcaacg tgttcagctg ctccgtgatg cacgaggccc tgcacaatca ctacacccag 1320
aagagcctga gcctgtcccc tggcaagggc ggcggcggat ctggcgtgca gctcctggag 1380
agcggcggag gcctggtcca gcccggcggc agcctgaggc tgagctgcgc cgccagcggc 1440
ttcaccttcg cctggtatga tatgggctgg gtgaggcagg cccccggcaa gggcctggag 1500
tgggtgtcca gcatcgactg gcacggggag gtgacctact acgccgacag cgtgaagggc 1560
aggttcacca tcagcaggga caacagcaag aacaccctgt acctgcagat gaacagcctg 1620
agggccgagg acaccgcagt gtactactgc gccaccgccg aggacgaacc cggctacgac 1680
tactggggcc agggcaccct ggtgactgtg agcagcaccg tggccgcccc ctcgggatcc 1740
gaagtgcagc tcctggagag cggcggcggc ctggtgcagc ccggcggcag cctgaggctg 1800
agctgcgccg ctagcggctt caccttcagg aacttcggca tgggctgggt caggcaggcc 1860
cccggcaagg gcctggagtg ggtcagctgg atcatcagct ccggcaccga gacctactac 1920
gccgacagcg tgaagggcag gttcaccatc agccgcgaca acagcaagaa caccctgtac 1980
ctgcagatga acagcctgag ggccgaggac accgccgtct actactgcgc caagagcctg 2040
ggcaggttcg actactgggg acaggggacc ctggtgactg tgagcagc 2088
<210> 258
<211> 2079
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 258
caggtgcagc tgcagcagcc tggagccgag ctggtgaagc ccggcgccag cgtgaaaatg 60
tcctgcaagg ccagcggcta caccttcacc agctacaaca tgcactgggt gaagcagacc 120
cccggcaggg gcctcgagtg gatcggagct atctaccccg gcaacggcga cactagctac 180
aaccagaagt tcaagggcaa ggccaccctg accgccgaca agagcagcag caccgcctac 240
atgcagctga gcagcctgac cagcgaggac agcgccgtgt attactgcgc caggagcacc 300
tactacggcg gcgactggta cttcaacgtc tggggcgccg gcacactagt gaccgtgtcc 360
agcgccagca ccaagggccc cagcgtgttc cccctggccc ccagcagcaa gagcaccagc 420
ggcggcacag ccgccctggg ctgcctggtg aaggactact tccccgaacc ggtgaccgtg 480
tcctggaaca gcggagccct gaccagcggc gtgcacacct tccccgccgt gctgcagagc 540
agcggcctgt acagcctgag cagcgtggtg accgtgccca gcagcagcct gggcacccag 600
acctacatct gtaacgtgaa ccacaagccc agcaacacca aggtggacaa gaaggtggag 660
cccaagagct gtgacaagac ccacacctgc cccccctgcc ctgcccccga gctgctggga 720
ggccccagcg tgttcctgtt cccccccaag cctaaggaca ccctgatgat cagcagaacc 780
cccgaggtga cctgtgtggt ggtggatgtg agccacgagg accctgaggt gaagttcaac 840
tggtacgtgg acggcgtgga ggtgcacaat gccaagacca agcccaggga ggagcagtac 900
aacagcacct accgggtggt gtccgtgctg accgtgctgc accaggattg gctgaacggc 960
aaggagtaca agtgtaaggt gtccaacaag gccctgcctg cccctatcga gaaaaccatc 1020
agcaaggcca agggccagcc cagagagccc caggtgtaca ccctgccccc tagcagagat 1080
gagctgacca agaaccaggt gtccctgacc tgcctggtga agggcttcta ccccagcgac 1140
atcgccgtgg agtgggagag caacggccag cccgagaaca actacaagac caccccccct 1200
gtgctggaca gcgatggcag cttcttcctg tacagcaagc tgaccgtgga caagagcaga 1260
tggcagcagg gcaacgtgtt cagctgctcc gtgatgcacg aggccctgca caatcactac 1320
acccagaaga gcctgagcct gtcccctggc aagaccgtgg ccgccccctc gggatctgac 1380
atccagatga cccagagccc cagcagcctg agcgccagcg tgggcgacag ggtgaccatt 1440
acctgcaggg ccagcaggcc catcagcgac tggctgcact ggtaccaaca gaagcccggc 1500
aaggctccca agctgctgat cgcctgggcc agcagcctgc agggaggcgt gcccagcagg 1560
tttagcggca gcggcagcgg caccgacttc accctcacca tctcttccct gcagcccgag 1620
gacttcgcca cctactactg cctgcaggag ggctgggggc cccctacttt cggccagggc 1680
accaaggtgg agatcaagag gaccgtggcc gccccctcgg gatccggcgt gcagctcctg 1740
gagagcggcg gaggcctggt ccagcccggc ggcagcctga ggctgagctg cgccgccagc 1800
ggcttcacct tcgcctggta tgatatgggc tgggtgaggc aggcccccgg caagggcctg 1860
gagtgggtgt ccagcatcga ctggcacggg gaggtgacct actacgccga cagcgtgaag 1920
ggcaggttca ccatcagcag ggacaacagc aagaacaccc tgtacctgca gatgaacagc 1980
ctgagggccg aggacaccgc agtgtactac tgcgccaccg ccgaggacga acccggctac 2040
gactactggg gccagggcac cctggtgact gtgagcagc 2079
<210> 259
<211> 2103
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 259
caggtgcagc tgcagcagcc tggagccgag ctggtgaagc ccggcgccag cgtgaaaatg 60
tcctgcaagg ccagcggcta caccttcacc agctacaaca tgcactgggt gaagcagacc 120
cccggcaggg gcctcgagtg gatcggagct atctaccccg gcaacggcga cactagctac 180
aaccagaagt tcaagggcaa ggccaccctg accgccgaca agagcagcag caccgcctac 240
atgcagctga gcagcctgac cagcgaggac agcgccgtgt attactgcgc caggagcacc 300
tactacggcg gcgactggta cttcaacgtc tggggcgccg gcacactagt gaccgtgtcc 360
agcgccagca ccaagggccc cagcgtgttc cccctggccc ccagcagcaa gagcaccagc 420
ggcggcacag ccgccctggg ctgcctggtg aaggactact tccccgaacc ggtgaccgtg 480
tcctggaaca gcggagccct gaccagcggc gtgcacacct tccccgccgt gctgcagagc 540
agcggcctgt acagcctgag cagcgtggtg accgtgccca gcagcagcct gggcacccag 600
acctacatct gtaacgtgaa ccacaagccc agcaacacca aggtggacaa gaaggtggag 660
cccaagagct gtgacaagac ccacacctgc cccccctgcc ctgcccccga gctgctggga 720
ggccccagcg tgttcctgtt cccccccaag cctaaggaca ccctgatgat cagcagaacc 780
cccgaggtga cctgtgtggt ggtggatgtg agccacgagg accctgaggt gaagttcaac 840
tggtacgtgg acggcgtgga ggtgcacaat gccaagacca agcccaggga ggagcagtac 900
aacagcacct accgggtggt gtccgtgctg accgtgctgc accaggattg gctgaacggc 960
aaggagtaca agtgtaaggt gtccaacaag gccctgcctg cccctatcga gaaaaccatc 1020
agcaaggcca agggccagcc cagagagccc caggtgtaca ccctgccccc tagcagagat 1080
gagctgacca agaaccaggt gtccctgacc tgcctggtga agggcttcta ccccagcgac 1140
atcgccgtgg agtgggagag caacggccag cccgagaaca actacaagac caccccccct 1200
gtgctggaca gcgatggcag cttcttcctg tacagcaagc tgaccgtgga caagagcaga 1260
tggcagcagg gcaacgtgtt cagctgctcc gtgatgcacg aggccctgca caatcactac 1320
acccagaaga gcctgagcct gtcccctggc aagaccgtgg ccgccccctc gggatctgaa 1380
gtgcagctcc tggagagcgg cggcggcctg gtgcagcccg gcggcagcct gaggctgagc 1440
tgcgccgcta gcggcttcac cttcaggaac ttcggcatgg gctgggtcag gcaggccccc 1500
ggcaagggcc tggagtgggt cagctggatc atcagctccg gcaccgagac ctactacgcc 1560
gacagcgtga agggcaggtt caccatcagc cgcgacaaca gcaagaacac cctgtacctg 1620
cagatgaaca gcctgagggc cgaggacacc gccgtctact actgcgccaa gagcctgggc 1680
aggttcgact actggggaca ggggaccctg gtgactgtga gcagcaccgt ggccgccccc 1740
tcgggatccg gcgtgcagct cctggagagc ggcggaggcc tggtccagcc cggcggcagc 1800
ctgaggctga gctgcgccgc cagcggcttc accttcgcct ggtatgatat gggctgggtg 1860
aggcaggccc ccggcaaggg cctggagtgg gtgtccagca tcgactggca cggggaggtg 1920
acctactacg ccgacagcgt gaagggcagg ttcaccatca gcagggacaa cagcaagaac 1980
accctgtacc tgcagatgaa cagcctgagg gccgaggaca ccgcagtgta ctactgcgcc 2040
accgccgagg acgaacccgg ctacgactac tggggccagg gcaccctggt gactgtgagc 2100
agc 2103
<210> 260
<211> 1701
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 260
gaggtgcagc tggtggaaag cggcggcggc ctggtgcagc ccggcggctc cctgaggctg 60
agctgcgccg ctagcggcta caccttcacc agctactggc tccactgggt caggcaggcc 120
ccaggcaagg gactggagtg ggtgggcatg atcgacccca gcaacagcga caccaggttc 180
aaccccaact tcaaggacag gttcaccatc agcgccgaca ctagcaagaa caccgcctac 240
ctgcagatga acagcctgag ggccgaggac accgccgtgt attactgcgc cacctacagg 300
agctacgtca cccccctgga ttactggggc cagggcacac tagtgaccgt gtccagcgcc 360
agcaccaagg gccccagcgt gttccccctg gcccccagca gcaagagcac cagcggcggc 420
acagccgccc tgggctgcct ggtgaaggac tacttccccg aaccggtgac cgtgtcctgg 480
aacagcggag ccctgaccag cggcgtgcac accttccccg ccgtgctgca gagcagcggc 540
ctgtacagcc tgagcagcgt ggtgaccgtg cccagcagca gcctgggcac ccagacctac 600
atctgtaacg tgaaccacaa gcccagcaac accaaggtgg acaagaaggt ggagcccaag 660
agctgtgaca agacccacac ctgccccccc tgccctgccc ccgagctgct gggaggcccc 720
agcgtgttcc tgttcccccc caagcctaag gacaccctga tgatcagcag aacccccgag 780
gtgacctgtg tggtggtgga tgtgagccac gaggaccctg aggtgaagtt caactggtac 840
gtggacggcg tggaggtgca caatgccaag accaagccca gggaggagca gtacaacagc 900
acctaccggg tggtgtccgt gctgaccgtg ctgcaccagg attggctgaa cggcaaggag 960
tacaagtgta aggtgtccaa caaggccctg cctgccccta tcgagaaaac catcagcaag 1020
gccaagggcc agcccagaga gccccaggtg tacaccctgc cccctagcag agatgagctg 1080
accaagaacc aggtgtccct gagctgcgcc gtgaagggct tctaccccag cgacatcgcc 1140
gtggagtggg agagcaacgg ccagcccgag aacaactaca agaccacccc ccctgtgctg 1200
gacagcgatg gcagcttctt cctggtgagc aagctgaccg tggacaagag cagatggcag 1260
cagggcaacg tgttcagctg ctccgtgatg cacgaggccc tgcacaatca ctacacccag 1320
aagagcctga gcctgtcccc tggcaaggga tccgaggtgc agctcctggt cagcggcggc 1380
ggcctggtcc agcccggagg ctcactgagg ctgagctgcg ccgctagcgg cttcaccttc 1440
aaggcctacc ccatgatgtg ggtcaggcag gcccccggca aaggcctgga gtgggtgtct 1500
gagatcagcc ccagcggcag ctacacctac tacgccgaca gcgtgaaggg caggttcacc 1560
atcagcaggg acaacagcaa gaacaccctg tacctgcaga tgaactctct gagggccgag 1620
gacaccgccg tgtactactg cgccaaggac cccaggaagc tggactattg gggccagggc 1680
actctggtga ccgtgagcag c 1701
<210> 261
<211> 1020
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 261
tgccccccct gccctgcccc cgagctgctg ggaggcccca gcgtgttcct gttccccccc 60
aagcctaagg acaccctgat gatcagcaga acccccgagg tgacctgtgt ggtggtggat 120
gtgagccacg aggaccctga ggtgaagttc aactggtacg tggacggcgt ggaggtgcac 180
aatgccaaga ccaagcccag ggaggagcag tacaacagca cctaccgggt ggtgtccgtg 240
ctgaccgtgc tgcaccagga ttggctgaac ggcaaggagt acaagtgtaa ggtgtccaac 300
aaggccctgc ctgcccctat cgagaaaacc atcagcaagg ccaagggcca gcccagagag 360
ccccaggtgt acaccctgcc ccctagcaga gatgagctga ccaagaacca ggtgtccctg 420
tggtgcctgg tgaagggctt ctaccccagc gacatcgccg tggagtggga gagcaacggc 480
cagcccgaga acaactacaa gaccaccccc cctgtgctgg acagcgatgg cagcttcttc 540
ctgtacagca agctgaccgt ggacaagagc agatggcagc agggcaacgt gttcagctgc 600
tccgtgatgc acgaggccct gcacaatcac tacacccaga agagcctgag cctgtcccct 660
ggcaagggat ccgaggtgca gctcctggtc agcggcggcg gcctggtcca gcccggaggc 720
tcactgaggc tgagctgcgc cgctagcggc ttcaccttca aggcctaccc catgatgtgg 780
gtcaggcagg cccccggcaa aggcctggag tgggtgtctg agatcagccc cagcggcagc 840
tacacctact acgccgacag cgtgaagggc aggttcacca tcagcaggga caacagcaag 900
aacaccctgt acctgcagat gaactctctg agggccgagg acaccgccgt gtactactgc 960
gccaaggacc ccaggaagct ggactattgg ggccagggca ctctggtgac cgtgagcagc 1020
<210> 262
<211> 660
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 262
gacatccaga tgacccagag ccccagcagc ctgagcgcct cagtgggaga cagggtgacc 60
atcacctgca agagcagcca gagcctcctg tacaccagca gccagaagaa ctacctggcc 120
tggtaccagc agaaacccgg caaggccccc aagctgctga tctactgggc tagcaccagg 180
gagtcaggcg tgcccagcag gttcagcggc agcggcagcg gcaccgactt cactctgacc 240
atcagcagcc tgcagcccga ggacttcgcc acctactact gccagcagta ctacgcctat 300
ccctggacct tcggccaggg caccaaggtg gagatcaagc gtacggtggc cgcccccagc 360
gtgttcatct tcccccccag cgatgagcag ctgaagagcg gcaccgccag cgtggtgtgt 420
ctgctgaaca acttctaccc ccgggaggcc aaggtgcagt ggaaggtgga caatgccctg 480
cagagcggca acagccagga gagcgtgacc gagcaggaca gcaaggactc cacctacagc 540
ctgagcagca ccctgaccct gagcaaggcc gactacgaga agcacaaggt gtacgcctgt 600
gaggtgaccc accagggcct gtccagcccc gtgaccaaga gcttcaaccg gggcgagtgc 660
<210> 263
<211> 1656
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 263
gaggtgcagc tggtggaaag cggcggcggc ctggtgcagc ccggcggctc cctgaggctg 60
agctgcgccg ctagcggcta caccttcacc agctactggc tccactgggt caggcaggcc 120
ccaggcaagg gactggagtg ggtgggcatg atcgacccca gcaacagcga caccaggttc 180
aaccccaact tcaaggacag gttcaccatc agcgccgaca ctagcaagaa caccgcctac 240
ctgcagatga acagcctgag ggccgaggac accgccgtgt attactgcgc cacctacagg 300
agctacgtca cccccctgga ttactggggc cagggcacac tagtcaccgt gagcagcgcc 360
agcaccaagg gccccagcgt gttccccctg gccccctgca gcagaagcac cagcgagagc 420
acagccgccc tgggctgcct ggtgaaggac tacttccccg agcccgtgac cgtgagctgg 480
aacagcggag ccctgaccag cggcgtgcac accttccccg ccgtgctgca gagcagcggc 540
ctgtacagcc tgagcagcgt ggtgaccgtg cccagcagca gcctgggcac caagacctac 600
acctgcaacg tggaccacaa gcccagcaac accaaggtgg acaagcgggt ggcccccgag 660
ttcctgggcg gaccctccgt gttcctgttc ccccccaagc ccaaggacac cctgatgatc 720
agccggaccc ccgaggtgac ctgcgtggtg gtggacgtga gccaggaaga tcccgaggtc 780
cagttcaatt ggtacgtgga cggcgtggag gtgcacaacg ccaagaccaa gccccgggag 840
gaacagttca acagcaccta ccgggtggtg tccgtgctga ccgtgctgca ccaggactgg 900
ctgaacggca aagaatacaa gtgcaaggtg tccaacaagg gcctgcccag ctccatcgag 960
aaaaccatca gcaaggccaa gggccagcct cgggagcccc aggtgtacac cctgccccca 1020
tcccaggaag agatgaccaa gaaccaggtg tccctgacct gtctggtgaa gggcttctac 1080
cccagcgaca tcgccgtgga gtgggagagc aacggccagc ccgagaacaa ctacaagacc 1140
accccccctg tgctggacag cgacggcagc ttcttcctgt acagcaggct gaccgtggac 1200
aagagccggt ggcaggaagg caacgtcttt agctgcagcg tgatgcacga ggccctgcac 1260
aaccactaca cccagaagag cctgagcctg tccctgggca agggatccga ggtgcagctc 1320
ctggtcagcg gcggcggcct ggtccagccc ggaggctcac tgaggctgag ctgcgccgct 1380
agcggcttca ccttcaaggc ctaccccatg atgtgggtca ggcaggcccc cggcaaaggc 1440
ctggagtggg tgtctgagat cagccccagc ggcagctaca cctactacgc cgacagcgtg 1500
aagggcaggt tcaccatcag cagggacaac agcaagaaca ccctgtacct gcagatgaac 1560
tctctgaggg ccgaggacac cgccgtgtac tactgcgcca aggaccccag gaagctggac 1620
tattggggcc agggcactct ggtgaccgtg agcagc 1656
<210> 264
<211> 1347
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 264
gaggtgcagc tggtggaaag cggcggcggc ctggtgcagc ccggcggctc cctgaggctg 60
agctgcgccg ctagcggcta caccttcacc agctactggc tccactgggt caggcaggcc 120
ccaggcaagg gactggagtg ggtgggcatg atcgacccca gcaacagcga caccaggttc 180
aaccccaact tcaaggacag gttcaccatc agcgccgaca ctagcaagaa caccgcctac 240
ctgcagatga acagcctgag ggccgaggac accgccgtgt attactgcgc cacctacagg 300
agctacgtca cccccctgga ttactggggc cagggcacac tagtgaccgt gtccagcgcc 360
agcaccaagg gccccagcgt gttccccctg gcccccagca gcaagagcac cagcggcggc 420
acagccgccc tgggctgcct ggtgaaggac tacttccccg aaccggtgac cgtgtcctgg 480
aacagcggag ccctgaccag cggcgtgcac accttccccg ccgtgctgca gagcagcggc 540
ctgtacagcc tgagcagcgt ggtgaccgtg cccagcagca gcctgggcac ccagacctac 600
atctgtaacg tgaaccacaa gcccagcaac accaaggtgg acaagaaggt ggagcccaag 660
agctgtgaca agacccacac ctgccccccc tgccctgccc ccgagctgct gggaggcccc 720
agcgtgttcc tgttcccccc caagcctaag gacaccctga tgatcagcag aacccccgag 780
gtgacctgtg tggtggtgga tgtgagccac gaggaccctg aggtgaagtt caactggtac 840
gtggacggcg tggaggtgca caatgccaag accaagccca gggaggagca gtacaacagc 900
acctaccggg tggtgtccgt gctgaccgtg ctgcaccagg attggctgaa cggcaaggag 960
tacaagtgta aggtgtccaa caaggccctg cctgccccta tcgagaaaac catcagcaag 1020
gccaagggcc agcccagaga gccccaggtg tacaccctgc cccctagcag agatgagctg 1080
accaagaacc aggtgtccct gagctgcgcc gtgaagggct tctaccccag cgacatcgcc 1140
gtggagtggg agagcaacgg ccagcccgag aacaactaca agaccacccc ccctgtgctg 1200
gacagcgatg gcagcttctt cctggtgagc aagctgaccg tggacaagag cagatggcag 1260
cagggcaacg tgttcagctg ctccgtgatg cacgaggccc tgcacaatca ctacacccag 1320
aagagcctga gcctgtcccc tggcaag 1347
<210> 265
<211> 666
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 265
tgccccccct gccctgcccc cgagctgctg ggaggcccca gcgtgttcct gttccccccc 60
aagcctaagg acaccctgat gatcagcaga acccccgagg tgacctgtgt ggtggtggat 120
gtgagccacg aggaccctga ggtgaagttc aactggtacg tggacggcgt ggaggtgcac 180
aatgccaaga ccaagcccag ggaggagcag tacaacagca cctaccgggt ggtgtccgtg 240
ctgaccgtgc tgcaccagga ttggctgaac ggcaaggagt acaagtgtaa ggtgtccaac 300
aaggccctgc ctgcccctat cgagaaaacc atcagcaagg ccaagggcca gcccagagag 360
ccccaggtgt acaccctgcc ccctagcaga gatgagctga ccaagaacca ggtgtccctg 420
tggtgcctgg tgaagggctt ctaccccagc gacatcgccg tggagtggga gagcaacggc 480
cagcccgaga acaactacaa gaccaccccc cctgtgctgg acagcgatgg cagcttcttc 540
ctgtacagca agctgaccgt ggacaagagc agatggcagc agggcaacgt gttcagctgc 600
tccgtgatgc acgaggccct gcacaatcac tacacccaga agagcctgag cctgtcccct 660
ggcaag 666
<210> 266
<211> 1302
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 266
gaggtgcagc tggtggaaag cggcggcggc ctggtgcagc ccggcggctc cctgaggctg 60
agctgcgccg ctagcggcta caccttcacc agctactggc tccactgggt caggcaggcc 120
ccaggcaagg gactggagtg ggtgggcatg atcgacccca gcaacagcga caccaggttc 180
aaccccaact tcaaggacag gttcaccatc agcgccgaca ctagcaagaa caccgcctac 240
ctgcagatga acagcctgag ggccgaggac accgccgtgt attactgcgc cacctacagg 300
agctacgtca cccccctgga ttactggggc cagggcacac tagtcaccgt gagcagcgcc 360
agcaccaagg gccccagcgt gttccccctg gccccctgca gcagaagcac cagcgagagc 420
acagccgccc tgggctgcct ggtgaaggac tacttccccg agcccgtgac cgtgagctgg 480
aacagcggag ccctgaccag cggcgtgcac accttccccg ccgtgctgca gagcagcggc 540
ctgtacagcc tgagcagcgt ggtgaccgtg cccagcagca gcctgggcac caagacctac 600
acctgcaacg tggaccacaa gcccagcaac accaaggtgg acaagcgggt ggcccccgag 660
ttcctgggcg gaccctccgt gttcctgttc ccccccaagc ccaaggacac cctgatgatc 720
agccggaccc ccgaggtgac ctgcgtggtg gtggacgtga gccaggaaga tcccgaggtc 780
cagttcaatt ggtacgtgga cggcgtggag gtgcacaacg ccaagaccaa gccccgggag 840
gaacagttca acagcaccta ccgggtggtg tccgtgctga ccgtgctgca ccaggactgg 900
ctgaacggca aagaatacaa gtgcaaggtg tccaacaagg gcctgcccag ctccatcgag 960
aaaaccatca gcaaggccaa gggccagcct cgggagcccc aggtgtacac cctgccccca 1020
tcccaggaag agatgaccaa gaaccaggtg tccctgacct gtctggtgaa gggcttctac 1080
cccagcgaca tcgccgtgga gtgggagagc aacggccagc ccgagaacaa ctacaagacc 1140
accccccctg tgctggacag cgacggcagc ttcttcctgt acagcaggct gaccgtggac 1200
aagagccggt ggcaggaagg caacgtcttt agctgcagcg tgatgcacga ggccctgcac 1260
aaccactaca cccagaagag cctgagcctg tccctgggca ag 1302
<210> 267
<211> 1701
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 267
caggtgaccc tgagggagag cggccccgcc ctggtgaagc ccacccagac cctgaccctg 60
acctgcacct tcagcggctt tagcctcagc acctccggca tgggcgtgag ctggatcagg 120
cagccacccg gcaaaggcct ggagtggctg gcccacatct actgggacga cgacaagagg 180
tacaacccca gcctgaagag ccggctgacc atcagcaagg ataccagcag gaaccaggtg 240
gtgctgacca tgaccaacat ggaccccgtg gacaccgcta cctactactg cgccaggagg 300
gagaccgtct tctactggta cttcgacgtg tggggaaggg gcacactagt caccgtgagc 360
agcgccagca ccaagggccc cagcgtgttc cccctggccc cctgcagcag aagcaccagc 420
gagagcacag ccgccctggg ctgcctggtg aaggactact tccccgagcc cgtgaccgtg 480
agctggaaca gcggagccct gaccagcggc gtgcacacct tccccgccgt gctgcagagc 540
agcggcctgt acagcctgag cagcgtggtg accgtgccca gcagcaactt cggcacccag 600
acctacacct gcaacgtgga ccacaagccc agcaacacca aggtggacaa gaccgtggag 660
cggaagtgct gcgtggagtg ccccccctgc cctgcccctc ctgtggccgg accctccgtg 720
ttcctgttcc cccccaagcc caaggacacc ctgatgatca gccggacccc cgaggtgacc 780
tgcgtggtgg tggacgtgag ccacgaggac cccgaggtgc agttcaattg gtacgtggac 840
ggcgtggagg tgcacaacgc caagaccaag ccccgggagg aacagttcaa cagcaccttc 900
cgggtggtgt ccgtgctgac cgtggtgcac caggactggc tgaacggcaa agaatacaag 960
tgcaaggtgt ccaacaaggg cctgcctgcc cccatcgaga aaaccatcag caagaccaag 1020
ggccagccca gggaacccca ggtgtacacc ctgcccccca gccgggagga aatgaccaag 1080
aaccaggtgt ccctgacctg tctggtgaag ggcttctacc ccagcgacat cgccgtggag 1140
tgggagagca acggccagcc cgagaacaac tacaagacca ccccccccat gctggacagc 1200
gacggcagct tcttcctgta cagcaagctg acagtggaca agagccggtg gcagcagggc 1260
aacgtgttca gctgcagcgt gatgcacgag gccctgcaca accactacac ccagaagagc 1320
ctgagcctgt cccccggcaa gggatccggc gtgcagctcc tggagagcgg cggaggcctg 1380
gtccagcccg gcggcagcct gaggctgagc tgcgccgcca gcggcttcac cttcgcctgg 1440
tatgatatgg gctgggtgag gcaggccccc ggcaagggcc tggagtgggt gtccagcatc 1500
gactggcacg gggaggtgac ctactacgcc gacagcgtga agggcaggtt caccatcagc 1560
agggacaaca gcaagaacac cctgtacctg cagatgaaca gcctgagggc cgaggacacc 1620
gcagtgtact actgcgccac cgccgaggac gaacccggct acgactactg gggccagggc 1680
accctggtga ctgtgagcag c 1701
<210> 268
<211> 1704
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 268
caggtgaccc tgagggagag cggccccgcc ctggtgaagc ccacccagac cctgaccctg 60
acctgcacct tcagcggctt tagcctcagc acctccggca tgggcgtgag ctggatcagg 120
cagccacccg gcaaaggcct ggagtggctg gcccacatct actgggacga cgacaagagg 180
tacaacccca gcctgaagag ccggctgacc atcagcaagg ataccagcag gaaccaggtg 240
gtgctgacca tgaccaacat ggaccccgtg gacaccgcta cctactactg cgccaggagg 300
gagaccgtct tctactggta cttcgacgtg tggggaaggg gcacactagt caccgtgagc 360
agcgccagca ccaagggccc cagcgtgttc cccctggccc cctgcagcag aagcaccagc 420
gagagcacag ccgccctggg ctgcctggtg aaggactact tccccgagcc cgtgaccgtg 480
agctggaaca gcggagccct gaccagcggc gtgcacacct tccccgccgt gctgcagagc 540
agcggcctgt acagcctgag cagcgtggtg accgtgccca gcagcagcct gggcaccaag 600
acctacacct gcaacgtgga ccacaagccc agcaacacca aggtggacaa gcgggtggag 660
agcaagtacg gccctccctg ccccagctgc cctgcccccg agttcctggg cggaccctcc 720
gtgttcctgt tcccccccaa gcccaaggac accctgatga tcagccggac ccccgaggtg 780
acctgcgtgg tggtggacgt gagccaggaa gatcccgagg tccagttcaa ttggtacgtg 840
gacggcgtgg aggtgcacaa cgccaagacc aagccccggg aggaacagtt caacagcacc 900
taccgggtgg tgtccgtgct gaccgtgctg caccaggact ggctgaacgg caaagaatac 960
aagtgcaagg tgtccaacaa gggcctgccc agctccatcg agaaaaccat cagcaaggcc 1020
aagggccagc ctcgggagcc ccaggtgtac accctgcccc catcccagga agagatgacc 1080
aagaaccagg tgtccctgac ctgtctggtg aagggcttct accccagcga catcgccgtg 1140
gagtgggaga gcaacggcca gcccgagaac aactacaaga ccaccccccc tgtgctggac 1200
agcgacggca gcttcttcct gtacagcagg ctgaccgtgg acaagagccg gtggcaggaa 1260
ggcaacgtct ttagctgcag cgtgatgcac gaggccctgc acaaccacta cacccagaag 1320
agcctgagcc tgtccctggg caagggatcc ggcgtgcagc tcctggagag cggcggaggc 1380
ctggtccagc ccggcggcag cctgaggctg agctgcgccg ccagcggctt caccttcgcc 1440
tggtatgata tgggctgggt gaggcaggcc cccggcaagg gcctggagtg ggtgtccagc 1500
atcgactggc acggggaggt gacctactac gccgacagcg tgaagggcag gttcaccatc 1560
agcagggaca acagcaagaa caccctgtac ctgcagatga acagcctgag ggccgaggac 1620
accgcagtgt actactgcgc caccgccgag gacgaacccg gctacgacta ctggggccag 1680
ggcaccctgg tgactgtgag cagc 1704
<210> 269
<211> 1704
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 269
caggtgaccc tgagggagag cggccccgcc ctggtgaagc ccacccagac cctgaccctg 60
acctgcacct tcagcggctt tagcctcagc acctccggca tgggcgtgag ctggatcagg 120
cagccacccg gcaaaggcct ggagtggctg gcccacatct actgggacga cgacaagagg 180
tacaacccca gcctgaagag ccggctgacc atcagcaagg ataccagcag gaaccaggtg 240
gtgctgacca tgaccaacat ggaccccgtg gacaccgcta cctactactg cgccaggagg 300
gagaccgtct tctactggta cttcgacgtg tggggaaggg gcacactagt caccgtgagc 360
agcgccagca ccaagggccc cagcgtgttc cccctggccc cctgcagcag aagcaccagc 420
gagagcacag ccgccctggg ctgcctggtg aaggactact tccccgagcc cgtgaccgtg 480
agctggaaca gcggagccct gaccagcggc gtgcacacct tccccgccgt gctgcagagc 540
agcggcctgt acagcctgag cagcgtggtg accgtgccca gcagcagcct gggcaccaag 600
acctacacct gcaacgtgga ccacaagccc agcaacacca aggtggacaa gcgggtggag 660
agcaagtacg gccctccctg ccccccctgc cctgcccccg agttcgaggg cggaccctcc 720
gtgttcctgt tcccccccaa gcccaaggac accctgatga tcagccggac ccccgaggtg 780
acctgcgtgg tggtggacgt gagccaggaa gatcccgagg tccagttcaa ttggtacgtg 840
gacggcgtgg aggtgcacaa cgccaagacc aagccccggg aggaacagtt caacagcacc 900
taccgggtgg tgtccgtgct gaccgtgctg caccaggact ggctgaacgg caaagaatac 960
aagtgcaagg tgtccaacaa gggcctgccc agctccatcg agaaaaccat cagcaaggcc 1020
aagggccagc ctcgggagcc ccaggtgtac accctgcccc catcccagga agagatgacc 1080
aagaaccagg tgtccctgac ctgtctggtg aagggcttct accccagcga catcgccgtg 1140
gagtgggaga gcaacggcca gcccgagaac aactacaaga ccaccccccc tgtgctggac 1200
agcgacggca gcttcttcct gtacagcagg ctgaccgtgg acaagagccg gtggcaggaa 1260
ggcaacgtct ttagctgcag cgtgatgcac gaggccctgc acaaccacta cacccagaag 1320
agcctgagcc tgtccctggg caagggatcc ggcgtgcagc tcctggagag cggcggaggc 1380
ctggtccagc ccggcggcag cctgaggctg agctgcgccg ccagcggctt caccttcgcc 1440
tggtatgata tgggctgggt gaggcaggcc cccggcaagg gcctggagtg ggtgtccagc 1500
atcgactggc acggggaggt gacctactac gccgacagcg tgaagggcag gttcaccatc 1560
agcagggaca acagcaagaa caccctgtac ctgcagatga acagcctgag ggccgaggac 1620
accgcagtgt actactgcgc caccgccgag gacgaacccg gctacgacta ctggggccag 1680
ggcaccctgg tgactgtgag cagc 1704
<210> 270
<211> 1641
<212> DNA
<213> 人工序列
<220>
<223> 人源化的
<400> 270
caggtgaccc tgagggagag cggccccgcc ctggtgaagc ccacccagac cctgaccctg 60
acctgcacct tcagcggctt tagcctcagc acctccggca tgggcgtgag ctggatcagg 120
cagccacccg gcaaaggcct ggagtggctg gcccacatct actgggacga cgacaagagg 180
tacaacccca gcctgaagag ccggctgacc atcagcaagg ataccagcag gaaccaggtg 240
gtgctgacca tgaccaacat ggaccccgtg gacaccgcta cctactactg cgccaggagg 300
gagaccgtct tctactggta cttcgacgtg tggggaaggg gcacactagt gaccgtgtcc 360
agcgccagca ccaagggccc cagcgtgttc cccctggccc ccagcagcaa gagcaccagc 420
ggcggcacag ccgccctggg ctgcctggtg aaggactact tccccgaacc ggtgaccgtg 480
tcctggaaca gcggagccct gaccagcggc gtgcacacct tccccgccgt gctgcagagc 540
agcggcctgt acagcctgag cagcgtggtg accgtgccca gcagcagcct gggcacccag 600
acctacatct gtaacgtgaa ccacaagccc agcaacacca aggtggacaa gaaggtggag 660
cccaagagct gtgacaagac ccacacctgc cccccctgcc ctgcccccga gctgctggga 720
ggccccagcg tgttcctgtt cccccccaag cctaaggaca ccctgatgat cagcagaacc 780
cccgaggtga cctgtgtggt ggtggatgtg agccacgagg accctgaggt gaagttcaac 840
tggtacgtgg acggcgtgga ggtgcacaat gccaagacca agcccaggga ggagcagtac 900
aacagcacct accgggtggt gtccgtgctg accgtgctgc accaggattg gctgaacggc 960
aaggagtaca agtgtaaggt gtccaacaag gccctgcctg cccctatcga gaaaaccatc 1020
agcaaggcca agggccagcc cagagagccc caggtgtaca ccctgccccc tagcagagat 1080
gagctgacca agaaccaggt gtccctgacc tgcctggtga agggcttcta ccccagcgac 1140
atcgccgtgg agtgggagag caacggccag cccgagaaca actacaagac caccccccct 1200
gtgctggaca gcgatggcag cttcttcctg tacagcaagc tgaccgtgga caagagcaga 1260
tggcagcagg gcaacgtgtt cagctgctcc gtgatgcacg aggccctgca caatcactac 1320
acccagaaga gcctgagcct gtcccctggc aagggatccg tgagcgacgt gccaagggac 1380
ctcgaggtgg tggcagccac tcccacctct ctgctgatca gctgggacac acacaacgcc 1440
tacaacggct actacaggat cacctacgga gagaccggcg gcaatagccc cgtgagggag 1500
ttcaccgtgc cccaccccga ggtgaccgcc accattagcg gcctgaagcc cggcgtggac 1560
gataccatca ccgtctacgc cgtgaccaac caccacatgc ccctgaggat cttcggcccc 1620
atcagcatca accataggac c 1641
Claims (10)
1.抗原结合构建体,所述抗原结合构建体包含连接到一个或多个表位结合结构域的蛋白质骨架,其中所述抗原结合构建体具有至少两个抗原结合位点,其中至少一个来自表位结合结构域,并且其中至少一个来自配对的VH/VL结构域,以及其中所述表位结合结构域选自非Ig骨架。
2.权利要求1的抗原结合构建体,其中至少一个表位结合结构域源自选自以下的骨架:CTLA-4 (Evibody);脂质运载蛋白;源自蛋白A的分子,例如蛋白A的Z-结构域(Affibody, SpA)、A-结构域(Avimer/Maxibody);热休克蛋白,例如GroEl和GroES;转铁蛋白 (trans-body);锚蛋白重复蛋白(DARPin);肽适体;C-型凝集素结构域(四连凝集素);人γ-晶体蛋白和人泛素(affilin);PDZ结构域;人蛋白酶抑制剂蝎毒素kunitz型结构域;和纤连蛋白 (adnectin)。
3.权利要求2的抗原结合构建体,其中所述表位结合结构域来源于选自Affibody、锚蛋白重复蛋白(DARPin)和adnectin的骨架。
4.前述权利要求中任一项的抗原结合构建体,其中所述结合构建体对不止一种抗原具有特异性。
5.前述权利要求中任一项的抗原结合构建体,其中所述第一结合位点对抗原上的第一表位具有特异性,所述第二结合位点对同一抗原上的第二表位具有特异性。
6.前述权利要求中任一项的抗原结合构建体,其中所述抗原结合构建体能够结合IL-13。
7.前述权利要求中任一项的抗原结合构建体,其中所述抗原结合构建体能够结合两种或更多种选自IL-13、IL-5和IL-4的抗原。
8.前述权利要求中任一项的抗原结合构建体,其中所述抗原结合构建体能够结合两种或更多种选自VEGF、IGF-1R和EGFR的抗原。
9.前述权利要求中任一项的抗原结合构建体,其中所述抗原结合构建体能够结合TNF。
10.前述权利要求中任一项的抗原结合构建体,其中所述蛋白质骨架为Ig骨架。
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US99144907P | 2007-11-30 | 2007-11-30 | |
US60/991449 | 2007-11-30 | ||
US2785808P | 2008-02-12 | 2008-02-12 | |
US61/027858 | 2008-02-12 | ||
US4657208P | 2008-04-21 | 2008-04-21 | |
US61/046572 | 2008-04-21 | ||
US8119108P | 2008-07-16 | 2008-07-16 | |
US61/081191 | 2008-07-16 | ||
US8443108P | 2008-07-29 | 2008-07-29 | |
US61/084431 | 2008-07-29 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008801263100A Division CN101932608A (zh) | 2007-11-30 | 2008-11-28 | 抗原结合构建体 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104650235A true CN104650235A (zh) | 2015-05-27 |
Family
ID=40491579
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410818231.3A Pending CN104650235A (zh) | 2007-11-30 | 2008-11-28 | 抗原结合构建体 |
CN2008801263100A Pending CN101932608A (zh) | 2007-11-30 | 2008-11-28 | 抗原结合构建体 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008801263100A Pending CN101932608A (zh) | 2007-11-30 | 2008-11-28 | 抗原结合构建体 |
Country Status (23)
Country | Link |
---|---|
US (3) | US20110008345A1 (zh) |
EP (3) | EP2641919A3 (zh) |
JP (1) | JP5791898B2 (zh) |
KR (1) | KR101710472B1 (zh) |
CN (2) | CN104650235A (zh) |
AR (1) | AR069495A1 (zh) |
AU (2) | AU2008328726B2 (zh) |
BR (1) | BRPI0819693A2 (zh) |
CA (1) | CA2706419A1 (zh) |
CL (1) | CL2008003561A1 (zh) |
CO (1) | CO6280497A2 (zh) |
DE (1) | DE112008003232T5 (zh) |
EA (1) | EA023031B1 (zh) |
ES (1) | ES2614284T3 (zh) |
GB (1) | GB2468232B (zh) |
IL (1) | IL205906A (zh) |
MA (1) | MA31940B1 (zh) |
MX (1) | MX2010005927A (zh) |
PE (1) | PE20091234A1 (zh) |
TW (1) | TW200944231A (zh) |
UY (1) | UY31504A1 (zh) |
WO (1) | WO2009068649A2 (zh) |
ZA (1) | ZA201003850B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108025071A (zh) * | 2015-09-17 | 2018-05-11 | 斯克利普斯研究院 | 双重可变结构域免疫缀合物及其用途 |
Families Citing this family (218)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090286962A1 (en) * | 2005-12-20 | 2009-11-19 | Woolven Benjamin P | Chimeric antibodies with part new world primate binding regions |
US7846439B2 (en) | 2006-02-01 | 2010-12-07 | Cephalon Australia Pty Ltd | Domain antibody construct |
EP2471816A1 (en) | 2006-08-30 | 2012-07-04 | Genentech, Inc. | Multispecific antibodies |
ES2667729T3 (es) | 2007-09-26 | 2018-05-14 | Ucb Biopharma Sprl | Fusiones de anticuerpos con doble especificidad |
CN104650235A (zh) * | 2007-11-30 | 2015-05-27 | 葛兰素集团有限公司 | 抗原结合构建体 |
GEP20156390B (en) | 2008-01-03 | 2015-11-10 | Scripps Research Inst | Antibody targeting through a modular recognition domain |
US8574577B2 (en) | 2008-01-03 | 2013-11-05 | The Scripps Research Institute | VEGF antibodies comprising modular recognition domains |
US8454960B2 (en) | 2008-01-03 | 2013-06-04 | The Scripps Research Institute | Multispecific antibody targeting and multivalency through modular recognition domains |
US8557243B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | EFGR antibodies comprising modular recognition domains |
US8557242B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | ERBB2 antibodies comprising modular recognition domains |
WO2010027981A1 (en) | 2008-09-03 | 2010-03-11 | Genentech, Inc. | Multispecific antibodies |
LT2334705T (lt) | 2008-09-26 | 2017-03-27 | Ucb Biopharma Sprl | Biologiniai produktai |
US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
JP2012509658A (ja) * | 2008-11-26 | 2012-04-26 | グラクソ グループ リミテッド | Il−13に結合するリガンド |
GB0904214D0 (en) | 2009-03-11 | 2009-04-22 | Ucb Pharma Sa | Biological products |
US9394374B2 (en) | 2009-05-28 | 2016-07-19 | Glaxo Group Limited | Antigen-binding proteins |
EP2435075A2 (en) * | 2009-05-28 | 2012-04-04 | Glaxo Group Limited | Antigen-binding proteins |
CA2763446A1 (en) * | 2009-05-28 | 2010-12-02 | Victoria Ballard | Stem cell targeting |
TW201107345A (en) | 2009-05-28 | 2011-03-01 | Glaxo Group Ltd | Immunoglobulins |
US20120064064A1 (en) * | 2009-05-28 | 2012-03-15 | Thil Dinuk Batuwangala | Antigen-binding proteins |
EP2481754B1 (en) * | 2009-09-22 | 2014-06-18 | Shanghai Yijie Biotechnology Co., Ltd | Specific binding proteins and uses thereof |
EP2308897A1 (en) * | 2009-10-09 | 2011-04-13 | Pierre Fabre Medicament | Chimeric antibodies specific for CD151 and use thereof in the treatment of cancer |
ES2728115T3 (es) | 2009-10-30 | 2019-10-22 | Janssen Biotech Inc | Antagonistas de IL-17A |
TW201120210A (en) * | 2009-11-05 | 2011-06-16 | Hoffmann La Roche | Glycosylated repeat-motif-molecule conjugates |
WO2011057347A1 (en) | 2009-11-12 | 2011-05-19 | Tgr Biosciences Pty Ltd | Analyte detection |
EA201290630A1 (ru) * | 2010-02-09 | 2013-03-29 | Глаксо Груп Лимитед | Лечение расстройства обмена веществ |
EP2536757B1 (en) | 2010-02-18 | 2015-03-25 | Bristol-Myers Squibb Company | Fibronectin based scaffold domain proteins that bind il-23 |
AR080794A1 (es) * | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 |
CA2796932A1 (en) | 2010-04-21 | 2011-10-27 | Glaxo Group Limited | Binding domains |
PT2569013T (pt) * | 2010-05-14 | 2017-02-08 | Univ Leland Stanford Junior | Anticorpos monoclonais humanizados e quiméricos para cd47 |
BR112012029280A2 (pt) | 2010-05-20 | 2016-11-29 | Glaxo Group Ltd | variante de domínio variável único de imunoglobulina antialbumina sérica, imunoglobulina anti-sa, ligando multiespecífico, proteína de fusão, composição, ácido nucleico, vetor, célula hospedeira isolada, e, uso de uma variante, ligando multiespecífico ou proteína de fusão |
TWI488966B (zh) * | 2010-07-09 | 2015-06-21 | 優普生物科技股份有限公司 | Dna疫苗 |
US20120100166A1 (en) | 2010-07-15 | 2012-04-26 | Zyngenia, Inc. | Ang-2 Binding Complexes and Uses Thereof |
WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
EP2603522A1 (en) | 2010-08-13 | 2013-06-19 | GlaxoSmithKline Intellectual Property Development Limited | Improved anti-serum albumin binding variants |
SG188204A1 (en) | 2010-08-20 | 2013-04-30 | Glaxo Group Ltd | Improved anti-serum albumin binding variants |
CA2821992A1 (en) | 2010-10-01 | 2012-04-05 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
DK2635607T3 (da) | 2010-11-05 | 2019-11-18 | Zymeworks Inc | Stabilt heterodimert antistofdesign med mutationer i fc-domænet |
JP2014501725A (ja) | 2010-11-24 | 2014-01-23 | グラクソ グループ リミテッド | Hgfを標的とする多特異的抗原結合タンパク質 |
KR20230057485A (ko) * | 2010-12-06 | 2023-04-28 | 씨젠 인크. | Liv-1에 대한 인간화 항체 및 이의 암을 치료하기 위한 용도 |
EP2655415A4 (en) * | 2010-12-22 | 2016-03-09 | Abbvie Inc | THREE VARIABLE DOMAIN LINK PROTEINS AND USES THEREOF |
US9260496B2 (en) | 2010-12-22 | 2016-02-16 | Bristol-Myers Squibb Company | Fibronectin based scaffold domain proteins that bind IL-23 |
DK2668210T3 (da) | 2011-01-26 | 2020-08-24 | Celldex Therapeutics Inc | Anti-kit antistoffer og anvendelser deraf |
JP2014505698A (ja) | 2011-02-02 | 2014-03-06 | グラクソ グループ リミテッド | 新規抗原結合タンパク質 |
CN102251013A (zh) * | 2011-02-22 | 2011-11-23 | 北京市肿瘤防治研究所 | 一个识别肿瘤起始细胞的抗体和抗原及其应用 |
PL3235508T3 (pl) * | 2011-03-16 | 2021-07-12 | Sanofi | Kompozycje zawierające białko podobne do przeciwciała z podwójnym regionem v |
DE12722942T1 (de) | 2011-03-31 | 2021-09-30 | Modernatx, Inc. | Freisetzung und formulierung von manipulierten nukleinsäuren |
EA201391488A1 (ru) * | 2011-04-07 | 2014-01-30 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | Композиции со сниженной вязкостью |
CA2837169C (en) | 2011-05-24 | 2021-11-09 | Zyngenia, Inc. | Multispecific complexes comprising angiopoietin-2-binding peptide and their uses |
MX2013014789A (es) * | 2011-06-16 | 2014-01-20 | Novartis Ag | Proteinas solubles para utilizarse como productos terapeuticos. |
EP3626739A1 (en) * | 2011-06-24 | 2020-03-25 | Stephen D. Gillies | Light chain immunoglobulin fusion proteins and methods of use thereof |
EP2546268A1 (en) * | 2011-07-13 | 2013-01-16 | F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. | Internalising immunoglobulin |
GB201112429D0 (en) * | 2011-07-19 | 2011-08-31 | Glaxo Group Ltd | Antigen-binding proteins with increased FcRn binding |
US9499612B2 (en) * | 2011-07-27 | 2016-11-22 | Glaxo Group Limited | Antigen binding constructs |
UA118833C2 (uk) | 2011-08-17 | 2019-03-25 | Ґлаксо Ґруп Лімітед | Одиничний варіабельний домен імуноглобуліну, який зв'язується з tnfr1 |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
EP3492109B1 (en) | 2011-10-03 | 2020-03-04 | ModernaTX, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
HRP20211773T1 (hr) | 2011-11-04 | 2022-03-04 | Zymeworks Inc. | Stabilna heterodimerni dizajn antitijela s mutacijama u fc domeni |
JP2015501844A (ja) | 2011-12-16 | 2015-01-19 | モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. | 修飾ヌクレオシド、ヌクレオチドおよび核酸組成物 |
KR102338833B1 (ko) | 2012-02-06 | 2021-12-13 | 인히브릭스, 인크. | Cd47 항체 및 그 사용 방법 |
GB2502127A (en) * | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
EP2833923A4 (en) | 2012-04-02 | 2016-02-24 | Moderna Therapeutics Inc | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US20130280282A1 (en) * | 2012-04-24 | 2013-10-24 | Daiichi Sankyo Co., Ltd. | Dr5 ligand drug conjugates |
SG11201406943XA (en) * | 2012-04-27 | 2014-12-30 | Cytomx Therapeutics Inc | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
CN102676569A (zh) * | 2012-05-08 | 2012-09-19 | 百泰生物药业有限公司 | 一种新型噬菌粒展示载体pCANTAB5M |
WO2013166594A1 (en) * | 2012-05-10 | 2013-11-14 | Zymeworks Inc. | Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain |
WO2014004586A1 (en) | 2012-06-25 | 2014-01-03 | Zymeworks Inc. | Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells |
CA2877584A1 (en) * | 2012-06-28 | 2014-01-03 | Molecular Partners Ag | Designed ankyrin repeat proteins binding to platelet-derived growth factor |
RS62509B1 (sr) | 2012-07-13 | 2021-11-30 | Roche Glycart Ag | Bispecifična anti-vegf/anti-ang-2 antitela i njihova upotreba u lečenju očnih vaskularnih bolesti |
SG11201500489YA (en) | 2012-07-25 | 2015-02-27 | Kolltan Pharmaceuticals Inc | Anti-kit antibodies and uses thereof |
EP2888279A1 (en) | 2012-08-22 | 2015-07-01 | Glaxo Group Limited | Anti lrp6 antibodies |
CN105121630B (zh) | 2012-10-03 | 2018-09-25 | 酵活有限公司 | 定量重链和轻链多肽对的方法 |
LT2922554T (lt) | 2012-11-26 | 2022-06-27 | Modernatx, Inc. | Terminaliai modifikuota rnr |
BR112015012385A2 (pt) | 2012-11-28 | 2019-08-27 | Zymeworks Inc | constructo de polipeptídeo de ligação de antígeno isolado, polinucleotídeo isolado ou conjunto de polinucleotídeos isolados, vetor ou conjunto de vetores, célula isolada, composição farmacêutica, uso do constructo, método para tratar um sujeito tendo uma doença ou distúrbio ou câncer ou doença vascular, método para inibir, reduzir ou bloquear um sinal dentro de uma célula, método para obter o constructo, método para preparar o constructo, meio de armazenamento legível por computador, método implementado por computador e método para produzir um constructo de polipeptídeo de ligação de antígeno bi-específico |
US9914785B2 (en) | 2012-11-28 | 2018-03-13 | Zymeworks Inc. | Engineered immunoglobulin heavy chain-light chain pairs and uses thereof |
WO2014111550A1 (en) | 2013-01-17 | 2014-07-24 | Glaxosmithkline Intellectual Property Development Limited | Modified anti-serum albumin binding proteins |
RU2015128651A (ru) | 2013-01-31 | 2017-03-06 | Глаксо Груп Лимитед | Способ продуцирования белка |
BR112015018851A2 (pt) * | 2013-02-06 | 2017-07-18 | Inhibrx Llc | anticorpos cd47 de não depleção de plaquetas e de não depleção de células vermelhas do sangue, e métodos de uso dos mesmos |
CA2896370A1 (en) | 2013-02-26 | 2014-09-04 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
BR112015023752B1 (pt) | 2013-03-15 | 2023-11-14 | Zyngenia, Inc. | Domínio de reconhecimento modular (mrd), complexo compreendendo mrd e cetuximabe, usos do complexo para inibir a angiogênese e tratar câncer e composição farmacêutica compreendendo o dito complexo |
EP3000827B1 (en) * | 2013-05-22 | 2020-04-22 | Seoul National University Hospital | Anti-tnf-alpha/cxcl10 double-targeting antibody and use thereof |
KR102236367B1 (ko) | 2013-07-26 | 2021-04-05 | 삼성전자주식회사 | DARPin을 포함하는 이중 특이 키메라 단백질 |
CN104341504B (zh) * | 2013-08-06 | 2017-10-24 | 百奥泰生物科技(广州)有限公司 | 双特异性抗体 |
WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
US9540440B2 (en) | 2013-10-30 | 2017-01-10 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
AU2014348552A1 (en) | 2013-11-13 | 2016-06-02 | Zymeworks Inc. | Monovalent antigen binding constructs targeting EGFR and/or HER2 and uses thereof |
CA2931356A1 (en) | 2013-11-27 | 2015-06-04 | Zymeworks Inc. | Bispecific antigen-binding constructs targeting her2 |
WO2015089283A1 (en) | 2013-12-11 | 2015-06-18 | Cytomx Therapeutics, Inc. | Antibodies that bind activatable antibodies and methods of use thereof |
TW201609805A (zh) | 2013-12-23 | 2016-03-16 | 美國禮來大藥廠 | 結合egfr及met之多功能抗體 |
RU2016129724A (ru) * | 2013-12-23 | 2018-01-30 | Займворкс Инк. | Антитела, содержащие с-концевые удлинения полипептида легкой цепи, их конъюгаты и способы применения |
AU2015205530B8 (en) * | 2014-01-13 | 2019-09-19 | Pieris Pharmaceuticals Gmbh | Multi-specific polypeptide useful for localized tumor immunomodulation |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
SI3116909T1 (sl) | 2014-03-14 | 2020-03-31 | Novartis Ag | Molekule protiteles na LAG-3 in njih uporaba |
JP2017513818A (ja) | 2014-03-15 | 2017-06-01 | ノバルティス アーゲー | キメラ抗原受容体を使用する癌の処置 |
WO2015181805A1 (en) | 2014-05-28 | 2015-12-03 | Zymeworks Inc. | Modified antigen binding polypeptide constructs and uses thereof |
KR20170010863A (ko) | 2014-07-01 | 2017-02-01 | 화이자 인코포레이티드 | 이중특이성 이종이량체성 디아바디 및 이의 용도 |
KR102272213B1 (ko) * | 2014-07-08 | 2021-07-01 | 삼성전자주식회사 | 표적화 부위, 절단 부위, 및 세포막 투과 부위를 포함하는 융합 단백질 및 그의 용도 |
MX2017001011A (es) | 2014-07-21 | 2018-05-28 | Novartis Ag | Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma. |
CA2955154C (en) | 2014-07-21 | 2023-10-31 | Novartis Ag | Treatment of cancer using a cd33 chimeric antigen receptor |
EP3193915A1 (en) | 2014-07-21 | 2017-07-26 | Novartis AG | Combinations of low, immune enhancing. doses of mtor inhibitors and cars |
WO2016014553A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
US20170209492A1 (en) | 2014-07-31 | 2017-07-27 | Novartis Ag | Subset-optimized chimeric antigen receptor-containing t-cells |
EP3180359A1 (en) | 2014-08-14 | 2017-06-21 | Novartis AG | Treatment of cancer using gfr alpha-4 chimeric antigen receptor |
ES2791248T3 (es) | 2014-08-19 | 2020-11-03 | Novartis Ag | Receptor antigénico quimérico (CAR) anti-CD123 para su uso en el tratamiento del cáncer |
AU2015317608B2 (en) | 2014-09-17 | 2021-03-11 | Novartis Ag | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
GB201416832D0 (en) | 2014-09-24 | 2014-11-05 | Glaxosmithkline Plc | Methods of treatment |
RU2609627C2 (ru) * | 2014-09-26 | 2017-02-02 | Закрытое Акционерное Общество "Биокад" | Высокоаффинные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh |
PE20171067A1 (es) | 2014-10-14 | 2017-07-24 | Novartis Ag | Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas |
US20180334490A1 (en) | 2014-12-03 | 2018-11-22 | Qilong H. Wu | Methods for b cell preconditioning in car therapy |
WO2016135041A1 (en) * | 2015-02-26 | 2016-09-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Fusion proteins and antibodies comprising thereof for promoting apoptosis |
RU2752918C2 (ru) | 2015-04-08 | 2021-08-11 | Новартис Аг | Cd20 терапия, cd22 терапия и комбинированная терапия клетками, экспрессирующими химерный антигенный рецептор (car) k cd19 |
EP3286211A1 (en) | 2015-04-23 | 2018-02-28 | Novartis AG | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
JP6783797B2 (ja) | 2015-05-04 | 2020-11-11 | ピエリス ファーマシューティカルズ ゲーエムベーハー | 抗がん融合ポリペプチド |
MX2018000948A (es) | 2015-07-23 | 2018-09-27 | Inhibrx Inc | Proteinas de fusion que se unen a gitir multivalentes y multiespecificas. |
EP3878465A1 (en) | 2015-07-29 | 2021-09-15 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
EP3317301B1 (en) | 2015-07-29 | 2021-04-07 | Novartis AG | Combination therapies comprising antibody molecules to lag-3 |
JP6878405B2 (ja) | 2015-07-29 | 2021-05-26 | ノバルティス アーゲー | Pd−1に対する抗体分子を含む組み合わせ治療 |
EA037487B1 (ru) * | 2015-08-24 | 2021-04-02 | Глэксосмитклайн Интеллекчуал Проперти (No.2) Лимитед | Биофармацевтические композиции |
JP2018533017A (ja) * | 2015-10-02 | 2018-11-08 | ティージーアール バイオサイエンシス ピーティーワイ エルティーディー. | 多基体による検体検出 |
JP6932693B2 (ja) | 2015-10-08 | 2021-09-08 | ザイムワークス,インコーポレイテッド | カッパ及びラムダ軽鎖を含む抗原結合ポリペプチド構築物及びその使用 |
CA3007421A1 (en) | 2015-12-17 | 2017-06-22 | Novartis Ag | Combination of c-met inhibitor with antibody molecule to pd-1 and uses thereof |
JP2019503349A (ja) | 2015-12-17 | 2019-02-07 | ノバルティス アーゲー | Pd−1に対する抗体分子およびその使用 |
WO2017125897A1 (en) | 2016-01-21 | 2017-07-27 | Novartis Ag | Multispecific molecules targeting cll-1 |
WO2017143406A1 (en) * | 2016-02-26 | 2017-08-31 | Imunexus Pty Ltd | Multi-specific molecules |
EP3423482A1 (en) | 2016-03-04 | 2019-01-09 | Novartis AG | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore |
MA45324A (fr) | 2016-03-15 | 2019-01-23 | Seattle Genetics Inc | Polythérapie utilisant un adc-liv1 et un agent chimiothérapeutique |
US11549099B2 (en) | 2016-03-23 | 2023-01-10 | Novartis Ag | Cell secreted minibodies and uses thereof |
MX2018012615A (es) | 2016-04-15 | 2019-05-30 | Novartis Ag | Composiciones y metodos para la expresion selectiva de proteinas. |
US20210177896A1 (en) | 2016-06-02 | 2021-06-17 | Novartis Ag | Therapeutic regimens for chimeric antigen receptor (car)- expressing cells |
CN106084067A (zh) * | 2016-06-15 | 2016-11-09 | 无锡市人民医院 | 具有肿瘤抑制作用的新型真核重组蛋白及其制备方法 |
AU2017295886C1 (en) | 2016-07-15 | 2024-05-16 | Novartis Ag | Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor |
WO2018014260A1 (en) * | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
SG11201900677SA (en) | 2016-07-28 | 2019-02-27 | Novartis Ag | Combination therapies of chimeric antigen receptors adn pd-1 inhibitors |
CN110267677A (zh) | 2016-08-01 | 2019-09-20 | 诺华股份有限公司 | 使用与原m2巨噬细胞分子抑制剂组合的嵌合抗原受体治疗癌症 |
TW202340473A (zh) | 2016-10-07 | 2023-10-16 | 瑞士商諾華公司 | 利用嵌合抗原受體之癌症治療 |
WO2018068201A1 (en) | 2016-10-11 | 2018-04-19 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against ctla-4 |
TW201829462A (zh) * | 2016-11-02 | 2018-08-16 | 英商葛蘭素史克智慧財產(第二)有限公司 | 結合蛋白 |
ES2912408T3 (es) | 2017-01-26 | 2022-05-25 | Novartis Ag | Composiciones de CD28 y métodos para terapia con receptores quiméricos para antígenos |
CN108456250A (zh) * | 2017-02-17 | 2018-08-28 | 科济生物医药(上海)有限公司 | 靶向il-13ra2的抗体及其应用 |
WO2018160731A1 (en) | 2017-02-28 | 2018-09-07 | Novartis Ag | Shp inhibitor compositions and uses for chimeric antigen receptor therapy |
CA3058477A1 (en) | 2017-04-11 | 2018-10-18 | Inhibrx, Inc. | Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same |
US20200055948A1 (en) | 2017-04-28 | 2020-02-20 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
EP3615068A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
BR112019025736A2 (pt) | 2017-06-06 | 2020-06-30 | Glaxosmithkline Llc | uso de um anticorpo e composições para tratar uma doença e para diminuir uma contagem absoluta de eosinófilo no sangue |
US11786607B2 (en) | 2017-06-15 | 2023-10-17 | Modernatx, Inc. | RNA formulations |
MA49457A (fr) | 2017-06-22 | 2020-04-29 | Novartis Ag | Molécules d'anticorps se liant à cd73 et leurs utilisations |
WO2019006007A1 (en) | 2017-06-27 | 2019-01-03 | Novartis Ag | POSOLOGICAL REGIMES FOR ANTI-TIM3 ANTIBODIES AND USES THEREOF |
CN111278858B (zh) | 2017-07-11 | 2024-07-23 | 指南针制药有限责任公司 | 结合人cd137的激动剂抗体及其用途 |
GB201711208D0 (en) | 2017-07-12 | 2017-08-23 | Iontas Ltd | Ion channel inhibitors |
AU2018302283A1 (en) | 2017-07-20 | 2020-02-06 | Novartis Ag | Dosage regimens of anti-LAG-3 antibodies and uses thereof |
WO2019028367A1 (en) | 2017-08-04 | 2019-02-07 | Regeneron Pharmaceuticals, Inc. | METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES |
WO2019046809A1 (en) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | METHODS OF MANUFACTURING LIPID NANOPARTICLES |
TWI801425B (zh) * | 2017-09-29 | 2023-05-11 | 大陸商江蘇恆瑞醫藥股份有限公司 | Il-5 抗體、其抗原結合片段及醫藥用途 |
WO2019089798A1 (en) | 2017-10-31 | 2019-05-09 | Novartis Ag | Anti-car compositions and methods |
US11718679B2 (en) | 2017-10-31 | 2023-08-08 | Compass Therapeutics Llc | CD137 antibodies and PD-1 antagonists and uses thereof |
KR20200089286A (ko) | 2017-11-16 | 2020-07-24 | 노파르티스 아게 | 조합 요법 |
US11851497B2 (en) | 2017-11-20 | 2023-12-26 | Compass Therapeutics Llc | CD137 antibodies and tumor antigen-targeting antibodies and uses thereof |
KR20200104333A (ko) | 2017-12-28 | 2020-09-03 | 난징 레전드 바이오테크 씨오., 엘티디. | Tigit에 대한 단일-도메인 항체 및 이의 변이체 |
WO2019134710A1 (en) * | 2018-01-08 | 2019-07-11 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
CN111699200B (zh) | 2018-01-15 | 2023-05-26 | 南京传奇生物科技有限公司 | 针对pd-1的单域抗体和其变体 |
WO2019152660A1 (en) | 2018-01-31 | 2019-08-08 | Novartis Ag | Combination therapy using a chimeric antigen receptor |
US20210147547A1 (en) | 2018-04-13 | 2021-05-20 | Novartis Ag | Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof |
EP3784351A1 (en) | 2018-04-27 | 2021-03-03 | Novartis AG | Car t cell therapies with enhanced efficacy |
WO2019226658A1 (en) | 2018-05-21 | 2019-11-28 | Compass Therapeutics Llc | Multispecific antigen-binding compositions and methods of use |
WO2019226617A1 (en) | 2018-05-21 | 2019-11-28 | Compass Therapeutics Llc | Compositions and methods for enhancing the killing of target cells by nk cells |
US20210213063A1 (en) | 2018-05-25 | 2021-07-15 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
WO2019232244A2 (en) | 2018-05-31 | 2019-12-05 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
US20210198370A1 (en) * | 2018-05-31 | 2021-07-01 | Board Of Regents, The University Of Texas System | Bi-specific antibodies and use thereof |
SG11202011830SA (en) | 2018-06-13 | 2020-12-30 | Novartis Ag | Bcma chimeric antigen receptors and uses thereof |
JP7472119B2 (ja) | 2018-06-19 | 2024-04-22 | アターガ,エルエルシー | 補体第5成分に対する抗体分子およびその使用 |
AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
WO2020021465A1 (en) | 2018-07-25 | 2020-01-30 | Advanced Accelerator Applications (Italy) S.R.L. | Method of treatment of neuroendocrine tumors |
GB2576914A (en) * | 2018-09-06 | 2020-03-11 | Kymab Ltd | Antigen-binding molecules comprising unpaired variable domains produced in mammals |
EP3852728B1 (en) | 2018-09-20 | 2024-09-18 | ModernaTX, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
BR112021008795A2 (pt) | 2018-11-13 | 2021-08-31 | Compass Therapeutics Llc | Construtos de ligação multiespecíficos contra moléculas de ponto de verificação e seus usos |
JP2022514315A (ja) | 2018-12-20 | 2022-02-10 | ノバルティス アーゲー | 3-(1-オキソイソインドリン-2-イル)ピペリジン-2,6-ジオン誘導体を含む投与計画及び薬剤組み合わせ |
CA3123356A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Combinations of a hdm2-p53 interaction inhibitor and a bcl2 inhibitor and their use for treating cancer |
CN113645996B (zh) * | 2019-02-01 | 2024-04-02 | 新石生物制药有限公司 | 抗claudin 18抗体及其使用方法 |
JP7483732B2 (ja) | 2019-02-15 | 2024-05-15 | ノバルティス アーゲー | 3-(1-オキソ-5-(ピペリジン-4-イル)イソインドリン-2-イル)ピペリジン-2,6-ジオン誘導体及びその使用 |
JP7488826B2 (ja) | 2019-02-15 | 2024-05-22 | ノバルティス アーゲー | 置換3-(1-オキソイソインドリン-2-イル)ピペリジン-2,6-ジオン誘導体及びその使用 |
US10871640B2 (en) | 2019-02-15 | 2020-12-22 | Perkinelmer Cellular Technologies Germany Gmbh | Methods and systems for automated imaging of three-dimensional objects |
WO2020172553A1 (en) | 2019-02-22 | 2020-08-27 | Novartis Ag | Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors |
MA55204A (fr) | 2019-03-06 | 2022-01-12 | Regeneron Pharma | Inhibiteurs de la voie il-4/il-13 pour une efficacité améliorée dans le traitement du cancer |
BR112021018627A2 (pt) | 2019-03-21 | 2021-11-23 | Regeneron Pharma | Combinação de inibidores da via de il-4/il-13 e ablação de células plasmáticas para o tratamento de alergia |
WO2020205523A1 (en) | 2019-03-29 | 2020-10-08 | Atarga, Llc | Anti fgf23 antibody |
US20230220109A1 (en) * | 2019-06-06 | 2023-07-13 | Janux Therapeutics, Inc. | Compositions and methods relating to tumor activated t cell engagers |
AU2020370832A1 (en) | 2019-10-21 | 2022-05-19 | Novartis Ag | TIM-3 inhibitors and uses thereof |
IL292347A (en) | 2019-10-21 | 2022-06-01 | Novartis Ag | Combination treatments with ventoclax and tim-3 inhibitors |
BR112022010206A2 (pt) | 2019-11-26 | 2022-11-29 | Novartis Ag | Receptores de antígeno quiméricos e usos dos mesmos |
CA3165399A1 (en) | 2019-12-20 | 2021-06-24 | Novartis Ag | Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases |
CN115298322A (zh) | 2020-01-17 | 2022-11-04 | 贝克顿迪金森公司 | 用于单细胞分泌组学的方法和组合物 |
US20230058489A1 (en) | 2020-01-17 | 2023-02-23 | Novartis Ag | Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia |
JP2023515211A (ja) | 2020-02-27 | 2023-04-12 | ノバルティス アーゲー | キメラ抗原受容体発現細胞を作製する方法 |
US20230321067A1 (en) | 2020-06-23 | 2023-10-12 | Novartis Ag | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
TWI818276B (zh) * | 2020-06-30 | 2023-10-11 | 大陸商和鉑醫藥(上海)有限責任公司 | Fab-HCAb結構的結合蛋白 |
AU2021308712A1 (en) | 2020-07-16 | 2023-02-02 | Novartis Ag | Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules |
WO2022026592A2 (en) | 2020-07-28 | 2022-02-03 | Celltas Bio, Inc. | Antibody molecules to coronavirus and uses thereof |
JP2023536164A (ja) | 2020-08-03 | 2023-08-23 | ノバルティス アーゲー | ヘテロアリール置換3-(1-オキソイソインドリン-2-イル)ピペリジン-2,6-ジオン誘導体及びその使用 |
US20230338587A1 (en) | 2020-08-31 | 2023-10-26 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
WO2022043557A1 (en) | 2020-08-31 | 2022-03-03 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
JP2023547499A (ja) | 2020-11-06 | 2023-11-10 | ノバルティス アーゲー | 抗体Fc変異体 |
US20240033358A1 (en) | 2020-11-13 | 2024-02-01 | Novartis Ag | Combination therapies with chimeric antigen receptor (car)-expressing cells |
EP4284510A1 (en) | 2021-01-29 | 2023-12-06 | Novartis AG | Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof |
TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途 |
AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
EP4405396A2 (en) | 2021-09-20 | 2024-07-31 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
WO2023092004A1 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
US20230220089A1 (en) | 2021-12-30 | 2023-07-13 | Regeneron Pharmaceuticals, Inc. | Methods for attenuating atopic march by administering an il-4/il-13 antagonist |
TW202342548A (zh) | 2022-02-07 | 2023-11-01 | 美商威特拉公司 | 抗獨特型(anti-idiotype)抗體分子及其用途 |
WO2023220695A2 (en) | 2022-05-13 | 2023-11-16 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
WO2024030976A2 (en) | 2022-08-03 | 2024-02-08 | Voyager Therapeutics, Inc. | Compositions and methods for crossing the blood brain barrier |
WO2024168061A2 (en) | 2023-02-07 | 2024-08-15 | Ayan Therapeutics Inc. | Antibody molecules binding to sars-cov-2 |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
ES2313867T3 (es) | 1991-12-02 | 2009-03-16 | Medical Research Council | Produccion de anticuerpos anti-auto de repertorios de segmentos de anticuerpo expresados en la superficie de fagos. |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
EP0656064B1 (en) * | 1992-08-17 | 1997-03-05 | Genentech, Inc. | Bispecific immunoadhesins |
GB9221657D0 (en) * | 1992-10-15 | 1992-11-25 | Scotgen Ltd | Recombinant bispecific antibodies |
GB9225453D0 (en) * | 1992-12-04 | 1993-01-27 | Medical Res Council | Binding proteins |
US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
GB9424449D0 (en) | 1994-12-02 | 1995-01-18 | Wellcome Found | Antibodies |
US5702892A (en) | 1995-05-09 | 1997-12-30 | The United States Of America As Represented By The Department Of Health And Human Services | Phage-display of immunoglobulin heavy chain libraries |
DK0859841T3 (da) | 1995-08-18 | 2002-09-09 | Morphosys Ag | Protein/(poly)peptidbiblioteker |
DE69838521T2 (de) | 1997-07-07 | 2008-05-21 | Medical Research Council | Methode zur Erhöhung der Konzentration von Nucleinsäuremolekülen |
DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
GB9809839D0 (en) | 1998-05-09 | 1998-07-08 | Glaxo Group Ltd | Antibody |
GB2361237A (en) | 1998-05-13 | 2001-10-17 | Diversys Ltd | Selection system |
IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
GB9900298D0 (en) | 1999-01-07 | 1999-02-24 | Medical Res Council | Optical sorting method |
WO2001057065A2 (en) | 2000-02-03 | 2001-08-09 | Domantis Limited | Combinatorial protein domains |
US6846486B1 (en) * | 2000-02-24 | 2005-01-25 | Advanced Biotherapy Concepts, Inc. | Method of treating allergy by administering an anti-histamine antibody |
DK2857516T3 (en) * | 2000-04-11 | 2017-08-07 | Genentech Inc | Multivalent antibodies and uses thereof |
WO2002020565A2 (en) | 2000-09-08 | 2002-03-14 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
US7589180B2 (en) | 2001-05-11 | 2009-09-15 | Abbott Laboratories Inc. | Specific binding proteins and uses thereof |
ES2337986T3 (es) | 2001-08-10 | 2010-05-03 | Aberdeen University | Dominios de union de antigenos de peces. |
US20050142539A1 (en) * | 2002-01-14 | 2005-06-30 | William Herman | Targeted ligands |
US7317091B2 (en) * | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
ATE416190T1 (de) | 2003-07-04 | 2008-12-15 | Affibody Ab | Polypeptide mit bindungsaffinität für her2 |
AU2003275958A1 (en) | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of tear lipocalin |
CA2552435A1 (en) | 2003-12-05 | 2005-06-23 | Compound Therapeutics, Inc. | Inhibitors of type 2 vascular endothelial growth factor receptors |
US7767792B2 (en) | 2004-02-20 | 2010-08-03 | Ludwig Institute For Cancer Research Ltd. | Antibodies to EGF receptor epitope peptides |
AR049390A1 (es) * | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
RS51326B (sr) | 2004-08-05 | 2010-12-31 | Genentech Inc. | Humanizovani anti-cmet antagonisti |
WO2006036877A2 (en) * | 2004-09-27 | 2006-04-06 | Cornell Research Foundation, Inc. | Recombinant bifunctional protein of human lutropin receptor and human chorionic gonadotropin b-subunit and uses thereof |
EP2495257A3 (en) * | 2005-08-19 | 2012-10-17 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
EP1957541A2 (en) * | 2005-11-21 | 2008-08-20 | Laboratoires Serono SA | Compositions and methods of producing hybrid antigen binding molecules and uses thereof |
CA2631184A1 (en) | 2005-11-28 | 2007-05-31 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
TW200804425A (en) * | 2005-12-06 | 2008-01-16 | Domantis Ltd | Ligands that have binding specificity for EGFR and/or VEGF and methods of use therefor |
CN101370881B (zh) * | 2006-01-18 | 2013-05-29 | 西巴控股有限公司 | 低挥发性有机化合物溶剂型涂料的多用途添加剂 |
AU2007209201A1 (en) * | 2006-01-24 | 2007-08-02 | Domantis Limited | Fusion proteins that contain natural junctions |
CA2638794A1 (en) | 2006-02-15 | 2007-08-23 | Imclone Systems Incorporated | Functional antibodies |
US20110059101A9 (en) * | 2006-03-13 | 2011-03-10 | Ablynx N.V. | Amino Acid Sequences Directed Against Il-6 And Polypetides Comprising The Same For The Treatment Of Diseases And Disorders Associated With Il-6 Mediated Signalling |
EP1958957A1 (en) | 2007-02-16 | 2008-08-20 | NascaCell Technologies AG | Polypeptide comprising a knottin protein moiety |
BRPI0811857A2 (pt) * | 2007-05-14 | 2014-10-21 | Biogen Idec Inc | Regiões fc (scfc) de cadeia simples, polipeptídeos de aglutinação que as compreendem e métodos relacionados. |
EP2050764A1 (en) * | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
CN104650235A (zh) * | 2007-11-30 | 2015-05-27 | 葛兰素集团有限公司 | 抗原结合构建体 |
AU2009213141A1 (en) * | 2008-02-14 | 2009-08-20 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins that bind EGFR |
DK3037104T3 (da) * | 2009-10-20 | 2020-07-20 | Abbvie Inc | Isolering og renselse af anti-il-13 antistoffer ved brug af protein a beslægtet kromatografi |
-
2008
- 2008-11-28 CN CN201410818231.3A patent/CN104650235A/zh active Pending
- 2008-11-28 CA CA2706419A patent/CA2706419A1/en not_active Abandoned
- 2008-11-28 GB GB1008468.9A patent/GB2468232B/en not_active Expired - Fee Related
- 2008-11-28 ES ES08854122.2T patent/ES2614284T3/es active Active
- 2008-11-28 BR BRPI0819693-1A patent/BRPI0819693A2/pt not_active IP Right Cessation
- 2008-11-28 US US12/744,799 patent/US20110008345A1/en not_active Abandoned
- 2008-11-28 CL CL2008003561A patent/CL2008003561A1/es unknown
- 2008-11-28 UY UY31504A patent/UY31504A1/es unknown
- 2008-11-28 JP JP2010535396A patent/JP5791898B2/ja not_active Expired - Fee Related
- 2008-11-28 MX MX2010005927A patent/MX2010005927A/es active IP Right Grant
- 2008-11-28 PE PE2008001998A patent/PE20091234A1/es not_active Application Discontinuation
- 2008-11-28 KR KR1020107014403A patent/KR101710472B1/ko active IP Right Grant
- 2008-11-28 TW TW097146549A patent/TW200944231A/zh unknown
- 2008-11-28 AR ARP080105206A patent/AR069495A1/es not_active Application Discontinuation
- 2008-11-28 US US12/324,905 patent/US20090148905A1/en not_active Abandoned
- 2008-11-28 CN CN2008801263100A patent/CN101932608A/zh active Pending
- 2008-11-28 WO PCT/EP2008/066438 patent/WO2009068649A2/en active Application Filing
- 2008-11-28 EP EP13154223.5A patent/EP2641919A3/en not_active Withdrawn
- 2008-11-28 DE DE112008003232T patent/DE112008003232T5/de not_active Withdrawn
- 2008-11-28 EA EA201000704A patent/EA023031B1/ru not_active IP Right Cessation
- 2008-11-28 EP EP08854122.2A patent/EP2222709B1/en active Active
- 2008-11-28 AU AU2008328726A patent/AU2008328726B2/en not_active Ceased
- 2008-11-28 EP EP13154451.2A patent/EP2615115A3/en not_active Withdrawn
-
2010
- 2010-05-23 IL IL205906A patent/IL205906A/en not_active IP Right Cessation
- 2010-05-28 ZA ZA2010/03850A patent/ZA201003850B/en unknown
- 2010-05-28 CO CO10064737A patent/CO6280497A2/es not_active Application Discontinuation
- 2010-06-25 MA MA32954A patent/MA31940B1/fr unknown
-
2014
- 2014-09-11 AU AU2014224077A patent/AU2014224077A1/en not_active Abandoned
-
2015
- 2015-06-15 US US14/739,099 patent/US20160207993A1/en not_active Abandoned
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108025071A (zh) * | 2015-09-17 | 2018-05-11 | 斯克利普斯研究院 | 双重可变结构域免疫缀合物及其用途 |
CN108025071B (zh) * | 2015-09-17 | 2022-11-01 | 斯克利普斯研究院 | 双重可变结构域免疫缀合物及其用途 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101710472B1 (ko) | 항원-결합 작제물 | |
AU2020200981B2 (en) | Multispecific antibodies, multispecific activatable antibodies and methods of using the same | |
KR102037541B1 (ko) | 폴리펩티드 구축물 및 이의 용도 | |
KR101833602B1 (ko) | 이중특이적 t 세포 활성화 항원 결합 분자 | |
KR102161460B1 (ko) | St2 항원 결합 단백질 | |
KR20180099723A (ko) | 항-tl1a/항-tnf-알파 이중특이적 항원 결합 단백질 및 그의 용도 | |
KR20170081188A (ko) | Folr1 및 cd3에 대한 t 세포 활성화 이중특이적 항원 결합 분자 | |
JP2012518398A (ja) | 抗原結合性構築物 | |
KR20180054877A (ko) | 공자극 tnf 수용체에 대해 4가를 갖는 이중특이적 항체 | |
KR20150122203A (ko) | T 세포 활성화 이중특이적 항원 결합 분자 | |
CN110845618A (zh) | 双特异性t细胞活化抗原结合分子 | |
JP2009523460A (ja) | Il−4および/またはil−13に結合するリガンド | |
CN109952112A (zh) | Cd123结合蛋白和相关的组合物和方法 | |
EP2435482B1 (en) | Antigen-binding proteins | |
JP2012527875A (ja) | 抗原結合タンパク質 | |
TW202227492A (zh) | 抗切斷型突變calr-cd3雙特異性抗體及醫藥組合物 | |
JP2024038187A (ja) | 安定化された免疫グロブリンドメイン | |
US20110305693A1 (en) | Anitigen-binding constructs | |
JP2012518400A (ja) | 多価および/または複数特異的rankl結合性構築物 | |
JP2012527878A (ja) | 抗原結合タンパク質 | |
KR20200135331A (ko) | 고양이 맥도너 육종(fms)-유사 티로신 키나제 3 수용체 리간드(flt3l)에 대한 항체 및 자가면역 및 염증 질환을 치료하기 위한 이의 용도 | |
WO2023011431A1 (zh) | 一种cd16抗体及其应用 | |
RU2801209C2 (ru) | Собачьи антитела с модифицированными последовательностями ch2-ch3 | |
RU2815683C2 (ru) | Мультспецифические антитела, мультспецифические активируемые антитела и способы их применения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150527 |